data_6pq2_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6pq2 _Structure_validation_residue.Date_analyzed 2019-09-13 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.46 HD22 HG22 ' A' ' 100' ' ' THR . 3.2 pp . . . . . 0 N--CA 1.482 1.143 0 N-CA-C 111.628 0.233 . . . . 73.53 111.628 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.649 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 73.6 Cg_endo -73.71 -167.57 0.39 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.685 2.257 . . . . 72.41 111.377 171.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.467 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 12.7 tp -75.96 142.69 41.91 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.603 -0.517 . . . . 74.43 109.603 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.573 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 6.3 tp 68.89 -57.98 0.5 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 126.95 2.1 . . . . 74.45 112.02 -167.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.649 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 65.7 t80 -72.65 135.33 45.44 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.697 1.199 . . . . 74.11 112.534 -173.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.536 HG23 HG11 ' A' ' 102' ' ' VAL . 55.4 m -153.97 101.25 2.49 Favored Pre-proline 0 CA--C 1.544 0.74 0 C-N-CA 123.985 0.914 . . . . 72.02 109.895 177.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -76.08 83.0 2.06 Favored 'Trans proline' 0 C--N 1.369 1.611 0 C-N-CA 122.128 1.885 . . . . 74.12 112.304 -173.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.536 HG11 HG23 ' A' ' 100' ' ' THR . 30.1 m . . . . . 0 CA--C 1.538 0.497 0 CA-C-N 114.935 -1.03 . . . . 65.55 109.729 173.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 . . . . . 0 N--CA 1.472 0.653 0 N-CA-C 108.948 -0.76 . . . . 75.41 108.948 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -93.31 104.41 16.58 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.561 -1.274 . . . . 70.23 107.561 -177.018 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.542 HD11 ' HA ' ' A' ' 99' ' ' PHE . 10.3 mt -94.08 109.78 21.52 Favored 'General case' 0 C--N 1.342 0.253 0 N-CA-C 107.093 -1.447 . . . . 72.12 107.093 -177.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.8 ttt180 -108.63 109.71 20.98 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.702 -0.481 . . . . 74.12 109.702 176.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -122.95 144.76 49.02 Favored 'General case' 0 C--O 1.242 0.693 0 N-CA-C 109.116 -0.698 . . . . 72.23 109.116 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -81.81 122.41 27.67 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.957 -1.127 . . . . 74.54 107.957 177.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.435 HD13 ' HG2' ' A' ' 136' ' ' ARG . 47.3 tp -99.32 103.38 20.2 Favored Pre-proline 0 CA--C 1.542 0.645 0 C-N-CA 123.565 0.746 . . . . 74.11 110.083 -171.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.13 114.39 3.97 Favored 'Trans proline' 0 C--N 1.374 1.894 0 C-N-CA 121.956 1.77 . . . . 74.14 110.017 176.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.516 HD23 HD11 ' A' ' 149' ' ' ILE . 14.2 tp -136.06 122.45 20.62 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 109.155 -0.683 . . . . 74.43 109.155 -168.401 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 3.0 m -69.61 162.31 27.87 Favored 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.987 0.915 . . . . 74.24 111.121 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 69.3 mt -63.93 -36.39 83.79 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.017 0.527 . . . . 73.42 112.37 -177.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -69.21 -40.19 78.15 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.292 0.637 . . . . 73.22 109.38 179.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.484 ' HG3' ' NH2' ' A' ' 136' ' ' ARG . 24.6 mm-40 -62.64 -44.27 96.7 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.477 1.111 . . . . 73.13 110.531 177.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.89 -37.29 78.93 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 115.158 -0.928 . . . . 74.41 111.408 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.5 t80 -65.84 -49.26 68.82 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.452 1.501 . . . . 71.43 110.881 -178.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -80.24 -41.22 25.51 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 115.28 -0.873 . . . . 74.0 111.157 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.512 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.36 58.35 8.83 Favored Glycine 0 C--N 1.345 1.073 0 O-C-N 123.543 0.527 . . . . 65.4 113.085 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -94.51 -130.69 6.0 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 110.966 -0.854 . . . . 75.31 110.966 174.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -107.76 160.3 15.83 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.284 0.564 . . . . 64.41 110.046 169.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.484 ' NH2' ' HG3' ' A' ' 129' ' ' GLU . 5.5 tpp180 -133.02 121.92 23.44 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.495 -1.298 . . . . 73.54 107.495 172.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 62.9 t -72.8 124.34 29.44 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-O 121.082 0.468 . . . . 73.34 110.084 175.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.553 HG21 HD11 ' A' ' 98' ' ' LEU . 32.9 m -127.33 145.2 35.19 Favored 'Isoleucine or valine' 0 C--O 1.251 1.142 0 C-N-CA 125.08 1.352 . . . . 74.22 108.105 -177.356 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -104.23 106.28 16.73 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.166 -0.679 . . . . 72.35 109.166 -176.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.584 HG12 ' HB2' ' A' ' 143' ' ' ARG . 2.4 p -106.45 100.18 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.829 0.851 . . . . 61.13 109.411 -176.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.92 23.91 14.26 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.426 0.691 . . . . 63.34 111.927 177.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.27 2.91 56.74 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 116.02 -0.537 . . . . 65.21 112.924 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.584 ' HB2' HG12 ' A' ' 140' ' ' VAL . 48.0 mtp180 -100.56 119.91 39.24 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 108.948 -0.76 . . . . 73.33 108.948 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.0 tmm_? -81.79 107.37 14.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.002 -0.74 . . . . 65.42 109.002 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 24.4 m -124.92 156.37 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 C-N-CA 123.701 0.8 . . . . 75.24 109.776 176.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.6 p -107.96 119.12 38.55 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 123.147 0.579 . . . . 73.45 110.192 174.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.0 p -99.16 132.28 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.671 -0.492 . . . . 64.25 109.671 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -80.36 120.19 24.07 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.877 0.37 . . . . 74.23 110.162 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.516 HD11 HD23 ' A' ' 125' ' ' LEU . 7.5 pt -95.08 142.01 24.03 Favored Pre-proline 0 CA--C 1.556 1.182 0 C-N-CA 124.135 0.974 . . . . 71.53 109.341 179.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.405 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 52.6 Cg_endo -72.56 143.86 39.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.267 1.978 . . . . 74.33 112.5 178.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.33 133.54 19.43 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 122.633 2.222 . . . . 73.13 111.915 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.84 30.01 53.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.64 -0.709 . . . . 61.14 113.253 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.405 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 8.2 p -82.72 148.09 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 117.363 0.581 . . . . 72.53 109.634 179.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 -126.47 177.71 6.31 Favored 'General case' 0 N--CA 1.479 0.988 0 CA-C-O 121.567 0.699 . . . . 74.03 112.122 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.6 tp10 -61.37 129.17 39.88 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 113.835 -1.53 . . . . 75.41 110.78 177.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.66 4.66 90.0 Favored Glycine 0 C--N 1.344 0.984 0 O-C-N 123.701 0.626 . . . . 54.13 113.551 178.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 67.0 m -82.23 119.67 24.38 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 117.444 0.622 . . . . 72.53 109.457 175.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.3 p -98.55 125.29 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-O 121.213 0.53 . . . . 75.31 110.054 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.8 mt -91.75 104.03 15.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 C-N-CA 124.334 1.053 . . . . 72.55 108.173 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.461 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 74.8 ttt180 -94.45 114.66 26.72 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 110.139 -0.319 . . . . 74.41 110.139 -177.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 19.5 t -122.85 98.4 42.77 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 123.59 0.756 . . . . 74.03 109.092 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.06 125.72 12.86 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.931 2.421 . . . . 72.51 112.74 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 104.64 -24.49 28.46 Favored Glycine 0 N--CA 1.474 1.19 0 CA-C-O 120.151 -0.25 . . . . 75.52 113.167 176.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.3 ttm -89.57 -18.92 25.66 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.362 0.665 . . . . 72.34 111.338 -174.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -69.8 -100.76 0.04 OUTLIER Glycine 0 C--N 1.346 1.103 0 CA-C-O 119.677 -0.513 . . . . 74.11 113.197 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -53.36 107.78 0.65 Allowed Glycine 0 C--N 1.355 1.59 0 C-N-CA 123.103 0.383 . . . . 70.33 113.248 179.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 13.0 mm-40 -84.76 169.53 14.13 Favored 'General case' 0 C--O 1.237 0.431 0 C-N-CA 123.602 0.761 . . . . 73.32 110.096 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 108.33 -138.47 14.67 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.716 -0.675 . . . . 60.03 111.672 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.441 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 58.0 t30 -77.15 -51.55 2.02 Favored Pre-proline 0 CA--C 1.569 1.706 0 CA-C-O 118.285 -0.864 . . . . 73.35 111.541 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.441 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 72.8 Cg_endo -95.29 109.79 0.13 Allowed 'Trans proline' 0 C--N 1.394 2.958 0 C-N-CA 122.38 2.053 . . . . 62.22 112.746 177.239 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -60.45 125.95 18.72 Favored 'Trans proline' 0 C--N 1.381 2.261 0 C-N-CA 122.512 2.141 . . . . 73.11 111.654 175.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -112.27 177.33 18.51 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 116.412 -0.358 . . . . 72.23 113.88 -176.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.23 146.13 28.75 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.762 0.825 . . . . 72.12 110.318 -175.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.461 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 59.0 tp -113.38 134.51 54.6 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.196 0.598 . . . . 72.0 109.846 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 76.3 mt -129.61 105.2 7.9 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.437 1.095 . . . . 75.44 109.301 176.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.466 HD23 HD12 ' A' ' 98' ' ' LEU . 68.0 mt -107.55 102.73 11.96 Favored 'General case' 0 N--CA 1.479 1.013 0 O-C-N 122.109 -0.37 . . . . 65.2 110.009 174.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.7 t -85.93 99.04 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 N-CA-C 108.369 -0.974 . . . . 74.15 108.369 -175.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 87.0 t -56.23 116.81 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.45 1.1 . . . . 74.0 111.724 -177.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -113.07 104.21 12.15 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 125.576 1.551 . . . . 72.34 107.784 177.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 74.8 mt -69.39 130.38 42.38 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 122.918 0.487 . . . . 62.43 111.526 -174.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 92.1 mt -84.84 139.02 37.31 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.53 0.732 . . . . 74.42 110.128 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -65.38 116.54 3.95 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 123.193 2.595 . . . . 73.21 112.021 -175.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.543 -0.741 . . . . 73.32 109.415 -178.185 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.51 ' HB3' ' HA ' ' A' ' 100' ' ' THR . 0.5 OUTLIER . . . . . 0 CA--C 1.554 1.116 0 N-CA-C 109.058 -0.719 . . . . 65.24 109.058 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -66.62 -49.27 1.73 Allowed 'Trans proline' 0 C--N 1.385 2.498 0 C-N-CA 122.612 2.208 . . . . 73.13 111.691 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.512 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.4 tp -179.52 154.36 0.61 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.627 1.571 . . . . 74.14 106.945 -175.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.512 ' H ' HD12 ' A' ' 97' ' ' LEU . 7.4 tp 53.04 -75.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 125.976 1.71 . . . . 74.11 111.551 -174.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.67 ' HA ' HD11 ' A' ' 119' ' ' LEU . 85.4 t80 -50.54 129.18 21.84 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.097 1.759 . . . . 74.31 112.341 171.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.531 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 55.2 m -142.18 105.99 5.65 Favored Pre-proline 0 N--CA 1.471 0.587 0 C-N-CA 124.105 0.962 . . . . 74.21 108.442 172.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -76.85 87.55 1.47 Allowed 'Trans proline' 0 C--N 1.366 1.453 0 C-N-CA 121.517 1.478 . . . . 64.43 112.42 -170.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 CA--C 1.546 0.791 0 CA-C-N 114.735 -1.12 . . . . 74.23 109.995 177.425 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.432 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 94.2 mtt180 . . . . . 0 N--CA 1.476 0.862 0 N-CA-C 110.077 -0.342 . . . . 73.15 110.077 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.7 105.95 18.17 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 107.345 -1.354 . . . . 65.31 107.345 -177.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.67 HD11 ' HA ' ' A' ' 99' ' ' PHE . 12.5 mt -92.87 108.96 20.4 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 107.26 -1.385 . . . . 75.13 107.26 -176.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 74.4 ttt180 -119.33 105.87 11.74 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.131 0.972 . . . . 73.14 108.663 -175.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.58 145.23 40.34 Favored 'General case' 0 C--O 1.242 0.67 0 C-N-CA 123.722 0.809 . . . . 74.14 109.567 -174.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -76.66 137.59 39.52 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.536 -0.542 . . . . 64.02 109.536 175.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 19.9 tp -101.62 105.36 40.27 Favored Pre-proline 0 CA--C 1.542 0.671 0 C-N-CA 123.992 0.917 . . . . 71.31 110.201 -178.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -60.64 122.78 11.8 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.488 2.125 . . . . 74.11 110.342 169.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.474 HD21 HD11 ' A' ' 149' ' ' ILE . 25.3 tp -147.83 133.79 19.17 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.889 -0.782 . . . . 73.33 108.889 -175.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.9 p -81.21 163.66 22.86 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 110.129 -0.323 . . . . 73.25 110.129 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.0 mt -61.92 -32.7 73.13 Favored 'General case' 0 N--CA 1.482 1.168 0 C-N-CA 123.607 0.763 . . . . 74.51 110.971 179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -70.72 -50.23 38.51 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 114.987 -1.006 . . . . 75.15 109.406 -177.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -70.13 -26.65 64.05 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.794 0.837 . . . . 75.33 111.859 -179.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.75 -40.31 69.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.216 0.606 . . . . 75.43 110.744 174.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -64.43 -46.4 83.36 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.911 0.884 . . . . 64.44 110.698 175.504 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -63.36 -49.67 72.96 Favored 'General case' 0 C--N 1.351 0.671 0 O-C-N 123.71 0.631 . . . . 73.22 110.362 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.486 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 56.63 70.39 0.99 Allowed Glycine 0 C--N 1.349 1.276 0 O-C-N 124.128 0.893 . . . . 75.11 112.771 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -121.06 -121.37 2.81 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.35 -1.1 . . . . 72.4 110.35 174.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.551 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 7.0 mp0 -99.69 154.96 17.88 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 123.143 0.577 . . . . 74.31 109.528 172.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.437 ' HB2' HD13 ' A' ' 149' ' ' ILE . 14.0 tpt180 -137.04 122.55 19.61 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 108.162 -1.051 . . . . 75.42 108.162 178.479 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.1 t -74.34 119.44 21.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 O-C-N 123.577 0.548 . . . . 75.14 109.886 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.498 HG21 HD12 ' A' ' 98' ' ' LEU . 28.5 m -122.68 147.38 26.89 Favored 'Isoleucine or valine' 0 C--O 1.251 1.147 0 C-N-CA 124.769 1.228 . . . . 75.43 109.067 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -100.91 127.83 47.22 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.987 0.915 . . . . 74.11 109.268 -177.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.557 HG21 ' HB2' ' A' ' 99' ' ' PHE . 3.1 p -142.66 103.67 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 123.287 0.635 . . . . 72.54 111.118 -174.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 55.38 29.69 13.55 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 124.448 1.099 . . . . 64.41 113.14 172.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.65 26.34 10.85 Favored Glycine 0 C--N 1.348 1.248 0 CA-C-N 116.36 -0.382 . . . . 61.42 112.658 179.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.474 ' HB2' HG13 ' A' ' 140' ' ' VAL . 54.3 mmt-85 -131.87 136.18 47.25 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.842 0.857 . . . . 72.42 110.049 -178.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 16.1 ttp180 -95.67 105.88 17.92 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 107.917 -1.142 . . . . 75.33 107.917 171.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 33.0 m -125.44 151.37 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 109.915 -0.402 . . . . 71.45 109.915 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.551 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 34.6 p -106.11 117.65 34.58 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.296 0.638 . . . . 74.15 109.924 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.2 p -98.8 133.35 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 108.664 -0.865 . . . . 75.22 108.664 176.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.4 ttt85 -82.4 125.74 31.39 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.203 0.525 . . . . 74.24 109.754 -178.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.486 HG13 ' HA2' ' A' ' 133' ' ' GLY . 3.3 pt -107.56 145.8 32.04 Favored Pre-proline 0 CA--C 1.557 1.219 0 C-N-CA 124.882 1.273 . . . . 72.23 108.686 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.436 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 56.7 Cg_endo -71.08 146.56 52.38 Favored 'Trans proline' 0 CA--C 1.566 2.099 0 C-N-CA 122.161 1.907 . . . . 72.31 112.823 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -66.79 134.95 36.57 Favored 'Trans proline' 0 C--N 1.38 2.23 0 C-N-CA 123.172 2.581 . . . . 64.1 111.962 172.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.16 28.03 62.95 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-N 115.724 -0.671 . . . . 74.11 113.024 -177.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.436 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 14.7 p -78.19 147.2 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.256 -0.646 . . . . 74.13 109.256 177.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -129.61 177.23 7.37 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 122.011 0.91 . . . . 75.31 113.085 -167.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.5 tp10 -62.58 121.4 13.23 Favored 'General case' 0 C--O 1.241 0.644 0 CA-C-N 113.463 -1.699 . . . . 74.04 110.414 174.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.73 2.83 69.21 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 115.892 -0.595 . . . . 74.52 112.822 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 59.5 m -86.39 122.04 29.79 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 109.458 -0.571 . . . . 73.33 109.458 174.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.5 p -101.23 126.35 55.05 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.232 0.539 . . . . 74.41 110.051 178.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 60.7 mt -93.94 102.92 14.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.941 1.296 . . . . 70.41 107.914 176.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -98.38 121.62 40.53 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.956 -0.387 . . . . 75.33 109.956 -179.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 4.2 t -115.47 99.62 52.64 Favored Pre-proline 0 CA--C 1.556 1.192 0 N-CA-C 107.692 -1.225 . . . . 75.03 107.692 173.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -68.25 131.39 23.36 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 123.098 2.532 . . . . 61.32 113.63 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 75.87 24.07 70.51 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.085 -0.962 . . . . 64.23 113.784 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.7 tpt -126.28 -9.2 6.4 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 123.62 0.768 . . . . 72.43 111.21 -176.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -71.11 -94.7 0.07 OUTLIER Glycine 0 C--N 1.347 1.172 0 CA-C-O 120.175 -0.236 . . . . 74.34 112.848 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -68.84 106.96 1.91 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.966 -0.352 . . . . 74.3 112.433 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -72.43 137.46 46.48 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.647 0.779 . . . . 71.23 111.013 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.2 -163.75 32.55 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 116.006 -0.543 . . . . 75.42 112.157 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -72.94 -43.95 8.17 Favored Pre-proline 0 CA--C 1.565 1.537 0 CA-C-O 118.968 -0.539 . . . . 73.3 110.725 174.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -93.34 108.37 0.18 Allowed 'Trans proline' 0 C--N 1.386 2.511 0 C-N-CA 122.081 1.854 . . . . 73.32 111.254 163.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -82.74 137.67 8.99 Favored 'Trans proline' 0 C--N 1.372 1.807 0 C-N-CA 122.361 2.041 . . . . 70.1 112.243 -178.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . 0.432 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -99.04 179.93 31.36 Favored Glycine 0 C--N 1.343 0.935 0 CA-C-N 115.933 -0.576 . . . . 63.22 113.14 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -87.88 149.03 24.34 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 122.844 0.458 . . . . 74.0 111.239 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.474 HD23 HD11 ' A' ' 98' ' ' LEU . 41.8 tp -112.42 128.64 56.37 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 122.844 0.458 . . . . 74.55 109.915 177.301 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 74.3 mt -127.46 115.48 18.96 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 124.196 0.998 . . . . 72.51 109.157 178.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.465 HD23 HD13 ' A' ' 98' ' ' LEU . 72.9 mt -117.07 103.42 10.22 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 123.178 0.591 . . . . 75.32 110.489 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.6 t -89.79 98.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.072 0 C-N-CA 122.524 0.33 . . . . 73.0 110.331 -173.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.8 t -60.09 113.87 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 C-N-CA 124.203 1.001 . . . . 64.01 112.694 -173.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 22.1 mmm180 -105.0 109.14 21.01 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.126 1.77 . . . . 73.03 108.649 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 86.6 mt -71.87 119.0 15.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.387 0.275 . . . . 74.14 110.449 179.152 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 78.4 mt -79.05 147.35 69.63 Favored Pre-proline 0 CA--C 1.545 0.784 0 C-N-CA 123.693 0.797 . . . . 65.15 110.79 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -61.1 110.0 0.79 Allowed 'Trans proline' 0 C--N 1.373 1.82 0 C-N-CA 123.368 2.712 . . . . 75.33 111.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 77.6 t60 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.733 -0.651 . . . . 63.24 110.289 178.507 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.562 1.426 0 N-CA-C 114.26 1.207 . . . . 74.52 114.26 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.66 -66.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.388 2.65 0 C-N-CA 122.738 2.292 . . . . 74.12 111.477 174.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.491 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.2 tp -178.89 149.44 0.45 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 125.236 1.414 . . . . 74.42 107.809 175.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.648 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 13.2 tp 56.99 8.6 0.52 Allowed 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 124.422 1.089 . . . . 74.44 112.494 -174.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.593 ' HA ' HD13 ' A' ' 119' ' ' LEU . 77.2 t80 -150.87 124.49 9.05 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 123.927 0.891 . . . . 74.2 109.261 -165.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.529 ' H ' HD22 ' A' ' 119' ' ' LEU . 95.7 m -150.5 95.24 3.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 C-N-CA 124.639 1.175 . . . . 75.11 108.155 176.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.6 104.65 1.16 Allowed 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 121.921 1.748 . . . . 73.42 110.804 -176.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.8 m . . . . . 0 C--O 1.244 0.789 0 C-N-CA 123.793 0.837 . . . . 75.51 109.466 178.307 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 24.2 ptt180 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.687 0.279 . . . . 73.23 110.922 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -92.61 114.71 27.34 Favored 'General case' 0 C--N 1.348 0.519 0 N-CA-C 107.686 -1.227 . . . . 74.42 107.686 175.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.593 HD13 ' HA ' ' A' ' 99' ' ' PHE . 31.2 mt -93.44 107.22 19.1 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 106.991 -1.485 . . . . 75.14 106.991 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.493 ' H ' ' HB ' ' A' ' 100' ' ' THR . 19.6 ttt180 -116.0 105.83 13.09 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.03 -0.73 . . . . 74.14 109.03 178.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 141.36 48.17 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.829 0.852 . . . . 71.13 108.772 -177.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.14 129.6 34.62 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.372 -0.603 . . . . 73.13 109.372 174.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.462 HD13 HD12 ' A' ' 176' ' ' LEU . 1.7 tt -101.6 109.64 59.75 Favored Pre-proline 0 CA--C 1.55 0.965 0 C-N-CA 123.479 0.712 . . . . 73.23 109.379 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.41 ' HA ' ' HB2' ' A' ' 179' ' ' ARG . 52.3 Cg_endo -67.4 121.82 8.98 Favored 'Trans proline' 0 C--N 1.377 2.079 0 C-N-CA 122.559 2.173 . . . . 71.41 110.954 172.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.1 tp -140.67 135.09 31.29 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 108.805 -0.813 . . . . 75.02 108.805 -173.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.5 p -76.15 167.12 22.44 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.892 -0.41 . . . . 74.52 109.892 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.502 HD13 ' HB2' ' A' ' 183' ' ' HIS . 86.6 mt -66.77 -31.11 71.54 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.033 0.533 . . . . 74.14 110.644 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -71.11 -49.49 43.79 Favored 'General case' 0 C--O 1.22 -0.497 0 CA-C-N 114.701 -1.136 . . . . 75.53 109.135 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -74.35 -19.6 60.39 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.405 0.682 . . . . 71.34 111.452 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.54 -45.21 72.78 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.138 0.575 . . . . 72.23 109.853 167.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.03 -41.37 95.32 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 123.938 0.895 . . . . 75.11 111.006 176.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -75.48 -39.76 58.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.131 0.572 . . . . 74.33 110.679 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.25 -114.11 6.26 Favored Glycine 0 C--N 1.345 1.081 0 CA-C-N 115.273 -0.876 . . . . 73.11 111.207 -172.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.12 -132.71 39.58 Favored Glycine 0 C--N 1.351 1.382 0 CA-C-O 119.668 -0.518 . . . . 75.15 112.413 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.569 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 10.3 mp0 -105.75 158.22 16.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.847 0.859 . . . . 75.14 109.958 176.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.645 ' HB2' HD13 ' A' ' 149' ' ' ILE . 23.4 tpt85 -133.91 120.87 20.92 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.733 0.813 . . . . 72.52 109.063 178.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.6 t -74.88 109.08 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 C-N-CA 124.165 0.986 . . . . 73.51 109.626 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.491 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 26.1 m -128.03 149.15 32.68 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 C-N-CA 124.075 0.95 . . . . 73.12 110.098 -174.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -97.73 103.75 15.72 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 123.649 0.78 . . . . 75.41 111.322 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.648 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.3 p -103.94 102.26 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.103 0.961 . . . . 71.45 109.569 -179.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.93 27.74 17.16 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 124.321 1.049 . . . . 63.51 112.201 177.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.54 -13.09 59.78 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-O 119.317 -0.713 . . . . 75.11 114.227 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.23 152.25 19.32 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 118.164 0.982 . . . . 74.11 110.093 177.165 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 -100.17 109.01 21.27 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.587 0.755 . . . . 73.41 109.602 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 86.3 t -122.66 136.84 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 N-CA-C 108.572 -0.899 . . . . 75.44 108.572 175.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.569 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 77.5 p -95.5 113.09 24.72 Favored 'General case' 0 C--O 1.242 0.658 0 N-CA-C 109.168 -0.679 . . . . 60.53 109.168 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -97.84 136.48 28.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 123.57 0.748 . . . . 55.44 109.216 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -81.03 127.27 32.41 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.369 0.605 . . . . 64.12 110.568 -176.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.645 HD13 ' HB2' ' A' ' 136' ' ' ARG . 7.5 pt -118.07 145.32 36.62 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.658 1.583 . . . . 73.11 108.43 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.04 138.2 27.8 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.456 2.104 . . . . 73.5 112.599 178.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.73 143.66 51.7 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.336 2.024 . . . . 74.13 111.544 169.012 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.0 26.48 58.11 Favored Glycine 0 C--N 1.343 0.932 0 CA-C-N 116.278 -0.419 . . . . 60.32 112.897 -173.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.6 p -87.58 150.85 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 C-N-CA 123.2 0.6 . . . . 75.33 109.869 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 42.6 mtp180 -123.16 177.86 5.36 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 121.722 0.773 . . . . 75.41 112.358 -177.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -58.37 137.27 57.35 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 113.282 -1.781 . . . . 75.41 111.038 174.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.76 -14.15 38.55 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-O 119.352 -0.693 . . . . 30.23 113.976 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 63.5 m -71.11 118.37 13.81 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 117.558 0.679 . . . . 74.24 109.593 -179.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.65 132.52 42.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 122.99 0.516 . . . . 74.31 109.716 -179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.06 104.65 16.93 Favored 'Isoleucine or valine' 0 C--O 1.241 0.606 0 C-N-CA 124.876 1.27 . . . . 72.35 107.588 -177.456 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.426 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 64.7 ttt180 -91.61 112.64 24.65 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 109.94 -0.393 . . . . 74.33 109.94 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 8.6 t -104.11 100.12 19.78 Favored Pre-proline 0 CA--C 1.557 1.219 0 N-CA-C 106.989 -1.485 . . . . 74.21 106.989 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -66.63 128.83 19.8 Favored 'Trans proline' 0 C--N 1.375 1.943 0 C-N-CA 122.878 2.385 . . . . 74.32 113.096 -174.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.56 22.78 78.13 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.939 -0.573 . . . . 73.54 114.207 176.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.1 tpt -107.45 -23.96 11.99 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 123.385 0.674 . . . . 71.15 110.969 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -66.45 -84.14 0.1 OUTLIER Glycine 0 C--N 1.344 1.024 0 CA-C-N 116.359 -0.382 . . . . 73.2 112.865 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -71.46 93.09 0.52 Allowed Glycine 0 C--N 1.346 1.109 0 N-CA-C 111.466 -0.653 . . . . 61.3 111.466 173.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.4 mm-40 -78.78 143.61 35.94 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.757 0.823 . . . . 62.55 111.756 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.13 -168.24 25.78 Favored Glycine 0 C--O 1.241 0.583 0 CA-C-N 114.8 -1.091 . . . . 65.0 110.377 -177.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 17.3 m120 -62.16 -44.37 88.79 Favored Pre-proline 0 CA--C 1.562 1.416 0 CA-C-O 118.655 -0.688 . . . . 75.43 110.82 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -82.96 114.43 2.26 Favored 'Trans proline' 0 C--N 1.394 2.972 0 C-N-CA 121.872 1.714 . . . . 74.34 111.717 167.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -82.94 150.27 14.03 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.222 1.948 . . . . 73.05 113.059 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -132.84 151.66 20.07 Favored Glycine 0 N--CA 1.473 1.123 0 N-CA-C 110.326 -1.109 . . . . 42.24 110.326 170.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.58 156.06 39.39 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.489 0.715 . . . . 63.22 112.49 -175.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.435 HD22 HD13 ' A' ' 98' ' ' LEU . 65.5 tp -116.22 127.94 55.19 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 108.428 -0.953 . . . . 75.51 108.428 172.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 54.5 mt -128.26 118.34 23.11 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 124.825 1.25 . . . . 72.32 108.689 -178.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.462 HD12 HD13 ' A' ' 123' ' ' LEU . 86.1 mt -120.68 103.31 9.02 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 123.061 0.545 . . . . 71.31 111.043 -178.298 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.9 t -85.43 96.02 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.587 -0.523 . . . . 74.52 109.587 -176.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.4 t -55.5 126.76 13.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.921 0.888 . . . . 71.34 111.807 -178.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . 0.41 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 31.6 mmt180 -112.48 113.12 25.14 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 125.19 1.396 . . . . 74.34 107.687 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 50.3 mt -74.56 119.53 18.88 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.255 -0.646 . . . . 75.43 109.255 176.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 67.0 mt -82.33 131.24 56.46 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 108.317 -0.994 . . . . 72.25 108.317 176.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -68.31 143.03 56.87 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.961 2.441 . . . . 71.11 112.284 -174.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.502 ' HB2' HD13 ' A' ' 127' ' ' LEU . 47.0 m80 . . . . . 0 N--CA 1.485 1.319 0 C-N-CA 124.03 0.932 . . . . 73.22 108.806 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.425 ' HB2' ' O ' ' A' ' 99' ' ' PHE . 2.6 pt? . . . . . 0 CA--C 1.563 1.452 0 N-CA-C 112.238 0.459 . . . . 74.11 112.238 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 10.3 Cg_endo -86.75 -79.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 123.009 2.473 . . . . 75.22 111.248 177.691 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.475 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.5 tp -157.83 142.23 16.18 Favored 'General case' 0 C--N 1.348 0.521 0 N-CA-C 108.292 -1.003 . . . . 64.45 108.292 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.697 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 5.2 tp 57.09 7.75 0.46 Allowed 'General case' 0 CA--C 1.57 1.713 0 C-N-CA 126.096 1.758 . . . . 74.32 113.172 -173.099 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.614 ' HA ' HD12 ' A' ' 119' ' ' LEU . 86.7 t80 -139.12 128.79 24.63 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.825 0.85 . . . . 74.12 109.333 -171.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.524 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 86.2 m -153.05 98.62 2.76 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 124.192 0.997 . . . . 74.44 109.342 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -72.16 83.18 1.23 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.444 2.096 . . . . 75.51 112.242 -173.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 20.6 m . . . . . 0 N--CA 1.474 0.75 0 CA-C-N 115.406 -0.816 . . . . 75.13 109.691 175.385 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.482 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.0 OUTLIER . . . . . 0 N--CA 1.479 0.992 0 N-CA-C 110.209 -0.293 . . . . 75.04 110.209 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -95.35 107.32 19.44 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 107.086 -1.45 . . . . 73.45 107.086 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.614 HD12 ' HA ' ' A' ' 99' ' ' PHE . 15.7 mt -92.76 108.46 20.0 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 107.593 -1.262 . . . . 73.11 107.593 -174.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.504 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 20.8 ttt180 -106.17 104.71 14.47 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 109.049 -0.723 . . . . 73.12 109.049 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -123.19 134.34 54.17 Favored 'General case' 0 C--O 1.237 0.411 0 N-CA-C 108.929 -0.767 . . . . 61.33 108.929 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -80.87 121.78 26.39 Favored 'General case' 0 C--O 1.241 0.637 0 N-CA-C 108.254 -1.017 . . . . 71.33 108.254 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.51 HD23 ' HG2' ' A' ' 136' ' ' ARG . 5.5 tt -99.06 109.74 55.26 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 108.159 -1.052 . . . . 71.14 108.159 -171.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -72.75 115.23 4.26 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 121.904 1.736 . . . . 64.13 110.443 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.551 HD23 HD13 ' A' ' 149' ' ' ILE . 29.0 tp -128.81 137.51 51.55 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.601 0.76 . . . . 73.32 109.498 -173.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 74.3 p -79.87 162.62 24.91 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.11 -0.33 . . . . 53.22 110.11 -178.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.97 -26.95 65.3 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.393 0.677 . . . . 74.21 110.962 -178.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -68.55 -50.31 52.82 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 114.934 -1.03 . . . . 62.11 109.093 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 -73.63 -21.23 60.36 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 114.991 -1.004 . . . . 74.35 112.324 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.09 -44.89 64.76 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.991 0.517 . . . . 72.22 109.74 170.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -62.13 -42.35 99.16 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.666 1.186 . . . . 72.34 110.921 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -74.42 -48.8 25.51 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.607 0.363 . . . . 74.04 110.427 -178.493 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.637 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 62.49 52.34 49.73 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 123.997 0.81 . . . . 74.11 113.853 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -101.37 -130.49 7.06 Favored Glycine 0 C--N 1.347 1.148 0 N-CA-C 111.452 -0.659 . . . . 62.51 111.452 177.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -97.28 158.61 15.37 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.072 0.549 . . . . 72.53 110.149 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.51 ' HG2' HD23 ' A' ' 123' ' ' LEU . 41.0 tpt85 -136.84 119.69 16.3 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.214 -0.903 . . . . 74.52 108.975 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.8 t -86.39 105.96 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 123.397 0.679 . . . . 73.13 109.643 -177.143 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.495 HG23 HD11 ' A' ' 98' ' ' LEU . 34.3 m -117.01 162.6 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.001 1.321 . . . . 70.3 108.345 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -123.98 112.69 17.49 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 122.497 0.319 . . . . 73.45 111.263 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.697 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.9 p -106.46 105.44 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 124.469 1.107 . . . . 75.4 109.965 -178.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 58.02 28.74 16.71 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.633 0.773 . . . . 71.51 112.122 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.25 2.76 55.74 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-O 119.566 -0.574 . . . . 75.24 114.069 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.6 mtt180 -100.73 121.8 42.27 Favored 'General case' 0 N--CA 1.486 1.349 0 CA-C-N 117.735 0.767 . . . . 74.02 110.724 -178.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -74.96 126.32 30.75 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.463 0.705 . . . . 75.42 109.319 172.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 3.2 p -148.79 131.0 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.068 0.547 . . . . 74.32 110.464 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 12.5 p -91.42 105.85 18.07 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 123.547 0.739 . . . . 74.32 109.647 176.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.8 p -99.35 132.56 44.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 123.906 0.882 . . . . 75.01 109.036 176.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 58.1 ttt85 -81.92 129.16 34.68 Favored 'General case' 0 C--O 1.242 0.667 0 CA-C-O 121.59 0.709 . . . . 75.35 110.696 -176.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.551 HD13 HD23 ' A' ' 125' ' ' LEU . 2.4 pt -98.56 145.2 29.48 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.637 1.575 . . . . 71.14 108.734 174.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.91 143.88 62.44 Favored 'Trans proline' 0 CA--C 1.562 1.906 0 C-N-CA 121.986 1.791 . . . . 74.21 112.215 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.637 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 30.5 Cg_endo -62.27 130.16 29.45 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.18 2.586 . . . . 74.31 111.787 175.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 64.76 46.77 88.76 Favored Glycine 0 C--N 1.344 1.021 0 O-C-N 123.966 0.791 . . . . 72.24 111.614 -175.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.424 HG23 HG21 ' A' ' 178' ' ' VAL . 8.2 p -75.72 145.6 10.41 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 CA-C-O 121.187 0.517 . . . . 74.42 110.256 179.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.4 mtp180 -104.07 169.78 8.3 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.19 0.996 . . . . 75.2 111.974 -172.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.6 tp10 -68.19 134.6 50.72 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-N 113.834 -1.53 . . . . 74.22 110.331 176.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.05 2.79 66.81 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-O 118.968 -0.907 . . . . 74.13 114.395 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.7 m -71.13 117.63 12.89 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 118.213 1.006 . . . . 74.02 108.869 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.7 p -93.37 132.25 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 109.34 -0.615 . . . . 74.4 109.34 -178.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 50.0 mt -105.93 104.12 16.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 107.807 -1.183 . . . . 71.45 107.807 -178.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 36.1 ttm180 -91.46 104.74 17.22 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 109.632 -0.507 . . . . 73.23 109.632 177.521 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.4 t -97.12 111.58 58.35 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 107.361 -1.348 . . . . 74.3 107.361 174.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -69.86 124.62 11.22 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 123.17 2.58 . . . . 72.12 113.46 -170.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 69.38 16.01 70.96 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 114.743 0.657 . . . . 70.03 114.743 173.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.9 mmt -113.83 12.64 18.26 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 123.317 0.647 . . . . 74.03 111.659 -177.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -96.43 -102.17 2.01 Favored Glycine 0 C--N 1.338 0.661 0 O-C-N 123.472 0.483 . . . . 71.14 112.588 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . 0.482 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -65.48 121.47 20.41 Favored Glycine 0 C--N 1.353 1.523 0 O-C-N 123.948 0.44 . . . . 64.03 113.587 -173.194 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -71.22 146.95 48.71 Favored 'General case' 0 C--O 1.246 0.92 0 C-N-CA 123.414 0.686 . . . . 74.22 110.952 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 155.32 -169.38 33.26 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.025 -0.989 . . . . 75.34 111.093 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -74.34 -48.91 5.46 Favored Pre-proline 0 CA--C 1.566 1.572 0 CA-C-O 118.621 -0.704 . . . . 73.34 109.378 174.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -83.55 111.59 1.79 Allowed 'Trans proline' 0 C--N 1.394 2.962 0 C-N-CA 121.641 1.56 . . . . 72.32 110.264 164.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -69.52 128.89 16.91 Favored 'Trans proline' 0 C--N 1.369 1.64 0 C-N-CA 122.261 1.974 . . . . 72.3 111.854 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -90.99 166.78 31.31 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-O 119.873 -0.404 . . . . 73.53 112.129 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -82.45 158.68 23.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 122.989 0.516 . . . . 75.31 111.11 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.554 HD21 HD13 ' A' ' 98' ' ' LEU . 40.9 tp -118.29 131.55 56.34 Favored 'General case' 0 C--O 1.223 -0.3 0 C-N-CA 123.69 0.796 . . . . 74.34 109.463 -178.001 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 87.0 mt -128.8 125.54 38.0 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.028 0.931 . . . . 73.23 109.804 -177.617 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 80.8 mt -125.27 103.03 7.73 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.221 0.609 . . . . 74.1 111.124 178.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 39.4 t -85.59 94.34 4.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.306 -0.998 . . . . 72.32 108.306 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.424 HG21 HG23 ' A' ' 153' ' ' VAL . 98.7 t -58.49 114.83 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 C-N-CA 123.739 0.816 . . . . 73.03 111.049 -177.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -106.44 104.41 14.09 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 124.506 1.123 . . . . 74.45 108.751 178.284 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 72.3 mt -68.94 105.05 2.25 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 109.669 -0.493 . . . . 71.44 109.669 178.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.3 mt -60.74 149.66 78.84 Favored Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 124.295 1.038 . . . . 75.24 111.399 175.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -70.73 165.86 30.68 Favored 'Trans proline' 0 C--N 1.373 1.844 0 C-N-CA 122.314 2.009 . . . . 71.12 111.311 174.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 . . . . . 0 CA--C 1.552 1.039 0 N-CA-C 108.907 -0.775 . . . . 72.34 108.907 174.33 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.551 0.996 0 CA-C-O 119.822 -0.132 . . . . 74.34 111.004 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.1 -67.12 0.03 OUTLIER 'Trans proline' 0 C--N 1.382 2.308 0 C-N-CA 122.055 1.837 . . . . 73.53 110.969 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.514 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 5.7 tp -171.6 143.62 1.76 Allowed 'General case' 0 C--N 1.35 0.62 0 C-N-CA 124.202 1.001 . . . . 73.52 108.457 176.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.658 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 6.1 tp 59.36 4.22 0.47 Allowed 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 125.628 1.571 . . . . 72.31 113.158 -173.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.581 ' HB2' HG22 ' A' ' 140' ' ' VAL . 82.7 t80 -139.95 130.43 25.51 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 107.789 -1.189 . . . . 74.54 107.789 -171.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.478 HG23 HG11 ' A' ' 102' ' ' VAL . 75.9 m -149.45 98.02 3.49 Favored Pre-proline 0 N--CA 1.469 0.483 0 O-C-N 124.327 1.017 . . . . 65.52 109.641 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -70.88 80.8 1.17 Allowed 'Trans proline' 0 C--N 1.367 1.516 0 C-N-CA 122.682 2.255 . . . . 74.44 112.679 -176.089 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.478 HG11 HG23 ' A' ' 100' ' ' THR . 29.9 m . . . . . 0 N--CA 1.474 0.726 0 C-N-CA 124.586 1.154 . . . . 72.32 109.342 171.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.426 ' H ' ' HA3' ' A' ' 166' ' ' GLY . 13.7 mtm180 . . . . . 0 N--CA 1.478 0.957 0 N-CA-C 109.323 -0.621 . . . . 71.22 109.323 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -103.54 104.24 14.29 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.037 -1.468 . . . . 73.11 107.037 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.507 HD11 ' HA ' ' A' ' 99' ' ' PHE . 12.9 mt -93.55 110.26 21.85 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.846 -1.168 . . . . 74.44 107.846 -174.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.437 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 73.6 ttt-85 -107.49 104.53 14.12 Favored 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 108.732 -0.84 . . . . 75.05 108.732 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -121.11 126.93 51.02 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.692 0.797 . . . . 72.13 109.42 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -73.26 118.25 15.99 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 123.54 0.736 . . . . 72.13 109.563 176.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 5.3 tt -100.83 111.15 62.7 Favored Pre-proline 0 CA--C 1.549 0.934 0 C-N-CA 123.938 0.895 . . . . 73.41 108.849 -175.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.04 126.03 13.27 Favored 'Trans proline' 0 C--N 1.379 2.168 0 C-N-CA 122.555 2.17 . . . . 72.52 111.43 175.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.449 HD23 HD12 ' A' ' 149' ' ' ILE . 15.9 tp -148.15 133.83 18.87 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.231 -0.655 . . . . 75.51 109.231 -173.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.8 p -87.66 171.62 10.32 Favored 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 118.084 0.402 . . . . 62.45 110.312 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.21 -35.66 81.07 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.595 0.758 . . . . 75.41 111.362 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -63.96 -50.56 68.13 Favored 'General case' 0 C--N 1.35 0.61 0 CA-C-N 114.718 -1.128 . . . . 74.23 109.258 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 22.3 mm-40 -73.7 -24.69 59.97 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-N 114.58 -1.191 . . . . 74.34 111.334 -176.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.42 -38.91 81.66 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.212 -0.904 . . . . 71.4 110.345 173.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -72.66 -39.19 67.33 Favored 'General case' 0 CA--C 1.547 0.84 0 CA-C-N 115.473 -0.785 . . . . 73.43 110.423 176.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.71 -48.85 67.95 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 122.34 0.256 . . . . 75.4 111.045 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.568 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.25 59.37 10.98 Favored Glycine 0 C--N 1.345 1.061 0 O-C-N 124.015 0.822 . . . . 51.23 113.567 175.241 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.416 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -121.69 -155.64 9.51 Favored Glycine 0 C--N 1.34 0.783 0 N-CA-C 111.64 -0.584 . . . . 71.4 111.64 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.614 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.0 mp0 -75.12 122.74 24.05 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 109.929 -0.397 . . . . 72.43 109.929 179.07 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.438 ' HB2' HD11 ' A' ' 149' ' ' ILE . 12.8 tpt180 -109.59 119.53 39.7 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.391 -1.337 . . . . 75.51 107.391 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 50.7 t -83.1 106.63 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.476 0.71 . . . . 73.41 109.191 -172.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.514 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 33.4 m -116.85 163.24 14.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.887 0 C-N-CA 125.551 1.54 . . . . 74.24 108.806 -177.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -122.84 111.56 16.82 Favored 'General case' 0 N--CA 1.481 1.097 0 O-C-N 121.748 -0.595 . . . . 63.52 110.667 -178.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.658 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.4 p -104.14 109.74 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 125.015 1.326 . . . . 74.34 109.471 -177.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.94 22.39 13.02 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 123.837 0.855 . . . . 71.13 112.76 176.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.95 -13.83 58.88 Favored Glycine 0 C--N 1.352 1.439 0 CA-C-O 120.016 -0.325 . . . . 63.22 113.413 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 26.1 tpt180 -90.72 127.55 36.35 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 123.803 0.841 . . . . 63.12 109.401 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 15.5 tpp85 -89.2 130.1 35.67 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.577 -0.527 . . . . 74.32 109.577 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.8 p -147.47 148.98 15.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 C-N-CA 124.193 0.997 . . . . 75.55 109.555 -179.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.614 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 42.9 p -101.17 109.27 21.13 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.371 0.669 . . . . 73.43 110.156 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.77 124.83 53.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 123.316 0.646 . . . . 74.44 109.37 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 41.5 ttt180 -71.83 127.93 34.13 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 120.916 0.389 . . . . 75.54 110.494 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.568 HG13 ' HA2' ' A' ' 133' ' ' GLY . 2.7 pt -100.99 147.66 34.01 Favored Pre-proline 0 CA--C 1.558 1.265 0 C-N-CA 124.956 1.302 . . . . 74.02 108.223 174.136 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.11 135.61 19.11 Favored 'Trans proline' 0 CA--C 1.558 1.7 0 C-N-CA 122.36 2.04 . . . . 75.45 112.087 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.81 135.43 48.34 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.407 2.071 . . . . 70.43 111.81 173.187 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.54 62.56 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-N 115.669 -0.696 . . . . 62.03 112.42 -174.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.485 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 11.0 p -73.4 147.44 9.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 N-CA-C 109.273 -0.64 . . . . 74.21 109.273 178.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 56.1 mtp85 -138.89 178.95 6.78 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.706 0.765 . . . . 73.55 111.587 -173.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.01 120.0 6.76 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 113.348 -1.751 . . . . 72.35 110.578 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.23 -10.51 67.51 Favored Glycine 0 C--N 1.341 0.817 0 O-C-N 124.28 0.987 . . . . 65.01 113.797 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.3 m -70.3 121.54 17.84 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.416 -0.587 . . . . 74.33 109.416 178.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -105.01 122.45 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 109.41 -0.589 . . . . 74.21 109.41 -178.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.614 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 32.3 mt -91.53 101.95 13.02 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 107.782 -1.192 . . . . 64.44 107.782 -178.103 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.535 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 48.7 ttp85 -96.02 110.25 22.51 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.889 -0.411 . . . . 54.13 109.889 -176.58 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.6 t -103.96 96.46 9.39 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 107.636 -1.246 . . . . 74.43 107.636 170.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -65.78 127.0 16.96 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.815 2.344 . . . . 74.11 112.006 -176.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.9 -23.01 37.71 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-O 119.775 -0.459 . . . . 61.44 113.758 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.0 tpt -76.48 -32.5 58.38 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.255 0.622 . . . . 73.41 111.94 -174.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -65.57 -81.55 0.13 Allowed Glycine 0 CA--C 1.536 1.399 0 O-C-N 123.606 0.566 . . . . 73.12 113.384 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . 0.426 ' HA3' ' H ' ' A' ' 117' ' ' ARG . . . -65.35 92.68 0.15 Allowed Glycine 0 C--N 1.345 1.077 0 C-N-CA 123.017 0.341 . . . . 73.52 113.347 174.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.9 mm-40 -91.2 153.08 20.26 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.266 1.027 . . . . 73.55 110.044 170.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 137.44 -62.94 0.58 Allowed Glycine 0 C--N 1.338 0.655 0 N-CA-C 111.203 -0.759 . . . . 54.04 111.203 178.364 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.535 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 24.3 t-20 -155.89 -56.48 0.02 OUTLIER Pre-proline 0 CA--C 1.567 1.601 0 CA-C-O 118.184 -0.912 . . . . 75.23 110.643 179.426 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.535 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 57.0 Cg_endo -90.04 113.71 0.52 Allowed 'Trans proline' 0 C--N 1.402 3.38 0 C-N-CA 122.769 2.313 . . . . 75.45 110.633 174.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -64.84 123.09 11.13 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 122.417 2.078 . . . . 74.55 111.059 -176.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -111.53 160.84 13.0 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 120.013 -0.326 . . . . 73.4 112.393 -176.403 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -77.68 139.65 39.47 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.06 0.544 . . . . 71.24 111.159 -174.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.535 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 64.2 tp -101.31 126.99 48.12 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.792 -1.188 . . . . 75.41 107.792 171.536 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.437 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 75.2 mt -127.16 103.18 7.29 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 124.695 1.198 . . . . 75.24 109.118 -175.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.614 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 88.0 mt -100.23 101.47 12.5 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 122.784 0.434 . . . . 74.12 110.02 178.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.1 t -86.81 99.52 8.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 108.799 -0.815 . . . . 75.3 108.799 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.91 114.26 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 CA-C-N 115.156 -0.929 . . . . 73.24 111.632 -173.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 6.3 mmp_? -99.36 113.16 25.33 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 125.142 1.377 . . . . 73.33 108.528 172.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.436 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 44.3 mt -72.3 127.51 32.78 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.852 -0.425 . . . . 71.13 109.852 175.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.1 mt -83.92 148.54 54.25 Favored Pre-proline 0 C--O 1.242 0.662 0 C-N-CA 123.883 0.873 . . . . 72.24 109.883 178.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.8 172.53 9.41 Favored 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 122.827 2.352 . . . . 70.0 111.831 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.533 -0.746 . . . . 75.13 110.163 -177.415 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.558 1.286 0 N-CA-C 114.755 1.391 . . . . 70.04 114.755 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -66.83 -174.3 0.46 Allowed 'Trans proline' 0 C--N 1.369 1.63 0 C-N-CA 122.617 2.211 . . . . 73.51 111.142 163.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.48 HD13 ' HG ' ' A' ' 123' ' ' LEU . 8.6 tp -72.73 133.47 44.58 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.518 -0.549 . . . . 73.54 109.518 176.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.559 HD23 HG23 ' A' ' 138' ' ' VAL . 13.4 tp 73.17 -39.98 0.46 Allowed 'General case' 0 N--CA 1.484 1.255 0 C-N-CA 127.268 2.227 . . . . 74.2 113.077 -176.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -88.12 131.34 34.73 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.141 0.976 . . . . 75.22 111.528 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.522 HG21 HG12 ' A' ' 102' ' ' VAL . 93.6 m -151.29 92.21 3.78 Favored Pre-proline 0 CA--C 1.55 0.964 0 C-N-CA 123.592 0.757 . . . . 74.14 109.823 178.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -74.06 82.23 1.82 Allowed 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.646 2.23 . . . . 55.21 113.302 -168.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.522 HG12 HG21 ' A' ' 100' ' ' THR . 28.6 m . . . . . 0 N--CA 1.474 0.731 0 C-N-CA 123.985 0.914 . . . . 75.45 109.972 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.441 ' HD2' ' H ' ' A' ' 117' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.474 0.75 0 CA-C-O 121.19 0.519 . . . . 74.4 111.038 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -101.54 108.78 20.45 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.638 -0.875 . . . . 74.33 108.638 -173.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.406 HD22 ' O ' ' A' ' 100' ' ' THR . 15.2 mt -89.93 110.63 21.58 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.796 -1.186 . . . . 73.03 107.796 -169.299 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -107.17 109.31 21.1 Favored 'General case' 0 C--N 1.344 0.349 0 N-CA-C 108.997 -0.742 . . . . 63.22 108.997 173.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.487 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -126.5 141.97 51.69 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.277 -1.008 . . . . 74.34 108.277 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -74.32 135.06 42.54 Favored 'General case' 0 C--O 1.243 0.73 0 N-CA-C 109.051 -0.722 . . . . 73.33 109.051 173.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.48 ' HG ' HD13 ' A' ' 97' ' ' LEU . 1.9 tt -100.83 103.11 22.51 Favored Pre-proline 0 CA--C 1.543 0.708 0 N-CA-C 107.929 -1.138 . . . . 75.41 107.929 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.415 ' HB2' HD11 ' A' ' 181' ' ' LEU . 52.1 Cg_endo -67.83 115.48 3.79 Favored 'Trans proline' 0 C--N 1.376 2.013 0 C-N-CA 122.49 2.126 . . . . 70.41 110.052 174.439 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.565 HD21 HD12 ' A' ' 149' ' ' ILE . 17.0 tp -137.6 135.31 36.48 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.074 -0.713 . . . . 71.41 109.074 -169.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.0 p -77.28 164.58 25.44 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 118.76 0.709 . . . . 72.2 110.581 178.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -63.28 -30.91 71.96 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.728 0.811 . . . . 71.44 111.877 -177.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -75.0 -46.95 31.67 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.561 0.745 . . . . 75.42 110.13 -178.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 73.3 mm-40 -60.62 -35.69 76.78 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 123.911 0.757 . . . . 73.21 111.048 176.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.51 -51.63 61.98 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 124.099 0.874 . . . . 62.41 111.21 174.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -58.04 -50.82 72.1 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.928 1.291 . . . . 74.33 111.688 -176.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 56.1 m80 -78.18 -41.18 35.46 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.819 -0.628 . . . . 74.33 109.881 -176.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 73.94 -167.86 54.37 Favored Glycine 0 C--N 1.352 1.451 0 CA-C-N 116.03 -0.532 . . . . 72.15 112.072 -173.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.456 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 122.85 -165.08 15.57 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 111.766 -0.534 . . . . 70.01 111.766 177.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.47 ' HA ' ' HA ' ' A' ' 148' ' ' ARG . 1.5 mp0 -84.78 125.71 32.8 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 121.125 0.488 . . . . 75.02 110.304 178.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 tpp180 -112.88 122.37 47.44 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.929 1.291 . . . . 75.14 107.92 175.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 15.4 t -101.86 106.93 20.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 N-CA-C 109.334 -0.617 . . . . 73.33 109.334 -171.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.559 HG23 HD23 ' A' ' 98' ' ' LEU . 30.0 m -124.46 153.52 31.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.298 1.039 . . . . 74.14 108.835 -175.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -107.03 132.56 52.82 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 122.592 0.357 . . . . 74.55 111.517 -171.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.1 p -113.26 104.8 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 125.21 1.404 . . . . 65.22 109.881 176.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.67 15.54 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 113.187 0.81 . . . . 70.42 113.187 173.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.0 8.73 47.24 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.908 -0.385 . . . . 54.44 113.696 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 7.2 tpp180 -115.72 116.39 27.99 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.336 0.655 . . . . 73.31 109.238 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -87.1 106.38 17.83 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.071 0.548 . . . . 74.22 109.879 -173.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 78.4 t -112.87 133.96 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.228 1.011 . . . . 71.12 110.729 -176.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 45.5 t -92.1 104.48 16.87 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.55 0.74 . . . . 75.01 109.951 175.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.551 HG23 HD12 ' A' ' 176' ' ' LEU . 6.3 p -99.99 122.38 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 123.65 0.78 . . . . 74.34 110.181 175.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . 0.47 ' HA ' ' HA ' ' A' ' 135' ' ' GLU . 61.1 ttt180 -77.09 112.18 13.48 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.673 0.389 . . . . 71.25 110.086 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.565 HD12 HD21 ' A' ' 125' ' ' LEU . 4.4 pt -77.94 138.4 61.43 Favored Pre-proline 0 CA--C 1.56 1.36 0 C-N-CA 123.794 0.838 . . . . 71.05 109.212 170.665 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -60.0 136.8 71.86 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.911 2.407 . . . . 75.13 113.271 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.431 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 32.3 Cg_exo -61.59 113.05 1.64 Allowed 'Trans proline' 0 C--N 1.375 1.95 0 C-N-CA 122.776 2.318 . . . . 62.41 111.585 171.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.89 39.76 16.17 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.051 -0.522 . . . . 73.42 112.076 -173.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.6 p -75.46 145.32 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 N-CA-C 109.399 -0.593 . . . . 71.14 109.399 175.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -112.62 173.1 6.54 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 121.472 0.653 . . . . 73.2 112.009 -173.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -63.77 133.97 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 113.927 -1.488 . . . . 60.12 111.107 178.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.36 -21.65 33.99 Favored Glycine 0 C--N 1.349 1.263 0 CA-C-N 115.833 -0.622 . . . . 62.32 113.583 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 72.7 m -63.66 121.52 14.13 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 123.695 0.798 . . . . 73.43 111.876 -172.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.4 p -95.39 125.29 48.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 CA-C-O 121.302 0.572 . . . . 73.2 110.268 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.0 mt -93.73 115.23 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.355 1.062 . . . . 71.22 108.29 -178.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 -101.26 119.94 39.51 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 122.848 0.459 . . . . 75.14 110.497 -176.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -117.4 99.31 52.52 Favored Pre-proline 0 CA--C 1.552 1.045 0 N-CA-C 107.574 -1.269 . . . . 62.05 107.574 169.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.77 138.81 81.85 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.791 2.328 . . . . 72.32 113.913 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.6 5.13 72.58 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 115.07 -0.968 . . . . 63.02 115.094 175.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 13.6 tpt -101.99 -16.0 16.62 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 117.638 0.719 . . . . 71.34 112.359 -170.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -73.82 -81.72 0.41 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 120.154 -0.248 . . . . 60.2 112.769 178.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -60.39 93.78 0.07 OUTLIER Glycine 0 C--N 1.352 1.42 0 C-N-CA 123.1 0.381 . . . . 54.23 112.95 172.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -91.98 171.01 9.4 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.495 1.118 . . . . 74.33 111.46 175.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 113.76 -65.68 0.27 Allowed Glycine 0 C--N 1.345 1.046 0 CA-C-N 115.579 -0.737 . . . . 74.43 111.792 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -168.62 -32.35 0.0 OUTLIER Pre-proline 0 CA--C 1.565 1.554 0 CA-C-O 117.48 -1.248 . . . . 75.04 112.66 -179.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -92.32 106.81 0.22 Allowed 'Trans proline' 0 C--N 1.403 3.442 0 CA-C-N 122.37 1.882 . . . . 73.21 110.611 168.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_exo -66.16 124.85 13.14 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.277 1.984 . . . . 74.31 111.811 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -120.96 155.95 16.19 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.25 -1.14 . . . . 51.31 110.25 172.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -76.81 162.69 27.45 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.687 0.795 . . . . 71.13 111.033 -173.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.454 HD23 HD11 ' A' ' 98' ' ' LEU . 55.9 tp -122.6 130.58 53.16 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.047 0.539 . . . . 74.43 109.795 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.41 128.77 46.36 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.805 1.242 . . . . 73.14 109.05 177.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.551 HD12 HG23 ' A' ' 147' ' ' VAL . 88.0 mt -129.17 102.31 6.41 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.198 0.599 . . . . 73.44 110.948 178.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.0 t -85.69 99.32 7.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.66 0 N-CA-C 109.563 -0.532 . . . . 73.31 109.563 -173.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.7 t -56.14 114.51 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.344 1.058 . . . . 71.14 111.907 -178.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -113.09 102.6 10.55 Favored 'General case' 0 C--O 1.239 0.517 0 C-N-CA 124.77 1.228 . . . . 75.4 108.598 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 68.6 mt -70.28 116.93 11.2 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 115.256 -0.884 . . . . 72.21 110.962 -177.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.415 HD11 ' HB2' ' A' ' 124' ' ' PRO . 58.0 mt -77.26 146.75 75.05 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 115.416 -0.811 . . . . 74.14 110.378 -177.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -60.64 115.05 2.42 Favored 'Trans proline' 0 C--N 1.373 1.817 0 C-N-CA 123.279 2.653 . . . . 72.51 111.873 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 . . . . . 0 C--O 1.249 1.073 0 N-CA-C 109.331 -0.618 . . . . 63.02 109.331 -179.856 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 3.4 pp . . . . . 0 CA--C 1.566 1.587 0 N-CA-C 112.341 0.497 . . . . 74.24 112.341 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -69.87 -164.05 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 123.611 2.874 . . . . 74.21 113.433 168.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.583 HD12 ' HD2' ' A' ' 124' ' ' PRO . 0.6 OUTLIER -60.31 -46.56 89.44 Favored 'General case' 0 N--CA 1.483 1.203 0 C-N-CA 124.446 1.098 . . . . 73.45 112.031 -179.009 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.506 HD22 ' HB ' ' A' ' 140' ' ' VAL . 3.9 tt -139.19 90.04 2.39 Favored 'General case' 0 C--O 1.211 -0.962 0 N-CA-C 108.04 -1.096 . . . . 72.24 108.04 173.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 73.5 t80 172.5 107.05 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 125.518 1.527 . . . . 75.42 107.373 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.54 HG23 HG13 ' A' ' 102' ' ' VAL . 93.9 m -127.79 94.64 36.77 Favored Pre-proline 0 C--O 1.239 0.511 0 N-CA-C 109.763 -0.458 . . . . 62.33 109.763 -178.001 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -70.1 85.28 0.67 Allowed 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 122.556 2.17 . . . . 73.21 112.293 -175.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.54 HG13 HG23 ' A' ' 100' ' ' THR . 22.6 m . . . . . 0 N--CA 1.47 0.541 0 C-N-CA 124.001 0.92 . . . . 74.02 109.582 174.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.426 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 12.5 mmm-85 . . . . . 0 N--CA 1.474 0.743 0 N-CA-C 107.952 -1.129 . . . . 73.42 107.952 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -96.69 104.44 16.43 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.458 -0.941 . . . . 71.12 108.458 -171.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.439 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.1 mt -92.39 111.48 23.07 Favored 'General case' 0 C--N 1.344 0.344 0 N-CA-C 107.917 -1.142 . . . . 75.24 107.917 -172.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -110.08 105.58 14.75 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 108.686 -0.857 . . . . 72.34 108.686 174.081 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.13 160.92 35.81 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 123.929 0.892 . . . . 71.22 109.6 -176.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 88.7 mt-10 -99.79 136.39 39.79 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.437 0.695 . . . . 73.1 110.12 -173.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.526 ' HA ' HD12 ' A' ' 97' ' ' LEU . 1.6 tt -105.05 101.33 29.49 Favored Pre-proline 0 CA--C 1.545 0.75 0 C-N-CA 124.247 1.019 . . . . 73.43 108.759 -176.14 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.583 ' HD2' HD12 ' A' ' 97' ' ' LEU . 30.2 Cg_endo -62.74 120.04 7.38 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.478 2.119 . . . . 74.01 110.285 170.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.565 HD22 HD13 ' A' ' 149' ' ' ILE . 15.2 tp -145.89 135.7 23.43 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.948 0.499 . . . . 75.04 109.664 -172.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.3 p -88.24 168.8 12.41 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.974 0.51 . . . . 74.13 110.72 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 72.2 mt -63.08 -36.99 85.43 Favored 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 123.395 0.678 . . . . 73.34 111.928 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -63.55 -54.77 30.93 Favored 'General case' 0 N--CA 1.475 0.811 0 O-C-N 123.953 0.783 . . . . 71.44 108.983 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -64.19 -34.18 77.5 Favored 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 114.759 -1.109 . . . . 74.15 111.699 -177.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 153' ' ' VAL . . . -59.9 -49.62 76.96 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.218 0.949 . . . . 65.22 110.475 175.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -69.61 -34.71 74.47 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 115.008 -0.996 . . . . 73.21 111.129 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -66.77 -47.08 73.3 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.833 0.453 . . . . 75.51 110.57 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.508 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.3 41.03 94.85 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 115.532 -0.758 . . . . 73.43 112.648 -174.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -84.39 -163.9 36.87 Favored Glycine 0 C--N 1.347 1.162 0 O-C-N 123.904 0.414 . . . . 63.23 112.984 -178.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.4 mp0 -85.44 144.67 27.85 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.437 -0.579 . . . . 74.42 109.437 170.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.511 ' HG2' HD21 ' A' ' 123' ' ' LEU . 11.0 tpt180 -125.69 120.32 30.39 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 123.935 0.894 . . . . 73.13 108.621 -177.153 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.44 123.53 37.94 Favored 'Isoleucine or valine' 0 C--O 1.24 0.573 0 N-CA-C 109.373 -0.602 . . . . 74.04 109.373 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.496 HG12 HD23 ' A' ' 97' ' ' LEU . 27.2 m -138.25 162.49 30.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 125.02 1.328 . . . . 73.22 108.54 179.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -119.83 129.28 54.35 Favored 'General case' 0 N--CA 1.479 1.019 0 O-C-N 122.053 -0.405 . . . . 74.51 110.644 -178.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.506 ' HB ' HD22 ' A' ' 98' ' ' LEU . 5.3 p -119.89 113.63 41.4 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.599 1.159 . . . . 74.35 110.045 175.231 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 56.35 33.27 22.03 Favored 'General case' 0 N--CA 1.487 1.425 0 C-N-CA 123.782 0.833 . . . . 73.54 112.389 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.29 19.28 59.09 Favored Glycine 0 C--N 1.351 1.413 0 CA-C-N 115.858 -0.61 . . . . 54.1 113.638 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 75.9 mtp180 -125.42 125.61 43.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 123.722 0.809 . . . . 75.0 110.198 -176.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.3 ttp180 -73.51 120.33 18.97 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 122.904 0.482 . . . . 74.11 110.734 178.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 20.5 m -125.24 141.22 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.716 0.807 . . . . 75.0 109.77 170.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.9 p -106.62 111.71 24.38 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.817 0.847 . . . . 75.2 109.353 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -101.08 130.75 50.0 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 123.716 0.806 . . . . 75.1 110.083 178.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 39.0 ttt180 -81.6 114.3 20.2 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.494 -0.928 . . . . 73.24 108.494 178.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.565 HD13 HD22 ' A' ' 125' ' ' LEU . 5.2 pt -84.51 146.39 47.07 Favored Pre-proline 0 CA--C 1.554 1.132 0 C-N-CA 123.844 0.858 . . . . 74.32 109.469 177.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -66.4 141.76 63.12 Favored 'Trans proline' 0 CA--C 1.562 1.894 0 C-N-CA 122.826 2.351 . . . . 74.34 112.922 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -67.92 127.95 16.97 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 123.127 2.551 . . . . 75.35 111.496 172.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 74.71 26.34 67.54 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 123.783 0.677 . . . . 71.04 113.317 -175.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.417 ' O ' ' HB3' ' A' ' 130' ' ' ALA . 12.6 p -71.71 146.37 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 117.421 0.61 . . . . 74.44 110.735 -178.124 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.508 ' HA ' HD11 ' A' ' 180' ' ' LEU . 29.7 mtp-105 -120.99 173.22 7.39 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 121.888 0.851 . . . . 73.24 112.571 -170.064 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -64.45 120.83 13.03 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 113.292 -1.776 . . . . 73.34 109.961 174.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 104.34 -23.61 31.28 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-O 119.407 -0.663 . . . . 72.32 112.965 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 58.5 m -64.25 121.08 13.4 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 123.061 0.544 . . . . 74.22 110.458 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.2 p -102.39 127.49 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 CA-C-O 121.26 0.552 . . . . 73.03 110.022 -179.102 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.44 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 54.6 mt -92.64 101.1 12.25 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 107.829 -1.174 . . . . 75.12 107.829 -179.389 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -86.99 110.04 19.78 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.657 -0.498 . . . . 71.35 109.657 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.449 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 12.6 t -111.19 93.54 18.57 Favored Pre-proline 0 CA--C 1.555 1.163 0 N-CA-C 107.685 -1.228 . . . . 63.31 107.685 173.034 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.13 122.29 7.06 Favored 'Trans proline' 0 C--N 1.369 1.618 0 C-N-CA 122.441 2.094 . . . . 75.05 112.207 -177.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.39 -20.91 36.36 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-N 116.537 -0.301 . . . . 63.41 113.476 177.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 86.1 mmm -104.62 16.16 26.59 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 123.398 0.679 . . . . 73.21 112.081 -177.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.59 -101.93 0.54 Allowed Glycine 0 C--N 1.345 1.061 0 CA-C-O 119.664 -0.52 . . . . 72.32 111.931 172.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . 0.426 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -68.84 102.78 0.95 Allowed Glycine 0 C--N 1.349 1.299 0 CA-C-N 116.93 0.365 . . . . 74.21 112.313 177.087 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 7.5 mm-40 -89.27 157.82 18.07 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 124.151 0.981 . . . . 74.14 110.075 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 147.77 -66.39 0.4 Allowed Glycine 0 C--N 1.344 1.014 0 N-CA-C 110.758 -0.937 . . . . 45.12 110.758 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 36.2 t30 -159.12 -54.12 0.01 OUTLIER Pre-proline 0 CA--C 1.562 1.429 0 C-N-CA 124.291 1.036 . . . . 73.15 110.122 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -85.37 110.54 1.23 Allowed 'Trans proline' 0 C--N 1.399 3.231 0 C-N-CA 121.594 1.53 . . . . 74.11 110.505 171.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.82 123.28 11.12 Favored 'Trans proline' 0 C--N 1.383 2.381 0 C-N-CA 122.163 1.909 . . . . 75.21 110.996 -174.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -96.1 163.08 23.07 Favored Glycine 0 C--N 1.338 0.642 0 O-C-N 123.649 0.593 . . . . 71.32 111.912 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -84.36 152.39 24.12 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 108.791 -0.818 . . . . 70.52 108.791 -179.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.449 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 57.6 tp -120.68 132.0 54.86 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.957 0.503 . . . . 74.11 109.744 178.206 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 84.1 mt -128.39 103.33 7.09 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.189 0.996 . . . . 74.34 109.153 177.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.472 HD22 ' HG ' ' A' ' 98' ' ' LEU . 86.8 mt -102.51 101.2 11.37 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 121.04 0.447 . . . . 75.4 110.369 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.1 t -83.96 99.55 6.53 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 108.621 -0.881 . . . . 74.45 108.621 -176.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.5 t -59.32 117.42 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 123.919 0.888 . . . . 73.22 111.455 -177.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -100.95 105.23 16.45 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 114.466 -1.243 . . . . 64.03 108.389 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.508 HD11 ' HA ' ' A' ' 154' ' ' ARG . 30.3 mt -69.28 108.77 3.8 Favored 'General case' 0 C--N 1.348 0.511 0 N-CA-C 109.128 -0.693 . . . . 72.02 109.128 174.03 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.4 mt -68.56 159.0 83.62 Favored Pre-proline 0 CA--C 1.544 0.72 0 CA-C-N 115.057 -0.974 . . . . 74.21 110.45 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -74.12 51.91 2.56 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 123.533 2.822 . . . . 72.14 112.764 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.5 t-80 . . . . . 0 C--O 1.255 1.347 0 C-N-CA 124.697 1.199 . . . . 75.12 107.962 177.304 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.6 pt? . . . . . 0 CA--C 1.555 1.145 0 N-CA-C 111.56 0.207 . . . . 72.11 111.56 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.438 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 97.5 Cg_endo -81.67 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.922 2.414 . . . . 74.44 111.3 166.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.512 HD13 ' H ' ' A' ' 98' ' ' LEU . 7.1 tp -81.83 139.99 34.43 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.261 0.624 . . . . 74.45 110.254 -179.48 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.537 HD22 HG23 ' A' ' 138' ' ' VAL . 19.3 tp 64.63 -13.06 0.11 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 127.031 2.132 . . . . 75.31 113.606 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.438 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 47.3 t80 -119.78 122.07 40.57 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 124.376 1.07 . . . . 74.42 108.91 -173.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.501 HG23 HG11 ' A' ' 102' ' ' VAL . 85.7 m -135.36 90.25 21.07 Favored Pre-proline 0 C--O 1.235 0.329 0 C-N-CA 123.739 0.816 . . . . 74.05 108.804 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -65.85 93.61 0.27 Allowed 'Trans proline' 0 C--N 1.372 1.769 0 C-N-CA 121.6 1.533 . . . . 65.32 112.027 -174.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.501 HG11 HG23 ' A' ' 100' ' ' THR . 27.4 m . . . . . 0 N--CA 1.465 0.32 0 C-N-CA 125.266 1.427 . . . . 75.43 109.375 177.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.591 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 46.7 mtt-85 . . . . . 0 N--CA 1.476 0.854 0 N-CA-C 109.882 -0.414 . . . . 72.15 109.882 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -99.29 105.02 16.98 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 106.469 -1.678 . . . . 63.45 106.469 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.471 HD23 ' O ' ' A' ' 100' ' ' THR . 12.6 mt -88.33 106.93 18.55 Favored 'General case' 0 C--N 1.345 0.378 0 N-CA-C 105.78 -1.933 . . . . 73.14 105.78 -177.309 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.4 ttm-85 -106.91 102.3 11.67 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.824 -1.176 . . . . 75.33 107.824 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.446 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -125.45 136.04 52.97 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.125 -1.065 . . . . 74.1 108.125 -175.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -82.86 129.37 34.99 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.853 -0.612 . . . . 71.03 109.732 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.49 HD13 HD11 ' A' ' 176' ' ' LEU . 2.2 tt -101.18 105.05 36.93 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 123.681 0.792 . . . . 75.51 109.558 -172.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.542 ' HB2' HD13 ' A' ' 181' ' ' LEU . 33.9 Cg_endo -61.48 116.22 3.27 Favored 'Trans proline' 0 C--N 1.378 2.089 0 C-N-CA 122.958 2.439 . . . . 71.31 111.213 170.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.481 HD23 HD13 ' A' ' 149' ' ' ILE . 30.9 tp -145.61 124.53 12.73 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 123.77 0.828 . . . . 74.43 109.026 -170.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.1 p -75.49 168.24 20.38 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 122.538 0.335 . . . . 74.33 110.978 -175.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 74.7 mt -63.22 -37.36 86.92 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.642 0.777 . . . . 74.34 110.901 178.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 24.7 mp0 -64.19 -52.36 59.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.95 1.3 . . . . 61.31 110.136 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -69.75 -32.71 71.39 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.456 -0.793 . . . . 51.54 111.43 -177.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.57 -45.28 93.64 Favored 'General case' 0 C--N 1.349 0.582 0 O-C-N 123.87 0.731 . . . . 65.42 110.269 174.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -66.14 -39.35 89.78 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.377 1.071 . . . . 73.22 110.641 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.0 m80 -61.98 -47.43 84.87 Favored 'General case' 0 C--N 1.358 0.945 0 O-C-N 123.717 0.636 . . . . 72.52 110.447 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.415 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.08 52.78 47.6 Favored Glycine 0 C--N 1.352 1.427 0 O-C-N 124.046 0.841 . . . . 74.03 112.516 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -106.41 -141.82 10.52 Favored Glycine 0 C--N 1.339 0.712 0 N-CA-C 111.531 -0.628 . . . . 72.33 111.531 177.673 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.569 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.9 mp0 -93.68 148.87 21.71 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 108.261 -1.014 . . . . 63.23 108.261 169.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.465 ' HG3' HG12 ' A' ' 138' ' ' VAL . 40.5 tpt85 -123.31 117.68 25.8 Favored 'General case' 0 N--CA 1.463 0.18 0 N-CA-C 107.441 -1.318 . . . . 75.44 107.441 177.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.5 t -86.21 106.0 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 109.165 -0.679 . . . . 74.02 109.165 -174.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.537 HG23 HD22 ' A' ' 98' ' ' LEU . 33.1 m -125.91 157.79 35.51 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 C-N-CA 124.93 1.292 . . . . 74.12 108.342 -178.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -113.65 120.29 40.39 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 118.534 0.606 . . . . 74.42 111.382 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 6.4 p -105.61 104.6 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.757 0.823 . . . . 74.44 109.665 173.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.22 29.6 18.81 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.354 0.661 . . . . 65.13 112.384 172.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.35 -14.23 58.17 Favored Glycine 0 N--CA 1.475 1.287 0 N-CA-C 113.705 0.242 . . . . 54.24 113.705 -178.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -92.78 117.65 30.24 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.027 -0.731 . . . . 73.22 109.027 -178.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 26.5 ttm180 -88.76 105.93 18.02 Favored 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 108.808 -0.812 . . . . 74.13 108.808 -173.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.57 128.87 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 124.214 1.005 . . . . 73.32 110.797 -175.42 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.569 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 51.0 p -90.14 107.43 19.13 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 123.841 0.857 . . . . 45.52 109.699 173.213 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.81 130.1 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 123.721 0.808 . . . . 72.52 109.995 -178.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 75.8 ttt180 -78.82 113.97 17.35 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.555 0.693 . . . . 74.43 110.547 -174.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.481 HD13 HD23 ' A' ' 125' ' ' LEU . 4.5 pt -90.25 142.22 28.29 Favored Pre-proline 0 CA--C 1.56 1.358 0 C-N-CA 124.93 1.292 . . . . 62.04 109.772 178.501 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.417 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 19.8 Cg_endo -69.34 142.91 51.13 Favored 'Trans proline' 0 CA--C 1.564 2.018 0 C-N-CA 122.156 1.904 . . . . 73.11 112.849 174.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.59 127.92 14.58 Favored 'Trans proline' 0 C--N 1.381 2.242 0 C-N-CA 122.832 2.355 . . . . 74.45 111.475 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 82.72 23.41 56.03 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.657 -0.701 . . . . 75.12 113.416 -174.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.417 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 14.2 p -74.5 150.22 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.926 0.49 . . . . 73.04 110.185 178.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -131.64 178.55 6.66 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 121.83 0.824 . . . . 74.23 112.6 -169.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.82 131.46 50.96 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 113.389 -1.732 . . . . 72.54 111.412 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.55 -8.05 70.35 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-O 119.464 -0.631 . . . . 34.01 113.357 177.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 49.3 m -72.43 119.23 16.35 Favored 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.848 -0.797 . . . . 74.24 108.848 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.67 134.27 41.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.286 0.634 . . . . 64.42 109.747 -175.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.469 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 47.4 mt -106.9 103.43 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.224 1.01 . . . . 74.25 108.35 -176.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 30.2 ttm180 -87.29 111.21 20.82 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 123.134 0.574 . . . . 75.3 109.959 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.91 102.95 53.96 Favored Pre-proline 0 CA--C 1.554 1.106 0 N-CA-C 108.336 -0.987 . . . . 72.33 108.336 173.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -68.83 139.43 43.53 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 122.909 2.406 . . . . 74.13 112.52 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 81.31 -8.41 58.32 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.575 -0.569 . . . . 64.25 114.446 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.0 mtt -113.35 17.58 18.4 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 117.944 0.872 . . . . 75.11 111.22 -174.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -92.96 -107.04 1.76 Allowed Glycine 0 C--N 1.347 1.19 0 CA-C-O 119.508 -0.607 . . . . 72.02 112.066 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -64.85 90.48 0.1 OUTLIER Glycine 0 C--N 1.355 1.599 0 CA-C-N 116.937 0.369 . . . . 72.13 112.78 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -79.66 147.71 31.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.496 0.719 . . . . 74.22 111.165 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.09 -124.81 1.48 Allowed Glycine 0 C--N 1.342 0.885 0 N-CA-C 110.001 -1.24 . . . . 74.03 110.001 -176.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.41 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 2.0 m-20 -85.16 -50.61 0.54 Allowed Pre-proline 0 CA--C 1.563 1.463 0 CA-C-O 118.63 -0.7 . . . . 74.1 110.004 169.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.41 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -99.66 103.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.395 2.995 0 C-N-CA 123.317 2.678 . . . . 53.43 112.434 177.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.52 123.19 12.26 Favored 'Trans proline' 0 C--N 1.377 2.056 0 C-N-CA 122.293 1.996 . . . . 74.31 111.369 -177.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -94.29 -171.63 38.2 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 116.179 -0.464 . . . . 74.55 112.977 -176.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -99.65 144.85 28.25 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 123.113 0.565 . . . . 70.41 110.28 -177.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.499 HD23 HD12 ' A' ' 98' ' ' LEU . 46.8 tp -109.9 129.49 55.65 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.425 0.69 . . . . 74.33 109.174 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.442 HD11 HH21 ' A' ' 160' ' ' ARG . 88.9 mt -128.85 109.33 11.18 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.887 0.875 . . . . 74.5 109.793 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.49 HD11 HD13 ' A' ' 123' ' ' LEU . 83.6 mt -110.19 102.99 11.63 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.056 0.542 . . . . 74.33 111.713 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.88 94.56 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.941 0 C-N-CA 123.322 0.649 . . . . 75.23 109.904 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 84.7 t -54.39 114.76 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 124.105 0.962 . . . . 74.42 112.054 -179.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 29.8 mmt180 -98.29 115.24 27.99 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.116 1.366 . . . . 73.04 108.406 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 66.7 mt -70.31 114.41 8.41 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 120.689 0.281 . . . . 75.31 110.5 178.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.542 HD13 ' HB2' ' A' ' 124' ' ' PRO . 45.2 mt -89.96 156.9 46.56 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 123.568 0.747 . . . . 72.32 110.825 175.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -71.18 -162.85 0.11 Allowed 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 123.041 2.494 . . . . 61.2 112.286 168.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 6.7 p80 . . . . . 0 CA--C 1.553 1.091 0 C-N-CA 123.811 0.844 . . . . 71.01 109.16 -177.868 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.559 1.326 0 N-CA-C 114.168 1.173 . . . . 74.3 114.168 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.45 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 13.0 Cg_exo -70.91 -161.5 0.09 OUTLIER 'Trans proline' 0 C--N 1.375 1.969 0 C-N-CA 122.698 2.265 . . . . 75.42 111.989 171.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.627 HD12 ' HA ' ' A' ' 123' ' ' LEU . 1.1 tp -58.19 -42.85 87.03 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 124.107 0.963 . . . . 74.53 112.569 -175.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 1.7 tt -141.06 96.52 3.01 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 107.801 -1.185 . . . . 74.31 107.801 171.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.45 ' HB3' ' HD2' ' A' ' 96' ' ' PRO . 53.7 t80 165.36 119.6 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 126.518 1.927 . . . . 72.45 107.431 172.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.564 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 32.7 m -145.54 86.68 7.28 Favored Pre-proline 0 CA--C 1.55 0.961 0 CA-C-N 118.147 0.43 . . . . 63.2 110.653 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -74.11 86.0 1.32 Allowed 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.371 2.047 . . . . 71.53 111.623 -177.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.499 HG12 HG21 ' A' ' 100' ' ' THR . 18.0 m . . . . . 0 N--CA 1.481 1.094 0 C-N-CA 124.585 1.154 . . . . 74.23 112.553 -175.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.643 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.7 mmp_? . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 107.057 -1.46 . . . . 73.35 107.057 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.2 105.45 17.8 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 107.578 -1.267 . . . . 64.4 107.578 -170.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.564 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.8 mt -94.28 110.83 22.55 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 108.244 -1.021 . . . . 75.53 108.244 -178.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.1 ttt180 -110.86 112.76 24.83 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 108.731 -0.841 . . . . 75.24 108.731 168.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -131.39 153.95 49.14 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.814 -0.81 . . . . 63.05 108.814 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -92.61 142.22 27.63 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.935 -0.765 . . . . 74.44 108.935 -176.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.627 ' HA ' HD12 ' A' ' 97' ' ' LEU . 12.1 tp -103.14 102.46 28.43 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 124.247 1.019 . . . . 74.25 109.457 -177.734 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.583 ' HD2' HD12 ' A' ' 97' ' ' LEU . 34.6 Cg_endo -65.49 115.71 3.51 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.053 1.835 . . . . 74.43 109.449 168.465 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.421 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 24.3 tp -145.81 122.1 10.9 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.282 -1.007 . . . . 71.14 108.282 -174.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 80.7 p -75.4 165.31 25.33 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 123.281 0.363 . . . . 74.54 110.19 -176.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.436 HD11 ' HB3' ' A' ' 183' ' ' HIS . 77.6 mt -60.8 -33.31 72.8 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.75 0.82 . . . . 72.42 111.998 -172.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -73.91 -49.58 24.15 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.274 -0.875 . . . . 75.41 109.272 -178.136 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -68.52 -24.17 64.63 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 115.007 -0.997 . . . . 74.23 111.374 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.67 -47.34 66.77 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.015 0.926 . . . . 73.32 109.967 172.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -60.87 -44.09 97.54 Favored 'General case' 0 C--N 1.352 0.677 0 O-C-N 124.637 1.211 . . . . 63.31 110.867 177.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -71.16 -45.88 62.61 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 123.531 0.519 . . . . 74.24 111.104 -174.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.424 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 71.4 -138.08 27.11 Favored Glycine 0 CA--C 1.53 1.008 0 CA-C-N 116.175 -0.466 . . . . 73.33 112.275 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.46 -160.19 45.39 Favored Glycine 0 C--N 1.349 1.256 0 CA-C-O 119.882 -0.399 . . . . 74.04 112.379 178.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.561 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 8.9 mp0 -77.46 138.34 39.19 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 117.316 0.558 . . . . 74.24 109.91 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.499 ' HB2' HD13 ' A' ' 149' ' ' ILE . 23.1 tpt180 -117.69 119.09 33.89 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.392 -0.966 . . . . 73.45 108.392 -176.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 42.9 t -83.51 103.74 11.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 N-CA-C 108.57 -0.9 . . . . 71.11 108.57 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.446 HG12 ' HG3' ' A' ' 136' ' ' ARG . 18.8 m -123.81 160.83 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 N-CA-C 107.643 -1.243 . . . . 73.35 107.643 177.551 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -125.95 115.75 20.4 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 119.232 0.923 . . . . 74.24 111.123 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.6 p -105.41 111.16 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 124.378 1.071 . . . . 73.41 110.771 178.398 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.5 29.83 19.43 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 124.147 0.979 . . . . 72.04 112.369 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.16 -13.03 62.04 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-N 116.351 -0.386 . . . . 73.42 113.29 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.66 115.96 28.58 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.309 0.644 . . . . 75.33 109.817 176.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 32.8 ttm180 -92.49 103.65 16.04 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 108.182 -1.044 . . . . 75.43 108.182 -176.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 27.0 m -109.57 155.63 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.719 1.208 . . . . 74.1 111.4 -172.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.561 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 47.9 m -101.73 115.98 31.72 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.859 0.864 . . . . 71.32 109.708 176.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.502 HG13 HD11 ' A' ' 176' ' ' LEU . 74.5 t -99.35 113.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 124.28 1.032 . . . . 64.55 108.85 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -74.55 102.58 4.57 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 109.145 -0.687 . . . . 71.24 109.145 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.499 HD13 ' HB2' ' A' ' 136' ' ' ARG . 5.6 pt -96.15 141.93 23.84 Favored Pre-proline 0 CA--C 1.555 1.171 0 C-N-CA 124.418 1.087 . . . . 72.3 109.51 -178.587 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.0 132.83 35.95 Favored 'Trans proline' 0 CA--C 1.564 2.015 0 C-N-CA 122.371 2.047 . . . . 74.12 112.344 178.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -66.98 132.69 28.86 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 122.984 2.456 . . . . 74.41 112.225 174.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.12 34.59 41.14 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.649 -0.705 . . . . 50.21 112.121 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.405 HG23 HG22 ' A' ' 178' ' ' VAL . 14.6 p -76.44 140.17 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 122.99 0.516 . . . . 73.41 111.025 -176.162 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 -94.97 177.09 6.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.832 0.825 . . . . 74.03 112.772 -173.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -72.7 129.92 39.33 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.518 -1.674 . . . . 75.23 110.753 176.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.8 10.33 86.28 Favored Glycine 0 C--N 1.345 1.031 0 CA-C-N 115.45 -0.795 . . . . 74.43 113.884 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 44.9 m -78.29 118.39 20.45 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.274 -0.639 . . . . 74.53 109.274 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -94.46 127.28 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-O 121.273 0.558 . . . . 75.54 110.333 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 51.7 mt -100.97 101.19 11.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 N-CA-C 107.598 -1.26 . . . . 75.11 107.598 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.502 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 38.9 ttt180 -89.45 113.98 25.41 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 109.92 -0.4 . . . . 74.55 109.92 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.408 HG12 ' SD ' ' A' ' 164' ' ' MET . 6.5 t -114.49 94.64 37.04 Favored Pre-proline 0 CA--C 1.555 1.149 0 N-CA-C 108.324 -0.991 . . . . 75.12 108.324 173.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.56 135.2 48.1 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 123.032 2.488 . . . . 75.42 112.268 177.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.95 -7.88 79.84 Favored Glycine 0 C--N 1.345 1.072 0 CA-C-O 119.543 -0.587 . . . . 54.14 114.2 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.408 ' SD ' HG12 ' A' ' 161' ' ' VAL . 27.6 ttt -100.38 -7.83 23.98 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.636 0.774 . . . . 75.44 110.772 179.263 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -81.58 -112.94 0.37 Allowed Glycine 0 C--N 1.348 1.207 0 CA-C-N 116.078 -0.51 . . . . 73.23 112.316 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . 0.643 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -67.0 95.61 0.28 Allowed Glycine 0 C--N 1.347 1.177 0 CA-C-N 116.869 0.334 . . . . 75.31 113.877 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -71.93 108.54 5.24 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 123.566 0.747 . . . . 73.22 110.46 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -171.64 -169.85 34.98 Favored Glycine 0 C--N 1.342 0.883 0 CA-C-N 115.861 -0.608 . . . . 65.04 112.304 178.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -61.0 -42.93 89.28 Favored Pre-proline 0 CA--C 1.563 1.442 0 C-N-CA 123.497 0.719 . . . . 73.02 111.652 176.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -88.17 106.67 0.54 Allowed 'Trans proline' 0 C--N 1.387 2.584 0 C-N-CA 121.623 1.549 . . . . 75.03 110.176 160.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -67.21 125.63 13.81 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 121.994 1.796 . . . . 74.41 111.858 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -97.14 154.93 20.58 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-N 115.876 -0.602 . . . . 55.14 111.926 -177.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -95.39 163.43 13.25 Favored 'General case' 0 C--O 1.245 0.827 0 C-N-CA 122.899 0.48 . . . . 75.43 109.931 -178.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.502 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.2 tp -117.62 139.75 50.57 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 115.088 -0.96 . . . . 73.13 109.758 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 30.7 mt -128.93 101.6 6.15 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.89 1.276 . . . . 64.34 108.416 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.502 HD11 HG13 ' A' ' 147' ' ' VAL . 54.5 mt -103.2 101.28 11.22 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 118.318 0.508 . . . . 74.12 110.162 176.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.63 100.6 10.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 115.435 -0.802 . . . . 71.1 109.138 -174.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.507 HG21 HD21 ' A' ' 123' ' ' LEU . 58.2 t -57.76 111.36 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.066 0.946 . . . . 72.42 112.01 -177.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -101.44 111.1 23.23 Favored 'General case' 0 C--O 1.243 0.753 0 C-N-CA 124.388 1.075 . . . . 75.51 108.914 170.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.421 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 62.7 mt -70.5 114.5 8.67 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.389 0.676 . . . . 75.25 109.846 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.424 HD11 ' HB2' ' A' ' 124' ' ' PRO . 86.5 mt -72.66 155.44 90.92 Favored Pre-proline 0 CA--C 1.548 0.888 0 C-N-CA 123.237 0.615 . . . . 72.43 110.728 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.66 142.75 60.23 Favored 'Trans proline' 0 C--N 1.375 1.942 0 C-N-CA 123.249 2.633 . . . . 74.41 112.454 173.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.436 ' HB3' HD11 ' A' ' 127' ' ' LEU . 48.1 p-80 . . . . . 0 CA--C 1.555 1.17 0 CA-C-O 118.942 -0.551 . . . . 75.23 110.986 -179.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.454 HD21 HG21 ' A' ' 100' ' ' THR . 3.9 pp . . . . . 0 CA--C 1.553 1.095 0 N-CA-C 109.96 -0.385 . . . . 73.14 109.96 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -85.48 -161.43 0.13 Allowed 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 122.757 2.304 . . . . 62.2 110.98 164.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.485 HD13 ' H ' ' A' ' 98' ' ' LEU . 7.0 tp -74.25 149.92 40.54 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.262 0.625 . . . . 75.31 109.412 177.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.582 HD23 ' HB ' ' A' ' 140' ' ' VAL . 8.2 tp 57.74 1.67 0.14 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 125.798 1.639 . . . . 75.5 114.108 -178.228 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.595 ' HA ' HD11 ' A' ' 119' ' ' LEU . 43.3 t80 -139.91 133.7 30.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 123.336 0.655 . . . . 75.21 109.698 -170.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.562 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 85.9 m -152.94 97.05 2.87 Favored Pre-proline 0 CA--C 1.551 1.009 0 C-N-CA 123.8 0.84 . . . . 73.32 109.476 -177.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.76 77.23 2.29 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 123.02 2.48 . . . . 63.41 112.799 -170.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.502 HG13 HG22 ' A' ' 100' ' ' THR . 9.0 m . . . . . 0 C--O 1.242 0.694 0 CA-C-N 115.494 -0.775 . . . . 75.2 110.457 178.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.7 mmm-85 . . . . . 0 N--CA 1.48 1.049 0 N-CA-C 109.133 -0.691 . . . . 73.03 109.133 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.05 106.59 16.64 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 108.691 -0.855 . . . . 75.53 108.691 -171.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.595 HD11 ' HA ' ' A' ' 99' ' ' PHE . 12.3 mt -96.43 109.46 22.01 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 107.478 -1.305 . . . . 75.54 107.478 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 39.8 ttt180 -121.18 106.45 11.53 Favored 'General case' 0 C--O 1.238 0.465 0 N-CA-C 108.557 -0.905 . . . . 75.12 108.557 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -128.9 141.23 51.35 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.543 -0.91 . . . . 72.45 108.543 -177.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -81.56 130.99 35.26 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 108.895 -0.78 . . . . 64.5 108.895 175.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.549 HD12 HD13 ' A' ' 176' ' ' LEU . 1.6 tt -101.38 108.24 54.37 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 108.103 -1.073 . . . . 75.41 108.103 -175.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.7 113.87 3.33 Favored 'Trans proline' 0 C--N 1.378 2.097 0 C-N-CA 121.775 1.65 . . . . 73.1 109.42 171.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.558 HD23 HD13 ' A' ' 149' ' ' ILE . 13.5 tp -131.72 122.78 26.44 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.388 -0.968 . . . . 71.13 108.388 -169.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.9 p -69.71 166.15 19.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.549 0.34 . . . . 74.04 110.537 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 99.7 mt -62.34 -29.2 70.29 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 122.778 0.431 . . . . 73.2 110.882 176.065 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -67.8 -57.67 5.91 Favored 'General case' 0 C--N 1.349 0.555 0 C-N-CA 123.907 0.883 . . . . 72.22 109.263 177.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -60.08 -36.49 77.5 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.507 1.123 . . . . 75.04 111.713 -178.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.404 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.1 -55.72 11.44 Favored 'General case' 0 C--O 1.239 0.551 0 O-C-N 124.061 0.851 . . . . 73.3 111.212 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.4 ' HA ' ' HA2' ' A' ' 152' ' ' GLY . 65.0 t80 -57.84 -48.28 80.23 Favored 'General case' 0 C--N 1.359 0.99 0 O-C-N 124.554 1.159 . . . . 73.34 111.399 -177.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.9 m80 -72.92 -43.84 61.92 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 116.017 -0.538 . . . . 63.11 110.19 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.407 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 77.87 -124.01 6.62 Favored Glycine 0 C--N 1.344 0.988 0 CA-C-N 115.762 -0.654 . . . . 72.31 111.566 -176.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 73.49 -129.8 12.67 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 111.151 -0.78 . . . . 72.1 111.151 -176.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.514 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 6.7 mp0 -111.73 161.37 16.36 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.102 0.961 . . . . 73.44 110.179 176.15 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.617 ' HB2' HD12 ' A' ' 149' ' ' ILE . 20.8 tpt180 -134.01 121.99 22.37 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.212 1.005 . . . . 74.12 109.401 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 60.9 t -75.14 107.68 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.89 0.876 . . . . 71.41 109.417 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.481 HG21 HD13 ' A' ' 98' ' ' LEU . 27.0 m -122.96 163.8 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 125.257 1.423 . . . . 73.02 109.354 -179.129 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -120.99 113.02 19.47 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 122.911 0.485 . . . . 73.23 111.505 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.582 ' HB ' HD23 ' A' ' 98' ' ' LEU . 2.6 p -102.76 102.33 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 C-N-CA 123.649 0.78 . . . . 73.23 108.972 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.25 25.44 14.87 Favored 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 115.215 -0.902 . . . . 72.32 110.665 -169.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.9 6.17 62.17 Favored Glycine 0 C--N 1.358 1.804 0 CA-C-N 115.63 -0.714 . . . . 72.45 113.802 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.477 ' HB3' HG11 ' A' ' 140' ' ' VAL . 13.8 tpt180 -92.27 116.98 29.43 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.09 -0.707 . . . . 73.34 109.09 -179.781 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -80.89 109.8 15.81 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.809 -0.441 . . . . 74.42 109.809 -174.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 32.1 m -134.11 152.53 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 124.254 1.022 . . . . 71.25 109.218 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.514 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 45.1 m -104.36 114.86 29.38 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.736 0.414 . . . . 62.42 110.02 178.034 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.4 p -99.85 133.13 43.84 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 124.289 1.036 . . . . 72.1 109.9 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 38.9 ttp180 -75.81 115.46 15.53 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.091 0.556 . . . . 72.5 111.122 -174.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.617 HD12 ' HB2' ' A' ' 136' ' ' ARG . 6.1 pt -99.34 143.26 26.09 Favored Pre-proline 0 CA--C 1.558 1.256 0 C-N-CA 124.864 1.266 . . . . 74.53 109.315 177.59 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.427 ' HB2' ' HB ' ' A' ' 153' ' ' VAL . 52.7 Cg_exo -57.59 134.74 65.16 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.091 2.527 . . . . 71.24 113.094 178.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.407 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 34.7 Cg_exo -62.72 114.53 2.44 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 70.31 111.112 172.361 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' A' ' 131' ' ' PHE . . . 89.98 18.72 49.73 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.577 -0.568 . . . . 74.24 113.191 -178.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.427 ' HB ' ' HB2' ' A' ' 150' ' ' PRO . 13.2 p -64.0 141.68 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 C-N-CA 122.971 0.508 . . . . 64.43 111.395 -175.126 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -113.12 177.7 4.54 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 123.777 0.831 . . . . 74.3 112.706 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.69 135.7 57.76 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.535 -1.666 . . . . 73.13 111.744 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.58 6.66 77.52 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.905 0.753 . . . . 61.31 114.232 176.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.8 m -81.83 119.82 24.39 Favored 'General case' 0 C--N 1.349 0.564 0 N-CA-C 109.179 -0.675 . . . . 62.31 109.179 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.2 p -97.56 123.39 49.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.903 0 CA-C-O 121.313 0.578 . . . . 74.02 110.366 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.501 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.3 mt -93.29 103.73 14.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 124.379 1.071 . . . . 72.51 108.619 -175.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 43.0 ttm180 -90.18 111.36 22.49 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 122.767 0.427 . . . . 75.4 110.025 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 6.3 t -111.18 106.32 57.29 Favored Pre-proline 0 CA--C 1.552 1.05 0 N-CA-C 107.526 -1.287 . . . . 75.02 107.526 172.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.35 125.35 12.78 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.857 2.372 . . . . 72.13 112.691 -172.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.9 11.86 85.12 Favored Glycine 0 C--N 1.349 1.291 0 CA-C-O 119.792 -0.449 . . . . 75.12 114.044 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.415 ' HE1' ' HA ' ' A' ' 164' ' ' MET . 1.2 tpt -100.99 -4.4 27.58 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-N 117.24 0.52 . . . . 74.53 110.766 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -74.11 -110.58 0.08 OUTLIER Glycine 0 C--N 1.344 0.996 0 CA-C-N 116.073 -0.512 . . . . 74.34 112.474 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -63.94 108.19 2.12 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 111.777 -0.529 . . . . 70.45 111.777 178.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.9 mm-40 -88.14 116.84 26.61 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.255 0.622 . . . . 72.04 110.308 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 169.22 -155.85 26.5 Favored Glycine 0 C--O 1.245 0.816 0 N-CA-C 110.359 -1.097 . . . . 72.03 110.359 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.447 ' O ' ' HD3' ' A' ' 171' ' ' PRO . 15.0 m120 -65.42 -34.52 9.72 Favored Pre-proline 0 N--CA 1.487 1.398 0 CA-C-O 118.274 -0.869 . . . . 73.1 112.053 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -90.64 99.6 0.26 Allowed 'Trans proline' 0 C--N 1.394 2.924 0 C-N-CA 122.527 2.152 . . . . 71.12 111.655 164.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.447 ' HD3' ' O ' ' A' ' 169' ' ' ASN . 10.6 Cg_exo -70.86 123.28 9.6 Favored 'Trans proline' 0 C--N 1.382 2.331 0 C-N-CA 121.683 1.588 . . . . 74.13 110.613 174.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -100.94 156.58 19.23 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.569 -0.613 . . . . 64.12 111.569 -178.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -83.99 143.57 29.7 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 109.849 -0.426 . . . . 74.21 109.849 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.487 HD22 HD12 ' A' ' 98' ' ' LEU . 64.1 tp -106.98 129.89 54.71 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.179 0.592 . . . . 71.24 109.851 -179.544 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.428 HD21 ' HE ' ' A' ' 160' ' ' ARG . 98.1 mt -128.75 112.15 13.88 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.448 1.099 . . . . 73.35 110.025 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.549 HD13 HD12 ' A' ' 123' ' ' LEU . 81.9 mt -108.54 103.83 13.04 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.247 0.619 . . . . 73.31 110.96 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.52 94.62 4.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 N-CA-C 108.851 -0.796 . . . . 75.34 108.851 -176.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.4 t -57.63 118.68 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.877 0.871 . . . . 51.43 111.382 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -114.07 107.22 15.36 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 124.648 1.179 . . . . 74.5 108.22 175.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.05 122.07 18.68 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.526 0.517 . . . . 75.01 110.857 -176.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 93.0 mt -79.11 141.06 57.74 Favored Pre-proline 0 CA--C 1.544 0.745 0 CA-C-N 115.362 -0.835 . . . . 71.22 109.556 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.2 166.22 30.33 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.988 2.459 . . . . 73.52 112.591 -176.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.4 p-80 . . . . . 0 CA--C 1.56 1.327 0 C-N-CA 122.546 0.339 . . . . 72.53 110.299 178.835 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 pt? . . . . . 0 CA--C 1.562 1.429 0 N-CA-C 110.247 -0.279 . . . . 70.21 110.247 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -86.82 -67.79 0.01 OUTLIER 'Trans proline' 0 C--N 1.38 2.19 0 C-N-CA 122.865 2.376 . . . . 72.21 111.811 175.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.512 HD11 ' H ' ' A' ' 98' ' ' LEU . 6.6 tp -159.74 140.92 12.6 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 108.516 -0.92 . . . . 72.24 108.516 176.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.7 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 11.5 tp 60.58 3.48 0.6 Allowed 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 126.461 1.904 . . . . 73.52 112.95 -178.207 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.672 ' HA ' HD11 ' A' ' 119' ' ' LEU . 75.0 t80 -135.35 133.25 38.57 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.271 1.028 . . . . 72.43 108.377 -173.196 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.492 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 89.3 m -153.6 102.17 2.54 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 123.75 0.82 . . . . 74.42 109.645 177.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -72.94 91.02 0.83 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 122.559 2.173 . . . . 72.03 111.631 -175.338 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 28.7 m . . . . . 0 N--CA 1.48 1.042 0 C-N-CA 124.178 0.991 . . . . 75.3 110.912 -178.491 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.417 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 3.9 mmp_? . . . . . 0 N--CA 1.484 1.238 0 N-CA-C 108.76 -0.83 . . . . 75.53 108.76 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -98.12 102.51 14.28 Favored 'General case' 0 CA--C 1.511 -0.542 0 N-CA-C 106.486 -1.672 . . . . 74.54 106.486 -173.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.672 HD11 ' HA ' ' A' ' 99' ' ' PHE . 16.5 mt -93.52 106.33 18.31 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.605 -1.257 . . . . 75.22 107.605 -169.056 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -111.02 103.24 11.69 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.904 -1.147 . . . . 75.13 107.904 -179.001 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.46 151.69 51.32 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.583 -0.735 . . . . 75.31 110.235 -168.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.519 ' HB3' ' HG3' ' A' ' 179' ' ' ARG . 40.4 mt-10 -81.55 124.17 29.27 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 114.6 -1.182 . . . . 72.45 109.342 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.457 HD13 HD11 ' A' ' 176' ' ' LEU . 3.2 tt -99.52 103.81 23.46 Favored Pre-proline 0 CA--C 1.54 0.583 0 N-CA-C 106.898 -1.519 . . . . 72.31 106.898 178.41 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.3 114.48 3.46 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 121.925 1.75 . . . . 72.34 110.438 175.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.505 HD23 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -139.23 120.08 14.35 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.039 -1.097 . . . . 74.53 108.039 -172.709 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.4 ' HA ' ' HB2' ' A' ' 181' ' ' LEU . 4.9 m -69.73 160.82 30.96 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 123.748 0.819 . . . . 75.13 111.112 -176.094 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 83.2 mt -56.17 -39.28 72.11 Favored 'General case' 0 N--CA 1.484 1.225 0 C-N-CA 123.894 0.878 . . . . 74.2 112.13 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -69.12 -44.19 72.91 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.447 0.699 . . . . 73.53 110.414 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -61.44 -39.15 89.76 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.321 1.048 . . . . 73.03 111.16 -179.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.427 ' HB2' ' O ' ' A' ' 153' ' ' VAL . . . -72.98 -44.23 61.31 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-N 114.31 -1.314 . . . . 75.44 111.145 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -56.92 -47.83 79.66 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.803 1.241 . . . . 74.03 110.913 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -69.83 -48.55 58.53 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.716 -0.675 . . . . 72.23 110.181 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.564 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 55.65 76.37 0.2 Allowed Glycine 0 C--N 1.356 1.639 0 O-C-N 124.469 1.105 . . . . 52.13 113.638 176.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -112.57 -131.39 5.57 Favored Glycine 0 C--N 1.343 0.922 0 N-CA-C 111.328 -0.709 . . . . 73.05 111.328 177.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -100.96 152.19 20.86 Favored 'General case' 0 C--O 1.245 0.834 0 N-CA-C 108.694 -0.854 . . . . 62.32 108.694 170.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 tpp85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.003 0.921 . . . . 75.02 108.867 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.28 131.04 40.46 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 N-CA-C 108.582 -0.896 . . . . 74.32 108.582 175.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 27.1 m -125.14 161.19 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 123.604 0.762 . . . . 75.4 110.147 -178.419 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -97.56 141.71 30.27 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 124.075 0.95 . . . . 65.05 108.539 -178.354 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.7 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.0 p -150.1 109.31 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.199 0 C-N-CA 124.733 1.213 . . . . 73.22 111.394 -177.198 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.13 17.36 8.01 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 114.449 1.277 . . . . 72.52 114.449 164.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.12 22.34 13.36 Favored Glycine 0 N--CA 1.479 1.561 0 N-CA-C 112.514 -0.235 . . . . 64.25 112.514 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.401 ' HB2' HG11 ' A' ' 140' ' ' VAL . 24.7 mmm180 -134.75 153.86 51.83 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.906 1.282 . . . . 75.1 107.864 178.144 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -117.69 108.01 14.89 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.034 -0.728 . . . . 75.12 109.034 175.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 63.2 t -116.56 139.19 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 123.477 0.711 . . . . 74.44 110.174 -174.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.7 p -85.99 140.13 30.58 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 123.733 0.813 . . . . 73.02 111.087 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.4 HG21 HD12 ' A' ' 176' ' ' LEU . 14.7 p -133.55 157.59 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 124.641 1.176 . . . . 64.25 108.52 174.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 -107.32 128.72 54.7 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.783 -0.451 . . . . 75.24 109.783 177.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.505 HD12 HD23 ' A' ' 125' ' ' LEU . 15.7 pt -101.9 126.84 32.6 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.058 0.943 . . . . 71.15 108.65 176.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -65.32 147.07 87.3 Favored 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.362 2.042 . . . . 70.54 113.547 -178.017 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.564 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 38.5 Cg_exo -62.88 121.92 10.0 Favored 'Trans proline' 0 C--N 1.385 2.452 0 C-N-CA 123.821 3.014 . . . . 71.11 112.159 179.156 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 72.33 40.13 55.83 Favored Glycine 0 C--N 1.339 0.747 0 O-C-N 124.051 0.844 . . . . 73.31 112.563 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.427 ' O ' ' HB2' ' A' ' 130' ' ' ALA . 14.6 p -76.87 148.93 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 109.872 -0.418 . . . . 65.44 109.872 178.32 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 68.7 mtp180 -126.51 177.97 6.16 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-O 121.509 0.671 . . . . 73.33 112.413 -172.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -59.31 133.88 56.49 Favored 'General case' 0 CA--C 1.547 0.851 0 CA-C-N 113.409 -1.723 . . . . 73.4 111.865 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.31 -16.75 47.06 Favored Glycine 0 C--N 1.345 1.057 0 CA-C-O 119.388 -0.673 . . . . 41.41 113.312 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 48.3 m -67.15 118.72 10.95 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.36 0.58 . . . . 75.2 110.445 -173.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.9 p -94.12 125.0 46.8 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-O 121.528 0.68 . . . . 73.35 109.923 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 43.4 mt -94.82 99.75 9.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 107.061 -1.459 . . . . 71.33 107.061 174.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 46.6 ttt-85 -83.97 123.42 29.96 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 109.297 -0.631 . . . . 75.31 109.297 175.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.7 t -116.32 111.42 42.24 Favored Pre-proline 0 CA--C 1.555 1.168 0 N-CA-C 106.858 -1.534 . . . . 73.12 106.858 168.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.07 126.08 12.7 Favored 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.673 2.249 . . . . 75.32 112.25 -175.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.92 8.8 86.81 Favored Glycine 0 C--N 1.345 1.042 0 CA-C-N 115.774 -0.648 . . . . 74.55 114.57 171.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.413 ' HA ' HE22 ' A' ' 167' ' ' GLN . 24.0 mmt -114.07 15.35 18.36 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.154 0.582 . . . . 74.23 111.293 -176.685 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.21 -96.03 0.98 Allowed Glycine 0 C--N 1.344 0.973 0 N-CA-C 110.377 -1.089 . . . . 43.41 110.377 169.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . 0.417 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -79.12 95.29 1.4 Allowed Glycine 0 C--N 1.346 1.087 0 N-CA-C 112.177 -0.369 . . . . 71.2 112.177 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.413 HE22 ' HA ' ' A' ' 164' ' ' MET . 11.3 mm-40 -65.85 131.6 46.68 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.485 0.714 . . . . 70.31 111.508 -177.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 170.11 174.87 38.61 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.781 -0.928 . . . . 74.23 110.781 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.445 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 15.3 m120 -59.04 -42.37 93.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.358 0.663 . . . . 72.32 111.326 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.445 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 1.8 Cg_endo -87.42 101.34 0.5 Allowed 'Trans proline' 0 C--N 1.387 2.596 0 C-N-CA 122.429 2.086 . . . . 75.13 109.489 158.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.48 126.95 12.01 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 121.984 1.789 . . . . 71.51 111.911 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.99 151.14 21.94 Favored Glycine 0 C--N 1.343 0.946 0 CA-C-N 115.309 -0.859 . . . . 73.22 111.975 -179.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -77.74 159.4 29.1 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.512 0.725 . . . . 61.54 110.045 -170.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.455 HD21 HD13 ' A' ' 98' ' ' LEU . 47.5 tp -125.05 125.3 43.61 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.52 -0.548 . . . . 75.15 109.52 176.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 88.6 mt -127.4 101.47 6.47 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.88 0.872 . . . . 65.41 109.378 179.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.492 HD23 HD12 ' A' ' 98' ' ' LEU . 91.1 mt -102.96 102.23 12.28 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.992 0.517 . . . . 73.33 111.06 -178.147 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.99 107.57 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.011 -0.737 . . . . 72.54 109.011 -176.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.8 t -62.54 117.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.146 0.978 . . . . 73.25 111.078 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . 0.519 ' HG3' ' HB3' ' A' ' 122' ' ' GLU . 13.1 mmm180 -110.95 106.48 15.61 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 124.997 1.319 . . . . 73.12 108.092 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.403 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 65.8 mt -69.16 116.5 9.67 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 123.206 0.602 . . . . 72.31 110.815 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.4 ' HB2' ' HA ' ' A' ' 126' ' ' THR . 81.9 mt -75.07 139.24 72.64 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 115.944 -0.571 . . . . 73.12 109.67 178.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -71.88 179.03 5.16 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.118 2.545 . . . . 74.41 112.872 177.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 . . . . . 0 C--O 1.252 1.234 0 N-CA-C 109.208 -0.664 . . . . 71.53 109.208 174.592 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.559 1.304 0 N-CA-C 113.837 1.051 . . . . 54.14 113.837 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . 0.472 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 22.0 Cg_endo -62.51 178.17 1.01 Allowed 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.58 2.187 . . . . 75.03 112.473 168.711 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.538 HD12 ' HD2' ' A' ' 124' ' ' PRO . 1.7 tp -43.22 -53.97 4.8 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 125.287 1.435 . . . . 75.43 112.529 -174.038 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.416 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 12.7 tp -119.3 91.92 3.67 Favored 'General case' 0 C--O 1.215 -0.757 0 N-CA-C 107.619 -1.252 . . . . 63.23 107.619 172.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.526 ' HA ' HD11 ' A' ' 119' ' ' LEU . 62.3 t80 168.52 131.54 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 124.361 1.064 . . . . 73.13 109.071 173.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.547 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 51.5 m -156.68 98.95 2.07 Favored Pre-proline 0 N--CA 1.475 0.787 0 N-CA-C 107.824 -1.176 . . . . 74.22 107.824 173.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -79.51 74.99 5.29 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 122.575 2.184 . . . . 72.2 112.553 -169.08 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 4.4 m . . . . . 0 CA--C 1.545 0.783 0 CA-C-N 115.541 -0.754 . . . . 63.45 109.997 179.448 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.56 1.348 0 CA-C-O 121.217 0.532 . . . . 75.5 111.065 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.57 130.74 40.88 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.228 -1.027 . . . . 74.43 108.228 -172.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.547 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 14.9 mt -100.73 112.83 25.31 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 108.111 -1.07 . . . . 64.24 108.111 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 75.0 ttt-85 -119.33 108.69 14.91 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 123.883 0.873 . . . . 73.02 110.208 -179.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.405 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -146.29 170.26 17.13 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 123.911 0.885 . . . . 74.04 108.701 179.004 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -97.03 145.21 26.17 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.969 0.414 . . . . 75.35 110.746 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.515 HD21 ' HG2' ' A' ' 136' ' ' ARG . 1.1 tt -103.01 103.9 36.74 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 124.901 1.28 . . . . 71.02 109.053 -177.11 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.538 ' HD2' HD12 ' A' ' 97' ' ' LEU . 37.7 Cg_endo -65.17 115.91 3.57 Favored 'Trans proline' 0 C--N 1.38 2.204 0 C-N-CA 122.107 1.871 . . . . 75.12 109.594 169.163 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.533 HD23 HD12 ' A' ' 149' ' ' ILE . 28.7 tp -137.15 127.02 25.69 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.361 0.664 . . . . 75.04 110.125 -172.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.9 p -78.18 167.91 20.67 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.062 0.545 . . . . 75.4 111.121 -175.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 76.9 mt -65.58 -37.3 86.25 Favored 'General case' 0 C--O 1.246 0.907 0 C-N-CA 123.981 0.913 . . . . 71.22 111.366 -173.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.47 -51.74 40.21 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 114.694 -1.139 . . . . 72.25 108.68 -177.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -62.43 -38.08 88.35 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.771 -1.104 . . . . 75.01 111.793 -178.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.39 -47.23 85.06 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 124.074 0.859 . . . . 73.21 110.453 176.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -66.48 -35.23 79.76 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 124.271 0.982 . . . . 75.53 111.136 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -67.32 -47.66 69.87 Favored 'General case' 0 C--N 1.363 1.18 0 CA-C-O 120.885 0.374 . . . . 74.33 110.018 177.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.576 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.19 56.01 24.57 Favored Glycine 0 C--N 1.341 0.852 0 CA-C-N 114.584 -1.189 . . . . 62.34 112.452 -174.259 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -103.3 -141.09 11.15 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 111.873 -0.491 . . . . 63.33 111.873 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -98.77 141.65 31.3 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.027 -0.731 . . . . 71.14 109.027 171.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.515 ' HG2' HD21 ' A' ' 123' ' ' LEU . 23.1 tpt180 -115.48 119.72 37.13 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.757 -1.201 . . . . 75.13 107.757 178.218 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 57.7 t -85.71 109.13 18.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 123.273 0.629 . . . . 74.11 109.519 -177.058 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.424 HG12 HD23 ' A' ' 97' ' ' LEU . 18.2 m -117.83 164.17 14.35 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 C-N-CA 125.609 1.563 . . . . 73.31 108.429 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -124.66 138.86 54.28 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 118.655 0.661 . . . . 70.41 111.413 -178.081 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.442 HG11 ' HB2' ' A' ' 143' ' ' ARG . 5.6 p -128.76 107.21 15.39 Favored 'Isoleucine or valine' 0 C--N 1.359 0.987 0 C-N-CA 124.838 1.255 . . . . 71.35 110.994 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.98 24.51 11.13 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.482 0.713 . . . . 62.53 112.166 175.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.39 18.09 29.48 Favored Glycine 0 C--N 1.348 1.246 0 CA-C-N 116.288 -0.415 . . . . 72.12 113.608 -178.282 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.442 ' HB2' HG11 ' A' ' 140' ' ' VAL . 10.8 mmm180 -117.64 123.09 45.29 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 123.773 0.829 . . . . 74.11 109.891 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.9 tpt180 -84.25 106.35 15.8 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 108.935 -0.765 . . . . 75.22 108.935 -176.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 88.4 t -115.98 132.17 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.87 0.868 . . . . 72.32 109.693 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 30.1 m -98.95 112.55 24.63 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.865 0.866 . . . . 74.41 109.23 176.121 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.465 HG23 HD13 ' A' ' 176' ' ' LEU . 3.8 p -99.72 121.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 124.023 0.929 . . . . 74.01 109.382 176.496 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -73.1 119.49 17.41 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.021 0.528 . . . . 74.42 110.182 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.576 HG13 ' HA2' ' A' ' 133' ' ' GLY . 4.9 pt -92.18 142.64 26.43 Favored Pre-proline 0 CA--C 1.563 1.478 0 C-N-CA 124.331 1.052 . . . . 72.42 109.948 177.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -58.84 148.36 84.24 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 123.555 2.837 . . . . 71.51 113.84 176.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.538 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 59.5 Cg_endo -70.31 113.04 3.33 Favored 'Trans proline' 0 C--N 1.377 2.044 0 C-N-CA 122.829 2.352 . . . . 74.15 111.414 177.408 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.22 39.01 37.93 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.826 -0.624 . . . . 74.12 112.34 -175.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 8.7 p -71.08 144.75 13.18 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 123.159 0.584 . . . . 74.24 110.143 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.502 ' HA ' HD13 ' A' ' 180' ' ' LEU . 64.6 mtp180 -119.24 177.13 5.01 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 121.766 0.794 . . . . 75.33 112.821 -171.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -64.89 130.25 42.75 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 113.535 -1.666 . . . . 73.51 111.121 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.52 -5.55 84.83 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-N 115.95 -0.568 . . . . 55.43 113.92 179.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.9 m -75.48 119.67 19.87 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-N 117.29 0.545 . . . . 73.33 109.742 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.6 t -98.51 116.63 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.069 0.547 . . . . 64.44 109.858 -174.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 57.5 mt -88.25 101.65 11.88 Favored 'Isoleucine or valine' 0 C--O 1.241 0.609 0 N-CA-C 108.074 -1.084 . . . . 75.51 108.074 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.459 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 13.4 ttp180 -91.79 113.79 26.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 114.821 -1.081 . . . . 74.35 109.477 178.14 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.0 t -114.85 113.83 44.35 Favored Pre-proline 0 CA--C 1.549 0.925 0 N-CA-C 108.922 -0.77 . . . . 74.43 108.922 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.04 124.23 12.73 Favored 'Trans proline' 0 C--N 1.377 2.065 0 C-N-CA 122.852 2.368 . . . . 73.35 112.595 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.41 -3.33 85.2 Favored Glycine 0 C--N 1.344 1.01 0 N-CA-C 114.911 0.724 . . . . 70.33 114.911 171.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.473 ' HE1' ' HA ' ' A' ' 164' ' ' MET . 1.7 tpt -88.06 -7.62 56.72 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 117.622 0.711 . . . . 71.52 111.037 -175.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -75.81 -111.67 0.11 Allowed Glycine 0 C--N 1.349 1.278 0 N-CA-C 112.057 -0.417 . . . . 74.1 112.057 175.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.65 103.92 1.52 Allowed Glycine 0 C--N 1.344 1.017 0 CA-C-N 117.134 0.467 . . . . 73.14 113.304 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -65.98 147.89 52.66 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.483 0.713 . . . . 64.21 110.935 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 140.07 -171.78 23.73 Favored Glycine 0 N--CA 1.473 1.129 0 C-N-CA 123.136 0.398 . . . . 71.11 112.203 -177.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 45.7 m-80 -61.84 -46.15 92.6 Favored Pre-proline 0 CA--C 1.559 1.32 0 CA-C-O 118.394 -0.812 . . . . 71.35 111.698 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -88.33 103.66 0.46 Allowed 'Trans proline' 0 C--N 1.391 2.77 0 C-N-CA 121.842 1.695 . . . . 71.05 110.15 163.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -76.58 125.02 7.99 Favored 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 122.211 1.94 . . . . 70.22 110.723 -177.167 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -81.42 148.82 28.31 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 116.1 -0.5 . . . . 74.43 112.396 -178.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -78.19 151.93 32.93 Favored 'General case' 0 C--O 1.247 0.935 0 CA-C-O 121.102 0.477 . . . . 73.51 110.102 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 43.3 tp -114.17 131.89 56.29 Favored 'General case' 0 C--O 1.223 -0.334 0 C-N-CA 122.803 0.441 . . . . 75.25 110.075 177.162 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 73.1 mt -128.2 104.6 7.84 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 124.495 1.118 . . . . 74.21 108.902 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.465 HD13 HG23 ' A' ' 147' ' ' VAL . 66.6 mt -113.63 105.53 13.43 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.392 0.677 . . . . 74.22 110.565 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.8 t -84.72 103.8 12.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 109.239 -0.652 . . . . 74.11 109.239 -175.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.4 t -58.84 125.5 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 O-C-N 123.697 0.623 . . . . 62.35 111.539 -177.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -115.12 107.72 15.7 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 125.144 1.377 . . . . 73.33 107.499 176.038 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.502 HD13 ' HA ' ' A' ' 154' ' ' ARG . 54.1 mt -69.19 110.09 4.39 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.504 -0.925 . . . . 74.45 108.504 177.056 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 84.9 mt -68.82 129.84 92.11 Favored Pre-proline 0 CA--C 1.544 0.742 0 CA-C-N 115.715 -0.675 . . . . 75.53 110.013 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -65.43 158.68 51.5 Favored 'Trans proline' 0 C--N 1.369 1.625 0 C-N-CA 122.978 2.452 . . . . 74.01 111.825 176.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.6 t-80 . . . . . 0 CA--C 1.552 1.028 0 C-N-CA 123.509 0.724 . . . . 75.25 110.239 174.243 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.505 2.319 0 N-CA-C 114.482 1.29 . . . . 74.3 114.482 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -70.32 -43.35 2.24 Favored 'Trans proline' 0 C--N 1.38 2.229 0 C-N-CA 122.514 2.143 . . . . 71.24 112.153 -173.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.547 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.3 tp -175.39 145.43 0.75 Allowed 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.175 1.39 . . . . 65.21 107.804 -176.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.54 ' H ' HD11 ' A' ' 97' ' ' LEU . 4.2 tt 52.77 -78.27 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 126.924 2.09 . . . . 72.23 111.782 -174.589 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.642 ' HA ' HD12 ' A' ' 119' ' ' LEU . 78.2 t80 -57.01 120.71 8.45 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.909 1.283 . . . . 63.0 112.444 -178.06 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.525 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 88.8 m -138.62 97.97 9.02 Favored Pre-proline 0 CA--C 1.545 0.778 0 C-N-CA 124.287 1.035 . . . . 74.13 109.17 176.669 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.92 103.01 1.12 Allowed 'Trans proline' 0 C--N 1.367 1.527 0 C-N-CA 122.447 2.098 . . . . 72.53 111.708 -176.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.473 0.712 0 C-N-CA 124.249 1.02 . . . . 74.24 111.378 179.207 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.778 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 68.3 mtt180 . . . . . 0 N--CA 1.477 0.901 0 N-CA-C 109.722 -0.474 . . . . 74.02 109.722 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -99.44 107.43 19.64 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.903 -1.147 . . . . 44.52 107.903 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.642 HD12 ' HA ' ' A' ' 99' ' ' PHE . 13.5 mt -93.63 109.52 21.15 Favored 'General case' 0 C--O 1.22 -0.454 0 N-CA-C 106.769 -1.567 . . . . 75.02 106.769 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -121.11 107.94 13.21 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.953 0.901 . . . . 72.54 108.634 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.23 156.3 47.83 Favored 'General case' 0 C--O 1.24 0.6 0 C-N-CA 123.162 0.585 . . . . 73.35 110.401 -174.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -75.66 125.95 30.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.497 1.119 . . . . 75.15 108.942 179.11 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.537 HD12 ' HG2' ' A' ' 136' ' ' ARG . 26.1 tp -100.66 101.42 15.35 Favored Pre-proline 0 CA--C 1.543 0.681 0 C-N-CA 123.507 0.723 . . . . 72.22 109.331 178.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.64 114.98 4.17 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.251 1.967 . . . . 64.32 110.002 175.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.508 HD21 HD12 ' A' ' 149' ' ' ILE . 18.6 tp -131.89 135.62 46.79 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 108.223 -1.029 . . . . 75.33 108.223 -173.405 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.483 ' HG1' ' HG2' ' A' ' 129' ' ' GLU . 38.8 p -81.84 171.59 14.32 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.588 -0.523 . . . . 75.23 109.588 -179.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 88.7 mt -68.05 -32.73 73.28 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 122.925 0.49 . . . . 74.3 110.343 176.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -69.48 -49.44 54.7 Favored 'General case' 0 N--CA 1.47 0.56 0 O-C-N 124.013 0.82 . . . . 75.22 109.433 -177.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.483 ' HG2' ' HG1' ' A' ' 126' ' ' THR . 17.5 mm-40 -68.66 -34.6 75.98 Favored 'General case' 0 N--CA 1.472 0.648 0 O-C-N 124.016 0.823 . . . . 73.32 111.127 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.51 -48.56 81.25 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.908 0.755 . . . . 75.1 110.599 173.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -65.09 -37.14 86.55 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 124.464 1.106 . . . . 73.11 110.905 179.275 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -64.2 -42.32 96.69 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 123.635 0.584 . . . . 71.43 110.136 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.455 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 58.63 35.56 81.57 Favored Glycine 0 C--N 1.349 1.251 0 O-C-N 124.234 0.959 . . . . 71.4 112.326 -174.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -87.71 -136.47 5.12 Favored Glycine 0 C--N 1.342 0.888 0 N-CA-C 112.045 -0.422 . . . . 52.53 112.045 -175.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.58 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 15.3 mp0 -111.43 139.77 46.58 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.052 -1.092 . . . . 54.34 108.052 173.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.537 ' HG2' HD12 ' A' ' 123' ' ' LEU . 37.9 tpt85 -112.81 120.51 41.74 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 124.323 1.049 . . . . 74.53 108.183 -177.195 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 91.2 t -81.39 106.3 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.79 0.836 . . . . 73.33 109.395 -176.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.547 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 20.4 m -111.35 159.92 11.0 Favored 'Isoleucine or valine' 0 C--O 1.245 0.839 0 C-N-CA 124.516 1.127 . . . . 74.33 111.113 -174.595 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -93.72 136.94 33.49 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.624 1.17 . . . . 65.45 109.056 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.457 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 1.5 p -151.9 100.35 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 C-N-CA 124.02 0.928 . . . . 74.43 110.445 176.043 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.02 21.26 11.63 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 113.526 0.936 . . . . 71.02 113.526 171.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.55 -7.37 55.89 Favored Glycine 0 N--CA 1.479 1.525 0 C-N-CA 123.162 0.41 . . . . 70.25 113.162 -176.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.04 150.2 21.52 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.83 0.852 . . . . 75.43 109.461 173.749 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 55.7 ttp180 -113.36 108.84 17.77 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 107.282 -1.377 . . . . 74.21 107.282 176.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 70.1 t -121.77 134.48 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 C-N-CA 123.379 0.672 . . . . 72.33 110.619 -173.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.58 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 29.1 p -95.37 109.21 21.41 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 123.483 0.713 . . . . 72.23 109.165 176.488 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -98.91 128.24 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.508 0.723 . . . . 71.32 109.338 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -70.43 122.91 20.52 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 109.287 -0.634 . . . . 72.42 109.287 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.508 HD12 HD21 ' A' ' 125' ' ' LEU . 4.3 pt -98.69 149.49 35.79 Favored Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 124.875 1.27 . . . . 75.13 109.623 176.576 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -63.82 143.41 85.98 Favored 'Trans proline' 0 C--N 1.377 2.062 0 C-N-CA 122.77 2.313 . . . . 74.55 112.755 176.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.455 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 42.3 Cg_endo -68.35 123.53 10.66 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 122.755 2.303 . . . . 73.5 111.91 174.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.48 26.71 64.95 Favored Glycine 0 C--N 1.347 1.179 0 CA-C-N 115.849 -0.614 . . . . 71.23 113.101 -178.444 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 7.4 p -67.68 145.9 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 C-N-CA 123.658 0.783 . . . . 73.3 111.363 -177.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.504 ' HA ' HD11 ' A' ' 180' ' ' LEU . 60.5 mtp180 -120.13 169.42 10.24 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-O 121.855 0.836 . . . . 75.1 112.832 -172.158 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -61.12 119.85 9.16 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 113.062 -1.881 . . . . 64.35 109.623 173.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 116.23 -25.4 9.33 Favored Glycine 0 N--CA 1.477 1.377 0 O-C-N 123.325 0.391 . . . . 61.15 112.583 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.6 m -69.88 123.92 22.71 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.479 0.712 . . . . 54.31 110.924 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.0 p -100.94 131.08 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 108.666 -0.864 . . . . 71.32 108.666 172.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 34.9 mt -100.05 102.15 13.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 107.859 -1.163 . . . . 72.42 107.859 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.511 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 51.1 ttp85 -87.73 106.43 18.05 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.538 -0.541 . . . . 75.43 109.538 175.182 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.1 t -100.48 96.44 5.29 Favored Pre-proline 0 CA--C 1.555 1.173 0 N-CA-C 107.481 -1.303 . . . . 73.3 107.481 173.361 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.66 143.67 42.58 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.958 2.438 . . . . 71.34 111.564 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . 0.688 ' HA2' ' HB2' ' A' ' 171' ' ' PRO . . . 85.47 -24.79 6.93 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-N 116.068 -0.514 . . . . 63.4 113.595 177.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.7 mmt -98.73 14.76 27.54 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.956 0.902 . . . . 73.32 111.013 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.86 -119.94 1.72 Allowed Glycine 0 C--N 1.348 1.21 0 N-CA-C 111.758 -0.537 . . . . 60.05 111.758 175.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . 0.778 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.94 112.8 3.57 Favored Glycine 0 C--N 1.348 1.231 0 CA-C-N 117.11 0.455 . . . . 72.44 112.453 -177.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -81.53 139.3 35.2 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.581 0.752 . . . . 71.35 110.502 -177.185 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -173.37 -142.64 3.94 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.509 -1.037 . . . . 75.52 110.509 -179.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.4 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 39.3 t30 -73.81 -49.41 6.11 Favored Pre-proline 0 CA--C 1.563 1.471 0 N-CA-C 109.151 -0.685 . . . . 72.3 109.151 169.318 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.4 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 93.1 Cg_endo -91.8 135.14 1.58 Allowed 'Trans proline' 0 C--N 1.389 2.709 0 C-N-CA 121.935 1.757 . . . . 72.44 111.748 165.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.688 ' HB2' ' HA2' ' A' ' 163' ' ' GLY . 55.8 Cg_endo -67.56 128.35 17.99 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.406 2.071 . . . . 61.14 111.599 172.307 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.27 162.84 32.47 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-N 116.095 -0.502 . . . . 61.3 113.108 -179.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -86.73 145.81 26.51 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.67 0.788 . . . . 65.4 110.532 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.511 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 42.8 tp -111.21 135.1 52.24 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.835 0.854 . . . . 62.21 109.288 173.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 66.7 mt -127.67 102.18 6.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.062 1.345 . . . . 73.0 108.813 178.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 98.1 mt -102.41 101.41 11.63 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.406 0.682 . . . . 75.41 109.481 177.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.7 t -85.66 97.87 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 109.043 -0.725 . . . . 75.13 109.043 -174.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 86.7 t -57.96 104.87 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 124.415 1.086 . . . . 74.12 111.47 -176.161 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -98.35 101.64 13.15 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-N 113.803 -1.544 . . . . 74.42 108.375 170.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.504 HD11 ' HA ' ' A' ' 154' ' ' ARG . 47.3 mt -69.64 126.77 30.73 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.634 -0.506 . . . . 73.13 109.634 176.509 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 59.5 mt -77.01 140.46 66.56 Favored Pre-proline 0 CA--C 1.548 0.865 0 N-CA-C 108.772 -0.825 . . . . 75.22 108.772 178.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -49.23 -73.54 0.04 OUTLIER 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 123.994 3.129 . . . . 71.04 113.165 -174.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 . . . . . 0 C--O 1.252 1.192 0 C-N-CA 124.538 1.135 . . . . 73.45 108.382 177.855 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . 0.465 ' HG ' ' HA ' ' A' ' 100' ' ' THR . 2.7 tt . . . . . 0 CA--C 1.556 1.21 0 N-CA-C 109.601 -0.518 . . . . 72.14 109.601 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -75.4 -60.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.385 2.495 0 C-N-CA 121.951 1.768 . . . . 74.43 111.828 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.463 HD13 ' H ' ' A' ' 98' ' ' LEU . 6.2 tp -169.32 135.96 1.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.696 -1.594 . . . . 73.42 106.696 -173.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.536 HD13 HD11 ' A' ' 176' ' ' LEU . 14.8 tp 70.67 -60.42 0.5 Allowed 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.89 2.076 . . . . 72.02 112.511 -173.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.689 ' HB2' ' HA ' ' A' ' 140' ' ' VAL . 32.7 t80 -61.45 113.29 2.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.201 1.0 . . . . 72.53 111.782 179.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.465 ' HA ' ' HG ' ' A' ' 95' ' ' LEU . 98.2 m -133.4 95.3 18.29 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 124.045 0.938 . . . . 73.54 109.575 175.471 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.47 84.25 1.41 Allowed 'Trans proline' 0 C--N 1.369 1.658 0 C-N-CA 122.317 2.011 . . . . 73.23 112.802 -175.591 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.438 HG11 HG22 ' A' ' 100' ' ' THR . 23.3 m . . . . . 0 N--CA 1.472 0.633 0 CA-C-N 115.062 -0.972 . . . . 72.34 110.57 177.325 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 . . . . . 0 N--CA 1.477 0.891 0 N-CA-C 108.64 -0.874 . . . . 74.55 108.64 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -96.87 106.19 18.46 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 106.801 -1.555 . . . . 61.35 106.801 -178.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 15.7 mt -92.71 107.13 18.98 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 106.297 -1.742 . . . . 75.41 106.297 -172.127 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.487 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 59.6 ttt-85 -114.99 105.97 13.6 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.008 -1.108 . . . . 74.05 108.008 -176.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.52 146.67 50.43 Favored 'General case' 0 C--O 1.24 0.601 0 N-CA-C 108.742 -0.836 . . . . 61.03 108.742 -179.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -71.84 131.35 42.91 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 108.621 -0.881 . . . . 72.42 108.621 173.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.525 HD22 ' HG2' ' A' ' 136' ' ' ARG . 1.5 tt -98.4 103.27 17.41 Favored Pre-proline 0 CA--C 1.532 0.275 0 N-CA-C 106.352 -1.721 . . . . 73.23 106.352 176.431 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.452 ' HB2' HD13 ' A' ' 181' ' ' LEU . 50.5 Cg_endo -65.61 116.0 3.69 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 121.935 1.757 . . . . 74.35 109.786 174.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.463 HD23 HD13 ' A' ' 149' ' ' ILE . 15.6 tp -147.75 120.32 8.55 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.395 -0.595 . . . . 64.33 109.395 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.409 HG21 ' HB2' ' A' ' 181' ' ' LEU . 71.4 p -77.13 168.04 20.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.807 0.443 . . . . 72.21 111.724 -177.288 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.3 mt -55.64 -47.2 77.02 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 123.872 0.869 . . . . 74.13 112.137 -177.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -66.71 -41.4 88.02 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 115.959 -0.564 . . . . 74.3 111.279 -178.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -68.31 -31.86 71.59 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 122.91 0.484 . . . . 72.32 111.592 178.165 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -72.21 -39.38 68.59 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 123.337 0.655 . . . . 75.42 111.07 177.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -63.21 -56.52 15.93 Favored 'General case' 0 N--CA 1.472 0.628 0 O-C-N 124.619 1.199 . . . . 75.44 110.011 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 50.3 m80 -70.24 -34.96 73.49 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.469 -0.787 . . . . 73.32 111.16 -177.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 68.94 -135.35 28.07 Favored Glycine 0 C--N 1.353 1.513 0 N-CA-C 111.949 -0.46 . . . . 72.32 111.949 -177.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.49 -143.28 16.5 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 112.201 -0.36 . . . . 71.41 112.201 178.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -104.44 148.36 26.52 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.237 0.541 . . . . 71.31 111.31 -178.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.525 ' HG2' HD22 ' A' ' 123' ' ' LEU . 2.2 tpp180 -137.16 119.1 15.28 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 106.741 -1.577 . . . . 75.13 106.741 175.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.59 115.97 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.704 0 CA-C-O 121.864 0.84 . . . . 75.41 109.801 -174.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 11.4 m -122.7 164.33 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.981 1.312 . . . . 74.03 108.828 -171.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -123.16 125.42 45.1 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 118.457 0.571 . . . . 74.41 111.936 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.689 ' HA ' ' HB2' ' A' ' 99' ' ' PHE . 4.0 p -113.52 111.37 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.368 1.067 . . . . 71.31 110.17 175.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.34 26.3 14.97 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 123.807 0.843 . . . . 61.52 112.854 172.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.86 -12.03 60.84 Favored Glycine 0 C--N 1.352 1.421 0 CA-C-N 116.51 -0.314 . . . . 53.45 113.104 -177.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.1 tpp180 -92.22 115.86 28.44 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.637 0.775 . . . . 75.41 110.03 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 3.1 tpp180 -87.0 106.95 18.19 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.934 -0.765 . . . . 70.43 108.934 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 34.4 m -116.22 156.35 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 C-N-CA 123.911 0.884 . . . . 73.14 110.923 -178.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.0 p -91.32 141.95 28.22 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.53 0.732 . . . . 71.32 110.099 175.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 43.2 t -128.38 111.51 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 C-N-CA 124.747 1.219 . . . . 74.24 108.855 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -80.07 102.32 9.26 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.446 0.641 . . . . 74.24 109.417 178.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.463 HD13 HD23 ' A' ' 125' ' ' LEU . 16.5 pt -82.74 131.66 53.99 Favored Pre-proline 0 CA--C 1.559 1.296 0 CA-C-N 114.81 -1.086 . . . . 75.43 109.907 178.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 37.1 Cg_exo -64.22 135.86 48.87 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 122.656 2.237 . . . . 55.13 113.437 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -67.04 121.32 8.48 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 122.345 2.03 . . . . 71.13 110.742 168.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 87.82 27.47 26.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 115.549 -0.75 . . . . 73.23 113.22 -172.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.66 142.88 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 117.443 0.622 . . . . 74.34 109.74 176.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -112.7 177.6 4.58 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 121.635 0.731 . . . . 72.42 112.407 -172.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -65.02 133.49 51.79 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 113.56 -1.654 . . . . 62.44 110.644 176.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 83.8 -14.02 44.96 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-O 119.24 -0.755 . . . . 63.23 113.353 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 68.4 m -66.28 117.79 9.05 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 117.422 0.611 . . . . 63.31 109.667 -175.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.21 133.57 33.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 CA-C-O 121.362 0.601 . . . . 75.32 110.001 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.533 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 94.0 mt -99.95 102.3 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 N-CA-C 106.519 -1.66 . . . . 73.22 106.519 177.145 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.541 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 61.1 ttp85 -99.31 110.18 22.73 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.354 -0.385 . . . . 70.44 110.184 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.93 100.55 10.05 Favored Pre-proline 0 CA--C 1.557 1.241 0 N-CA-C 107.525 -1.287 . . . . 72.41 107.525 170.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.45 136.7 29.17 Favored 'Trans proline' 0 C--N 1.376 1.976 0 C-N-CA 122.937 2.424 . . . . 75.41 112.637 -173.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.15 -21.82 11.37 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.889 -0.596 . . . . 64.22 113.883 177.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 56.8 mtt -100.52 16.42 24.74 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 123.563 0.745 . . . . 74.21 111.402 -173.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . 0.545 ' HA2' HD12 ' A' ' 174' ' ' LEU . . . -85.27 -103.45 0.67 Allowed Glycine 0 C--N 1.351 1.407 0 CA-C-N 116.196 -0.457 . . . . 74.23 112.236 176.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -66.86 103.18 0.86 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.807 -0.517 . . . . 53.11 111.807 175.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -88.61 152.7 21.67 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.704 0.801 . . . . 75.45 110.419 -179.115 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 134.17 -137.0 8.96 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.462 -1.055 . . . . 74.25 110.462 -172.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.526 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 14.9 m120 -71.97 -56.48 4.55 Favored Pre-proline 0 CA--C 1.563 1.479 0 CA-C-N 117.704 0.752 . . . . 74.34 111.243 176.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.526 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -93.82 119.64 0.34 Allowed 'Trans proline' 0 C--N 1.396 3.041 0 C-N-CA 122.443 2.095 . . . . 71.35 112.434 178.388 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -63.03 125.2 15.36 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.82 2.347 . . . . 75.13 112.271 174.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.83 173.77 23.89 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 116.576 -0.284 . . . . 74.32 112.472 177.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -95.05 134.93 37.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.082 0.553 . . . . 74.11 109.878 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.545 HD12 ' HA2' ' A' ' 165' ' ' GLY . 17.1 tp -97.79 119.36 36.25 Favored 'General case' 0 C--O 1.216 -0.673 0 N-CA-C 107.989 -1.115 . . . . 73.42 107.989 -178.533 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.487 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 65.6 mt -123.48 120.15 32.06 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.761 0.824 . . . . 71.34 109.598 -170.108 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.536 HD11 HD13 ' A' ' 98' ' ' LEU . 41.9 mt -123.0 101.12 7.24 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 123.254 0.622 . . . . 74.34 110.937 177.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.1 t -85.84 96.38 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 108.409 -0.96 . . . . 70.24 108.409 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.8 t -56.02 126.51 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.199 1.0 . . . . 75.33 111.721 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.8 mmm-85 -112.87 110.01 19.83 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.786 -1.191 . . . . 75.03 107.786 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 46.0 mt -70.67 96.04 1.17 Allowed 'General case' 0 C--O 1.238 0.481 0 N-CA-C 109.408 -0.59 . . . . 75.33 109.408 178.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.452 HD13 ' HB2' ' A' ' 124' ' ' PRO . 80.4 mt -71.56 149.3 93.4 Favored Pre-proline 0 C--O 1.246 0.873 0 CA-C-N 114.711 -1.131 . . . . 71.42 110.445 -179.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -57.86 142.86 96.52 Favored 'Trans proline' 0 C--N 1.372 1.801 0 C-N-CA 122.557 2.171 . . . . 71.53 111.656 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 27.9 p80 . . . . . 0 CA--C 1.558 1.265 0 C-N-CA 123.543 0.737 . . . . 74.32 111.328 179.228 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.3 pt? . . . . . 0 CA--C 1.545 0.776 0 N-CA-C 110.251 -0.277 . . . . 73.11 110.251 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_exo -73.34 -160.9 0.1 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 122.8 2.333 . . . . 72.51 111.25 167.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.525 HD13 ' H ' ' A' ' 98' ' ' LEU . 9.1 tp -72.04 141.47 49.28 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.819 -0.808 . . . . 74.05 108.819 171.532 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.583 HD12 HG21 ' A' ' 138' ' ' VAL . 6.0 tp 65.58 -68.16 0.12 Allowed 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 126.83 2.052 . . . . 73.31 111.579 -174.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.536 ' HA ' HD11 ' A' ' 119' ' ' LEU . 59.8 t80 -59.78 127.83 33.91 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.213 1.005 . . . . 70.41 111.708 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.503 HG21 HG11 ' A' ' 102' ' ' VAL . 56.3 m -141.75 104.61 5.81 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 124.086 0.954 . . . . 75.2 109.228 175.116 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.1 87.1 1.05 Allowed 'Trans proline' 0 C--N 1.362 1.278 0 C-N-CA 122.299 2.0 . . . . 60.31 112.97 -170.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.503 HG11 HG21 ' A' ' 100' ' ' THR . 22.8 m . . . . . 0 C--O 1.239 0.525 0 CA-C-N 114.451 -1.25 . . . . 75.24 109.846 174.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 42.9 mtt180 . . . . . 0 N--CA 1.473 0.693 0 N-CA-C 109.775 -0.454 . . . . 75.21 109.775 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -98.91 104.17 16.19 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.873 -1.529 . . . . 71.23 106.873 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.536 HD11 ' HA ' ' A' ' 99' ' ' PHE . 11.5 mt -92.71 110.44 21.88 Favored 'General case' 0 C--N 1.343 0.323 0 N-CA-C 106.633 -1.617 . . . . 73.41 106.633 -173.402 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -117.76 108.55 15.52 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 108.975 -0.75 . . . . 75.34 108.975 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.48 154.02 51.15 Favored 'General case' 0 C--O 1.24 0.592 0 C-N-CA 123.193 0.597 . . . . 53.01 110.682 -171.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -72.13 131.58 43.0 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.291 -0.868 . . . . 62.24 109.109 173.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.555 HD23 ' HG2' ' A' ' 136' ' ' ARG . 2.4 tt -101.47 102.61 22.59 Favored Pre-proline 0 CA--C 1.544 0.733 0 N-CA-C 107.949 -1.13 . . . . 73.43 107.949 176.047 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.74 115.79 3.94 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 121.928 1.752 . . . . 72.21 110.019 173.143 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 46.3 tp -142.75 131.52 22.73 Favored 'General case' 0 C--O 1.225 -0.194 0 C-N-CA 123.648 0.779 . . . . 71.13 109.012 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 55.0 p -80.13 163.61 23.98 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 122.865 0.466 . . . . 74.42 111.286 -176.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.9 mt -58.77 -51.82 68.35 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.666 0.787 . . . . 74.3 112.826 -171.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -64.83 -40.13 94.68 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 122.742 0.417 . . . . 74.41 111.109 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -69.49 -26.04 64.35 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 112.288 0.477 . . . . 74.03 112.288 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.401 ' HB2' ' O ' ' A' ' 153' ' ' VAL . . . -69.11 -46.68 67.1 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 123.619 0.768 . . . . 63.21 109.743 172.096 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -61.93 -42.03 98.63 Favored 'General case' 0 CA--C 1.546 0.801 0 CA-C-N 114.614 -1.176 . . . . 74.34 111.039 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.4 m80 -72.97 -42.2 63.6 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 122.804 0.442 . . . . 72.34 110.317 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.85 -128.76 9.79 Favored Glycine 0 C--N 1.345 1.032 0 CA-C-N 115.309 -0.86 . . . . 53.13 111.308 -172.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.4 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 80.38 -158.5 41.79 Favored Glycine 0 C--N 1.348 1.24 0 CA-C-N 116.834 0.317 . . . . 52.31 112.805 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -84.0 147.16 27.59 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 117.329 0.564 . . . . 72.23 109.763 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.567 ' HB2' HD11 ' A' ' 149' ' ' ILE . 27.0 tpt180 -128.33 121.2 28.63 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.433 0.693 . . . . 73.22 109.178 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.401 HG11 ' HG3' ' A' ' 144' ' ' ARG . 93.1 t -79.22 106.87 10.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.455 0 C-N-CA 123.975 0.91 . . . . 73.03 109.265 178.055 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.583 HG21 HD12 ' A' ' 98' ' ' LEU . 20.7 m -111.13 159.64 10.97 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 123.863 0.865 . . . . 74.13 109.377 176.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -116.79 138.12 51.72 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 107.703 -1.221 . . . . 74.43 107.703 -176.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.53 HG13 ' HB2' ' A' ' 143' ' ' ARG . 3.7 p -150.15 107.12 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 C-N-CA 123.212 0.605 . . . . 73.42 111.498 -176.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.18 20.6 8.63 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 113.359 0.874 . . . . 72.45 113.359 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.9 28.31 7.87 Favored Glycine 0 C--N 1.344 0.976 0 C-N-CA 122.903 0.287 . . . . 73.12 112.582 -175.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.53 ' HB2' HG13 ' A' ' 140' ' ' VAL . 82.3 mtt85 -133.68 156.64 47.55 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 123.533 0.733 . . . . 74.15 110.095 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.401 ' HG3' HG11 ' A' ' 137' ' ' VAL . 31.6 ttm180 -109.86 119.77 40.39 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.754 0.822 . . . . 75.44 109.169 170.457 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.42 ' O ' HG23 ' A' ' 138' ' ' VAL . 69.8 t -115.69 135.63 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 108.421 -0.955 . . . . 71.42 108.421 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 28.9 p -103.2 104.78 14.96 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 109.141 -0.688 . . . . 72.03 109.141 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 4.7 p -98.3 120.29 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 109.172 -0.677 . . . . 74.32 109.172 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 47.3 ttp180 -78.21 100.37 6.62 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-O 121.415 0.626 . . . . 74.2 109.33 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.567 HD11 ' HB2' ' A' ' 136' ' ' ARG . 3.1 pt -79.55 144.9 62.03 Favored Pre-proline 0 CA--C 1.563 1.449 0 CA-C-N 114.639 -1.164 . . . . 72.33 109.766 178.444 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -61.93 136.82 63.71 Favored 'Trans proline' 0 CA--C 1.562 1.891 0 C-N-CA 123.005 2.47 . . . . 75.32 113.393 -179.033 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -62.18 113.12 1.76 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.948 2.432 . . . . 72.03 111.179 172.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.47 35.51 8.59 Favored Glycine 0 C--N 1.34 0.765 0 O-C-N 123.616 0.573 . . . . 72.41 112.379 -176.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.401 ' O ' ' HB2' ' A' ' 130' ' ' ALA . 12.6 p -76.65 145.85 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 N-CA-C 109.818 -0.438 . . . . 74.01 109.818 176.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -118.39 177.15 4.92 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.651 0.739 . . . . 75.14 112.636 -171.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -64.68 135.05 55.47 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 113.989 -1.459 . . . . 73.3 110.974 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.22 -6.13 64.73 Favored Glycine 0 C--N 1.343 0.959 0 CA-C-N 115.767 -0.652 . . . . 75.1 113.646 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 56.0 m -74.85 118.89 18.31 Favored 'General case' 0 C--N 1.351 0.647 0 CA-C-N 117.502 0.651 . . . . 72.43 109.506 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.0 p -99.05 134.25 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 123.087 0.555 . . . . 74.42 110.413 -177.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 67.7 mt -105.94 105.87 19.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 C-N-CA 124.328 1.051 . . . . 73.14 108.71 -175.125 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 58.0 ttm-85 -87.96 111.86 21.94 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.81 0.444 . . . . 74.41 110.405 -178.318 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -123.95 98.95 38.66 Favored Pre-proline 0 CA--C 1.554 1.124 0 C-N-CA 123.942 0.897 . . . . 74.2 109.0 179.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.28 131.75 21.13 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.488 2.126 . . . . 75.32 112.22 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.89 -23.17 37.07 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.761 -0.654 . . . . 62.02 113.56 176.099 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.2 mpt? -89.57 6.56 40.55 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.107 0.563 . . . . 74.24 111.288 178.004 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -85.51 -108.37 0.7 Allowed Glycine 0 C--N 1.344 1.001 0 N-CA-C 111.556 -0.617 . . . . 74.32 111.556 174.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.6 108.93 2.64 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 112.286 -0.326 . . . . 74.35 112.286 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.552 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -88.36 148.46 24.24 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.194 0.598 . . . . 63.1 110.885 -179.493 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.48 -138.51 8.49 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 111.062 -0.815 . . . . 73.51 111.062 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.444 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 3.4 m-20 -78.41 -49.16 1.82 Allowed Pre-proline 0 CA--C 1.566 1.578 0 CA-C-O 118.29 -0.862 . . . . 74.21 110.644 175.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.444 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -94.97 106.41 0.12 Allowed 'Trans proline' 0 C--N 1.396 3.034 0 C-N-CA 122.658 2.238 . . . . 73.44 111.905 172.09 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.37 125.23 13.63 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 122.025 1.817 . . . . 70.51 111.456 174.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -99.97 173.96 26.06 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 116.041 -0.527 . . . . 74.41 111.975 175.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -92.48 152.57 19.6 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 123.309 0.644 . . . . 72.31 110.663 -174.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 59.3 tp -114.23 133.76 55.4 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.901 0.88 . . . . 71.33 109.75 179.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.3 mt -129.85 103.46 6.82 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.021 0.928 . . . . 74.52 110.428 176.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.511 HD22 HD13 ' A' ' 98' ' ' LEU . 82.8 mt -101.77 103.18 13.9 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 123.072 0.549 . . . . 72.3 111.212 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.9 t -84.11 97.68 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 N-CA-C 108.954 -0.758 . . . . 70.35 108.954 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 89.5 t -57.03 130.26 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 124.024 0.93 . . . . 73.34 111.436 -178.199 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -121.4 105.32 10.4 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 125.068 1.347 . . . . 63.4 107.912 -177.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 24.1 mt -70.32 109.8 4.92 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.377 -0.601 . . . . 74.41 109.377 178.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.8 mt -72.27 149.97 91.82 Favored Pre-proline 0 CA--C 1.549 0.942 0 C-N-CA 123.062 0.545 . . . . 75.22 110.097 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -58.93 97.49 0.09 OUTLIER 'Trans proline' 0 C--N 1.376 2.005 0 C-N-CA 122.898 2.399 . . . . 74.04 110.98 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 124.772 1.229 . . . . 75.02 109.702 -172.574 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 tt . . . . . 0 CA--C 1.556 1.202 0 N-CA-C 111.664 0.246 . . . . 72.12 111.664 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -90.81 -152.04 0.04 OUTLIER 'Trans proline' 0 CA--C 1.553 1.434 0 C-N-CA 122.827 2.351 . . . . 73.44 111.101 168.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.555 HD12 ' H ' ' A' ' 98' ' ' LEU . 12.1 tp -74.69 144.52 43.71 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.961 0.905 . . . . 73.24 109.41 175.24 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.555 ' H ' HD12 ' A' ' 97' ' ' LEU . 9.0 tp 64.4 -67.79 0.11 Allowed 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.731 2.412 . . . . 74.42 112.002 -171.422 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.686 ' HA ' HD11 ' A' ' 119' ' ' LEU . 60.7 t80 -64.58 130.01 42.01 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.411 1.084 . . . . 75.31 111.531 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.473 HG23 HG11 ' A' ' 102' ' ' VAL . 39.7 m -146.09 98.29 4.39 Favored Pre-proline 0 CA--C 1.54 0.58 0 C-N-CA 124.679 1.192 . . . . 75.14 108.766 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.26 87.11 0.92 Allowed 'Trans proline' 0 C--N 1.366 1.471 0 C-N-CA 122.192 1.928 . . . . 72.01 112.554 -171.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.473 HG11 HG23 ' A' ' 100' ' ' THR . 14.7 m . . . . . 0 CA--C 1.541 0.621 0 C-N-CA 124.332 1.053 . . . . 71.33 108.745 173.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.662 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 37.5 mtm180 . . . . . 0 N--CA 1.476 0.875 0 N-CA-C 109.495 -0.558 . . . . 72.44 109.495 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -99.8 107.49 19.54 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 108.188 -1.041 . . . . 62.1 108.188 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.686 HD11 ' HA ' ' A' ' 99' ' ' PHE . 16.4 mt -93.63 111.05 22.66 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 107.64 -1.244 . . . . 73.54 107.64 -175.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.3 ttp85 -114.6 105.61 13.28 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 108.896 -0.779 . . . . 73.34 108.896 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 145.66 50.96 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 123.68 0.792 . . . . 74.51 109.633 -175.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.463 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 3.2 mp0 -74.16 131.73 41.55 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 123.667 0.787 . . . . 62.31 109.225 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.513 HD11 ' HG2' ' A' ' 136' ' ' ARG . 40.9 tp -100.12 102.89 19.57 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 124.29 1.036 . . . . 71.1 109.134 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -67.86 114.56 3.39 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 122.274 1.982 . . . . 74.11 109.956 176.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.471 HD23 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -143.86 131.43 21.15 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.066 -0.716 . . . . 74.11 109.066 -171.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.8 p -80.52 170.51 16.25 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 110.296 -0.261 . . . . 73.34 110.296 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 84.8 mt -61.37 -34.74 75.83 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.837 0.855 . . . . 72.54 111.157 -178.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -72.79 -51.67 18.07 Favored 'General case' 0 C--N 1.345 0.379 0 CA-C-N 114.776 -1.102 . . . . 75.34 108.803 -176.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -66.94 -26.72 66.98 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.01 -0.996 . . . . 63.44 111.575 -176.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.436 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -74.87 -50.47 16.89 Favored 'General case' 0 C--N 1.348 0.521 0 C-N-CA 123.901 0.88 . . . . 74.3 111.375 176.102 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -58.61 -46.15 87.66 Favored 'General case' 0 C--N 1.361 1.068 0 O-C-N 124.308 1.005 . . . . 75.53 110.664 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -77.78 -40.63 40.11 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.279 -0.873 . . . . 74.42 111.033 -176.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.58 -164.53 50.9 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 111.828 -0.509 . . . . 63.13 111.828 -175.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.456 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 119.49 -161.11 14.18 Favored Glycine 0 N--CA 1.473 1.12 0 N-CA-C 111.774 -0.53 . . . . 62.12 111.774 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -81.52 141.63 33.63 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.046 0.539 . . . . 75.23 110.253 177.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.513 ' HG2' HD11 ' A' ' 123' ' ' LEU . 19.4 tpp180 -126.75 121.28 31.56 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.969 0.908 . . . . 64.41 108.768 178.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 56.0 t -81.28 107.63 13.72 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 C-N-CA 123.339 0.656 . . . . 75.23 109.614 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.544 HG22 HD13 ' A' ' 98' ' ' LEU . 25.5 m -116.37 164.63 12.53 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 C-N-CA 125.297 1.439 . . . . 75.53 109.318 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -122.41 131.48 53.9 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 123.446 0.699 . . . . 64.42 109.575 -171.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 5.2 p -142.54 102.41 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.321 0 C-N-CA 124.211 1.004 . . . . 75.51 111.656 -174.002 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.55 25.93 14.86 Favored 'General case' 0 N--CA 1.493 1.681 0 C-N-CA 124.229 1.012 . . . . 74.51 112.759 175.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.56 -0.8 53.01 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 123.901 0.762 . . . . 75.34 113.438 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.5 mmm180 -104.07 141.89 35.42 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.421 0.689 . . . . 75.41 110.367 -177.458 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -97.81 113.89 25.8 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.753 0.821 . . . . 75.11 109.284 178.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 73.6 t -118.51 129.6 74.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 123.859 0.864 . . . . 74.52 109.561 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 33.5 p -97.39 106.58 18.92 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 109.063 -0.717 . . . . 73.33 109.063 174.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.3 p -98.7 125.9 51.99 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 123.494 0.717 . . . . 75.35 109.76 -177.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.2 ttt180 -81.99 105.06 12.79 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.379 0.672 . . . . 74.41 109.62 -177.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.471 HD12 HD23 ' A' ' 125' ' ' LEU . 4.8 pt -87.24 146.03 39.18 Favored Pre-proline 0 C--O 1.253 1.265 0 C-N-CA 124.68 1.192 . . . . 74.42 109.343 176.493 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.475 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 57.0 Cg_endo -72.04 143.09 39.69 Favored 'Trans proline' 0 CA--C 1.56 1.799 0 C-N-CA 122.441 2.094 . . . . 72.24 112.76 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.39 130.49 22.53 Favored 'Trans proline' 0 C--N 1.375 1.941 0 C-N-CA 122.493 2.129 . . . . 72.35 111.262 171.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.82 27.57 45.73 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 115.548 -0.751 . . . . 75.11 112.243 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.475 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 12.4 p -76.62 147.71 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 108.989 -0.745 . . . . 74.34 108.989 176.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.0 mtp180 -125.12 176.06 6.96 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-O 121.993 0.901 . . . . 72.32 112.591 -166.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -64.42 123.9 20.38 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-N 113.292 -1.776 . . . . 71.4 110.332 175.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.54 89.55 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.798 0.686 . . . . 61.24 113.611 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.3 m -76.54 118.49 19.25 Favored 'General case' 0 C--N 1.35 0.614 0 N-CA-C 108.778 -0.823 . . . . 71.44 108.778 176.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.12 124.7 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 CA-C-O 121.437 0.637 . . . . 71.33 109.677 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.5 mt -95.14 102.85 14.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 C-N-CA 124.324 1.05 . . . . 74.1 108.23 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.513 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 35.1 ttm180 -87.28 107.91 18.72 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 109.49 -0.559 . . . . 74.43 109.49 174.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.9 t -105.7 107.69 59.92 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 107.428 -1.323 . . . . 71.11 107.428 173.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -66.02 135.4 40.61 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.484 2.123 . . . . 74.52 112.043 -177.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 80.39 -5.33 64.19 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 114.723 0.649 . . . . 73.12 114.723 174.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 96.3 mmm -103.9 16.58 26.01 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 117.807 0.803 . . . . 74.45 111.842 -176.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -90.88 -142.29 10.07 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 116.149 -0.478 . . . . 54.21 111.983 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . 0.662 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.69 127.93 8.58 Favored Glycine 0 C--N 1.343 0.965 0 N-CA-C 111.638 -0.585 . . . . 63.51 111.638 -177.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.9 mm-40 -83.61 151.64 25.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 123.46 0.704 . . . . 75.5 110.513 -175.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -148.75 -125.85 1.48 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 109.559 -1.417 . . . . 74.12 109.559 177.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.555 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 23.2 t30 -74.63 -51.26 4.14 Favored Pre-proline 0 CA--C 1.564 1.493 0 N-CA-C 108.118 -1.067 . . . . 72.3 108.118 161.265 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.555 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 49.4 Cg_endo -100.13 164.45 0.47 Allowed 'Trans proline' 0 C--N 1.39 2.731 0 C-N-CA 122.74 2.294 . . . . 74.32 111.689 165.324 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.21 136.68 14.61 Favored 'Trans proline' 0 CA--C 1.557 1.67 0 C-N-CA 121.794 1.662 . . . . 73.24 112.182 174.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -86.78 179.7 48.89 Favored Glycine 0 C--N 1.348 1.218 0 CA-C-O 119.999 -0.334 . . . . 72.2 112.552 175.16 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -97.48 148.53 23.13 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.043 0.537 . . . . 74.32 110.956 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.513 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 56.8 tp -107.01 132.73 52.62 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.052 0.941 . . . . 72.55 110.368 -178.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 93.6 mt -129.37 104.02 7.25 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 125.023 1.329 . . . . 74.23 109.609 176.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.492 HD23 HD11 ' A' ' 98' ' ' LEU . 65.9 mt -104.54 103.44 13.12 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 122.98 0.512 . . . . 62.44 110.518 176.476 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.5 t -84.83 93.6 3.57 Favored 'Isoleucine or valine' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 75.34 108.603 -177.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.485 HG22 HD21 ' A' ' 123' ' ' LEU . 97.3 t -56.7 127.66 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.098 0.959 . . . . 75.54 111.264 -178.429 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . 0.463 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.9 mmt180 -121.57 114.49 21.27 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 124.546 1.138 . . . . 73.12 108.435 -179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 75.1 mt -72.48 106.16 4.46 Favored 'General case' 0 C--O 1.241 0.648 0 O-C-N 123.826 0.704 . . . . 73.44 110.132 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 72.1 mt -66.22 153.77 91.6 Favored Pre-proline 0 CA--C 1.546 0.807 0 CA-C-N 115.868 -0.605 . . . . 64.2 110.522 179.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -56.99 140.79 93.39 Favored 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 122.899 2.4 . . . . 62.41 111.218 173.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 . . . . . 0 C--O 1.251 1.159 0 N-CA-C 109.329 -0.619 . . . . 74.51 109.329 -179.098 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.3 pt? . . . . . 0 N--CA 1.488 1.464 0 N-CA-C 113.346 0.869 . . . . 65.51 113.346 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.69 -44.63 7.87 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 122.074 1.849 . . . . 70.03 110.832 176.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.55 HD13 ' H ' ' A' ' 98' ' ' LEU . 5.6 tp -177.99 144.52 0.34 Allowed 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.495 1.518 . . . . 70.31 107.807 177.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.757 HD23 ' HB ' ' A' ' 140' ' ' VAL . 18.2 tp 62.68 -70.16 0.06 Allowed 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 126.779 2.031 . . . . 75.23 112.226 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.497 ' HA ' HD12 ' A' ' 119' ' ' LEU . 76.8 t80 -63.23 130.76 45.93 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.335 1.054 . . . . 75.35 110.785 174.37 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.456 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 52.3 m -139.65 102.55 7.12 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 124.2 1.0 . . . . 63.1 109.475 177.049 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.87 89.68 0.86 Allowed 'Trans proline' 0 C--N 1.359 1.106 0 C-N-CA 121.676 1.584 . . . . 73.43 111.159 -177.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.474 0.755 0 CA-C-N 115.789 -0.641 . . . . 74.13 109.601 170.628 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 . . . . . 0 CA--C 1.537 0.451 0 N-CA-C 108.144 -1.058 . . . . 74.04 108.144 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -94.44 104.87 16.84 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 107.314 -1.365 . . . . 75.22 107.314 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.497 HD12 ' HA ' ' A' ' 99' ' ' PHE . 11.8 mt -92.53 111.83 23.55 Favored 'General case' 0 C--N 1.345 0.384 0 N-CA-C 107.785 -1.191 . . . . 71.5 107.785 -172.079 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 68.6 ttt180 -120.13 107.82 13.5 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.253 1.021 . . . . 75.25 108.724 -177.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.19 148.16 50.85 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.066 0.546 . . . . 73.24 111.531 -171.371 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.558 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.5 mp0 -68.3 125.06 25.24 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.403 1.081 . . . . 63.25 109.443 170.338 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.412 HD12 HD11 ' A' ' 176' ' ' LEU . 2.5 tt -101.67 102.9 24.78 Favored Pre-proline 0 CA--C 1.543 0.687 0 N-CA-C 108.104 -1.073 . . . . 71.02 108.104 175.142 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.39 115.54 3.57 Favored 'Trans proline' 0 C--N 1.378 2.107 0 C-N-CA 121.689 1.592 . . . . 75.4 109.636 171.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.559 HD22 HD13 ' A' ' 149' ' ' ILE . 14.0 tp -137.64 123.11 19.6 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.6 -0.889 . . . . 72.5 108.6 -170.166 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.9 p -73.81 169.99 16.23 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 117.785 0.266 . . . . 63.21 110.705 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.1 mt -62.76 -33.43 75.14 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.575 0.75 . . . . 75.44 111.042 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -71.76 -45.51 61.45 Favored 'General case' 0 C--N 1.352 0.683 0 O-C-N 123.783 0.677 . . . . 73.13 109.312 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -64.18 -35.46 80.88 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 123.695 0.798 . . . . 75.24 111.634 176.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.43 -42.91 67.67 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.46 0.704 . . . . 75.42 111.867 -179.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.1 t80 -68.39 -50.88 49.8 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-N 114.884 -1.053 . . . . 71.4 110.102 -179.09 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -75.06 -42.0 57.86 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 115.669 -0.696 . . . . 74.31 111.213 -174.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.31 -134.5 16.82 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.564 0.54 . . . . 73.31 111.844 -177.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 76.27 -146.69 33.53 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-O 119.658 -0.523 . . . . 71.41 111.856 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.421 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 1.4 mp0 -85.18 146.69 26.98 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 117.83 0.815 . . . . 74.22 110.412 178.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.59 ' HB2' HD12 ' A' ' 149' ' ' ILE . 24.7 tpt180 -129.05 121.55 28.11 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.244 1.018 . . . . 73.24 108.936 177.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.5 t -82.18 108.72 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 C-N-CA 123.499 0.72 . . . . 73.02 109.736 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.482 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 33.6 m -128.11 162.15 34.92 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.012 0 C-N-CA 124.995 1.318 . . . . 73.34 108.825 178.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -107.32 138.09 44.16 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 122.882 0.473 . . . . 74.32 110.191 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.757 ' HB ' HD23 ' A' ' 98' ' ' LEU . 3.0 p -123.27 105.87 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 124.564 1.146 . . . . 74.24 109.06 171.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.11 14.87 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.744 0.818 . . . . 74.24 112.863 174.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.28 11.03 43.32 Favored Glycine 0 C--N 1.35 1.349 0 CA-C-O 119.901 -0.388 . . . . 64.55 113.843 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -115.31 118.38 33.09 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 117.429 0.615 . . . . 74.44 110.192 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -82.51 106.14 14.13 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.43 0.692 . . . . 72.25 109.956 -178.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 25.9 m -121.44 155.6 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.6 0.76 . . . . 62.42 110.342 -179.246 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.421 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 14.1 p -106.61 110.15 22.26 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.635 0.774 . . . . 63.25 109.646 175.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -99.22 128.99 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 124.061 0.944 . . . . 74.31 109.205 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -77.95 109.2 11.79 Favored 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.051 0.453 . . . . 74.55 110.506 -175.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.59 HD12 ' HB2' ' A' ' 136' ' ' ARG . 5.0 pt -86.55 142.74 35.25 Favored Pre-proline 0 CA--C 1.558 1.253 0 C-N-CA 124.484 1.113 . . . . 75.54 108.775 173.397 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.47 137.24 20.47 Favored 'Trans proline' 0 CA--C 1.562 1.902 0 C-N-CA 122.191 1.927 . . . . 65.34 111.822 177.353 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -63.44 135.9 52.11 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 122.761 2.308 . . . . 72.05 112.327 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.51 14.6 61.41 Favored Glycine 0 CA--C 1.534 1.253 0 O-C-N 123.636 0.585 . . . . 65.25 113.401 -176.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.18 143.26 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.324 0.649 . . . . 64.03 110.374 -177.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -118.49 177.5 4.8 Favored 'General case' 0 N--CA 1.484 1.24 0 CA-C-O 121.651 0.738 . . . . 74.32 112.894 -169.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -63.49 126.69 28.32 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 113.855 -1.52 . . . . 71.44 110.11 174.807 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -10.15 65.46 Favored Glycine 0 CA--C 1.532 1.129 0 O-C-N 124.111 0.882 . . . . 75.12 113.968 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.1 m -69.86 120.33 15.43 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-N 117.861 0.83 . . . . 74.14 109.989 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.61 139.86 17.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 C-N-CA 122.817 0.447 . . . . 74.34 110.077 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 44.6 mt -110.94 102.23 13.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 N-CA-C 106.85 -1.537 . . . . 70.31 106.85 178.359 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.435 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 6.0 ttp180 -88.15 102.17 14.53 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 108.961 -0.755 . . . . 73.24 108.961 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -95.2 113.05 60.66 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 107.746 -1.205 . . . . 72.15 107.746 175.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.39 128.45 15.47 Favored 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 122.847 2.365 . . . . 71.33 112.688 -169.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 63.49 23.42 66.74 Favored Glycine 0 C--N 1.351 1.392 0 O-C-N 123.592 0.558 . . . . 62.22 114.371 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.8 tpp -100.62 -18.4 16.58 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.487 0.715 . . . . 74.31 111.066 -177.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -72.45 -95.9 0.08 OUTLIER Glycine 0 C--N 1.345 1.035 0 CA-C-N 115.832 -0.622 . . . . 62.42 113.256 -175.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -72.36 86.75 0.5 Allowed Glycine 0 C--N 1.346 1.117 0 N-CA-C 112.252 -0.339 . . . . 71.45 112.252 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . 0.599 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -81.93 121.64 26.75 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.376 0.67 . . . . 62.33 109.978 179.654 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 162.31 -142.12 7.72 Favored Glycine 0 C--O 1.241 0.591 0 N-CA-C 111.282 -0.727 . . . . 71.33 111.282 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.511 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 19.3 m120 -67.43 -49.43 42.25 Favored Pre-proline 0 CA--C 1.566 1.56 0 CA-C-O 118.271 -0.871 . . . . 75.42 110.886 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.511 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -96.48 106.69 0.1 OUTLIER 'Trans proline' 0 C--N 1.395 3.023 0 C-N-CA 123.125 2.55 . . . . 74.32 111.485 170.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.01 129.87 24.28 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.641 2.227 . . . . 70.54 111.778 178.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -117.97 157.33 15.22 Favored Glycine 0 C--N 1.338 0.642 0 N-CA-C 111.501 -0.64 . . . . 54.33 111.501 178.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -89.7 158.85 17.38 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 123.603 0.761 . . . . 73.34 110.558 -177.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.435 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 67.0 tp -115.7 132.64 56.57 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.834 0.853 . . . . 74.32 109.948 -177.675 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.7 mt -127.84 101.41 6.33 Favored 'General case' 0 CA--C 1.549 0.925 0 C-N-CA 125.35 1.46 . . . . 73.04 109.236 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.495 HD21 HD13 ' A' ' 98' ' ' LEU . 75.7 mt -101.46 100.83 11.33 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 123.11 0.564 . . . . 71.42 110.923 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 4.7 t -85.53 95.26 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 N-CA-C 108.409 -0.96 . . . . 75.02 108.409 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 73.9 t -54.67 135.03 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.695 1.198 . . . . 71.24 111.629 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . 0.558 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.3 mmt180 -128.27 107.68 9.97 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.312 -1.366 . . . . 72.23 107.312 -177.669 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 53.3 mt -69.98 121.62 17.75 Favored 'General case' 0 N--CA 1.47 0.534 0 O-C-N 123.438 0.461 . . . . 75.53 109.943 -177.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 83.8 mt -85.46 140.64 36.2 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.894 -0.594 . . . . 72.02 110.268 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.56 -15.9 34.14 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.667 2.245 . . . . 75.22 111.872 172.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 35.9 m80 . . . . . 0 C--N 1.356 0.849 0 C-N-CA 124.308 1.043 . . . . 74.44 108.264 176.994 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 113.688 0.996 . . . . 74.3 113.688 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -64.71 -55.93 0.47 Allowed 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.494 2.129 . . . . 65.34 112.0 177.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.479 HD13 ' H ' ' A' ' 98' ' ' LEU . 7.2 tp -177.55 134.88 0.18 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.785 1.234 . . . . 74.42 108.18 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.479 ' H ' HD13 ' A' ' 97' ' ' LEU . 15.4 tp 66.86 -63.57 0.26 Allowed 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 126.89 2.076 . . . . 74.41 111.379 -174.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.418 ' HB2' HG23 ' A' ' 140' ' ' VAL . 40.7 t80 -69.43 126.02 28.49 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.696 1.198 . . . . 73.1 111.433 176.8 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.538 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 87.1 m -138.77 88.45 13.88 Favored Pre-proline 0 N--CA 1.47 0.57 0 C-N-CA 124.444 1.098 . . . . 71.44 108.657 176.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.4 83.96 0.61 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 122.461 2.107 . . . . 74.2 112.615 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.514 HG13 HG23 ' A' ' 100' ' ' THR . 21.2 m . . . . . 0 CA--C 1.538 0.506 0 CA-C-N 114.612 -1.176 . . . . 73.11 108.857 172.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.403 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 45.2 mtt180 . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 110.432 -0.21 . . . . 71.52 110.432 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -98.05 109.17 21.97 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 107.491 -1.3 . . . . 75.35 107.491 177.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.538 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 15.0 mt -91.47 108.04 19.62 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 106.165 -1.791 . . . . 74.22 106.165 177.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 34.7 ttt180 -118.89 106.16 12.21 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.104 -1.073 . . . . 71.03 108.104 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -131.0 144.54 51.55 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.165 0.586 . . . . 74.33 109.54 -175.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.597 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.2 mp0 -72.8 129.01 37.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 114.88 -1.055 . . . . 75.43 108.536 173.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.52 HD23 ' HG2' ' A' ' 136' ' ' ARG . 3.0 tt -99.76 102.39 16.97 Favored Pre-proline 0 CA--C 1.536 0.438 0 N-CA-C 106.609 -1.626 . . . . 74.15 106.609 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -65.93 113.86 2.75 Favored 'Trans proline' 0 C--N 1.376 2.026 0 C-N-CA 121.839 1.693 . . . . 73.14 110.271 174.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.502 HD21 HD12 ' A' ' 149' ' ' ILE . 17.8 tp -144.36 121.9 11.75 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.796 -1.187 . . . . 72.34 107.796 -173.812 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.3 p -73.96 168.34 19.67 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 117.761 0.255 . . . . 75.21 110.478 -177.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.8 mt -57.58 -36.43 71.7 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.249 0.619 . . . . 74.42 110.918 176.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 21.2 mp0 -71.88 -46.75 56.78 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 124.611 1.165 . . . . 60.02 110.386 -176.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -72.06 -27.49 62.72 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.601 0.76 . . . . 74.45 111.911 -179.051 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -69.41 -46.02 67.82 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.426 0.69 . . . . 73.13 109.926 173.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -58.96 -41.56 87.77 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 124.718 1.207 . . . . 73.42 110.849 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.45 -49.1 67.83 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.59 0.556 . . . . 71.54 109.541 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.479 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.01 56.93 22.41 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.062 -0.972 . . . . 45.35 113.106 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -92.0 -148.17 21.91 Favored Glycine 0 C--N 1.345 1.033 0 O-C-N 123.491 0.171 . . . . 61.44 112.808 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -95.4 132.32 40.59 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 107.757 -1.201 . . . . 73.43 107.757 169.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.52 ' HG2' HD23 ' A' ' 123' ' ' LEU . 12.8 tpp180 -111.62 116.94 31.65 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 107.678 -1.23 . . . . 74.14 107.678 -178.405 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.51 HG21 ' HG2' ' A' ' 144' ' ' ARG . 12.1 p -98.76 118.12 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 N-CA-C 108.133 -1.062 . . . . 72.24 108.133 -176.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.417 HG11 ' HG3' ' A' ' 136' ' ' ARG . 35.6 m -134.22 161.84 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.849 0.86 . . . . 74.14 110.008 -173.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -96.97 136.88 36.91 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 123.679 0.792 . . . . 65.33 110.093 -173.596 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.418 HG23 ' HB2' ' A' ' 99' ' ' PHE . 5.4 p -144.49 111.59 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.607 1.163 . . . . 74.53 109.631 177.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.4 22.01 12.95 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 123.684 0.794 . . . . 70.51 113.025 173.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.92 -16.12 58.76 Favored Glycine 0 C--N 1.345 1.049 0 C-N-CA 123.827 0.727 . . . . 73.11 112.653 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 19.4 tpp180 -95.72 123.92 39.51 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.249 1.02 . . . . 72.31 109.551 178.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.51 ' HG2' HG21 ' A' ' 137' ' ' VAL . 22.6 ttp180 -89.51 107.05 18.85 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 108.728 -0.841 . . . . 74.31 108.728 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 70.0 t -112.7 136.79 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 C-N-CA 124.112 0.965 . . . . 75.31 110.508 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 31.9 p -96.18 120.83 37.17 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.279 0.632 . . . . 72.54 110.669 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.5 p -106.37 131.02 57.14 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.943 1.297 . . . . 72.54 109.345 174.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 46.7 ttp180 -79.02 122.34 26.07 Favored 'General case' 0 C--O 1.243 0.72 0 CA-C-O 120.969 0.414 . . . . 71.52 109.98 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.502 HD12 HD21 ' A' ' 125' ' ' LEU . 10.3 pt -96.5 140.71 22.32 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 124.26 1.024 . . . . 73.1 109.823 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_exo -66.18 142.66 68.13 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.058 2.505 . . . . 72.1 113.045 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.404 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 31.6 Cg_endo -66.17 130.91 25.29 Favored 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 122.327 2.018 . . . . 74.45 110.802 170.144 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 70.81 26.29 74.26 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 115.532 -0.758 . . . . 62.42 113.945 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.0 p -68.77 137.37 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-N 117.201 0.5 . . . . 74.12 110.755 -178.672 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -98.37 175.77 5.93 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.875 0.845 . . . . 75.52 112.963 -168.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -69.65 134.0 48.21 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 113.547 -1.661 . . . . 74.11 110.669 177.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 73.89 10.17 80.27 Favored Glycine 0 C--N 1.342 0.914 0 CA-C-N 116.062 -0.517 . . . . 72.43 113.452 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.5 m -81.32 118.9 23.02 Favored 'General case' 0 C--N 1.347 0.473 0 N-CA-C 108.626 -0.879 . . . . 74.12 108.626 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 3.3 p -99.91 115.03 40.08 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.351 0.596 . . . . 73.32 109.796 -175.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 55.5 mt -90.05 104.49 15.24 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 124.516 1.126 . . . . 74.55 108.212 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.532 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 24.8 ttp180 -90.32 117.9 29.4 Favored 'General case' 0 C--N 1.344 0.355 0 N-CA-C 110.548 -0.168 . . . . 73.34 110.548 -179.655 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.0 t -109.11 95.28 17.29 Favored Pre-proline 0 CA--C 1.555 1.157 0 N-CA-C 107.5 -1.296 . . . . 64.12 107.5 166.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -70.26 136.29 31.33 Favored 'Trans proline' 0 C--N 1.373 1.857 0 C-N-CA 122.888 2.392 . . . . 74.44 111.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.39 2.24 82.92 Favored Glycine 0 CA--C 1.531 1.089 0 CA-C-O 119.635 -0.536 . . . . 65.32 114.118 178.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 41.4 tpp -128.51 12.99 6.48 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 117.872 0.836 . . . . 74.45 110.726 -177.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.38 -106.74 0.78 Allowed Glycine 0 C--N 1.344 1.021 0 CA-C-N 115.866 -0.606 . . . . 73.11 111.896 178.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -61.38 105.11 0.8 Allowed Glycine 0 C--N 1.347 1.179 0 C-N-CA 123.018 0.342 . . . . 74.31 113.502 -177.248 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -89.69 134.7 34.02 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.862 0.865 . . . . 71.44 109.176 173.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -178.9 -51.14 0.08 OUTLIER Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.031 -1.228 . . . . 74.34 110.031 177.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.441 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 25.1 t-20 -166.25 -54.76 0.01 OUTLIER Pre-proline 0 CA--C 1.556 1.192 0 C-N-CA 124.952 1.301 . . . . 75.1 108.173 169.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.441 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 82.1 Cg_endo -82.54 134.49 7.63 Favored 'Trans proline' 0 C--N 1.399 3.196 0 C-N-CA 121.721 1.614 . . . . 74.42 110.411 170.004 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.76 125.84 10.87 Favored 'Trans proline' 0 C--N 1.367 1.537 0 C-N-CA 122.228 1.952 . . . . 74.55 111.824 178.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -95.13 -172.18 37.03 Favored Glycine 0 C--N 1.349 1.273 0 CA-C-N 116.182 -0.463 . . . . 65.42 113.416 175.495 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.6 144.33 28.02 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.417 0.687 . . . . 70.42 110.5 178.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.532 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.6 tp -107.99 129.68 55.1 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-N 115.312 -0.858 . . . . 74.32 108.879 178.315 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.4 mt -128.27 102.56 6.73 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 124.472 1.109 . . . . 75.53 109.187 -178.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.424 HD21 HD13 ' A' ' 98' ' ' LEU . 89.4 mt -104.08 101.36 11.12 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 121.0 0.428 . . . . 73.13 110.486 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.46 95.75 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.47 -0.937 . . . . 72.22 108.47 -176.195 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.7 t -55.63 124.11 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 124.142 0.977 . . . . 74.32 111.355 -179.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . 0.597 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 28.2 mmt180 -116.38 104.48 11.51 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.383 1.073 . . . . 74.51 108.459 -179.323 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.453 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 60.8 mt -70.05 111.05 5.44 Favored 'General case' 0 C--N 1.343 0.323 0 C-N-CA 123.685 0.794 . . . . 75.43 110.732 -178.028 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 63.3 mt -94.73 144.22 27.51 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.324 0.65 . . . . 64.31 110.044 -179.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.93 -33.23 4.84 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 122.425 2.083 . . . . 74.12 110.773 167.17 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 . . . . . 0 N--CA 1.48 1.069 0 C-N-CA 124.82 1.248 . . . . 73.3 108.15 175.829 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pp . . . . . 0 CA--C 1.56 1.363 0 N-CA-C 114.391 1.256 . . . . 72.42 114.391 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.93 -61.87 0.16 Allowed 'Trans proline' 0 C--N 1.382 2.341 0 C-N-CA 122.519 2.146 . . . . 72.3 110.509 176.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.436 HD13 ' H ' ' A' ' 98' ' ' LEU . 7.8 tp -172.68 144.33 1.39 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.599 1.16 . . . . 74.12 107.901 172.272 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.562 HD13 HG22 ' A' ' 138' ' ' VAL . 8.9 tp 64.31 -66.36 0.12 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 126.346 1.858 . . . . 71.34 111.828 -169.08 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.403 ' HB2' HG21 ' A' ' 140' ' ' VAL . 77.4 t80 -59.55 137.47 58.01 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 124.733 1.213 . . . . 74.12 111.972 178.147 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.552 HG22 HG11 ' A' ' 102' ' ' VAL . 61.2 m -157.66 108.93 1.81 Allowed Pre-proline 0 N--CA 1.475 0.822 0 C-N-CA 124.755 1.222 . . . . 74.2 109.225 177.358 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -81.42 68.15 8.24 Favored 'Trans proline' 0 C--N 1.371 1.736 0 C-N-CA 122.381 2.054 . . . . 72.42 112.582 -172.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.552 HG11 HG22 ' A' ' 100' ' ' THR . 9.6 m . . . . . 0 N--CA 1.486 1.333 0 CA-C-N 114.78 -1.1 . . . . 73.44 112.663 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.527 ' HG3' ' HA3' ' A' ' 166' ' ' GLY . 21.2 ptt180 . . . . . 0 CA--C 1.554 1.108 0 N-CA-C 108.98 -0.748 . . . . 75.31 108.98 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.472 ' HA ' ' O ' ' A' ' 173' ' ' ASP . 0.1 OUTLIER -101.99 115.06 29.74 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.875 0.87 . . . . 72.51 110.681 -157.955 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.481 HD21 ' O ' ' A' ' 100' ' ' THR . 13.8 mt -90.86 109.53 20.74 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 106.841 -1.54 . . . . 72.44 106.841 178.147 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.18 110.64 21.92 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 123.129 0.572 . . . . 75.53 110.376 -178.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.88 138.59 52.73 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.799 -0.815 . . . . 72.0 108.799 177.002 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mp0 -77.82 122.21 25.12 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.51 -0.922 . . . . 73.1 108.51 176.419 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.521 HD13 HD11 ' A' ' 176' ' ' LEU . 1.0 OUTLIER -99.67 111.05 60.87 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 108.667 -0.864 . . . . 75.02 108.667 -172.281 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.415 ' HB2' HD13 ' A' ' 181' ' ' LEU . 52.6 Cg_endo -67.89 116.67 4.42 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.06 1.84 . . . . 70.54 109.788 170.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.491 HD22 HD12 ' A' ' 149' ' ' ILE . 23.6 tp -131.45 133.04 44.78 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 108.715 -0.846 . . . . 73.4 108.715 -172.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 45.1 p -75.48 157.17 34.4 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.36 -0.607 . . . . 75.02 109.36 -178.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.54 -31.15 71.89 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.274 0.63 . . . . 75.34 111.074 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -70.78 -51.64 25.66 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.768 0.827 . . . . 74.23 110.107 179.458 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -65.45 -34.16 77.64 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.485 0.714 . . . . 74.24 111.581 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.43 -45.56 86.99 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 124.027 0.829 . . . . 71.54 110.699 173.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -66.08 -35.75 81.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 124.177 0.991 . . . . 63.01 111.116 179.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -73.65 -43.16 60.2 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.997 0.519 . . . . 65.11 109.865 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.426 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 67.23 51.37 38.68 Favored Glycine 0 C--N 1.347 1.149 0 CA-C-N 114.877 -1.056 . . . . 75.11 111.742 -168.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -89.84 -150.55 23.57 Favored Glycine 0 C--N 1.347 1.177 0 CA-C-O 120.841 0.134 . . . . 72.22 112.971 -177.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.411 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 7.5 mp0 -101.36 140.97 34.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.576 -0.898 . . . . 72.55 108.576 169.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 24.4 tpt85 -120.56 121.53 38.6 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.074 0.949 . . . . 73.21 108.548 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 12.2 p -84.73 117.89 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.784 0.802 . . . . 73.44 109.769 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.562 HG22 HD13 ' A' ' 98' ' ' LEU . 34.6 m -126.46 160.3 34.41 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 C-N-CA 125.444 1.498 . . . . 72.43 107.974 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -125.62 112.7 16.46 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-N 118.981 0.809 . . . . 62.24 111.801 -172.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.497 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.5 p -105.55 105.55 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 C-N-CA 125.608 1.563 . . . . 70.42 111.004 -176.572 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.25 28.5 15.26 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 124.146 0.978 . . . . 72.22 112.521 177.111 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.11 -10.49 58.38 Favored Glycine 0 C--N 1.356 1.687 0 CA-C-O 119.79 -0.45 . . . . 72.43 114.085 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -90.25 118.32 29.67 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 108.605 -0.887 . . . . 74.35 108.605 174.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 48.4 ttt85 -98.8 109.74 22.45 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 109.248 -0.649 . . . . 73.45 109.248 -177.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.1 p -130.75 146.07 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.527 1.131 . . . . 71.33 110.377 -172.272 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.411 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 28.4 m -93.18 119.19 32.09 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 123.693 0.797 . . . . 73.22 110.464 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -101.26 130.13 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.114 0.966 . . . . 75.4 109.944 175.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 36.9 ttp180 -75.84 134.77 40.27 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.248 0.547 . . . . 71.01 110.137 178.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.491 HD12 HD22 ' A' ' 125' ' ' LEU . 2.8 pt -108.65 145.66 32.07 Favored Pre-proline 0 CA--C 1.564 1.492 0 C-N-CA 125.11 1.364 . . . . 72.43 108.985 -179.473 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.52 145.99 97.75 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 123.037 2.491 . . . . 72.31 113.565 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.415 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 60.5 Cg_endo -71.06 117.08 4.97 Favored 'Trans proline' 0 C--N 1.38 2.212 0 C-N-CA 122.709 2.273 . . . . 65.01 112.294 178.585 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 78.97 31.97 41.57 Favored Glycine 0 CA--C 1.533 1.176 0 CA-C-N 115.738 -0.664 . . . . 71.2 112.606 -176.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.6 p -72.82 146.17 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 123.395 0.678 . . . . 73.25 110.309 179.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.526 ' HA ' HD13 ' A' ' 180' ' ' LEU . 92.7 mtt180 -123.23 177.58 5.51 Favored 'General case' 0 N--CA 1.476 0.873 0 CA-C-O 121.808 0.813 . . . . 73.44 112.851 -171.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.0 tp10 -60.09 132.94 55.48 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 113.185 -1.825 . . . . 74.23 111.325 178.021 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.36 -27.31 15.81 Favored Glycine 0 C--N 1.34 0.775 0 CA-C-O 119.381 -0.677 . . . . 60.4 112.565 179.225 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.6 m -62.57 121.26 12.88 Favored 'General case' 0 C--N 1.354 0.763 0 C-N-CA 123.433 0.693 . . . . 73.35 111.004 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.1 126.46 51.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.091 -0.707 . . . . 71.11 109.091 177.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.408 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.4 mt -95.74 103.87 15.18 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 N-CA-C 108.012 -1.107 . . . . 75.32 108.012 -176.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.579 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 53.2 ttp180 -89.02 106.73 18.62 Favored 'General case' 0 C--N 1.355 0.848 0 N-CA-C 110.342 -0.244 . . . . 74.31 110.342 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.6 t -110.48 96.9 29.44 Favored Pre-proline 0 CA--C 1.553 1.078 0 N-CA-C 108.629 -0.878 . . . . 73.33 108.629 174.565 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.46 144.19 92.47 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.137 2.558 . . . . 72.22 112.842 176.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.69 -24.33 5.92 Favored Glycine 0 CA--C 1.539 1.584 0 CA-C-O 119.549 -0.584 . . . . 74.54 114.351 176.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 17.2 mmt -90.38 -2.54 57.97 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 117.7 0.75 . . . . 75.43 111.717 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.12 -115.12 0.54 Allowed Glycine 0 C--N 1.341 0.843 0 N-CA-C 111.346 -0.702 . . . . 73.13 111.346 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . 0.527 ' HA3' ' HG3' ' A' ' 117' ' ' ARG . . . -58.35 107.56 1.16 Allowed Glycine 0 C--N 1.354 1.555 0 CA-C-N 117.165 0.483 . . . . 61.43 113.237 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -80.03 171.57 14.92 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.937 0.895 . . . . 74.43 110.733 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 106.9 -147.07 16.14 Favored Glycine 0 N--CA 1.473 1.165 0 CA-C-O 119.619 -0.545 . . . . 64.42 111.819 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . 0.417 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 5.6 t-20 -69.82 -52.64 13.16 Favored Pre-proline 0 CA--C 1.566 1.584 0 CA-C-O 118.146 -0.931 . . . . 75.4 111.303 178.285 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.417 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 88.0 Cg_endo -89.93 108.64 0.39 Allowed 'Trans proline' 0 C--N 1.397 3.079 0 C-N-CA 122.188 1.926 . . . . 73.21 112.907 178.557 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -66.71 127.67 17.55 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.187 2.591 . . . . 73.22 112.776 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -110.64 162.67 12.47 Favored Glycine 0 C--N 1.341 0.846 0 CA-C-N 115.542 -0.754 . . . . 63.23 112.915 -178.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 118' ' ' ASP . 4.6 m-20 -80.15 150.3 30.24 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.83 0.852 . . . . 74.23 110.559 178.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.579 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 62.5 tp -106.58 135.79 47.49 Favored 'General case' 0 C--O 1.216 -0.676 0 N-CA-C 108.302 -0.999 . . . . 75.21 108.302 173.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.9 mt -128.44 103.31 7.06 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 123.715 0.806 . . . . 74.3 109.293 179.143 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.521 HD11 HD13 ' A' ' 123' ' ' LEU . 83.4 mt -107.35 103.08 12.34 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 122.684 0.394 . . . . 74.01 110.92 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.64 96.88 5.72 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.732 -0.667 . . . . 73.43 109.467 -174.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -54.59 130.21 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 C-N-CA 124.888 1.275 . . . . 75.51 111.848 -177.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -123.86 100.24 6.66 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 125.344 1.458 . . . . 72.23 107.626 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.526 HD13 ' HA ' ' A' ' 154' ' ' ARG . 35.5 mt -70.06 107.91 3.84 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-O 121.168 0.509 . . . . 75.01 111.151 -176.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.415 HD13 ' HB2' ' A' ' 124' ' ' PRO . 48.7 mt -75.98 130.72 77.58 Favored Pre-proline 0 CA--C 1.553 1.083 0 N-CA-C 108.23 -1.026 . . . . 74.2 108.23 175.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.22 -63.17 0.07 OUTLIER 'Trans proline' 0 CA--C 1.559 1.749 0 C-N-CA 123.074 2.516 . . . . 72.33 113.207 -176.216 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 . . . . . 0 N--CA 1.489 1.504 0 C-N-CA 123.888 0.875 . . . . 72.34 108.902 177.684 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pt? . . . . . 0 CA--C 1.566 1.561 0 N-CA-C 111.667 0.247 . . . . 64.34 111.667 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -74.21 -48.98 0.19 Allowed 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.386 2.058 . . . . 71.0 112.354 176.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.5 HD13 ' H ' ' A' ' 98' ' ' LEU . 7.6 tp 168.25 150.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 126.792 2.037 . . . . 74.31 106.321 -170.553 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.597 HD21 ' HB ' ' A' ' 140' ' ' VAL . 14.2 tp 57.54 -72.51 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 126.108 1.763 . . . . 75.41 111.587 -173.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.581 ' HA ' HD12 ' A' ' 119' ' ' LEU . 87.6 t80 -57.9 123.1 14.62 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.741 1.616 . . . . 72.2 111.948 172.086 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 98.9 m -145.44 99.17 4.52 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.113 0.965 . . . . 74.15 109.47 175.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -77.4 74.65 5.02 Favored 'Trans proline' 0 C--N 1.371 1.761 0 C-N-CA 122.462 2.108 . . . . 73.22 113.09 -172.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 3.6 m . . . . . 0 CA--C 1.546 0.811 0 CA-C-N 116.102 -0.499 . . . . 74.34 109.861 176.638 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 38.3 ptt180 . . . . . 0 CA--C 1.536 0.415 0 N-CA-C 108.711 -0.848 . . . . 74.54 108.711 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -92.59 118.99 31.59 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 106.976 -1.49 . . . . 71.24 106.976 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.581 HD12 ' HA ' ' A' ' 99' ' ' PHE . 18.4 mt -89.73 108.68 19.83 Favored 'General case' 0 C--O 1.225 -0.228 0 N-CA-C 106.725 -1.584 . . . . 72.25 106.725 -174.241 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -117.42 107.56 14.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.113 -1.069 . . . . 70.44 108.113 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.61 140.05 50.42 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 108.577 -0.898 . . . . 51.31 108.577 -179.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.78 129.41 37.0 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 109.189 -0.671 . . . . 65.32 109.189 173.297 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.464 HD12 HD12 ' A' ' 176' ' ' LEU . 2.0 tt -100.02 109.55 56.53 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 108.749 -0.834 . . . . 75.12 108.749 -173.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.03 113.86 2.77 Favored 'Trans proline' 0 C--N 1.378 2.115 0 C-N-CA 122.116 1.877 . . . . 75.13 110.19 171.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.55 HD22 HD11 ' A' ' 149' ' ' ILE . 12.0 tp -133.21 125.91 30.43 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 108.045 -1.095 . . . . 72.44 108.045 -169.448 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 43.0 p -73.16 171.7 12.46 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 117.975 0.352 . . . . 71.41 110.69 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 96.7 mt -71.39 -23.83 61.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 123.157 0.583 . . . . 65.0 111.009 178.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -72.03 -50.68 26.5 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.634 -0.876 . . . . 72.32 108.634 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.645 ' HG3' HH21 ' A' ' 136' ' ' ARG . 29.4 mm-40 -57.55 -40.52 79.04 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.841 1.256 . . . . 74.53 111.384 176.214 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.56 64.22 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 114.965 -1.016 . . . . 73.03 111.177 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -60.73 -58.45 8.4 Favored 'General case' 0 C--N 1.349 0.564 0 O-C-N 124.679 1.237 . . . . 74.44 110.266 -176.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.8 m80 -67.66 -38.59 84.0 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 123.958 0.786 . . . . 74.12 111.047 -175.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 73.49 -112.81 4.0 Favored Glycine 0 C--N 1.343 0.947 0 N-CA-C 110.47 -1.052 . . . . 73.52 110.47 -170.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.12 -130.85 22.26 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 111.551 -0.62 . . . . 54.53 111.551 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 9.3 mp0 -121.43 157.65 30.08 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.975 0.91 . . . . 73.1 109.452 174.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.645 HH21 ' HG3' ' A' ' 129' ' ' GLU . 5.3 tpp180 -135.02 124.03 24.19 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.234 1.414 . . . . 74.41 107.975 177.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.3 p -84.9 127.09 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.091 0 C-N-CA 123.137 0.575 . . . . 72.11 110.228 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.507 HG21 HD22 ' A' ' 98' ' ' LEU . 30.7 m -140.71 158.01 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.938 1.295 . . . . 72.12 109.102 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -88.19 135.48 33.42 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 123.162 0.585 . . . . 71.34 111.284 -174.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.597 ' HB ' HD21 ' A' ' 98' ' ' LEU . 7.2 p -136.86 118.56 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 124.396 1.078 . . . . 70.44 109.288 168.25 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.39 20.29 11.74 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 123.92 0.888 . . . . 70.12 112.229 177.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.43 -9.47 66.98 Favored Glycine 0 C--N 1.358 1.78 0 C-N-CA 123.051 0.357 . . . . 54.1 113.216 -177.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -104.0 128.82 51.57 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.076 0.951 . . . . 75.2 109.983 -178.331 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.32 141.66 43.35 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.527 -0.545 . . . . 73.52 109.527 177.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.81 126.49 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.64 1.176 . . . . 74.14 108.619 178.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 44.7 m -82.49 109.82 17.05 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.396 0.678 . . . . 75.21 109.612 175.29 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.5 130.24 47.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 C-N-CA 123.999 0.92 . . . . 71.45 109.248 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -69.81 118.7 12.99 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.043 0.537 . . . . 75.22 109.96 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.55 HD11 HD22 ' A' ' 125' ' ' LEU . 17.2 pt -108.02 131.53 21.68 Favored Pre-proline 0 CA--C 1.564 1.508 0 C-N-CA 124.509 1.124 . . . . 73.41 108.866 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -62.06 140.05 82.11 Favored 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.67 2.247 . . . . 72.4 113.763 -174.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -64.61 127.55 19.12 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 123.329 2.686 . . . . 75.03 112.696 175.568 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 76.76 30.09 56.58 Favored Glycine 0 CA--C 1.528 0.847 0 O-C-N 123.49 0.494 . . . . 50.5 112.406 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.8 p -73.74 137.36 23.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.78 0 C-N-CA 122.89 0.476 . . . . 75.44 110.367 -177.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -103.67 173.31 6.36 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.135 0.969 . . . . 75.13 111.886 -171.176 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.8 tp10 -63.83 122.2 15.86 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-N 113.09 -1.868 . . . . 74.1 109.346 167.204 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 102.06 -8.39 55.67 Favored Glycine 0 N--CA 1.474 1.215 0 CA-C-O 119.758 -0.468 . . . . 74.41 113.127 178.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.0 m -78.37 121.99 25.19 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.094 0.447 . . . . 73.32 109.937 177.055 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.8 p -99.15 141.68 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 109.019 -0.734 . . . . 73.22 109.019 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.524 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 65.4 mt -108.43 104.21 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.344 1.058 . . . . 73.45 108.724 -176.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -88.68 121.12 30.72 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 123.261 0.625 . . . . 74.31 109.782 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -124.23 106.56 30.64 Favored Pre-proline 0 CA--C 1.557 1.23 0 N-CA-C 107.65 -1.241 . . . . 74.32 107.65 173.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.91 139.35 36.04 Favored 'Trans proline' 0 C--N 1.373 1.836 0 C-N-CA 122.935 2.423 . . . . 71.52 113.31 -174.647 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 77.4 0.15 71.12 Favored Glycine 0 C--N 1.352 1.426 0 CA-C-N 115.471 -0.786 . . . . 72.41 114.264 173.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 93.6 mmm -103.6 15.2 29.49 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.685 0.794 . . . . 75.32 111.712 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -94.35 -108.24 2.07 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 111.534 -0.626 . . . . 64.15 111.534 174.029 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -66.1 106.28 1.54 Allowed Glycine 0 C--N 1.344 1.011 0 C-N-CA 123.693 0.663 . . . . 71.42 112.575 175.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -83.8 165.18 19.03 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 123.75 0.82 . . . . 65.12 109.878 175.541 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 111.79 -141.6 16.71 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 111.184 -0.766 . . . . 61.31 111.184 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -76.61 -52.37 2.18 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 118.247 -0.882 . . . . 74.44 111.159 172.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -82.51 118.91 2.93 Favored 'Trans proline' 0 C--N 1.391 2.776 0 C-N-CA 121.627 1.551 . . . . 63.25 111.657 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_endo -84.9 126.71 3.41 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.718 2.279 . . . . 73.41 113.593 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -110.2 161.89 12.79 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 115.928 -0.578 . . . . 75.31 112.021 174.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -99.89 162.48 12.96 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 124.676 1.19 . . . . 72.45 110.009 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.517 HD21 HD11 ' A' ' 98' ' ' LEU . 54.3 tp -116.32 128.38 55.5 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.733 0.813 . . . . 63.54 109.796 178.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 90.7 mt -128.54 120.51 26.86 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 124.314 1.046 . . . . 75.11 109.729 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.524 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 93.7 mt -118.99 104.17 10.24 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 123.369 0.668 . . . . 75.23 110.745 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.4 t -86.22 98.5 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.982 0 CA-C-N 115.397 -0.82 . . . . 71.02 109.404 -172.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.3 t -61.29 117.0 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 123.987 0.915 . . . . 74.33 112.426 -173.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -112.88 101.08 9.16 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 126.103 1.761 . . . . 75.14 108.63 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.415 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 43.5 mt -71.49 114.25 9.37 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.148 -0.478 . . . . 70.34 110.779 -177.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 87.3 mt -61.53 146.73 89.4 Favored Pre-proline 0 CA--C 1.549 0.907 0 CA-C-N 114.752 -1.113 . . . . 61.54 110.636 178.348 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -64.39 -168.15 0.1 OUTLIER 'Trans proline' 0 C--N 1.378 2.131 0 C-N-CA 123.154 2.569 . . . . 74.32 113.81 -173.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 . . . . . 0 C--O 1.253 1.238 0 CA-C-O 118.014 -0.993 . . . . 75.52 108.664 -179.85 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' MET . . . . . 0.432 ' O ' ' HG ' ' A' ' 95' ' ' LEU . 34.2 tpp . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 110.611 -0.144 . . . . 71.11 110.611 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.46 HD22 HG22 ' A' ' 100' ' ' THR . 3.2 pp 58.54 111.11 0.02 OUTLIER Pre-proline 0 N--CA 1.482 1.143 0 C-N-CA 127.18 2.192 . . . . 73.53 111.628 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.649 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 73.6 Cg_endo -73.71 -167.57 0.39 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.685 2.257 . . . . 72.41 111.377 171.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.467 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 12.7 tp -75.96 142.69 41.91 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.603 -0.517 . . . . 74.43 109.603 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.573 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 6.3 tp 68.89 -57.98 0.5 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 126.95 2.1 . . . . 74.45 112.02 -167.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.649 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 65.7 t80 -72.65 135.33 45.44 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.697 1.199 . . . . 74.11 112.534 -173.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.536 HG23 HG11 ' A' ' 102' ' ' VAL . 55.4 m -153.97 101.25 2.49 Favored Pre-proline 0 CA--C 1.544 0.74 0 C-N-CA 123.985 0.914 . . . . 72.02 109.895 177.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -76.08 83.0 2.06 Favored 'Trans proline' 0 C--N 1.369 1.611 0 C-N-CA 122.128 1.885 . . . . 74.12 112.304 -173.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.536 HG11 HG23 ' A' ' 100' ' ' THR . 30.1 m -88.94 151.28 3.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-N 114.935 -1.03 . . . . 65.55 109.729 173.317 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -106.54 162.47 13.71 Favored 'General case' 0 C--O 1.242 0.67 0 N-CA-C 109.481 -0.563 . . . . 73.24 109.481 173.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 22.1 ttmm -145.39 98.82 3.21 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 108.518 -0.919 . . . . 74.34 108.518 175.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -143.96 7.42 1.89 Allowed Glycine 0 N--CA 1.469 0.899 0 CA-C-N 115.787 -0.642 . . . . 62.41 112.196 175.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 30.5 p -72.68 96.93 2.08 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 123.193 0.597 . . . . 74.43 109.699 174.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.16 -178.14 21.01 Favored Glycine 0 C--N 1.344 1.006 0 CA-C-N 115.86 -0.609 . . . . 70.31 112.055 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -170.3 131.64 2.29 Favored Glycine 0 C--N 1.344 0.973 0 N-CA-C 111.938 -0.465 . . . . 71.11 111.938 179.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 39.9 t -136.3 -55.54 0.75 Allowed 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.977 -0.749 . . . . 72.44 108.977 174.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 169.98 45.29 0.03 OUTLIER Glycine 0 C--N 1.349 1.27 0 CA-C-N 115.771 -0.649 . . . . 74.42 112.132 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 161.8 -170.93 37.63 Favored Glycine 0 C--N 1.344 0.979 0 N-CA-C 112.034 -0.427 . . . . 63.23 112.034 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.2 m -73.53 107.87 6.06 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 122.786 0.434 . . . . 71.04 110.103 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -94.71 70.65 1.14 Allowed Glycine 0 C--N 1.345 1.053 0 N-CA-C 110.839 -0.904 . . . . 72.01 110.839 173.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -141.79 32.41 2.03 Favored Glycine 0 C--N 1.347 1.15 0 CA-C-N 115.856 -0.172 . . . . 65.51 113.513 -175.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 41.6 t -73.87 130.11 39.25 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 122.818 0.447 . . . . 75.01 110.045 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.483 ' H ' ' HB2' ' A' ' 170' ' ' PRO . . . 75.0 104.06 0.1 OUTLIER Glycine 0 C--N 1.345 1.04 0 O-C-N 124.099 0.874 . . . . 63.41 113.104 176.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 -86.1 131.17 34.32 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.948 -0.76 . . . . 75.41 108.948 175.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -93.31 104.41 16.58 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.561 -1.274 . . . . 70.23 107.561 -177.018 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.542 HD11 ' HA ' ' A' ' 99' ' ' PHE . 10.3 mt -94.08 109.78 21.52 Favored 'General case' 0 C--N 1.342 0.253 0 N-CA-C 107.093 -1.447 . . . . 72.12 107.093 -177.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.8 ttt180 -108.63 109.71 20.98 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.702 -0.481 . . . . 74.12 109.702 176.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -122.95 144.76 49.02 Favored 'General case' 0 C--O 1.242 0.693 0 N-CA-C 109.116 -0.698 . . . . 72.23 109.116 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -81.81 122.41 27.67 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.957 -1.127 . . . . 74.54 107.957 177.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.435 HD13 ' HG2' ' A' ' 136' ' ' ARG . 47.3 tp -99.32 103.38 20.2 Favored Pre-proline 0 CA--C 1.542 0.645 0 C-N-CA 123.565 0.746 . . . . 74.11 110.083 -171.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.13 114.39 3.97 Favored 'Trans proline' 0 C--N 1.374 1.894 0 C-N-CA 121.956 1.77 . . . . 74.14 110.017 176.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.516 HD23 HD11 ' A' ' 149' ' ' ILE . 14.2 tp -136.06 122.45 20.62 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 109.155 -0.683 . . . . 74.43 109.155 -168.401 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 3.0 m -69.61 162.31 27.87 Favored 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.987 0.915 . . . . 74.24 111.121 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 69.3 mt -63.93 -36.39 83.79 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.017 0.527 . . . . 73.42 112.37 -177.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -69.21 -40.19 78.15 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.292 0.637 . . . . 73.22 109.38 179.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.484 ' HG3' ' NH2' ' A' ' 136' ' ' ARG . 24.6 mm-40 -62.64 -44.27 96.7 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.477 1.111 . . . . 73.13 110.531 177.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.89 -37.29 78.93 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 115.158 -0.928 . . . . 74.41 111.408 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.5 t80 -65.84 -49.26 68.82 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.452 1.501 . . . . 71.43 110.881 -178.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -80.24 -41.22 25.51 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 115.28 -0.873 . . . . 74.0 111.157 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.512 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.36 58.35 8.83 Favored Glycine 0 C--N 1.345 1.073 0 O-C-N 123.543 0.527 . . . . 65.4 113.085 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -94.51 -130.69 6.0 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 110.966 -0.854 . . . . 75.31 110.966 174.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -107.76 160.3 15.83 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.284 0.564 . . . . 64.41 110.046 169.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.484 ' NH2' ' HG3' ' A' ' 129' ' ' GLU . 5.5 tpp180 -133.02 121.92 23.44 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.495 -1.298 . . . . 73.54 107.495 172.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 62.9 t -72.8 124.34 29.44 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-O 121.082 0.468 . . . . 73.34 110.084 175.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.553 HG21 HD11 ' A' ' 98' ' ' LEU . 32.9 m -127.33 145.2 35.19 Favored 'Isoleucine or valine' 0 C--O 1.251 1.142 0 C-N-CA 125.08 1.352 . . . . 74.22 108.105 -177.356 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -104.23 106.28 16.73 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.166 -0.679 . . . . 72.35 109.166 -176.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.584 HG12 ' HB2' ' A' ' 143' ' ' ARG . 2.4 p -106.45 100.18 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.829 0.851 . . . . 61.13 109.411 -176.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.92 23.91 14.26 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.426 0.691 . . . . 63.34 111.927 177.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.27 2.91 56.74 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 116.02 -0.537 . . . . 65.21 112.924 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.584 ' HB2' HG12 ' A' ' 140' ' ' VAL . 48.0 mtp180 -100.56 119.91 39.24 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 108.948 -0.76 . . . . 73.33 108.948 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.0 tmm_? -81.79 107.37 14.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.002 -0.74 . . . . 65.42 109.002 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 24.4 m -124.92 156.37 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 C-N-CA 123.701 0.8 . . . . 75.24 109.776 176.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.6 p -107.96 119.12 38.55 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 123.147 0.579 . . . . 73.45 110.192 174.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.0 p -99.16 132.28 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.671 -0.492 . . . . 64.25 109.671 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -80.36 120.19 24.07 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.877 0.37 . . . . 74.23 110.162 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.516 HD11 HD23 ' A' ' 125' ' ' LEU . 7.5 pt -95.08 142.01 24.03 Favored Pre-proline 0 CA--C 1.556 1.182 0 C-N-CA 124.135 0.974 . . . . 71.53 109.341 179.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.405 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 52.6 Cg_endo -72.56 143.86 39.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.267 1.978 . . . . 74.33 112.5 178.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.33 133.54 19.43 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 122.633 2.222 . . . . 73.13 111.915 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.84 30.01 53.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.64 -0.709 . . . . 61.14 113.253 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.405 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 8.2 p -82.72 148.09 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 117.363 0.581 . . . . 72.53 109.634 179.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 -126.47 177.71 6.31 Favored 'General case' 0 N--CA 1.479 0.988 0 CA-C-O 121.567 0.699 . . . . 74.03 112.122 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.6 tp10 -61.37 129.17 39.88 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 113.835 -1.53 . . . . 75.41 110.78 177.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.66 4.66 90.0 Favored Glycine 0 C--N 1.344 0.984 0 O-C-N 123.701 0.626 . . . . 54.13 113.551 178.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 67.0 m -82.23 119.67 24.38 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 117.444 0.622 . . . . 72.53 109.457 175.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.3 p -98.55 125.29 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-O 121.213 0.53 . . . . 75.31 110.054 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.8 mt -91.75 104.03 15.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 C-N-CA 124.334 1.053 . . . . 72.55 108.173 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.461 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 74.8 ttt180 -94.45 114.66 26.72 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 110.139 -0.319 . . . . 74.41 110.139 -177.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 19.5 t -122.85 98.4 42.77 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 123.59 0.756 . . . . 74.03 109.092 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.06 125.72 12.86 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.931 2.421 . . . . 72.51 112.74 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 104.64 -24.49 28.46 Favored Glycine 0 N--CA 1.474 1.19 0 CA-C-O 120.151 -0.25 . . . . 75.52 113.167 176.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.3 ttm -89.57 -18.92 25.66 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.362 0.665 . . . . 72.34 111.338 -174.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -69.8 -100.76 0.04 OUTLIER Glycine 0 C--N 1.346 1.103 0 CA-C-O 119.677 -0.513 . . . . 74.11 113.197 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -53.36 107.78 0.65 Allowed Glycine 0 C--N 1.355 1.59 0 C-N-CA 123.103 0.383 . . . . 70.33 113.248 179.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 13.0 mm-40 -84.76 169.53 14.13 Favored 'General case' 0 C--O 1.237 0.431 0 C-N-CA 123.602 0.761 . . . . 73.32 110.096 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 108.33 -138.47 14.67 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.716 -0.675 . . . . 60.03 111.672 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.441 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 58.0 t30 -77.15 -51.55 2.02 Favored Pre-proline 0 CA--C 1.569 1.706 0 CA-C-O 118.285 -0.864 . . . . 73.35 111.541 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.483 ' HB2' ' H ' ' A' ' 116' ' ' GLY . 72.8 Cg_endo -95.29 109.79 0.13 Allowed 'Trans proline' 0 C--N 1.394 2.958 0 C-N-CA 122.38 2.053 . . . . 62.22 112.746 177.239 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -60.45 125.95 18.72 Favored 'Trans proline' 0 C--N 1.381 2.261 0 C-N-CA 122.512 2.141 . . . . 73.11 111.654 175.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -112.27 177.33 18.51 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 116.412 -0.358 . . . . 72.23 113.88 -176.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.23 146.13 28.75 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.762 0.825 . . . . 72.12 110.318 -175.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.461 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 59.0 tp -113.38 134.51 54.6 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.196 0.598 . . . . 72.0 109.846 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 76.3 mt -129.61 105.2 7.9 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.437 1.095 . . . . 75.44 109.301 176.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.466 HD23 HD12 ' A' ' 98' ' ' LEU . 68.0 mt -107.55 102.73 11.96 Favored 'General case' 0 N--CA 1.479 1.013 0 O-C-N 122.109 -0.37 . . . . 65.2 110.009 174.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.7 t -85.93 99.04 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 N-CA-C 108.369 -0.974 . . . . 74.15 108.369 -175.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 87.0 t -56.23 116.81 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.45 1.1 . . . . 74.0 111.724 -177.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -113.07 104.21 12.15 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 125.576 1.551 . . . . 72.34 107.784 177.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 74.8 mt -69.39 130.38 42.38 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 122.918 0.487 . . . . 62.43 111.526 -174.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 92.1 mt -84.84 139.02 37.31 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.53 0.732 . . . . 74.42 110.128 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -65.38 116.54 3.95 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 123.193 2.595 . . . . 73.21 112.021 -175.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.543 -0.741 . . . . 73.32 109.415 -178.185 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' MET . . . . . 0.438 ' SD ' ' N ' ' A' ' 94' ' ' MET . 1.3 mpt? . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.484 -0.562 . . . . 71.21 109.484 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.51 ' HB3' ' HA ' ' A' ' 100' ' ' THR . 0.5 OUTLIER -95.09 99.55 4.5 Favored Pre-proline 0 CA--C 1.554 1.116 0 N-CA-C 109.058 -0.719 . . . . 65.24 109.058 166.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -66.62 -49.27 1.73 Allowed 'Trans proline' 0 C--N 1.385 2.498 0 C-N-CA 122.612 2.208 . . . . 73.13 111.691 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.512 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.4 tp -179.52 154.36 0.61 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.627 1.571 . . . . 74.14 106.945 -175.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.512 ' H ' HD12 ' A' ' 97' ' ' LEU . 7.4 tp 53.04 -75.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 125.976 1.71 . . . . 74.11 111.551 -174.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.67 ' HA ' HD11 ' A' ' 119' ' ' LEU . 85.4 t80 -50.54 129.18 21.84 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.097 1.759 . . . . 74.31 112.341 171.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.531 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 55.2 m -142.18 105.99 5.65 Favored Pre-proline 0 N--CA 1.471 0.587 0 C-N-CA 124.105 0.962 . . . . 74.21 108.442 172.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -76.85 87.55 1.47 Allowed 'Trans proline' 0 C--N 1.366 1.453 0 C-N-CA 121.517 1.478 . . . . 64.43 112.42 -170.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.6 m -86.61 147.07 5.6 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-N 114.735 -1.12 . . . . 74.23 109.995 177.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.8 t -79.69 -15.2 58.0 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 122.761 0.424 . . . . 71.32 111.145 -178.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 56.7 tttm -58.73 121.48 11.17 Favored 'General case' 0 C--N 1.354 0.767 0 C-N-CA 123.671 0.788 . . . . 72.35 111.213 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -84.38 -124.92 1.22 Allowed Glycine 0 C--N 1.344 0.998 0 CA-C-N 115.298 -0.864 . . . . 74.42 113.131 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 16.4 m -86.74 -12.31 48.57 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 123.268 0.627 . . . . 62.42 110.867 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 82.85 -41.98 2.93 Favored Glycine 0 C--N 1.35 1.347 0 C-N-CA 123.12 0.391 . . . . 73.41 113.67 174.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.56 57.71 3.05 Favored Glycine 0 C--N 1.344 0.986 0 N-CA-C 111.402 -0.679 . . . . 72.45 111.402 -175.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.8 p -70.76 84.79 0.65 Allowed 'General case' 0 C--O 1.245 0.861 0 C-N-CA 123.49 0.716 . . . . 73.31 110.66 178.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 68.73 -84.06 0.21 Allowed Glycine 0 C--N 1.352 1.457 0 CA-C-N 115.281 -0.872 . . . . 72.33 111.581 -175.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -174.23 25.37 0.07 OUTLIER Glycine 0 C--N 1.335 0.516 0 N-CA-C 111.248 -0.741 . . . . 74.31 111.248 173.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 45.4 m -125.83 119.69 28.53 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.884 0.874 . . . . 72.44 109.859 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 67.58 -100.45 0.61 Allowed Glycine 0 C--N 1.352 1.435 0 O-C-N 124.266 0.978 . . . . 63.03 112.999 177.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 136.99 129.68 2.8 Favored Glycine 0 C--N 1.341 0.829 0 N-CA-C 111.704 -0.558 . . . . 70.33 111.704 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 78.9 p -73.91 110.99 8.64 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 123.209 0.603 . . . . 73.43 109.479 174.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -72.87 -152.62 1.87 Allowed Glycine 0 C--N 1.349 1.278 0 N-CA-C 114.569 0.588 . . . . 61.32 114.569 -172.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.432 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 94.2 mtt180 -82.49 131.08 35.22 Favored 'General case' 0 N--CA 1.476 0.862 0 O-C-N 122.461 -0.435 . . . . 73.15 110.077 -178.092 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.7 105.95 18.17 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 107.345 -1.354 . . . . 65.31 107.345 -177.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.67 HD11 ' HA ' ' A' ' 99' ' ' PHE . 12.5 mt -92.87 108.96 20.4 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 107.26 -1.385 . . . . 75.13 107.26 -176.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 74.4 ttt180 -119.33 105.87 11.74 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.131 0.972 . . . . 73.14 108.663 -175.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.58 145.23 40.34 Favored 'General case' 0 C--O 1.242 0.67 0 C-N-CA 123.722 0.809 . . . . 74.14 109.567 -174.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -76.66 137.59 39.52 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.536 -0.542 . . . . 64.02 109.536 175.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 19.9 tp -101.62 105.36 40.27 Favored Pre-proline 0 CA--C 1.542 0.671 0 C-N-CA 123.992 0.917 . . . . 71.31 110.201 -178.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -60.64 122.78 11.8 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.488 2.125 . . . . 74.11 110.342 169.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.474 HD21 HD11 ' A' ' 149' ' ' ILE . 25.3 tp -147.83 133.79 19.17 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.889 -0.782 . . . . 73.33 108.889 -175.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.9 p -81.21 163.66 22.86 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 110.129 -0.323 . . . . 73.25 110.129 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.0 mt -61.92 -32.7 73.13 Favored 'General case' 0 N--CA 1.482 1.168 0 C-N-CA 123.607 0.763 . . . . 74.51 110.971 179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -70.72 -50.23 38.51 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 114.987 -1.006 . . . . 75.15 109.406 -177.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -70.13 -26.65 64.05 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.794 0.837 . . . . 75.33 111.859 -179.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.75 -40.31 69.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.216 0.606 . . . . 75.43 110.744 174.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -64.43 -46.4 83.36 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.911 0.884 . . . . 64.44 110.698 175.504 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -63.36 -49.67 72.96 Favored 'General case' 0 C--N 1.351 0.671 0 O-C-N 123.71 0.631 . . . . 73.22 110.362 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.486 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 56.63 70.39 0.99 Allowed Glycine 0 C--N 1.349 1.276 0 O-C-N 124.128 0.893 . . . . 75.11 112.771 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -121.06 -121.37 2.81 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.35 -1.1 . . . . 72.4 110.35 174.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.551 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 7.0 mp0 -99.69 154.96 17.88 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 123.143 0.577 . . . . 74.31 109.528 172.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.437 ' HB2' HD13 ' A' ' 149' ' ' ILE . 14.0 tpt180 -137.04 122.55 19.61 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 108.162 -1.051 . . . . 75.42 108.162 178.479 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.1 t -74.34 119.44 21.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 O-C-N 123.577 0.548 . . . . 75.14 109.886 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.498 HG21 HD12 ' A' ' 98' ' ' LEU . 28.5 m -122.68 147.38 26.89 Favored 'Isoleucine or valine' 0 C--O 1.251 1.147 0 C-N-CA 124.769 1.228 . . . . 75.43 109.067 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -100.91 127.83 47.22 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.987 0.915 . . . . 74.11 109.268 -177.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.557 HG21 ' HB2' ' A' ' 99' ' ' PHE . 3.1 p -142.66 103.67 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 123.287 0.635 . . . . 72.54 111.118 -174.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 55.38 29.69 13.55 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 124.448 1.099 . . . . 64.41 113.14 172.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.65 26.34 10.85 Favored Glycine 0 C--N 1.348 1.248 0 CA-C-N 116.36 -0.382 . . . . 61.42 112.658 179.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.474 ' HB2' HG13 ' A' ' 140' ' ' VAL . 54.3 mmt-85 -131.87 136.18 47.25 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.842 0.857 . . . . 72.42 110.049 -178.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 16.1 ttp180 -95.67 105.88 17.92 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 107.917 -1.142 . . . . 75.33 107.917 171.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 33.0 m -125.44 151.37 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 109.915 -0.402 . . . . 71.45 109.915 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.551 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 34.6 p -106.11 117.65 34.58 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.296 0.638 . . . . 74.15 109.924 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.2 p -98.8 133.35 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 108.664 -0.865 . . . . 75.22 108.664 176.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.4 ttt85 -82.4 125.74 31.39 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.203 0.525 . . . . 74.24 109.754 -178.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.486 HG13 ' HA2' ' A' ' 133' ' ' GLY . 3.3 pt -107.56 145.8 32.04 Favored Pre-proline 0 CA--C 1.557 1.219 0 C-N-CA 124.882 1.273 . . . . 72.23 108.686 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.436 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 56.7 Cg_endo -71.08 146.56 52.38 Favored 'Trans proline' 0 CA--C 1.566 2.099 0 C-N-CA 122.161 1.907 . . . . 72.31 112.823 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -66.79 134.95 36.57 Favored 'Trans proline' 0 C--N 1.38 2.23 0 C-N-CA 123.172 2.581 . . . . 64.1 111.962 172.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.16 28.03 62.95 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-N 115.724 -0.671 . . . . 74.11 113.024 -177.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.436 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 14.7 p -78.19 147.2 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.256 -0.646 . . . . 74.13 109.256 177.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -129.61 177.23 7.37 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 122.011 0.91 . . . . 75.31 113.085 -167.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.5 tp10 -62.58 121.4 13.23 Favored 'General case' 0 C--O 1.241 0.644 0 CA-C-N 113.463 -1.699 . . . . 74.04 110.414 174.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.73 2.83 69.21 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 115.892 -0.595 . . . . 74.52 112.822 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 59.5 m -86.39 122.04 29.79 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 109.458 -0.571 . . . . 73.33 109.458 174.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.5 p -101.23 126.35 55.05 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.232 0.539 . . . . 74.41 110.051 178.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 60.7 mt -93.94 102.92 14.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.941 1.296 . . . . 70.41 107.914 176.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -98.38 121.62 40.53 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.956 -0.387 . . . . 75.33 109.956 -179.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 4.2 t -115.47 99.62 52.64 Favored Pre-proline 0 CA--C 1.556 1.192 0 N-CA-C 107.692 -1.225 . . . . 75.03 107.692 173.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -68.25 131.39 23.36 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 123.098 2.532 . . . . 61.32 113.63 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 75.87 24.07 70.51 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.085 -0.962 . . . . 64.23 113.784 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.7 tpt -126.28 -9.2 6.4 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 123.62 0.768 . . . . 72.43 111.21 -176.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -71.11 -94.7 0.07 OUTLIER Glycine 0 C--N 1.347 1.172 0 CA-C-O 120.175 -0.236 . . . . 74.34 112.848 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -68.84 106.96 1.91 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.966 -0.352 . . . . 74.3 112.433 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -72.43 137.46 46.48 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.647 0.779 . . . . 71.23 111.013 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.2 -163.75 32.55 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 116.006 -0.543 . . . . 75.42 112.157 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -72.94 -43.95 8.17 Favored Pre-proline 0 CA--C 1.565 1.537 0 CA-C-O 118.968 -0.539 . . . . 73.3 110.725 174.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -93.34 108.37 0.18 Allowed 'Trans proline' 0 C--N 1.386 2.511 0 C-N-CA 122.081 1.854 . . . . 73.32 111.254 163.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -82.74 137.67 8.99 Favored 'Trans proline' 0 C--N 1.372 1.807 0 C-N-CA 122.361 2.041 . . . . 70.1 112.243 -178.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.432 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -99.04 179.93 31.36 Favored Glycine 0 C--N 1.343 0.935 0 CA-C-N 115.933 -0.576 . . . . 63.22 113.14 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -87.88 149.03 24.34 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 122.844 0.458 . . . . 74.0 111.239 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.474 HD23 HD11 ' A' ' 98' ' ' LEU . 41.8 tp -112.42 128.64 56.37 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 122.844 0.458 . . . . 74.55 109.915 177.301 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 74.3 mt -127.46 115.48 18.96 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 124.196 0.998 . . . . 72.51 109.157 178.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.465 HD23 HD13 ' A' ' 98' ' ' LEU . 72.9 mt -117.07 103.42 10.22 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 123.178 0.591 . . . . 75.32 110.489 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.6 t -89.79 98.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.072 0 C-N-CA 122.524 0.33 . . . . 73.0 110.331 -173.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.8 t -60.09 113.87 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 C-N-CA 124.203 1.001 . . . . 64.01 112.694 -173.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 22.1 mmm180 -105.0 109.14 21.01 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.126 1.77 . . . . 73.03 108.649 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 86.6 mt -71.87 119.0 15.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.387 0.275 . . . . 74.14 110.449 179.152 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 78.4 mt -79.05 147.35 69.63 Favored Pre-proline 0 CA--C 1.545 0.784 0 C-N-CA 123.693 0.797 . . . . 65.15 110.79 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -61.1 110.0 0.79 Allowed 'Trans proline' 0 C--N 1.373 1.82 0 C-N-CA 123.368 2.712 . . . . 75.33 111.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 77.6 t60 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.733 -0.651 . . . . 63.24 110.289 178.507 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 96.9 mmm . . . . . 0 N--CA 1.487 1.382 0 N-CA-C 110.171 -0.307 . . . . 74.22 110.171 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 37.11 89.32 0.08 OUTLIER Pre-proline 0 CA--C 1.562 1.426 0 C-N-CA 126.219 1.808 . . . . 74.52 114.26 -176.321 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.66 -66.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.388 2.65 0 C-N-CA 122.738 2.292 . . . . 74.12 111.477 174.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.491 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.2 tp -178.89 149.44 0.45 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 125.236 1.414 . . . . 74.42 107.809 175.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.648 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 13.2 tp 56.99 8.6 0.52 Allowed 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 124.422 1.089 . . . . 74.44 112.494 -174.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.593 ' HA ' HD13 ' A' ' 119' ' ' LEU . 77.2 t80 -150.87 124.49 9.05 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 123.927 0.891 . . . . 74.2 109.261 -165.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.529 ' H ' HD22 ' A' ' 119' ' ' LEU . 95.7 m -150.5 95.24 3.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 C-N-CA 124.639 1.175 . . . . 75.11 108.155 176.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.6 104.65 1.16 Allowed 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 121.921 1.748 . . . . 73.42 110.804 -176.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.17 174.04 3.22 Favored 'Isoleucine or valine' 0 C--O 1.244 0.789 0 C-N-CA 123.793 0.837 . . . . 75.51 109.466 178.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 54.0 p -112.47 86.78 2.43 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.41 0.684 . . . . 53.23 109.283 177.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -79.32 149.64 31.7 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.143 -0.935 . . . . 73.43 109.676 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 70.36 48.23 38.85 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 111.335 -0.706 . . . . 61.43 111.335 -174.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 48.0 t -68.41 -25.41 65.02 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.124 0.97 . . . . 62.52 112.274 -173.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.49 92.42 0.59 Allowed Glycine 0 C--N 1.353 1.521 0 CA-C-O 120.104 -0.275 . . . . 60.21 112.813 -178.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 74.41 26.83 66.98 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.894 -0.392 . . . . 73.42 112.401 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 18.5 m 63.0 14.4 7.53 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 124.654 1.181 . . . . 74.11 112.36 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -128.12 -59.72 0.12 Allowed Glycine 0 C--N 1.348 1.245 0 N-CA-C 110.416 -1.073 . . . . 72.53 110.416 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 67.7 -96.31 0.36 Allowed Glycine 0 C--N 1.348 1.218 0 N-CA-C 111.319 -0.712 . . . . 74.41 111.319 -179.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.5 p -84.07 -2.29 56.42 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 124.08 0.952 . . . . 74.13 111.516 175.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 115.37 -106.46 1.59 Allowed Glycine 0 C--N 1.347 1.185 0 N-CA-C 110.905 -0.878 . . . . 62.14 110.905 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -112.66 100.6 1.13 Allowed Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.244 -0.742 . . . . 74.31 111.244 178.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 52.9 m -131.64 149.08 52.61 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 123.708 0.803 . . . . 72.33 110.576 177.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -74.98 -161.75 9.06 Favored Glycine 0 C--N 1.351 1.412 0 O-C-N 123.534 0.521 . . . . 74.12 111.933 173.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 24.2 ptt180 -97.34 149.33 22.21 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 123.199 0.6 . . . . 73.23 110.922 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -92.61 114.71 27.34 Favored 'General case' 0 C--N 1.348 0.519 0 N-CA-C 107.686 -1.227 . . . . 74.42 107.686 175.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.593 HD13 ' HA ' ' A' ' 99' ' ' PHE . 31.2 mt -93.44 107.22 19.1 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 106.991 -1.485 . . . . 75.14 106.991 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.493 ' H ' ' HB ' ' A' ' 100' ' ' THR . 19.6 ttt180 -116.0 105.83 13.09 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.03 -0.73 . . . . 74.14 109.03 178.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 141.36 48.17 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.829 0.852 . . . . 71.13 108.772 -177.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.14 129.6 34.62 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.372 -0.603 . . . . 73.13 109.372 174.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.462 HD13 HD12 ' A' ' 176' ' ' LEU . 1.7 tt -101.6 109.64 59.75 Favored Pre-proline 0 CA--C 1.55 0.965 0 C-N-CA 123.479 0.712 . . . . 73.23 109.379 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.41 ' HA ' ' HB2' ' A' ' 179' ' ' ARG . 52.3 Cg_endo -67.4 121.82 8.98 Favored 'Trans proline' 0 C--N 1.377 2.079 0 C-N-CA 122.559 2.173 . . . . 71.41 110.954 172.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.1 tp -140.67 135.09 31.29 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 108.805 -0.813 . . . . 75.02 108.805 -173.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.5 p -76.15 167.12 22.44 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.892 -0.41 . . . . 74.52 109.892 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.502 HD13 ' HB2' ' A' ' 183' ' ' HIS . 86.6 mt -66.77 -31.11 71.54 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.033 0.533 . . . . 74.14 110.644 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -71.11 -49.49 43.79 Favored 'General case' 0 C--O 1.22 -0.497 0 CA-C-N 114.701 -1.136 . . . . 75.53 109.135 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -74.35 -19.6 60.39 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.405 0.682 . . . . 71.34 111.452 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.54 -45.21 72.78 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.138 0.575 . . . . 72.23 109.853 167.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.03 -41.37 95.32 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 123.938 0.895 . . . . 75.11 111.006 176.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -75.48 -39.76 58.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.131 0.572 . . . . 74.33 110.679 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.25 -114.11 6.26 Favored Glycine 0 C--N 1.345 1.081 0 CA-C-N 115.273 -0.876 . . . . 73.11 111.207 -172.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.12 -132.71 39.58 Favored Glycine 0 C--N 1.351 1.382 0 CA-C-O 119.668 -0.518 . . . . 75.15 112.413 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.569 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 10.3 mp0 -105.75 158.22 16.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.847 0.859 . . . . 75.14 109.958 176.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.645 ' HB2' HD13 ' A' ' 149' ' ' ILE . 23.4 tpt85 -133.91 120.87 20.92 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.733 0.813 . . . . 72.52 109.063 178.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.6 t -74.88 109.08 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 C-N-CA 124.165 0.986 . . . . 73.51 109.626 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.491 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 26.1 m -128.03 149.15 32.68 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 C-N-CA 124.075 0.95 . . . . 73.12 110.098 -174.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -97.73 103.75 15.72 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 123.649 0.78 . . . . 75.41 111.322 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.648 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.3 p -103.94 102.26 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.103 0.961 . . . . 71.45 109.569 -179.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.93 27.74 17.16 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 124.321 1.049 . . . . 63.51 112.201 177.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.54 -13.09 59.78 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-O 119.317 -0.713 . . . . 75.11 114.227 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.23 152.25 19.32 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 118.164 0.982 . . . . 74.11 110.093 177.165 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 -100.17 109.01 21.27 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.587 0.755 . . . . 73.41 109.602 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 86.3 t -122.66 136.84 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 N-CA-C 108.572 -0.899 . . . . 75.44 108.572 175.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.569 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 77.5 p -95.5 113.09 24.72 Favored 'General case' 0 C--O 1.242 0.658 0 N-CA-C 109.168 -0.679 . . . . 60.53 109.168 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -97.84 136.48 28.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 123.57 0.748 . . . . 55.44 109.216 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -81.03 127.27 32.41 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.369 0.605 . . . . 64.12 110.568 -176.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.645 HD13 ' HB2' ' A' ' 136' ' ' ARG . 7.5 pt -118.07 145.32 36.62 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.658 1.583 . . . . 73.11 108.43 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.04 138.2 27.8 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.456 2.104 . . . . 73.5 112.599 178.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.73 143.66 51.7 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.336 2.024 . . . . 74.13 111.544 169.012 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.0 26.48 58.11 Favored Glycine 0 C--N 1.343 0.932 0 CA-C-N 116.278 -0.419 . . . . 60.32 112.897 -173.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.6 p -87.58 150.85 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 C-N-CA 123.2 0.6 . . . . 75.33 109.869 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 42.6 mtp180 -123.16 177.86 5.36 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 121.722 0.773 . . . . 75.41 112.358 -177.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -58.37 137.27 57.35 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 113.282 -1.781 . . . . 75.41 111.038 174.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.76 -14.15 38.55 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-O 119.352 -0.693 . . . . 30.23 113.976 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 63.5 m -71.11 118.37 13.81 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 117.558 0.679 . . . . 74.24 109.593 -179.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.65 132.52 42.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 122.99 0.516 . . . . 74.31 109.716 -179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.06 104.65 16.93 Favored 'Isoleucine or valine' 0 C--O 1.241 0.606 0 C-N-CA 124.876 1.27 . . . . 72.35 107.588 -177.456 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.426 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 64.7 ttt180 -91.61 112.64 24.65 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 109.94 -0.393 . . . . 74.33 109.94 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 8.6 t -104.11 100.12 19.78 Favored Pre-proline 0 CA--C 1.557 1.219 0 N-CA-C 106.989 -1.485 . . . . 74.21 106.989 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -66.63 128.83 19.8 Favored 'Trans proline' 0 C--N 1.375 1.943 0 C-N-CA 122.878 2.385 . . . . 74.32 113.096 -174.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.56 22.78 78.13 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.939 -0.573 . . . . 73.54 114.207 176.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.1 tpt -107.45 -23.96 11.99 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 123.385 0.674 . . . . 71.15 110.969 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -66.45 -84.14 0.1 OUTLIER Glycine 0 C--N 1.344 1.024 0 CA-C-N 116.359 -0.382 . . . . 73.2 112.865 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -71.46 93.09 0.52 Allowed Glycine 0 C--N 1.346 1.109 0 N-CA-C 111.466 -0.653 . . . . 61.3 111.466 173.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.4 mm-40 -78.78 143.61 35.94 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.757 0.823 . . . . 62.55 111.756 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.13 -168.24 25.78 Favored Glycine 0 C--O 1.241 0.583 0 CA-C-N 114.8 -1.091 . . . . 65.0 110.377 -177.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 17.3 m120 -62.16 -44.37 88.79 Favored Pre-proline 0 CA--C 1.562 1.416 0 CA-C-O 118.655 -0.688 . . . . 75.43 110.82 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -82.96 114.43 2.26 Favored 'Trans proline' 0 C--N 1.394 2.972 0 C-N-CA 121.872 1.714 . . . . 74.34 111.717 167.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -82.94 150.27 14.03 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.222 1.948 . . . . 73.05 113.059 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -132.84 151.66 20.07 Favored Glycine 0 N--CA 1.473 1.123 0 N-CA-C 110.326 -1.109 . . . . 42.24 110.326 170.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.58 156.06 39.39 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.489 0.715 . . . . 63.22 112.49 -175.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.435 HD22 HD13 ' A' ' 98' ' ' LEU . 65.5 tp -116.22 127.94 55.19 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 108.428 -0.953 . . . . 75.51 108.428 172.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 54.5 mt -128.26 118.34 23.11 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 124.825 1.25 . . . . 72.32 108.689 -178.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.462 HD12 HD13 ' A' ' 123' ' ' LEU . 86.1 mt -120.68 103.31 9.02 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 123.061 0.545 . . . . 71.31 111.043 -178.298 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.9 t -85.43 96.02 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.587 -0.523 . . . . 74.52 109.587 -176.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.4 t -55.5 126.76 13.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.921 0.888 . . . . 71.34 111.807 -178.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.41 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 31.6 mmt180 -112.48 113.12 25.14 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 125.19 1.396 . . . . 74.34 107.687 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 50.3 mt -74.56 119.53 18.88 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.255 -0.646 . . . . 75.43 109.255 176.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 67.0 mt -82.33 131.24 56.46 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 108.317 -0.994 . . . . 72.25 108.317 176.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -68.31 143.03 56.87 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.961 2.441 . . . . 71.11 112.284 -174.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.502 ' HB2' HD13 ' A' ' 127' ' ' LEU . 47.0 m80 . . . . . 0 N--CA 1.485 1.319 0 C-N-CA 124.03 0.932 . . . . 73.22 108.806 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 85.2 mtp . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.753 -0.091 . . . . 71.42 110.753 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.425 ' HB2' ' O ' ' A' ' 99' ' ' PHE . 2.6 pt? -47.57 123.89 9.36 Favored Pre-proline 0 CA--C 1.563 1.452 0 C-N-CA 124.92 1.288 . . . . 74.11 112.238 178.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 10.3 Cg_endo -86.75 -79.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 123.009 2.473 . . . . 75.22 111.248 177.691 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.475 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.5 tp -157.83 142.23 16.18 Favored 'General case' 0 C--N 1.348 0.521 0 N-CA-C 108.292 -1.003 . . . . 64.45 108.292 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.697 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 5.2 tp 57.09 7.75 0.46 Allowed 'General case' 0 CA--C 1.57 1.713 0 C-N-CA 126.096 1.758 . . . . 74.32 113.172 -173.099 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.614 ' HA ' HD12 ' A' ' 119' ' ' LEU . 86.7 t80 -139.12 128.79 24.63 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.825 0.85 . . . . 74.12 109.333 -171.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.524 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 86.2 m -153.05 98.62 2.76 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 124.192 0.997 . . . . 74.44 109.342 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -72.16 83.18 1.23 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.444 2.096 . . . . 75.51 112.242 -173.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 20.6 m -85.05 173.48 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 CA-C-N 115.406 -0.816 . . . . 75.13 109.691 175.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 3.7 t -142.57 70.13 1.32 Allowed 'General case' 0 N--CA 1.473 0.684 0 CA-C-O 122.339 1.066 . . . . 73.34 109.324 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -89.76 97.55 11.26 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 114.63 -1.168 . . . . 75.25 110.346 -176.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -75.08 137.39 22.02 Favored Glycine 0 C--N 1.347 1.173 0 CA-C-N 116.037 -0.528 . . . . 75.34 111.972 178.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.7 m -63.48 -39.36 94.26 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 123.802 0.841 . . . . 61.42 110.665 176.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 63.11 57.17 16.6 Favored Glycine 0 C--N 1.351 1.396 0 CA-C-N 115.27 -0.877 . . . . 71.53 112.853 179.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.67 151.12 8.43 Favored Glycine 0 C--N 1.345 1.047 0 CA-C-O 119.59 -0.561 . . . . 72.43 112.111 179.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.7 p -69.4 -50.38 46.44 Favored 'General case' 0 N--CA 1.474 0.775 0 C-N-CA 123.82 0.848 . . . . 74.21 110.544 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -65.93 -23.15 70.91 Favored Glycine 0 C--N 1.354 1.563 0 O-C-N 123.905 0.753 . . . . 61.31 112.441 175.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -75.99 76.12 1.45 Allowed Glycine 0 C--N 1.348 1.199 0 N-CA-C 111.968 -0.453 . . . . 72.22 111.968 174.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 32.8 t -87.77 83.25 7.17 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 108.39 -0.967 . . . . 74.43 108.39 177.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 74.3 -85.19 0.71 Allowed Glycine 0 C--N 1.347 1.157 0 CA-C-N 115.276 -0.874 . . . . 74.44 112.12 -178.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.68 -55.29 4.99 Favored Glycine 0 C--N 1.348 1.249 0 N-CA-C 111.482 -0.647 . . . . 73.42 111.482 -174.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 19.8 p -146.49 140.97 26.6 Favored 'General case' 0 C--O 1.242 0.664 0 C-N-CA 125.031 1.333 . . . . 73.14 108.108 173.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.35 -121.31 0.12 Allowed Glycine 0 C--N 1.346 1.112 0 CA-C-O 119.989 -0.34 . . . . 72.31 112.334 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.482 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.0 OUTLIER -97.54 133.39 42.17 Favored 'General case' 0 N--CA 1.479 0.992 0 CA-C-N 117.591 0.696 . . . . 75.04 110.209 178.708 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -95.35 107.32 19.44 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 107.086 -1.45 . . . . 73.45 107.086 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.614 HD12 ' HA ' ' A' ' 99' ' ' PHE . 15.7 mt -92.76 108.46 20.0 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 107.593 -1.262 . . . . 73.11 107.593 -174.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.504 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 20.8 ttt180 -106.17 104.71 14.47 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 109.049 -0.723 . . . . 73.12 109.049 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -123.19 134.34 54.17 Favored 'General case' 0 C--O 1.237 0.411 0 N-CA-C 108.929 -0.767 . . . . 61.33 108.929 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -80.87 121.78 26.39 Favored 'General case' 0 C--O 1.241 0.637 0 N-CA-C 108.254 -1.017 . . . . 71.33 108.254 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.51 HD23 ' HG2' ' A' ' 136' ' ' ARG . 5.5 tt -99.06 109.74 55.26 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 108.159 -1.052 . . . . 71.14 108.159 -171.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -72.75 115.23 4.26 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 121.904 1.736 . . . . 64.13 110.443 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.551 HD23 HD13 ' A' ' 149' ' ' ILE . 29.0 tp -128.81 137.51 51.55 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.601 0.76 . . . . 73.32 109.498 -173.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 74.3 p -79.87 162.62 24.91 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.11 -0.33 . . . . 53.22 110.11 -178.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.97 -26.95 65.3 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.393 0.677 . . . . 74.21 110.962 -178.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -68.55 -50.31 52.82 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 114.934 -1.03 . . . . 62.11 109.093 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 -73.63 -21.23 60.36 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 114.991 -1.004 . . . . 74.35 112.324 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.09 -44.89 64.76 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.991 0.517 . . . . 72.22 109.74 170.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -62.13 -42.35 99.16 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.666 1.186 . . . . 72.34 110.921 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -74.42 -48.8 25.51 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.607 0.363 . . . . 74.04 110.427 -178.493 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.637 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 62.49 52.34 49.73 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 123.997 0.81 . . . . 74.11 113.853 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -101.37 -130.49 7.06 Favored Glycine 0 C--N 1.347 1.148 0 N-CA-C 111.452 -0.659 . . . . 62.51 111.452 177.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -97.28 158.61 15.37 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.072 0.549 . . . . 72.53 110.149 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.51 ' HG2' HD23 ' A' ' 123' ' ' LEU . 41.0 tpt85 -136.84 119.69 16.3 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.214 -0.903 . . . . 74.52 108.975 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.8 t -86.39 105.96 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 123.397 0.679 . . . . 73.13 109.643 -177.143 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.495 HG23 HD11 ' A' ' 98' ' ' LEU . 34.3 m -117.01 162.6 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.001 1.321 . . . . 70.3 108.345 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -123.98 112.69 17.49 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 122.497 0.319 . . . . 73.45 111.263 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.697 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.9 p -106.46 105.44 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 124.469 1.107 . . . . 75.4 109.965 -178.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 58.02 28.74 16.71 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.633 0.773 . . . . 71.51 112.122 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.25 2.76 55.74 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-O 119.566 -0.574 . . . . 75.24 114.069 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.6 mtt180 -100.73 121.8 42.27 Favored 'General case' 0 N--CA 1.486 1.349 0 CA-C-N 117.735 0.767 . . . . 74.02 110.724 -178.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -74.96 126.32 30.75 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.463 0.705 . . . . 75.42 109.319 172.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 3.2 p -148.79 131.0 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.068 0.547 . . . . 74.32 110.464 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 12.5 p -91.42 105.85 18.07 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 123.547 0.739 . . . . 74.32 109.647 176.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.8 p -99.35 132.56 44.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 123.906 0.882 . . . . 75.01 109.036 176.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 58.1 ttt85 -81.92 129.16 34.68 Favored 'General case' 0 C--O 1.242 0.667 0 CA-C-O 121.59 0.709 . . . . 75.35 110.696 -176.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.551 HD13 HD23 ' A' ' 125' ' ' LEU . 2.4 pt -98.56 145.2 29.48 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.637 1.575 . . . . 71.14 108.734 174.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.91 143.88 62.44 Favored 'Trans proline' 0 CA--C 1.562 1.906 0 C-N-CA 121.986 1.791 . . . . 74.21 112.215 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.637 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 30.5 Cg_endo -62.27 130.16 29.45 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.18 2.586 . . . . 74.31 111.787 175.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 64.76 46.77 88.76 Favored Glycine 0 C--N 1.344 1.021 0 O-C-N 123.966 0.791 . . . . 72.24 111.614 -175.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.424 HG23 HG21 ' A' ' 178' ' ' VAL . 8.2 p -75.72 145.6 10.41 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 CA-C-O 121.187 0.517 . . . . 74.42 110.256 179.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.4 mtp180 -104.07 169.78 8.3 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.19 0.996 . . . . 75.2 111.974 -172.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.6 tp10 -68.19 134.6 50.72 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-N 113.834 -1.53 . . . . 74.22 110.331 176.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.05 2.79 66.81 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-O 118.968 -0.907 . . . . 74.13 114.395 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.7 m -71.13 117.63 12.89 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 118.213 1.006 . . . . 74.02 108.869 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.7 p -93.37 132.25 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 109.34 -0.615 . . . . 74.4 109.34 -178.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 50.0 mt -105.93 104.12 16.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 107.807 -1.183 . . . . 71.45 107.807 -178.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 36.1 ttm180 -91.46 104.74 17.22 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 109.632 -0.507 . . . . 73.23 109.632 177.521 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.4 t -97.12 111.58 58.35 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 107.361 -1.348 . . . . 74.3 107.361 174.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -69.86 124.62 11.22 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 123.17 2.58 . . . . 72.12 113.46 -170.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 69.38 16.01 70.96 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 114.743 0.657 . . . . 70.03 114.743 173.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.9 mmt -113.83 12.64 18.26 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 123.317 0.647 . . . . 74.03 111.659 -177.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -96.43 -102.17 2.01 Favored Glycine 0 C--N 1.338 0.661 0 O-C-N 123.472 0.483 . . . . 71.14 112.588 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.482 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -65.48 121.47 20.41 Favored Glycine 0 C--N 1.353 1.523 0 O-C-N 123.948 0.44 . . . . 64.03 113.587 -173.194 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -71.22 146.95 48.71 Favored 'General case' 0 C--O 1.246 0.92 0 C-N-CA 123.414 0.686 . . . . 74.22 110.952 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 155.32 -169.38 33.26 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.025 -0.989 . . . . 75.34 111.093 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -74.34 -48.91 5.46 Favored Pre-proline 0 CA--C 1.566 1.572 0 CA-C-O 118.621 -0.704 . . . . 73.34 109.378 174.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -83.55 111.59 1.79 Allowed 'Trans proline' 0 C--N 1.394 2.962 0 C-N-CA 121.641 1.56 . . . . 72.32 110.264 164.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -69.52 128.89 16.91 Favored 'Trans proline' 0 C--N 1.369 1.64 0 C-N-CA 122.261 1.974 . . . . 72.3 111.854 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -90.99 166.78 31.31 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-O 119.873 -0.404 . . . . 73.53 112.129 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -82.45 158.68 23.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 122.989 0.516 . . . . 75.31 111.11 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.554 HD21 HD13 ' A' ' 98' ' ' LEU . 40.9 tp -118.29 131.55 56.34 Favored 'General case' 0 C--O 1.223 -0.3 0 C-N-CA 123.69 0.796 . . . . 74.34 109.463 -178.001 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 87.0 mt -128.8 125.54 38.0 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.028 0.931 . . . . 73.23 109.804 -177.617 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 80.8 mt -125.27 103.03 7.73 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.221 0.609 . . . . 74.1 111.124 178.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 39.4 t -85.59 94.34 4.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.306 -0.998 . . . . 72.32 108.306 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.424 HG21 HG23 ' A' ' 153' ' ' VAL . 98.7 t -58.49 114.83 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 C-N-CA 123.739 0.816 . . . . 73.03 111.049 -177.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -106.44 104.41 14.09 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 124.506 1.123 . . . . 74.45 108.751 178.284 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 72.3 mt -68.94 105.05 2.25 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 109.669 -0.493 . . . . 71.44 109.669 178.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.3 mt -60.74 149.66 78.84 Favored Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 124.295 1.038 . . . . 75.24 111.399 175.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -70.73 165.86 30.68 Favored 'Trans proline' 0 C--N 1.373 1.844 0 C-N-CA 122.314 2.009 . . . . 71.12 111.311 174.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 . . . . . 0 CA--C 1.552 1.039 0 N-CA-C 108.907 -0.775 . . . . 72.34 108.907 174.33 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' MET . . . . . 0.438 ' HG3' ' H ' ' A' ' 95' ' ' LEU . 5.6 tpt . . . . . 0 N--CA 1.475 0.779 0 N-CA-C 108.354 -0.98 . . . . 75.44 108.354 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.438 ' H ' ' HG3' ' A' ' 94' ' ' MET . 0.8 OUTLIER -101.45 99.39 11.21 Favored Pre-proline 0 CA--C 1.551 0.996 0 C-N-CA 124.067 0.947 . . . . 74.34 111.004 178.487 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.1 -67.12 0.03 OUTLIER 'Trans proline' 0 C--N 1.382 2.308 0 C-N-CA 122.055 1.837 . . . . 73.53 110.969 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.514 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 5.7 tp -171.6 143.62 1.76 Allowed 'General case' 0 C--N 1.35 0.62 0 C-N-CA 124.202 1.001 . . . . 73.52 108.457 176.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.658 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 6.1 tp 59.36 4.22 0.47 Allowed 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 125.628 1.571 . . . . 72.31 113.158 -173.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.581 ' HB2' HG22 ' A' ' 140' ' ' VAL . 82.7 t80 -139.95 130.43 25.51 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 107.789 -1.189 . . . . 74.54 107.789 -171.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.478 HG23 HG11 ' A' ' 102' ' ' VAL . 75.9 m -149.45 98.02 3.49 Favored Pre-proline 0 N--CA 1.469 0.483 0 O-C-N 124.327 1.017 . . . . 65.52 109.641 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -70.88 80.8 1.17 Allowed 'Trans proline' 0 C--N 1.367 1.516 0 C-N-CA 122.682 2.255 . . . . 74.44 112.679 -176.089 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.478 HG11 HG23 ' A' ' 100' ' ' THR . 29.9 m -84.81 163.18 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 124.586 1.154 . . . . 72.32 109.342 171.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 16.9 p -146.14 77.92 1.5 Allowed 'General case' 0 C--O 1.243 0.721 0 C-N-CA 123.918 0.887 . . . . 73.31 109.124 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 19.3 pttm -80.01 121.97 26.15 Favored 'General case' 0 C--N 1.359 1.007 0 N-CA-C 109.244 -0.65 . . . . 74.33 109.244 177.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 84.38 164.69 38.12 Favored Glycine 0 C--N 1.341 0.814 0 CA-C-N 116.132 -0.485 . . . . 65.2 112.184 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 38.6 m -103.95 20.06 18.87 Favored 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 124.144 0.978 . . . . 72.42 111.177 -179.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 78.83 -107.25 2.47 Favored Glycine 0 C--N 1.348 1.206 0 N-CA-C 110.399 -1.08 . . . . 64.44 110.399 -173.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 59.09 -146.31 43.04 Favored Glycine 0 C--N 1.348 1.201 0 O-C-N 123.811 0.36 . . . . 73.43 112.781 179.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.3 p -74.68 99.28 3.64 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 123.13 0.572 . . . . 63.52 109.473 172.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -99.49 147.45 18.34 Favored Glycine 0 C--N 1.34 0.792 0 N-CA-C 111.267 -0.733 . . . . 65.24 111.267 176.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -92.61 -140.28 9.61 Favored Glycine 0 C--N 1.345 1.033 0 N-CA-C 111.816 -0.514 . . . . 51.35 111.816 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 32.0 p -77.87 101.87 7.0 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 109.076 -0.712 . . . . 72.15 109.076 176.072 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -76.03 76.83 1.38 Allowed Glycine 0 C--N 1.344 1.003 0 CA-C-N 115.999 -0.546 . . . . 73.35 112.295 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -59.93 -44.9 96.71 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 111.615 -0.594 . . . . 75.11 111.615 177.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 24.6 m -116.11 112.94 22.45 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.289 1.035 . . . . 75.32 108.64 171.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.7 -96.24 0.15 Allowed Glycine 0 C--N 1.351 1.387 0 O-C-N 123.431 0.457 . . . . 72.32 113.037 177.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.426 ' H ' ' HA3' ' A' ' 166' ' ' GLY . 13.7 mtm180 -97.87 130.98 44.74 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 109.323 -0.621 . . . . 71.22 109.323 175.713 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -103.54 104.24 14.29 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.037 -1.468 . . . . 73.11 107.037 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.507 HD11 ' HA ' ' A' ' 99' ' ' PHE . 12.9 mt -93.55 110.26 21.85 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.846 -1.168 . . . . 74.44 107.846 -174.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.437 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 73.6 ttt-85 -107.49 104.53 14.12 Favored 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 108.732 -0.84 . . . . 75.05 108.732 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -121.11 126.93 51.02 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.692 0.797 . . . . 72.13 109.42 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -73.26 118.25 15.99 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 123.54 0.736 . . . . 72.13 109.563 176.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 5.3 tt -100.83 111.15 62.7 Favored Pre-proline 0 CA--C 1.549 0.934 0 C-N-CA 123.938 0.895 . . . . 73.41 108.849 -175.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.04 126.03 13.27 Favored 'Trans proline' 0 C--N 1.379 2.168 0 C-N-CA 122.555 2.17 . . . . 72.52 111.43 175.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.449 HD23 HD12 ' A' ' 149' ' ' ILE . 15.9 tp -148.15 133.83 18.87 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.231 -0.655 . . . . 75.51 109.231 -173.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.8 p -87.66 171.62 10.32 Favored 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 118.084 0.402 . . . . 62.45 110.312 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.21 -35.66 81.07 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.595 0.758 . . . . 75.41 111.362 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -63.96 -50.56 68.13 Favored 'General case' 0 C--N 1.35 0.61 0 CA-C-N 114.718 -1.128 . . . . 74.23 109.258 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 22.3 mm-40 -73.7 -24.69 59.97 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-N 114.58 -1.191 . . . . 74.34 111.334 -176.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.42 -38.91 81.66 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.212 -0.904 . . . . 71.4 110.345 173.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -72.66 -39.19 67.33 Favored 'General case' 0 CA--C 1.547 0.84 0 CA-C-N 115.473 -0.785 . . . . 73.43 110.423 176.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.71 -48.85 67.95 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 122.34 0.256 . . . . 75.4 111.045 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.568 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.25 59.37 10.98 Favored Glycine 0 C--N 1.345 1.061 0 O-C-N 124.015 0.822 . . . . 51.23 113.567 175.241 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.416 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -121.69 -155.64 9.51 Favored Glycine 0 C--N 1.34 0.783 0 N-CA-C 111.64 -0.584 . . . . 71.4 111.64 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.614 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.0 mp0 -75.12 122.74 24.05 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 109.929 -0.397 . . . . 72.43 109.929 179.07 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.438 ' HB2' HD11 ' A' ' 149' ' ' ILE . 12.8 tpt180 -109.59 119.53 39.7 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.391 -1.337 . . . . 75.51 107.391 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 50.7 t -83.1 106.63 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.476 0.71 . . . . 73.41 109.191 -172.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.514 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 33.4 m -116.85 163.24 14.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.887 0 C-N-CA 125.551 1.54 . . . . 74.24 108.806 -177.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -122.84 111.56 16.82 Favored 'General case' 0 N--CA 1.481 1.097 0 O-C-N 121.748 -0.595 . . . . 63.52 110.667 -178.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.658 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.4 p -104.14 109.74 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 125.015 1.326 . . . . 74.34 109.471 -177.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.94 22.39 13.02 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 123.837 0.855 . . . . 71.13 112.76 176.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.95 -13.83 58.88 Favored Glycine 0 C--N 1.352 1.439 0 CA-C-O 120.016 -0.325 . . . . 63.22 113.413 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 26.1 tpt180 -90.72 127.55 36.35 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 123.803 0.841 . . . . 63.12 109.401 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 15.5 tpp85 -89.2 130.1 35.67 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.577 -0.527 . . . . 74.32 109.577 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.8 p -147.47 148.98 15.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 C-N-CA 124.193 0.997 . . . . 75.55 109.555 -179.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.614 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 42.9 p -101.17 109.27 21.13 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.371 0.669 . . . . 73.43 110.156 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.77 124.83 53.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 123.316 0.646 . . . . 74.44 109.37 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 41.5 ttt180 -71.83 127.93 34.13 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 120.916 0.389 . . . . 75.54 110.494 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.568 HG13 ' HA2' ' A' ' 133' ' ' GLY . 2.7 pt -100.99 147.66 34.01 Favored Pre-proline 0 CA--C 1.558 1.265 0 C-N-CA 124.956 1.302 . . . . 74.02 108.223 174.136 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.11 135.61 19.11 Favored 'Trans proline' 0 CA--C 1.558 1.7 0 C-N-CA 122.36 2.04 . . . . 75.45 112.087 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.81 135.43 48.34 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.407 2.071 . . . . 70.43 111.81 173.187 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.54 62.56 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-N 115.669 -0.696 . . . . 62.03 112.42 -174.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.485 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 11.0 p -73.4 147.44 9.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 N-CA-C 109.273 -0.64 . . . . 74.21 109.273 178.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 56.1 mtp85 -138.89 178.95 6.78 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.706 0.765 . . . . 73.55 111.587 -173.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.01 120.0 6.76 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 113.348 -1.751 . . . . 72.35 110.578 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.23 -10.51 67.51 Favored Glycine 0 C--N 1.341 0.817 0 O-C-N 124.28 0.987 . . . . 65.01 113.797 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.3 m -70.3 121.54 17.84 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.416 -0.587 . . . . 74.33 109.416 178.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -105.01 122.45 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 109.41 -0.589 . . . . 74.21 109.41 -178.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.614 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 32.3 mt -91.53 101.95 13.02 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 107.782 -1.192 . . . . 64.44 107.782 -178.103 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.535 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 48.7 ttp85 -96.02 110.25 22.51 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.889 -0.411 . . . . 54.13 109.889 -176.58 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.6 t -103.96 96.46 9.39 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 107.636 -1.246 . . . . 74.43 107.636 170.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -65.78 127.0 16.96 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.815 2.344 . . . . 74.11 112.006 -176.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.9 -23.01 37.71 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-O 119.775 -0.459 . . . . 61.44 113.758 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.0 tpt -76.48 -32.5 58.38 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.255 0.622 . . . . 73.41 111.94 -174.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -65.57 -81.55 0.13 Allowed Glycine 0 CA--C 1.536 1.399 0 O-C-N 123.606 0.566 . . . . 73.12 113.384 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.426 ' HA3' ' H ' ' A' ' 117' ' ' ARG . . . -65.35 92.68 0.15 Allowed Glycine 0 C--N 1.345 1.077 0 C-N-CA 123.017 0.341 . . . . 73.52 113.347 174.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.9 mm-40 -91.2 153.08 20.26 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.266 1.027 . . . . 73.55 110.044 170.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 137.44 -62.94 0.58 Allowed Glycine 0 C--N 1.338 0.655 0 N-CA-C 111.203 -0.759 . . . . 54.04 111.203 178.364 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.535 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 24.3 t-20 -155.89 -56.48 0.02 OUTLIER Pre-proline 0 CA--C 1.567 1.601 0 CA-C-O 118.184 -0.912 . . . . 75.23 110.643 179.426 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.535 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 57.0 Cg_endo -90.04 113.71 0.52 Allowed 'Trans proline' 0 C--N 1.402 3.38 0 C-N-CA 122.769 2.313 . . . . 75.45 110.633 174.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -64.84 123.09 11.13 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 122.417 2.078 . . . . 74.55 111.059 -176.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -111.53 160.84 13.0 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 120.013 -0.326 . . . . 73.4 112.393 -176.403 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -77.68 139.65 39.47 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.06 0.544 . . . . 71.24 111.159 -174.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.535 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 64.2 tp -101.31 126.99 48.12 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.792 -1.188 . . . . 75.41 107.792 171.536 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.437 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 75.2 mt -127.16 103.18 7.29 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 124.695 1.198 . . . . 75.24 109.118 -175.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.614 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 88.0 mt -100.23 101.47 12.5 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 122.784 0.434 . . . . 74.12 110.02 178.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.1 t -86.81 99.52 8.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 108.799 -0.815 . . . . 75.3 108.799 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.91 114.26 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 CA-C-N 115.156 -0.929 . . . . 73.24 111.632 -173.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 6.3 mmp_? -99.36 113.16 25.33 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 125.142 1.377 . . . . 73.33 108.528 172.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.436 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 44.3 mt -72.3 127.51 32.78 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.852 -0.425 . . . . 71.13 109.852 175.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.1 mt -83.92 148.54 54.25 Favored Pre-proline 0 C--O 1.242 0.662 0 C-N-CA 123.883 0.873 . . . . 72.24 109.883 178.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.8 172.53 9.41 Favored 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 122.827 2.352 . . . . 70.0 111.831 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.533 -0.746 . . . . 75.13 110.163 -177.415 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 64.1 mtt . . . . . 0 N--CA 1.484 1.228 0 CA-C-O 120.533 0.206 . . . . 72.35 111.478 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 35.21 93.47 0.05 OUTLIER Pre-proline 0 CA--C 1.558 1.286 0 C-N-CA 126.803 2.041 . . . . 70.04 114.755 -174.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -66.83 -174.3 0.46 Allowed 'Trans proline' 0 C--N 1.369 1.63 0 C-N-CA 122.617 2.211 . . . . 73.51 111.142 163.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.48 HD13 ' HG ' ' A' ' 123' ' ' LEU . 8.6 tp -72.73 133.47 44.58 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.518 -0.549 . . . . 73.54 109.518 176.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.559 HD23 HG23 ' A' ' 138' ' ' VAL . 13.4 tp 73.17 -39.98 0.46 Allowed 'General case' 0 N--CA 1.484 1.255 0 C-N-CA 127.268 2.227 . . . . 74.2 113.077 -176.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -88.12 131.34 34.73 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.141 0.976 . . . . 75.22 111.528 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.522 HG21 HG12 ' A' ' 102' ' ' VAL . 93.6 m -151.29 92.21 3.78 Favored Pre-proline 0 CA--C 1.55 0.964 0 C-N-CA 123.592 0.757 . . . . 74.14 109.823 178.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -74.06 82.23 1.82 Allowed 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.646 2.23 . . . . 55.21 113.302 -168.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.522 HG12 HG21 ' A' ' 100' ' ' THR . 28.6 m -107.66 -165.6 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 123.985 0.914 . . . . 75.45 109.972 178.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.9 t -120.54 -30.46 4.52 Favored 'General case' 0 CA--C 1.546 0.788 0 C-N-CA 123.137 0.575 . . . . 73.22 109.937 171.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.0 tppt? -173.48 150.38 1.8 Allowed 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.015 0.926 . . . . 75.51 109.459 -175.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -164.16 -60.88 0.02 OUTLIER Glycine 0 C--N 1.347 1.17 0 C-N-CA 121.244 -0.503 . . . . 65.41 114.13 -178.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' SER . . . . . 0.583 ' HG ' ' HB3' ' A' ' 173' ' ' ASP . 81.8 p -79.32 -50.71 10.45 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 122.793 0.437 . . . . 72.03 111.32 -173.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -179.39 144.51 6.17 Favored Glycine 0 C--N 1.341 0.837 0 C-N-CA 121.621 -0.323 . . . . 54.51 112.944 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -164.58 66.98 0.22 Allowed Glycine 0 C--N 1.346 1.13 0 N-CA-C 110.974 -0.85 . . . . 72.22 110.974 177.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 50.9 m -71.95 98.24 2.01 Favored 'General case' 0 C--O 1.241 0.61 0 C-N-CA 123.502 0.721 . . . . 75.12 110.599 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -179.8 69.46 0.07 OUTLIER Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.393 -1.083 . . . . 61.14 110.393 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -80.06 47.42 3.36 Favored Glycine 0 C--N 1.349 1.301 0 C-N-CA 123.18 0.419 . . . . 64.13 113.704 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.0 m -137.84 21.1 2.86 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.483 1.113 . . . . 70.3 109.452 176.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 164.21 -35.05 0.29 Allowed Glycine 0 C--N 1.352 1.436 0 CA-C-N 115.808 -0.633 . . . . 63.41 112.141 -177.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 106.94 -155.33 16.43 Favored Glycine 0 C--N 1.346 1.119 0 C-N-CA 123.113 0.387 . . . . 74.14 112.719 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 50.3 m -151.8 -176.48 5.65 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 123.764 0.826 . . . . 74.31 110.885 -175.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -82.86 173.57 52.48 Favored Glycine 0 C--N 1.354 1.56 0 CA-C-N 116.262 -0.426 . . . . 73.32 113.181 173.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.441 ' HD2' ' H ' ' A' ' 117' ' ' ARG . 0.0 OUTLIER -82.56 139.33 33.9 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.67 0.788 . . . . 74.4 111.038 -177.887 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -101.54 108.78 20.45 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.638 -0.875 . . . . 74.33 108.638 -173.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.406 HD22 ' O ' ' A' ' 100' ' ' THR . 15.2 mt -89.93 110.63 21.58 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.796 -1.186 . . . . 73.03 107.796 -169.299 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -107.17 109.31 21.1 Favored 'General case' 0 C--N 1.344 0.349 0 N-CA-C 108.997 -0.742 . . . . 63.22 108.997 173.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.487 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -126.5 141.97 51.69 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.277 -1.008 . . . . 74.34 108.277 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -74.32 135.06 42.54 Favored 'General case' 0 C--O 1.243 0.73 0 N-CA-C 109.051 -0.722 . . . . 73.33 109.051 173.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.48 ' HG ' HD13 ' A' ' 97' ' ' LEU . 1.9 tt -100.83 103.11 22.51 Favored Pre-proline 0 CA--C 1.543 0.708 0 N-CA-C 107.929 -1.138 . . . . 75.41 107.929 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.415 ' HB2' HD11 ' A' ' 181' ' ' LEU . 52.1 Cg_endo -67.83 115.48 3.79 Favored 'Trans proline' 0 C--N 1.376 2.013 0 C-N-CA 122.49 2.126 . . . . 70.41 110.052 174.439 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.565 HD21 HD12 ' A' ' 149' ' ' ILE . 17.0 tp -137.6 135.31 36.48 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.074 -0.713 . . . . 71.41 109.074 -169.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.0 p -77.28 164.58 25.44 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 118.76 0.709 . . . . 72.2 110.581 178.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -63.28 -30.91 71.96 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.728 0.811 . . . . 71.44 111.877 -177.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -75.0 -46.95 31.67 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.561 0.745 . . . . 75.42 110.13 -178.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 73.3 mm-40 -60.62 -35.69 76.78 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 123.911 0.757 . . . . 73.21 111.048 176.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.51 -51.63 61.98 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 124.099 0.874 . . . . 62.41 111.21 174.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -58.04 -50.82 72.1 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.928 1.291 . . . . 74.33 111.688 -176.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 56.1 m80 -78.18 -41.18 35.46 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.819 -0.628 . . . . 74.33 109.881 -176.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 73.94 -167.86 54.37 Favored Glycine 0 C--N 1.352 1.451 0 CA-C-N 116.03 -0.532 . . . . 72.15 112.072 -173.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.456 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 122.85 -165.08 15.57 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 111.766 -0.534 . . . . 70.01 111.766 177.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.47 ' HA ' ' HA ' ' A' ' 148' ' ' ARG . 1.5 mp0 -84.78 125.71 32.8 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 121.125 0.488 . . . . 75.02 110.304 178.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 tpp180 -112.88 122.37 47.44 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.929 1.291 . . . . 75.14 107.92 175.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 15.4 t -101.86 106.93 20.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 N-CA-C 109.334 -0.617 . . . . 73.33 109.334 -171.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.559 HG23 HD23 ' A' ' 98' ' ' LEU . 30.0 m -124.46 153.52 31.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.298 1.039 . . . . 74.14 108.835 -175.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -107.03 132.56 52.82 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 122.592 0.357 . . . . 74.55 111.517 -171.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.1 p -113.26 104.8 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 125.21 1.404 . . . . 65.22 109.881 176.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.67 15.54 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 113.187 0.81 . . . . 70.42 113.187 173.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.0 8.73 47.24 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.908 -0.385 . . . . 54.44 113.696 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 7.2 tpp180 -115.72 116.39 27.99 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.336 0.655 . . . . 73.31 109.238 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -87.1 106.38 17.83 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.071 0.548 . . . . 74.22 109.879 -173.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 78.4 t -112.87 133.96 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.228 1.011 . . . . 71.12 110.729 -176.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 45.5 t -92.1 104.48 16.87 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.55 0.74 . . . . 75.01 109.951 175.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.551 HG23 HD12 ' A' ' 176' ' ' LEU . 6.3 p -99.99 122.38 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 123.65 0.78 . . . . 74.34 110.181 175.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . 0.47 ' HA ' ' HA ' ' A' ' 135' ' ' GLU . 61.1 ttt180 -77.09 112.18 13.48 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.673 0.389 . . . . 71.25 110.086 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.565 HD12 HD21 ' A' ' 125' ' ' LEU . 4.4 pt -77.94 138.4 61.43 Favored Pre-proline 0 CA--C 1.56 1.36 0 C-N-CA 123.794 0.838 . . . . 71.05 109.212 170.665 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -60.0 136.8 71.86 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.911 2.407 . . . . 75.13 113.271 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.431 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 32.3 Cg_exo -61.59 113.05 1.64 Allowed 'Trans proline' 0 C--N 1.375 1.95 0 C-N-CA 122.776 2.318 . . . . 62.41 111.585 171.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.89 39.76 16.17 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.051 -0.522 . . . . 73.42 112.076 -173.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.6 p -75.46 145.32 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 N-CA-C 109.399 -0.593 . . . . 71.14 109.399 175.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -112.62 173.1 6.54 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 121.472 0.653 . . . . 73.2 112.009 -173.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -63.77 133.97 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 113.927 -1.488 . . . . 60.12 111.107 178.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.36 -21.65 33.99 Favored Glycine 0 C--N 1.349 1.263 0 CA-C-N 115.833 -0.622 . . . . 62.32 113.583 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 72.7 m -63.66 121.52 14.13 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 123.695 0.798 . . . . 73.43 111.876 -172.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.4 p -95.39 125.29 48.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 CA-C-O 121.302 0.572 . . . . 73.2 110.268 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.0 mt -93.73 115.23 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.355 1.062 . . . . 71.22 108.29 -178.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 -101.26 119.94 39.51 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 122.848 0.459 . . . . 75.14 110.497 -176.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -117.4 99.31 52.52 Favored Pre-proline 0 CA--C 1.552 1.045 0 N-CA-C 107.574 -1.269 . . . . 62.05 107.574 169.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.77 138.81 81.85 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.791 2.328 . . . . 72.32 113.913 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.6 5.13 72.58 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 115.07 -0.968 . . . . 63.02 115.094 175.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 13.6 tpt -101.99 -16.0 16.62 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 117.638 0.719 . . . . 71.34 112.359 -170.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -73.82 -81.72 0.41 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 120.154 -0.248 . . . . 60.2 112.769 178.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -60.39 93.78 0.07 OUTLIER Glycine 0 C--N 1.352 1.42 0 C-N-CA 123.1 0.381 . . . . 54.23 112.95 172.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -91.98 171.01 9.4 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.495 1.118 . . . . 74.33 111.46 175.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 113.76 -65.68 0.27 Allowed Glycine 0 C--N 1.345 1.046 0 CA-C-N 115.579 -0.737 . . . . 74.43 111.792 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -168.62 -32.35 0.0 OUTLIER Pre-proline 0 CA--C 1.565 1.554 0 CA-C-O 117.48 -1.248 . . . . 75.04 112.66 -179.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -92.32 106.81 0.22 Allowed 'Trans proline' 0 C--N 1.403 3.442 0 CA-C-N 122.37 1.882 . . . . 73.21 110.611 168.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_exo -66.16 124.85 13.14 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.277 1.984 . . . . 74.31 111.811 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -120.96 155.95 16.19 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.25 -1.14 . . . . 51.31 110.25 172.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.583 ' HB3' ' HG ' ' A' ' 106' ' ' SER . 3.2 t70 -76.81 162.69 27.45 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.687 0.795 . . . . 71.13 111.033 -173.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.454 HD23 HD11 ' A' ' 98' ' ' LEU . 55.9 tp -122.6 130.58 53.16 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.047 0.539 . . . . 74.43 109.795 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.41 128.77 46.36 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.805 1.242 . . . . 73.14 109.05 177.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.551 HD12 HG23 ' A' ' 147' ' ' VAL . 88.0 mt -129.17 102.31 6.41 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.198 0.599 . . . . 73.44 110.948 178.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.0 t -85.69 99.32 7.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.66 0 N-CA-C 109.563 -0.532 . . . . 73.31 109.563 -173.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.7 t -56.14 114.51 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.344 1.058 . . . . 71.14 111.907 -178.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -113.09 102.6 10.55 Favored 'General case' 0 C--O 1.239 0.517 0 C-N-CA 124.77 1.228 . . . . 75.4 108.598 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 68.6 mt -70.28 116.93 11.2 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 115.256 -0.884 . . . . 72.21 110.962 -177.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.415 HD11 ' HB2' ' A' ' 124' ' ' PRO . 58.0 mt -77.26 146.75 75.05 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 115.416 -0.811 . . . . 74.14 110.378 -177.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -60.64 115.05 2.42 Favored 'Trans proline' 0 C--N 1.373 1.817 0 C-N-CA 123.279 2.653 . . . . 72.51 111.873 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 . . . . . 0 C--O 1.249 1.073 0 N-CA-C 109.331 -0.618 . . . . 63.02 109.331 -179.856 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 26.6 ptt? . . . . . 0 N--CA 1.484 1.262 0 N-CA-C 110.572 -0.158 . . . . 70.03 110.572 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 3.4 pp -45.51 130.12 6.31 Favored Pre-proline 0 CA--C 1.566 1.587 0 C-N-CA 124.761 1.224 . . . . 74.24 112.341 168.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -69.87 -164.05 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 123.611 2.874 . . . . 74.21 113.433 168.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.583 HD12 ' HD2' ' A' ' 124' ' ' PRO . 0.6 OUTLIER -60.31 -46.56 89.44 Favored 'General case' 0 N--CA 1.483 1.203 0 C-N-CA 124.446 1.098 . . . . 73.45 112.031 -179.009 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.506 HD22 ' HB ' ' A' ' 140' ' ' VAL . 3.9 tt -139.19 90.04 2.39 Favored 'General case' 0 C--O 1.211 -0.962 0 N-CA-C 108.04 -1.096 . . . . 72.24 108.04 173.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 73.5 t80 172.5 107.05 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 125.518 1.527 . . . . 75.42 107.373 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.54 HG23 HG13 ' A' ' 102' ' ' VAL . 93.9 m -127.79 94.64 36.77 Favored Pre-proline 0 C--O 1.239 0.511 0 N-CA-C 109.763 -0.458 . . . . 62.33 109.763 -178.001 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -70.1 85.28 0.67 Allowed 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 122.556 2.17 . . . . 73.21 112.293 -175.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.54 HG13 HG23 ' A' ' 100' ' ' THR . 22.6 m -98.06 150.12 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 C-N-CA 124.001 0.92 . . . . 74.02 109.582 174.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -95.99 143.56 27.06 Favored 'General case' 0 C--O 1.246 0.89 0 N-CA-C 108.327 -0.99 . . . . 74.24 108.327 171.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 17.2 tppt? -77.91 108.83 11.44 Favored 'General case' 0 C--O 1.241 0.625 0 N-CA-C 110.113 -0.328 . . . . 72.32 110.113 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -70.08 99.48 0.71 Allowed Glycine 0 C--N 1.345 1.08 0 N-CA-C 109.71 -1.356 . . . . 73.0 109.71 168.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 21.1 t -66.27 -21.76 66.29 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.635 0.774 . . . . 72.51 111.605 -174.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -99.72 30.06 10.78 Favored Glycine 0 C--N 1.349 1.291 0 C-N-CA 123.11 0.386 . . . . 75.33 112.315 173.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -72.82 -71.87 1.03 Allowed Glycine 0 C--N 1.358 1.8 0 CA-C-O 119.972 -0.349 . . . . 72.41 113.398 -176.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 81.0 p -162.78 15.91 0.08 Allowed 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 123.329 0.652 . . . . 61.5 111.733 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 75.62 86.55 0.31 Allowed Glycine 0 C--N 1.353 1.511 0 CA-C-O 120.039 -0.312 . . . . 54.23 112.553 -177.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -74.26 91.27 0.73 Allowed Glycine 0 C--N 1.352 1.462 0 N-CA-C 111.553 -0.619 . . . . 65.0 111.553 178.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 17.5 m -63.57 98.9 0.19 Allowed 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 124.592 1.157 . . . . 72.43 113.035 -171.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 80.64 -70.64 2.98 Favored Glycine 0 C--N 1.343 0.966 0 CA-C-N 115.753 -0.658 . . . . 64.31 113.362 172.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -84.13 -150.05 10.63 Favored Glycine 0 N--CA 1.471 1.003 0 CA-C-O 119.937 -0.368 . . . . 62.45 112.473 177.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.1 t 63.09 77.45 0.33 Allowed 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.406 1.082 . . . . 73.32 111.507 178.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -84.79 -102.28 0.63 Allowed Glycine 0 CA--C 1.521 0.437 0 CA-C-N 114.59 -1.186 . . . . 43.23 111.003 174.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.426 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 12.5 mmm-85 -97.63 117.89 32.93 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 107.952 -1.129 . . . . 73.42 107.952 174.421 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -96.69 104.44 16.43 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.458 -0.941 . . . . 71.12 108.458 -171.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.439 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.1 mt -92.39 111.48 23.07 Favored 'General case' 0 C--N 1.344 0.344 0 N-CA-C 107.917 -1.142 . . . . 75.24 107.917 -172.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -110.08 105.58 14.75 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 108.686 -0.857 . . . . 72.34 108.686 174.081 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.13 160.92 35.81 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 123.929 0.892 . . . . 71.22 109.6 -176.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 88.7 mt-10 -99.79 136.39 39.79 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.437 0.695 . . . . 73.1 110.12 -173.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.526 ' HA ' HD12 ' A' ' 97' ' ' LEU . 1.6 tt -105.05 101.33 29.49 Favored Pre-proline 0 CA--C 1.545 0.75 0 C-N-CA 124.247 1.019 . . . . 73.43 108.759 -176.14 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.583 ' HD2' HD12 ' A' ' 97' ' ' LEU . 30.2 Cg_endo -62.74 120.04 7.38 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.478 2.119 . . . . 74.01 110.285 170.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.565 HD22 HD13 ' A' ' 149' ' ' ILE . 15.2 tp -145.89 135.7 23.43 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.948 0.499 . . . . 75.04 109.664 -172.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.3 p -88.24 168.8 12.41 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.974 0.51 . . . . 74.13 110.72 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 72.2 mt -63.08 -36.99 85.43 Favored 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 123.395 0.678 . . . . 73.34 111.928 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -63.55 -54.77 30.93 Favored 'General case' 0 N--CA 1.475 0.811 0 O-C-N 123.953 0.783 . . . . 71.44 108.983 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -64.19 -34.18 77.5 Favored 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 114.759 -1.109 . . . . 74.15 111.699 -177.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 153' ' ' VAL . . . -59.9 -49.62 76.96 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.218 0.949 . . . . 65.22 110.475 175.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -69.61 -34.71 74.47 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 115.008 -0.996 . . . . 73.21 111.129 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -66.77 -47.08 73.3 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.833 0.453 . . . . 75.51 110.57 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.508 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.3 41.03 94.85 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 115.532 -0.758 . . . . 73.43 112.648 -174.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -84.39 -163.9 36.87 Favored Glycine 0 C--N 1.347 1.162 0 O-C-N 123.904 0.414 . . . . 63.23 112.984 -178.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.4 mp0 -85.44 144.67 27.85 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.437 -0.579 . . . . 74.42 109.437 170.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.511 ' HG2' HD21 ' A' ' 123' ' ' LEU . 11.0 tpt180 -125.69 120.32 30.39 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 123.935 0.894 . . . . 73.13 108.621 -177.153 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.44 123.53 37.94 Favored 'Isoleucine or valine' 0 C--O 1.24 0.573 0 N-CA-C 109.373 -0.602 . . . . 74.04 109.373 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.496 HG12 HD23 ' A' ' 97' ' ' LEU . 27.2 m -138.25 162.49 30.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 125.02 1.328 . . . . 73.22 108.54 179.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -119.83 129.28 54.35 Favored 'General case' 0 N--CA 1.479 1.019 0 O-C-N 122.053 -0.405 . . . . 74.51 110.644 -178.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.506 ' HB ' HD22 ' A' ' 98' ' ' LEU . 5.3 p -119.89 113.63 41.4 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.599 1.159 . . . . 74.35 110.045 175.231 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 56.35 33.27 22.03 Favored 'General case' 0 N--CA 1.487 1.425 0 C-N-CA 123.782 0.833 . . . . 73.54 112.389 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.29 19.28 59.09 Favored Glycine 0 C--N 1.351 1.413 0 CA-C-N 115.858 -0.61 . . . . 54.1 113.638 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 75.9 mtp180 -125.42 125.61 43.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 123.722 0.809 . . . . 75.0 110.198 -176.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.3 ttp180 -73.51 120.33 18.97 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 122.904 0.482 . . . . 74.11 110.734 178.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 20.5 m -125.24 141.22 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.716 0.807 . . . . 75.0 109.77 170.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.9 p -106.62 111.71 24.38 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.817 0.847 . . . . 75.2 109.353 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -101.08 130.75 50.0 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 123.716 0.806 . . . . 75.1 110.083 178.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 39.0 ttt180 -81.6 114.3 20.2 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.494 -0.928 . . . . 73.24 108.494 178.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.565 HD13 HD22 ' A' ' 125' ' ' LEU . 5.2 pt -84.51 146.39 47.07 Favored Pre-proline 0 CA--C 1.554 1.132 0 C-N-CA 123.844 0.858 . . . . 74.32 109.469 177.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -66.4 141.76 63.12 Favored 'Trans proline' 0 CA--C 1.562 1.894 0 C-N-CA 122.826 2.351 . . . . 74.34 112.922 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -67.92 127.95 16.97 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 123.127 2.551 . . . . 75.35 111.496 172.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 74.71 26.34 67.54 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 123.783 0.677 . . . . 71.04 113.317 -175.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.417 ' O ' ' HB3' ' A' ' 130' ' ' ALA . 12.6 p -71.71 146.37 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 117.421 0.61 . . . . 74.44 110.735 -178.124 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.508 ' HA ' HD11 ' A' ' 180' ' ' LEU . 29.7 mtp-105 -120.99 173.22 7.39 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 121.888 0.851 . . . . 73.24 112.571 -170.064 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -64.45 120.83 13.03 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 113.292 -1.776 . . . . 73.34 109.961 174.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 104.34 -23.61 31.28 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-O 119.407 -0.663 . . . . 72.32 112.965 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 58.5 m -64.25 121.08 13.4 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 123.061 0.544 . . . . 74.22 110.458 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.2 p -102.39 127.49 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 CA-C-O 121.26 0.552 . . . . 73.03 110.022 -179.102 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.44 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 54.6 mt -92.64 101.1 12.25 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 107.829 -1.174 . . . . 75.12 107.829 -179.389 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -86.99 110.04 19.78 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.657 -0.498 . . . . 71.35 109.657 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.449 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 12.6 t -111.19 93.54 18.57 Favored Pre-proline 0 CA--C 1.555 1.163 0 N-CA-C 107.685 -1.228 . . . . 63.31 107.685 173.034 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.13 122.29 7.06 Favored 'Trans proline' 0 C--N 1.369 1.618 0 C-N-CA 122.441 2.094 . . . . 75.05 112.207 -177.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.39 -20.91 36.36 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-N 116.537 -0.301 . . . . 63.41 113.476 177.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 86.1 mmm -104.62 16.16 26.59 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 123.398 0.679 . . . . 73.21 112.081 -177.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.59 -101.93 0.54 Allowed Glycine 0 C--N 1.345 1.061 0 CA-C-O 119.664 -0.52 . . . . 72.32 111.931 172.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.426 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -68.84 102.78 0.95 Allowed Glycine 0 C--N 1.349 1.299 0 CA-C-N 116.93 0.365 . . . . 74.21 112.313 177.087 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 7.5 mm-40 -89.27 157.82 18.07 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 124.151 0.981 . . . . 74.14 110.075 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 147.77 -66.39 0.4 Allowed Glycine 0 C--N 1.344 1.014 0 N-CA-C 110.758 -0.937 . . . . 45.12 110.758 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 36.2 t30 -159.12 -54.12 0.01 OUTLIER Pre-proline 0 CA--C 1.562 1.429 0 C-N-CA 124.291 1.036 . . . . 73.15 110.122 178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -85.37 110.54 1.23 Allowed 'Trans proline' 0 C--N 1.399 3.231 0 C-N-CA 121.594 1.53 . . . . 74.11 110.505 171.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.82 123.28 11.12 Favored 'Trans proline' 0 C--N 1.383 2.381 0 C-N-CA 122.163 1.909 . . . . 75.21 110.996 -174.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -96.1 163.08 23.07 Favored Glycine 0 C--N 1.338 0.642 0 O-C-N 123.649 0.593 . . . . 71.32 111.912 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -84.36 152.39 24.12 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 108.791 -0.818 . . . . 70.52 108.791 -179.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.449 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 57.6 tp -120.68 132.0 54.86 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.957 0.503 . . . . 74.11 109.744 178.206 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 84.1 mt -128.39 103.33 7.09 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.189 0.996 . . . . 74.34 109.153 177.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.472 HD22 ' HG ' ' A' ' 98' ' ' LEU . 86.8 mt -102.51 101.2 11.37 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 121.04 0.447 . . . . 75.4 110.369 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.1 t -83.96 99.55 6.53 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 108.621 -0.881 . . . . 74.45 108.621 -176.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.5 t -59.32 117.42 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 123.919 0.888 . . . . 73.22 111.455 -177.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -100.95 105.23 16.45 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 114.466 -1.243 . . . . 64.03 108.389 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.508 HD11 ' HA ' ' A' ' 154' ' ' ARG . 30.3 mt -69.28 108.77 3.8 Favored 'General case' 0 C--N 1.348 0.511 0 N-CA-C 109.128 -0.693 . . . . 72.02 109.128 174.03 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.4 mt -68.56 159.0 83.62 Favored Pre-proline 0 CA--C 1.544 0.72 0 CA-C-N 115.057 -0.974 . . . . 74.21 110.45 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -74.12 51.91 2.56 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 123.533 2.822 . . . . 72.14 112.764 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.5 t-80 . . . . . 0 C--O 1.255 1.347 0 C-N-CA 124.697 1.199 . . . . 75.12 107.962 177.304 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 22.3 ptm . . . . . 0 N--CA 1.483 1.218 0 N-CA-C 110.136 -0.32 . . . . 71.22 110.136 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -56.57 123.8 59.01 Favored Pre-proline 0 CA--C 1.555 1.145 0 C-N-CA 124.116 0.966 . . . . 72.11 111.56 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.438 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 97.5 Cg_endo -81.67 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.922 2.414 . . . . 74.44 111.3 166.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.512 HD13 ' H ' ' A' ' 98' ' ' LEU . 7.1 tp -81.83 139.99 34.43 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.261 0.624 . . . . 74.45 110.254 -179.48 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.537 HD22 HG23 ' A' ' 138' ' ' VAL . 19.3 tp 64.63 -13.06 0.11 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 127.031 2.132 . . . . 75.31 113.606 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.438 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 47.3 t80 -119.78 122.07 40.57 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 124.376 1.07 . . . . 74.42 108.91 -173.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.501 HG23 HG11 ' A' ' 102' ' ' VAL . 85.7 m -135.36 90.25 21.07 Favored Pre-proline 0 C--O 1.235 0.329 0 C-N-CA 123.739 0.816 . . . . 74.05 108.804 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -65.85 93.61 0.27 Allowed 'Trans proline' 0 C--N 1.372 1.769 0 C-N-CA 121.6 1.533 . . . . 65.32 112.027 -174.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.501 HG11 HG23 ' A' ' 100' ' ' THR . 27.4 m -123.66 168.5 16.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 C-N-CA 125.266 1.427 . . . . 75.43 109.375 177.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.403 ' OG1' ' HA3' ' A' ' 114' ' ' GLY . 10.0 t -148.88 143.13 26.05 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 107.62 -1.252 . . . . 74.43 107.62 173.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 21.8 ttmt -81.46 71.41 8.46 Favored 'General case' 0 N--CA 1.48 1.064 0 CA-C-O 121.865 0.841 . . . . 72.14 109.595 -175.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 73.38 -175.22 46.51 Favored Glycine 0 C--N 1.351 1.376 0 CA-C-N 114.622 -1.172 . . . . 72.34 111.917 -169.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 50.5 m -75.4 -34.7 61.08 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 108.963 -0.754 . . . . 71.12 108.963 167.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -174.01 82.64 0.08 OUTLIER Glycine 0 C--N 1.342 0.903 0 N-CA-C 109.734 -1.347 . . . . 72.53 109.734 178.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -63.38 89.74 0.07 OUTLIER Glycine 0 C--N 1.35 1.341 0 O-C-N 123.921 0.424 . . . . 73.23 113.333 -174.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 23.2 t 54.14 38.12 28.48 Favored 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 124.351 1.06 . . . . 74.52 110.61 -175.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 98.4 -119.48 6.47 Favored Glycine 0 C--N 1.344 1.015 0 CA-C-N 114.899 -1.046 . . . . 73.15 110.807 -173.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 60.58 35.51 89.43 Favored Glycine 0 C--N 1.356 1.647 0 O-C-N 124.324 0.661 . . . . 73.15 113.11 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.456 ' HB2' ' HG ' ' A' ' 115' ' ' SER . 40.3 m 66.6 -2.83 0.98 Allowed 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 125.029 1.332 . . . . 61.52 113.735 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 128.42 -143.88 14.8 Favored Glycine 0 C--N 1.342 0.878 0 N-CA-C 110.625 -0.99 . . . . 65.3 110.625 -169.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.403 ' HA3' ' OG1' ' A' ' 103' ' ' THR . . . -90.3 57.66 3.53 Favored Glycine 0 C--N 1.342 0.908 0 N-CA-C 111.79 -0.524 . . . . 75.41 111.79 176.525 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' SER . . . . . 0.456 ' HG ' ' HB2' ' A' ' 112' ' ' SER . 69.8 m -78.38 157.15 29.15 Favored 'General case' 0 C--O 1.24 0.554 0 C-N-CA 123.978 0.911 . . . . 71.45 112.212 -173.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 64.07 58.74 9.85 Favored Glycine 0 C--N 1.352 1.45 0 O-C-N 123.918 0.761 . . . . 73.22 112.187 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.591 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 46.7 mtt-85 -69.84 132.08 45.48 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.297 0.639 . . . . 72.15 109.882 -176.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -99.29 105.02 16.98 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 106.469 -1.678 . . . . 63.45 106.469 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.471 HD23 ' O ' ' A' ' 100' ' ' THR . 12.6 mt -88.33 106.93 18.55 Favored 'General case' 0 C--N 1.345 0.378 0 N-CA-C 105.78 -1.933 . . . . 73.14 105.78 -177.309 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.4 ttm-85 -106.91 102.3 11.67 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.824 -1.176 . . . . 75.33 107.824 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.446 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -125.45 136.04 52.97 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.125 -1.065 . . . . 74.1 108.125 -175.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -82.86 129.37 34.99 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.853 -0.612 . . . . 71.03 109.732 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.49 HD13 HD11 ' A' ' 176' ' ' LEU . 2.2 tt -101.18 105.05 36.93 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 123.681 0.792 . . . . 75.51 109.558 -172.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.542 ' HB2' HD13 ' A' ' 181' ' ' LEU . 33.9 Cg_endo -61.48 116.22 3.27 Favored 'Trans proline' 0 C--N 1.378 2.089 0 C-N-CA 122.958 2.439 . . . . 71.31 111.213 170.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.481 HD23 HD13 ' A' ' 149' ' ' ILE . 30.9 tp -145.61 124.53 12.73 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 123.77 0.828 . . . . 74.43 109.026 -170.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.1 p -75.49 168.24 20.38 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 122.538 0.335 . . . . 74.33 110.978 -175.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 74.7 mt -63.22 -37.36 86.92 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.642 0.777 . . . . 74.34 110.901 178.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 24.7 mp0 -64.19 -52.36 59.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.95 1.3 . . . . 61.31 110.136 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -69.75 -32.71 71.39 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.456 -0.793 . . . . 51.54 111.43 -177.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.57 -45.28 93.64 Favored 'General case' 0 C--N 1.349 0.582 0 O-C-N 123.87 0.731 . . . . 65.42 110.269 174.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -66.14 -39.35 89.78 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.377 1.071 . . . . 73.22 110.641 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.0 m80 -61.98 -47.43 84.87 Favored 'General case' 0 C--N 1.358 0.945 0 O-C-N 123.717 0.636 . . . . 72.52 110.447 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.415 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.08 52.78 47.6 Favored Glycine 0 C--N 1.352 1.427 0 O-C-N 124.046 0.841 . . . . 74.03 112.516 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -106.41 -141.82 10.52 Favored Glycine 0 C--N 1.339 0.712 0 N-CA-C 111.531 -0.628 . . . . 72.33 111.531 177.673 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.569 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.9 mp0 -93.68 148.87 21.71 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 108.261 -1.014 . . . . 63.23 108.261 169.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.465 ' HG3' HG12 ' A' ' 138' ' ' VAL . 40.5 tpt85 -123.31 117.68 25.8 Favored 'General case' 0 N--CA 1.463 0.18 0 N-CA-C 107.441 -1.318 . . . . 75.44 107.441 177.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.5 t -86.21 106.0 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 109.165 -0.679 . . . . 74.02 109.165 -174.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.537 HG23 HD22 ' A' ' 98' ' ' LEU . 33.1 m -125.91 157.79 35.51 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 C-N-CA 124.93 1.292 . . . . 74.12 108.342 -178.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -113.65 120.29 40.39 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 118.534 0.606 . . . . 74.42 111.382 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 6.4 p -105.61 104.6 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.757 0.823 . . . . 74.44 109.665 173.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.22 29.6 18.81 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.354 0.661 . . . . 65.13 112.384 172.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.35 -14.23 58.17 Favored Glycine 0 N--CA 1.475 1.287 0 N-CA-C 113.705 0.242 . . . . 54.24 113.705 -178.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -92.78 117.65 30.24 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.027 -0.731 . . . . 73.22 109.027 -178.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 26.5 ttm180 -88.76 105.93 18.02 Favored 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 108.808 -0.812 . . . . 74.13 108.808 -173.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.57 128.87 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 124.214 1.005 . . . . 73.32 110.797 -175.42 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.569 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 51.0 p -90.14 107.43 19.13 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 123.841 0.857 . . . . 45.52 109.699 173.213 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.81 130.1 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 123.721 0.808 . . . . 72.52 109.995 -178.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 75.8 ttt180 -78.82 113.97 17.35 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.555 0.693 . . . . 74.43 110.547 -174.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.481 HD13 HD23 ' A' ' 125' ' ' LEU . 4.5 pt -90.25 142.22 28.29 Favored Pre-proline 0 CA--C 1.56 1.358 0 C-N-CA 124.93 1.292 . . . . 62.04 109.772 178.501 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.417 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 19.8 Cg_endo -69.34 142.91 51.13 Favored 'Trans proline' 0 CA--C 1.564 2.018 0 C-N-CA 122.156 1.904 . . . . 73.11 112.849 174.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.59 127.92 14.58 Favored 'Trans proline' 0 C--N 1.381 2.242 0 C-N-CA 122.832 2.355 . . . . 74.45 111.475 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 82.72 23.41 56.03 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.657 -0.701 . . . . 75.12 113.416 -174.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.417 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 14.2 p -74.5 150.22 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.926 0.49 . . . . 73.04 110.185 178.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -131.64 178.55 6.66 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 121.83 0.824 . . . . 74.23 112.6 -169.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.82 131.46 50.96 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 113.389 -1.732 . . . . 72.54 111.412 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.55 -8.05 70.35 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-O 119.464 -0.631 . . . . 34.01 113.357 177.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 49.3 m -72.43 119.23 16.35 Favored 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.848 -0.797 . . . . 74.24 108.848 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.67 134.27 41.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.286 0.634 . . . . 64.42 109.747 -175.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.469 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 47.4 mt -106.9 103.43 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.224 1.01 . . . . 74.25 108.35 -176.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 30.2 ttm180 -87.29 111.21 20.82 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 123.134 0.574 . . . . 75.3 109.959 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.91 102.95 53.96 Favored Pre-proline 0 CA--C 1.554 1.106 0 N-CA-C 108.336 -0.987 . . . . 72.33 108.336 173.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -68.83 139.43 43.53 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 122.909 2.406 . . . . 74.13 112.52 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 81.31 -8.41 58.32 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.575 -0.569 . . . . 64.25 114.446 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.0 mtt -113.35 17.58 18.4 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 117.944 0.872 . . . . 75.11 111.22 -174.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -92.96 -107.04 1.76 Allowed Glycine 0 C--N 1.347 1.19 0 CA-C-O 119.508 -0.607 . . . . 72.02 112.066 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -64.85 90.48 0.1 OUTLIER Glycine 0 C--N 1.355 1.599 0 CA-C-N 116.937 0.369 . . . . 72.13 112.78 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -79.66 147.71 31.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.496 0.719 . . . . 74.22 111.165 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.09 -124.81 1.48 Allowed Glycine 0 C--N 1.342 0.885 0 N-CA-C 110.001 -1.24 . . . . 74.03 110.001 -176.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.41 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 2.0 m-20 -85.16 -50.61 0.54 Allowed Pre-proline 0 CA--C 1.563 1.463 0 CA-C-O 118.63 -0.7 . . . . 74.1 110.004 169.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.41 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -99.66 103.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.395 2.995 0 C-N-CA 123.317 2.678 . . . . 53.43 112.434 177.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.52 123.19 12.26 Favored 'Trans proline' 0 C--N 1.377 2.056 0 C-N-CA 122.293 1.996 . . . . 74.31 111.369 -177.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -94.29 -171.63 38.2 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 116.179 -0.464 . . . . 74.55 112.977 -176.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -99.65 144.85 28.25 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 123.113 0.565 . . . . 70.41 110.28 -177.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.499 HD23 HD12 ' A' ' 98' ' ' LEU . 46.8 tp -109.9 129.49 55.65 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.425 0.69 . . . . 74.33 109.174 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.442 HD11 HH21 ' A' ' 160' ' ' ARG . 88.9 mt -128.85 109.33 11.18 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.887 0.875 . . . . 74.5 109.793 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.49 HD11 HD13 ' A' ' 123' ' ' LEU . 83.6 mt -110.19 102.99 11.63 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.056 0.542 . . . . 74.33 111.713 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.88 94.56 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.941 0 C-N-CA 123.322 0.649 . . . . 75.23 109.904 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 84.7 t -54.39 114.76 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 124.105 0.962 . . . . 74.42 112.054 -179.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 29.8 mmt180 -98.29 115.24 27.99 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.116 1.366 . . . . 73.04 108.406 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 66.7 mt -70.31 114.41 8.41 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 120.689 0.281 . . . . 75.31 110.5 178.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.542 HD13 ' HB2' ' A' ' 124' ' ' PRO . 45.2 mt -89.96 156.9 46.56 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 123.568 0.747 . . . . 72.32 110.825 175.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -71.18 -162.85 0.11 Allowed 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 123.041 2.494 . . . . 61.2 112.286 168.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 6.7 p80 . . . . . 0 CA--C 1.553 1.091 0 C-N-CA 123.811 0.844 . . . . 71.01 109.16 -177.868 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 84.4 mtp . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 110.006 -0.368 . . . . 75.21 110.006 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 37.24 96.33 0.04 OUTLIER Pre-proline 0 CA--C 1.559 1.326 0 C-N-CA 126.285 1.834 . . . . 74.3 114.168 -178.03 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.45 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 13.0 Cg_exo -70.91 -161.5 0.09 OUTLIER 'Trans proline' 0 C--N 1.375 1.969 0 C-N-CA 122.698 2.265 . . . . 75.42 111.989 171.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.627 HD12 ' HA ' ' A' ' 123' ' ' LEU . 1.1 tp -58.19 -42.85 87.03 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 124.107 0.963 . . . . 74.53 112.569 -175.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 1.7 tt -141.06 96.52 3.01 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 107.801 -1.185 . . . . 74.31 107.801 171.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.45 ' HB3' ' HD2' ' A' ' 96' ' ' PRO . 53.7 t80 165.36 119.6 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 126.518 1.927 . . . . 72.45 107.431 172.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.564 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 32.7 m -145.54 86.68 7.28 Favored Pre-proline 0 CA--C 1.55 0.961 0 CA-C-N 118.147 0.43 . . . . 63.2 110.653 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -74.11 86.0 1.32 Allowed 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.371 2.047 . . . . 71.53 111.623 -177.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.499 HG12 HG21 ' A' ' 100' ' ' THR . 18.0 m -82.07 -174.78 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.585 1.154 . . . . 74.23 112.553 -175.231 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 2.2 t -121.48 92.24 3.7 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.301 1.04 . . . . 74.03 108.597 175.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -118.28 142.6 47.33 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 123.612 0.765 . . . . 74.33 110.241 178.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -153.14 140.75 7.82 Favored Glycine 0 C--N 1.346 1.085 0 N-CA-C 111.721 -0.551 . . . . 71.44 111.721 178.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 30.2 t -100.45 -170.05 1.81 Allowed 'General case' 0 CA--C 1.552 1.026 0 C-N-CA 123.968 0.907 . . . . 73.35 109.843 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.23 66.71 3.88 Favored Glycine 0 C--N 1.349 1.279 0 CA-C-O 120.16 -0.245 . . . . 44.04 113.67 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 57.0 -95.53 0.04 OUTLIER Glycine 0 C--N 1.355 1.627 0 C-N-CA 123.876 0.75 . . . . 64.5 114.063 174.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 44.2 m -94.12 90.75 6.51 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 123.652 0.781 . . . . 74.4 109.155 176.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 141.68 167.08 11.1 Favored Glycine 0 C--N 1.345 1.061 0 CA-C-N 116.44 -0.346 . . . . 51.01 112.511 178.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -150.78 81.79 0.18 Allowed Glycine 0 C--N 1.346 1.118 0 N-CA-C 111.178 -0.769 . . . . 72.43 111.178 178.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.8 t -69.05 -54.93 12.49 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.144 0.578 . . . . 64.14 110.45 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -76.17 136.79 20.2 Favored Glycine 0 C--N 1.343 0.923 0 N-CA-C 111.173 -0.771 . . . . 73.41 111.173 174.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -77.58 72.02 2.24 Favored Glycine 0 C--N 1.347 1.17 0 N-CA-C 111.495 -0.642 . . . . 73.03 111.495 177.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 45.1 m -129.58 102.7 6.49 Favored 'General case' 0 C--O 1.242 0.668 0 C-N-CA 124.197 0.999 . . . . 62.22 110.22 -174.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -85.66 -121.0 1.11 Allowed Glycine 0 C--N 1.345 1.035 0 N-CA-C 110.185 -1.166 . . . . 51.44 110.185 170.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.643 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.7 mmp_? -96.56 117.85 31.81 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 107.057 -1.46 . . . . 73.35 107.057 165.649 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.2 105.45 17.8 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 107.578 -1.267 . . . . 64.4 107.578 -170.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.564 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.8 mt -94.28 110.83 22.55 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 108.244 -1.021 . . . . 75.53 108.244 -178.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.1 ttt180 -110.86 112.76 24.83 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 108.731 -0.841 . . . . 75.24 108.731 168.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -131.39 153.95 49.14 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.814 -0.81 . . . . 63.05 108.814 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -92.61 142.22 27.63 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.935 -0.765 . . . . 74.44 108.935 -176.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.627 ' HA ' HD12 ' A' ' 97' ' ' LEU . 12.1 tp -103.14 102.46 28.43 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 124.247 1.019 . . . . 74.25 109.457 -177.734 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.583 ' HD2' HD12 ' A' ' 97' ' ' LEU . 34.6 Cg_endo -65.49 115.71 3.51 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.053 1.835 . . . . 74.43 109.449 168.465 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.421 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 24.3 tp -145.81 122.1 10.9 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.282 -1.007 . . . . 71.14 108.282 -174.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 80.7 p -75.4 165.31 25.33 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 123.281 0.363 . . . . 74.54 110.19 -176.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.436 HD11 ' HB3' ' A' ' 183' ' ' HIS . 77.6 mt -60.8 -33.31 72.8 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.75 0.82 . . . . 72.42 111.998 -172.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -73.91 -49.58 24.15 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.274 -0.875 . . . . 75.41 109.272 -178.136 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -68.52 -24.17 64.63 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 115.007 -0.997 . . . . 74.23 111.374 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.67 -47.34 66.77 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.015 0.926 . . . . 73.32 109.967 172.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -60.87 -44.09 97.54 Favored 'General case' 0 C--N 1.352 0.677 0 O-C-N 124.637 1.211 . . . . 63.31 110.867 177.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -71.16 -45.88 62.61 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 123.531 0.519 . . . . 74.24 111.104 -174.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.424 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 71.4 -138.08 27.11 Favored Glycine 0 CA--C 1.53 1.008 0 CA-C-N 116.175 -0.466 . . . . 73.33 112.275 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.46 -160.19 45.39 Favored Glycine 0 C--N 1.349 1.256 0 CA-C-O 119.882 -0.399 . . . . 74.04 112.379 178.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.561 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 8.9 mp0 -77.46 138.34 39.19 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 117.316 0.558 . . . . 74.24 109.91 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.499 ' HB2' HD13 ' A' ' 149' ' ' ILE . 23.1 tpt180 -117.69 119.09 33.89 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.392 -0.966 . . . . 73.45 108.392 -176.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 42.9 t -83.51 103.74 11.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 N-CA-C 108.57 -0.9 . . . . 71.11 108.57 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.446 HG12 ' HG3' ' A' ' 136' ' ' ARG . 18.8 m -123.81 160.83 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 N-CA-C 107.643 -1.243 . . . . 73.35 107.643 177.551 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -125.95 115.75 20.4 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 119.232 0.923 . . . . 74.24 111.123 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.6 p -105.41 111.16 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 124.378 1.071 . . . . 73.41 110.771 178.398 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.5 29.83 19.43 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 124.147 0.979 . . . . 72.04 112.369 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.16 -13.03 62.04 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-N 116.351 -0.386 . . . . 73.42 113.29 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.66 115.96 28.58 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.309 0.644 . . . . 75.33 109.817 176.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 32.8 ttm180 -92.49 103.65 16.04 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 108.182 -1.044 . . . . 75.43 108.182 -176.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 27.0 m -109.57 155.63 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.719 1.208 . . . . 74.1 111.4 -172.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.561 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 47.9 m -101.73 115.98 31.72 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.859 0.864 . . . . 71.32 109.708 176.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.502 HG13 HD11 ' A' ' 176' ' ' LEU . 74.5 t -99.35 113.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 124.28 1.032 . . . . 64.55 108.85 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -74.55 102.58 4.57 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 109.145 -0.687 . . . . 71.24 109.145 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.499 HD13 ' HB2' ' A' ' 136' ' ' ARG . 5.6 pt -96.15 141.93 23.84 Favored Pre-proline 0 CA--C 1.555 1.171 0 C-N-CA 124.418 1.087 . . . . 72.3 109.51 -178.587 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.0 132.83 35.95 Favored 'Trans proline' 0 CA--C 1.564 2.015 0 C-N-CA 122.371 2.047 . . . . 74.12 112.344 178.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -66.98 132.69 28.86 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 122.984 2.456 . . . . 74.41 112.225 174.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.12 34.59 41.14 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.649 -0.705 . . . . 50.21 112.121 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.405 HG23 HG22 ' A' ' 178' ' ' VAL . 14.6 p -76.44 140.17 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 122.99 0.516 . . . . 73.41 111.025 -176.162 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 -94.97 177.09 6.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.832 0.825 . . . . 74.03 112.772 -173.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -72.7 129.92 39.33 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.518 -1.674 . . . . 75.23 110.753 176.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.8 10.33 86.28 Favored Glycine 0 C--N 1.345 1.031 0 CA-C-N 115.45 -0.795 . . . . 74.43 113.884 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 44.9 m -78.29 118.39 20.45 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.274 -0.639 . . . . 74.53 109.274 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -94.46 127.28 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-O 121.273 0.558 . . . . 75.54 110.333 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 51.7 mt -100.97 101.19 11.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 N-CA-C 107.598 -1.26 . . . . 75.11 107.598 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.502 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 38.9 ttt180 -89.45 113.98 25.41 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 109.92 -0.4 . . . . 74.55 109.92 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.408 HG12 ' SD ' ' A' ' 164' ' ' MET . 6.5 t -114.49 94.64 37.04 Favored Pre-proline 0 CA--C 1.555 1.149 0 N-CA-C 108.324 -0.991 . . . . 75.12 108.324 173.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.56 135.2 48.1 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 123.032 2.488 . . . . 75.42 112.268 177.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.95 -7.88 79.84 Favored Glycine 0 C--N 1.345 1.072 0 CA-C-O 119.543 -0.587 . . . . 54.14 114.2 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.408 ' SD ' HG12 ' A' ' 161' ' ' VAL . 27.6 ttt -100.38 -7.83 23.98 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.636 0.774 . . . . 75.44 110.772 179.263 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -81.58 -112.94 0.37 Allowed Glycine 0 C--N 1.348 1.207 0 CA-C-N 116.078 -0.51 . . . . 73.23 112.316 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.643 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -67.0 95.61 0.28 Allowed Glycine 0 C--N 1.347 1.177 0 CA-C-N 116.869 0.334 . . . . 75.31 113.877 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -71.93 108.54 5.24 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 123.566 0.747 . . . . 73.22 110.46 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -171.64 -169.85 34.98 Favored Glycine 0 C--N 1.342 0.883 0 CA-C-N 115.861 -0.608 . . . . 65.04 112.304 178.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -61.0 -42.93 89.28 Favored Pre-proline 0 CA--C 1.563 1.442 0 C-N-CA 123.497 0.719 . . . . 73.02 111.652 176.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -88.17 106.67 0.54 Allowed 'Trans proline' 0 C--N 1.387 2.584 0 C-N-CA 121.623 1.549 . . . . 75.03 110.176 160.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -67.21 125.63 13.81 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 121.994 1.796 . . . . 74.41 111.858 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -97.14 154.93 20.58 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-N 115.876 -0.602 . . . . 55.14 111.926 -177.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -95.39 163.43 13.25 Favored 'General case' 0 C--O 1.245 0.827 0 C-N-CA 122.899 0.48 . . . . 75.43 109.931 -178.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.502 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.2 tp -117.62 139.75 50.57 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 115.088 -0.96 . . . . 73.13 109.758 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 30.7 mt -128.93 101.6 6.15 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.89 1.276 . . . . 64.34 108.416 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.502 HD11 HG13 ' A' ' 147' ' ' VAL . 54.5 mt -103.2 101.28 11.22 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 118.318 0.508 . . . . 74.12 110.162 176.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.63 100.6 10.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 115.435 -0.802 . . . . 71.1 109.138 -174.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.507 HG21 HD21 ' A' ' 123' ' ' LEU . 58.2 t -57.76 111.36 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.066 0.946 . . . . 72.42 112.01 -177.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -101.44 111.1 23.23 Favored 'General case' 0 C--O 1.243 0.753 0 C-N-CA 124.388 1.075 . . . . 75.51 108.914 170.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.421 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 62.7 mt -70.5 114.5 8.67 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.389 0.676 . . . . 75.25 109.846 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.424 HD11 ' HB2' ' A' ' 124' ' ' PRO . 86.5 mt -72.66 155.44 90.92 Favored Pre-proline 0 CA--C 1.548 0.888 0 C-N-CA 123.237 0.615 . . . . 72.43 110.728 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.66 142.75 60.23 Favored 'Trans proline' 0 C--N 1.375 1.942 0 C-N-CA 123.249 2.633 . . . . 74.41 112.454 173.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.436 ' HB3' HD11 ' A' ' 127' ' ' LEU . 48.1 p-80 . . . . . 0 CA--C 1.555 1.17 0 CA-C-O 118.942 -0.551 . . . . 75.23 110.986 -179.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 25.1 mmt . . . . . 0 N--CA 1.484 1.246 0 N-CA-C 109.81 -0.441 . . . . 75.13 109.81 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.454 HD21 HG21 ' A' ' 100' ' ' THR . 3.9 pp -91.17 121.94 67.07 Favored Pre-proline 0 CA--C 1.553 1.095 0 N-CA-C 109.96 -0.385 . . . . 73.14 109.96 178.076 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -85.48 -161.43 0.13 Allowed 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 122.757 2.304 . . . . 62.2 110.98 164.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.485 HD13 ' H ' ' A' ' 98' ' ' LEU . 7.0 tp -74.25 149.92 40.54 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.262 0.625 . . . . 75.31 109.412 177.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.582 HD23 ' HB ' ' A' ' 140' ' ' VAL . 8.2 tp 57.74 1.67 0.14 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 125.798 1.639 . . . . 75.5 114.108 -178.228 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.595 ' HA ' HD11 ' A' ' 119' ' ' LEU . 43.3 t80 -139.91 133.7 30.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 123.336 0.655 . . . . 75.21 109.698 -170.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.562 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 85.9 m -152.94 97.05 2.87 Favored Pre-proline 0 CA--C 1.551 1.009 0 C-N-CA 123.8 0.84 . . . . 73.32 109.476 -177.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.76 77.23 2.29 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 123.02 2.48 . . . . 63.41 112.799 -170.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.502 HG13 HG22 ' A' ' 100' ' ' THR . 9.0 m -95.93 163.43 2.34 Favored 'Isoleucine or valine' 0 C--O 1.242 0.694 0 CA-C-N 115.494 -0.775 . . . . 75.2 110.457 178.366 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -119.45 134.48 55.2 Favored 'General case' 0 C--O 1.245 0.819 0 N-CA-C 107.224 -1.398 . . . . 75.41 107.224 163.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . 0.575 ' HE3' ' HA ' ' A' ' 115' ' ' SER . 25.0 ttmm -73.64 -24.67 60.04 Favored 'General case' 0 CA--C 1.549 0.937 0 C-N-CA 123.006 0.523 . . . . 73.34 111.115 -175.084 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -155.17 -177.09 28.1 Favored Glycine 0 C--N 1.346 1.089 0 CA-C-N 116.219 -0.446 . . . . 64.13 112.336 179.255 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 24.0 p -72.86 -54.1 9.66 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 123.52 0.728 . . . . 65.02 109.611 176.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -93.15 67.04 1.78 Allowed Glycine 0 C--N 1.348 1.195 0 N-CA-C 111.25 -0.74 . . . . 75.13 111.25 175.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -86.13 54.04 4.68 Favored Glycine 0 C--N 1.354 1.536 0 C-N-CA 122.887 0.28 . . . . 70.23 112.455 -178.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 50.6 m -70.49 98.1 1.4 Allowed 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.532 0.733 . . . . 74.21 110.427 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 72.25 -97.54 0.77 Allowed Glycine 0 C--N 1.345 1.061 0 CA-C-N 115.798 -0.637 . . . . 62.12 111.913 -177.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 89.83 51.05 2.93 Favored Glycine 0 C--N 1.347 1.147 0 N-CA-C 111.328 -0.709 . . . . 72.44 111.328 -177.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.2 p -70.29 145.35 51.34 Favored 'General case' 0 CA--C 1.553 1.087 0 C-N-CA 123.347 0.659 . . . . 74.43 110.824 -179.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.2 -140.74 15.16 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 111.746 -0.542 . . . . 62.12 111.746 -175.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.6 50.42 3.78 Favored Glycine 0 C--N 1.346 1.092 0 N-CA-C 111.781 -0.528 . . . . 71.01 111.781 177.128 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' SER . . . . . 0.575 ' HA ' ' HE3' ' A' ' 104' ' ' LYS . 70.2 m -146.39 22.07 1.34 Allowed 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.655 0.782 . . . . 72.13 111.116 -172.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -82.01 -152.92 10.7 Favored Glycine 0 C--N 1.344 0.973 0 CA-C-N 116.36 -0.382 . . . . 45.31 113.778 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.7 mmm-85 -89.24 118.48 28.96 Favored 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 109.133 -0.691 . . . . 73.03 109.133 -173.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.05 106.59 16.64 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 108.691 -0.855 . . . . 75.53 108.691 -171.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.595 HD11 ' HA ' ' A' ' 99' ' ' PHE . 12.3 mt -96.43 109.46 22.01 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 107.478 -1.305 . . . . 75.54 107.478 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 39.8 ttt180 -121.18 106.45 11.53 Favored 'General case' 0 C--O 1.238 0.465 0 N-CA-C 108.557 -0.905 . . . . 75.12 108.557 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -128.9 141.23 51.35 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.543 -0.91 . . . . 72.45 108.543 -177.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -81.56 130.99 35.26 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 108.895 -0.78 . . . . 64.5 108.895 175.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.549 HD12 HD13 ' A' ' 176' ' ' LEU . 1.6 tt -101.38 108.24 54.37 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 108.103 -1.073 . . . . 75.41 108.103 -175.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.7 113.87 3.33 Favored 'Trans proline' 0 C--N 1.378 2.097 0 C-N-CA 121.775 1.65 . . . . 73.1 109.42 171.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.558 HD23 HD13 ' A' ' 149' ' ' ILE . 13.5 tp -131.72 122.78 26.44 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.388 -0.968 . . . . 71.13 108.388 -169.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.9 p -69.71 166.15 19.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.549 0.34 . . . . 74.04 110.537 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 99.7 mt -62.34 -29.2 70.29 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 122.778 0.431 . . . . 73.2 110.882 176.065 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -67.8 -57.67 5.91 Favored 'General case' 0 C--N 1.349 0.555 0 C-N-CA 123.907 0.883 . . . . 72.22 109.263 177.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -60.08 -36.49 77.5 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.507 1.123 . . . . 75.04 111.713 -178.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.404 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.1 -55.72 11.44 Favored 'General case' 0 C--O 1.239 0.551 0 O-C-N 124.061 0.851 . . . . 73.3 111.212 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.4 ' HA ' ' HA2' ' A' ' 152' ' ' GLY . 65.0 t80 -57.84 -48.28 80.23 Favored 'General case' 0 C--N 1.359 0.99 0 O-C-N 124.554 1.159 . . . . 73.34 111.399 -177.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.9 m80 -72.92 -43.84 61.92 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 116.017 -0.538 . . . . 63.11 110.19 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.407 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 77.87 -124.01 6.62 Favored Glycine 0 C--N 1.344 0.988 0 CA-C-N 115.762 -0.654 . . . . 72.31 111.566 -176.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 73.49 -129.8 12.67 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 111.151 -0.78 . . . . 72.1 111.151 -176.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.514 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 6.7 mp0 -111.73 161.37 16.36 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.102 0.961 . . . . 73.44 110.179 176.15 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.617 ' HB2' HD12 ' A' ' 149' ' ' ILE . 20.8 tpt180 -134.01 121.99 22.37 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.212 1.005 . . . . 74.12 109.401 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 60.9 t -75.14 107.68 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.89 0.876 . . . . 71.41 109.417 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.481 HG21 HD13 ' A' ' 98' ' ' LEU . 27.0 m -122.96 163.8 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 125.257 1.423 . . . . 73.02 109.354 -179.129 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -120.99 113.02 19.47 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 122.911 0.485 . . . . 73.23 111.505 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.582 ' HB ' HD23 ' A' ' 98' ' ' LEU . 2.6 p -102.76 102.33 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 C-N-CA 123.649 0.78 . . . . 73.23 108.972 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.25 25.44 14.87 Favored 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 115.215 -0.902 . . . . 72.32 110.665 -169.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.9 6.17 62.17 Favored Glycine 0 C--N 1.358 1.804 0 CA-C-N 115.63 -0.714 . . . . 72.45 113.802 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.477 ' HB3' HG11 ' A' ' 140' ' ' VAL . 13.8 tpt180 -92.27 116.98 29.43 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.09 -0.707 . . . . 73.34 109.09 -179.781 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -80.89 109.8 15.81 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.809 -0.441 . . . . 74.42 109.809 -174.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 32.1 m -134.11 152.53 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 124.254 1.022 . . . . 71.25 109.218 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.514 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 45.1 m -104.36 114.86 29.38 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.736 0.414 . . . . 62.42 110.02 178.034 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.4 p -99.85 133.13 43.84 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 124.289 1.036 . . . . 72.1 109.9 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 38.9 ttp180 -75.81 115.46 15.53 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.091 0.556 . . . . 72.5 111.122 -174.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.617 HD12 ' HB2' ' A' ' 136' ' ' ARG . 6.1 pt -99.34 143.26 26.09 Favored Pre-proline 0 CA--C 1.558 1.256 0 C-N-CA 124.864 1.266 . . . . 74.53 109.315 177.59 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.427 ' HB2' ' HB ' ' A' ' 153' ' ' VAL . 52.7 Cg_exo -57.59 134.74 65.16 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.091 2.527 . . . . 71.24 113.094 178.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.407 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 34.7 Cg_exo -62.72 114.53 2.44 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 70.31 111.112 172.361 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' A' ' 131' ' ' PHE . . . 89.98 18.72 49.73 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.577 -0.568 . . . . 74.24 113.191 -178.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.427 ' HB ' ' HB2' ' A' ' 150' ' ' PRO . 13.2 p -64.0 141.68 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 C-N-CA 122.971 0.508 . . . . 64.43 111.395 -175.126 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -113.12 177.7 4.54 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 123.777 0.831 . . . . 74.3 112.706 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.69 135.7 57.76 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.535 -1.666 . . . . 73.13 111.744 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.58 6.66 77.52 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.905 0.753 . . . . 61.31 114.232 176.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.8 m -81.83 119.82 24.39 Favored 'General case' 0 C--N 1.349 0.564 0 N-CA-C 109.179 -0.675 . . . . 62.31 109.179 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.2 p -97.56 123.39 49.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.903 0 CA-C-O 121.313 0.578 . . . . 74.02 110.366 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.501 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.3 mt -93.29 103.73 14.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 124.379 1.071 . . . . 72.51 108.619 -175.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 43.0 ttm180 -90.18 111.36 22.49 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 122.767 0.427 . . . . 75.4 110.025 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 6.3 t -111.18 106.32 57.29 Favored Pre-proline 0 CA--C 1.552 1.05 0 N-CA-C 107.526 -1.287 . . . . 75.02 107.526 172.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.35 125.35 12.78 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.857 2.372 . . . . 72.13 112.691 -172.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.9 11.86 85.12 Favored Glycine 0 C--N 1.349 1.291 0 CA-C-O 119.792 -0.449 . . . . 75.12 114.044 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.415 ' HE1' ' HA ' ' A' ' 164' ' ' MET . 1.2 tpt -100.99 -4.4 27.58 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-N 117.24 0.52 . . . . 74.53 110.766 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -74.11 -110.58 0.08 OUTLIER Glycine 0 C--N 1.344 0.996 0 CA-C-N 116.073 -0.512 . . . . 74.34 112.474 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -63.94 108.19 2.12 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 111.777 -0.529 . . . . 70.45 111.777 178.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.9 mm-40 -88.14 116.84 26.61 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.255 0.622 . . . . 72.04 110.308 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 169.22 -155.85 26.5 Favored Glycine 0 C--O 1.245 0.816 0 N-CA-C 110.359 -1.097 . . . . 72.03 110.359 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.447 ' O ' ' HD3' ' A' ' 171' ' ' PRO . 15.0 m120 -65.42 -34.52 9.72 Favored Pre-proline 0 N--CA 1.487 1.398 0 CA-C-O 118.274 -0.869 . . . . 73.1 112.053 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -90.64 99.6 0.26 Allowed 'Trans proline' 0 C--N 1.394 2.924 0 C-N-CA 122.527 2.152 . . . . 71.12 111.655 164.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.447 ' HD3' ' O ' ' A' ' 169' ' ' ASN . 10.6 Cg_exo -70.86 123.28 9.6 Favored 'Trans proline' 0 C--N 1.382 2.331 0 C-N-CA 121.683 1.588 . . . . 74.13 110.613 174.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -100.94 156.58 19.23 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.569 -0.613 . . . . 64.12 111.569 -178.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -83.99 143.57 29.7 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 109.849 -0.426 . . . . 74.21 109.849 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.487 HD22 HD12 ' A' ' 98' ' ' LEU . 64.1 tp -106.98 129.89 54.71 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.179 0.592 . . . . 71.24 109.851 -179.544 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.428 HD21 ' HE ' ' A' ' 160' ' ' ARG . 98.1 mt -128.75 112.15 13.88 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.448 1.099 . . . . 73.35 110.025 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.549 HD13 HD12 ' A' ' 123' ' ' LEU . 81.9 mt -108.54 103.83 13.04 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.247 0.619 . . . . 73.31 110.96 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.52 94.62 4.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 N-CA-C 108.851 -0.796 . . . . 75.34 108.851 -176.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.4 t -57.63 118.68 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.877 0.871 . . . . 51.43 111.382 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -114.07 107.22 15.36 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 124.648 1.179 . . . . 74.5 108.22 175.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.05 122.07 18.68 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.526 0.517 . . . . 75.01 110.857 -176.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 93.0 mt -79.11 141.06 57.74 Favored Pre-proline 0 CA--C 1.544 0.745 0 CA-C-N 115.362 -0.835 . . . . 71.22 109.556 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.2 166.22 30.33 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.988 2.459 . . . . 73.52 112.591 -176.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.4 p-80 . . . . . 0 CA--C 1.56 1.327 0 C-N-CA 122.546 0.339 . . . . 72.53 110.299 178.835 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 20.6 ptp . . . . . 0 CA--C 1.54 0.589 0 CA-C-O 120.196 0.046 . . . . 73.35 111.102 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 pt? -112.36 103.42 55.4 Favored Pre-proline 0 CA--C 1.562 1.429 0 C-N-CA 123.265 0.626 . . . . 70.21 110.247 175.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -86.82 -67.79 0.01 OUTLIER 'Trans proline' 0 C--N 1.38 2.19 0 C-N-CA 122.865 2.376 . . . . 72.21 111.811 175.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.512 HD11 ' H ' ' A' ' 98' ' ' LEU . 6.6 tp -159.74 140.92 12.6 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 108.516 -0.92 . . . . 72.24 108.516 176.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.7 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 11.5 tp 60.58 3.48 0.6 Allowed 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 126.461 1.904 . . . . 73.52 112.95 -178.207 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.672 ' HA ' HD11 ' A' ' 119' ' ' LEU . 75.0 t80 -135.35 133.25 38.57 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.271 1.028 . . . . 72.43 108.377 -173.196 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.492 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 89.3 m -153.6 102.17 2.54 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 123.75 0.82 . . . . 74.42 109.645 177.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -72.94 91.02 0.83 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 122.559 2.173 . . . . 72.03 111.631 -175.338 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 28.7 m -101.37 167.76 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 124.178 0.991 . . . . 75.3 110.912 -178.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.3 t -88.02 -45.38 10.24 Favored 'General case' 0 CA--C 1.551 0.993 0 N-CA-C 109.485 -0.561 . . . . 72.14 109.485 172.079 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . 0.448 ' HD2' ' HA3' ' A' ' 110' ' ' GLY . 15.4 tppt? 174.06 115.66 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 125.034 1.334 . . . . 72.43 109.497 177.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -158.02 63.47 0.31 Allowed Glycine 0 C--N 1.34 0.776 0 N-CA-C 110.418 -1.073 . . . . 71.51 110.418 175.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 14.6 m -72.34 82.43 1.04 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 123.32 0.648 . . . . 74.23 109.907 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 84.03 -48.72 4.1 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-N 115.85 -0.614 . . . . 74.22 112.704 -175.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -143.78 -48.9 0.04 OUTLIER Glycine 0 C--N 1.343 0.945 0 N-CA-C 110.623 -0.991 . . . . 70.14 110.623 173.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.8 t -154.19 -167.31 2.6 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 124.585 1.154 . . . . 64.11 108.25 178.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.448 ' HA3' ' HD2' ' A' ' 104' ' ' LYS . . . -162.61 0.31 0.06 OUTLIER Glycine 0 C--N 1.346 1.107 0 CA-C-O 119.562 -0.577 . . . . 71.4 113.459 174.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 75.77 -78.68 1.18 Allowed Glycine 0 C--N 1.349 1.278 0 CA-C-N 116.956 0.378 . . . . 73.22 112.443 -179.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 42.4 t -70.48 100.99 1.88 Allowed 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 123.703 0.801 . . . . 72.41 109.612 177.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -72.38 -39.35 57.24 Favored Glycine 0 C--N 1.348 1.233 0 CA-C-N 114.902 -1.045 . . . . 64.11 114.631 -172.219 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -90.43 55.96 3.51 Favored Glycine 0 N--CA 1.471 1.024 0 CA-C-N 116.631 0.215 . . . . 71.55 112.833 -174.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 25.7 p -171.92 112.9 0.32 Allowed 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.585 0.754 . . . . 71.32 109.975 -177.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 85.77 106.82 0.72 Allowed Glycine 0 C--N 1.348 1.244 0 CA-C-O 119.872 -0.405 . . . . 75.32 113.049 177.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.417 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 3.9 mmp_? -86.72 118.45 26.13 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 108.76 -0.83 . . . . 75.53 108.76 175.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -98.12 102.51 14.28 Favored 'General case' 0 CA--C 1.511 -0.542 0 N-CA-C 106.486 -1.672 . . . . 74.54 106.486 -173.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.672 HD11 ' HA ' ' A' ' 99' ' ' PHE . 16.5 mt -93.52 106.33 18.31 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.605 -1.257 . . . . 75.22 107.605 -169.056 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -111.02 103.24 11.69 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.904 -1.147 . . . . 75.13 107.904 -179.001 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.46 151.69 51.32 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.583 -0.735 . . . . 75.31 110.235 -168.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.519 ' HB3' ' HG3' ' A' ' 179' ' ' ARG . 40.4 mt-10 -81.55 124.17 29.27 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 114.6 -1.182 . . . . 72.45 109.342 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.457 HD13 HD11 ' A' ' 176' ' ' LEU . 3.2 tt -99.52 103.81 23.46 Favored Pre-proline 0 CA--C 1.54 0.583 0 N-CA-C 106.898 -1.519 . . . . 72.31 106.898 178.41 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.3 114.48 3.46 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 121.925 1.75 . . . . 72.34 110.438 175.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.505 HD23 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -139.23 120.08 14.35 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.039 -1.097 . . . . 74.53 108.039 -172.709 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.4 ' HA ' ' HB2' ' A' ' 181' ' ' LEU . 4.9 m -69.73 160.82 30.96 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 123.748 0.819 . . . . 75.13 111.112 -176.094 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 83.2 mt -56.17 -39.28 72.11 Favored 'General case' 0 N--CA 1.484 1.225 0 C-N-CA 123.894 0.878 . . . . 74.2 112.13 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -69.12 -44.19 72.91 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.447 0.699 . . . . 73.53 110.414 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -61.44 -39.15 89.76 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.321 1.048 . . . . 73.03 111.16 -179.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.427 ' HB2' ' O ' ' A' ' 153' ' ' VAL . . . -72.98 -44.23 61.31 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-N 114.31 -1.314 . . . . 75.44 111.145 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -56.92 -47.83 79.66 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.803 1.241 . . . . 74.03 110.913 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -69.83 -48.55 58.53 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.716 -0.675 . . . . 72.23 110.181 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.564 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 55.65 76.37 0.2 Allowed Glycine 0 C--N 1.356 1.639 0 O-C-N 124.469 1.105 . . . . 52.13 113.638 176.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -112.57 -131.39 5.57 Favored Glycine 0 C--N 1.343 0.922 0 N-CA-C 111.328 -0.709 . . . . 73.05 111.328 177.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -100.96 152.19 20.86 Favored 'General case' 0 C--O 1.245 0.834 0 N-CA-C 108.694 -0.854 . . . . 62.32 108.694 170.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 tpp85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.003 0.921 . . . . 75.02 108.867 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.28 131.04 40.46 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 N-CA-C 108.582 -0.896 . . . . 74.32 108.582 175.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 27.1 m -125.14 161.19 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 123.604 0.762 . . . . 75.4 110.147 -178.419 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -97.56 141.71 30.27 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 124.075 0.95 . . . . 65.05 108.539 -178.354 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.7 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.0 p -150.1 109.31 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.199 0 C-N-CA 124.733 1.213 . . . . 73.22 111.394 -177.198 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.13 17.36 8.01 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 114.449 1.277 . . . . 72.52 114.449 164.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.12 22.34 13.36 Favored Glycine 0 N--CA 1.479 1.561 0 N-CA-C 112.514 -0.235 . . . . 64.25 112.514 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.401 ' HB2' HG11 ' A' ' 140' ' ' VAL . 24.7 mmm180 -134.75 153.86 51.83 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.906 1.282 . . . . 75.1 107.864 178.144 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -117.69 108.01 14.89 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.034 -0.728 . . . . 75.12 109.034 175.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 63.2 t -116.56 139.19 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 123.477 0.711 . . . . 74.44 110.174 -174.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.7 p -85.99 140.13 30.58 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 123.733 0.813 . . . . 73.02 111.087 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.4 HG21 HD12 ' A' ' 176' ' ' LEU . 14.7 p -133.55 157.59 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 124.641 1.176 . . . . 64.25 108.52 174.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 -107.32 128.72 54.7 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.783 -0.451 . . . . 75.24 109.783 177.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.505 HD12 HD23 ' A' ' 125' ' ' LEU . 15.7 pt -101.9 126.84 32.6 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.058 0.943 . . . . 71.15 108.65 176.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -65.32 147.07 87.3 Favored 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.362 2.042 . . . . 70.54 113.547 -178.017 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.564 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 38.5 Cg_exo -62.88 121.92 10.0 Favored 'Trans proline' 0 C--N 1.385 2.452 0 C-N-CA 123.821 3.014 . . . . 71.11 112.159 179.156 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 72.33 40.13 55.83 Favored Glycine 0 C--N 1.339 0.747 0 O-C-N 124.051 0.844 . . . . 73.31 112.563 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.427 ' O ' ' HB2' ' A' ' 130' ' ' ALA . 14.6 p -76.87 148.93 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 109.872 -0.418 . . . . 65.44 109.872 178.32 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 68.7 mtp180 -126.51 177.97 6.16 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-O 121.509 0.671 . . . . 73.33 112.413 -172.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -59.31 133.88 56.49 Favored 'General case' 0 CA--C 1.547 0.851 0 CA-C-N 113.409 -1.723 . . . . 73.4 111.865 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.31 -16.75 47.06 Favored Glycine 0 C--N 1.345 1.057 0 CA-C-O 119.388 -0.673 . . . . 41.41 113.312 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 48.3 m -67.15 118.72 10.95 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.36 0.58 . . . . 75.2 110.445 -173.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.9 p -94.12 125.0 46.8 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-O 121.528 0.68 . . . . 73.35 109.923 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 43.4 mt -94.82 99.75 9.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 107.061 -1.459 . . . . 71.33 107.061 174.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 46.6 ttt-85 -83.97 123.42 29.96 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 109.297 -0.631 . . . . 75.31 109.297 175.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.7 t -116.32 111.42 42.24 Favored Pre-proline 0 CA--C 1.555 1.168 0 N-CA-C 106.858 -1.534 . . . . 73.12 106.858 168.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.07 126.08 12.7 Favored 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.673 2.249 . . . . 75.32 112.25 -175.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.92 8.8 86.81 Favored Glycine 0 C--N 1.345 1.042 0 CA-C-N 115.774 -0.648 . . . . 74.55 114.57 171.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.413 ' HA ' HE22 ' A' ' 167' ' ' GLN . 24.0 mmt -114.07 15.35 18.36 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.154 0.582 . . . . 74.23 111.293 -176.685 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.21 -96.03 0.98 Allowed Glycine 0 C--N 1.344 0.973 0 N-CA-C 110.377 -1.089 . . . . 43.41 110.377 169.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.417 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -79.12 95.29 1.4 Allowed Glycine 0 C--N 1.346 1.087 0 N-CA-C 112.177 -0.369 . . . . 71.2 112.177 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.413 HE22 ' HA ' ' A' ' 164' ' ' MET . 11.3 mm-40 -65.85 131.6 46.68 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.485 0.714 . . . . 70.31 111.508 -177.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 170.11 174.87 38.61 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.781 -0.928 . . . . 74.23 110.781 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.445 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 15.3 m120 -59.04 -42.37 93.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.358 0.663 . . . . 72.32 111.326 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.445 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 1.8 Cg_endo -87.42 101.34 0.5 Allowed 'Trans proline' 0 C--N 1.387 2.596 0 C-N-CA 122.429 2.086 . . . . 75.13 109.489 158.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.48 126.95 12.01 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 121.984 1.789 . . . . 71.51 111.911 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.99 151.14 21.94 Favored Glycine 0 C--N 1.343 0.946 0 CA-C-N 115.309 -0.859 . . . . 73.22 111.975 -179.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -77.74 159.4 29.1 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.512 0.725 . . . . 61.54 110.045 -170.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.455 HD21 HD13 ' A' ' 98' ' ' LEU . 47.5 tp -125.05 125.3 43.61 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.52 -0.548 . . . . 75.15 109.52 176.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 88.6 mt -127.4 101.47 6.47 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.88 0.872 . . . . 65.41 109.378 179.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.492 HD23 HD12 ' A' ' 98' ' ' LEU . 91.1 mt -102.96 102.23 12.28 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.992 0.517 . . . . 73.33 111.06 -178.147 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.99 107.57 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.011 -0.737 . . . . 72.54 109.011 -176.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.8 t -62.54 117.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.146 0.978 . . . . 73.25 111.078 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.519 ' HG3' ' HB3' ' A' ' 122' ' ' GLU . 13.1 mmm180 -110.95 106.48 15.61 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 124.997 1.319 . . . . 73.12 108.092 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.403 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 65.8 mt -69.16 116.5 9.67 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 123.206 0.602 . . . . 72.31 110.815 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.4 ' HB2' ' HA ' ' A' ' 126' ' ' THR . 81.9 mt -75.07 139.24 72.64 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 115.944 -0.571 . . . . 73.12 109.67 178.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -71.88 179.03 5.16 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.118 2.545 . . . . 74.41 112.872 177.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 . . . . . 0 C--O 1.252 1.234 0 N-CA-C 109.208 -0.664 . . . . 71.53 109.208 174.592 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 61.3 mtt . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 110.307 -0.257 . . . . 72.53 110.307 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER 35.03 86.2 0.14 Allowed Pre-proline 0 CA--C 1.559 1.304 0 C-N-CA 126.582 1.953 . . . . 54.14 113.837 -173.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . 0.472 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 22.0 Cg_endo -62.51 178.17 1.01 Allowed 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.58 2.187 . . . . 75.03 112.473 168.711 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.538 HD12 ' HD2' ' A' ' 124' ' ' PRO . 1.7 tp -43.22 -53.97 4.8 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 125.287 1.435 . . . . 75.43 112.529 -174.038 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.416 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 12.7 tp -119.3 91.92 3.67 Favored 'General case' 0 C--O 1.215 -0.757 0 N-CA-C 107.619 -1.252 . . . . 63.23 107.619 172.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.526 ' HA ' HD11 ' A' ' 119' ' ' LEU . 62.3 t80 168.52 131.54 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 124.361 1.064 . . . . 73.13 109.071 173.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.547 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 51.5 m -156.68 98.95 2.07 Favored Pre-proline 0 N--CA 1.475 0.787 0 N-CA-C 107.824 -1.176 . . . . 74.22 107.824 173.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -79.51 74.99 5.29 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 122.575 2.184 . . . . 72.2 112.553 -169.08 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 4.4 m -83.53 172.9 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 CA-C-N 115.541 -0.754 . . . . 63.45 109.997 179.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 60.6 p -81.88 -76.33 0.26 Allowed 'General case' 0 CA--C 1.547 0.845 0 CA-C-N 116.112 -0.495 . . . . 61.23 109.791 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 4.3 tppp? 42.21 87.03 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 125.397 1.479 . . . . 75.25 112.727 -175.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 149.22 -13.56 1.09 Allowed Glycine 0 N--CA 1.463 0.485 0 CA-C-N 115.171 -0.922 . . . . 74.04 111.445 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 47.7 m -64.15 87.33 0.05 OUTLIER 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 124.157 0.983 . . . . 73.14 110.592 178.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 59.37 -103.23 0.38 Allowed Glycine 0 C--N 1.347 1.184 0 CA-C-N 115.485 -0.78 . . . . 63.44 112.699 -179.306 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.05 33.75 6.18 Favored Glycine 0 C--N 1.345 1.069 0 CA-C-O 120.054 -0.303 . . . . 72.21 112.782 -177.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.4 p -82.67 90.17 6.81 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 109.184 -0.673 . . . . 73.44 109.184 173.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 69.58 85.4 0.13 Allowed Glycine 0 C--N 1.351 1.396 0 CA-C-N 115.998 -0.546 . . . . 74.44 111.876 -178.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -75.29 75.05 1.4 Allowed Glycine 0 C--N 1.35 1.348 0 C-N-CA 123.12 0.391 . . . . 61.31 112.711 -177.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 43.2 m -133.85 129.33 36.31 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 124.538 1.135 . . . . 72.04 108.419 177.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -65.47 -55.92 18.09 Favored Glycine 0 C--N 1.35 1.336 0 O-C-N 124.098 0.874 . . . . 51.24 113.236 -173.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -86.12 48.12 3.88 Favored Glycine 0 C--N 1.348 1.204 0 C-N-CA 122.787 0.232 . . . . 73.25 112.926 -177.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 50.9 m -144.23 103.94 4.05 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.805 0.842 . . . . 74.24 109.706 -178.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -96.13 -161.83 33.02 Favored Glycine 0 C--N 1.338 0.66 0 N-CA-C 111.127 -0.789 . . . . 64.31 111.127 171.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -59.21 123.79 17.83 Favored 'General case' 0 CA--C 1.56 1.348 0 C-N-CA 123.822 0.849 . . . . 75.5 111.065 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.57 130.74 40.88 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.228 -1.027 . . . . 74.43 108.228 -172.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.547 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 14.9 mt -100.73 112.83 25.31 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 108.111 -1.07 . . . . 64.24 108.111 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 75.0 ttt-85 -119.33 108.69 14.91 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 123.883 0.873 . . . . 73.02 110.208 -179.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.405 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -146.29 170.26 17.13 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 123.911 0.885 . . . . 74.04 108.701 179.004 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -97.03 145.21 26.17 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.969 0.414 . . . . 75.35 110.746 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.515 HD21 ' HG2' ' A' ' 136' ' ' ARG . 1.1 tt -103.01 103.9 36.74 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 124.901 1.28 . . . . 71.02 109.053 -177.11 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.538 ' HD2' HD12 ' A' ' 97' ' ' LEU . 37.7 Cg_endo -65.17 115.91 3.57 Favored 'Trans proline' 0 C--N 1.38 2.204 0 C-N-CA 122.107 1.871 . . . . 75.12 109.594 169.163 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.533 HD23 HD12 ' A' ' 149' ' ' ILE . 28.7 tp -137.15 127.02 25.69 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.361 0.664 . . . . 75.04 110.125 -172.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.9 p -78.18 167.91 20.67 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.062 0.545 . . . . 75.4 111.121 -175.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 76.9 mt -65.58 -37.3 86.25 Favored 'General case' 0 C--O 1.246 0.907 0 C-N-CA 123.981 0.913 . . . . 71.22 111.366 -173.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.47 -51.74 40.21 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 114.694 -1.139 . . . . 72.25 108.68 -177.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -62.43 -38.08 88.35 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.771 -1.104 . . . . 75.01 111.793 -178.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.39 -47.23 85.06 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 124.074 0.859 . . . . 73.21 110.453 176.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -66.48 -35.23 79.76 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 124.271 0.982 . . . . 75.53 111.136 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -67.32 -47.66 69.87 Favored 'General case' 0 C--N 1.363 1.18 0 CA-C-O 120.885 0.374 . . . . 74.33 110.018 177.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.576 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.19 56.01 24.57 Favored Glycine 0 C--N 1.341 0.852 0 CA-C-N 114.584 -1.189 . . . . 62.34 112.452 -174.259 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -103.3 -141.09 11.15 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 111.873 -0.491 . . . . 63.33 111.873 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -98.77 141.65 31.3 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.027 -0.731 . . . . 71.14 109.027 171.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.515 ' HG2' HD21 ' A' ' 123' ' ' LEU . 23.1 tpt180 -115.48 119.72 37.13 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.757 -1.201 . . . . 75.13 107.757 178.218 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 57.7 t -85.71 109.13 18.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 123.273 0.629 . . . . 74.11 109.519 -177.058 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.424 HG12 HD23 ' A' ' 97' ' ' LEU . 18.2 m -117.83 164.17 14.35 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 C-N-CA 125.609 1.563 . . . . 73.31 108.429 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -124.66 138.86 54.28 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 118.655 0.661 . . . . 70.41 111.413 -178.081 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.442 HG11 ' HB2' ' A' ' 143' ' ' ARG . 5.6 p -128.76 107.21 15.39 Favored 'Isoleucine or valine' 0 C--N 1.359 0.987 0 C-N-CA 124.838 1.255 . . . . 71.35 110.994 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.98 24.51 11.13 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.482 0.713 . . . . 62.53 112.166 175.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.39 18.09 29.48 Favored Glycine 0 C--N 1.348 1.246 0 CA-C-N 116.288 -0.415 . . . . 72.12 113.608 -178.282 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.442 ' HB2' HG11 ' A' ' 140' ' ' VAL . 10.8 mmm180 -117.64 123.09 45.29 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 123.773 0.829 . . . . 74.11 109.891 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.9 tpt180 -84.25 106.35 15.8 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 108.935 -0.765 . . . . 75.22 108.935 -176.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 88.4 t -115.98 132.17 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.87 0.868 . . . . 72.32 109.693 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 30.1 m -98.95 112.55 24.63 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.865 0.866 . . . . 74.41 109.23 176.121 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.465 HG23 HD13 ' A' ' 176' ' ' LEU . 3.8 p -99.72 121.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 124.023 0.929 . . . . 74.01 109.382 176.496 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -73.1 119.49 17.41 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.021 0.528 . . . . 74.42 110.182 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.576 HG13 ' HA2' ' A' ' 133' ' ' GLY . 4.9 pt -92.18 142.64 26.43 Favored Pre-proline 0 CA--C 1.563 1.478 0 C-N-CA 124.331 1.052 . . . . 72.42 109.948 177.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -58.84 148.36 84.24 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 123.555 2.837 . . . . 71.51 113.84 176.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.538 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 59.5 Cg_endo -70.31 113.04 3.33 Favored 'Trans proline' 0 C--N 1.377 2.044 0 C-N-CA 122.829 2.352 . . . . 74.15 111.414 177.408 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.22 39.01 37.93 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.826 -0.624 . . . . 74.12 112.34 -175.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 8.7 p -71.08 144.75 13.18 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 123.159 0.584 . . . . 74.24 110.143 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.502 ' HA ' HD13 ' A' ' 180' ' ' LEU . 64.6 mtp180 -119.24 177.13 5.01 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 121.766 0.794 . . . . 75.33 112.821 -171.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -64.89 130.25 42.75 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 113.535 -1.666 . . . . 73.51 111.121 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.52 -5.55 84.83 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-N 115.95 -0.568 . . . . 55.43 113.92 179.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.9 m -75.48 119.67 19.87 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-N 117.29 0.545 . . . . 73.33 109.742 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.6 t -98.51 116.63 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.069 0.547 . . . . 64.44 109.858 -174.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 57.5 mt -88.25 101.65 11.88 Favored 'Isoleucine or valine' 0 C--O 1.241 0.609 0 N-CA-C 108.074 -1.084 . . . . 75.51 108.074 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.459 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 13.4 ttp180 -91.79 113.79 26.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 114.821 -1.081 . . . . 74.35 109.477 178.14 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.0 t -114.85 113.83 44.35 Favored Pre-proline 0 CA--C 1.549 0.925 0 N-CA-C 108.922 -0.77 . . . . 74.43 108.922 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.04 124.23 12.73 Favored 'Trans proline' 0 C--N 1.377 2.065 0 C-N-CA 122.852 2.368 . . . . 73.35 112.595 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.41 -3.33 85.2 Favored Glycine 0 C--N 1.344 1.01 0 N-CA-C 114.911 0.724 . . . . 70.33 114.911 171.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.473 ' HE1' ' HA ' ' A' ' 164' ' ' MET . 1.7 tpt -88.06 -7.62 56.72 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 117.622 0.711 . . . . 71.52 111.037 -175.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -75.81 -111.67 0.11 Allowed Glycine 0 C--N 1.349 1.278 0 N-CA-C 112.057 -0.417 . . . . 74.1 112.057 175.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.65 103.92 1.52 Allowed Glycine 0 C--N 1.344 1.017 0 CA-C-N 117.134 0.467 . . . . 73.14 113.304 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -65.98 147.89 52.66 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.483 0.713 . . . . 64.21 110.935 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 140.07 -171.78 23.73 Favored Glycine 0 N--CA 1.473 1.129 0 C-N-CA 123.136 0.398 . . . . 71.11 112.203 -177.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 45.7 m-80 -61.84 -46.15 92.6 Favored Pre-proline 0 CA--C 1.559 1.32 0 CA-C-O 118.394 -0.812 . . . . 71.35 111.698 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -88.33 103.66 0.46 Allowed 'Trans proline' 0 C--N 1.391 2.77 0 C-N-CA 121.842 1.695 . . . . 71.05 110.15 163.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -76.58 125.02 7.99 Favored 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 122.211 1.94 . . . . 70.22 110.723 -177.167 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -81.42 148.82 28.31 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 116.1 -0.5 . . . . 74.43 112.396 -178.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -78.19 151.93 32.93 Favored 'General case' 0 C--O 1.247 0.935 0 CA-C-O 121.102 0.477 . . . . 73.51 110.102 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 43.3 tp -114.17 131.89 56.29 Favored 'General case' 0 C--O 1.223 -0.334 0 C-N-CA 122.803 0.441 . . . . 75.25 110.075 177.162 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 73.1 mt -128.2 104.6 7.84 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 124.495 1.118 . . . . 74.21 108.902 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.465 HD13 HG23 ' A' ' 147' ' ' VAL . 66.6 mt -113.63 105.53 13.43 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.392 0.677 . . . . 74.22 110.565 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.8 t -84.72 103.8 12.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 109.239 -0.652 . . . . 74.11 109.239 -175.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.4 t -58.84 125.5 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 O-C-N 123.697 0.623 . . . . 62.35 111.539 -177.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -115.12 107.72 15.7 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 125.144 1.377 . . . . 73.33 107.499 176.038 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.502 HD13 ' HA ' ' A' ' 154' ' ' ARG . 54.1 mt -69.19 110.09 4.39 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.504 -0.925 . . . . 74.45 108.504 177.056 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 84.9 mt -68.82 129.84 92.11 Favored Pre-proline 0 CA--C 1.544 0.742 0 CA-C-N 115.715 -0.675 . . . . 75.53 110.013 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -65.43 158.68 51.5 Favored 'Trans proline' 0 C--N 1.369 1.625 0 C-N-CA 122.978 2.452 . . . . 74.01 111.825 176.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.6 t-80 . . . . . 0 CA--C 1.552 1.028 0 C-N-CA 123.509 0.724 . . . . 75.25 110.239 174.243 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 26.6 ptt? . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 118.929 -0.558 . . . . 64.4 109.726 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER 29.35 82.29 0.21 Allowed Pre-proline 0 N--CA 1.505 2.319 0 C-N-CA 126.024 1.729 . . . . 74.3 114.482 -178.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -70.32 -43.35 2.24 Favored 'Trans proline' 0 C--N 1.38 2.229 0 C-N-CA 122.514 2.143 . . . . 71.24 112.153 -173.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.547 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.3 tp -175.39 145.43 0.75 Allowed 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.175 1.39 . . . . 65.21 107.804 -176.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.54 ' H ' HD11 ' A' ' 97' ' ' LEU . 4.2 tt 52.77 -78.27 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 126.924 2.09 . . . . 72.23 111.782 -174.589 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.642 ' HA ' HD12 ' A' ' 119' ' ' LEU . 78.2 t80 -57.01 120.71 8.45 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.909 1.283 . . . . 63.0 112.444 -178.06 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.525 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 88.8 m -138.62 97.97 9.02 Favored Pre-proline 0 CA--C 1.545 0.778 0 C-N-CA 124.287 1.035 . . . . 74.13 109.17 176.669 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.92 103.01 1.12 Allowed 'Trans proline' 0 C--N 1.367 1.527 0 C-N-CA 122.447 2.098 . . . . 72.53 111.708 -176.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.7 m -100.2 177.26 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 C-N-CA 124.249 1.02 . . . . 74.24 111.378 179.207 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 41.7 p -111.17 -10.25 14.31 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 123.705 0.802 . . . . 74.33 111.367 177.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 44.9 tttm -67.76 -32.51 73.15 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 123.552 0.741 . . . . 74.23 112.882 -174.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -79.28 19.97 5.25 Favored Glycine 0 CA--C 1.535 1.287 0 CA-C-O 119.62 -0.545 . . . . 71.34 114.377 -176.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 68.5 p -83.99 -58.51 2.75 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.965 0.906 . . . . 74.12 110.545 178.07 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.582 ' HA2' ' HG ' ' A' ' 112' ' ' SER . . . -179.04 146.48 7.24 Favored Glycine 0 C--N 1.35 1.357 0 CA-C-N 116.114 -0.494 . . . . 73.44 112.869 -177.244 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.81 -153.26 25.19 Favored Glycine 0 C--N 1.35 1.329 0 N-CA-C 111.714 -0.555 . . . . 60.23 111.714 176.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 47.5 t -76.32 -30.39 57.67 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 123.643 0.777 . . . . 74.31 110.583 176.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -117.43 20.86 10.99 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-N 115.914 -0.584 . . . . 73.31 111.879 175.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -137.48 140.64 11.48 Favored Glycine 0 C--N 1.344 1.006 0 N-CA-C 110.766 -0.934 . . . . 55.41 110.766 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.582 ' HG ' ' HA2' ' A' ' 107' ' ' GLY . 95.8 p 53.75 -78.23 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 125.818 1.647 . . . . 72.1 112.758 -176.168 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -73.56 86.54 0.62 Allowed Glycine 0 CA--C 1.528 0.902 0 N-CA-C 112.254 -0.338 . . . . 73.24 112.254 176.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 126.34 -33.96 3.33 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-O 120.023 -0.32 . . . . 72.11 112.841 174.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 64.6 m -151.04 150.23 30.49 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 123.005 0.522 . . . . 73.24 111.491 -175.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.413 ' HA2' ' HG2' ' A' ' 170' ' ' PRO . . . -95.03 -151.3 28.22 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-N 115.271 -0.877 . . . . 52.23 112.365 172.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.778 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 68.3 mtt180 -85.55 135.88 33.64 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.545 0.738 . . . . 74.02 109.722 -178.315 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -99.44 107.43 19.64 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.903 -1.147 . . . . 44.52 107.903 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.642 HD12 ' HA ' ' A' ' 99' ' ' PHE . 13.5 mt -93.63 109.52 21.15 Favored 'General case' 0 C--O 1.22 -0.454 0 N-CA-C 106.769 -1.567 . . . . 75.02 106.769 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -121.11 107.94 13.21 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.953 0.901 . . . . 72.54 108.634 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.23 156.3 47.83 Favored 'General case' 0 C--O 1.24 0.6 0 C-N-CA 123.162 0.585 . . . . 73.35 110.401 -174.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -75.66 125.95 30.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.497 1.119 . . . . 75.15 108.942 179.11 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.537 HD12 ' HG2' ' A' ' 136' ' ' ARG . 26.1 tp -100.66 101.42 15.35 Favored Pre-proline 0 CA--C 1.543 0.681 0 C-N-CA 123.507 0.723 . . . . 72.22 109.331 178.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.64 114.98 4.17 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.251 1.967 . . . . 64.32 110.002 175.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.508 HD21 HD12 ' A' ' 149' ' ' ILE . 18.6 tp -131.89 135.62 46.79 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 108.223 -1.029 . . . . 75.33 108.223 -173.405 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.483 ' HG1' ' HG2' ' A' ' 129' ' ' GLU . 38.8 p -81.84 171.59 14.32 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.588 -0.523 . . . . 75.23 109.588 -179.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 88.7 mt -68.05 -32.73 73.28 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 122.925 0.49 . . . . 74.3 110.343 176.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -69.48 -49.44 54.7 Favored 'General case' 0 N--CA 1.47 0.56 0 O-C-N 124.013 0.82 . . . . 75.22 109.433 -177.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.483 ' HG2' ' HG1' ' A' ' 126' ' ' THR . 17.5 mm-40 -68.66 -34.6 75.98 Favored 'General case' 0 N--CA 1.472 0.648 0 O-C-N 124.016 0.823 . . . . 73.32 111.127 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.51 -48.56 81.25 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.908 0.755 . . . . 75.1 110.599 173.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -65.09 -37.14 86.55 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 124.464 1.106 . . . . 73.11 110.905 179.275 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -64.2 -42.32 96.69 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 123.635 0.584 . . . . 71.43 110.136 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.455 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 58.63 35.56 81.57 Favored Glycine 0 C--N 1.349 1.251 0 O-C-N 124.234 0.959 . . . . 71.4 112.326 -174.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -87.71 -136.47 5.12 Favored Glycine 0 C--N 1.342 0.888 0 N-CA-C 112.045 -0.422 . . . . 52.53 112.045 -175.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.58 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 15.3 mp0 -111.43 139.77 46.58 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.052 -1.092 . . . . 54.34 108.052 173.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.537 ' HG2' HD12 ' A' ' 123' ' ' LEU . 37.9 tpt85 -112.81 120.51 41.74 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 124.323 1.049 . . . . 74.53 108.183 -177.195 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 91.2 t -81.39 106.3 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.79 0.836 . . . . 73.33 109.395 -176.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.547 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 20.4 m -111.35 159.92 11.0 Favored 'Isoleucine or valine' 0 C--O 1.245 0.839 0 C-N-CA 124.516 1.127 . . . . 74.33 111.113 -174.595 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -93.72 136.94 33.49 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.624 1.17 . . . . 65.45 109.056 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.457 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 1.5 p -151.9 100.35 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 C-N-CA 124.02 0.928 . . . . 74.43 110.445 176.043 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.02 21.26 11.63 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 113.526 0.936 . . . . 71.02 113.526 171.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.55 -7.37 55.89 Favored Glycine 0 N--CA 1.479 1.525 0 C-N-CA 123.162 0.41 . . . . 70.25 113.162 -176.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.04 150.2 21.52 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.83 0.852 . . . . 75.43 109.461 173.749 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 55.7 ttp180 -113.36 108.84 17.77 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 107.282 -1.377 . . . . 74.21 107.282 176.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 70.1 t -121.77 134.48 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 C-N-CA 123.379 0.672 . . . . 72.33 110.619 -173.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.58 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 29.1 p -95.37 109.21 21.41 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 123.483 0.713 . . . . 72.23 109.165 176.488 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -98.91 128.24 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.508 0.723 . . . . 71.32 109.338 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -70.43 122.91 20.52 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 109.287 -0.634 . . . . 72.42 109.287 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.508 HD12 HD21 ' A' ' 125' ' ' LEU . 4.3 pt -98.69 149.49 35.79 Favored Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 124.875 1.27 . . . . 75.13 109.623 176.576 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -63.82 143.41 85.98 Favored 'Trans proline' 0 C--N 1.377 2.062 0 C-N-CA 122.77 2.313 . . . . 74.55 112.755 176.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.455 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 42.3 Cg_endo -68.35 123.53 10.66 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 122.755 2.303 . . . . 73.5 111.91 174.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.48 26.71 64.95 Favored Glycine 0 C--N 1.347 1.179 0 CA-C-N 115.849 -0.614 . . . . 71.23 113.101 -178.444 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 7.4 p -67.68 145.9 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 C-N-CA 123.658 0.783 . . . . 73.3 111.363 -177.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.504 ' HA ' HD11 ' A' ' 180' ' ' LEU . 60.5 mtp180 -120.13 169.42 10.24 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-O 121.855 0.836 . . . . 75.1 112.832 -172.158 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -61.12 119.85 9.16 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 113.062 -1.881 . . . . 64.35 109.623 173.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 116.23 -25.4 9.33 Favored Glycine 0 N--CA 1.477 1.377 0 O-C-N 123.325 0.391 . . . . 61.15 112.583 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.6 m -69.88 123.92 22.71 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.479 0.712 . . . . 54.31 110.924 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.0 p -100.94 131.08 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 108.666 -0.864 . . . . 71.32 108.666 172.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 34.9 mt -100.05 102.15 13.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 107.859 -1.163 . . . . 72.42 107.859 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.511 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 51.1 ttp85 -87.73 106.43 18.05 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.538 -0.541 . . . . 75.43 109.538 175.182 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.1 t -100.48 96.44 5.29 Favored Pre-proline 0 CA--C 1.555 1.173 0 N-CA-C 107.481 -1.303 . . . . 73.3 107.481 173.361 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.66 143.67 42.58 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.958 2.438 . . . . 71.34 111.564 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . 0.688 ' HA2' ' HB2' ' A' ' 171' ' ' PRO . . . 85.47 -24.79 6.93 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-N 116.068 -0.514 . . . . 63.4 113.595 177.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.7 mmt -98.73 14.76 27.54 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.956 0.902 . . . . 73.32 111.013 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.86 -119.94 1.72 Allowed Glycine 0 C--N 1.348 1.21 0 N-CA-C 111.758 -0.537 . . . . 60.05 111.758 175.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.778 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.94 112.8 3.57 Favored Glycine 0 C--N 1.348 1.231 0 CA-C-N 117.11 0.455 . . . . 72.44 112.453 -177.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -81.53 139.3 35.2 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.581 0.752 . . . . 71.35 110.502 -177.185 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -173.37 -142.64 3.94 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.509 -1.037 . . . . 75.52 110.509 -179.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.4 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 39.3 t30 -73.81 -49.41 6.11 Favored Pre-proline 0 CA--C 1.563 1.471 0 N-CA-C 109.151 -0.685 . . . . 72.3 109.151 169.318 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.538 ' HG3' ' HA ' ' A' ' 112' ' ' SER . 93.1 Cg_endo -91.8 135.14 1.58 Allowed 'Trans proline' 0 C--N 1.389 2.709 0 C-N-CA 121.935 1.757 . . . . 72.44 111.748 165.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.688 ' HB2' ' HA2' ' A' ' 163' ' ' GLY . 55.8 Cg_endo -67.56 128.35 17.99 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.406 2.071 . . . . 61.14 111.599 172.307 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.27 162.84 32.47 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-N 116.095 -0.502 . . . . 61.3 113.108 -179.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -86.73 145.81 26.51 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.67 0.788 . . . . 65.4 110.532 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.511 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 42.8 tp -111.21 135.1 52.24 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.835 0.854 . . . . 62.21 109.288 173.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 66.7 mt -127.67 102.18 6.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.062 1.345 . . . . 73.0 108.813 178.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 98.1 mt -102.41 101.41 11.63 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.406 0.682 . . . . 75.41 109.481 177.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.7 t -85.66 97.87 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 109.043 -0.725 . . . . 75.13 109.043 -174.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 86.7 t -57.96 104.87 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 124.415 1.086 . . . . 74.12 111.47 -176.161 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -98.35 101.64 13.15 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-N 113.803 -1.544 . . . . 74.42 108.375 170.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.504 HD11 ' HA ' ' A' ' 154' ' ' ARG . 47.3 mt -69.64 126.77 30.73 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.634 -0.506 . . . . 73.13 109.634 176.509 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 59.5 mt -77.01 140.46 66.56 Favored Pre-proline 0 CA--C 1.548 0.865 0 N-CA-C 108.772 -0.825 . . . . 75.22 108.772 178.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -49.23 -73.54 0.04 OUTLIER 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 123.994 3.129 . . . . 71.04 113.165 -174.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 . . . . . 0 C--O 1.252 1.192 0 C-N-CA 124.538 1.135 . . . . 73.45 108.382 177.855 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 11.3 ttt . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 110.222 -0.288 . . . . 72.12 110.222 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . 0.465 ' HG ' ' HA ' ' A' ' 100' ' ' THR . 2.7 tt 66.73 70.89 0.47 Allowed Pre-proline 0 CA--C 1.556 1.21 0 C-N-CA 124.316 1.046 . . . . 72.14 109.601 172.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -75.4 -60.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.385 2.495 0 C-N-CA 121.951 1.768 . . . . 74.43 111.828 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.463 HD13 ' H ' ' A' ' 98' ' ' LEU . 6.2 tp -169.32 135.96 1.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.696 -1.594 . . . . 73.42 106.696 -173.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.536 HD13 HD11 ' A' ' 176' ' ' LEU . 14.8 tp 70.67 -60.42 0.5 Allowed 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.89 2.076 . . . . 72.02 112.511 -173.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.689 ' HB2' ' HA ' ' A' ' 140' ' ' VAL . 32.7 t80 -61.45 113.29 2.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.201 1.0 . . . . 72.53 111.782 179.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.465 ' HA ' ' HG ' ' A' ' 95' ' ' LEU . 98.2 m -133.4 95.3 18.29 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 124.045 0.938 . . . . 73.54 109.575 175.471 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.47 84.25 1.41 Allowed 'Trans proline' 0 C--N 1.369 1.658 0 C-N-CA 122.317 2.011 . . . . 73.23 112.802 -175.591 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.438 HG11 HG22 ' A' ' 100' ' ' THR . 23.3 m -86.55 167.09 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-N 115.062 -0.972 . . . . 72.34 110.57 177.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.4 t -115.79 37.59 3.57 Favored 'General case' 0 CA--C 1.553 1.072 0 C-N-CA 123.205 0.602 . . . . 72.44 109.568 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . 0.404 ' HE3' ' HA ' ' A' ' 104' ' ' LYS . 0.5 OUTLIER 72.18 -70.46 0.16 Allowed 'General case' 0 N--CA 1.49 1.539 0 C-N-CA 125.018 1.327 . . . . 72.2 109.946 -172.838 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 176.82 156.93 16.75 Favored Glycine 0 C--N 1.343 0.933 0 O-C-N 123.041 0.213 . . . . 75.23 112.83 176.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 67.4 m -80.97 -26.84 36.27 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 123.735 0.814 . . . . 74.05 110.732 172.304 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.21 158.71 51.96 Favored Glycine 0 C--N 1.348 1.228 0 O-C-N 124.071 0.857 . . . . 72.15 112.271 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -55.93 113.31 3.86 Favored Glycine 0 C--N 1.347 1.193 0 O-C-N 124.299 0.647 . . . . 72.02 112.404 178.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 12.1 m -77.11 -10.21 59.24 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 123.307 0.643 . . . . 71.22 111.314 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 80.18 -70.9 2.86 Favored Glycine 0 C--N 1.357 1.718 0 C-N-CA 123.174 0.416 . . . . 62.5 112.416 178.392 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -165.81 -137.78 2.28 Favored Glycine 0 C--N 1.341 0.814 0 N-CA-C 110.547 -1.021 . . . . 72.02 110.547 176.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 63.2 p -76.67 -5.76 49.28 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.168 0.587 . . . . 71.15 112.249 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -83.46 60.97 4.82 Favored Glycine 0 C--N 1.355 1.624 0 O-C-N 123.534 0.521 . . . . 62.43 113.189 -176.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -144.9 154.67 26.03 Favored Glycine 0 C--N 1.34 0.803 0 N-CA-C 110.372 -1.091 . . . . 73.14 110.372 176.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 27.2 m -93.8 -167.29 1.66 Allowed 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 123.215 0.606 . . . . 64.13 110.447 178.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -80.73 -159.88 22.29 Favored Glycine 0 C--N 1.344 0.974 0 N-CA-C 115.253 0.861 . . . . 73.33 115.253 -173.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 -68.89 128.55 37.08 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 108.64 -0.874 . . . . 74.55 108.64 -177.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -96.87 106.19 18.46 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 106.801 -1.555 . . . . 61.35 106.801 -178.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 15.7 mt -92.71 107.13 18.98 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 106.297 -1.742 . . . . 75.41 106.297 -172.127 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.487 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 59.6 ttt-85 -114.99 105.97 13.6 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.008 -1.108 . . . . 74.05 108.008 -176.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.52 146.67 50.43 Favored 'General case' 0 C--O 1.24 0.601 0 N-CA-C 108.742 -0.836 . . . . 61.03 108.742 -179.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -71.84 131.35 42.91 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 108.621 -0.881 . . . . 72.42 108.621 173.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.525 HD22 ' HG2' ' A' ' 136' ' ' ARG . 1.5 tt -98.4 103.27 17.41 Favored Pre-proline 0 CA--C 1.532 0.275 0 N-CA-C 106.352 -1.721 . . . . 73.23 106.352 176.431 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.452 ' HB2' HD13 ' A' ' 181' ' ' LEU . 50.5 Cg_endo -65.61 116.0 3.69 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 121.935 1.757 . . . . 74.35 109.786 174.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.463 HD23 HD13 ' A' ' 149' ' ' ILE . 15.6 tp -147.75 120.32 8.55 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.395 -0.595 . . . . 64.33 109.395 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.409 HG21 ' HB2' ' A' ' 181' ' ' LEU . 71.4 p -77.13 168.04 20.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.807 0.443 . . . . 72.21 111.724 -177.288 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.3 mt -55.64 -47.2 77.02 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 123.872 0.869 . . . . 74.13 112.137 -177.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -66.71 -41.4 88.02 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 115.959 -0.564 . . . . 74.3 111.279 -178.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -68.31 -31.86 71.59 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 122.91 0.484 . . . . 72.32 111.592 178.165 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -72.21 -39.38 68.59 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 123.337 0.655 . . . . 75.42 111.07 177.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -63.21 -56.52 15.93 Favored 'General case' 0 N--CA 1.472 0.628 0 O-C-N 124.619 1.199 . . . . 75.44 110.011 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 50.3 m80 -70.24 -34.96 73.49 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.469 -0.787 . . . . 73.32 111.16 -177.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 68.94 -135.35 28.07 Favored Glycine 0 C--N 1.353 1.513 0 N-CA-C 111.949 -0.46 . . . . 72.32 111.949 -177.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.49 -143.28 16.5 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 112.201 -0.36 . . . . 71.41 112.201 178.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -104.44 148.36 26.52 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.237 0.541 . . . . 71.31 111.31 -178.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.525 ' HG2' HD22 ' A' ' 123' ' ' LEU . 2.2 tpp180 -137.16 119.1 15.28 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 106.741 -1.577 . . . . 75.13 106.741 175.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.59 115.97 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.704 0 CA-C-O 121.864 0.84 . . . . 75.41 109.801 -174.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 11.4 m -122.7 164.33 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.981 1.312 . . . . 74.03 108.828 -171.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -123.16 125.42 45.1 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 118.457 0.571 . . . . 74.41 111.936 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.689 ' HA ' ' HB2' ' A' ' 99' ' ' PHE . 4.0 p -113.52 111.37 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.368 1.067 . . . . 71.31 110.17 175.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.34 26.3 14.97 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 123.807 0.843 . . . . 61.52 112.854 172.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.86 -12.03 60.84 Favored Glycine 0 C--N 1.352 1.421 0 CA-C-N 116.51 -0.314 . . . . 53.45 113.104 -177.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.1 tpp180 -92.22 115.86 28.44 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.637 0.775 . . . . 75.41 110.03 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 3.1 tpp180 -87.0 106.95 18.19 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.934 -0.765 . . . . 70.43 108.934 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 34.4 m -116.22 156.35 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 C-N-CA 123.911 0.884 . . . . 73.14 110.923 -178.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.0 p -91.32 141.95 28.22 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.53 0.732 . . . . 71.32 110.099 175.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 43.2 t -128.38 111.51 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 C-N-CA 124.747 1.219 . . . . 74.24 108.855 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -80.07 102.32 9.26 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.446 0.641 . . . . 74.24 109.417 178.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.463 HD13 HD23 ' A' ' 125' ' ' LEU . 16.5 pt -82.74 131.66 53.99 Favored Pre-proline 0 CA--C 1.559 1.296 0 CA-C-N 114.81 -1.086 . . . . 75.43 109.907 178.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 37.1 Cg_exo -64.22 135.86 48.87 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 122.656 2.237 . . . . 55.13 113.437 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -67.04 121.32 8.48 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 122.345 2.03 . . . . 71.13 110.742 168.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 87.82 27.47 26.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 115.549 -0.75 . . . . 73.23 113.22 -172.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.66 142.88 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 117.443 0.622 . . . . 74.34 109.74 176.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -112.7 177.6 4.58 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 121.635 0.731 . . . . 72.42 112.407 -172.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -65.02 133.49 51.79 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 113.56 -1.654 . . . . 62.44 110.644 176.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 83.8 -14.02 44.96 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-O 119.24 -0.755 . . . . 63.23 113.353 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 68.4 m -66.28 117.79 9.05 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 117.422 0.611 . . . . 63.31 109.667 -175.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.21 133.57 33.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 CA-C-O 121.362 0.601 . . . . 75.32 110.001 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.533 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 94.0 mt -99.95 102.3 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 N-CA-C 106.519 -1.66 . . . . 73.22 106.519 177.145 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.541 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 61.1 ttp85 -99.31 110.18 22.73 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.354 -0.385 . . . . 70.44 110.184 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.93 100.55 10.05 Favored Pre-proline 0 CA--C 1.557 1.241 0 N-CA-C 107.525 -1.287 . . . . 72.41 107.525 170.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.45 136.7 29.17 Favored 'Trans proline' 0 C--N 1.376 1.976 0 C-N-CA 122.937 2.424 . . . . 75.41 112.637 -173.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.15 -21.82 11.37 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.889 -0.596 . . . . 64.22 113.883 177.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 56.8 mtt -100.52 16.42 24.74 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 123.563 0.745 . . . . 74.21 111.402 -173.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . 0.545 ' HA2' HD12 ' A' ' 174' ' ' LEU . . . -85.27 -103.45 0.67 Allowed Glycine 0 C--N 1.351 1.407 0 CA-C-N 116.196 -0.457 . . . . 74.23 112.236 176.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -66.86 103.18 0.86 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.807 -0.517 . . . . 53.11 111.807 175.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -88.61 152.7 21.67 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.704 0.801 . . . . 75.45 110.419 -179.115 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 134.17 -137.0 8.96 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.462 -1.055 . . . . 74.25 110.462 -172.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.526 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 14.9 m120 -71.97 -56.48 4.55 Favored Pre-proline 0 CA--C 1.563 1.479 0 CA-C-N 117.704 0.752 . . . . 74.34 111.243 176.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.526 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -93.82 119.64 0.34 Allowed 'Trans proline' 0 C--N 1.396 3.041 0 C-N-CA 122.443 2.095 . . . . 71.35 112.434 178.388 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -63.03 125.2 15.36 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.82 2.347 . . . . 75.13 112.271 174.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.83 173.77 23.89 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 116.576 -0.284 . . . . 74.32 112.472 177.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -95.05 134.93 37.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.082 0.553 . . . . 74.11 109.878 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.545 HD12 ' HA2' ' A' ' 165' ' ' GLY . 17.1 tp -97.79 119.36 36.25 Favored 'General case' 0 C--O 1.216 -0.673 0 N-CA-C 107.989 -1.115 . . . . 73.42 107.989 -178.533 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.487 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 65.6 mt -123.48 120.15 32.06 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.761 0.824 . . . . 71.34 109.598 -170.108 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.536 HD11 HD13 ' A' ' 98' ' ' LEU . 41.9 mt -123.0 101.12 7.24 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 123.254 0.622 . . . . 74.34 110.937 177.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.1 t -85.84 96.38 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 108.409 -0.96 . . . . 70.24 108.409 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.8 t -56.02 126.51 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.199 1.0 . . . . 75.33 111.721 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.8 mmm-85 -112.87 110.01 19.83 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.786 -1.191 . . . . 75.03 107.786 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 46.0 mt -70.67 96.04 1.17 Allowed 'General case' 0 C--O 1.238 0.481 0 N-CA-C 109.408 -0.59 . . . . 75.33 109.408 178.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.452 HD13 ' HB2' ' A' ' 124' ' ' PRO . 80.4 mt -71.56 149.3 93.4 Favored Pre-proline 0 C--O 1.246 0.873 0 CA-C-N 114.711 -1.131 . . . . 71.42 110.445 -179.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -57.86 142.86 96.52 Favored 'Trans proline' 0 C--N 1.372 1.801 0 C-N-CA 122.557 2.171 . . . . 71.53 111.656 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 27.9 p80 . . . . . 0 CA--C 1.558 1.265 0 C-N-CA 123.543 0.737 . . . . 74.32 111.328 179.228 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 120.951 0.405 . . . . 71.42 110.377 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -107.7 112.59 62.05 Favored Pre-proline 0 CA--C 1.545 0.776 0 CA-C-N 115.237 -0.892 . . . . 73.11 110.251 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_exo -73.34 -160.9 0.1 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 122.8 2.333 . . . . 72.51 111.25 167.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.525 HD13 ' H ' ' A' ' 98' ' ' LEU . 9.1 tp -72.04 141.47 49.28 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.819 -0.808 . . . . 74.05 108.819 171.532 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.583 HD12 HG21 ' A' ' 138' ' ' VAL . 6.0 tp 65.58 -68.16 0.12 Allowed 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 126.83 2.052 . . . . 73.31 111.579 -174.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.536 ' HA ' HD11 ' A' ' 119' ' ' LEU . 59.8 t80 -59.78 127.83 33.91 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.213 1.005 . . . . 70.41 111.708 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.503 HG21 HG11 ' A' ' 102' ' ' VAL . 56.3 m -141.75 104.61 5.81 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 124.086 0.954 . . . . 75.2 109.228 175.116 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.1 87.1 1.05 Allowed 'Trans proline' 0 C--N 1.362 1.278 0 C-N-CA 122.299 2.0 . . . . 60.31 112.97 -170.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.503 HG11 HG21 ' A' ' 100' ' ' THR . 22.8 m -113.37 170.81 4.18 Favored 'Isoleucine or valine' 0 C--O 1.239 0.525 0 CA-C-N 114.451 -1.25 . . . . 75.24 109.846 174.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.8 t -159.59 146.67 16.71 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 123.933 0.893 . . . . 74.25 109.392 173.105 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 32.0 mtmm -122.28 98.37 5.9 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.561 -0.903 . . . . 74.43 108.561 177.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -100.88 -114.21 3.71 Favored Glycine 0 N--CA 1.477 1.395 0 CA-C-O 119.185 -0.786 . . . . 62.25 111.558 177.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 78.0 p 48.16 55.12 9.19 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 125.646 1.578 . . . . 73.03 111.963 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 72.24 -93.6 0.61 Allowed Glycine 0 C--N 1.342 0.875 0 N-CA-C 110.439 -1.064 . . . . 70.02 110.439 -169.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 64.35 73.9 0.52 Allowed Glycine 0 C--N 1.351 1.379 0 O-C-N 123.83 0.371 . . . . 73.42 112.867 176.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.3 m -65.14 -45.73 83.83 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.839 0.855 . . . . 75.32 111.893 -173.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 75.78 -95.18 1.0 Allowed Glycine 0 C--N 1.347 1.139 0 CA-C-N 115.703 -0.68 . . . . 64.14 112.782 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 88.57 -7.85 80.7 Favored Glycine 0 C--N 1.346 1.107 0 N-CA-C 114.054 0.382 . . . . 72.52 114.054 179.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.6 t -158.17 137.45 11.7 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.299 0.64 . . . . 72.23 110.256 -176.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.68 -174.78 41.99 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 123.574 0.546 . . . . 72.55 113.877 176.039 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.01 -87.51 1.15 Allowed Glycine 0 C--N 1.342 0.9 0 CA-C-O 119.653 -0.526 . . . . 52.53 111.971 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.0 m 59.78 47.8 9.88 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 124.211 1.004 . . . . 71.24 111.436 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -68.85 -112.6 0.02 OUTLIER Glycine 0 CA--C 1.528 0.888 0 CA-C-N 115.035 -0.984 . . . . 74.44 112.598 176.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 42.9 mtt180 -98.26 135.29 40.1 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.072 0.549 . . . . 75.21 109.775 174.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -98.91 104.17 16.19 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.873 -1.529 . . . . 71.23 106.873 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.536 HD11 ' HA ' ' A' ' 99' ' ' PHE . 11.5 mt -92.71 110.44 21.88 Favored 'General case' 0 C--N 1.343 0.323 0 N-CA-C 106.633 -1.617 . . . . 73.41 106.633 -173.402 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -117.76 108.55 15.52 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 108.975 -0.75 . . . . 75.34 108.975 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.48 154.02 51.15 Favored 'General case' 0 C--O 1.24 0.592 0 C-N-CA 123.193 0.597 . . . . 53.01 110.682 -171.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -72.13 131.58 43.0 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.291 -0.868 . . . . 62.24 109.109 173.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.555 HD23 ' HG2' ' A' ' 136' ' ' ARG . 2.4 tt -101.47 102.61 22.59 Favored Pre-proline 0 CA--C 1.544 0.733 0 N-CA-C 107.949 -1.13 . . . . 73.43 107.949 176.047 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.74 115.79 3.94 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 121.928 1.752 . . . . 72.21 110.019 173.143 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 46.3 tp -142.75 131.52 22.73 Favored 'General case' 0 C--O 1.225 -0.194 0 C-N-CA 123.648 0.779 . . . . 71.13 109.012 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 55.0 p -80.13 163.61 23.98 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 122.865 0.466 . . . . 74.42 111.286 -176.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.9 mt -58.77 -51.82 68.35 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.666 0.787 . . . . 74.3 112.826 -171.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -64.83 -40.13 94.68 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 122.742 0.417 . . . . 74.41 111.109 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -69.49 -26.04 64.35 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 112.288 0.477 . . . . 74.03 112.288 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.401 ' HB2' ' O ' ' A' ' 153' ' ' VAL . . . -69.11 -46.68 67.1 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 123.619 0.768 . . . . 63.21 109.743 172.096 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -61.93 -42.03 98.63 Favored 'General case' 0 CA--C 1.546 0.801 0 CA-C-N 114.614 -1.176 . . . . 74.34 111.039 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.4 m80 -72.97 -42.2 63.6 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 122.804 0.442 . . . . 72.34 110.317 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.85 -128.76 9.79 Favored Glycine 0 C--N 1.345 1.032 0 CA-C-N 115.309 -0.86 . . . . 53.13 111.308 -172.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.4 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 80.38 -158.5 41.79 Favored Glycine 0 C--N 1.348 1.24 0 CA-C-N 116.834 0.317 . . . . 52.31 112.805 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -84.0 147.16 27.59 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 117.329 0.564 . . . . 72.23 109.763 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.567 ' HB2' HD11 ' A' ' 149' ' ' ILE . 27.0 tpt180 -128.33 121.2 28.63 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.433 0.693 . . . . 73.22 109.178 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.401 HG11 ' HG3' ' A' ' 144' ' ' ARG . 93.1 t -79.22 106.87 10.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.455 0 C-N-CA 123.975 0.91 . . . . 73.03 109.265 178.055 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.583 HG21 HD12 ' A' ' 98' ' ' LEU . 20.7 m -111.13 159.64 10.97 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 123.863 0.865 . . . . 74.13 109.377 176.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -116.79 138.12 51.72 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 107.703 -1.221 . . . . 74.43 107.703 -176.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.53 HG13 ' HB2' ' A' ' 143' ' ' ARG . 3.7 p -150.15 107.12 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 C-N-CA 123.212 0.605 . . . . 73.42 111.498 -176.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.18 20.6 8.63 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 113.359 0.874 . . . . 72.45 113.359 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.9 28.31 7.87 Favored Glycine 0 C--N 1.344 0.976 0 C-N-CA 122.903 0.287 . . . . 73.12 112.582 -175.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.53 ' HB2' HG13 ' A' ' 140' ' ' VAL . 82.3 mtt85 -133.68 156.64 47.55 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 123.533 0.733 . . . . 74.15 110.095 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.401 ' HG3' HG11 ' A' ' 137' ' ' VAL . 31.6 ttm180 -109.86 119.77 40.39 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.754 0.822 . . . . 75.44 109.169 170.457 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.42 ' O ' HG23 ' A' ' 138' ' ' VAL . 69.8 t -115.69 135.63 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 108.421 -0.955 . . . . 71.42 108.421 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 28.9 p -103.2 104.78 14.96 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 109.141 -0.688 . . . . 72.03 109.141 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 4.7 p -98.3 120.29 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 109.172 -0.677 . . . . 74.32 109.172 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 47.3 ttp180 -78.21 100.37 6.62 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-O 121.415 0.626 . . . . 74.2 109.33 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.567 HD11 ' HB2' ' A' ' 136' ' ' ARG . 3.1 pt -79.55 144.9 62.03 Favored Pre-proline 0 CA--C 1.563 1.449 0 CA-C-N 114.639 -1.164 . . . . 72.33 109.766 178.444 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -61.93 136.82 63.71 Favored 'Trans proline' 0 CA--C 1.562 1.891 0 C-N-CA 123.005 2.47 . . . . 75.32 113.393 -179.033 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -62.18 113.12 1.76 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.948 2.432 . . . . 72.03 111.179 172.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.47 35.51 8.59 Favored Glycine 0 C--N 1.34 0.765 0 O-C-N 123.616 0.573 . . . . 72.41 112.379 -176.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.401 ' O ' ' HB2' ' A' ' 130' ' ' ALA . 12.6 p -76.65 145.85 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 N-CA-C 109.818 -0.438 . . . . 74.01 109.818 176.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -118.39 177.15 4.92 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.651 0.739 . . . . 75.14 112.636 -171.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -64.68 135.05 55.47 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 113.989 -1.459 . . . . 73.3 110.974 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.22 -6.13 64.73 Favored Glycine 0 C--N 1.343 0.959 0 CA-C-N 115.767 -0.652 . . . . 75.1 113.646 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 56.0 m -74.85 118.89 18.31 Favored 'General case' 0 C--N 1.351 0.647 0 CA-C-N 117.502 0.651 . . . . 72.43 109.506 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.0 p -99.05 134.25 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 123.087 0.555 . . . . 74.42 110.413 -177.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 67.7 mt -105.94 105.87 19.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 C-N-CA 124.328 1.051 . . . . 73.14 108.71 -175.125 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 58.0 ttm-85 -87.96 111.86 21.94 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.81 0.444 . . . . 74.41 110.405 -178.318 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -123.95 98.95 38.66 Favored Pre-proline 0 CA--C 1.554 1.124 0 C-N-CA 123.942 0.897 . . . . 74.2 109.0 179.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.28 131.75 21.13 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.488 2.126 . . . . 75.32 112.22 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.89 -23.17 37.07 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.761 -0.654 . . . . 62.02 113.56 176.099 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.2 mpt? -89.57 6.56 40.55 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.107 0.563 . . . . 74.24 111.288 178.004 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -85.51 -108.37 0.7 Allowed Glycine 0 C--N 1.344 1.001 0 N-CA-C 111.556 -0.617 . . . . 74.32 111.556 174.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.6 108.93 2.64 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 112.286 -0.326 . . . . 74.35 112.286 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.552 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -88.36 148.46 24.24 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.194 0.598 . . . . 63.1 110.885 -179.493 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.48 -138.51 8.49 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 111.062 -0.815 . . . . 73.51 111.062 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.444 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 3.4 m-20 -78.41 -49.16 1.82 Allowed Pre-proline 0 CA--C 1.566 1.578 0 CA-C-O 118.29 -0.862 . . . . 74.21 110.644 175.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.444 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -94.97 106.41 0.12 Allowed 'Trans proline' 0 C--N 1.396 3.034 0 C-N-CA 122.658 2.238 . . . . 73.44 111.905 172.09 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.37 125.23 13.63 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 122.025 1.817 . . . . 70.51 111.456 174.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -99.97 173.96 26.06 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 116.041 -0.527 . . . . 74.41 111.975 175.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -92.48 152.57 19.6 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 123.309 0.644 . . . . 72.31 110.663 -174.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 59.3 tp -114.23 133.76 55.4 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.901 0.88 . . . . 71.33 109.75 179.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.3 mt -129.85 103.46 6.82 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.021 0.928 . . . . 74.52 110.428 176.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.511 HD22 HD13 ' A' ' 98' ' ' LEU . 82.8 mt -101.77 103.18 13.9 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 123.072 0.549 . . . . 72.3 111.212 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.9 t -84.11 97.68 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 N-CA-C 108.954 -0.758 . . . . 70.35 108.954 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 89.5 t -57.03 130.26 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 124.024 0.93 . . . . 73.34 111.436 -178.199 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -121.4 105.32 10.4 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 125.068 1.347 . . . . 63.4 107.912 -177.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 24.1 mt -70.32 109.8 4.92 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.377 -0.601 . . . . 74.41 109.377 178.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.8 mt -72.27 149.97 91.82 Favored Pre-proline 0 CA--C 1.549 0.942 0 C-N-CA 123.062 0.545 . . . . 75.22 110.097 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -58.93 97.49 0.09 OUTLIER 'Trans proline' 0 C--N 1.376 2.005 0 C-N-CA 122.898 2.399 . . . . 74.04 110.98 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 124.772 1.229 . . . . 75.02 109.702 -172.574 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 22.6 ptt? . . . . . 0 N--CA 1.482 1.139 0 CA-C-O 120.432 0.158 . . . . 73.01 111.019 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 tt 63.26 74.08 0.47 Allowed Pre-proline 0 CA--C 1.556 1.202 0 C-N-CA 124.858 1.263 . . . . 72.12 111.664 166.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -90.81 -152.04 0.04 OUTLIER 'Trans proline' 0 CA--C 1.553 1.434 0 C-N-CA 122.827 2.351 . . . . 73.44 111.101 168.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.555 HD12 ' H ' ' A' ' 98' ' ' LEU . 12.1 tp -74.69 144.52 43.71 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.961 0.905 . . . . 73.24 109.41 175.24 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.555 ' H ' HD12 ' A' ' 97' ' ' LEU . 9.0 tp 64.4 -67.79 0.11 Allowed 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.731 2.412 . . . . 74.42 112.002 -171.422 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.686 ' HA ' HD11 ' A' ' 119' ' ' LEU . 60.7 t80 -64.58 130.01 42.01 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.411 1.084 . . . . 75.31 111.531 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.473 HG23 HG11 ' A' ' 102' ' ' VAL . 39.7 m -146.09 98.29 4.39 Favored Pre-proline 0 CA--C 1.54 0.58 0 C-N-CA 124.679 1.192 . . . . 75.14 108.766 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.26 87.11 0.92 Allowed 'Trans proline' 0 C--N 1.366 1.471 0 C-N-CA 122.192 1.928 . . . . 72.01 112.554 -171.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.473 HG11 HG23 ' A' ' 100' ' ' THR . 14.7 m -98.42 152.12 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 C-N-CA 124.332 1.053 . . . . 71.33 108.745 173.362 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -102.81 -24.62 13.7 Favored 'General case' 0 C--O 1.244 0.781 0 C-N-CA 123.275 0.63 . . . . 61.43 111.341 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.8 pptp? -85.56 162.64 18.79 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-O 121.386 0.612 . . . . 74.33 110.818 -171.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 175.14 171.08 38.86 Favored Glycine 0 C--N 1.337 0.638 0 CA-C-N 115.029 -0.987 . . . . 64.21 111.375 176.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 44.7 t -74.13 -7.16 51.58 Favored 'General case' 0 CA--C 1.553 1.078 0 C-N-CA 123.553 0.741 . . . . 73.03 111.38 178.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.13 54.25 4.71 Favored Glycine 0 C--N 1.356 1.647 0 C-N-CA 123.142 0.401 . . . . 64.03 113.126 177.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.8 24.25 0.42 Allowed Glycine 0 C--N 1.341 0.826 0 N-CA-C 109.88 -1.288 . . . . 71.54 109.88 173.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.8 t -157.63 -43.39 0.07 Allowed 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 124.788 1.235 . . . . 74.51 109.138 -176.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 156.22 -169.78 33.79 Favored Glycine 0 C--N 1.355 1.633 0 CA-C-N 115.959 -0.564 . . . . 74.2 112.408 177.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 151.92 165.12 12.79 Favored Glycine 0 CA--C 1.529 0.915 0 C-N-CA 122.686 0.184 . . . . 73.04 112.914 176.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.3 m -71.01 90.41 0.83 Allowed 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.6 0.76 . . . . 75.13 109.668 174.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 88.72 -43.66 3.1 Favored Glycine 0 C--N 1.349 1.261 0 CA-C-N 115.929 -0.578 . . . . 74.44 111.719 -171.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 135.01 -167.37 24.09 Favored Glycine 0 C--N 1.343 0.945 0 N-CA-C 110.471 -1.051 . . . . 75.15 110.471 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 46.8 m -148.95 125.52 11.02 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.088 -0.708 . . . . 64.32 109.088 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -83.62 -140.16 4.11 Favored Glycine 0 CA--C 1.531 1.051 0 N-CA-C 112.199 -0.36 . . . . 62.11 112.199 175.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.662 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 37.5 mtm180 -90.08 141.27 28.85 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 123.672 0.789 . . . . 72.44 109.495 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -99.8 107.49 19.54 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 108.188 -1.041 . . . . 62.1 108.188 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.686 HD11 ' HA ' ' A' ' 99' ' ' PHE . 16.4 mt -93.63 111.05 22.66 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 107.64 -1.244 . . . . 73.54 107.64 -175.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.3 ttp85 -114.6 105.61 13.28 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 108.896 -0.779 . . . . 73.34 108.896 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 145.66 50.96 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 123.68 0.792 . . . . 74.51 109.633 -175.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.463 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 3.2 mp0 -74.16 131.73 41.55 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 123.667 0.787 . . . . 62.31 109.225 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.513 HD11 ' HG2' ' A' ' 136' ' ' ARG . 40.9 tp -100.12 102.89 19.57 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 124.29 1.036 . . . . 71.1 109.134 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -67.86 114.56 3.39 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 122.274 1.982 . . . . 74.11 109.956 176.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.471 HD23 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -143.86 131.43 21.15 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.066 -0.716 . . . . 74.11 109.066 -171.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.8 p -80.52 170.51 16.25 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 110.296 -0.261 . . . . 73.34 110.296 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 84.8 mt -61.37 -34.74 75.83 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.837 0.855 . . . . 72.54 111.157 -178.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -72.79 -51.67 18.07 Favored 'General case' 0 C--N 1.345 0.379 0 CA-C-N 114.776 -1.102 . . . . 75.34 108.803 -176.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -66.94 -26.72 66.98 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.01 -0.996 . . . . 63.44 111.575 -176.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.436 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -74.87 -50.47 16.89 Favored 'General case' 0 C--N 1.348 0.521 0 C-N-CA 123.901 0.88 . . . . 74.3 111.375 176.102 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -58.61 -46.15 87.66 Favored 'General case' 0 C--N 1.361 1.068 0 O-C-N 124.308 1.005 . . . . 75.53 110.664 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -77.78 -40.63 40.11 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.279 -0.873 . . . . 74.42 111.033 -176.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.58 -164.53 50.9 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 111.828 -0.509 . . . . 63.13 111.828 -175.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.456 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 119.49 -161.11 14.18 Favored Glycine 0 N--CA 1.473 1.12 0 N-CA-C 111.774 -0.53 . . . . 62.12 111.774 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -81.52 141.63 33.63 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.046 0.539 . . . . 75.23 110.253 177.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.513 ' HG2' HD11 ' A' ' 123' ' ' LEU . 19.4 tpp180 -126.75 121.28 31.56 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.969 0.908 . . . . 64.41 108.768 178.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 56.0 t -81.28 107.63 13.72 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 C-N-CA 123.339 0.656 . . . . 75.23 109.614 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.544 HG22 HD13 ' A' ' 98' ' ' LEU . 25.5 m -116.37 164.63 12.53 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 C-N-CA 125.297 1.439 . . . . 75.53 109.318 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -122.41 131.48 53.9 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 123.446 0.699 . . . . 64.42 109.575 -171.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 5.2 p -142.54 102.41 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.321 0 C-N-CA 124.211 1.004 . . . . 75.51 111.656 -174.002 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.55 25.93 14.86 Favored 'General case' 0 N--CA 1.493 1.681 0 C-N-CA 124.229 1.012 . . . . 74.51 112.759 175.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.56 -0.8 53.01 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 123.901 0.762 . . . . 75.34 113.438 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.5 mmm180 -104.07 141.89 35.42 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.421 0.689 . . . . 75.41 110.367 -177.458 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -97.81 113.89 25.8 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.753 0.821 . . . . 75.11 109.284 178.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 73.6 t -118.51 129.6 74.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 123.859 0.864 . . . . 74.52 109.561 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 33.5 p -97.39 106.58 18.92 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 109.063 -0.717 . . . . 73.33 109.063 174.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.3 p -98.7 125.9 51.99 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 123.494 0.717 . . . . 75.35 109.76 -177.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.2 ttt180 -81.99 105.06 12.79 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.379 0.672 . . . . 74.41 109.62 -177.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.471 HD12 HD23 ' A' ' 125' ' ' LEU . 4.8 pt -87.24 146.03 39.18 Favored Pre-proline 0 C--O 1.253 1.265 0 C-N-CA 124.68 1.192 . . . . 74.42 109.343 176.493 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.475 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 57.0 Cg_endo -72.04 143.09 39.69 Favored 'Trans proline' 0 CA--C 1.56 1.799 0 C-N-CA 122.441 2.094 . . . . 72.24 112.76 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.39 130.49 22.53 Favored 'Trans proline' 0 C--N 1.375 1.941 0 C-N-CA 122.493 2.129 . . . . 72.35 111.262 171.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.82 27.57 45.73 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 115.548 -0.751 . . . . 75.11 112.243 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.475 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 12.4 p -76.62 147.71 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 108.989 -0.745 . . . . 74.34 108.989 176.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.0 mtp180 -125.12 176.06 6.96 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-O 121.993 0.901 . . . . 72.32 112.591 -166.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -64.42 123.9 20.38 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-N 113.292 -1.776 . . . . 71.4 110.332 175.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.54 89.55 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.798 0.686 . . . . 61.24 113.611 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.3 m -76.54 118.49 19.25 Favored 'General case' 0 C--N 1.35 0.614 0 N-CA-C 108.778 -0.823 . . . . 71.44 108.778 176.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.12 124.7 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 CA-C-O 121.437 0.637 . . . . 71.33 109.677 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.5 mt -95.14 102.85 14.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 C-N-CA 124.324 1.05 . . . . 74.1 108.23 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.513 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 35.1 ttm180 -87.28 107.91 18.72 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 109.49 -0.559 . . . . 74.43 109.49 174.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.9 t -105.7 107.69 59.92 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 107.428 -1.323 . . . . 71.11 107.428 173.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -66.02 135.4 40.61 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.484 2.123 . . . . 74.52 112.043 -177.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 80.39 -5.33 64.19 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 114.723 0.649 . . . . 73.12 114.723 174.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 96.3 mmm -103.9 16.58 26.01 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 117.807 0.803 . . . . 74.45 111.842 -176.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -90.88 -142.29 10.07 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 116.149 -0.478 . . . . 54.21 111.983 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.662 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.69 127.93 8.58 Favored Glycine 0 C--N 1.343 0.965 0 N-CA-C 111.638 -0.585 . . . . 63.51 111.638 -177.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.9 mm-40 -83.61 151.64 25.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 123.46 0.704 . . . . 75.5 110.513 -175.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -148.75 -125.85 1.48 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 109.559 -1.417 . . . . 74.12 109.559 177.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.555 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 23.2 t30 -74.63 -51.26 4.14 Favored Pre-proline 0 CA--C 1.564 1.493 0 N-CA-C 108.118 -1.067 . . . . 72.3 108.118 161.265 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.555 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 49.4 Cg_endo -100.13 164.45 0.47 Allowed 'Trans proline' 0 C--N 1.39 2.731 0 C-N-CA 122.74 2.294 . . . . 74.32 111.689 165.324 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.21 136.68 14.61 Favored 'Trans proline' 0 CA--C 1.557 1.67 0 C-N-CA 121.794 1.662 . . . . 73.24 112.182 174.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -86.78 179.7 48.89 Favored Glycine 0 C--N 1.348 1.218 0 CA-C-O 119.999 -0.334 . . . . 72.2 112.552 175.16 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -97.48 148.53 23.13 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.043 0.537 . . . . 74.32 110.956 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.513 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 56.8 tp -107.01 132.73 52.62 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.052 0.941 . . . . 72.55 110.368 -178.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 93.6 mt -129.37 104.02 7.25 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 125.023 1.329 . . . . 74.23 109.609 176.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.492 HD23 HD11 ' A' ' 98' ' ' LEU . 65.9 mt -104.54 103.44 13.12 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 122.98 0.512 . . . . 62.44 110.518 176.476 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.5 t -84.83 93.6 3.57 Favored 'Isoleucine or valine' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 75.34 108.603 -177.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.485 HG22 HD21 ' A' ' 123' ' ' LEU . 97.3 t -56.7 127.66 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.098 0.959 . . . . 75.54 111.264 -178.429 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.463 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.9 mmt180 -121.57 114.49 21.27 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 124.546 1.138 . . . . 73.12 108.435 -179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 75.1 mt -72.48 106.16 4.46 Favored 'General case' 0 C--O 1.241 0.648 0 O-C-N 123.826 0.704 . . . . 73.44 110.132 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 72.1 mt -66.22 153.77 91.6 Favored Pre-proline 0 CA--C 1.546 0.807 0 CA-C-N 115.868 -0.605 . . . . 64.2 110.522 179.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -56.99 140.79 93.39 Favored 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 122.899 2.4 . . . . 62.41 111.218 173.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 . . . . . 0 C--O 1.251 1.159 0 N-CA-C 109.329 -0.619 . . . . 74.51 109.329 -179.098 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 62.4 mtt . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 110.0 -0.37 . . . . 75.32 110.0 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.3 pt? 37.16 75.21 0.54 Allowed Pre-proline 0 N--CA 1.488 1.464 0 C-N-CA 125.757 1.623 . . . . 65.51 113.346 -173.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.69 -44.63 7.87 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 122.074 1.849 . . . . 70.03 110.832 176.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.55 HD13 ' H ' ' A' ' 98' ' ' LEU . 5.6 tp -177.99 144.52 0.34 Allowed 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.495 1.518 . . . . 70.31 107.807 177.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.757 HD23 ' HB ' ' A' ' 140' ' ' VAL . 18.2 tp 62.68 -70.16 0.06 Allowed 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 126.779 2.031 . . . . 75.23 112.226 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.497 ' HA ' HD12 ' A' ' 119' ' ' LEU . 76.8 t80 -63.23 130.76 45.93 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.335 1.054 . . . . 75.35 110.785 174.37 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.456 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 52.3 m -139.65 102.55 7.12 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 124.2 1.0 . . . . 63.1 109.475 177.049 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.87 89.68 0.86 Allowed 'Trans proline' 0 C--N 1.359 1.106 0 C-N-CA 121.676 1.584 . . . . 73.43 111.159 -177.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.5 m -85.55 172.17 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 CA-C-N 115.789 -0.641 . . . . 74.13 109.601 170.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.9 t -128.77 119.02 23.8 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 108.461 -0.94 . . . . 74.51 108.461 177.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 14.7 mmmm -95.2 85.69 4.36 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-O 121.066 0.46 . . . . 74.44 110.651 -174.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -116.91 24.97 9.16 Favored Glycine 0 C--N 1.344 1.004 0 N-CA-C 110.748 -0.941 . . . . 72.21 110.748 170.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 16.7 p -70.13 93.35 0.81 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 123.64 0.776 . . . . 71.11 110.74 -178.206 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.94 -43.1 3.2 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-N 115.625 -0.716 . . . . 73.53 113.27 178.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.9 -123.53 5.84 Favored Glycine 0 C--N 1.348 1.209 0 N-CA-C 110.483 -1.047 . . . . 74.05 110.483 -178.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 30.3 t -79.11 83.41 5.18 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 123.424 0.689 . . . . 71.25 110.193 -179.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -128.89 100.92 0.53 Allowed Glycine 0 C--N 1.342 0.916 0 N-CA-C 110.525 -1.03 . . . . 63.44 110.525 -177.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -67.84 83.89 0.16 Allowed Glycine 0 C--N 1.346 1.088 0 O-C-N 124.302 0.648 . . . . 72.0 112.806 -178.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.0 m -97.28 22.23 8.95 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 124.418 1.087 . . . . 75.11 110.667 -178.046 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 92.47 -107.05 3.47 Favored Glycine 0 C--N 1.349 1.294 0 N-CA-C 111.321 -0.712 . . . . 51.24 111.321 -174.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.53 -51.48 16.28 Favored Glycine 0 C--N 1.351 1.381 0 N-CA-C 111.753 -0.539 . . . . 73.41 111.753 177.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 13.1 m 60.51 15.12 5.34 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 124.542 1.137 . . . . 71.12 112.747 174.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -79.08 -163.36 25.24 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 115.535 0.974 . . . . 72.31 115.535 -168.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 -80.06 117.62 21.05 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 108.144 -1.058 . . . . 74.04 108.144 -173.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -94.44 104.87 16.84 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 107.314 -1.365 . . . . 75.22 107.314 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.497 HD12 ' HA ' ' A' ' 99' ' ' PHE . 11.8 mt -92.53 111.83 23.55 Favored 'General case' 0 C--N 1.345 0.384 0 N-CA-C 107.785 -1.191 . . . . 71.5 107.785 -172.079 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 68.6 ttt180 -120.13 107.82 13.5 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.253 1.021 . . . . 75.25 108.724 -177.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.19 148.16 50.85 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.066 0.546 . . . . 73.24 111.531 -171.371 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.558 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.5 mp0 -68.3 125.06 25.24 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.403 1.081 . . . . 63.25 109.443 170.338 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.412 HD12 HD11 ' A' ' 176' ' ' LEU . 2.5 tt -101.67 102.9 24.78 Favored Pre-proline 0 CA--C 1.543 0.687 0 N-CA-C 108.104 -1.073 . . . . 71.02 108.104 175.142 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.39 115.54 3.57 Favored 'Trans proline' 0 C--N 1.378 2.107 0 C-N-CA 121.689 1.592 . . . . 75.4 109.636 171.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.559 HD22 HD13 ' A' ' 149' ' ' ILE . 14.0 tp -137.64 123.11 19.6 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.6 -0.889 . . . . 72.5 108.6 -170.166 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.9 p -73.81 169.99 16.23 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 117.785 0.266 . . . . 63.21 110.705 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.1 mt -62.76 -33.43 75.14 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.575 0.75 . . . . 75.44 111.042 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -71.76 -45.51 61.45 Favored 'General case' 0 C--N 1.352 0.683 0 O-C-N 123.783 0.677 . . . . 73.13 109.312 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -64.18 -35.46 80.88 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 123.695 0.798 . . . . 75.24 111.634 176.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.43 -42.91 67.67 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.46 0.704 . . . . 75.42 111.867 -179.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.1 t80 -68.39 -50.88 49.8 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-N 114.884 -1.053 . . . . 71.4 110.102 -179.09 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -75.06 -42.0 57.86 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 115.669 -0.696 . . . . 74.31 111.213 -174.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.31 -134.5 16.82 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.564 0.54 . . . . 73.31 111.844 -177.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 76.27 -146.69 33.53 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-O 119.658 -0.523 . . . . 71.41 111.856 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.421 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 1.4 mp0 -85.18 146.69 26.98 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 117.83 0.815 . . . . 74.22 110.412 178.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.59 ' HB2' HD12 ' A' ' 149' ' ' ILE . 24.7 tpt180 -129.05 121.55 28.11 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.244 1.018 . . . . 73.24 108.936 177.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.5 t -82.18 108.72 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 C-N-CA 123.499 0.72 . . . . 73.02 109.736 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.482 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 33.6 m -128.11 162.15 34.92 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.012 0 C-N-CA 124.995 1.318 . . . . 73.34 108.825 178.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -107.32 138.09 44.16 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 122.882 0.473 . . . . 74.32 110.191 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.757 ' HB ' HD23 ' A' ' 98' ' ' LEU . 3.0 p -123.27 105.87 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 124.564 1.146 . . . . 74.24 109.06 171.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.11 14.87 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.744 0.818 . . . . 74.24 112.863 174.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.28 11.03 43.32 Favored Glycine 0 C--N 1.35 1.349 0 CA-C-O 119.901 -0.388 . . . . 64.55 113.843 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -115.31 118.38 33.09 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 117.429 0.615 . . . . 74.44 110.192 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -82.51 106.14 14.13 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.43 0.692 . . . . 72.25 109.956 -178.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 25.9 m -121.44 155.6 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.6 0.76 . . . . 62.42 110.342 -179.246 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.421 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 14.1 p -106.61 110.15 22.26 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.635 0.774 . . . . 63.25 109.646 175.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -99.22 128.99 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 124.061 0.944 . . . . 74.31 109.205 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -77.95 109.2 11.79 Favored 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.051 0.453 . . . . 74.55 110.506 -175.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.59 HD12 ' HB2' ' A' ' 136' ' ' ARG . 5.0 pt -86.55 142.74 35.25 Favored Pre-proline 0 CA--C 1.558 1.253 0 C-N-CA 124.484 1.113 . . . . 75.54 108.775 173.397 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.47 137.24 20.47 Favored 'Trans proline' 0 CA--C 1.562 1.902 0 C-N-CA 122.191 1.927 . . . . 65.34 111.822 177.353 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_exo -63.44 135.9 52.11 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 122.761 2.308 . . . . 72.05 112.327 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.51 14.6 61.41 Favored Glycine 0 CA--C 1.534 1.253 0 O-C-N 123.636 0.585 . . . . 65.25 113.401 -176.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.18 143.26 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.324 0.649 . . . . 64.03 110.374 -177.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -118.49 177.5 4.8 Favored 'General case' 0 N--CA 1.484 1.24 0 CA-C-O 121.651 0.738 . . . . 74.32 112.894 -169.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -63.49 126.69 28.32 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 113.855 -1.52 . . . . 71.44 110.11 174.807 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -10.15 65.46 Favored Glycine 0 CA--C 1.532 1.129 0 O-C-N 124.111 0.882 . . . . 75.12 113.968 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.1 m -69.86 120.33 15.43 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-N 117.861 0.83 . . . . 74.14 109.989 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.61 139.86 17.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 C-N-CA 122.817 0.447 . . . . 74.34 110.077 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 44.6 mt -110.94 102.23 13.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 N-CA-C 106.85 -1.537 . . . . 70.31 106.85 178.359 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.435 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 6.0 ttp180 -88.15 102.17 14.53 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 108.961 -0.755 . . . . 73.24 108.961 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -95.2 113.05 60.66 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 107.746 -1.205 . . . . 72.15 107.746 175.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.39 128.45 15.47 Favored 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 122.847 2.365 . . . . 71.33 112.688 -169.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 63.49 23.42 66.74 Favored Glycine 0 C--N 1.351 1.392 0 O-C-N 123.592 0.558 . . . . 62.22 114.371 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.8 tpp -100.62 -18.4 16.58 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.487 0.715 . . . . 74.31 111.066 -177.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -72.45 -95.9 0.08 OUTLIER Glycine 0 C--N 1.345 1.035 0 CA-C-N 115.832 -0.622 . . . . 62.42 113.256 -175.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -72.36 86.75 0.5 Allowed Glycine 0 C--N 1.346 1.117 0 N-CA-C 112.252 -0.339 . . . . 71.45 112.252 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.599 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -81.93 121.64 26.75 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.376 0.67 . . . . 62.33 109.978 179.654 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 162.31 -142.12 7.72 Favored Glycine 0 C--O 1.241 0.591 0 N-CA-C 111.282 -0.727 . . . . 71.33 111.282 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.511 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 19.3 m120 -67.43 -49.43 42.25 Favored Pre-proline 0 CA--C 1.566 1.56 0 CA-C-O 118.271 -0.871 . . . . 75.42 110.886 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.511 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -96.48 106.69 0.1 OUTLIER 'Trans proline' 0 C--N 1.395 3.023 0 C-N-CA 123.125 2.55 . . . . 74.32 111.485 170.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.01 129.87 24.28 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.641 2.227 . . . . 70.54 111.778 178.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -117.97 157.33 15.22 Favored Glycine 0 C--N 1.338 0.642 0 N-CA-C 111.501 -0.64 . . . . 54.33 111.501 178.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -89.7 158.85 17.38 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 123.603 0.761 . . . . 73.34 110.558 -177.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.435 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 67.0 tp -115.7 132.64 56.57 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.834 0.853 . . . . 74.32 109.948 -177.675 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.7 mt -127.84 101.41 6.33 Favored 'General case' 0 CA--C 1.549 0.925 0 C-N-CA 125.35 1.46 . . . . 73.04 109.236 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.495 HD21 HD13 ' A' ' 98' ' ' LEU . 75.7 mt -101.46 100.83 11.33 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 123.11 0.564 . . . . 71.42 110.923 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 4.7 t -85.53 95.26 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 N-CA-C 108.409 -0.96 . . . . 75.02 108.409 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 73.9 t -54.67 135.03 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.695 1.198 . . . . 71.24 111.629 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.558 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.3 mmt180 -128.27 107.68 9.97 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.312 -1.366 . . . . 72.23 107.312 -177.669 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 53.3 mt -69.98 121.62 17.75 Favored 'General case' 0 N--CA 1.47 0.534 0 O-C-N 123.438 0.461 . . . . 75.53 109.943 -177.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 83.8 mt -85.46 140.64 36.2 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.894 -0.594 . . . . 72.02 110.268 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.56 -15.9 34.14 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.667 2.245 . . . . 75.22 111.872 172.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 35.9 m80 . . . . . 0 C--N 1.356 0.849 0 C-N-CA 124.308 1.043 . . . . 74.44 108.264 176.994 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 84.3 mtp . . . . . 0 N--CA 1.488 1.448 0 N-CA-C 109.663 -0.495 . . . . 75.35 109.663 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 40.88 81.85 0.24 Allowed Pre-proline 0 N--CA 1.491 1.586 0 C-N-CA 125.906 1.683 . . . . 74.3 113.688 -177.311 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -64.71 -55.93 0.47 Allowed 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.494 2.129 . . . . 65.34 112.0 177.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.479 HD13 ' H ' ' A' ' 98' ' ' LEU . 7.2 tp -177.55 134.88 0.18 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.785 1.234 . . . . 74.42 108.18 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.479 ' H ' HD13 ' A' ' 97' ' ' LEU . 15.4 tp 66.86 -63.57 0.26 Allowed 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 126.89 2.076 . . . . 74.41 111.379 -174.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.418 ' HB2' HG23 ' A' ' 140' ' ' VAL . 40.7 t80 -69.43 126.02 28.49 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.696 1.198 . . . . 73.1 111.433 176.8 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.538 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 87.1 m -138.77 88.45 13.88 Favored Pre-proline 0 N--CA 1.47 0.57 0 C-N-CA 124.444 1.098 . . . . 71.44 108.657 176.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.4 83.96 0.61 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 122.461 2.107 . . . . 74.2 112.615 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.514 HG13 HG23 ' A' ' 100' ' ' THR . 21.2 m -96.22 -179.31 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 CA-C-N 114.612 -1.176 . . . . 73.11 108.857 172.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.4 t -132.27 151.16 51.96 Favored 'General case' 0 C--O 1.244 0.78 0 N-CA-C 108.833 -0.803 . . . . 70.33 108.833 174.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 36.8 ttmt -134.34 107.41 7.61 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 120.932 0.396 . . . . 75.53 110.47 178.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -162.5 27.11 0.24 Allowed Glycine 0 C--N 1.339 0.749 0 CA-C-N 114.854 -1.067 . . . . 50.44 110.561 172.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 49.2 m -81.95 72.39 9.0 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 123.958 0.903 . . . . 72.25 109.859 -178.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 74.94 174.05 33.05 Favored Glycine 0 C--N 1.35 1.311 0 CA-C-N 115.374 -0.83 . . . . 75.32 112.927 -176.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.19 153.99 10.77 Favored Glycine 0 CA--C 1.533 1.217 0 N-CA-C 113.703 0.241 . . . . 71.35 113.703 177.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 46.7 t -166.06 169.36 14.64 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.097 0.959 . . . . 73.11 109.633 -177.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 160.86 162.76 12.94 Favored Glycine 0 C--N 1.344 0.982 0 N-CA-C 112.219 -0.352 . . . . 73.3 112.219 177.244 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -65.05 -56.21 17.36 Favored Glycine 0 C--N 1.349 1.295 0 N-CA-C 111.626 -0.59 . . . . 44.11 111.626 177.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.8 m -97.27 -27.63 14.42 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 123.603 0.761 . . . . 52.1 109.793 171.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -72.78 85.57 0.55 Allowed Glycine 0 C--N 1.358 1.757 0 O-C-N 123.645 0.591 . . . . 64.42 114.145 -172.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -175.15 91.84 0.09 OUTLIER Glycine 0 C--N 1.34 0.77 0 N-CA-C 110.49 -1.044 . . . . 71.14 110.49 179.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 40.5 m -66.37 154.22 40.67 Favored 'General case' 0 C--O 1.243 0.728 0 C-N-CA 123.749 0.82 . . . . 73.1 110.699 176.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.03 -168.62 22.9 Favored Glycine 0 C--N 1.344 1.01 0 CA-C-N 116.329 -0.396 . . . . 70.12 112.72 172.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.403 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 45.2 mtt180 -73.57 153.35 40.27 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 123.579 0.752 . . . . 71.52 110.432 -175.278 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -98.05 109.17 21.97 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 107.491 -1.3 . . . . 75.35 107.491 177.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.538 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 15.0 mt -91.47 108.04 19.62 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 106.165 -1.791 . . . . 74.22 106.165 177.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 34.7 ttt180 -118.89 106.16 12.21 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.104 -1.073 . . . . 71.03 108.104 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -131.0 144.54 51.55 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.165 0.586 . . . . 74.33 109.54 -175.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.597 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.2 mp0 -72.8 129.01 37.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 114.88 -1.055 . . . . 75.43 108.536 173.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.52 HD23 ' HG2' ' A' ' 136' ' ' ARG . 3.0 tt -99.76 102.39 16.97 Favored Pre-proline 0 CA--C 1.536 0.438 0 N-CA-C 106.609 -1.626 . . . . 74.15 106.609 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -65.93 113.86 2.75 Favored 'Trans proline' 0 C--N 1.376 2.026 0 C-N-CA 121.839 1.693 . . . . 73.14 110.271 174.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.502 HD21 HD12 ' A' ' 149' ' ' ILE . 17.8 tp -144.36 121.9 11.75 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.796 -1.187 . . . . 72.34 107.796 -173.812 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.3 p -73.96 168.34 19.67 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 117.761 0.255 . . . . 75.21 110.478 -177.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.8 mt -57.58 -36.43 71.7 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.249 0.619 . . . . 74.42 110.918 176.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 21.2 mp0 -71.88 -46.75 56.78 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 124.611 1.165 . . . . 60.02 110.386 -176.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -72.06 -27.49 62.72 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.601 0.76 . . . . 74.45 111.911 -179.051 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -69.41 -46.02 67.82 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.426 0.69 . . . . 73.13 109.926 173.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -58.96 -41.56 87.77 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 124.718 1.207 . . . . 73.42 110.849 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.45 -49.1 67.83 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.59 0.556 . . . . 71.54 109.541 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.479 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.01 56.93 22.41 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.062 -0.972 . . . . 45.35 113.106 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -92.0 -148.17 21.91 Favored Glycine 0 C--N 1.345 1.033 0 O-C-N 123.491 0.171 . . . . 61.44 112.808 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -95.4 132.32 40.59 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 107.757 -1.201 . . . . 73.43 107.757 169.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.52 ' HG2' HD23 ' A' ' 123' ' ' LEU . 12.8 tpp180 -111.62 116.94 31.65 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 107.678 -1.23 . . . . 74.14 107.678 -178.405 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.51 HG21 ' HG2' ' A' ' 144' ' ' ARG . 12.1 p -98.76 118.12 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 N-CA-C 108.133 -1.062 . . . . 72.24 108.133 -176.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.417 HG11 ' HG3' ' A' ' 136' ' ' ARG . 35.6 m -134.22 161.84 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.849 0.86 . . . . 74.14 110.008 -173.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -96.97 136.88 36.91 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 123.679 0.792 . . . . 65.33 110.093 -173.596 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.418 HG23 ' HB2' ' A' ' 99' ' ' PHE . 5.4 p -144.49 111.59 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.607 1.163 . . . . 74.53 109.631 177.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.4 22.01 12.95 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 123.684 0.794 . . . . 70.51 113.025 173.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.92 -16.12 58.76 Favored Glycine 0 C--N 1.345 1.049 0 C-N-CA 123.827 0.727 . . . . 73.11 112.653 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 19.4 tpp180 -95.72 123.92 39.51 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.249 1.02 . . . . 72.31 109.551 178.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.51 ' HG2' HG21 ' A' ' 137' ' ' VAL . 22.6 ttp180 -89.51 107.05 18.85 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 108.728 -0.841 . . . . 74.31 108.728 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 70.0 t -112.7 136.79 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 C-N-CA 124.112 0.965 . . . . 75.31 110.508 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 31.9 p -96.18 120.83 37.17 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.279 0.632 . . . . 72.54 110.669 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.5 p -106.37 131.02 57.14 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.943 1.297 . . . . 72.54 109.345 174.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 46.7 ttp180 -79.02 122.34 26.07 Favored 'General case' 0 C--O 1.243 0.72 0 CA-C-O 120.969 0.414 . . . . 71.52 109.98 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.502 HD12 HD21 ' A' ' 125' ' ' LEU . 10.3 pt -96.5 140.71 22.32 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 124.26 1.024 . . . . 73.1 109.823 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_exo -66.18 142.66 68.13 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.058 2.505 . . . . 72.1 113.045 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.404 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 31.6 Cg_endo -66.17 130.91 25.29 Favored 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 122.327 2.018 . . . . 74.45 110.802 170.144 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 70.81 26.29 74.26 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 115.532 -0.758 . . . . 62.42 113.945 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.0 p -68.77 137.37 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-N 117.201 0.5 . . . . 74.12 110.755 -178.672 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -98.37 175.77 5.93 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.875 0.845 . . . . 75.52 112.963 -168.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -69.65 134.0 48.21 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 113.547 -1.661 . . . . 74.11 110.669 177.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 73.89 10.17 80.27 Favored Glycine 0 C--N 1.342 0.914 0 CA-C-N 116.062 -0.517 . . . . 72.43 113.452 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.5 m -81.32 118.9 23.02 Favored 'General case' 0 C--N 1.347 0.473 0 N-CA-C 108.626 -0.879 . . . . 74.12 108.626 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 3.3 p -99.91 115.03 40.08 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.351 0.596 . . . . 73.32 109.796 -175.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 55.5 mt -90.05 104.49 15.24 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 124.516 1.126 . . . . 74.55 108.212 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.532 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 24.8 ttp180 -90.32 117.9 29.4 Favored 'General case' 0 C--N 1.344 0.355 0 N-CA-C 110.548 -0.168 . . . . 73.34 110.548 -179.655 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.0 t -109.11 95.28 17.29 Favored Pre-proline 0 CA--C 1.555 1.157 0 N-CA-C 107.5 -1.296 . . . . 64.12 107.5 166.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -70.26 136.29 31.33 Favored 'Trans proline' 0 C--N 1.373 1.857 0 C-N-CA 122.888 2.392 . . . . 74.44 111.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.39 2.24 82.92 Favored Glycine 0 CA--C 1.531 1.089 0 CA-C-O 119.635 -0.536 . . . . 65.32 114.118 178.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 41.4 tpp -128.51 12.99 6.48 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 117.872 0.836 . . . . 74.45 110.726 -177.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.38 -106.74 0.78 Allowed Glycine 0 C--N 1.344 1.021 0 CA-C-N 115.866 -0.606 . . . . 73.11 111.896 178.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -61.38 105.11 0.8 Allowed Glycine 0 C--N 1.347 1.179 0 C-N-CA 123.018 0.342 . . . . 74.31 113.502 -177.248 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -89.69 134.7 34.02 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.862 0.865 . . . . 71.44 109.176 173.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -178.9 -51.14 0.08 OUTLIER Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.031 -1.228 . . . . 74.34 110.031 177.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.441 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 25.1 t-20 -166.25 -54.76 0.01 OUTLIER Pre-proline 0 CA--C 1.556 1.192 0 C-N-CA 124.952 1.301 . . . . 75.1 108.173 169.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.441 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 82.1 Cg_endo -82.54 134.49 7.63 Favored 'Trans proline' 0 C--N 1.399 3.196 0 C-N-CA 121.721 1.614 . . . . 74.42 110.411 170.004 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.76 125.84 10.87 Favored 'Trans proline' 0 C--N 1.367 1.537 0 C-N-CA 122.228 1.952 . . . . 74.55 111.824 178.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -95.13 -172.18 37.03 Favored Glycine 0 C--N 1.349 1.273 0 CA-C-N 116.182 -0.463 . . . . 65.42 113.416 175.495 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.6 144.33 28.02 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.417 0.687 . . . . 70.42 110.5 178.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.532 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.6 tp -107.99 129.68 55.1 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-N 115.312 -0.858 . . . . 74.32 108.879 178.315 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.4 mt -128.27 102.56 6.73 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 124.472 1.109 . . . . 75.53 109.187 -178.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.424 HD21 HD13 ' A' ' 98' ' ' LEU . 89.4 mt -104.08 101.36 11.12 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 121.0 0.428 . . . . 73.13 110.486 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.46 95.75 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.47 -0.937 . . . . 72.22 108.47 -176.195 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.7 t -55.63 124.11 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 124.142 0.977 . . . . 74.32 111.355 -179.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.597 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 28.2 mmt180 -116.38 104.48 11.51 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.383 1.073 . . . . 74.51 108.459 -179.323 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.453 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 60.8 mt -70.05 111.05 5.44 Favored 'General case' 0 C--N 1.343 0.323 0 C-N-CA 123.685 0.794 . . . . 75.43 110.732 -178.028 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 63.3 mt -94.73 144.22 27.51 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.324 0.65 . . . . 64.31 110.044 -179.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.93 -33.23 4.84 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 122.425 2.083 . . . . 74.12 110.773 167.17 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 . . . . . 0 N--CA 1.48 1.069 0 C-N-CA 124.82 1.248 . . . . 73.3 108.15 175.829 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 110.275 -0.268 . . . . 75.4 110.275 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pp 36.7 81.06 0.25 Allowed Pre-proline 0 CA--C 1.56 1.363 0 C-N-CA 126.057 1.743 . . . . 72.42 114.391 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.93 -61.87 0.16 Allowed 'Trans proline' 0 C--N 1.382 2.341 0 C-N-CA 122.519 2.146 . . . . 72.3 110.509 176.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.436 HD13 ' H ' ' A' ' 98' ' ' LEU . 7.8 tp -172.68 144.33 1.39 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.599 1.16 . . . . 74.12 107.901 172.272 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.562 HD13 HG22 ' A' ' 138' ' ' VAL . 8.9 tp 64.31 -66.36 0.12 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 126.346 1.858 . . . . 71.34 111.828 -169.08 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.403 ' HB2' HG21 ' A' ' 140' ' ' VAL . 77.4 t80 -59.55 137.47 58.01 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 124.733 1.213 . . . . 74.12 111.972 178.147 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.552 HG22 HG11 ' A' ' 102' ' ' VAL . 61.2 m -157.66 108.93 1.81 Allowed Pre-proline 0 N--CA 1.475 0.822 0 C-N-CA 124.755 1.222 . . . . 74.2 109.225 177.358 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -81.42 68.15 8.24 Favored 'Trans proline' 0 C--N 1.371 1.736 0 C-N-CA 122.381 2.054 . . . . 72.42 112.582 -172.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.552 HG11 HG22 ' A' ' 100' ' ' THR . 9.6 m -62.06 -29.34 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 CA-C-N 114.78 -1.1 . . . . 73.44 112.663 -179.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.6 t 44.44 33.03 0.81 Allowed 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 125.69 1.596 . . . . 74.22 113.824 176.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.2 164.86 11.59 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 124.517 1.127 . . . . 71.33 110.981 -175.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 177.97 -51.74 0.1 OUTLIER Glycine 0 C--N 1.339 0.697 0 N-CA-C 110.564 -1.014 . . . . 74.32 110.564 178.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.4 m 61.06 20.07 10.54 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 124.643 1.177 . . . . 65.21 112.759 176.262 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 158.13 156.43 7.97 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 112.048 -0.421 . . . . 64.11 112.048 -177.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.41 -23.09 57.46 Favored Glycine 0 C--N 1.348 1.195 0 C-N-CA 122.974 0.321 . . . . 73.22 112.843 177.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 59.8 p -137.73 154.31 49.64 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.655 0.782 . . . . 63.31 110.738 -178.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -152.62 167.18 31.46 Favored Glycine 0 C--N 1.353 1.523 0 C-N-CA 123.537 0.589 . . . . 75.54 111.887 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -68.34 -47.85 55.47 Favored Glycine 0 C--N 1.348 1.236 0 C-N-CA 123.034 0.349 . . . . 74.22 113.536 -173.072 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 22.7 t -76.97 -38.56 52.99 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.402 0.681 . . . . 55.32 109.553 177.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -173.69 146.57 8.9 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 115.023 -0.99 . . . . 65.45 111.631 -179.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.61 -39.01 30.83 Favored Glycine 0 C--N 1.342 0.908 0 O-C-N 123.724 0.308 . . . . 65.3 112.96 177.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 51.4 m -102.14 150.2 23.51 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.811 0.844 . . . . 75.32 110.064 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.73 ' HA2' ' HA2' ' A' ' 172' ' ' GLY . . . 149.67 75.22 0.02 OUTLIER Glycine 0 C--N 1.347 1.185 0 O-C-N 123.207 0.317 . . . . 53.24 113.053 175.465 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.527 ' HG3' ' HA3' ' A' ' 166' ' ' GLY . 21.2 ptt180 -95.8 124.28 39.75 Favored 'General case' 0 CA--C 1.554 1.108 0 N-CA-C 108.98 -0.748 . . . . 75.31 108.98 170.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.472 ' HA ' ' O ' ' A' ' 173' ' ' ASP . 0.1 OUTLIER -101.99 115.06 29.74 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.875 0.87 . . . . 72.51 110.681 -157.955 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.481 HD21 ' O ' ' A' ' 100' ' ' THR . 13.8 mt -90.86 109.53 20.74 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 106.841 -1.54 . . . . 72.44 106.841 178.147 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.18 110.64 21.92 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 123.129 0.572 . . . . 75.53 110.376 -178.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.88 138.59 52.73 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.799 -0.815 . . . . 72.0 108.799 177.002 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mp0 -77.82 122.21 25.12 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.51 -0.922 . . . . 73.1 108.51 176.419 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.521 HD13 HD11 ' A' ' 176' ' ' LEU . 1.0 OUTLIER -99.67 111.05 60.87 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 108.667 -0.864 . . . . 75.02 108.667 -172.281 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.415 ' HB2' HD13 ' A' ' 181' ' ' LEU . 52.6 Cg_endo -67.89 116.67 4.42 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.06 1.84 . . . . 70.54 109.788 170.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.491 HD22 HD12 ' A' ' 149' ' ' ILE . 23.6 tp -131.45 133.04 44.78 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 108.715 -0.846 . . . . 73.4 108.715 -172.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 45.1 p -75.48 157.17 34.4 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.36 -0.607 . . . . 75.02 109.36 -178.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.54 -31.15 71.89 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.274 0.63 . . . . 75.34 111.074 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -70.78 -51.64 25.66 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.768 0.827 . . . . 74.23 110.107 179.458 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -65.45 -34.16 77.64 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.485 0.714 . . . . 74.24 111.581 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.43 -45.56 86.99 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 124.027 0.829 . . . . 71.54 110.699 173.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -66.08 -35.75 81.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 124.177 0.991 . . . . 63.01 111.116 179.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -73.65 -43.16 60.2 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.997 0.519 . . . . 65.11 109.865 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.426 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 67.23 51.37 38.68 Favored Glycine 0 C--N 1.347 1.149 0 CA-C-N 114.877 -1.056 . . . . 75.11 111.742 -168.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -89.84 -150.55 23.57 Favored Glycine 0 C--N 1.347 1.177 0 CA-C-O 120.841 0.134 . . . . 72.22 112.971 -177.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.411 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 7.5 mp0 -101.36 140.97 34.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.576 -0.898 . . . . 72.55 108.576 169.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 24.4 tpt85 -120.56 121.53 38.6 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.074 0.949 . . . . 73.21 108.548 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 12.2 p -84.73 117.89 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.784 0.802 . . . . 73.44 109.769 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.562 HG22 HD13 ' A' ' 98' ' ' LEU . 34.6 m -126.46 160.3 34.41 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 C-N-CA 125.444 1.498 . . . . 72.43 107.974 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -125.62 112.7 16.46 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-N 118.981 0.809 . . . . 62.24 111.801 -172.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.497 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.5 p -105.55 105.55 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 C-N-CA 125.608 1.563 . . . . 70.42 111.004 -176.572 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.25 28.5 15.26 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 124.146 0.978 . . . . 72.22 112.521 177.111 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.11 -10.49 58.38 Favored Glycine 0 C--N 1.356 1.687 0 CA-C-O 119.79 -0.45 . . . . 72.43 114.085 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -90.25 118.32 29.67 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 108.605 -0.887 . . . . 74.35 108.605 174.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 48.4 ttt85 -98.8 109.74 22.45 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 109.248 -0.649 . . . . 73.45 109.248 -177.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.1 p -130.75 146.07 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.527 1.131 . . . . 71.33 110.377 -172.272 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.411 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 28.4 m -93.18 119.19 32.09 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 123.693 0.797 . . . . 73.22 110.464 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -101.26 130.13 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.114 0.966 . . . . 75.4 109.944 175.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 36.9 ttp180 -75.84 134.77 40.27 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.248 0.547 . . . . 71.01 110.137 178.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.491 HD12 HD22 ' A' ' 125' ' ' LEU . 2.8 pt -108.65 145.66 32.07 Favored Pre-proline 0 CA--C 1.564 1.492 0 C-N-CA 125.11 1.364 . . . . 72.43 108.985 -179.473 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.52 145.99 97.75 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 123.037 2.491 . . . . 72.31 113.565 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.415 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 60.5 Cg_endo -71.06 117.08 4.97 Favored 'Trans proline' 0 C--N 1.38 2.212 0 C-N-CA 122.709 2.273 . . . . 65.01 112.294 178.585 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 78.97 31.97 41.57 Favored Glycine 0 CA--C 1.533 1.176 0 CA-C-N 115.738 -0.664 . . . . 71.2 112.606 -176.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.6 p -72.82 146.17 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 123.395 0.678 . . . . 73.25 110.309 179.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.526 ' HA ' HD13 ' A' ' 180' ' ' LEU . 92.7 mtt180 -123.23 177.58 5.51 Favored 'General case' 0 N--CA 1.476 0.873 0 CA-C-O 121.808 0.813 . . . . 73.44 112.851 -171.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.0 tp10 -60.09 132.94 55.48 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 113.185 -1.825 . . . . 74.23 111.325 178.021 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.36 -27.31 15.81 Favored Glycine 0 C--N 1.34 0.775 0 CA-C-O 119.381 -0.677 . . . . 60.4 112.565 179.225 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.6 m -62.57 121.26 12.88 Favored 'General case' 0 C--N 1.354 0.763 0 C-N-CA 123.433 0.693 . . . . 73.35 111.004 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.1 126.46 51.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.091 -0.707 . . . . 71.11 109.091 177.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.408 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.4 mt -95.74 103.87 15.18 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 N-CA-C 108.012 -1.107 . . . . 75.32 108.012 -176.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.579 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 53.2 ttp180 -89.02 106.73 18.62 Favored 'General case' 0 C--N 1.355 0.848 0 N-CA-C 110.342 -0.244 . . . . 74.31 110.342 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.6 t -110.48 96.9 29.44 Favored Pre-proline 0 CA--C 1.553 1.078 0 N-CA-C 108.629 -0.878 . . . . 73.33 108.629 174.565 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.46 144.19 92.47 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.137 2.558 . . . . 72.22 112.842 176.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.69 -24.33 5.92 Favored Glycine 0 CA--C 1.539 1.584 0 CA-C-O 119.549 -0.584 . . . . 74.54 114.351 176.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 17.2 mmt -90.38 -2.54 57.97 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 117.7 0.75 . . . . 75.43 111.717 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.12 -115.12 0.54 Allowed Glycine 0 C--N 1.341 0.843 0 N-CA-C 111.346 -0.702 . . . . 73.13 111.346 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.527 ' HA3' ' HG3' ' A' ' 117' ' ' ARG . . . -58.35 107.56 1.16 Allowed Glycine 0 C--N 1.354 1.555 0 CA-C-N 117.165 0.483 . . . . 61.43 113.237 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -80.03 171.57 14.92 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.937 0.895 . . . . 74.43 110.733 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 106.9 -147.07 16.14 Favored Glycine 0 N--CA 1.473 1.165 0 CA-C-O 119.619 -0.545 . . . . 64.42 111.819 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.417 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 5.6 t-20 -69.82 -52.64 13.16 Favored Pre-proline 0 CA--C 1.566 1.584 0 CA-C-O 118.146 -0.931 . . . . 75.4 111.303 178.285 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.417 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 88.0 Cg_endo -89.93 108.64 0.39 Allowed 'Trans proline' 0 C--N 1.397 3.079 0 C-N-CA 122.188 1.926 . . . . 73.21 112.907 178.557 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -66.71 127.67 17.55 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.187 2.591 . . . . 73.22 112.776 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.73 ' HA2' ' HA2' ' A' ' 116' ' ' GLY . . . -110.64 162.67 12.47 Favored Glycine 0 C--N 1.341 0.846 0 CA-C-N 115.542 -0.754 . . . . 63.23 112.915 -178.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 118' ' ' ASP . 4.6 m-20 -80.15 150.3 30.24 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.83 0.852 . . . . 74.23 110.559 178.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.579 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 62.5 tp -106.58 135.79 47.49 Favored 'General case' 0 C--O 1.216 -0.676 0 N-CA-C 108.302 -0.999 . . . . 75.21 108.302 173.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.9 mt -128.44 103.31 7.06 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 123.715 0.806 . . . . 74.3 109.293 179.143 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.521 HD11 HD13 ' A' ' 123' ' ' LEU . 83.4 mt -107.35 103.08 12.34 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 122.684 0.394 . . . . 74.01 110.92 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.64 96.88 5.72 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.732 -0.667 . . . . 73.43 109.467 -174.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -54.59 130.21 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 C-N-CA 124.888 1.275 . . . . 75.51 111.848 -177.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -123.86 100.24 6.66 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 125.344 1.458 . . . . 72.23 107.626 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.526 HD13 ' HA ' ' A' ' 154' ' ' ARG . 35.5 mt -70.06 107.91 3.84 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-O 121.168 0.509 . . . . 75.01 111.151 -176.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.415 HD13 ' HB2' ' A' ' 124' ' ' PRO . 48.7 mt -75.98 130.72 77.58 Favored Pre-proline 0 CA--C 1.553 1.083 0 N-CA-C 108.23 -1.026 . . . . 74.2 108.23 175.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.22 -63.17 0.07 OUTLIER 'Trans proline' 0 CA--C 1.559 1.749 0 C-N-CA 123.074 2.516 . . . . 72.33 113.207 -176.216 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 . . . . . 0 N--CA 1.489 1.504 0 C-N-CA 123.888 0.875 . . . . 72.34 108.902 177.684 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 27.2 ptt? . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 119.317 -0.373 . . . . 74.51 110.366 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -51.98 115.19 6.28 Favored Pre-proline 0 CA--C 1.566 1.561 0 C-N-CA 124.302 1.041 . . . . 64.34 111.667 179.306 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -74.21 -48.98 0.19 Allowed 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.386 2.058 . . . . 71.0 112.354 176.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.5 HD13 ' H ' ' A' ' 98' ' ' LEU . 7.6 tp 168.25 150.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 126.792 2.037 . . . . 74.31 106.321 -170.553 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.597 HD21 ' HB ' ' A' ' 140' ' ' VAL . 14.2 tp 57.54 -72.51 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 126.108 1.763 . . . . 75.41 111.587 -173.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.581 ' HA ' HD12 ' A' ' 119' ' ' LEU . 87.6 t80 -57.9 123.1 14.62 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.741 1.616 . . . . 72.2 111.948 172.086 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 98.9 m -145.44 99.17 4.52 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.113 0.965 . . . . 74.15 109.47 175.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -77.4 74.65 5.02 Favored 'Trans proline' 0 C--N 1.371 1.761 0 C-N-CA 122.462 2.108 . . . . 73.22 113.09 -172.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 3.6 m -78.62 176.82 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.811 0 CA-C-N 116.102 -0.499 . . . . 74.34 109.861 176.638 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 2.0 t -121.67 127.71 51.07 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.498 0.719 . . . . 65.13 109.144 176.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . 0.453 ' HE2' ' HB2' ' A' ' 115' ' ' SER . 0.0 OUTLIER -77.8 90.75 4.07 Favored 'General case' 0 C--O 1.241 0.638 0 N-CA-C 108.536 -0.913 . . . . 73.03 108.536 173.293 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -71.25 130.75 19.25 Favored Glycine 0 CA--C 1.524 0.65 0 CA-C-N 114.373 -1.285 . . . . 73.22 111.81 175.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 40.0 t -163.65 -66.0 0.04 OUTLIER 'General case' 0 C--O 1.242 0.677 0 N-CA-C 107.071 -1.455 . . . . 73.33 107.071 176.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.19 -98.4 0.04 OUTLIER Glycine 0 C--N 1.355 1.622 0 CA-C-N 114.844 -1.071 . . . . 72.44 113.662 176.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 70.44 -82.45 0.37 Allowed Glycine 0 C--N 1.353 1.473 0 C-N-CA 123.943 0.782 . . . . 64.33 111.926 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 31.9 t -143.07 97.2 3.05 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.678 -1.23 . . . . 71.14 107.678 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 91.68 -109.45 3.73 Favored Glycine 0 C--N 1.343 0.956 0 N-CA-C 111.062 -0.815 . . . . 64.11 111.062 -173.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 76.4 77.39 0.76 Allowed Glycine 0 C--N 1.347 1.162 0 N-CA-C 111.818 -0.513 . . . . 73.11 111.818 -177.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 25.8 m -62.27 -31.55 72.14 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 123.782 0.833 . . . . 72.02 112.044 -179.089 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 163.06 -62.47 0.26 Allowed Glycine 0 C--N 1.337 0.613 0 N-CA-C 111.264 -0.734 . . . . 74.2 111.264 177.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.14 -88.68 0.4 Allowed Glycine 0 C--N 1.346 1.109 0 O-C-N 124.3 0.647 . . . . 71.01 111.899 -176.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' SER . . . . . 0.453 ' HB2' ' HE2' ' A' ' 104' ' ' LYS . 12.7 m -96.16 152.99 18.04 Favored 'General case' 0 C--O 1.244 0.766 0 C-N-CA 123.745 0.818 . . . . 72.23 108.816 177.018 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -84.3 -165.31 39.04 Favored Glycine 0 N--CA 1.465 0.627 0 CA-C-N 116.1 -0.5 . . . . 72.02 113.697 -175.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 38.3 ptt180 -87.47 130.93 34.51 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 108.711 -0.848 . . . . 74.54 108.711 174.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -92.59 118.99 31.59 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 106.976 -1.49 . . . . 71.24 106.976 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.581 HD12 ' HA ' ' A' ' 99' ' ' PHE . 18.4 mt -89.73 108.68 19.83 Favored 'General case' 0 C--O 1.225 -0.228 0 N-CA-C 106.725 -1.584 . . . . 72.25 106.725 -174.241 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -117.42 107.56 14.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.113 -1.069 . . . . 70.44 108.113 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.61 140.05 50.42 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 108.577 -0.898 . . . . 51.31 108.577 -179.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.78 129.41 37.0 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 109.189 -0.671 . . . . 65.32 109.189 173.297 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.464 HD12 HD12 ' A' ' 176' ' ' LEU . 2.0 tt -100.02 109.55 56.53 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 108.749 -0.834 . . . . 75.12 108.749 -173.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.03 113.86 2.77 Favored 'Trans proline' 0 C--N 1.378 2.115 0 C-N-CA 122.116 1.877 . . . . 75.13 110.19 171.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.55 HD22 HD11 ' A' ' 149' ' ' ILE . 12.0 tp -133.21 125.91 30.43 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 108.045 -1.095 . . . . 72.44 108.045 -169.448 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 43.0 p -73.16 171.7 12.46 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 117.975 0.352 . . . . 71.41 110.69 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 96.7 mt -71.39 -23.83 61.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 123.157 0.583 . . . . 65.0 111.009 178.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -72.03 -50.68 26.5 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.634 -0.876 . . . . 72.32 108.634 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.645 ' HG3' HH21 ' A' ' 136' ' ' ARG . 29.4 mm-40 -57.55 -40.52 79.04 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.841 1.256 . . . . 74.53 111.384 176.214 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.56 64.22 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 114.965 -1.016 . . . . 73.03 111.177 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -60.73 -58.45 8.4 Favored 'General case' 0 C--N 1.349 0.564 0 O-C-N 124.679 1.237 . . . . 74.44 110.266 -176.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.8 m80 -67.66 -38.59 84.0 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 123.958 0.786 . . . . 74.12 111.047 -175.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 73.49 -112.81 4.0 Favored Glycine 0 C--N 1.343 0.947 0 N-CA-C 110.47 -1.052 . . . . 73.52 110.47 -170.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.12 -130.85 22.26 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 111.551 -0.62 . . . . 54.53 111.551 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 9.3 mp0 -121.43 157.65 30.08 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.975 0.91 . . . . 73.1 109.452 174.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.645 HH21 ' HG3' ' A' ' 129' ' ' GLU . 5.3 tpp180 -135.02 124.03 24.19 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.234 1.414 . . . . 74.41 107.975 177.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.3 p -84.9 127.09 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.091 0 C-N-CA 123.137 0.575 . . . . 72.11 110.228 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.507 HG21 HD22 ' A' ' 98' ' ' LEU . 30.7 m -140.71 158.01 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.938 1.295 . . . . 72.12 109.102 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -88.19 135.48 33.42 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 123.162 0.585 . . . . 71.34 111.284 -174.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.597 ' HB ' HD21 ' A' ' 98' ' ' LEU . 7.2 p -136.86 118.56 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 124.396 1.078 . . . . 70.44 109.288 168.25 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.39 20.29 11.74 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 123.92 0.888 . . . . 70.12 112.229 177.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.43 -9.47 66.98 Favored Glycine 0 C--N 1.358 1.78 0 C-N-CA 123.051 0.357 . . . . 54.1 113.216 -177.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -104.0 128.82 51.57 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.076 0.951 . . . . 75.2 109.983 -178.331 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.32 141.66 43.35 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.527 -0.545 . . . . 73.52 109.527 177.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.81 126.49 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.64 1.176 . . . . 74.14 108.619 178.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 44.7 m -82.49 109.82 17.05 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.396 0.678 . . . . 75.21 109.612 175.29 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.5 130.24 47.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 C-N-CA 123.999 0.92 . . . . 71.45 109.248 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -69.81 118.7 12.99 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.043 0.537 . . . . 75.22 109.96 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.55 HD11 HD22 ' A' ' 125' ' ' LEU . 17.2 pt -108.02 131.53 21.68 Favored Pre-proline 0 CA--C 1.564 1.508 0 C-N-CA 124.509 1.124 . . . . 73.41 108.866 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -62.06 140.05 82.11 Favored 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.67 2.247 . . . . 72.4 113.763 -174.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -64.61 127.55 19.12 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 123.329 2.686 . . . . 75.03 112.696 175.568 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 76.76 30.09 56.58 Favored Glycine 0 CA--C 1.528 0.847 0 O-C-N 123.49 0.494 . . . . 50.5 112.406 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.8 p -73.74 137.36 23.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.78 0 C-N-CA 122.89 0.476 . . . . 75.44 110.367 -177.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -103.67 173.31 6.36 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.135 0.969 . . . . 75.13 111.886 -171.176 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.8 tp10 -63.83 122.2 15.86 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-N 113.09 -1.868 . . . . 74.1 109.346 167.204 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 102.06 -8.39 55.67 Favored Glycine 0 N--CA 1.474 1.215 0 CA-C-O 119.758 -0.468 . . . . 74.41 113.127 178.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.0 m -78.37 121.99 25.19 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.094 0.447 . . . . 73.32 109.937 177.055 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.8 p -99.15 141.68 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 109.019 -0.734 . . . . 73.22 109.019 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.524 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 65.4 mt -108.43 104.21 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.344 1.058 . . . . 73.45 108.724 -176.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -88.68 121.12 30.72 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 123.261 0.625 . . . . 74.31 109.782 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -124.23 106.56 30.64 Favored Pre-proline 0 CA--C 1.557 1.23 0 N-CA-C 107.65 -1.241 . . . . 74.32 107.65 173.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.91 139.35 36.04 Favored 'Trans proline' 0 C--N 1.373 1.836 0 C-N-CA 122.935 2.423 . . . . 71.52 113.31 -174.647 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 77.4 0.15 71.12 Favored Glycine 0 C--N 1.352 1.426 0 CA-C-N 115.471 -0.786 . . . . 72.41 114.264 173.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 93.6 mmm -103.6 15.2 29.49 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.685 0.794 . . . . 75.32 111.712 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -94.35 -108.24 2.07 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 111.534 -0.626 . . . . 64.15 111.534 174.029 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -66.1 106.28 1.54 Allowed Glycine 0 C--N 1.344 1.011 0 C-N-CA 123.693 0.663 . . . . 71.42 112.575 175.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -83.8 165.18 19.03 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 123.75 0.82 . . . . 65.12 109.878 175.541 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 111.79 -141.6 16.71 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 111.184 -0.766 . . . . 61.31 111.184 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -76.61 -52.37 2.18 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 118.247 -0.882 . . . . 74.44 111.159 172.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -82.51 118.91 2.93 Favored 'Trans proline' 0 C--N 1.391 2.776 0 C-N-CA 121.627 1.551 . . . . 63.25 111.657 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_endo -84.9 126.71 3.41 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.718 2.279 . . . . 73.41 113.593 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -110.2 161.89 12.79 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 115.928 -0.578 . . . . 75.31 112.021 174.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -99.89 162.48 12.96 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 124.676 1.19 . . . . 72.45 110.009 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.517 HD21 HD11 ' A' ' 98' ' ' LEU . 54.3 tp -116.32 128.38 55.5 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.733 0.813 . . . . 63.54 109.796 178.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 90.7 mt -128.54 120.51 26.86 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 124.314 1.046 . . . . 75.11 109.729 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.524 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 93.7 mt -118.99 104.17 10.24 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 123.369 0.668 . . . . 75.23 110.745 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.4 t -86.22 98.5 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.982 0 CA-C-N 115.397 -0.82 . . . . 71.02 109.404 -172.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.3 t -61.29 117.0 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 123.987 0.915 . . . . 74.33 112.426 -173.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -112.88 101.08 9.16 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 126.103 1.761 . . . . 75.14 108.63 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.415 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 43.5 mt -71.49 114.25 9.37 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.148 -0.478 . . . . 70.34 110.779 -177.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 87.3 mt -61.53 146.73 89.4 Favored Pre-proline 0 CA--C 1.549 0.907 0 CA-C-N 114.752 -1.113 . . . . 61.54 110.636 178.348 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -64.39 -168.15 0.1 OUTLIER 'Trans proline' 0 C--N 1.378 2.131 0 C-N-CA 123.154 2.569 . . . . 74.32 113.81 -173.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 . . . . . 0 C--O 1.253 1.238 0 CA-C-O 118.014 -0.993 . . . . 75.52 108.664 -179.85 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.554 HD22 HG23 ' A' ' 100' ' ' THR . 3.2 pp . . . . . 0 N--CA 1.482 1.143 0 N-CA-C 111.628 0.233 . . . . 63.420000000000002 111.628 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.656 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 73.6 Cg_endo -73.71 -167.57 0.39 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.685 2.257 . . . . 72.409999999999997 111.377 171.117 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.475 HD12 ' H ' ' A' ' 98' ' ' LEU . 12.7 tp -75.96 142.69 41.91 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.603 -0.517 . . . . 51.43 109.603 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.589 HD13 HG21 ' A' ' 138' ' ' VAL . 6.3 tp 68.89 -57.98 0.5 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 126.95 2.1 . . . . 74.450000000000003 112.02 -167.626 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.656 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 65.7 t80 -72.65 135.33 45.44 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.697 1.199 . . . . 72.319999999999993 112.534 -173.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.554 HG23 HD22 ' A' ' 95' ' ' LEU . 55.4 m -153.97 101.25 2.49 Favored Pre-proline 0 CA--C 1.544 0.74 0 C-N-CA 123.985 0.914 . . . . 62.149999999999999 109.895 177.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -76.08 83.0 2.06 Favored 'Trans proline' 0 C--N 1.369 1.611 0 C-N-CA 122.128 1.885 . . . . 64.519999999999996 112.304 -173.265 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.529 HG13 HG22 ' A' ' 100' ' ' THR . 30.1 m . . . . . 0 CA--C 1.538 0.497 0 CA-C-N 114.935 -1.03 . . . . 65.549999999999997 109.729 173.317 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 . . . . . 0 N--CA 1.472 0.653 0 N-CA-C 108.948 -0.76 . . . . 63.229999999999997 108.948 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -93.31 104.41 16.58 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.561 -1.274 . . . . 64.329999999999998 107.561 -177.018 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.574 HD13 ' HA ' ' A' ' 99' ' ' PHE . 10.3 mt -94.08 109.78 21.52 Favored 'General case' 0 C--N 1.342 0.253 0 N-CA-C 107.093 -1.447 . . . . 71.120000000000005 107.093 -177.525 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.8 ttt180 -108.63 109.71 20.98 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.702 -0.481 . . . . 73.349999999999994 109.702 176.036 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -122.95 144.76 49.02 Favored 'General case' 0 C--O 1.242 0.693 0 N-CA-C 109.116 -0.698 . . . . 32.240000000000002 109.116 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -81.81 122.41 27.67 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.957 -1.127 . . . . 74.540000000000006 107.957 177.329 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.457 HD11 ' HG2' ' A' ' 136' ' ' ARG . 47.3 tp -99.32 103.38 20.2 Favored Pre-proline 0 CA--C 1.542 0.645 0 C-N-CA 123.565 0.746 . . . . 72.319999999999993 110.083 -171.761 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.13 114.39 3.97 Favored 'Trans proline' 0 C--N 1.374 1.894 0 C-N-CA 121.956 1.77 . . . . 72.340000000000003 110.017 176.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.536 HD21 HD12 ' A' ' 149' ' ' ILE . 14.2 tp -136.06 122.45 20.62 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 109.155 -0.683 . . . . 74.430000000000007 109.155 -168.401 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 3.0 m -69.61 162.31 27.87 Favored 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.987 0.915 . . . . 74.239999999999995 111.121 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 69.3 mt -63.93 -36.39 83.79 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.017 0.527 . . . . 73.310000000000002 112.37 -177.122 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -69.21 -40.19 78.15 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.292 0.637 . . . . 73.219999999999999 109.38 179.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.481 ' HG3' ' NH2' ' A' ' 136' ' ' ARG . 24.6 mm-40 -62.64 -44.27 96.7 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.477 1.111 . . . . 73.129999999999995 110.531 177.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.89 -37.29 78.93 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 115.158 -0.928 . . . . 73.109999999999999 111.408 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.5 t80 -65.84 -49.26 68.82 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.452 1.501 . . . . 71.430000000000007 110.881 -178.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -80.24 -41.22 25.51 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 115.28 -0.873 . . . . 73.209999999999994 111.157 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.528 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.36 58.35 8.83 Favored Glycine 0 C--N 1.345 1.073 0 O-C-N 123.543 0.527 . . . . 65.400000000000006 113.085 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -94.51 -130.69 6.0 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 110.966 -0.854 . . . . 75.310000000000002 110.966 174.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -107.76 160.3 15.83 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.284 0.564 . . . . 64.409999999999997 110.046 169.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.481 ' NH2' ' HG3' ' A' ' 129' ' ' GLU . 5.5 tpp180 -133.02 121.92 23.44 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.495 -1.298 . . . . 73.340000000000003 107.495 172.703 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 62.9 t -72.8 124.34 29.44 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-O 121.082 0.468 . . . . 73.340000000000003 110.084 175.236 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.589 HG21 HD13 ' A' ' 98' ' ' LEU . 32.9 m -127.33 145.2 35.19 Favored 'Isoleucine or valine' 0 C--O 1.251 1.142 0 C-N-CA 125.08 1.352 . . . . 74.219999999999999 108.105 -177.356 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -104.23 106.28 16.73 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.166 -0.679 . . . . 72.349999999999994 109.166 -176.307 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.609 HG13 ' HB2' ' A' ' 143' ' ' ARG . 2.4 p -106.45 100.18 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.829 0.851 . . . . 50.340000000000003 109.411 -176.135 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.92 23.91 14.26 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.426 0.691 . . . . 54.340000000000003 111.927 177.009 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.27 2.91 56.74 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 116.02 -0.537 . . . . 52.340000000000003 112.924 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.609 ' HB2' HG13 ' A' ' 140' ' ' VAL . 48.0 mtp180 -100.56 119.91 39.24 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 108.948 -0.76 . . . . 62.420000000000002 108.948 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.0 tmm_? -81.79 107.37 14.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.002 -0.74 . . . . 52.520000000000003 109.002 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 24.4 m -124.92 156.37 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 C-N-CA 123.701 0.8 . . . . 73.540000000000006 109.776 176.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.6 p -107.96 119.12 38.55 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 123.147 0.579 . . . . 73.450000000000003 110.192 174.252 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.0 p -99.16 132.28 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.671 -0.492 . . . . 64.25 109.671 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -80.36 120.19 24.07 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.877 0.37 . . . . 74.230000000000004 110.162 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.536 HD12 HD21 ' A' ' 125' ' ' LEU . 7.5 pt -95.08 142.01 24.03 Favored Pre-proline 0 CA--C 1.556 1.182 0 C-N-CA 124.135 0.974 . . . . 71.530000000000001 109.341 179.111 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -72.56 143.86 39.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.267 1.978 . . . . 74.329999999999998 112.5 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.33 133.54 19.43 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 122.633 2.222 . . . . 73.129999999999995 111.915 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.84 30.01 53.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.64 -0.709 . . . . 61.140000000000001 113.253 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 8.2 p -82.72 148.09 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 117.363 0.581 . . . . 72.049999999999997 109.634 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 -126.47 177.71 6.31 Favored 'General case' 0 N--CA 1.479 0.988 0 CA-C-O 121.567 0.699 . . . . 73.510000000000005 112.122 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.6 tp10 -61.37 129.17 39.88 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 113.835 -1.53 . . . . 75.409999999999997 110.78 177.109 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.66 4.66 90.0 Favored Glycine 0 C--N 1.344 0.984 0 O-C-N 123.701 0.626 . . . . 54.130000000000003 113.551 178.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 67.0 m -82.23 119.67 24.38 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 117.444 0.622 . . . . 72.530000000000001 109.457 175.619 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.3 p -98.55 125.29 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-O 121.213 0.53 . . . . 35.299999999999997 110.054 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.8 mt -91.75 104.03 15.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 C-N-CA 124.334 1.053 . . . . 72.549999999999997 108.173 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.464 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 74.8 ttt180 -94.45 114.66 26.72 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 110.139 -0.319 . . . . 73.549999999999997 110.139 -177.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 19.5 t -122.85 98.4 42.77 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 123.59 0.756 . . . . 73.430000000000007 109.092 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.06 125.72 12.86 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.931 2.421 . . . . 72.510000000000005 112.74 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 104.64 -24.49 28.46 Favored Glycine 0 N--CA 1.474 1.19 0 CA-C-O 120.151 -0.25 . . . . 62.310000000000002 113.167 176.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.3 ttm -89.57 -18.92 25.66 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.362 0.665 . . . . 72.340000000000003 111.338 -174.556 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -69.8 -100.76 0.04 OUTLIER Glycine 0 C--N 1.346 1.103 0 CA-C-O 119.677 -0.513 . . . . 74.109999999999999 113.197 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -53.36 107.78 0.65 Allowed Glycine 0 C--N 1.355 1.59 0 C-N-CA 123.103 0.383 . . . . 70.329999999999998 113.248 179.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 13.0 mm-40 -84.76 169.53 14.13 Favored 'General case' 0 C--O 1.237 0.431 0 C-N-CA 123.602 0.761 . . . . 73.319999999999993 110.096 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 108.33 -138.47 14.67 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.716 -0.675 . . . . 60.030000000000001 111.672 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.437 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 58.0 t30 -77.15 -51.55 2.02 Favored Pre-proline 0 CA--C 1.569 1.706 0 CA-C-O 118.285 -0.864 . . . . 73.349999999999994 111.541 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.437 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 72.8 Cg_endo -95.29 109.79 0.13 Allowed 'Trans proline' 0 C--N 1.394 2.958 0 C-N-CA 122.38 2.053 . . . . 62.219999999999999 112.746 177.239 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -60.45 125.95 18.72 Favored 'Trans proline' 0 C--N 1.381 2.261 0 C-N-CA 122.512 2.141 . . . . 61.119999999999997 111.654 175.072 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -112.27 177.33 18.51 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 116.412 -0.358 . . . . 72.230000000000004 113.88 -176.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.23 146.13 28.75 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.762 0.825 . . . . 72.120000000000005 110.318 -175.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 59.0 tp -113.38 134.51 54.6 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.196 0.598 . . . . 72.0 109.846 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 76.3 mt -129.61 105.2 7.9 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.437 1.095 . . . . 75.439999999999998 109.301 176.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.474 HD21 HD12 ' A' ' 98' ' ' LEU . 68.0 mt -107.55 102.73 11.96 Favored 'General case' 0 N--CA 1.479 1.013 0 O-C-N 122.109 -0.37 . . . . 62.439999999999998 110.009 174.687 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.7 t -85.93 99.04 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 N-CA-C 108.369 -0.974 . . . . 74.150000000000006 108.369 -175.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 87.0 t -56.23 116.81 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.45 1.1 . . . . 73.519999999999996 111.724 -177.078 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -113.07 104.21 12.15 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 125.576 1.551 . . . . 71.209999999999994 107.784 177.37 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 74.8 mt -69.39 130.38 42.38 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 122.918 0.487 . . . . 60.350000000000001 111.526 -174.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 92.1 mt -84.84 139.02 37.31 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.53 0.732 . . . . 72.439999999999998 110.128 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -65.38 116.54 3.95 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 123.193 2.595 . . . . 54.329999999999998 112.021 -175.059 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.543 -0.741 . . . . 73.319999999999993 109.415 -178.185 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.527 ' HB3' ' HA ' ' A' ' 100' ' ' THR . 0.5 OUTLIER . . . . . 0 CA--C 1.554 1.116 0 N-CA-C 109.058 -0.719 . . . . 65.239999999999995 109.058 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -66.62 -49.27 1.73 Allowed 'Trans proline' 0 C--N 1.385 2.498 0 C-N-CA 122.612 2.208 . . . . 70.329999999999998 111.691 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.526 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.4 tp -179.52 154.36 0.61 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.627 1.571 . . . . 74.140000000000001 106.945 -175.261 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.553 HD11 HD21 ' A' ' 174' ' ' LEU . 7.4 tp 53.04 -75.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 125.976 1.71 . . . . 63.229999999999997 111.551 -174.515 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.74 ' HA ' HD13 ' A' ' 119' ' ' LEU . 85.4 t80 -50.54 129.18 21.84 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.097 1.759 . . . . 74.310000000000002 112.341 171.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.557 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 55.2 m -142.18 105.99 5.65 Favored Pre-proline 0 N--CA 1.471 0.587 0 C-N-CA 124.105 0.962 . . . . 71.030000000000001 108.442 172.436 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -76.85 87.55 1.47 Allowed 'Trans proline' 0 C--N 1.366 1.453 0 C-N-CA 121.517 1.478 . . . . 64.430000000000007 112.42 -170.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 CA--C 1.546 0.791 0 CA-C-N 114.735 -1.12 . . . . 74.230000000000004 109.995 177.425 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.431 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 94.2 mtt180 . . . . . 0 N--CA 1.476 0.862 0 N-CA-C 110.077 -0.342 . . . . 73.150000000000006 110.077 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.7 105.95 18.17 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 107.345 -1.354 . . . . 65.310000000000002 107.345 -177.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.74 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.5 mt -92.87 108.96 20.4 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 107.26 -1.385 . . . . 71.400000000000006 107.26 -176.778 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 74.4 ttt180 -119.33 105.87 11.74 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.131 0.972 . . . . 73.140000000000001 108.663 -175.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.58 145.23 40.34 Favored 'General case' 0 C--O 1.242 0.67 0 C-N-CA 123.722 0.809 . . . . 53.100000000000001 109.567 -174.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -76.66 137.59 39.52 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.536 -0.542 . . . . 64.019999999999996 109.536 175.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.411 ' HA ' ' HD2' ' A' ' 124' ' ' PRO . 19.9 tp -101.62 105.36 40.27 Favored Pre-proline 0 CA--C 1.542 0.671 0 C-N-CA 123.992 0.917 . . . . 71.310000000000002 110.201 -178.357 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 123' ' ' LEU . 23.5 Cg_endo -60.64 122.78 11.8 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.488 2.125 . . . . 74.109999999999999 110.342 169.12 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.468 HD21 HD12 ' A' ' 149' ' ' ILE . 25.3 tp -147.83 133.79 19.17 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.889 -0.782 . . . . 73.329999999999998 108.889 -175.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.9 p -81.21 163.66 22.86 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 110.129 -0.323 . . . . 72.120000000000005 110.129 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.0 mt -61.92 -32.7 73.13 Favored 'General case' 0 N--CA 1.482 1.168 0 C-N-CA 123.607 0.763 . . . . 63.210000000000001 110.971 179.537 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -70.72 -50.23 38.51 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 114.987 -1.006 . . . . 75.150000000000006 109.406 -177.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -70.13 -26.65 64.05 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.794 0.837 . . . . 73.219999999999999 111.859 -179.197 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.75 -40.31 69.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.216 0.606 . . . . 75.430000000000007 110.744 174.437 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -64.43 -46.4 83.36 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.911 0.884 . . . . 64.439999999999998 110.698 175.504 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -63.36 -49.67 72.96 Favored 'General case' 0 C--N 1.351 0.671 0 O-C-N 123.71 0.631 . . . . 73.219999999999999 110.362 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.505 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 56.63 70.39 0.99 Allowed Glycine 0 C--N 1.349 1.276 0 O-C-N 124.128 0.893 . . . . 75.109999999999999 112.771 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -121.06 -121.37 2.81 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.35 -1.1 . . . . 72.400000000000006 110.35 174.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.557 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 7.0 mp0 -99.69 154.96 17.88 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 123.143 0.577 . . . . 42.329999999999998 109.528 172.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.458 ' HB2' HD13 ' A' ' 149' ' ' ILE . 14.0 tpt180 -137.04 122.55 19.61 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 108.162 -1.051 . . . . 75.420000000000002 108.162 178.479 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.1 t -74.34 119.44 21.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 O-C-N 123.577 0.548 . . . . 75.140000000000001 109.886 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.548 HG21 HD13 ' A' ' 98' ' ' LEU . 28.5 m -122.68 147.38 26.89 Favored 'Isoleucine or valine' 0 C--O 1.251 1.147 0 C-N-CA 124.769 1.228 . . . . 55.210000000000001 109.067 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -100.91 127.83 47.22 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.987 0.915 . . . . 74.109999999999999 109.268 -177.178 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.562 HG23 ' HB2' ' A' ' 99' ' ' PHE . 3.1 p -142.66 103.67 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 123.287 0.635 . . . . 72.540000000000006 111.118 -174.614 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 55.38 29.69 13.55 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 124.448 1.099 . . . . 64.409999999999997 113.14 172.029 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.65 26.34 10.85 Favored Glycine 0 C--N 1.348 1.248 0 CA-C-N 116.36 -0.382 . . . . 41.100000000000001 112.658 179.153 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.496 ' HB2' HG13 ' A' ' 140' ' ' VAL . 54.3 mmt-85 -131.87 136.18 47.25 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.842 0.857 . . . . 72.420000000000002 110.049 -178.417 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 16.1 ttp180 -95.67 105.88 17.92 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 107.917 -1.142 . . . . 75.329999999999998 107.917 171.249 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 33.0 m -125.44 151.37 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 109.915 -0.402 . . . . 31.219999999999999 109.915 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.557 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 34.6 p -106.11 117.65 34.58 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.296 0.638 . . . . 72.340000000000003 109.924 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.2 p -98.8 133.35 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 108.664 -0.865 . . . . 72.219999999999999 108.664 176.367 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.4 ttt85 -82.4 125.74 31.39 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.203 0.525 . . . . 65.519999999999996 109.754 -178.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.505 HG13 ' HA2' ' A' ' 133' ' ' GLY . 3.3 pt -107.56 145.8 32.04 Favored Pre-proline 0 CA--C 1.557 1.219 0 C-N-CA 124.882 1.273 . . . . 53.420000000000002 108.686 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.43 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 56.7 Cg_endo -71.08 146.56 52.38 Favored 'Trans proline' 0 CA--C 1.566 2.099 0 C-N-CA 122.161 1.907 . . . . 72.310000000000002 112.823 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 23.9 Cg_exo -66.79 134.95 36.57 Favored 'Trans proline' 0 C--N 1.38 2.23 0 C-N-CA 123.172 2.581 . . . . 64.099999999999994 111.962 172.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.16 28.03 62.95 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-N 115.724 -0.671 . . . . 74.109999999999999 113.024 -177.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.43 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 14.7 p -78.19 147.2 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.256 -0.646 . . . . 74.129999999999995 109.256 177.238 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -129.61 177.23 7.37 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 122.011 0.91 . . . . 62.109999999999999 113.085 -167.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.5 tp10 -62.58 121.4 13.23 Favored 'General case' 0 C--O 1.241 0.644 0 CA-C-N 113.463 -1.699 . . . . 74.040000000000006 110.414 174.385 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.73 2.83 69.21 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 115.892 -0.595 . . . . 60.399999999999999 112.822 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 59.5 m -86.39 122.04 29.79 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 109.458 -0.571 . . . . 73.329999999999998 109.458 174.028 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.5 p -101.23 126.35 55.05 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.232 0.539 . . . . 74.409999999999997 110.051 178.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 60.7 mt -93.94 102.92 14.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.941 1.296 . . . . 70.409999999999997 107.914 176.32 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -98.38 121.62 40.53 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.956 -0.387 . . . . 75.329999999999998 109.956 -179.09 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 4.2 t -115.47 99.62 52.64 Favored Pre-proline 0 CA--C 1.556 1.192 0 N-CA-C 107.692 -1.225 . . . . 74.530000000000001 107.692 173.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -68.25 131.39 23.36 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 123.098 2.532 . . . . 60.25 113.63 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 75.87 24.07 70.51 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.085 -0.962 . . . . 45.030000000000001 113.784 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.7 tpt -126.28 -9.2 6.4 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 123.62 0.768 . . . . 71.420000000000002 111.21 -176.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -71.11 -94.7 0.07 OUTLIER Glycine 0 C--N 1.347 1.172 0 CA-C-O 120.175 -0.236 . . . . 74.340000000000003 112.848 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -68.84 106.96 1.91 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.966 -0.352 . . . . 44.420000000000002 112.433 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -72.43 137.46 46.48 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.647 0.779 . . . . 71.230000000000004 111.013 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.2 -163.75 32.55 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 116.006 -0.543 . . . . 75.420000000000002 112.157 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -72.94 -43.95 8.17 Favored Pre-proline 0 CA--C 1.565 1.537 0 CA-C-O 118.968 -0.539 . . . . 73.299999999999997 110.725 174.172 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -93.34 108.37 0.18 Allowed 'Trans proline' 0 C--N 1.386 2.511 0 C-N-CA 122.081 1.854 . . . . 73.319999999999993 111.254 163.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -82.74 137.67 8.99 Favored 'Trans proline' 0 C--N 1.372 1.807 0 C-N-CA 122.361 2.041 . . . . 62.140000000000001 112.243 -178.598 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' GLY . . . . . 0.431 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -99.04 179.93 31.36 Favored Glycine 0 C--N 1.343 0.935 0 CA-C-N 115.933 -0.576 . . . . 45.420000000000002 113.14 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -87.88 149.03 24.34 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 122.844 0.458 . . . . 74.0 111.239 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.553 HD21 HD11 ' A' ' 98' ' ' LEU . 41.8 tp -112.42 128.64 56.37 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 122.844 0.458 . . . . 74.549999999999997 109.915 177.301 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 74.3 mt -127.46 115.48 18.96 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 124.196 0.998 . . . . 72.510000000000005 109.157 178.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.5 HD21 HD12 ' A' ' 98' ' ' LEU . 72.9 mt -117.07 103.42 10.22 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 123.178 0.591 . . . . 75.319999999999993 110.489 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.6 t -89.79 98.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.072 0 C-N-CA 122.524 0.33 . . . . 73.0 110.331 -173.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.8 t -60.09 113.87 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 C-N-CA 124.203 1.001 . . . . 55.539999999999999 112.694 -173.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 22.1 mmm180 -105.0 109.14 21.01 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.126 1.77 . . . . 73.030000000000001 108.649 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 86.6 mt -71.87 119.0 15.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.387 0.275 . . . . 74.140000000000001 110.449 179.152 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 78.4 mt -79.05 147.35 69.63 Favored Pre-proline 0 CA--C 1.545 0.784 0 C-N-CA 123.693 0.797 . . . . 54.32 110.79 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -61.1 110.0 0.79 Allowed 'Trans proline' 0 C--N 1.373 1.82 0 C-N-CA 123.368 2.712 . . . . 75.329999999999998 111.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 77.6 t60 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.733 -0.651 . . . . 63.240000000000002 110.289 178.507 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.562 1.426 0 N-CA-C 114.26 1.207 . . . . 65.040000000000006 114.26 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.66 -66.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.388 2.65 0 C-N-CA 122.738 2.292 . . . . 74.120000000000005 111.477 174.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.2 tp -178.89 149.44 0.45 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 125.236 1.414 . . . . 63.130000000000003 107.809 175.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.663 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 13.2 tp 56.99 8.6 0.52 Allowed 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 124.422 1.089 . . . . 74.439999999999998 112.494 -174.678 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.642 ' HA ' HD13 ' A' ' 119' ' ' LEU . 77.2 t80 -150.87 124.49 9.05 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 123.927 0.891 . . . . 74.200000000000003 109.261 -165.608 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.602 ' H ' HD22 ' A' ' 119' ' ' LEU . 95.7 m -150.5 95.24 3.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 C-N-CA 124.639 1.175 . . . . 75.109999999999999 108.155 176.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.6 104.65 1.16 Allowed 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 121.921 1.748 . . . . 55.130000000000003 110.804 -176.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.8 m . . . . . 0 C--O 1.244 0.789 0 C-N-CA 123.793 0.837 . . . . 75.510000000000005 109.466 178.307 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 24.2 ptt180 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.687 0.279 . . . . 64.219999999999999 110.922 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -92.61 114.71 27.34 Favored 'General case' 0 C--N 1.348 0.519 0 N-CA-C 107.686 -1.227 . . . . 72.310000000000002 107.686 175.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.642 HD13 ' HA ' ' A' ' 99' ' ' PHE . 31.2 mt -93.44 107.22 19.1 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 106.991 -1.485 . . . . 64.049999999999997 106.991 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.485 ' H ' ' HB ' ' A' ' 100' ' ' THR . 19.6 ttt180 -116.0 105.83 13.09 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.03 -0.73 . . . . 72.310000000000002 109.03 178.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 141.36 48.17 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.829 0.852 . . . . 45.210000000000001 108.772 -177.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.14 129.6 34.62 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.372 -0.603 . . . . 73.129999999999995 109.372 174.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.483 HD12 HD13 ' A' ' 176' ' ' LEU . 1.7 tt -101.6 109.64 59.75 Favored Pre-proline 0 CA--C 1.55 0.965 0 C-N-CA 123.479 0.712 . . . . 70.439999999999998 109.379 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -67.4 121.82 8.98 Favored 'Trans proline' 0 C--N 1.377 2.079 0 C-N-CA 122.559 2.173 . . . . 71.409999999999997 110.954 172.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.1 tp -140.67 135.09 31.29 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 108.805 -0.813 . . . . 73.120000000000005 108.805 -173.262 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.5 p -76.15 167.12 22.44 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.892 -0.41 . . . . 71.329999999999998 109.892 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.516 HD12 ' HB2' ' A' ' 183' ' ' HIS . 86.6 mt -66.77 -31.11 71.54 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.033 0.533 . . . . 74.140000000000001 110.644 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -71.11 -49.49 43.79 Favored 'General case' 0 C--O 1.22 -0.497 0 CA-C-N 114.701 -1.136 . . . . 71.310000000000002 109.135 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -74.35 -19.6 60.39 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.405 0.682 . . . . 71.340000000000003 111.452 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.54 -45.21 72.78 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.138 0.575 . . . . 52.329999999999998 109.853 167.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.03 -41.37 95.32 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 123.938 0.895 . . . . 75.109999999999999 111.006 176.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -75.48 -39.76 58.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.131 0.572 . . . . 74.329999999999998 110.679 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.25 -114.11 6.26 Favored Glycine 0 C--N 1.345 1.081 0 CA-C-N 115.273 -0.876 . . . . 73.109999999999999 111.207 -172.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.12 -132.71 39.58 Favored Glycine 0 C--N 1.351 1.382 0 CA-C-O 119.668 -0.518 . . . . 75.150000000000006 112.413 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.575 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 10.3 mp0 -105.75 158.22 16.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.847 0.859 . . . . 75.140000000000001 109.958 176.246 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.632 ' HB2' HD13 ' A' ' 149' ' ' ILE . 23.4 tpt85 -133.91 120.87 20.92 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.733 0.813 . . . . 72.519999999999996 109.063 178.452 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.6 t -74.88 109.08 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 C-N-CA 124.165 0.986 . . . . 73.510000000000005 109.626 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.49 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 26.1 m -128.03 149.15 32.68 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 C-N-CA 124.075 0.95 . . . . 72.450000000000003 110.098 -174.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -97.73 103.75 15.72 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 123.649 0.78 . . . . 63.130000000000003 111.322 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.663 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.3 p -103.94 102.26 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.103 0.961 . . . . 71.140000000000001 109.569 -179.03 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.93 27.74 17.16 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 124.321 1.049 . . . . 63.509999999999998 112.201 177.564 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.54 -13.09 59.78 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-O 119.317 -0.713 . . . . 71.010000000000005 114.227 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.23 152.25 19.32 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 118.164 0.982 . . . . 74.109999999999999 110.093 177.165 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 -100.17 109.01 21.27 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.587 0.755 . . . . 61.140000000000001 109.602 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 86.3 t -122.66 136.84 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 N-CA-C 108.572 -0.899 . . . . 74.140000000000001 108.572 175.746 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.575 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 77.5 p -95.5 113.09 24.72 Favored 'General case' 0 C--O 1.242 0.658 0 N-CA-C 109.168 -0.679 . . . . 60.530000000000001 109.168 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -97.84 136.48 28.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 123.57 0.748 . . . . 53.539999999999999 109.216 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -81.03 127.27 32.41 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.369 0.605 . . . . 64.120000000000005 110.568 -176.439 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.632 HD13 ' HB2' ' A' ' 136' ' ' ARG . 7.5 pt -118.07 145.32 36.62 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.658 1.583 . . . . 73.040000000000006 108.43 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.04 138.2 27.8 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.456 2.104 . . . . 73.5 112.599 178.082 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.73 143.66 51.7 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.336 2.024 . . . . 63.420000000000002 111.544 169.012 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.0 26.48 58.11 Favored Glycine 0 C--N 1.343 0.932 0 CA-C-N 116.278 -0.419 . . . . 53.219999999999999 112.897 -173.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.6 p -87.58 150.85 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 C-N-CA 123.2 0.6 . . . . 71.340000000000003 109.869 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 42.6 mtp180 -123.16 177.86 5.36 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 121.722 0.773 . . . . 75.409999999999997 112.358 -177.104 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -58.37 137.27 57.35 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 113.282 -1.781 . . . . 75.409999999999997 111.038 174.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.76 -14.15 38.55 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-O 119.352 -0.693 . . . . 30.23 113.976 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 63.5 m -71.11 118.37 13.81 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 117.558 0.679 . . . . 74.239999999999995 109.593 -179.104 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.65 132.52 42.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 122.99 0.516 . . . . 64.430000000000007 109.716 -179.521 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.06 104.65 16.93 Favored 'Isoleucine or valine' 0 C--O 1.241 0.606 0 C-N-CA 124.876 1.27 . . . . 65.040000000000006 107.588 -177.456 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.426 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 64.7 ttt180 -91.61 112.64 24.65 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 109.94 -0.393 . . . . 74.120000000000005 109.94 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 8.6 t -104.11 100.12 19.78 Favored Pre-proline 0 CA--C 1.557 1.219 0 N-CA-C 106.989 -1.485 . . . . 74.209999999999994 106.989 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -66.63 128.83 19.8 Favored 'Trans proline' 0 C--N 1.375 1.943 0 C-N-CA 122.878 2.385 . . . . 70.109999999999999 113.096 -174.364 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.56 22.78 78.13 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.939 -0.573 . . . . 73.540000000000006 114.207 176.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.1 tpt -107.45 -23.96 11.99 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 123.385 0.674 . . . . 51.450000000000003 110.969 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -66.45 -84.14 0.1 OUTLIER Glycine 0 C--N 1.344 1.024 0 CA-C-N 116.359 -0.382 . . . . 73.200000000000003 112.865 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -71.46 93.09 0.52 Allowed Glycine 0 C--N 1.346 1.109 0 N-CA-C 111.466 -0.653 . . . . 61.299999999999997 111.466 173.754 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 15.3 mm100 -78.78 143.61 35.94 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.757 0.823 . . . . 61.409999999999997 111.756 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.13 -168.24 25.78 Favored Glycine 0 C--O 1.241 0.583 0 CA-C-N 114.8 -1.091 . . . . 65.0 110.377 -177.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 17.3 m120 -62.16 -44.37 88.79 Favored Pre-proline 0 CA--C 1.562 1.416 0 CA-C-O 118.655 -0.688 . . . . 75.430000000000007 110.82 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -82.96 114.43 2.26 Favored 'Trans proline' 0 C--N 1.394 2.972 0 C-N-CA 121.872 1.714 . . . . 74.340000000000003 111.717 167.627 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -82.94 150.27 14.03 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.222 1.948 . . . . 63.310000000000002 113.059 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -132.84 151.66 20.07 Favored Glycine 0 N--CA 1.473 1.123 0 N-CA-C 110.326 -1.109 . . . . 42.240000000000002 110.326 170.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.58 156.06 39.39 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.489 0.715 . . . . 51.43 112.49 -175.417 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.507 HD21 HD11 ' A' ' 98' ' ' LEU . 65.5 tp -116.22 127.94 55.19 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 108.428 -0.953 . . . . 75.510000000000005 108.428 172.783 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 54.5 mt -128.26 118.34 23.11 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 124.825 1.25 . . . . 63.030000000000001 108.689 -178.088 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.483 HD13 HD12 ' A' ' 123' ' ' LEU . 86.1 mt -120.68 103.31 9.02 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 123.061 0.545 . . . . 71.310000000000002 111.043 -178.298 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.9 t -85.43 96.02 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.587 -0.523 . . . . 74.519999999999996 109.587 -176.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.4 t -55.5 126.76 13.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.921 0.888 . . . . 51.350000000000001 111.807 -178.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -112.48 113.12 25.14 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 125.19 1.396 . . . . 74.340000000000003 107.687 177.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 50.3 mt -74.56 119.53 18.88 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.255 -0.646 . . . . 75.430000000000007 109.255 176.032 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 67.0 mt -82.33 131.24 56.46 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 108.317 -0.994 . . . . 72.25 108.317 176.334 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -68.31 143.03 56.87 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.961 2.441 . . . . 62.409999999999997 112.284 -174.752 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.516 ' HB2' HD12 ' A' ' 127' ' ' LEU . 47.0 m80 . . . . . 0 N--CA 1.485 1.319 0 C-N-CA 124.03 0.932 . . . . 62.119999999999997 108.806 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.429 ' HB2' ' O ' ' A' ' 99' ' ' PHE . 2.6 pt? . . . . . 0 CA--C 1.563 1.452 0 N-CA-C 112.238 0.459 . . . . 70.439999999999998 112.238 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.431 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 10.3 Cg_endo -86.75 -79.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 123.009 2.473 . . . . 74.109999999999999 111.248 177.691 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.475 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.5 tp -157.83 142.23 16.18 Favored 'General case' 0 C--N 1.348 0.521 0 N-CA-C 108.292 -1.003 . . . . 63.409999999999997 108.292 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.712 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 5.2 tp 57.09 7.75 0.46 Allowed 'General case' 0 CA--C 1.57 1.713 0 C-N-CA 126.096 1.758 . . . . 53.210000000000001 113.172 -173.099 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.647 ' HA ' HD13 ' A' ' 119' ' ' LEU . 86.7 t80 -139.12 128.79 24.63 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.825 0.85 . . . . 63.310000000000002 109.333 -171.025 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.534 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 86.2 m -153.05 98.62 2.76 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 124.192 0.997 . . . . 74.439999999999998 109.342 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -72.16 83.18 1.23 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.444 2.096 . . . . 75.510000000000005 112.242 -173.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 20.6 m . . . . . 0 N--CA 1.474 0.75 0 CA-C-N 115.406 -0.816 . . . . 75.129999999999995 109.691 175.385 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.503 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.0 OUTLIER . . . . . 0 N--CA 1.479 0.992 0 N-CA-C 110.209 -0.293 . . . . 62.43 110.209 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -95.35 107.32 19.44 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 107.086 -1.45 . . . . 73.450000000000003 107.086 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.647 HD13 ' HA ' ' A' ' 99' ' ' PHE . 15.7 mt -92.76 108.46 20.0 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 107.593 -1.262 . . . . 64.25 107.593 -174.281 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.518 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 20.8 ttt180 -106.17 104.71 14.47 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 109.049 -0.723 . . . . 65.140000000000001 109.049 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -123.19 134.34 54.17 Favored 'General case' 0 C--O 1.237 0.411 0 N-CA-C 108.929 -0.767 . . . . 51.439999999999998 108.929 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -80.87 121.78 26.39 Favored 'General case' 0 C--O 1.241 0.637 0 N-CA-C 108.254 -1.017 . . . . 61.310000000000002 108.254 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.572 HD21 ' HG2' ' A' ' 136' ' ' ARG . 5.5 tt -99.06 109.74 55.26 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 108.159 -1.052 . . . . 70.109999999999999 108.159 -171.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -72.75 115.23 4.26 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 121.904 1.736 . . . . 62.240000000000002 110.443 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.604 HD21 HD12 ' A' ' 149' ' ' ILE . 29.0 tp -128.81 137.51 51.55 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.601 0.76 . . . . 73.209999999999994 109.498 -173.438 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 74.3 p -79.87 162.62 24.91 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.11 -0.33 . . . . 35.200000000000003 110.11 -178.631 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.97 -26.95 65.3 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.393 0.677 . . . . 73.239999999999995 110.962 -178.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -68.55 -50.31 52.82 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 114.934 -1.03 . . . . 62.109999999999999 109.093 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 -73.63 -21.23 60.36 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 114.991 -1.004 . . . . 74.349999999999994 112.324 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.09 -44.89 64.76 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.991 0.517 . . . . 72.219999999999999 109.74 170.665 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -62.13 -42.35 99.16 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.666 1.186 . . . . 72.340000000000003 110.921 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -74.42 -48.8 25.51 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.607 0.363 . . . . 73.519999999999996 110.427 -178.493 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.604 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 62.49 52.34 49.73 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 123.997 0.81 . . . . 74.109999999999999 113.853 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -101.37 -130.49 7.06 Favored Glycine 0 C--N 1.347 1.148 0 N-CA-C 111.452 -0.659 . . . . 62.509999999999998 111.452 177.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -97.28 158.61 15.37 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.072 0.549 . . . . 72.530000000000001 110.149 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.572 ' HG2' HD21 ' A' ' 123' ' ' LEU . 41.0 tpt85 -136.84 119.69 16.3 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.214 -0.903 . . . . 74.519999999999996 108.975 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.8 t -86.39 105.96 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 123.397 0.679 . . . . 70.209999999999994 109.643 -177.143 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.52 HG21 HD13 ' A' ' 98' ' ' LEU . 34.3 m -117.01 162.6 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.001 1.321 . . . . 70.299999999999997 108.345 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -123.98 112.69 17.49 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 122.497 0.319 . . . . 73.450000000000003 111.263 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.712 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.9 p -106.46 105.44 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 124.469 1.107 . . . . 75.400000000000006 109.965 -178.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 58.02 28.74 16.71 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.633 0.773 . . . . 61.130000000000003 112.122 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.25 2.76 55.74 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-O 119.566 -0.574 . . . . 75.239999999999995 114.069 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.6 mtt180 -100.73 121.8 42.27 Favored 'General case' 0 N--CA 1.486 1.349 0 CA-C-N 117.735 0.767 . . . . 64.519999999999996 110.724 -178.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -74.96 126.32 30.75 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.463 0.705 . . . . 74.030000000000001 109.319 172.241 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 3.2 p -148.79 131.0 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.068 0.547 . . . . 70.150000000000006 110.464 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 12.5 p -91.42 105.85 18.07 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 123.547 0.739 . . . . 74.319999999999993 109.647 176.243 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.8 p -99.35 132.56 44.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 123.906 0.882 . . . . 73.040000000000006 109.036 176.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 58.1 ttt85 -81.92 129.16 34.68 Favored 'General case' 0 C--O 1.242 0.667 0 CA-C-O 121.59 0.709 . . . . 75.349999999999994 110.696 -176.457 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.604 HD12 HD21 ' A' ' 125' ' ' LEU . 2.4 pt -98.56 145.2 29.48 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.637 1.575 . . . . 60.409999999999997 108.734 174.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.91 143.88 62.44 Favored 'Trans proline' 0 CA--C 1.562 1.906 0 C-N-CA 121.986 1.791 . . . . 74.209999999999994 112.215 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.604 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 30.5 Cg_endo -62.27 130.16 29.45 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.18 2.586 . . . . 54.32 111.787 175.717 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 64.76 46.77 88.76 Favored Glycine 0 C--N 1.344 1.021 0 O-C-N 123.966 0.791 . . . . 72.239999999999995 111.614 -175.541 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 178' ' ' VAL . 8.2 p -75.72 145.6 10.41 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 CA-C-O 121.187 0.517 . . . . 74.420000000000002 110.256 179.262 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.4 mtp180 -104.07 169.78 8.3 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.19 0.996 . . . . 75.120000000000005 111.974 -172.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.6 tp10 -68.19 134.6 50.72 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-N 113.834 -1.53 . . . . 74.219999999999999 110.331 176.489 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.05 2.79 66.81 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-O 118.968 -0.907 . . . . 74.129999999999995 114.395 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.7 m -71.13 117.63 12.89 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 118.213 1.006 . . . . 72.549999999999997 108.869 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.7 p -93.37 132.25 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 109.34 -0.615 . . . . 74.400000000000006 109.34 -178.297 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.546 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 50.0 mt -105.93 104.12 16.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 107.807 -1.183 . . . . 55.200000000000003 107.807 -178.488 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 36.1 ttm180 -91.46 104.74 17.22 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 109.632 -0.507 . . . . 61.25 109.632 177.521 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.4 t -97.12 111.58 58.35 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 107.361 -1.348 . . . . 74.299999999999997 107.361 174.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -69.86 124.62 11.22 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 123.17 2.58 . . . . 72.120000000000005 113.46 -170.343 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 69.38 16.01 70.96 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 114.743 0.657 . . . . 53.43 114.743 173.874 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.9 mmt -113.83 12.64 18.26 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 123.317 0.647 . . . . 74.030000000000001 111.659 -177.297 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -96.43 -102.17 2.01 Favored Glycine 0 C--N 1.338 0.661 0 O-C-N 123.472 0.483 . . . . 71.140000000000001 112.588 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' GLY . . . . . 0.503 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -65.48 121.47 20.41 Favored Glycine 0 C--N 1.353 1.523 0 O-C-N 123.948 0.44 . . . . 64.030000000000001 113.587 -173.194 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -71.22 146.95 48.71 Favored 'General case' 0 C--O 1.246 0.92 0 C-N-CA 123.414 0.686 . . . . 73.439999999999998 110.952 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 155.32 -169.38 33.26 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.025 -0.989 . . . . 75.340000000000003 111.093 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -74.34 -48.91 5.46 Favored Pre-proline 0 CA--C 1.566 1.572 0 CA-C-O 118.621 -0.704 . . . . 73.310000000000002 109.378 174.111 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -83.55 111.59 1.79 Allowed 'Trans proline' 0 C--N 1.394 2.962 0 C-N-CA 121.641 1.56 . . . . 62.109999999999999 110.264 164.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -69.52 128.89 16.91 Favored 'Trans proline' 0 C--N 1.369 1.64 0 C-N-CA 122.261 1.974 . . . . 65.010000000000005 111.854 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -90.99 166.78 31.31 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-O 119.873 -0.404 . . . . 73.530000000000001 112.129 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -82.45 158.68 23.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 122.989 0.516 . . . . 75.310000000000002 111.11 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.653 HD21 HD11 ' A' ' 98' ' ' LEU . 40.9 tp -118.29 131.55 56.34 Favored 'General case' 0 C--O 1.223 -0.3 0 C-N-CA 123.69 0.796 . . . . 74.340000000000003 109.463 -178.001 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.518 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 87.0 mt -128.8 125.54 38.0 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.028 0.931 . . . . 55.530000000000001 109.804 -177.617 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.612 HD21 HD12 ' A' ' 98' ' ' LEU . 80.8 mt -125.27 103.03 7.73 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.221 0.609 . . . . 63.119999999999997 111.124 178.549 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 39.4 t -85.59 94.34 4.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.306 -0.998 . . . . 51.43 108.306 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 153' ' ' VAL . 98.7 t -58.49 114.83 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 C-N-CA 123.739 0.816 . . . . 72.120000000000005 111.049 -177.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -106.44 104.41 14.09 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 124.506 1.123 . . . . 74.450000000000003 108.751 178.284 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 72.3 mt -68.94 105.05 2.25 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 109.669 -0.493 . . . . 53.25 109.669 178.785 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.3 mt -60.74 149.66 78.84 Favored Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 124.295 1.038 . . . . 52.020000000000003 111.399 175.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -70.73 165.86 30.68 Favored 'Trans proline' 0 C--N 1.373 1.844 0 C-N-CA 122.314 2.009 . . . . 71.120000000000005 111.311 174.239 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 . . . . . 0 CA--C 1.552 1.039 0 N-CA-C 108.907 -0.775 . . . . 72.340000000000003 108.907 174.33 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.407 ' HB3' ' HA ' ' A' ' 100' ' ' THR . 0.8 OUTLIER . . . . . 0 CA--C 1.551 0.996 0 CA-C-O 119.822 -0.132 . . . . 74.340000000000003 111.004 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.1 -67.12 0.03 OUTLIER 'Trans proline' 0 C--N 1.382 2.308 0 C-N-CA 122.055 1.837 . . . . 71.540000000000006 110.969 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.515 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 5.7 tp -171.6 143.62 1.76 Allowed 'General case' 0 C--N 1.35 0.62 0 C-N-CA 124.202 1.001 . . . . 73.519999999999996 108.457 176.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.664 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 6.1 tp 59.36 4.22 0.47 Allowed 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 125.628 1.571 . . . . 72.310000000000002 113.158 -173.031 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.596 ' HB2' HG23 ' A' ' 140' ' ' VAL . 82.7 t80 -139.95 130.43 25.51 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 107.789 -1.189 . . . . 60.32 107.789 -171.837 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.455 HG22 HG13 ' A' ' 102' ' ' VAL . 75.9 m -149.45 98.02 3.49 Favored Pre-proline 0 N--CA 1.469 0.483 0 O-C-N 124.327 1.017 . . . . 65.519999999999996 109.641 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -70.88 80.8 1.17 Allowed 'Trans proline' 0 C--N 1.367 1.516 0 C-N-CA 122.682 2.255 . . . . 53.32 112.679 -176.089 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.455 HG13 HG22 ' A' ' 100' ' ' THR . 29.9 m . . . . . 0 N--CA 1.474 0.726 0 C-N-CA 124.586 1.154 . . . . 71.239999999999995 109.342 171.541 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 13.7 mtm180 . . . . . 0 N--CA 1.478 0.957 0 N-CA-C 109.323 -0.621 . . . . 62.240000000000002 109.323 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -103.54 104.24 14.29 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.037 -1.468 . . . . 73.109999999999999 107.037 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.538 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.9 mt -93.55 110.26 21.85 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.846 -1.168 . . . . 74.439999999999998 107.846 -174.557 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.449 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 73.6 ttt-85 -107.49 104.53 14.12 Favored 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 108.732 -0.84 . . . . 73.430000000000007 108.732 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -121.11 126.93 51.02 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.692 0.797 . . . . 42.210000000000001 109.42 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -73.26 118.25 15.99 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 123.54 0.736 . . . . 72.129999999999995 109.563 176.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.422 HD21 ' HG2' ' A' ' 136' ' ' ARG . 5.3 tt -100.83 111.15 62.7 Favored Pre-proline 0 CA--C 1.549 0.934 0 C-N-CA 123.938 0.895 . . . . 54.229999999999997 108.849 -175.17 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.04 126.03 13.27 Favored 'Trans proline' 0 C--N 1.379 2.168 0 C-N-CA 122.555 2.17 . . . . 60.409999999999997 111.43 175.44 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.474 HD21 HD12 ' A' ' 149' ' ' ILE . 15.9 tp -148.15 133.83 18.87 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.231 -0.655 . . . . 72.019999999999996 109.231 -173.347 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.8 p -87.66 171.62 10.32 Favored 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 118.084 0.402 . . . . 62.450000000000003 110.312 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.21 -35.66 81.07 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.595 0.758 . . . . 70.230000000000004 111.362 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -63.96 -50.56 68.13 Favored 'General case' 0 C--N 1.35 0.61 0 CA-C-N 114.718 -1.128 . . . . 64.049999999999997 109.258 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 22.3 mm-40 -73.7 -24.69 59.97 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-N 114.58 -1.191 . . . . 72.530000000000001 111.334 -176.411 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.493 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.42 -38.91 81.66 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.212 -0.904 . . . . 71.400000000000006 110.345 173.779 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -72.66 -39.19 67.33 Favored 'General case' 0 CA--C 1.547 0.84 0 CA-C-N 115.473 -0.785 . . . . 71.310000000000002 110.423 176.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.71 -48.85 67.95 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 122.34 0.256 . . . . 75.400000000000006 111.045 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.588 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.25 59.37 10.98 Favored Glycine 0 C--N 1.345 1.061 0 O-C-N 124.015 0.822 . . . . 35.420000000000002 113.567 175.241 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.426 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -121.69 -155.64 9.51 Favored Glycine 0 C--N 1.34 0.783 0 N-CA-C 111.64 -0.584 . . . . 71.400000000000006 111.64 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.619 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.0 mp0 -75.12 122.74 24.05 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 109.929 -0.397 . . . . 72.430000000000007 109.929 179.07 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.442 ' HB2' HD13 ' A' ' 149' ' ' ILE . 12.8 tpt180 -109.59 119.53 39.7 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.391 -1.337 . . . . 64.329999999999998 107.391 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 50.7 t -83.1 106.63 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.476 0.71 . . . . 72.420000000000002 109.191 -172.442 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.515 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 33.4 m -116.85 163.24 14.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.887 0 C-N-CA 125.551 1.54 . . . . 64.219999999999999 108.806 -177.84 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -122.84 111.56 16.82 Favored 'General case' 0 N--CA 1.481 1.097 0 O-C-N 121.748 -0.595 . . . . 63.520000000000003 110.667 -178.654 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.664 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.4 p -104.14 109.74 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 125.015 1.326 . . . . 74.340000000000003 109.471 -177.188 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.94 22.39 13.02 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 123.837 0.855 . . . . 52.229999999999997 112.76 176.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.95 -13.83 58.88 Favored Glycine 0 C--N 1.352 1.439 0 CA-C-O 120.016 -0.325 . . . . 63.219999999999999 113.413 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 26.1 tpt180 -90.72 127.55 36.35 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 123.803 0.841 . . . . 63.119999999999997 109.401 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 15.5 tpp85 -89.2 130.1 35.67 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.577 -0.527 . . . . 74.319999999999993 109.577 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.8 p -147.47 148.98 15.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 C-N-CA 124.193 0.997 . . . . 75.549999999999997 109.555 -179.119 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.619 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 42.9 p -101.17 109.27 21.13 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.371 0.669 . . . . 63.130000000000003 110.156 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.77 124.83 53.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 123.316 0.646 . . . . 63.130000000000003 109.37 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 41.5 ttt180 -71.83 127.93 34.13 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 120.916 0.389 . . . . 74.109999999999999 110.494 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.588 HG13 ' HA2' ' A' ' 133' ' ' GLY . 2.7 pt -100.99 147.66 34.01 Favored Pre-proline 0 CA--C 1.558 1.265 0 C-N-CA 124.956 1.302 . . . . 74.019999999999996 108.223 174.136 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.11 135.61 19.11 Favored 'Trans proline' 0 CA--C 1.558 1.7 0 C-N-CA 122.36 2.04 . . . . 71.030000000000001 112.087 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.81 135.43 48.34 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.407 2.071 . . . . 64.450000000000003 111.81 173.187 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.54 62.56 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-N 115.669 -0.696 . . . . 62.030000000000001 112.42 -174.467 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.493 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 11.0 p -73.4 147.44 9.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 N-CA-C 109.273 -0.64 . . . . 73.120000000000005 109.273 178.162 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 56.1 mtp85 -138.89 178.95 6.78 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.706 0.765 . . . . 64.120000000000005 111.587 -173.442 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.01 120.0 6.76 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 113.348 -1.751 . . . . 72.349999999999994 110.578 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.23 -10.51 67.51 Favored Glycine 0 C--N 1.341 0.817 0 O-C-N 124.28 0.987 . . . . 50.119999999999997 113.797 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.3 m -70.3 121.54 17.84 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.416 -0.587 . . . . 74.329999999999998 109.416 178.014 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -105.01 122.45 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 109.41 -0.589 . . . . 74.040000000000006 109.41 -178.151 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.625 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 32.3 mt -91.53 101.95 13.02 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 107.782 -1.192 . . . . 64.439999999999998 107.782 -178.103 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.527 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 48.7 ttp85 -96.02 110.25 22.51 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.889 -0.411 . . . . 53.43 109.889 -176.58 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.6 t -103.96 96.46 9.39 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 107.636 -1.246 . . . . 61.020000000000003 107.636 170.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -65.78 127.0 16.96 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.815 2.344 . . . . 72.030000000000001 112.006 -176.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.9 -23.01 37.71 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-O 119.775 -0.459 . . . . 43.229999999999997 113.758 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.0 tpt -76.48 -32.5 58.38 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.255 0.622 . . . . 73.310000000000002 111.94 -174.156 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -65.57 -81.55 0.13 Allowed Glycine 0 CA--C 1.536 1.399 0 O-C-N 123.606 0.566 . . . . 73.120000000000005 113.384 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -65.35 92.68 0.15 Allowed Glycine 0 C--N 1.345 1.077 0 C-N-CA 123.017 0.341 . . . . 73.519999999999996 113.347 174.421 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -91.2 153.08 20.26 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.266 1.027 . . . . 73.549999999999997 110.044 170.557 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 137.44 -62.94 0.58 Allowed Glycine 0 C--N 1.338 0.655 0 N-CA-C 111.203 -0.759 . . . . 54.039999999999999 111.203 178.364 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.531 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 24.3 t-20 -155.89 -56.48 0.02 OUTLIER Pre-proline 0 CA--C 1.567 1.601 0 CA-C-O 118.184 -0.912 . . . . 75.230000000000004 110.643 179.426 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.531 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 57.0 Cg_endo -90.04 113.71 0.52 Allowed 'Trans proline' 0 C--N 1.402 3.38 0 C-N-CA 122.769 2.313 . . . . 74.430000000000007 110.633 174.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 170' ' ' PRO . 22.9 Cg_exo -64.84 123.09 11.13 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 122.417 2.078 . . . . 71.439999999999998 111.059 -176.483 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -111.53 160.84 13.0 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 120.013 -0.326 . . . . 73.400000000000006 112.393 -176.403 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -77.68 139.65 39.47 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.06 0.544 . . . . 63.229999999999997 111.159 -174.464 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.553 HD21 HD11 ' A' ' 98' ' ' LEU . 64.2 tp -101.31 126.99 48.12 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.792 -1.188 . . . . 70.420000000000002 107.792 171.536 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.449 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 75.2 mt -127.16 103.18 7.29 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 124.695 1.198 . . . . 74.030000000000001 109.118 -175.232 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.625 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 88.0 mt -100.23 101.47 12.5 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 122.784 0.434 . . . . 72.239999999999995 110.02 178.33 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.1 t -86.81 99.52 8.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 108.799 -0.815 . . . . 61.210000000000001 108.799 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.91 114.26 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 CA-C-N 115.156 -0.929 . . . . 43.25 111.632 -173.148 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 6.3 mmp_? -99.36 113.16 25.33 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 125.142 1.377 . . . . 53.43 108.528 172.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.429 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 44.3 mt -72.3 127.51 32.78 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.852 -0.425 . . . . 62.130000000000003 109.852 175.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.1 mt -83.92 148.54 54.25 Favored Pre-proline 0 C--O 1.242 0.662 0 C-N-CA 123.883 0.873 . . . . 71.239999999999995 109.883 178.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.8 172.53 9.41 Favored 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 122.827 2.352 . . . . 70.0 111.831 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.533 -0.746 . . . . 75.129999999999995 110.163 -177.415 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.558 1.286 0 N-CA-C 114.755 1.391 . . . . 52.420000000000002 114.755 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -66.83 -174.3 0.46 Allowed 'Trans proline' 0 C--N 1.369 1.63 0 C-N-CA 122.617 2.211 . . . . 73.510000000000005 111.142 163.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.495 HD11 ' HG ' ' A' ' 123' ' ' LEU . 8.6 tp -72.73 133.47 44.58 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.518 -0.549 . . . . 72.510000000000005 109.518 176.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.685 HD22 HG23 ' A' ' 138' ' ' VAL . 13.4 tp 73.17 -39.98 0.46 Allowed 'General case' 0 N--CA 1.484 1.255 0 C-N-CA 127.268 2.227 . . . . 74.200000000000003 113.077 -176.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -88.12 131.34 34.73 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.141 0.976 . . . . 71.209999999999994 111.528 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.531 HG22 HG13 ' A' ' 102' ' ' VAL . 93.6 m -151.29 92.21 3.78 Favored Pre-proline 0 CA--C 1.55 0.964 0 C-N-CA 123.592 0.757 . . . . 71.109999999999999 109.823 178.668 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -74.06 82.23 1.82 Allowed 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.646 2.23 . . . . 53.130000000000003 113.302 -168.151 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.531 HG13 HG22 ' A' ' 100' ' ' THR . 28.6 m . . . . . 0 N--CA 1.474 0.731 0 C-N-CA 123.985 0.914 . . . . 75.450000000000003 109.972 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.474 0.75 0 CA-C-O 121.19 0.519 . . . . 74.400000000000006 111.038 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -101.54 108.78 20.45 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.638 -0.875 . . . . 71.200000000000003 108.638 -173.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.429 HD22 ' O ' ' A' ' 100' ' ' THR . 15.2 mt -89.93 110.63 21.58 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.796 -1.186 . . . . 63.439999999999998 107.796 -169.299 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -107.17 109.31 21.1 Favored 'General case' 0 C--N 1.344 0.349 0 N-CA-C 108.997 -0.742 . . . . 54.229999999999997 108.997 173.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -126.5 141.97 51.69 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.277 -1.008 . . . . 74.340000000000003 108.277 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -74.32 135.06 42.54 Favored 'General case' 0 C--O 1.243 0.73 0 N-CA-C 109.051 -0.722 . . . . 72.349999999999994 109.051 173.129 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.495 ' HG ' HD11 ' A' ' 97' ' ' LEU . 1.9 tt -100.83 103.11 22.51 Favored Pre-proline 0 CA--C 1.543 0.708 0 N-CA-C 107.929 -1.138 . . . . 75.409999999999997 107.929 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.423 ' HB2' HD11 ' A' ' 181' ' ' LEU . 52.1 Cg_endo -67.83 115.48 3.79 Favored 'Trans proline' 0 C--N 1.376 2.013 0 C-N-CA 122.49 2.126 . . . . 70.409999999999997 110.052 174.439 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.603 HD21 HD12 ' A' ' 149' ' ' ILE . 17.0 tp -137.6 135.31 36.48 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.074 -0.713 . . . . 71.409999999999997 109.074 -169.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.0 p -77.28 164.58 25.44 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 118.76 0.709 . . . . 54.43 110.581 178.629 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -63.28 -30.91 71.96 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.728 0.811 . . . . 64.219999999999999 111.877 -177.259 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -75.0 -46.95 31.67 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.561 0.745 . . . . 71.140000000000001 110.13 -178.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 73.3 mm-40 -60.62 -35.69 76.78 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 123.911 0.757 . . . . 73.209999999999994 111.048 176.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.51 -51.63 61.98 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 124.099 0.874 . . . . 34.32 111.21 174.276 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -58.04 -50.82 72.1 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.928 1.291 . . . . 74.329999999999998 111.688 -176.006 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 56.1 m80 -78.18 -41.18 35.46 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.819 -0.628 . . . . 74.329999999999998 109.881 -176.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 73.94 -167.86 54.37 Favored Glycine 0 C--N 1.352 1.451 0 CA-C-N 116.03 -0.532 . . . . 72.150000000000006 112.072 -173.589 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.472 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 122.85 -165.08 15.57 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 111.766 -0.534 . . . . 44.450000000000003 111.766 177.694 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.453 ' HA ' ' HA ' ' A' ' 148' ' ' ARG . 1.5 mp0 -84.78 125.71 32.8 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 121.125 0.488 . . . . 75.019999999999996 110.304 178.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 tpp180 -112.88 122.37 47.44 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.929 1.291 . . . . 75.140000000000001 107.92 175.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.4 t -101.86 106.93 20.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 N-CA-C 109.334 -0.617 . . . . 60.219999999999999 109.334 -171.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.685 HG23 HD22 ' A' ' 98' ' ' LEU . 30.0 m -124.46 153.52 31.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.298 1.039 . . . . 74.140000000000001 108.835 -175.645 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -107.03 132.56 52.82 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 122.592 0.357 . . . . 74.549999999999997 111.517 -171.281 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.1 p -113.26 104.8 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 125.21 1.404 . . . . 65.219999999999999 109.881 176.292 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.67 15.54 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 113.187 0.81 . . . . 70.420000000000002 113.187 173.554 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.0 8.73 47.24 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.908 -0.385 . . . . 45.399999999999999 113.696 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 7.2 tpp180 -115.72 116.39 27.99 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.336 0.655 . . . . 72.420000000000002 109.238 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -87.1 106.38 17.83 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.071 0.548 . . . . 73.530000000000001 109.879 -173.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 78.4 t -112.87 133.96 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.228 1.011 . . . . 71.120000000000005 110.729 -176.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 45.5 t -92.1 104.48 16.87 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.55 0.74 . . . . 75.010000000000005 109.951 175.787 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.587 HG21 HD12 ' A' ' 176' ' ' LEU . 6.3 p -99.99 122.38 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 123.65 0.78 . . . . 72.400000000000006 110.181 175.799 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 135' ' ' GLU . 61.1 ttt180 -77.09 112.18 13.48 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.673 0.389 . . . . 71.25 110.086 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.603 HD12 HD21 ' A' ' 125' ' ' LEU . 4.4 pt -77.94 138.4 61.43 Favored Pre-proline 0 CA--C 1.56 1.36 0 C-N-CA 123.794 0.838 . . . . 43.200000000000003 109.212 170.665 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -60.0 136.8 71.86 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.911 2.407 . . . . 75.129999999999995 113.271 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -61.59 113.05 1.64 Allowed 'Trans proline' 0 C--N 1.375 1.95 0 C-N-CA 122.776 2.318 . . . . 62.409999999999997 111.585 171.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.89 39.76 16.17 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.051 -0.522 . . . . 73.420000000000002 112.076 -173.667 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.415 HG21 HG21 ' A' ' 178' ' ' VAL . 12.6 p -75.46 145.32 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 N-CA-C 109.399 -0.593 . . . . 71.140000000000001 109.399 175.64 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -112.62 173.1 6.54 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 121.472 0.653 . . . . 73.200000000000003 112.009 -173.473 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -63.77 133.97 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 113.927 -1.488 . . . . 60.119999999999997 111.107 178.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.36 -21.65 33.99 Favored Glycine 0 C--N 1.349 1.263 0 CA-C-N 115.833 -0.622 . . . . 42.25 113.583 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 72.7 m -63.66 121.52 14.13 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 123.695 0.798 . . . . 73.430000000000007 111.876 -172.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.4 p -95.39 125.29 48.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 CA-C-O 121.302 0.572 . . . . 70.310000000000002 110.268 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.0 mt -93.73 115.23 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.355 1.062 . . . . 71.219999999999999 108.29 -178.745 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 -101.26 119.94 39.51 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 122.848 0.459 . . . . 72.519999999999996 110.497 -176.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -117.4 99.31 52.52 Favored Pre-proline 0 CA--C 1.552 1.045 0 N-CA-C 107.574 -1.269 . . . . 60.009999999999998 107.574 169.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.77 138.81 81.85 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.791 2.328 . . . . 72.319999999999993 113.913 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.6 5.13 72.58 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 115.07 -0.968 . . . . 63.020000000000003 115.094 175.276 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 13.6 tpt -101.99 -16.0 16.62 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 117.638 0.719 . . . . 70.409999999999997 112.359 -170.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -73.82 -81.72 0.41 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 120.154 -0.248 . . . . 60.200000000000003 112.769 178.264 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -60.39 93.78 0.07 OUTLIER Glycine 0 C--N 1.352 1.42 0 C-N-CA 123.1 0.381 . . . . 54.229999999999997 112.95 172.384 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -91.98 171.01 9.4 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.495 1.118 . . . . 73.040000000000006 111.46 175.408 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 113.76 -65.68 0.27 Allowed Glycine 0 C--N 1.345 1.046 0 CA-C-N 115.579 -0.737 . . . . 43.119999999999997 111.792 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.432 ' H ' ' CD ' ' A' ' 170' ' ' PRO . 3.3 p-10 -168.62 -32.35 0.0 OUTLIER Pre-proline 0 CA--C 1.565 1.554 0 CA-C-O 117.48 -1.248 . . . . 73.310000000000002 112.66 -179.36 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.432 ' CD ' ' H ' ' A' ' 169' ' ' ASN . 62.6 Cg_endo -92.32 106.81 0.22 Allowed 'Trans proline' 0 C--N 1.403 3.442 0 CA-C-N 122.37 1.882 . . . . 73.209999999999994 110.611 168.171 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_exo -66.16 124.85 13.14 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.277 1.984 . . . . 73.019999999999996 111.811 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -120.96 155.95 16.19 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.25 -1.14 . . . . 51.310000000000002 110.25 172.554 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -76.81 162.69 27.45 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.687 0.795 . . . . 71.129999999999995 111.033 -173.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.515 HD21 HD11 ' A' ' 98' ' ' LEU . 55.9 tp -122.6 130.58 53.16 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.047 0.539 . . . . 74.430000000000007 109.795 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.41 128.77 46.36 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.805 1.242 . . . . 64.200000000000003 109.05 177.639 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.587 HD12 HG21 ' A' ' 147' ' ' VAL . 88.0 mt -129.17 102.31 6.41 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.198 0.599 . . . . 62.329999999999998 110.948 178.599 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.0 t -85.69 99.32 7.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.66 0 N-CA-C 109.563 -0.532 . . . . 73.310000000000002 109.563 -173.133 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.415 HG21 HG21 ' A' ' 153' ' ' VAL . 96.7 t -56.14 114.51 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.344 1.058 . . . . 71.140000000000001 111.907 -178.103 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -113.09 102.6 10.55 Favored 'General case' 0 C--O 1.239 0.517 0 C-N-CA 124.77 1.228 . . . . 75.400000000000006 108.598 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 68.6 mt -70.28 116.93 11.2 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 115.256 -0.884 . . . . 72.209999999999994 110.962 -177.36 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.423 HD11 ' HB2' ' A' ' 124' ' ' PRO . 58.0 mt -77.26 146.75 75.05 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 115.416 -0.811 . . . . 74.140000000000001 110.378 -177.238 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -60.64 115.05 2.42 Favored 'Trans proline' 0 C--N 1.373 1.817 0 C-N-CA 123.279 2.653 . . . . 72.510000000000005 111.873 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 . . . . . 0 C--O 1.249 1.073 0 N-CA-C 109.331 -0.618 . . . . 63.020000000000003 109.331 -179.856 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 3.4 pp . . . . . 0 CA--C 1.566 1.587 0 N-CA-C 112.341 0.497 . . . . 74.239999999999995 112.341 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -69.87 -164.05 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 123.611 2.874 . . . . 62.409999999999997 113.433 168.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.73 HD13 ' HD2' ' A' ' 124' ' ' PRO . 0.6 OUTLIER -60.31 -46.56 89.44 Favored 'General case' 0 N--CA 1.483 1.203 0 C-N-CA 124.446 1.098 . . . . 70.340000000000003 112.031 -179.009 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.521 HD22 ' HB ' ' A' ' 140' ' ' VAL . 3.9 tt -139.19 90.04 2.39 Favored 'General case' 0 C--O 1.211 -0.962 0 N-CA-C 108.04 -1.096 . . . . 71.540000000000006 108.04 173.47 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 73.5 t80 172.5 107.05 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 125.518 1.527 . . . . 61.240000000000002 107.373 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.551 HG22 HG13 ' A' ' 102' ' ' VAL . 93.9 m -127.79 94.64 36.77 Favored Pre-proline 0 C--O 1.239 0.511 0 N-CA-C 109.763 -0.458 . . . . 44.329999999999998 109.763 -178.001 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -70.1 85.28 0.67 Allowed 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 122.556 2.17 . . . . 73.209999999999994 112.293 -175.527 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.551 HG13 HG22 ' A' ' 100' ' ' THR . 22.6 m . . . . . 0 N--CA 1.47 0.541 0 C-N-CA 124.001 0.92 . . . . 74.019999999999996 109.582 174.34 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.449 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 12.5 mmm-85 . . . . . 0 N--CA 1.474 0.743 0 N-CA-C 107.952 -1.129 . . . . 62.409999999999997 107.952 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -96.69 104.44 16.43 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.458 -0.941 . . . . 64.129999999999995 108.458 -171.473 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.453 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.1 mt -92.39 111.48 23.07 Favored 'General case' 0 C--N 1.344 0.344 0 N-CA-C 107.917 -1.142 . . . . 75.239999999999995 107.917 -172.201 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -110.08 105.58 14.75 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 108.686 -0.857 . . . . 43.25 108.686 174.081 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.13 160.92 35.81 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 123.929 0.892 . . . . 70.140000000000001 109.6 -176.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 88.7 mt-10 -99.79 136.39 39.79 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.437 0.695 . . . . 73.099999999999994 110.12 -173.015 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.614 ' HA ' HD13 ' A' ' 97' ' ' LEU . 1.6 tt -105.05 101.33 29.49 Favored Pre-proline 0 CA--C 1.545 0.75 0 C-N-CA 124.247 1.019 . . . . 63.229999999999997 108.759 -176.14 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.73 ' HD2' HD13 ' A' ' 97' ' ' LEU . 30.2 Cg_endo -62.74 120.04 7.38 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.478 2.119 . . . . 74.010000000000005 110.285 170.514 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.624 HD21 HD12 ' A' ' 149' ' ' ILE . 15.2 tp -145.89 135.7 23.43 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.948 0.499 . . . . 54.43 109.664 -172.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.3 p -88.24 168.8 12.41 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.974 0.51 . . . . 64.310000000000002 110.72 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 72.2 mt -63.08 -36.99 85.43 Favored 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 123.395 0.678 . . . . 62.130000000000003 111.928 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -63.55 -54.77 30.93 Favored 'General case' 0 N--CA 1.475 0.811 0 O-C-N 123.953 0.783 . . . . 61.299999999999997 108.983 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -64.19 -34.18 77.5 Favored 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 114.759 -1.109 . . . . 62.439999999999998 111.699 -177.693 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.41 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -59.9 -49.62 76.96 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.218 0.949 . . . . 65.219999999999999 110.475 175.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -69.61 -34.71 74.47 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 115.008 -0.996 . . . . 73.209999999999994 111.129 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -66.77 -47.08 73.3 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.833 0.453 . . . . 63.409999999999997 110.57 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.52 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.3 41.03 94.85 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 115.532 -0.758 . . . . 73.430000000000007 112.648 -174.595 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -84.39 -163.9 36.87 Favored Glycine 0 C--N 1.347 1.162 0 O-C-N 123.904 0.414 . . . . 42.140000000000001 112.984 -178.137 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.4 mp0 -85.44 144.67 27.85 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.437 -0.579 . . . . 72.349999999999994 109.437 170.315 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.589 ' HG2' HD21 ' A' ' 123' ' ' LEU . 11.0 tpt180 -125.69 120.32 30.39 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 123.935 0.894 . . . . 61.439999999999998 108.621 -177.153 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.44 123.53 37.94 Favored 'Isoleucine or valine' 0 C--O 1.24 0.573 0 N-CA-C 109.373 -0.602 . . . . 65.239999999999995 109.373 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.441 HG12 HD21 ' A' ' 97' ' ' LEU . 27.2 m -138.25 162.49 30.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 125.02 1.328 . . . . 53.109999999999999 108.54 179.454 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -119.83 129.28 54.35 Favored 'General case' 0 N--CA 1.479 1.019 0 O-C-N 122.053 -0.405 . . . . 74.230000000000004 110.644 -178.519 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.521 ' HB ' HD22 ' A' ' 98' ' ' LEU . 5.3 p -119.89 113.63 41.4 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.599 1.159 . . . . 74.349999999999994 110.045 175.231 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 56.35 33.27 22.03 Favored 'General case' 0 N--CA 1.487 1.425 0 C-N-CA 123.782 0.833 . . . . 64.209999999999994 112.389 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.29 19.28 59.09 Favored Glycine 0 C--N 1.351 1.413 0 CA-C-N 115.858 -0.61 . . . . 41.219999999999999 113.638 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 75.9 mtp180 -125.42 125.61 43.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 123.722 0.809 . . . . 62.210000000000001 110.198 -176.532 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.3 ttp180 -73.51 120.33 18.97 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 122.904 0.482 . . . . 74.109999999999999 110.734 178.118 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 20.5 m -125.24 141.22 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.716 0.807 . . . . 64.239999999999995 109.77 170.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.9 p -106.62 111.71 24.38 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.817 0.847 . . . . 73.530000000000001 109.353 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -101.08 130.75 50.0 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 123.716 0.806 . . . . 62.539999999999999 110.083 178.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 39.0 ttt180 -81.6 114.3 20.2 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.494 -0.928 . . . . 71.319999999999993 108.494 178.414 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.624 HD12 HD21 ' A' ' 125' ' ' LEU . 5.2 pt -84.51 146.39 47.07 Favored Pre-proline 0 CA--C 1.554 1.132 0 C-N-CA 123.844 0.858 . . . . 65.409999999999997 109.469 177.838 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.433 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 25.1 Cg_exo -66.4 141.76 63.12 Favored 'Trans proline' 0 CA--C 1.562 1.894 0 C-N-CA 122.826 2.351 . . . . 74.340000000000003 112.922 177.565 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 22.4 Cg_exo -67.92 127.95 16.97 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 123.127 2.551 . . . . 61.520000000000003 111.496 172.492 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 74.71 26.34 67.54 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 123.783 0.677 . . . . 45.219999999999999 113.317 -175.317 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.41 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 12.6 p -71.71 146.37 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 117.421 0.61 . . . . 74.439999999999998 110.735 -178.124 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.497 ' HA ' HD11 ' A' ' 180' ' ' LEU . 29.7 mtp-105 -120.99 173.22 7.39 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 121.888 0.851 . . . . 73.239999999999995 112.571 -170.064 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -64.45 120.83 13.03 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 113.292 -1.776 . . . . 73.340000000000003 109.961 174.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 104.34 -23.61 31.28 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-O 119.407 -0.663 . . . . 72.319999999999993 112.965 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 58.5 m -64.25 121.08 13.4 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 123.061 0.544 . . . . 73.400000000000006 110.458 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.2 p -102.39 127.49 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 CA-C-O 121.26 0.552 . . . . 73.030000000000001 110.022 -179.102 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.44 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 54.6 mt -92.64 101.1 12.25 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 107.829 -1.174 . . . . 72.430000000000007 107.829 -179.389 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -86.99 110.04 19.78 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.657 -0.498 . . . . 64.329999999999998 109.657 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.458 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 12.6 t -111.19 93.54 18.57 Favored Pre-proline 0 CA--C 1.555 1.163 0 N-CA-C 107.685 -1.228 . . . . 45.450000000000003 107.685 173.034 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.13 122.29 7.06 Favored 'Trans proline' 0 C--N 1.369 1.618 0 C-N-CA 122.441 2.094 . . . . 71.129999999999995 112.207 -177.255 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.39 -20.91 36.36 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-N 116.537 -0.301 . . . . 63.409999999999997 113.476 177.376 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.41 ' HB2' HG12 ' A' ' 161' ' ' VAL . 86.1 mmm -104.62 16.16 26.59 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 123.398 0.679 . . . . 73.209999999999994 112.081 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.59 -101.93 0.54 Allowed Glycine 0 C--N 1.345 1.061 0 CA-C-O 119.664 -0.52 . . . . 72.319999999999993 111.931 172.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' GLY . . . . . 0.449 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -68.84 102.78 0.95 Allowed Glycine 0 C--N 1.349 1.299 0 CA-C-N 116.93 0.365 . . . . 74.209999999999994 112.313 177.087 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 7.5 mm-40 -89.27 157.82 18.07 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 124.151 0.981 . . . . 71.140000000000001 110.075 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 147.77 -66.39 0.4 Allowed Glycine 0 C--N 1.344 1.014 0 N-CA-C 110.758 -0.937 . . . . 45.119999999999997 110.758 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.405 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 36.2 t30 -159.12 -54.12 0.01 OUTLIER Pre-proline 0 CA--C 1.562 1.429 0 C-N-CA 124.291 1.036 . . . . 73.150000000000006 110.122 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.405 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 80.5 Cg_endo -85.37 110.54 1.23 Allowed 'Trans proline' 0 C--N 1.399 3.231 0 C-N-CA 121.594 1.53 . . . . 74.109999999999999 110.505 171.485 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.82 123.28 11.12 Favored 'Trans proline' 0 C--N 1.383 2.381 0 C-N-CA 122.163 1.909 . . . . 75.209999999999994 110.996 -174.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -96.1 163.08 23.07 Favored Glycine 0 C--N 1.338 0.642 0 O-C-N 123.649 0.593 . . . . 71.319999999999993 111.912 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -84.36 152.39 24.12 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 108.791 -0.818 . . . . 70.519999999999996 108.791 -179.741 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.458 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 57.6 tp -120.68 132.0 54.86 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.957 0.503 . . . . 71.450000000000003 109.744 178.206 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 84.1 mt -128.39 103.33 7.09 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.189 0.996 . . . . 74.340000000000003 109.153 177.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.473 HD21 ' HG ' ' A' ' 98' ' ' LEU . 86.8 mt -102.51 101.2 11.37 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 121.04 0.447 . . . . 65.420000000000002 110.369 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.1 t -83.96 99.55 6.53 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 108.621 -0.881 . . . . 62.340000000000003 108.621 -176.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.5 t -59.32 117.42 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 123.919 0.888 . . . . 73.219999999999999 111.455 -177.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -100.95 105.23 16.45 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 114.466 -1.243 . . . . 63.350000000000001 108.389 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.497 HD11 ' HA ' ' A' ' 154' ' ' ARG . 30.3 mt -69.28 108.77 3.8 Favored 'General case' 0 C--N 1.348 0.511 0 N-CA-C 109.128 -0.693 . . . . 71.030000000000001 109.128 174.03 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.4 mt -68.56 159.0 83.62 Favored Pre-proline 0 CA--C 1.544 0.72 0 CA-C-N 115.057 -0.974 . . . . 73.049999999999997 110.45 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -74.12 51.91 2.56 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 123.533 2.822 . . . . 61.229999999999997 112.764 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.5 t-80 . . . . . 0 C--O 1.255 1.347 0 C-N-CA 124.697 1.199 . . . . 75.120000000000005 107.962 177.304 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.6 pt? . . . . . 0 CA--C 1.555 1.145 0 N-CA-C 111.56 0.207 . . . . 71.540000000000006 111.56 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.444 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 97.5 Cg_endo -81.67 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.922 2.414 . . . . 74.439999999999998 111.3 166.579 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.519 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.1 tp -81.83 139.99 34.43 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.261 0.624 . . . . 74.129999999999995 110.254 -179.48 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.676 HD22 HG23 ' A' ' 138' ' ' VAL . 19.3 tp 64.63 -13.06 0.11 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 127.031 2.132 . . . . 75.310000000000002 113.606 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.444 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 47.3 t80 -119.78 122.07 40.57 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 124.376 1.07 . . . . 73.319999999999993 108.91 -173.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.515 HG22 HG13 ' A' ' 102' ' ' VAL . 85.7 m -135.36 90.25 21.07 Favored Pre-proline 0 C--O 1.235 0.329 0 C-N-CA 123.739 0.816 . . . . 72.409999999999997 108.804 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -65.85 93.61 0.27 Allowed 'Trans proline' 0 C--N 1.372 1.769 0 C-N-CA 121.6 1.533 . . . . 63.399999999999999 112.027 -174.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 100' ' ' THR . 27.4 m . . . . . 0 N--CA 1.465 0.32 0 C-N-CA 125.266 1.427 . . . . 70.430000000000007 109.375 177.011 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.614 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 46.7 mtt-85 . . . . . 0 N--CA 1.476 0.854 0 N-CA-C 109.882 -0.414 . . . . 72.120000000000005 109.882 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -99.29 105.02 16.98 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 106.469 -1.678 . . . . 63.450000000000003 106.469 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.494 HD22 ' O ' ' A' ' 100' ' ' THR . 12.6 mt -88.33 106.93 18.55 Favored 'General case' 0 C--N 1.345 0.378 0 N-CA-C 105.78 -1.933 . . . . 70.209999999999994 105.78 -177.309 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.4 ttm-85 -106.91 102.3 11.67 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.824 -1.176 . . . . 75.329999999999998 107.824 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -125.45 136.04 52.97 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.125 -1.065 . . . . 62.32 108.125 -175.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -82.86 129.37 34.99 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.853 -0.612 . . . . 70.140000000000001 109.732 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.52 HD12 HD13 ' A' ' 176' ' ' LEU . 2.2 tt -101.18 105.05 36.93 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 123.681 0.792 . . . . 63.509999999999998 109.558 -172.782 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.579 ' HB2' HD11 ' A' ' 181' ' ' LEU . 33.9 Cg_endo -61.48 116.22 3.27 Favored 'Trans proline' 0 C--N 1.378 2.089 0 C-N-CA 122.958 2.439 . . . . 71.310000000000002 111.213 170.688 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.49 HD21 HD12 ' A' ' 149' ' ' ILE . 30.9 tp -145.61 124.53 12.73 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 123.77 0.828 . . . . 64.219999999999999 109.026 -170.574 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.1 p -75.49 168.24 20.38 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 122.538 0.335 . . . . 74.329999999999998 110.978 -175.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 74.7 mt -63.22 -37.36 86.92 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.642 0.777 . . . . 74.340000000000003 110.901 178.407 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 24.7 mp0 -64.19 -52.36 59.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.95 1.3 . . . . 61.310000000000002 110.136 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -69.75 -32.71 71.39 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.456 -0.793 . . . . 51.539999999999999 111.43 -177.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.57 -45.28 93.64 Favored 'General case' 0 C--N 1.349 0.582 0 O-C-N 123.87 0.731 . . . . 65.420000000000002 110.269 174.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -66.14 -39.35 89.78 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.377 1.071 . . . . 73.219999999999999 110.641 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.0 m80 -61.98 -47.43 84.87 Favored 'General case' 0 C--N 1.358 0.945 0 O-C-N 123.717 0.636 . . . . 72.519999999999996 110.447 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.429 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.08 52.78 47.6 Favored Glycine 0 C--N 1.352 1.427 0 O-C-N 124.046 0.841 . . . . 74.030000000000001 112.516 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -106.41 -141.82 10.52 Favored Glycine 0 C--N 1.339 0.712 0 N-CA-C 111.531 -0.628 . . . . 63.119999999999997 111.531 177.673 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.586 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.9 mp0 -93.68 148.87 21.71 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 108.261 -1.014 . . . . 63.229999999999997 108.261 169.702 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.463 ' HG3' HG13 ' A' ' 138' ' ' VAL . 40.5 tpt85 -123.31 117.68 25.8 Favored 'General case' 0 N--CA 1.463 0.18 0 N-CA-C 107.441 -1.318 . . . . 55.329999999999998 107.441 177.289 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.5 t -86.21 106.0 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 109.165 -0.679 . . . . 74.019999999999996 109.165 -174.435 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.676 HG23 HD22 ' A' ' 98' ' ' LEU . 33.1 m -125.91 157.79 35.51 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 C-N-CA 124.93 1.292 . . . . 74.120000000000005 108.342 -178.138 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -113.65 120.29 40.39 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 118.534 0.606 . . . . 62.450000000000003 111.382 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 6.4 p -105.61 104.6 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.757 0.823 . . . . 74.439999999999998 109.665 173.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.22 29.6 18.81 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.354 0.661 . . . . 53.109999999999999 112.384 172.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.35 -14.23 58.17 Favored Glycine 0 N--CA 1.475 1.287 0 N-CA-C 113.705 0.242 . . . . 54.240000000000002 113.705 -178.296 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -92.78 117.65 30.24 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.027 -0.731 . . . . 70.310000000000002 109.027 -178.624 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 26.5 ttm180 -88.76 105.93 18.02 Favored 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 108.808 -0.812 . . . . 72.150000000000006 108.808 -173.616 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.57 128.87 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 124.214 1.005 . . . . 73.319999999999993 110.797 -175.42 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.586 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 51.0 p -90.14 107.43 19.13 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 123.841 0.857 . . . . 45.520000000000003 109.699 173.213 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.81 130.1 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 123.721 0.808 . . . . 53.329999999999998 109.995 -178.856 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 75.8 ttt180 -78.82 113.97 17.35 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.555 0.693 . . . . 73.430000000000007 110.547 -174.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.49 HD12 HD21 ' A' ' 125' ' ' LEU . 4.5 pt -90.25 142.22 28.29 Favored Pre-proline 0 CA--C 1.56 1.358 0 C-N-CA 124.93 1.292 . . . . 62.039999999999999 109.772 178.501 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -69.34 142.91 51.13 Favored 'Trans proline' 0 CA--C 1.564 2.018 0 C-N-CA 122.156 1.904 . . . . 50.340000000000003 112.849 174.489 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.59 127.92 14.58 Favored 'Trans proline' 0 C--N 1.381 2.242 0 C-N-CA 122.832 2.355 . . . . 74.409999999999997 111.475 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 82.72 23.41 56.03 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.657 -0.701 . . . . 72.450000000000003 113.416 -174.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.2 p -74.5 150.22 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.926 0.49 . . . . 73.040000000000006 110.185 178.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -131.64 178.55 6.66 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 121.83 0.824 . . . . 74.010000000000005 112.6 -169.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.82 131.46 50.96 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 113.389 -1.732 . . . . 72.540000000000006 111.412 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.55 -8.05 70.35 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-O 119.464 -0.631 . . . . 23.030000000000001 113.357 177.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 49.3 m -72.43 119.23 16.35 Favored 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.848 -0.797 . . . . 72.25 108.848 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.67 134.27 41.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.286 0.634 . . . . 64.420000000000002 109.747 -175.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.471 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 47.4 mt -106.9 103.43 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.224 1.01 . . . . 74.25 108.35 -176.678 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.455 HH21 HD11 ' A' ' 175' ' ' LEU . 30.2 ttm180 -87.29 111.21 20.82 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 123.134 0.574 . . . . 74.010000000000005 109.959 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.91 102.95 53.96 Favored Pre-proline 0 CA--C 1.554 1.106 0 N-CA-C 108.336 -0.987 . . . . 72.329999999999998 108.336 173.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -68.83 139.43 43.53 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 122.909 2.406 . . . . 72.310000000000002 112.52 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 81.31 -8.41 58.32 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.575 -0.569 . . . . 64.25 114.446 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.0 mtt -113.35 17.58 18.4 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 117.944 0.872 . . . . 75.109999999999999 111.22 -174.112 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -92.96 -107.04 1.76 Allowed Glycine 0 C--N 1.347 1.19 0 CA-C-O 119.508 -0.607 . . . . 72.019999999999996 112.066 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' GLY . . . . . 0.614 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -64.85 90.48 0.1 OUTLIER Glycine 0 C--N 1.355 1.599 0 CA-C-N 116.937 0.369 . . . . 72.129999999999995 112.78 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -79.66 147.71 31.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.496 0.719 . . . . 74.219999999999999 111.165 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.09 -124.81 1.48 Allowed Glycine 0 C--N 1.342 0.885 0 N-CA-C 110.001 -1.24 . . . . 74.030000000000001 110.001 -176.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.406 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 2.0 m-20 -85.16 -50.61 0.54 Allowed Pre-proline 0 CA--C 1.563 1.463 0 CA-C-O 118.63 -0.7 . . . . 74.099999999999994 110.004 169.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.406 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -99.66 103.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.395 2.995 0 C-N-CA 123.317 2.678 . . . . 53.43 112.434 177.183 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.52 123.19 12.26 Favored 'Trans proline' 0 C--N 1.377 2.056 0 C-N-CA 122.293 1.996 . . . . 74.310000000000002 111.369 -177.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -94.29 -171.63 38.2 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 116.179 -0.464 . . . . 74.549999999999997 112.977 -176.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -99.65 144.85 28.25 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 123.113 0.565 . . . . 70.409999999999997 110.28 -177.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.567 HD21 HD11 ' A' ' 98' ' ' LEU . 46.8 tp -109.9 129.49 55.65 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.425 0.69 . . . . 65.099999999999994 109.174 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.455 HD11 HH21 ' A' ' 160' ' ' ARG . 88.9 mt -128.85 109.33 11.18 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.887 0.875 . . . . 51.5 109.793 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.52 HD13 HD12 ' A' ' 123' ' ' LEU . 83.6 mt -110.19 102.99 11.63 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.056 0.542 . . . . 74.329999999999998 111.713 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.88 94.56 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.941 0 C-N-CA 123.322 0.649 . . . . 75.230000000000004 109.904 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 84.7 t -54.39 114.76 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 124.105 0.962 . . . . 72.340000000000003 112.054 -179.549 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 29.8 mmt180 -98.29 115.24 27.99 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.116 1.366 . . . . 73.040000000000006 108.406 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 66.7 mt -70.31 114.41 8.41 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 120.689 0.281 . . . . 75.310000000000002 110.5 178.238 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.579 HD11 ' HB2' ' A' ' 124' ' ' PRO . 45.2 mt -89.96 156.9 46.56 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 123.568 0.747 . . . . 55.340000000000003 110.825 175.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -71.18 -162.85 0.11 Allowed 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 123.041 2.494 . . . . 61.200000000000003 112.286 168.131 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 6.7 p80 . . . . . 0 CA--C 1.553 1.091 0 C-N-CA 123.811 0.844 . . . . 71.010000000000005 109.16 -177.868 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.559 1.326 0 N-CA-C 114.168 1.173 . . . . 74.299999999999997 114.168 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.455 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 13.0 Cg_exo -70.91 -161.5 0.09 OUTLIER 'Trans proline' 0 C--N 1.375 1.969 0 C-N-CA 122.698 2.265 . . . . 75.420000000000002 111.989 171.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.674 HD13 ' HD2' ' A' ' 124' ' ' PRO . 1.1 tp -58.19 -42.85 87.03 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 124.107 0.963 . . . . 73.420000000000002 112.569 -175.594 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.401 HD22 ' HB ' ' A' ' 140' ' ' VAL . 1.7 tt -141.06 96.52 3.01 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 107.801 -1.185 . . . . 74.310000000000002 107.801 171.762 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.455 ' HB3' ' HD2' ' A' ' 96' ' ' PRO . 53.7 t80 165.36 119.6 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 126.518 1.927 . . . . 72.450000000000003 107.431 172.301 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.574 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 32.7 m -145.54 86.68 7.28 Favored Pre-proline 0 CA--C 1.55 0.961 0 CA-C-N 118.147 0.43 . . . . 63.200000000000003 110.653 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -74.11 86.0 1.32 Allowed 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.371 2.047 . . . . 71.530000000000001 111.623 -177.796 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.503 HG13 HG22 ' A' ' 100' ' ' THR . 18.0 m . . . . . 0 N--CA 1.481 1.094 0 C-N-CA 124.585 1.154 . . . . 53.32 112.553 -175.231 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.668 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.7 mmp_? . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 107.057 -1.46 . . . . 73.349999999999994 107.057 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.2 105.45 17.8 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 107.578 -1.267 . . . . 64.400000000000006 107.578 -170.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.574 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.8 mt -94.28 110.83 22.55 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 108.244 -1.021 . . . . 74.439999999999998 108.244 -178.688 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.1 ttt180 -110.86 112.76 24.83 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 108.731 -0.841 . . . . 75.239999999999995 108.731 168.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -131.39 153.95 49.14 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.814 -0.81 . . . . 51.210000000000001 108.814 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -92.61 142.22 27.63 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.935 -0.765 . . . . 74.439999999999998 108.935 -176.102 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.648 ' HA ' HD13 ' A' ' 97' ' ' LEU . 12.1 tp -103.14 102.46 28.43 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 124.247 1.019 . . . . 74.25 109.457 -177.734 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.674 ' HD2' HD13 ' A' ' 97' ' ' LEU . 34.6 Cg_endo -65.49 115.71 3.51 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.053 1.835 . . . . 74.430000000000007 109.449 168.465 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.425 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 24.3 tp -145.81 122.1 10.9 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.282 -1.007 . . . . 71.140000000000001 108.282 -174.595 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 80.7 p -75.4 165.31 25.33 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 123.281 0.363 . . . . 73.530000000000001 110.19 -176.235 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.477 HD12 ' HB3' ' A' ' 183' ' ' HIS . 77.6 mt -60.8 -33.31 72.8 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.75 0.82 . . . . 72.349999999999994 111.998 -172.45 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -73.91 -49.58 24.15 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.274 -0.875 . . . . 75.409999999999997 109.272 -178.136 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -68.52 -24.17 64.63 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 115.007 -0.997 . . . . 74.230000000000004 111.374 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.67 -47.34 66.77 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.015 0.926 . . . . 73.319999999999993 109.967 172.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -60.87 -44.09 97.54 Favored 'General case' 0 C--N 1.352 0.677 0 O-C-N 124.637 1.211 . . . . 60.420000000000002 110.867 177.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -71.16 -45.88 62.61 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 123.531 0.519 . . . . 74.239999999999995 111.104 -174.033 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.447 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 71.4 -138.08 27.11 Favored Glycine 0 CA--C 1.53 1.008 0 CA-C-N 116.175 -0.466 . . . . 73.329999999999998 112.275 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.46 -160.19 45.39 Favored Glycine 0 C--N 1.349 1.256 0 CA-C-O 119.882 -0.399 . . . . 62.210000000000001 112.379 178.639 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.567 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 8.9 mp0 -77.46 138.34 39.19 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 117.316 0.558 . . . . 60.240000000000002 109.91 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.501 ' HE ' HD11 ' A' ' 123' ' ' LEU . 23.1 tpt180 -117.69 119.09 33.89 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.392 -0.966 . . . . 73.120000000000005 108.392 -176.166 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 42.9 t -83.51 103.74 11.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 N-CA-C 108.57 -0.9 . . . . 71.109999999999999 108.57 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.443 HG13 ' HG3' ' A' ' 136' ' ' ARG . 18.8 m -123.81 160.83 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 N-CA-C 107.643 -1.243 . . . . 73.349999999999994 107.643 177.551 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -125.95 115.75 20.4 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 119.232 0.923 . . . . 74.239999999999995 111.123 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.401 ' HB ' HD22 ' A' ' 98' ' ' LEU . 2.6 p -105.41 111.16 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 124.378 1.071 . . . . 73.409999999999997 110.771 178.398 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.5 29.83 19.43 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 124.147 0.979 . . . . 72.040000000000006 112.369 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.16 -13.03 62.04 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-N 116.351 -0.386 . . . . 61.409999999999997 113.29 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.66 115.96 28.58 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.309 0.644 . . . . 75.329999999999998 109.817 176.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 32.8 ttm180 -92.49 103.65 16.04 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 108.182 -1.044 . . . . 75.430000000000007 108.182 -176.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 27.0 m -109.57 155.63 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.719 1.208 . . . . 65.129999999999995 111.4 -172.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.567 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 47.9 m -101.73 115.98 31.72 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.859 0.864 . . . . 51.130000000000003 109.708 176.847 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.525 HG11 HD12 ' A' ' 176' ' ' LEU . 74.5 t -99.35 113.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 124.28 1.032 . . . . 64.549999999999997 108.85 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -74.55 102.58 4.57 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 109.145 -0.687 . . . . 64.319999999999993 109.145 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.496 HD13 ' HB2' ' A' ' 136' ' ' ARG . 5.6 pt -96.15 141.93 23.84 Favored Pre-proline 0 CA--C 1.555 1.171 0 C-N-CA 124.418 1.087 . . . . 64.219999999999999 109.51 -178.587 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.428 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 28.8 Cg_endo -64.0 132.83 35.95 Favored 'Trans proline' 0 CA--C 1.564 2.015 0 C-N-CA 122.371 2.047 . . . . 73.140000000000001 112.344 178.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 25.7 Cg_exo -66.98 132.69 28.86 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 122.984 2.456 . . . . 74.409999999999997 112.225 174.004 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.12 34.59 41.14 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.649 -0.705 . . . . 50.210000000000001 112.121 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.419 HG21 HG21 ' A' ' 178' ' ' VAL . 14.6 p -76.44 140.17 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 122.99 0.516 . . . . 73.409999999999997 111.025 -176.162 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 -94.97 177.09 6.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.832 0.825 . . . . 73.0 112.772 -173.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -72.7 129.92 39.33 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.518 -1.674 . . . . 73.430000000000007 110.753 176.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.8 10.33 86.28 Favored Glycine 0 C--N 1.345 1.031 0 CA-C-N 115.45 -0.795 . . . . 74.430000000000007 113.884 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 44.9 m -78.29 118.39 20.45 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.274 -0.639 . . . . 74.530000000000001 109.274 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -94.46 127.28 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-O 121.273 0.558 . . . . 74.099999999999994 110.333 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 51.7 mt -100.97 101.19 11.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 N-CA-C 107.598 -1.26 . . . . 71.109999999999999 107.598 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.493 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 38.9 ttt180 -89.45 113.98 25.41 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 109.92 -0.4 . . . . 73.409999999999997 109.92 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.4 HG11 ' SD ' ' A' ' 164' ' ' MET . 6.5 t -114.49 94.64 37.04 Favored Pre-proline 0 CA--C 1.555 1.149 0 N-CA-C 108.324 -0.991 . . . . 65.230000000000004 108.324 173.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.56 135.2 48.1 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 123.032 2.488 . . . . 71.120000000000005 112.268 177.416 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.95 -7.88 79.84 Favored Glycine 0 C--N 1.345 1.072 0 CA-C-O 119.543 -0.587 . . . . 52.229999999999997 114.2 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.4 ' SD ' HG11 ' A' ' 161' ' ' VAL . 27.6 ttt -100.38 -7.83 23.98 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.636 0.774 . . . . 75.439999999999998 110.772 179.263 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -81.58 -112.94 0.37 Allowed Glycine 0 C--N 1.348 1.207 0 CA-C-N 116.078 -0.51 . . . . 73.230000000000004 112.316 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' GLY . . . . . 0.668 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -67.0 95.61 0.28 Allowed Glycine 0 C--N 1.347 1.177 0 CA-C-N 116.869 0.334 . . . . 75.310000000000002 113.877 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -71.93 108.54 5.24 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 123.566 0.747 . . . . 72.439999999999998 110.46 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -171.64 -169.85 34.98 Favored Glycine 0 C--N 1.342 0.883 0 CA-C-N 115.861 -0.608 . . . . 65.040000000000006 112.304 178.365 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -61.0 -42.93 89.28 Favored Pre-proline 0 CA--C 1.563 1.442 0 C-N-CA 123.497 0.719 . . . . 73.019999999999996 111.652 176.392 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -88.17 106.67 0.54 Allowed 'Trans proline' 0 C--N 1.387 2.584 0 C-N-CA 121.623 1.549 . . . . 74.299999999999997 110.176 160.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -67.21 125.63 13.81 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 121.994 1.796 . . . . 63.219999999999999 111.858 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -97.14 154.93 20.58 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-N 115.876 -0.602 . . . . 50.310000000000002 111.926 -177.542 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -95.39 163.43 13.25 Favored 'General case' 0 C--O 1.245 0.827 0 C-N-CA 122.899 0.48 . . . . 75.430000000000007 109.931 -178.595 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.2 tp -117.62 139.75 50.57 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 115.088 -0.96 . . . . 61.229999999999997 109.758 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 30.7 mt -128.93 101.6 6.15 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.89 1.276 . . . . 64.340000000000003 108.416 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.525 HD12 HG11 ' A' ' 147' ' ' VAL . 54.5 mt -103.2 101.28 11.22 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 118.318 0.508 . . . . 72.150000000000006 110.162 176.75 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.63 100.6 10.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 115.435 -0.802 . . . . 64.450000000000003 109.138 -174.644 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.543 HG22 HD23 ' A' ' 123' ' ' LEU . 58.2 t -57.76 111.36 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.066 0.946 . . . . 72.420000000000002 112.01 -177.271 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -101.44 111.1 23.23 Favored 'General case' 0 C--O 1.243 0.753 0 C-N-CA 124.388 1.075 . . . . 75.510000000000005 108.914 170.657 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.425 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 62.7 mt -70.5 114.5 8.67 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.389 0.676 . . . . 72.430000000000007 109.846 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.432 HD11 ' HB2' ' A' ' 124' ' ' PRO . 86.5 mt -72.66 155.44 90.92 Favored Pre-proline 0 CA--C 1.548 0.888 0 C-N-CA 123.237 0.615 . . . . 72.430000000000007 110.728 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.66 142.75 60.23 Favored 'Trans proline' 0 C--N 1.375 1.942 0 C-N-CA 123.249 2.633 . . . . 74.409999999999997 112.454 173.072 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.477 ' HB3' HD12 ' A' ' 127' ' ' LEU . 48.1 p-80 . . . . . 0 CA--C 1.555 1.17 0 CA-C-O 118.942 -0.551 . . . . 70.239999999999995 110.986 -179.315 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.488 HD22 HG23 ' A' ' 100' ' ' THR . 3.9 pp . . . . . 0 CA--C 1.553 1.095 0 N-CA-C 109.96 -0.385 . . . . 64.329999999999998 109.96 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.4 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 73.8 Cg_endo -85.48 -161.43 0.13 Allowed 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 122.757 2.304 . . . . 61.399999999999999 110.98 164.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.483 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.0 tp -74.25 149.92 40.54 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.262 0.625 . . . . 74.129999999999995 109.412 177.179 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.61 HD11 HD21 ' A' ' 174' ' ' LEU . 8.2 tp 57.74 1.67 0.14 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 125.798 1.639 . . . . 75.5 114.108 -178.228 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.664 ' HA ' HD13 ' A' ' 119' ' ' LEU . 43.3 t80 -139.91 133.7 30.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 123.336 0.655 . . . . 74.319999999999993 109.698 -170.31 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.564 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 85.9 m -152.94 97.05 2.87 Favored Pre-proline 0 CA--C 1.551 1.009 0 C-N-CA 123.8 0.84 . . . . 73.040000000000006 109.476 -177.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.76 77.23 2.29 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 123.02 2.48 . . . . 55.509999999999998 112.799 -170.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.524 HG13 HG22 ' A' ' 100' ' ' THR . 9.0 m . . . . . 0 C--O 1.242 0.694 0 CA-C-N 115.494 -0.775 . . . . 75.200000000000003 110.457 178.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.408 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 8.7 mmm-85 . . . . . 0 N--CA 1.48 1.049 0 N-CA-C 109.133 -0.691 . . . . 73.030000000000001 109.133 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.05 106.59 16.64 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 108.691 -0.855 . . . . 73.439999999999998 108.691 -171.314 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.664 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.3 mt -96.43 109.46 22.01 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 107.478 -1.305 . . . . 75.540000000000006 107.478 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 39.8 ttt180 -121.18 106.45 11.53 Favored 'General case' 0 C--O 1.238 0.465 0 N-CA-C 108.557 -0.905 . . . . 71.510000000000005 108.557 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -128.9 141.23 51.35 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.543 -0.91 . . . . 72.450000000000003 108.543 -177.499 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -81.56 130.99 35.26 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 108.895 -0.78 . . . . 64.5 108.895 175.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.597 HD12 HD13 ' A' ' 176' ' ' LEU . 1.6 tt -101.38 108.24 54.37 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 108.103 -1.073 . . . . 75.409999999999997 108.103 -175.633 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.7 113.87 3.33 Favored 'Trans proline' 0 C--N 1.378 2.097 0 C-N-CA 121.775 1.65 . . . . 73.099999999999994 109.42 171.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.566 HD21 HD12 ' A' ' 149' ' ' ILE . 13.5 tp -131.72 122.78 26.44 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.388 -0.968 . . . . 71.129999999999995 108.388 -169.172 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.9 p -69.71 166.15 19.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.549 0.34 . . . . 64.219999999999999 110.537 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 99.7 mt -62.34 -29.2 70.29 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 122.778 0.431 . . . . 73.200000000000003 110.882 176.065 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -67.8 -57.67 5.91 Favored 'General case' 0 C--N 1.349 0.555 0 C-N-CA 123.907 0.883 . . . . 72.219999999999999 109.263 177.405 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -60.08 -36.49 77.5 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.507 1.123 . . . . 70.219999999999999 111.713 -178.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.407 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.1 -55.72 11.44 Favored 'General case' 0 C--O 1.239 0.551 0 O-C-N 124.061 0.851 . . . . 73.299999999999997 111.212 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.409 ' HA ' ' HA2' ' A' ' 152' ' ' GLY . 65.0 t80 -57.84 -48.28 80.23 Favored 'General case' 0 C--N 1.359 0.99 0 O-C-N 124.554 1.159 . . . . 64.030000000000001 111.399 -177.059 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.9 m80 -72.92 -43.84 61.92 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 116.017 -0.538 . . . . 54.039999999999999 110.19 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.416 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 77.87 -124.01 6.62 Favored Glycine 0 C--N 1.344 0.988 0 CA-C-N 115.762 -0.654 . . . . 70.5 111.566 -176.757 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 73.49 -129.8 12.67 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 111.151 -0.78 . . . . 72.099999999999994 111.151 -176.562 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.531 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 6.7 mp0 -111.73 161.37 16.36 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.102 0.961 . . . . 72.099999999999994 110.179 176.15 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.626 ' HB2' HD13 ' A' ' 149' ' ' ILE . 20.8 tpt180 -134.01 121.99 22.37 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.212 1.005 . . . . 74.120000000000005 109.401 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 60.9 t -75.14 107.68 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.89 0.876 . . . . 62.420000000000002 109.417 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.528 HG21 HD13 ' A' ' 98' ' ' LEU . 27.0 m -122.96 163.8 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 125.257 1.423 . . . . 65.25 109.354 -179.129 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -120.99 113.02 19.47 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 122.911 0.485 . . . . 63.149999999999999 111.505 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.585 ' HB ' HD23 ' A' ' 98' ' ' LEU . 2.6 p -102.76 102.33 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 C-N-CA 123.649 0.78 . . . . 71.329999999999998 108.972 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.25 25.44 14.87 Favored 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 115.215 -0.902 . . . . 63.329999999999998 110.665 -169.377 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.9 6.17 62.17 Favored Glycine 0 C--N 1.358 1.804 0 CA-C-N 115.63 -0.714 . . . . 53.210000000000001 113.802 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.518 ' HB3' HG13 ' A' ' 140' ' ' VAL . 13.8 tpt180 -92.27 116.98 29.43 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.09 -0.707 . . . . 73.340000000000003 109.09 -179.781 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -80.89 109.8 15.81 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.809 -0.441 . . . . 70.109999999999999 109.809 -174.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 32.1 m -134.11 152.53 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 124.254 1.022 . . . . 43.409999999999997 109.218 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.531 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 45.1 m -104.36 114.86 29.38 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.736 0.414 . . . . 32.420000000000002 110.02 178.034 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.4 p -99.85 133.13 43.84 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 124.289 1.036 . . . . 43.119999999999997 109.9 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 38.9 ttp180 -75.81 115.46 15.53 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.091 0.556 . . . . 72.420000000000002 111.122 -174.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.626 HD13 ' HB2' ' A' ' 136' ' ' ARG . 6.1 pt -99.34 143.26 26.09 Favored Pre-proline 0 CA--C 1.558 1.256 0 C-N-CA 124.864 1.266 . . . . 50.149999999999999 109.315 177.59 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.411 ' HB2' ' HB ' ' A' ' 153' ' ' VAL . 52.7 Cg_exo -57.59 134.74 65.16 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.091 2.527 . . . . 71.239999999999995 113.094 178.616 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -62.72 114.53 2.44 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 70.310000000000002 111.112 172.361 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 131' ' ' PHE . . . 89.98 18.72 49.73 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.577 -0.568 . . . . 74.239999999999995 113.191 -178.628 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.411 ' HB ' ' HB2' ' A' ' 150' ' ' PRO . 13.2 p -64.0 141.68 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 C-N-CA 122.971 0.508 . . . . 64.430000000000007 111.395 -175.126 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -113.12 177.7 4.54 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 123.777 0.831 . . . . 72.420000000000002 112.706 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.69 135.7 57.76 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.535 -1.666 . . . . 73.129999999999995 111.744 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.58 6.66 77.52 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.905 0.753 . . . . 60.409999999999997 114.232 176.667 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.8 m -81.83 119.82 24.39 Favored 'General case' 0 C--N 1.349 0.564 0 N-CA-C 109.179 -0.675 . . . . 62.310000000000002 109.179 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.2 p -97.56 123.39 49.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.903 0 CA-C-O 121.313 0.578 . . . . 61.32 110.366 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.503 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.3 mt -93.29 103.73 14.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 124.379 1.071 . . . . 72.510000000000005 108.619 -175.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.452 ' HE ' HD21 ' A' ' 175' ' ' LEU . 43.0 ttm180 -90.18 111.36 22.49 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 122.767 0.427 . . . . 75.400000000000006 110.025 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 6.3 t -111.18 106.32 57.29 Favored Pre-proline 0 CA--C 1.552 1.05 0 N-CA-C 107.526 -1.287 . . . . 44.109999999999999 107.526 172.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.35 125.35 12.78 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.857 2.372 . . . . 71.400000000000006 112.691 -172.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.9 11.86 85.12 Favored Glycine 0 C--N 1.349 1.291 0 CA-C-O 119.792 -0.449 . . . . 75.120000000000005 114.044 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.2 tpt -100.99 -4.4 27.58 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-N 117.24 0.52 . . . . 74.530000000000001 110.766 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -74.11 -110.58 0.08 OUTLIER Glycine 0 C--N 1.344 0.996 0 CA-C-N 116.073 -0.512 . . . . 74.340000000000003 112.474 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -63.94 108.19 2.12 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 111.777 -0.529 . . . . 70.450000000000003 111.777 178.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.9 mm-40 -88.14 116.84 26.61 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.255 0.622 . . . . 72.040000000000006 110.308 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 169.22 -155.85 26.5 Favored Glycine 0 C--O 1.245 0.816 0 N-CA-C 110.359 -1.097 . . . . 72.030000000000001 110.359 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.457 ' O ' ' HD3' ' A' ' 171' ' ' PRO . 15.0 m120 -65.42 -34.52 9.72 Favored Pre-proline 0 N--CA 1.487 1.398 0 CA-C-O 118.274 -0.869 . . . . 73.099999999999994 112.053 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -90.64 99.6 0.26 Allowed 'Trans proline' 0 C--N 1.394 2.924 0 C-N-CA 122.527 2.152 . . . . 42.310000000000002 111.655 164.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.457 ' HD3' ' O ' ' A' ' 169' ' ' ASN . 10.6 Cg_exo -70.86 123.28 9.6 Favored 'Trans proline' 0 C--N 1.382 2.331 0 C-N-CA 121.683 1.588 . . . . 71.109999999999999 110.613 174.565 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -100.94 156.58 19.23 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.569 -0.613 . . . . 63.009999999999998 111.569 -178.63 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -83.99 143.57 29.7 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 109.849 -0.426 . . . . 74.209999999999994 109.849 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.61 HD21 HD11 ' A' ' 98' ' ' LEU . 64.1 tp -106.98 129.89 54.71 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.179 0.592 . . . . 64.150000000000006 109.851 -179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.452 HD21 ' HE ' ' A' ' 160' ' ' ARG . 98.1 mt -128.75 112.15 13.88 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.448 1.099 . . . . 73.349999999999994 110.025 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.597 HD13 HD12 ' A' ' 123' ' ' LEU . 81.9 mt -108.54 103.83 13.04 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.247 0.619 . . . . 73.310000000000002 110.96 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.52 94.62 4.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 N-CA-C 108.851 -0.796 . . . . 71.430000000000007 108.851 -176.024 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.4 t -57.63 118.68 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.877 0.871 . . . . 50.130000000000003 111.382 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -114.07 107.22 15.36 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 124.648 1.179 . . . . 74.329999999999998 108.22 175.549 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.05 122.07 18.68 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.526 0.517 . . . . 73.340000000000003 110.857 -176.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 93.0 mt -79.11 141.06 57.74 Favored Pre-proline 0 CA--C 1.544 0.745 0 CA-C-N 115.362 -0.835 . . . . 71.219999999999999 109.556 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.2 166.22 30.33 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.988 2.459 . . . . 72.099999999999994 112.591 -176.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.4 p-80 . . . . . 0 CA--C 1.56 1.327 0 C-N-CA 122.546 0.339 . . . . 71.140000000000001 110.299 178.835 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 pt? . . . . . 0 CA--C 1.562 1.429 0 N-CA-C 110.247 -0.279 . . . . 53.299999999999997 110.247 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -86.82 -67.79 0.01 OUTLIER 'Trans proline' 0 C--N 1.38 2.19 0 C-N-CA 122.865 2.376 . . . . 72.209999999999994 111.811 175.33 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.513 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.6 tp -159.74 140.92 12.6 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 108.516 -0.92 . . . . 71.129999999999995 108.516 176.206 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.712 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 11.5 tp 60.58 3.48 0.6 Allowed 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 126.461 1.904 . . . . 73.519999999999996 112.95 -178.207 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.739 ' HA ' HD13 ' A' ' 119' ' ' LEU . 75.0 t80 -135.35 133.25 38.57 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.271 1.028 . . . . 72.430000000000007 108.377 -173.196 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.507 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 89.3 m -153.6 102.17 2.54 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 123.75 0.82 . . . . 74.420000000000002 109.645 177.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -72.94 91.02 0.83 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 122.559 2.173 . . . . 72.030000000000001 111.631 -175.338 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 28.7 m . . . . . 0 N--CA 1.48 1.042 0 C-N-CA 124.178 0.991 . . . . 75.299999999999997 110.912 -178.491 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.439 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 3.9 mmp_? . . . . . 0 N--CA 1.484 1.238 0 N-CA-C 108.76 -0.83 . . . . 75.530000000000001 108.76 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -98.12 102.51 14.28 Favored 'General case' 0 CA--C 1.511 -0.542 0 N-CA-C 106.486 -1.672 . . . . 74.540000000000006 106.486 -173.599 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.739 HD13 ' HA ' ' A' ' 99' ' ' PHE . 16.5 mt -93.52 106.33 18.31 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.605 -1.257 . . . . 64.010000000000005 107.605 -169.056 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -111.02 103.24 11.69 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.904 -1.147 . . . . 71.209999999999994 107.904 -179.001 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.46 151.69 51.32 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.583 -0.735 . . . . 75.209999999999994 110.235 -168.711 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.529 ' HB3' ' HG3' ' A' ' 179' ' ' ARG . 40.4 mt-10 -81.55 124.17 29.27 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 114.6 -1.182 . . . . 72.450000000000003 109.342 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.53 HD12 HD13 ' A' ' 176' ' ' LEU . 3.2 tt -99.52 103.81 23.46 Favored Pre-proline 0 CA--C 1.54 0.583 0 N-CA-C 106.898 -1.519 . . . . 62.43 106.898 178.41 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.3 114.48 3.46 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 121.925 1.75 . . . . 72.340000000000003 110.438 175.595 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.499 HD21 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -139.23 120.08 14.35 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.039 -1.097 . . . . 71.430000000000007 108.039 -172.709 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 4.9 m -69.73 160.82 30.96 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 123.748 0.819 . . . . 75.129999999999995 111.112 -176.094 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 83.2 mt -56.17 -39.28 72.11 Favored 'General case' 0 N--CA 1.484 1.225 0 C-N-CA 123.894 0.878 . . . . 74.200000000000003 112.13 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -69.12 -44.19 72.91 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.447 0.699 . . . . 73.530000000000001 110.414 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -61.44 -39.15 89.76 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.321 1.048 . . . . 72.530000000000001 111.16 -179.12 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.447 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -72.98 -44.23 61.31 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-N 114.31 -1.314 . . . . 75.439999999999998 111.145 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -56.92 -47.83 79.66 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.803 1.241 . . . . 73.140000000000001 110.913 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -69.83 -48.55 58.53 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.716 -0.675 . . . . 61.399999999999999 110.181 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.549 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 55.65 76.37 0.2 Allowed Glycine 0 C--N 1.356 1.639 0 O-C-N 124.469 1.105 . . . . 25.219999999999999 113.638 176.552 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -112.57 -131.39 5.57 Favored Glycine 0 C--N 1.343 0.922 0 N-CA-C 111.328 -0.709 . . . . 60.039999999999999 111.328 177.193 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -100.96 152.19 20.86 Favored 'General case' 0 C--O 1.245 0.834 0 N-CA-C 108.694 -0.854 . . . . 61.039999999999999 108.694 170.838 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 tpp85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.003 0.921 . . . . 74.349999999999994 108.867 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.28 131.04 40.46 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 N-CA-C 108.582 -0.896 . . . . 64.319999999999993 108.582 175.546 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 27.1 m -125.14 161.19 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 123.604 0.762 . . . . 75.400000000000006 110.147 -178.419 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -97.56 141.71 30.27 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 124.075 0.95 . . . . 65.049999999999997 108.539 -178.354 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.712 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.0 p -150.1 109.31 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.199 0 C-N-CA 124.733 1.213 . . . . 73.219999999999999 111.394 -177.198 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.13 17.36 8.01 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 114.449 1.277 . . . . 72.519999999999996 114.449 164.787 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.12 22.34 13.36 Favored Glycine 0 N--CA 1.479 1.561 0 N-CA-C 112.514 -0.235 . . . . 64.25 112.514 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.423 ' HB2' HG13 ' A' ' 140' ' ' VAL . 24.7 mmm180 -134.75 153.86 51.83 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.906 1.282 . . . . 75.099999999999994 107.864 178.144 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -117.69 108.01 14.89 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.034 -0.728 . . . . 72.310000000000002 109.034 175.15 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 63.2 t -116.56 139.19 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 123.477 0.711 . . . . 74.439999999999998 110.174 -174.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.7 p -85.99 140.13 30.58 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 123.733 0.813 . . . . 73.019999999999996 111.087 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.415 HG21 HD12 ' A' ' 176' ' ' LEU . 14.7 p -133.55 157.59 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 124.641 1.176 . . . . 64.049999999999997 108.52 174.696 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 -107.32 128.72 54.7 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.783 -0.451 . . . . 75.239999999999995 109.783 177.484 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.499 HD12 HD21 ' A' ' 125' ' ' LEU . 15.7 pt -101.9 126.84 32.6 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.058 0.943 . . . . 71.150000000000006 108.65 176.799 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.408 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 27.9 Cg_endo -65.32 147.07 87.3 Favored 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.362 2.042 . . . . 70.540000000000006 113.547 -178.017 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.549 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 38.5 Cg_exo -62.88 121.92 10.0 Favored 'Trans proline' 0 C--N 1.385 2.452 0 C-N-CA 123.821 3.014 . . . . 70.329999999999998 112.159 179.156 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 72.33 40.13 55.83 Favored Glycine 0 C--N 1.339 0.747 0 O-C-N 124.051 0.844 . . . . 73.310000000000002 112.563 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.447 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 14.6 p -76.87 148.93 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 109.872 -0.418 . . . . 54.039999999999999 109.872 178.32 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 68.7 mtp180 -126.51 177.97 6.16 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-O 121.509 0.671 . . . . 60.030000000000001 112.413 -172.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -59.31 133.88 56.49 Favored 'General case' 0 CA--C 1.547 0.851 0 CA-C-N 113.409 -1.723 . . . . 64.209999999999994 111.865 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.31 -16.75 47.06 Favored Glycine 0 C--N 1.345 1.057 0 CA-C-O 119.388 -0.673 . . . . 20.23 113.312 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 48.3 m -67.15 118.72 10.95 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.36 0.58 . . . . 72.129999999999995 110.445 -173.399 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.9 p -94.12 125.0 46.8 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-O 121.528 0.68 . . . . 62.340000000000003 109.923 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 43.4 mt -94.82 99.75 9.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 107.061 -1.459 . . . . 63.100000000000001 107.061 174.319 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 46.6 ttt-85 -83.97 123.42 29.96 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 109.297 -0.631 . . . . 64.010000000000005 109.297 175.508 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.7 t -116.32 111.42 42.24 Favored Pre-proline 0 CA--C 1.555 1.168 0 N-CA-C 106.858 -1.534 . . . . 54.509999999999998 106.858 168.501 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.07 126.08 12.7 Favored 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.673 2.249 . . . . 71.040000000000006 112.25 -175.666 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.92 8.8 86.81 Favored Glycine 0 C--N 1.345 1.042 0 CA-C-N 115.774 -0.648 . . . . 74.549999999999997 114.57 171.466 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 24.0 mmt -114.07 15.35 18.36 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.154 0.582 . . . . 64.019999999999996 111.293 -176.685 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.21 -96.03 0.98 Allowed Glycine 0 C--N 1.344 0.973 0 N-CA-C 110.377 -1.089 . . . . 42.219999999999999 110.377 169.391 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' GLY . . . . . 0.439 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -79.12 95.29 1.4 Allowed Glycine 0 C--N 1.346 1.087 0 N-CA-C 112.177 -0.369 . . . . 71.200000000000003 112.177 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.6 mm100 -65.85 131.6 46.68 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.485 0.714 . . . . 70.310000000000002 111.508 -177.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 170.11 174.87 38.61 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.781 -0.928 . . . . 72.140000000000001 110.781 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.456 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 15.3 m120 -59.04 -42.37 93.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.358 0.663 . . . . 72.319999999999993 111.326 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.456 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 1.8 Cg_endo -87.42 101.34 0.5 Allowed 'Trans proline' 0 C--N 1.387 2.596 0 C-N-CA 122.429 2.086 . . . . 75.129999999999995 109.489 158.719 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.48 126.95 12.01 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 121.984 1.789 . . . . 61.329999999999998 111.911 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.99 151.14 21.94 Favored Glycine 0 C--N 1.343 0.946 0 CA-C-N 115.309 -0.859 . . . . 43.100000000000001 111.975 -179.131 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -77.74 159.4 29.1 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.512 0.725 . . . . 61.240000000000002 110.045 -170.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.534 HD21 HD11 ' A' ' 98' ' ' LEU . 47.5 tp -125.05 125.3 43.61 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.52 -0.548 . . . . 75.150000000000006 109.52 176.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 88.6 mt -127.4 101.47 6.47 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.88 0.872 . . . . 65.409999999999997 109.378 179.019 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.53 HD13 HD12 ' A' ' 123' ' ' LEU . 91.1 mt -102.96 102.23 12.28 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.992 0.517 . . . . 72.040000000000006 111.06 -178.147 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.99 107.57 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.011 -0.737 . . . . 71.519999999999996 109.011 -176.544 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.8 t -62.54 117.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.146 0.978 . . . . 73.25 111.078 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 179' ' ' ARG . . . . . 0.529 ' HG3' ' HB3' ' A' ' 122' ' ' GLU . 13.1 mmm180 -110.95 106.48 15.61 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 124.997 1.319 . . . . 71.230000000000004 108.092 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.406 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 65.8 mt -69.16 116.5 9.67 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 123.206 0.602 . . . . 72.310000000000002 110.815 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 81.9 mt -75.07 139.24 72.64 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 115.944 -0.571 . . . . 73.120000000000005 109.67 178.338 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -71.88 179.03 5.16 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.118 2.545 . . . . 72.319999999999993 112.872 177.454 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 . . . . . 0 C--O 1.252 1.234 0 N-CA-C 109.208 -0.664 . . . . 71.530000000000001 109.208 174.592 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.559 1.304 0 N-CA-C 113.837 1.051 . . . . 54.140000000000001 113.837 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.466 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 22.0 Cg_endo -62.51 178.17 1.01 Allowed 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.58 2.187 . . . . 75.030000000000001 112.473 168.711 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.651 HD13 ' HD2' ' A' ' 124' ' ' PRO . 1.7 tp -43.22 -53.97 4.8 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 125.287 1.435 . . . . 62.399999999999999 112.529 -174.038 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.434 ' O ' ' HB2' ' A' ' 99' ' ' PHE . 12.7 tp -119.3 91.92 3.67 Favored 'General case' 0 C--O 1.215 -0.757 0 N-CA-C 107.619 -1.252 . . . . 63.229999999999997 107.619 172.86 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.524 ' HA ' HD13 ' A' ' 119' ' ' LEU . 62.3 t80 168.52 131.54 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 124.361 1.064 . . . . 61.520000000000003 109.071 173.44 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.557 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 51.5 m -156.68 98.95 2.07 Favored Pre-proline 0 N--CA 1.475 0.787 0 N-CA-C 107.824 -1.176 . . . . 74.219999999999999 107.824 173.626 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -79.51 74.99 5.29 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 122.575 2.184 . . . . 70.120000000000005 112.553 -169.08 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 4.4 m . . . . . 0 CA--C 1.545 0.783 0 CA-C-N 115.541 -0.754 . . . . 52.539999999999999 109.997 179.448 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.56 1.348 0 CA-C-O 121.217 0.532 . . . . 75.5 111.065 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.57 130.74 40.88 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.228 -1.027 . . . . 74.430000000000007 108.228 -172.413 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.557 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 14.9 mt -100.73 112.83 25.31 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 108.111 -1.07 . . . . 64.239999999999995 108.111 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 75.0 ttt-85 -119.33 108.69 14.91 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 123.883 0.873 . . . . 73.019999999999996 110.208 -179.283 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -146.29 170.26 17.13 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 123.911 0.885 . . . . 74.040000000000006 108.701 179.004 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -97.03 145.21 26.17 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.969 0.414 . . . . 54.310000000000002 110.746 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.62 HD21 ' HG2' ' A' ' 136' ' ' ARG . 1.1 tt -103.01 103.9 36.74 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 124.901 1.28 . . . . 63.130000000000003 109.053 -177.11 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.651 ' HD2' HD13 ' A' ' 97' ' ' LEU . 37.7 Cg_endo -65.17 115.91 3.57 Favored 'Trans proline' 0 C--N 1.38 2.204 0 C-N-CA 122.107 1.871 . . . . 61.420000000000002 109.594 169.163 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.569 HD21 HD12 ' A' ' 149' ' ' ILE . 28.7 tp -137.15 127.02 25.69 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.361 0.664 . . . . 74.099999999999994 110.125 -172.779 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.9 p -78.18 167.91 20.67 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.062 0.545 . . . . 75.400000000000006 111.121 -175.505 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 76.9 mt -65.58 -37.3 86.25 Favored 'General case' 0 C--O 1.246 0.907 0 C-N-CA 123.981 0.913 . . . . 61.299999999999997 111.366 -173.65 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.47 -51.74 40.21 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 114.694 -1.139 . . . . 72.209999999999994 108.68 -177.386 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -62.43 -38.08 88.35 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.771 -1.104 . . . . 41.140000000000001 111.793 -178.123 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.39 -47.23 85.06 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 124.074 0.859 . . . . 73.209999999999994 110.453 176.101 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -66.48 -35.23 79.76 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 124.271 0.982 . . . . 75.530000000000001 111.136 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -67.32 -47.66 69.87 Favored 'General case' 0 C--N 1.363 1.18 0 CA-C-O 120.885 0.374 . . . . 73.030000000000001 110.018 177.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.58 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.19 56.01 24.57 Favored Glycine 0 C--N 1.341 0.852 0 CA-C-N 114.584 -1.189 . . . . 62.340000000000003 112.452 -174.259 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -103.3 -141.09 11.15 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 111.873 -0.491 . . . . 60.240000000000002 111.873 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -98.77 141.65 31.3 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.027 -0.731 . . . . 71.140000000000001 109.027 171.148 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.62 ' HG2' HD21 ' A' ' 123' ' ' LEU . 23.1 tpt180 -115.48 119.72 37.13 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.757 -1.201 . . . . 74.540000000000006 107.757 178.218 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 57.7 t -85.71 109.13 18.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 123.273 0.629 . . . . 61.310000000000002 109.519 -177.058 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.43 HG23 HD22 ' A' ' 98' ' ' LEU . 18.2 m -117.83 164.17 14.35 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 C-N-CA 125.609 1.563 . . . . 73.310000000000002 108.429 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -124.66 138.86 54.28 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 118.655 0.661 . . . . 70.409999999999997 111.413 -178.081 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.488 HG13 ' HB2' ' A' ' 143' ' ' ARG . 5.6 p -128.76 107.21 15.39 Favored 'Isoleucine or valine' 0 C--N 1.359 0.987 0 C-N-CA 124.838 1.255 . . . . 71.349999999999994 110.994 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.98 24.51 11.13 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.482 0.713 . . . . 55.520000000000003 112.166 175.811 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.39 18.09 29.48 Favored Glycine 0 C--N 1.348 1.246 0 CA-C-N 116.288 -0.415 . . . . 31.219999999999999 113.608 -178.282 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.488 ' HB2' HG13 ' A' ' 140' ' ' VAL . 10.8 mmm180 -117.64 123.09 45.29 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 123.773 0.829 . . . . 72.200000000000003 109.891 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.9 tpt180 -84.25 106.35 15.8 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 108.935 -0.765 . . . . 75.219999999999999 108.935 -176.505 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 88.4 t -115.98 132.17 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.87 0.868 . . . . 72.319999999999993 109.693 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 30.1 m -98.95 112.55 24.63 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.865 0.866 . . . . 74.409999999999997 109.23 176.121 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.486 HG21 HD12 ' A' ' 176' ' ' LEU . 3.8 p -99.72 121.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 124.023 0.929 . . . . 74.010000000000005 109.382 176.496 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -73.1 119.49 17.41 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.021 0.528 . . . . 74.420000000000002 110.182 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.58 HG13 ' HA2' ' A' ' 133' ' ' GLY . 4.9 pt -92.18 142.64 26.43 Favored Pre-proline 0 CA--C 1.563 1.478 0 C-N-CA 124.331 1.052 . . . . 63.030000000000001 109.948 177.571 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -58.84 148.36 84.24 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 123.555 2.837 . . . . 70.340000000000003 113.84 176.514 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.49 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 59.5 Cg_endo -70.31 113.04 3.33 Favored 'Trans proline' 0 C--N 1.377 2.044 0 C-N-CA 122.829 2.352 . . . . 72.319999999999993 111.414 177.408 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.22 39.01 37.93 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.826 -0.624 . . . . 64.319999999999993 112.34 -175.143 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 8.7 p -71.08 144.75 13.18 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 123.159 0.584 . . . . 74.239999999999995 110.143 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.506 ' HA ' HD11 ' A' ' 180' ' ' LEU . 64.6 mtp180 -119.24 177.13 5.01 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 121.766 0.794 . . . . 75.329999999999998 112.821 -171.376 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -64.89 130.25 42.75 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 113.535 -1.666 . . . . 73.510000000000005 111.121 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.52 -5.55 84.83 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-N 115.95 -0.568 . . . . 34.100000000000001 113.92 179.48 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.9 m -75.48 119.67 19.87 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-N 117.29 0.545 . . . . 72.420000000000002 109.742 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.6 t -98.51 116.63 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.069 0.547 . . . . 61.25 109.858 -174.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 57.5 mt -88.25 101.65 11.88 Favored 'Isoleucine or valine' 0 C--O 1.241 0.609 0 N-CA-C 108.074 -1.084 . . . . 73.310000000000002 108.074 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 13.4 ttp180 -91.79 113.79 26.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 114.821 -1.081 . . . . 74.349999999999994 109.477 178.14 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.0 t -114.85 113.83 44.35 Favored Pre-proline 0 CA--C 1.549 0.925 0 N-CA-C 108.922 -0.77 . . . . 72.140000000000001 108.922 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.04 124.23 12.73 Favored 'Trans proline' 0 C--N 1.377 2.065 0 C-N-CA 122.852 2.368 . . . . 62.420000000000002 112.595 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.41 -3.33 85.2 Favored Glycine 0 C--N 1.344 1.01 0 N-CA-C 114.911 0.724 . . . . 64.329999999999998 114.911 171.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.7 tpt -88.06 -7.62 56.72 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 117.622 0.711 . . . . 71.519999999999996 111.037 -175.813 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -75.81 -111.67 0.11 Allowed Glycine 0 C--N 1.349 1.278 0 N-CA-C 112.057 -0.417 . . . . 74.099999999999994 112.057 175.709 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.65 103.92 1.52 Allowed Glycine 0 C--N 1.344 1.017 0 CA-C-N 117.134 0.467 . . . . 31.219999999999999 113.304 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -65.98 147.89 52.66 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.483 0.713 . . . . 64.209999999999994 110.935 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 140.07 -171.78 23.73 Favored Glycine 0 N--CA 1.473 1.129 0 C-N-CA 123.136 0.398 . . . . 24.25 112.203 -177.751 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 45.7 m-80 -61.84 -46.15 92.6 Favored Pre-proline 0 CA--C 1.559 1.32 0 CA-C-O 118.394 -0.812 . . . . 71.349999999999994 111.698 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -88.33 103.66 0.46 Allowed 'Trans proline' 0 C--N 1.391 2.77 0 C-N-CA 121.842 1.695 . . . . 71.049999999999997 110.15 163.642 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -76.58 125.02 7.99 Favored 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 122.211 1.94 . . . . 70.219999999999999 110.723 -177.167 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -81.42 148.82 28.31 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 116.1 -0.5 . . . . 40.119999999999997 112.396 -178.503 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -78.19 151.93 32.93 Favored 'General case' 0 C--O 1.247 0.935 0 CA-C-O 121.102 0.477 . . . . 73.510000000000005 110.102 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.47 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 43.3 tp -114.17 131.89 56.29 Favored 'General case' 0 C--O 1.223 -0.334 0 C-N-CA 122.803 0.441 . . . . 73.099999999999994 110.075 177.162 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 73.1 mt -128.2 104.6 7.84 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 124.495 1.118 . . . . 74.209999999999994 108.902 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.486 HD12 HG21 ' A' ' 147' ' ' VAL . 66.6 mt -113.63 105.53 13.43 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.392 0.677 . . . . 64.430000000000007 110.565 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.8 t -84.72 103.8 12.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 109.239 -0.652 . . . . 64.400000000000006 109.239 -175.365 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.4 t -58.84 125.5 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 O-C-N 123.697 0.623 . . . . 61.219999999999999 111.539 -177.508 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -115.12 107.72 15.7 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 125.144 1.377 . . . . 64.319999999999993 107.499 176.038 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.506 HD11 ' HA ' ' A' ' 154' ' ' ARG . 54.1 mt -69.19 110.09 4.39 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.504 -0.925 . . . . 74.439999999999998 108.504 177.056 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 84.9 mt -68.82 129.84 92.11 Favored Pre-proline 0 CA--C 1.544 0.742 0 CA-C-N 115.715 -0.675 . . . . 75.530000000000001 110.013 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -65.43 158.68 51.5 Favored 'Trans proline' 0 C--N 1.369 1.625 0 C-N-CA 122.978 2.452 . . . . 74.010000000000005 111.825 176.329 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.6 t-80 . . . . . 0 CA--C 1.552 1.028 0 C-N-CA 123.509 0.724 . . . . 75.25 110.239 174.243 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.505 2.319 0 N-CA-C 114.482 1.29 . . . . 74.099999999999994 114.482 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -70.32 -43.35 2.24 Favored 'Trans proline' 0 C--N 1.38 2.229 0 C-N-CA 122.514 2.143 . . . . 63.340000000000003 112.153 -173.521 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.561 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.3 tp -175.39 145.43 0.75 Allowed 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.175 1.39 . . . . 65.209999999999994 107.804 -176.301 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.561 ' H ' HD12 ' A' ' 97' ' ' LEU . 4.2 tt 52.77 -78.27 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 126.924 2.09 . . . . 71.450000000000003 111.782 -174.589 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.672 ' HA ' HD13 ' A' ' 119' ' ' LEU . 78.2 t80 -57.01 120.71 8.45 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.909 1.283 . . . . 52.039999999999999 112.444 -178.06 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.555 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 88.8 m -138.62 97.97 9.02 Favored Pre-proline 0 CA--C 1.545 0.778 0 C-N-CA 124.287 1.035 . . . . 74.129999999999995 109.17 176.669 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.92 103.01 1.12 Allowed 'Trans proline' 0 C--N 1.367 1.527 0 C-N-CA 122.447 2.098 . . . . 65.209999999999994 111.708 -176.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.473 0.712 0 C-N-CA 124.249 1.02 . . . . 74.239999999999995 111.378 179.207 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.801 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 68.3 mtt180 . . . . . 0 N--CA 1.477 0.901 0 N-CA-C 109.722 -0.474 . . . . 74.019999999999996 109.722 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -99.44 107.43 19.64 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.903 -1.147 . . . . 44.520000000000003 107.903 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.672 HD13 ' HA ' ' A' ' 99' ' ' PHE . 13.5 mt -93.63 109.52 21.15 Favored 'General case' 0 C--O 1.22 -0.454 0 N-CA-C 106.769 -1.567 . . . . 74.409999999999997 106.769 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -121.11 107.94 13.21 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.953 0.901 . . . . 72.540000000000006 108.634 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.23 156.3 47.83 Favored 'General case' 0 C--O 1.24 0.6 0 C-N-CA 123.162 0.585 . . . . 73.349999999999994 110.401 -174.273 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -75.66 125.95 30.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.497 1.119 . . . . 75.150000000000006 108.942 179.11 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.575 HD11 ' HG2' ' A' ' 136' ' ' ARG . 26.1 tp -100.66 101.42 15.35 Favored Pre-proline 0 CA--C 1.543 0.681 0 C-N-CA 123.507 0.723 . . . . 43.25 109.331 178.546 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.64 114.98 4.17 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.251 1.967 . . . . 64.319999999999993 110.002 175.16 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.515 HD21 HD12 ' A' ' 149' ' ' ILE . 18.6 tp -131.89 135.62 46.79 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 108.223 -1.029 . . . . 74.319999999999993 108.223 -173.405 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 38.8 p -81.84 171.59 14.32 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.588 -0.523 . . . . 71.310000000000002 109.588 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 88.7 mt -68.05 -32.73 73.28 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 122.925 0.49 . . . . 74.299999999999997 110.343 176.14 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -69.48 -49.44 54.7 Favored 'General case' 0 N--CA 1.47 0.56 0 O-C-N 124.013 0.82 . . . . 64.239999999999995 109.433 -177.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -68.66 -34.6 75.98 Favored 'General case' 0 N--CA 1.472 0.648 0 O-C-N 124.016 0.823 . . . . 73.319999999999993 111.127 -178.166 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.51 -48.56 81.25 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.908 0.755 . . . . 54.030000000000001 110.599 173.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -65.09 -37.14 86.55 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 124.464 1.106 . . . . 72.430000000000007 110.905 179.275 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -64.2 -42.32 96.69 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 123.635 0.584 . . . . 71.430000000000007 110.136 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 58.63 35.56 81.57 Favored Glycine 0 C--N 1.349 1.251 0 O-C-N 124.234 0.959 . . . . 71.400000000000006 112.326 -174.712 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -87.71 -136.47 5.12 Favored Glycine 0 C--N 1.342 0.888 0 N-CA-C 112.045 -0.422 . . . . 52.530000000000001 112.045 -175.703 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.602 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 15.3 mp0 -111.43 139.77 46.58 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.052 -1.092 . . . . 43.140000000000001 108.052 173.694 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.575 ' HG2' HD11 ' A' ' 123' ' ' LEU . 37.9 tpt85 -112.81 120.51 41.74 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 124.323 1.049 . . . . 70.209999999999994 108.183 -177.195 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 91.2 t -81.39 106.3 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.79 0.836 . . . . 64.150000000000006 109.395 -176.876 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.53 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 20.4 m -111.35 159.92 11.0 Favored 'Isoleucine or valine' 0 C--O 1.245 0.839 0 C-N-CA 124.516 1.127 . . . . 74.329999999999998 111.113 -174.595 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -93.72 136.94 33.49 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.624 1.17 . . . . 65.450000000000003 109.056 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 1.5 p -151.9 100.35 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 C-N-CA 124.02 0.928 . . . . 74.430000000000007 110.445 176.043 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.02 21.26 11.63 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 113.526 0.936 . . . . 64.200000000000003 113.526 171.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.55 -7.37 55.89 Favored Glycine 0 N--CA 1.479 1.525 0 C-N-CA 123.162 0.41 . . . . 70.25 113.162 -176.864 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.04 150.2 21.52 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.83 0.852 . . . . 73.099999999999994 109.461 173.749 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 55.7 ttp180 -113.36 108.84 17.77 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 107.282 -1.377 . . . . 72.049999999999997 107.282 176.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.407 ' O ' HG22 ' A' ' 138' ' ' VAL . 70.1 t -121.77 134.48 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 C-N-CA 123.379 0.672 . . . . 72.329999999999998 110.619 -173.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.602 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 29.1 p -95.37 109.21 21.41 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 123.483 0.713 . . . . 41.149999999999999 109.165 176.488 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -98.91 128.24 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.508 0.723 . . . . 71.319999999999993 109.338 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -70.43 122.91 20.52 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 109.287 -0.634 . . . . 72.420000000000002 109.287 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.515 HD12 HD21 ' A' ' 125' ' ' LEU . 4.3 pt -98.69 149.49 35.79 Favored Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 124.875 1.27 . . . . 53.229999999999997 109.623 176.576 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -63.82 143.41 85.98 Favored 'Trans proline' 0 C--N 1.377 2.062 0 C-N-CA 122.77 2.313 . . . . 71.230000000000004 112.755 176.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.35 123.53 10.66 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 122.755 2.303 . . . . 40.509999999999998 111.91 174.899 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.48 26.71 64.95 Favored Glycine 0 C--N 1.347 1.179 0 CA-C-N 115.849 -0.614 . . . . 71.230000000000004 113.101 -178.444 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 7.4 p -67.68 145.9 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 C-N-CA 123.658 0.783 . . . . 63.119999999999997 111.363 -177.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.505 ' HA ' HD11 ' A' ' 180' ' ' LEU . 60.5 mtp180 -120.13 169.42 10.24 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-O 121.855 0.836 . . . . 75.099999999999994 112.832 -172.158 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -61.12 119.85 9.16 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 113.062 -1.881 . . . . 64.150000000000006 109.623 173.077 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 116.23 -25.4 9.33 Favored Glycine 0 N--CA 1.477 1.377 0 O-C-N 123.325 0.391 . . . . 61.149999999999999 112.583 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.6 m -69.88 123.92 22.71 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.479 0.712 . . . . 54.310000000000002 110.924 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.0 p -100.94 131.08 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 108.666 -0.864 . . . . 71.140000000000001 108.666 172.374 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 34.9 mt -100.05 102.15 13.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 107.859 -1.163 . . . . 71.150000000000006 107.859 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.489 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 51.1 ttp85 -87.73 106.43 18.05 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.538 -0.541 . . . . 72.230000000000004 109.538 175.182 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.1 t -100.48 96.44 5.29 Favored Pre-proline 0 CA--C 1.555 1.173 0 N-CA-C 107.481 -1.303 . . . . 73.299999999999997 107.481 173.361 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.66 143.67 42.58 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.958 2.438 . . . . 71.340000000000003 111.564 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' GLY . . . . . 0.713 ' HA2' ' HB2' ' A' ' 171' ' ' PRO . . . 85.47 -24.79 6.93 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-N 116.068 -0.514 . . . . 63.399999999999999 113.595 177.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.7 mmt -98.73 14.76 27.54 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.956 0.902 . . . . 71.209999999999994 111.013 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.86 -119.94 1.72 Allowed Glycine 0 C--N 1.348 1.21 0 N-CA-C 111.758 -0.537 . . . . 60.049999999999997 111.758 175.648 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' GLY . . . . . 0.801 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.94 112.8 3.57 Favored Glycine 0 C--N 1.348 1.231 0 CA-C-N 117.11 0.455 . . . . 72.439999999999998 112.453 -177.818 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -81.53 139.3 35.2 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.581 0.752 . . . . 70.549999999999997 110.502 -177.185 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -173.37 -142.64 3.94 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.509 -1.037 . . . . 75.519999999999996 110.509 -179.187 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.411 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 39.3 t30 -73.81 -49.41 6.11 Favored Pre-proline 0 CA--C 1.563 1.471 0 N-CA-C 109.151 -0.685 . . . . 64.299999999999997 109.151 169.318 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.411 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 93.1 Cg_endo -91.8 135.14 1.58 Allowed 'Trans proline' 0 C--N 1.389 2.709 0 C-N-CA 121.935 1.757 . . . . 72.439999999999998 111.748 165.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.713 ' HB2' ' HA2' ' A' ' 163' ' ' GLY . 55.8 Cg_endo -67.56 128.35 17.99 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.406 2.071 . . . . 61.140000000000001 111.599 172.307 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.27 162.84 32.47 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-N 116.095 -0.502 . . . . 43.340000000000003 113.108 -179.127 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -86.73 145.81 26.51 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.67 0.788 . . . . 65.400000000000006 110.532 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.489 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 42.8 tp -111.21 135.1 52.24 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.835 0.854 . . . . 62.210000000000001 109.288 173.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 66.7 mt -127.67 102.18 6.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.062 1.345 . . . . 54.420000000000002 108.813 178.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 98.1 mt -102.41 101.41 11.63 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.406 0.682 . . . . 73.150000000000006 109.481 177.738 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.7 t -85.66 97.87 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 109.043 -0.725 . . . . 75.129999999999995 109.043 -174.825 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 86.7 t -57.96 104.87 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 124.415 1.086 . . . . 71.129999999999995 111.47 -176.161 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -98.35 101.64 13.15 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-N 113.803 -1.544 . . . . 74.219999999999999 108.375 170.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.505 HD11 ' HA ' ' A' ' 154' ' ' ARG . 47.3 mt -69.64 126.77 30.73 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.634 -0.506 . . . . 73.129999999999995 109.634 176.509 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 59.5 mt -77.01 140.46 66.56 Favored Pre-proline 0 CA--C 1.548 0.865 0 N-CA-C 108.772 -0.825 . . . . 75.219999999999999 108.772 178.942 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -49.23 -73.54 0.04 OUTLIER 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 123.994 3.129 . . . . 54.229999999999997 113.165 -174.164 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 . . . . . 0 C--O 1.252 1.192 0 C-N-CA 124.538 1.135 . . . . 73.450000000000003 108.382 177.855 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.449 ' HG ' ' HA ' ' A' ' 100' ' ' THR . 2.7 tt . . . . . 0 CA--C 1.556 1.21 0 N-CA-C 109.601 -0.518 . . . . 62.5 109.601 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -75.4 -60.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.385 2.495 0 C-N-CA 121.951 1.768 . . . . 74.109999999999999 111.828 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.47 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.2 tp -169.32 135.96 1.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.696 -1.594 . . . . 73.420000000000002 106.696 -173.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.547 HD13 HD11 ' A' ' 176' ' ' LEU . 14.8 tp 70.67 -60.42 0.5 Allowed 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.89 2.076 . . . . 72.019999999999996 112.511 -173.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.706 ' HB2' ' HA ' ' A' ' 140' ' ' VAL . 32.7 t80 -61.45 113.29 2.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.201 1.0 . . . . 72.530000000000001 111.782 179.111 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.449 ' HA ' ' HG ' ' A' ' 95' ' ' LEU . 98.2 m -133.4 95.3 18.29 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 124.045 0.938 . . . . 73.540000000000006 109.575 175.471 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.47 84.25 1.41 Allowed 'Trans proline' 0 C--N 1.369 1.658 0 C-N-CA 122.317 2.011 . . . . 73.230000000000004 112.802 -175.591 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.43 HG13 HG22 ' A' ' 100' ' ' THR . 23.3 m . . . . . 0 N--CA 1.472 0.633 0 CA-C-N 115.062 -0.972 . . . . 64.409999999999997 110.57 177.325 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 . . . . . 0 N--CA 1.477 0.891 0 N-CA-C 108.64 -0.874 . . . . 71.430000000000007 108.64 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -96.87 106.19 18.46 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 106.801 -1.555 . . . . 60.119999999999997 106.801 -178.401 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 15.7 mt -92.71 107.13 18.98 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 106.297 -1.742 . . . . 71.0 106.297 -172.127 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.504 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 59.6 ttt-85 -114.99 105.97 13.6 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.008 -1.108 . . . . 74.049999999999997 108.008 -176.685 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.52 146.67 50.43 Favored 'General case' 0 C--O 1.24 0.601 0 N-CA-C 108.742 -0.836 . . . . 61.030000000000001 108.742 -179.094 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -71.84 131.35 42.91 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 108.621 -0.881 . . . . 70.409999999999997 108.621 173.049 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.544 HD21 ' HG2' ' A' ' 136' ' ' ARG . 1.5 tt -98.4 103.27 17.41 Favored Pre-proline 0 CA--C 1.532 0.275 0 N-CA-C 106.352 -1.721 . . . . 73.230000000000004 106.352 176.431 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.474 ' HB2' HD11 ' A' ' 181' ' ' LEU . 50.5 Cg_endo -65.61 116.0 3.69 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 121.935 1.757 . . . . 74.349999999999994 109.786 174.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.464 HD21 HD12 ' A' ' 149' ' ' ILE . 15.6 tp -147.75 120.32 8.55 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.395 -0.595 . . . . 60.119999999999997 109.395 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.455 HG22 ' HB2' ' A' ' 181' ' ' LEU . 71.4 p -77.13 168.04 20.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.807 0.443 . . . . 51.43 111.724 -177.288 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.3 mt -55.64 -47.2 77.02 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 123.872 0.869 . . . . 74.129999999999995 112.137 -177.388 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -66.71 -41.4 88.02 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 115.959 -0.564 . . . . 74.299999999999997 111.279 -178.576 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -68.31 -31.86 71.59 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 122.91 0.484 . . . . 52.329999999999998 111.592 178.165 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -72.21 -39.38 68.59 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 123.337 0.655 . . . . 61.439999999999998 111.07 177.793 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -63.21 -56.52 15.93 Favored 'General case' 0 N--CA 1.472 0.628 0 O-C-N 124.619 1.199 . . . . 61.229999999999997 110.011 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 50.3 m80 -70.24 -34.96 73.49 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.469 -0.787 . . . . 71.010000000000005 111.16 -177.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 68.94 -135.35 28.07 Favored Glycine 0 C--N 1.353 1.513 0 N-CA-C 111.949 -0.46 . . . . 33.520000000000003 111.949 -177.29 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.49 -143.28 16.5 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 112.201 -0.36 . . . . 62.439999999999998 112.201 178.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -104.44 148.36 26.52 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.237 0.541 . . . . 71.310000000000002 111.31 -178.604 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.544 ' HG2' HD21 ' A' ' 123' ' ' LEU . 2.2 tpp180 -137.16 119.1 15.28 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 106.741 -1.577 . . . . 74.430000000000007 106.741 175.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.59 115.97 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.704 0 CA-C-O 121.864 0.84 . . . . 75.409999999999997 109.801 -174.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 11.4 m -122.7 164.33 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.981 1.312 . . . . 74.030000000000001 108.828 -171.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -123.16 125.42 45.1 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 118.457 0.571 . . . . 74.409999999999997 111.936 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.706 ' HA ' ' HB2' ' A' ' 99' ' ' PHE . 4.0 p -113.52 111.37 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.368 1.067 . . . . 62.119999999999997 110.17 175.888 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.34 26.3 14.97 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 123.807 0.843 . . . . 61.520000000000003 112.854 172.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.86 -12.03 60.84 Favored Glycine 0 C--N 1.352 1.421 0 CA-C-N 116.51 -0.314 . . . . 53.450000000000003 113.104 -177.249 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.1 tpp180 -92.22 115.86 28.44 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.637 0.775 . . . . 75.409999999999997 110.03 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 3.1 tpp180 -87.0 106.95 18.19 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.934 -0.765 . . . . 65.239999999999995 108.934 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 34.4 m -116.22 156.35 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 C-N-CA 123.911 0.884 . . . . 73.140000000000001 110.923 -178.785 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.0 p -91.32 141.95 28.22 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.53 0.732 . . . . 61.0 110.099 175.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 43.2 t -128.38 111.51 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 C-N-CA 124.747 1.219 . . . . 74.239999999999995 108.855 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -80.07 102.32 9.26 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.446 0.641 . . . . 60.420000000000002 109.417 178.375 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.464 HD12 HD21 ' A' ' 125' ' ' LEU . 16.5 pt -82.74 131.66 53.99 Favored Pre-proline 0 CA--C 1.559 1.296 0 CA-C-N 114.81 -1.086 . . . . 75.430000000000007 109.907 178.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 37.1 Cg_exo -64.22 135.86 48.87 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 122.656 2.237 . . . . 55.130000000000003 113.437 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -67.04 121.32 8.48 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 122.345 2.03 . . . . 52.310000000000002 110.742 168.63 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 87.82 27.47 26.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 115.549 -0.75 . . . . 73.230000000000004 113.22 -172.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.66 142.88 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 117.443 0.622 . . . . 64.409999999999997 109.74 176.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -112.7 177.6 4.58 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 121.635 0.731 . . . . 72.409999999999997 112.407 -172.149 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -65.02 133.49 51.79 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 113.56 -1.654 . . . . 62.439999999999998 110.644 176.612 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 83.8 -14.02 44.96 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-O 119.24 -0.755 . . . . 53.340000000000003 113.353 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 68.4 m -66.28 117.79 9.05 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 117.422 0.611 . . . . 63.310000000000002 109.667 -175.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.21 133.57 33.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 CA-C-O 121.362 0.601 . . . . 75.319999999999993 110.001 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.538 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 94.0 mt -99.95 102.3 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 N-CA-C 106.519 -1.66 . . . . 72.040000000000006 106.519 177.145 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.536 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 61.1 ttp85 -99.31 110.18 22.73 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.354 -0.385 . . . . 70.439999999999998 110.184 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.93 100.55 10.05 Favored Pre-proline 0 CA--C 1.557 1.241 0 N-CA-C 107.525 -1.287 . . . . 72.409999999999997 107.525 170.23 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.45 136.7 29.17 Favored 'Trans proline' 0 C--N 1.376 1.976 0 C-N-CA 122.937 2.424 . . . . 75.409999999999997 112.637 -173.073 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.15 -21.82 11.37 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.889 -0.596 . . . . 64.219999999999999 113.883 177.146 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 56.8 mtt -100.52 16.42 24.74 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 123.563 0.745 . . . . 74.209999999999994 111.402 -173.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' GLY . . . . . 0.584 ' HA2' HD13 ' A' ' 174' ' ' LEU . . . -85.27 -103.45 0.67 Allowed Glycine 0 C--N 1.351 1.407 0 CA-C-N 116.196 -0.457 . . . . 74.230000000000004 112.236 176.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -66.86 103.18 0.86 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.807 -0.517 . . . . 25.219999999999999 111.807 175.529 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -88.61 152.7 21.67 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.704 0.801 . . . . 73.099999999999994 110.419 -179.115 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 134.17 -137.0 8.96 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.462 -1.055 . . . . 74.25 110.462 -172.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.533 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 14.9 m120 -71.97 -56.48 4.55 Favored Pre-proline 0 CA--C 1.563 1.479 0 CA-C-N 117.704 0.752 . . . . 73.25 111.243 176.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.533 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -93.82 119.64 0.34 Allowed 'Trans proline' 0 C--N 1.396 3.041 0 C-N-CA 122.443 2.095 . . . . 53.200000000000003 112.434 178.388 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -63.03 125.2 15.36 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.82 2.347 . . . . 73.430000000000007 112.271 174.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.83 173.77 23.89 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 116.576 -0.284 . . . . 74.319999999999993 112.472 177.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -95.05 134.93 37.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.082 0.553 . . . . 62.43 109.878 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.584 HD13 ' HA2' ' A' ' 165' ' ' GLY . 17.1 tp -97.79 119.36 36.25 Favored 'General case' 0 C--O 1.216 -0.673 0 N-CA-C 107.989 -1.115 . . . . 73.420000000000002 107.989 -178.533 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 65.6 mt -123.48 120.15 32.06 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.761 0.824 . . . . 71.340000000000003 109.598 -170.108 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.547 HD11 HD13 ' A' ' 98' ' ' LEU . 41.9 mt -123.0 101.12 7.24 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 123.254 0.622 . . . . 74.340000000000003 110.937 177.323 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.1 t -85.84 96.38 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 108.409 -0.96 . . . . 70.239999999999995 108.409 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.8 t -56.02 126.51 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.199 1.0 . . . . 53.149999999999999 111.721 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.8 mmm-85 -112.87 110.01 19.83 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.786 -1.191 . . . . 75.030000000000001 107.786 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 46.0 mt -70.67 96.04 1.17 Allowed 'General case' 0 C--O 1.238 0.481 0 N-CA-C 109.408 -0.59 . . . . 71.439999999999998 109.408 178.374 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.474 HD11 ' HB2' ' A' ' 124' ' ' PRO . 80.4 mt -71.56 149.3 93.4 Favored Pre-proline 0 C--O 1.246 0.873 0 CA-C-N 114.711 -1.131 . . . . 62.340000000000003 110.445 -179.284 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -57.86 142.86 96.52 Favored 'Trans proline' 0 C--N 1.372 1.801 0 C-N-CA 122.557 2.171 . . . . 71.530000000000001 111.656 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 27.9 p80 . . . . . 0 CA--C 1.558 1.265 0 C-N-CA 123.543 0.737 . . . . 74.310000000000002 111.328 179.228 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.3 pt? . . . . . 0 CA--C 1.545 0.776 0 N-CA-C 110.251 -0.277 . . . . 73.109999999999999 110.251 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_exo -73.34 -160.9 0.1 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 122.8 2.333 . . . . 72.510000000000005 111.25 167.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.541 HD12 ' H ' ' A' ' 98' ' ' LEU . 9.1 tp -72.04 141.47 49.28 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.819 -0.808 . . . . 71.230000000000004 108.819 171.532 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.677 HD13 HG21 ' A' ' 138' ' ' VAL . 6.0 tp 65.58 -68.16 0.12 Allowed 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 126.83 2.052 . . . . 45.310000000000002 111.579 -174.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.592 ' HA ' HD13 ' A' ' 119' ' ' LEU . 59.8 t80 -59.78 127.83 33.91 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.213 1.005 . . . . 70.409999999999997 111.708 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.502 HG22 HG13 ' A' ' 102' ' ' VAL . 56.3 m -141.75 104.61 5.81 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 124.086 0.954 . . . . 74.099999999999994 109.228 175.116 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.1 87.1 1.05 Allowed 'Trans proline' 0 C--N 1.362 1.278 0 C-N-CA 122.299 2.0 . . . . 60.310000000000002 112.97 -170.284 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.502 HG13 HG22 ' A' ' 100' ' ' THR . 22.8 m . . . . . 0 C--O 1.239 0.525 0 CA-C-N 114.451 -1.25 . . . . 73.319999999999993 109.846 174.608 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 42.9 mtt180 . . . . . 0 N--CA 1.473 0.693 0 N-CA-C 109.775 -0.454 . . . . 74.239999999999995 109.775 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -98.91 104.17 16.19 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.873 -1.529 . . . . 71.230000000000004 106.873 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.592 HD13 ' HA ' ' A' ' 99' ' ' PHE . 11.5 mt -92.71 110.44 21.88 Favored 'General case' 0 C--N 1.343 0.323 0 N-CA-C 106.633 -1.617 . . . . 65.209999999999994 106.633 -173.402 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -117.76 108.55 15.52 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 108.975 -0.75 . . . . 75.340000000000003 108.975 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.48 154.02 51.15 Favored 'General case' 0 C--O 1.24 0.592 0 C-N-CA 123.193 0.597 . . . . 32.439999999999998 110.682 -171.601 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -72.13 131.58 43.0 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.291 -0.868 . . . . 60.229999999999997 109.109 173.207 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.627 HD21 ' HG2' ' A' ' 136' ' ' ARG . 2.4 tt -101.47 102.61 22.59 Favored Pre-proline 0 CA--C 1.544 0.733 0 N-CA-C 107.949 -1.13 . . . . 73.430000000000007 107.949 176.047 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.74 115.79 3.94 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 121.928 1.752 . . . . 71.510000000000005 110.019 173.143 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 46.3 tp -142.75 131.52 22.73 Favored 'General case' 0 C--O 1.225 -0.194 0 C-N-CA 123.648 0.779 . . . . 71.129999999999995 109.012 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 55.0 p -80.13 163.61 23.98 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 122.865 0.466 . . . . 74.230000000000004 111.286 -176.745 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.9 mt -58.77 -51.82 68.35 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.666 0.787 . . . . 74.299999999999997 112.826 -171.204 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -64.83 -40.13 94.68 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 122.742 0.417 . . . . 74.019999999999996 111.109 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -69.49 -26.04 64.35 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 112.288 0.477 . . . . 74.030000000000001 112.288 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -69.11 -46.68 67.1 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 123.619 0.768 . . . . 63.210000000000001 109.743 172.096 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -61.93 -42.03 98.63 Favored 'General case' 0 CA--C 1.546 0.801 0 CA-C-N 114.614 -1.176 . . . . 64.409999999999997 111.039 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.4 m80 -72.97 -42.2 63.6 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 122.804 0.442 . . . . 72.340000000000003 110.317 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.85 -128.76 9.79 Favored Glycine 0 C--N 1.345 1.032 0 CA-C-N 115.309 -0.86 . . . . 53.130000000000003 111.308 -172.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.416 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 80.38 -158.5 41.79 Favored Glycine 0 C--N 1.348 1.24 0 CA-C-N 116.834 0.317 . . . . 43.530000000000001 112.805 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -84.0 147.16 27.59 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 117.329 0.564 . . . . 71.129999999999995 109.763 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.627 ' HG2' HD21 ' A' ' 123' ' ' LEU . 27.0 tpt180 -128.33 121.2 28.63 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.433 0.693 . . . . 73.219999999999999 109.178 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.416 HG13 ' HG3' ' A' ' 144' ' ' ARG . 93.1 t -79.22 106.87 10.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.455 0 C-N-CA 123.975 0.91 . . . . 73.030000000000001 109.265 178.055 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.677 HG21 HD13 ' A' ' 98' ' ' LEU . 20.7 m -111.13 159.64 10.97 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 123.863 0.865 . . . . 74.129999999999995 109.377 176.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -116.79 138.12 51.72 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 107.703 -1.221 . . . . 73.239999999999995 107.703 -176.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.572 HG13 ' HB2' ' A' ' 143' ' ' ARG . 3.7 p -150.15 107.12 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 C-N-CA 123.212 0.605 . . . . 60.530000000000001 111.498 -176.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.18 20.6 8.63 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 113.359 0.874 . . . . 44.5 113.359 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.9 28.31 7.87 Favored Glycine 0 C--N 1.344 0.976 0 C-N-CA 122.903 0.287 . . . . 73.120000000000005 112.582 -175.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.572 ' HB2' HG13 ' A' ' 140' ' ' VAL . 82.3 mtt85 -133.68 156.64 47.55 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 123.533 0.733 . . . . 74.129999999999995 110.095 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.416 ' HG3' HG13 ' A' ' 137' ' ' VAL . 31.6 ttm180 -109.86 119.77 40.39 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.754 0.822 . . . . 75.439999999999998 109.169 170.457 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.404 ' O ' HG22 ' A' ' 138' ' ' VAL . 69.8 t -115.69 135.63 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 108.421 -0.955 . . . . 53.240000000000002 108.421 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 28.9 p -103.2 104.78 14.96 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 109.141 -0.688 . . . . 72.030000000000001 109.141 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 4.7 p -98.3 120.29 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 109.172 -0.677 . . . . 74.319999999999993 109.172 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 47.3 ttp180 -78.21 100.37 6.62 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-O 121.415 0.626 . . . . 74.200000000000003 109.33 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.562 HD13 ' HB2' ' A' ' 136' ' ' ARG . 3.1 pt -79.55 144.9 62.03 Favored Pre-proline 0 CA--C 1.563 1.449 0 CA-C-N 114.639 -1.164 . . . . 72.329999999999998 109.766 178.444 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -61.93 136.82 63.71 Favored 'Trans proline' 0 CA--C 1.562 1.891 0 C-N-CA 123.005 2.47 . . . . 52.43 113.393 -179.033 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -62.18 113.12 1.76 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.948 2.432 . . . . 55.219999999999999 111.179 172.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.47 35.51 8.59 Favored Glycine 0 C--N 1.34 0.765 0 O-C-N 123.616 0.573 . . . . 72.409999999999997 112.379 -176.241 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.415 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 12.6 p -76.65 145.85 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 N-CA-C 109.818 -0.438 . . . . 70.239999999999995 109.818 176.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -118.39 177.15 4.92 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.651 0.739 . . . . 75.140000000000001 112.636 -171.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -64.68 135.05 55.47 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 113.989 -1.459 . . . . 63.420000000000002 110.974 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.22 -6.13 64.73 Favored Glycine 0 C--N 1.343 0.959 0 CA-C-N 115.767 -0.652 . . . . 75.099999999999994 113.646 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 56.0 m -74.85 118.89 18.31 Favored 'General case' 0 C--N 1.351 0.647 0 CA-C-N 117.502 0.651 . . . . 72.430000000000007 109.506 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.0 p -99.05 134.25 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 123.087 0.555 . . . . 64.010000000000005 110.413 -177.136 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 67.7 mt -105.94 105.87 19.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 C-N-CA 124.328 1.051 . . . . 73.140000000000001 108.71 -175.125 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 58.0 ttm-85 -87.96 111.86 21.94 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.81 0.444 . . . . 74.409999999999997 110.405 -178.318 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -123.95 98.95 38.66 Favored Pre-proline 0 CA--C 1.554 1.124 0 C-N-CA 123.942 0.897 . . . . 72.439999999999998 109.0 179.308 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.28 131.75 21.13 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.488 2.126 . . . . 75.319999999999993 112.22 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.89 -23.17 37.07 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.761 -0.654 . . . . 52.509999999999998 113.56 176.099 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.2 mpt? -89.57 6.56 40.55 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.107 0.563 . . . . 74.239999999999995 111.288 178.004 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -85.51 -108.37 0.7 Allowed Glycine 0 C--N 1.344 1.001 0 N-CA-C 111.556 -0.617 . . . . 74.319999999999993 111.556 174.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.6 108.93 2.64 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 112.286 -0.326 . . . . 74.349999999999994 112.286 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 15.1 mm-40 -88.36 148.46 24.24 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.194 0.598 . . . . 63.100000000000001 110.885 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.48 -138.51 8.49 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 111.062 -0.815 . . . . 73.510000000000005 111.062 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.457 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 3.4 m-20 -78.41 -49.16 1.82 Allowed Pre-proline 0 CA--C 1.566 1.578 0 CA-C-O 118.29 -0.862 . . . . 44.340000000000003 110.644 175.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.457 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -94.97 106.41 0.12 Allowed 'Trans proline' 0 C--N 1.396 3.034 0 C-N-CA 122.658 2.238 . . . . 63.229999999999997 111.905 172.09 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.37 125.23 13.63 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 122.025 1.817 . . . . 70.510000000000005 111.456 174.361 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -99.97 173.96 26.06 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 116.041 -0.527 . . . . 72.120000000000005 111.975 175.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -92.48 152.57 19.6 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 123.309 0.644 . . . . 72.310000000000002 110.663 -174.076 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.463 HD21 HD11 ' A' ' 98' ' ' LEU . 59.3 tp -114.23 133.76 55.4 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.901 0.88 . . . . 53.43 109.75 179.011 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.3 mt -129.85 103.46 6.82 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.021 0.928 . . . . 63.240000000000002 110.428 176.56 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.602 HD21 HD12 ' A' ' 98' ' ' LEU . 82.8 mt -101.77 103.18 13.9 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 123.072 0.549 . . . . 72.299999999999997 111.212 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.9 t -84.11 97.68 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 N-CA-C 108.954 -0.758 . . . . 64.310000000000002 108.954 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 89.5 t -57.03 130.26 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 124.024 0.93 . . . . 71.510000000000005 111.436 -178.199 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -121.4 105.32 10.4 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 125.068 1.347 . . . . 63.399999999999999 107.912 -177.21 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 24.1 mt -70.32 109.8 4.92 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.377 -0.601 . . . . 63.229999999999997 109.377 178.337 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.8 mt -72.27 149.97 91.82 Favored Pre-proline 0 CA--C 1.549 0.942 0 C-N-CA 123.062 0.545 . . . . 75.219999999999999 110.097 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -58.93 97.49 0.09 OUTLIER 'Trans proline' 0 C--N 1.376 2.005 0 C-N-CA 122.898 2.399 . . . . 61.329999999999998 110.98 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 124.772 1.229 . . . . 64.239999999999995 109.702 -172.574 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 tt . . . . . 0 CA--C 1.556 1.202 0 N-CA-C 111.664 0.246 . . . . 71.239999999999995 111.664 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -90.81 -152.04 0.04 OUTLIER 'Trans proline' 0 CA--C 1.553 1.434 0 C-N-CA 122.827 2.351 . . . . 73.439999999999998 111.101 168.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.584 HD12 ' H ' ' A' ' 98' ' ' LEU . 12.1 tp -74.69 144.52 43.71 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.961 0.905 . . . . 73.239999999999995 109.41 175.24 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.603 HD13 HG21 ' A' ' 138' ' ' VAL . 9.0 tp 64.4 -67.79 0.11 Allowed 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.731 2.412 . . . . 74.209999999999994 112.002 -171.422 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.713 ' HA ' HD13 ' A' ' 119' ' ' LEU . 60.7 t80 -64.58 130.01 42.01 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.411 1.084 . . . . 75.310000000000002 111.531 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.473 HG22 HG13 ' A' ' 102' ' ' VAL . 39.7 m -146.09 98.29 4.39 Favored Pre-proline 0 CA--C 1.54 0.58 0 C-N-CA 124.679 1.192 . . . . 75.140000000000001 108.766 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.26 87.11 0.92 Allowed 'Trans proline' 0 C--N 1.366 1.471 0 C-N-CA 122.192 1.928 . . . . 72.010000000000005 112.554 -171.538 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.473 HG13 HG22 ' A' ' 100' ' ' THR . 14.7 m . . . . . 0 CA--C 1.541 0.621 0 C-N-CA 124.332 1.053 . . . . 71.329999999999998 108.745 173.362 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.651 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 37.5 mtm180 . . . . . 0 N--CA 1.476 0.875 0 N-CA-C 109.495 -0.558 . . . . 61.340000000000003 109.495 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -99.8 107.49 19.54 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 108.188 -1.041 . . . . 62.100000000000001 108.188 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.713 HD13 ' HA ' ' A' ' 99' ' ' PHE . 16.4 mt -93.63 111.05 22.66 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 107.64 -1.244 . . . . 60.140000000000001 107.64 -175.834 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.3 ttp85 -114.6 105.61 13.28 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 108.896 -0.779 . . . . 73.340000000000003 108.896 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 145.66 50.96 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 123.68 0.792 . . . . 45.399999999999999 109.633 -175.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.504 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 3.2 mp0 -74.16 131.73 41.55 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 123.667 0.787 . . . . 54.25 109.225 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.532 HD11 ' HG2' ' A' ' 136' ' ' ARG . 40.9 tp -100.12 102.89 19.57 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 124.29 1.036 . . . . 71.099999999999994 109.134 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -67.86 114.56 3.39 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 122.274 1.982 . . . . 70.140000000000001 109.956 176.415 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.538 HD21 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -143.86 131.43 21.15 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.066 -0.716 . . . . 74.099999999999994 109.066 -171.339 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.8 p -80.52 170.51 16.25 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 110.296 -0.261 . . . . 62.119999999999997 110.296 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 84.8 mt -61.37 -34.74 75.83 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.837 0.855 . . . . 72.409999999999997 111.157 -178.257 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -72.79 -51.67 18.07 Favored 'General case' 0 C--N 1.345 0.379 0 CA-C-N 114.776 -1.102 . . . . 75.340000000000003 108.803 -176.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -66.94 -26.72 66.98 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.01 -0.996 . . . . 61.009999999999998 111.575 -176.272 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.447 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -74.87 -50.47 16.89 Favored 'General case' 0 C--N 1.348 0.521 0 C-N-CA 123.901 0.88 . . . . 55.0 111.375 176.102 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -58.61 -46.15 87.66 Favored 'General case' 0 C--N 1.361 1.068 0 O-C-N 124.308 1.005 . . . . 72.049999999999997 110.664 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -77.78 -40.63 40.11 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.279 -0.873 . . . . 74.420000000000002 111.033 -176.418 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.58 -164.53 50.9 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 111.828 -0.509 . . . . 63.130000000000003 111.828 -175.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.471 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 119.49 -161.11 14.18 Favored Glycine 0 N--CA 1.473 1.12 0 N-CA-C 111.774 -0.53 . . . . 62.119999999999997 111.774 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -81.52 141.63 33.63 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.046 0.539 . . . . 75.230000000000004 110.253 177.356 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.532 ' HG2' HD11 ' A' ' 123' ' ' LEU . 19.4 tpp180 -126.75 121.28 31.56 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.969 0.908 . . . . 60.439999999999998 108.768 178.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 56.0 t -81.28 107.63 13.72 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 C-N-CA 123.339 0.656 . . . . 75.230000000000004 109.614 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.603 HG21 HD13 ' A' ' 98' ' ' LEU . 25.5 m -116.37 164.63 12.53 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 C-N-CA 125.297 1.439 . . . . 72.200000000000003 109.318 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -122.41 131.48 53.9 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 123.446 0.699 . . . . 64.420000000000002 109.575 -171.33 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.415 ' HB ' HD23 ' A' ' 98' ' ' LEU . 5.2 p -142.54 102.41 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.321 0 C-N-CA 124.211 1.004 . . . . 72.219999999999999 111.656 -174.002 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.55 25.93 14.86 Favored 'General case' 0 N--CA 1.493 1.681 0 C-N-CA 124.229 1.012 . . . . 74.510000000000005 112.759 175.139 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.56 -0.8 53.01 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 123.901 0.762 . . . . 55.509999999999998 113.438 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.4 ' HB2' HG13 ' A' ' 140' ' ' VAL . 31.5 mmm180 -104.07 141.89 35.42 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.421 0.689 . . . . 64.340000000000003 110.367 -177.458 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -97.81 113.89 25.8 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.753 0.821 . . . . 73.150000000000006 109.284 178.306 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 73.6 t -118.51 129.6 74.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 123.859 0.864 . . . . 74.010000000000005 109.561 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 33.5 p -97.39 106.58 18.92 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 109.063 -0.717 . . . . 73.329999999999998 109.063 174.155 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.3 p -98.7 125.9 51.99 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 123.494 0.717 . . . . 71.409999999999997 109.76 -177.349 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.2 ttt180 -81.99 105.06 12.79 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.379 0.672 . . . . 70.219999999999999 109.62 -177.606 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.538 HD12 HD21 ' A' ' 125' ' ' LEU . 4.8 pt -87.24 146.03 39.18 Favored Pre-proline 0 C--O 1.253 1.265 0 C-N-CA 124.68 1.192 . . . . 74.420000000000002 109.343 176.493 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.455 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 57.0 Cg_endo -72.04 143.09 39.69 Favored 'Trans proline' 0 CA--C 1.56 1.799 0 C-N-CA 122.441 2.094 . . . . 72.239999999999995 112.76 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.39 130.49 22.53 Favored 'Trans proline' 0 C--N 1.375 1.941 0 C-N-CA 122.493 2.129 . . . . 52.340000000000003 111.262 171.34 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.82 27.57 45.73 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 115.548 -0.751 . . . . 51.409999999999997 112.243 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.455 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 12.4 p -76.62 147.71 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 108.989 -0.745 . . . . 51.030000000000001 108.989 176.737 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.0 mtp180 -125.12 176.06 6.96 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-O 121.993 0.901 . . . . 72.319999999999993 112.591 -166.171 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -64.42 123.9 20.38 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-N 113.292 -1.776 . . . . 71.400000000000006 110.332 175.703 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.54 89.55 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.798 0.686 . . . . 33.420000000000002 113.611 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.3 m -76.54 118.49 19.25 Favored 'General case' 0 C--N 1.35 0.614 0 N-CA-C 108.778 -0.823 . . . . 71.439999999999998 108.778 176.312 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.12 124.7 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 CA-C-O 121.437 0.637 . . . . 71.329999999999998 109.677 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.5 mt -95.14 102.85 14.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 C-N-CA 124.324 1.05 . . . . 73.25 108.23 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.503 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 35.1 ttm180 -87.28 107.91 18.72 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 109.49 -0.559 . . . . 74.310000000000002 109.49 174.578 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.9 t -105.7 107.69 59.92 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 107.428 -1.323 . . . . 71.109999999999999 107.428 173.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -66.02 135.4 40.61 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.484 2.123 . . . . 74.519999999999996 112.043 -177.131 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 80.39 -5.33 64.19 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 114.723 0.649 . . . . 73.120000000000005 114.723 174.722 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 96.3 mmm -103.9 16.58 26.01 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 117.807 0.803 . . . . 61.32 111.842 -176.224 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -90.88 -142.29 10.07 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 116.149 -0.478 . . . . 54.210000000000001 111.983 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' GLY . . . . . 0.651 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.69 127.93 8.58 Favored Glycine 0 C--N 1.343 0.965 0 N-CA-C 111.638 -0.585 . . . . 63.509999999999998 111.638 -177.638 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.9 mm-40 -83.61 151.64 25.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 123.46 0.704 . . . . 75.5 110.513 -175.476 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -148.75 -125.85 1.48 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 109.559 -1.417 . . . . 74.120000000000005 109.559 177.707 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.558 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 23.2 t30 -74.63 -51.26 4.14 Favored Pre-proline 0 CA--C 1.564 1.493 0 N-CA-C 108.118 -1.067 . . . . 71.549999999999997 108.118 161.265 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.558 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 49.4 Cg_endo -100.13 164.45 0.47 Allowed 'Trans proline' 0 C--N 1.39 2.731 0 C-N-CA 122.74 2.294 . . . . 72.120000000000005 111.689 165.324 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.21 136.68 14.61 Favored 'Trans proline' 0 CA--C 1.557 1.67 0 C-N-CA 121.794 1.662 . . . . 73.239999999999995 112.182 174.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -86.78 179.7 48.89 Favored Glycine 0 C--N 1.348 1.218 0 CA-C-O 119.999 -0.334 . . . . 24.420000000000002 112.552 175.16 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -97.48 148.53 23.13 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.043 0.537 . . . . 74.319999999999993 110.956 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.503 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 56.8 tp -107.01 132.73 52.62 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.052 0.941 . . . . 72.200000000000003 110.368 -178.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 93.6 mt -129.37 104.02 7.25 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 125.023 1.329 . . . . 73.209999999999994 109.609 176.26 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.524 HD21 HD12 ' A' ' 98' ' ' LEU . 65.9 mt -104.54 103.44 13.12 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 122.98 0.512 . . . . 54.329999999999998 110.518 176.476 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.5 t -84.83 93.6 3.57 Favored 'Isoleucine or valine' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 71.040000000000006 108.603 -177.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.499 HG22 HD23 ' A' ' 123' ' ' LEU . 97.3 t -56.7 127.66 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.098 0.959 . . . . 75.540000000000006 111.264 -178.429 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 179' ' ' ARG . . . . . 0.504 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.9 mmt180 -121.57 114.49 21.27 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 124.546 1.138 . . . . 70.510000000000005 108.435 -179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 75.1 mt -72.48 106.16 4.46 Favored 'General case' 0 C--O 1.241 0.648 0 O-C-N 123.826 0.704 . . . . 53.100000000000001 110.132 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 72.1 mt -66.22 153.77 91.6 Favored Pre-proline 0 CA--C 1.546 0.807 0 CA-C-N 115.868 -0.605 . . . . 64.200000000000003 110.522 179.026 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -56.99 140.79 93.39 Favored 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 122.899 2.4 . . . . 62.109999999999999 111.218 173.362 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 . . . . . 0 C--O 1.251 1.159 0 N-CA-C 109.329 -0.619 . . . . 72.299999999999997 109.329 -179.098 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.3 pt? . . . . . 0 N--CA 1.488 1.464 0 N-CA-C 113.346 0.869 . . . . 65.510000000000005 113.346 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.69 -44.63 7.87 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 122.074 1.849 . . . . 62.140000000000001 110.832 176.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.562 HD12 ' H ' ' A' ' 98' ' ' LEU . 5.6 tp -177.99 144.52 0.34 Allowed 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.495 1.518 . . . . 50.439999999999998 107.807 177.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.888 HD23 ' HB ' ' A' ' 140' ' ' VAL . 18.2 tp 62.68 -70.16 0.06 Allowed 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 126.779 2.031 . . . . 75.230000000000004 112.226 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.563 ' HA ' HD13 ' A' ' 119' ' ' LEU . 76.8 t80 -63.23 130.76 45.93 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.335 1.054 . . . . 75.349999999999994 110.785 174.37 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.487 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 52.3 m -139.65 102.55 7.12 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 124.2 1.0 . . . . 61.119999999999997 109.475 177.049 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.87 89.68 0.86 Allowed 'Trans proline' 0 C--N 1.359 1.106 0 C-N-CA 121.676 1.584 . . . . 73.430000000000007 111.159 -177.419 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.474 0.755 0 CA-C-N 115.789 -0.641 . . . . 74.129999999999995 109.601 170.628 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 . . . . . 0 CA--C 1.537 0.451 0 N-CA-C 108.144 -1.058 . . . . 74.040000000000006 108.144 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -94.44 104.87 16.84 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 107.314 -1.365 . . . . 75.219999999999999 107.314 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.563 HD13 ' HA ' ' A' ' 99' ' ' PHE . 11.8 mt -92.53 111.83 23.55 Favored 'General case' 0 C--N 1.345 0.384 0 N-CA-C 107.785 -1.191 . . . . 71.5 107.785 -172.079 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 68.6 ttt180 -120.13 107.82 13.5 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.253 1.021 . . . . 74.239999999999995 108.724 -177.581 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.19 148.16 50.85 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.066 0.546 . . . . 73.239999999999995 111.531 -171.371 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.593 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.5 mp0 -68.3 125.06 25.24 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.403 1.081 . . . . 63.25 109.443 170.338 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.45 HD12 HD13 ' A' ' 176' ' ' LEU . 2.5 tt -101.67 102.9 24.78 Favored Pre-proline 0 CA--C 1.543 0.687 0 N-CA-C 108.104 -1.073 . . . . 64.239999999999995 108.104 175.142 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.39 115.54 3.57 Favored 'Trans proline' 0 C--N 1.378 2.107 0 C-N-CA 121.689 1.592 . . . . 74.340000000000003 109.636 171.241 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.585 HD21 HD12 ' A' ' 149' ' ' ILE . 14.0 tp -137.64 123.11 19.6 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.6 -0.889 . . . . 61.399999999999999 108.6 -170.166 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.9 p -73.81 169.99 16.23 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 117.785 0.266 . . . . 62.219999999999999 110.705 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.1 mt -62.76 -33.43 75.14 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.575 0.75 . . . . 73.420000000000002 111.042 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -71.76 -45.51 61.45 Favored 'General case' 0 C--N 1.352 0.683 0 O-C-N 123.783 0.677 . . . . 73.129999999999995 109.312 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -64.18 -35.46 80.88 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 123.695 0.798 . . . . 72.209999999999994 111.634 176.572 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.43 -42.91 67.67 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.46 0.704 . . . . 75.420000000000002 111.867 -179.573 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.1 t80 -68.39 -50.88 49.8 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-N 114.884 -1.053 . . . . 71.400000000000006 110.102 -179.09 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -75.06 -42.0 57.86 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 115.669 -0.696 . . . . 74.310000000000002 111.213 -174.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.31 -134.5 16.82 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.564 0.54 . . . . 64.219999999999999 111.844 -177.756 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 76.27 -146.69 33.53 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-O 119.658 -0.523 . . . . 71.409999999999997 111.856 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.42 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 1.4 mp0 -85.18 146.69 26.98 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 117.83 0.815 . . . . 74.030000000000001 110.412 178.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.596 ' HB2' HD13 ' A' ' 149' ' ' ILE . 24.7 tpt180 -129.05 121.55 28.11 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.244 1.018 . . . . 73.239999999999995 108.936 177.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.5 t -82.18 108.72 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 C-N-CA 123.499 0.72 . . . . 73.019999999999996 109.736 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.574 HG23 HD22 ' A' ' 98' ' ' LEU . 33.6 m -128.11 162.15 34.92 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.012 0 C-N-CA 124.995 1.318 . . . . 42.25 108.825 178.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -107.32 138.09 44.16 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 122.882 0.473 . . . . 73.420000000000002 110.191 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.888 ' HB ' HD23 ' A' ' 98' ' ' LEU . 3.0 p -123.27 105.87 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 124.564 1.146 . . . . 74.239999999999995 109.06 171.727 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.11 14.87 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.744 0.818 . . . . 72.549999999999997 112.863 174.67 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.28 11.03 43.32 Favored Glycine 0 C--N 1.35 1.349 0 CA-C-O 119.901 -0.388 . . . . 64.549999999999997 113.843 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -115.31 118.38 33.09 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 117.429 0.615 . . . . 71.540000000000006 110.192 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -82.51 106.14 14.13 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.43 0.692 . . . . 72.120000000000005 109.956 -178.19 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 25.9 m -121.44 155.6 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.6 0.76 . . . . 62.420000000000002 110.342 -179.246 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.42 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 14.1 p -106.61 110.15 22.26 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.635 0.774 . . . . 53.210000000000001 109.646 175.053 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -99.22 128.99 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 124.061 0.944 . . . . 62.210000000000001 109.205 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -77.95 109.2 11.79 Favored 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.051 0.453 . . . . 63.350000000000001 110.506 -175.152 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.596 HD13 ' HB2' ' A' ' 136' ' ' ARG . 5.0 pt -86.55 142.74 35.25 Favored Pre-proline 0 CA--C 1.558 1.253 0 C-N-CA 124.484 1.113 . . . . 75.540000000000006 108.775 173.397 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.411 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 73.0 Cg_endo -75.47 137.24 20.47 Favored 'Trans proline' 0 CA--C 1.562 1.902 0 C-N-CA 122.191 1.927 . . . . 65.340000000000003 111.822 177.353 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 35.9 Cg_exo -63.44 135.9 52.11 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 122.761 2.308 . . . . 72.049999999999997 112.327 174.7 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.51 14.6 61.41 Favored Glycine 0 CA--C 1.534 1.253 0 O-C-N 123.636 0.585 . . . . 65.25 113.401 -176.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.18 143.26 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.324 0.649 . . . . 63.409999999999997 110.374 -177.134 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -118.49 177.5 4.8 Favored 'General case' 0 N--CA 1.484 1.24 0 CA-C-O 121.651 0.738 . . . . 55.039999999999999 112.894 -169.626 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -63.49 126.69 28.32 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 113.855 -1.52 . . . . 71.439999999999998 110.11 174.807 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -10.15 65.46 Favored Glycine 0 CA--C 1.532 1.129 0 O-C-N 124.111 0.882 . . . . 21.210000000000001 113.968 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.1 m -69.86 120.33 15.43 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-N 117.861 0.83 . . . . 74.140000000000001 109.989 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.61 139.86 17.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 C-N-CA 122.817 0.447 . . . . 71.319999999999993 110.077 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 44.6 mt -110.94 102.23 13.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 N-CA-C 106.85 -1.537 . . . . 55.509999999999998 106.85 178.359 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 6.0 ttp180 -88.15 102.17 14.53 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 108.961 -0.755 . . . . 65.140000000000001 108.961 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -95.2 113.05 60.66 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 107.746 -1.205 . . . . 54.240000000000002 107.746 175.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.39 128.45 15.47 Favored 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 122.847 2.365 . . . . 64.150000000000006 112.688 -169.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 63.49 23.42 66.74 Favored Glycine 0 C--N 1.351 1.392 0 O-C-N 123.592 0.558 . . . . 62.219999999999999 114.371 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.8 tpp -100.62 -18.4 16.58 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.487 0.715 . . . . 72.540000000000006 111.066 -177.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -72.45 -95.9 0.08 OUTLIER Glycine 0 C--N 1.345 1.035 0 CA-C-N 115.832 -0.622 . . . . 45.340000000000003 113.256 -175.376 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -72.36 86.75 0.5 Allowed Glycine 0 C--N 1.346 1.117 0 N-CA-C 112.252 -0.339 . . . . 71.450000000000003 112.252 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.8 mm-40 -81.93 121.64 26.75 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.376 0.67 . . . . 62.329999999999998 109.978 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 162.31 -142.12 7.72 Favored Glycine 0 C--O 1.241 0.591 0 N-CA-C 111.282 -0.727 . . . . 71.329999999999998 111.282 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.513 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 19.3 m120 -67.43 -49.43 42.25 Favored Pre-proline 0 CA--C 1.566 1.56 0 CA-C-O 118.271 -0.871 . . . . 72.219999999999999 110.886 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.513 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -96.48 106.69 0.1 OUTLIER 'Trans proline' 0 C--N 1.395 3.023 0 C-N-CA 123.125 2.55 . . . . 73.439999999999998 111.485 170.51 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.01 129.87 24.28 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.641 2.227 . . . . 34.229999999999997 111.778 178.767 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -117.97 157.33 15.22 Favored Glycine 0 C--N 1.338 0.642 0 N-CA-C 111.501 -0.64 . . . . 54.329999999999998 111.501 178.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -89.7 158.85 17.38 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 123.603 0.761 . . . . 72.329999999999998 110.558 -177.433 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.432 HD21 HD11 ' A' ' 98' ' ' LEU . 67.0 tp -115.7 132.64 56.57 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.834 0.853 . . . . 74.319999999999993 109.948 -177.675 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.7 mt -127.84 101.41 6.33 Favored 'General case' 0 CA--C 1.549 0.925 0 C-N-CA 125.35 1.46 . . . . 55.119999999999997 109.236 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.528 HD21 HD12 ' A' ' 98' ' ' LEU . 75.7 mt -101.46 100.83 11.33 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 123.11 0.564 . . . . 71.420000000000002 110.923 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 4.7 t -85.53 95.26 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 N-CA-C 108.409 -0.96 . . . . 75.019999999999996 108.409 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 73.9 t -54.67 135.03 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.695 1.198 . . . . 71.239999999999995 111.629 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 179' ' ' ARG . . . . . 0.593 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.3 mmt180 -128.27 107.68 9.97 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.312 -1.366 . . . . 63.329999999999998 107.312 -177.669 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 53.3 mt -69.98 121.62 17.75 Favored 'General case' 0 N--CA 1.47 0.534 0 O-C-N 123.438 0.461 . . . . 73.230000000000004 109.943 -177.443 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 83.8 mt -85.46 140.64 36.2 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.894 -0.594 . . . . 72.019999999999996 110.268 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.56 -15.9 34.14 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.667 2.245 . . . . 75.219999999999999 111.872 172.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 35.9 m80 . . . . . 0 C--N 1.356 0.849 0 C-N-CA 124.308 1.043 . . . . 64.519999999999996 108.264 176.994 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 113.688 0.996 . . . . 60.140000000000001 113.688 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -64.71 -55.93 0.47 Allowed 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.494 2.129 . . . . 61.329999999999998 112.0 177.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.485 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.2 tp -177.55 134.88 0.18 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.785 1.234 . . . . 74.420000000000002 108.18 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.526 HD22 HG23 ' A' ' 138' ' ' VAL . 15.4 tp 66.86 -63.57 0.26 Allowed 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 126.89 2.076 . . . . 73.340000000000003 111.379 -174.797 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -69.43 126.02 28.49 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.696 1.198 . . . . 73.099999999999994 111.433 176.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.543 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 87.1 m -138.77 88.45 13.88 Favored Pre-proline 0 N--CA 1.47 0.57 0 C-N-CA 124.444 1.098 . . . . 65.010000000000005 108.657 176.076 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.4 83.96 0.61 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 122.461 2.107 . . . . 74.200000000000003 112.615 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 100' ' ' THR . 21.2 m . . . . . 0 CA--C 1.538 0.506 0 CA-C-N 114.612 -1.176 . . . . 63.310000000000002 108.857 172.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.412 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 45.2 mtt180 . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 110.432 -0.21 . . . . 71.519999999999996 110.432 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -98.05 109.17 21.97 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 107.491 -1.3 . . . . 75.349999999999994 107.491 177.413 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.543 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 15.0 mt -91.47 108.04 19.62 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 106.165 -1.791 . . . . 74.219999999999999 106.165 177.848 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 34.7 ttt180 -118.89 106.16 12.21 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.104 -1.073 . . . . 71.030000000000001 108.104 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -131.0 144.54 51.55 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.165 0.586 . . . . 74.329999999999998 109.54 -175.573 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.644 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.2 mp0 -72.8 129.01 37.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 114.88 -1.055 . . . . 75.150000000000006 108.536 173.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.543 HD21 ' HG2' ' A' ' 136' ' ' ARG . 3.0 tt -99.76 102.39 16.97 Favored Pre-proline 0 CA--C 1.536 0.438 0 N-CA-C 106.609 -1.626 . . . . 54.25 106.609 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -65.93 113.86 2.75 Favored 'Trans proline' 0 C--N 1.376 2.026 0 C-N-CA 121.839 1.693 . . . . 73.140000000000001 110.271 174.638 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.523 HD21 HD12 ' A' ' 149' ' ' ILE . 17.8 tp -144.36 121.9 11.75 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.796 -1.187 . . . . 72.340000000000003 107.796 -173.812 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.3 p -73.96 168.34 19.67 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 117.761 0.255 . . . . 75.209999999999994 110.478 -177.331 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.8 mt -57.58 -36.43 71.7 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.249 0.619 . . . . 74.420000000000002 110.918 176.641 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 21.2 mp0 -71.88 -46.75 56.78 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 124.611 1.165 . . . . 60.020000000000003 110.386 -176.349 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -72.06 -27.49 62.72 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.601 0.76 . . . . 74.450000000000003 111.911 -179.051 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -69.41 -46.02 67.82 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.426 0.69 . . . . 64.340000000000003 109.926 173.352 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -58.96 -41.56 87.77 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 124.718 1.207 . . . . 61.049999999999997 110.849 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.45 -49.1 67.83 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.59 0.556 . . . . 71.340000000000003 109.541 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.49 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.01 56.93 22.41 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.062 -0.972 . . . . 24.329999999999998 113.106 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -92.0 -148.17 21.91 Favored Glycine 0 C--N 1.345 1.033 0 O-C-N 123.491 0.171 . . . . 61.119999999999997 112.808 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -95.4 132.32 40.59 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 107.757 -1.201 . . . . 73.430000000000007 107.757 169.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.543 ' HG2' HD21 ' A' ' 123' ' ' LEU . 12.8 tpp180 -111.62 116.94 31.65 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 107.678 -1.23 . . . . 72.540000000000006 107.678 -178.405 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 144' ' ' ARG . 12.1 p -98.76 118.12 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 N-CA-C 108.133 -1.062 . . . . 72.239999999999995 108.133 -176.746 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.526 HG23 HD22 ' A' ' 98' ' ' LEU . 35.6 m -134.22 161.84 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.849 0.86 . . . . 60.119999999999997 110.008 -173.825 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -96.97 136.88 36.91 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 123.679 0.792 . . . . 65.329999999999998 110.093 -173.596 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.433 ' HB ' HD23 ' A' ' 98' ' ' LEU . 5.4 p -144.49 111.59 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.607 1.163 . . . . 74.530000000000001 109.631 177.111 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.4 22.01 12.95 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 123.684 0.794 . . . . 51.020000000000003 113.025 173.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.92 -16.12 58.76 Favored Glycine 0 C--N 1.345 1.049 0 C-N-CA 123.827 0.727 . . . . 52.200000000000003 112.653 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 19.4 tpp180 -95.72 123.92 39.51 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.249 1.02 . . . . 72.310000000000002 109.551 178.42 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.522 ' HG2' HG22 ' A' ' 137' ' ' VAL . 22.6 ttp180 -89.51 107.05 18.85 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 108.728 -0.841 . . . . 74.310000000000002 108.728 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 70.0 t -112.7 136.79 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 C-N-CA 124.112 0.965 . . . . 75.310000000000002 110.508 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 31.9 p -96.18 120.83 37.17 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.279 0.632 . . . . 72.540000000000006 110.669 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.5 p -106.37 131.02 57.14 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.943 1.297 . . . . 51.049999999999997 109.345 174.005 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 46.7 ttp180 -79.02 122.34 26.07 Favored 'General case' 0 C--O 1.243 0.72 0 CA-C-O 120.969 0.414 . . . . 62.149999999999999 109.98 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.523 HD12 HD21 ' A' ' 125' ' ' LEU . 10.3 pt -96.5 140.71 22.32 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 124.26 1.024 . . . . 71.310000000000002 109.823 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 20.5 Cg_exo -66.18 142.66 68.13 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.058 2.505 . . . . 71.140000000000001 113.045 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -66.17 130.91 25.29 Favored 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 122.327 2.018 . . . . 72.239999999999995 110.802 170.144 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 70.81 26.29 74.26 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 115.532 -0.758 . . . . 62.420000000000002 113.945 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.0 p -68.77 137.37 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-N 117.201 0.5 . . . . 74.120000000000005 110.755 -178.672 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -98.37 175.77 5.93 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.875 0.845 . . . . 75.519999999999996 112.963 -168.256 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -69.65 134.0 48.21 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 113.547 -1.661 . . . . 74.109999999999999 110.669 177.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 73.89 10.17 80.27 Favored Glycine 0 C--N 1.342 0.914 0 CA-C-N 116.062 -0.517 . . . . 72.430000000000007 113.452 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.5 m -81.32 118.9 23.02 Favored 'General case' 0 C--N 1.347 0.473 0 N-CA-C 108.626 -0.879 . . . . 74.120000000000005 108.626 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 3.3 p -99.91 115.03 40.08 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.351 0.596 . . . . 54.020000000000003 109.796 -175.064 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 55.5 mt -90.05 104.49 15.24 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 124.516 1.126 . . . . 71.010000000000005 108.212 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.52 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 24.8 ttp180 -90.32 117.9 29.4 Favored 'General case' 0 C--N 1.344 0.355 0 N-CA-C 110.548 -0.168 . . . . 72.430000000000007 110.548 -179.655 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.0 t -109.11 95.28 17.29 Favored Pre-proline 0 CA--C 1.555 1.157 0 N-CA-C 107.5 -1.296 . . . . 64.120000000000005 107.5 166.711 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -70.26 136.29 31.33 Favored 'Trans proline' 0 C--N 1.373 1.857 0 C-N-CA 122.888 2.392 . . . . 72.25 111.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.39 2.24 82.92 Favored Glycine 0 CA--C 1.531 1.089 0 CA-C-O 119.635 -0.536 . . . . 65.319999999999993 114.118 178.826 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 41.4 tpp -128.51 12.99 6.48 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 117.872 0.836 . . . . 74.450000000000003 110.726 -177.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.38 -106.74 0.78 Allowed Glycine 0 C--N 1.344 1.021 0 CA-C-N 115.866 -0.606 . . . . 73.109999999999999 111.896 178.516 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -61.38 105.11 0.8 Allowed Glycine 0 C--N 1.347 1.179 0 C-N-CA 123.018 0.342 . . . . 74.310000000000002 113.502 -177.248 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -89.69 134.7 34.02 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.862 0.865 . . . . 54.439999999999998 109.176 173.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -178.9 -51.14 0.08 OUTLIER Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.031 -1.228 . . . . 74.340000000000003 110.031 177.445 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.458 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 25.1 t-20 -166.25 -54.76 0.01 OUTLIER Pre-proline 0 CA--C 1.556 1.192 0 C-N-CA 124.952 1.301 . . . . 65.420000000000002 108.173 169.544 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.458 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 82.1 Cg_endo -82.54 134.49 7.63 Favored 'Trans proline' 0 C--N 1.399 3.196 0 C-N-CA 121.721 1.614 . . . . 74.420000000000002 110.411 170.004 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.76 125.84 10.87 Favored 'Trans proline' 0 C--N 1.367 1.537 0 C-N-CA 122.228 1.952 . . . . 74.549999999999997 111.824 178.031 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 172' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -95.13 -172.18 37.03 Favored Glycine 0 C--N 1.349 1.273 0 CA-C-N 116.182 -0.463 . . . . 63.140000000000001 113.416 175.495 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.6 144.33 28.02 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.417 0.687 . . . . 70.420000000000002 110.5 178.241 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.52 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.6 tp -107.99 129.68 55.1 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-N 115.312 -0.858 . . . . 74.319999999999993 108.879 178.315 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.4 mt -128.27 102.56 6.73 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 124.472 1.109 . . . . 75.530000000000001 109.187 -178.707 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.436 HD21 HD12 ' A' ' 98' ' ' LEU . 89.4 mt -104.08 101.36 11.12 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 121.0 0.428 . . . . 73.129999999999995 110.486 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.46 95.75 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.47 -0.937 . . . . 62.049999999999997 108.47 -176.195 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.7 t -55.63 124.11 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 124.142 0.977 . . . . 70.409999999999997 111.355 -179.229 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 179' ' ' ARG . . . . . 0.644 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 28.2 mmt180 -116.38 104.48 11.51 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.383 1.073 . . . . 74.129999999999995 108.459 -179.323 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.46 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 60.8 mt -70.05 111.05 5.44 Favored 'General case' 0 C--N 1.343 0.323 0 C-N-CA 123.685 0.794 . . . . 75.430000000000007 110.732 -178.028 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 63.3 mt -94.73 144.22 27.51 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.324 0.65 . . . . 54.100000000000001 110.044 -179.284 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.93 -33.23 4.84 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 122.425 2.083 . . . . 73.209999999999994 110.773 167.17 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 . . . . . 0 N--CA 1.48 1.069 0 C-N-CA 124.82 1.248 . . . . 73.299999999999997 108.15 175.829 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pp . . . . . 0 CA--C 1.56 1.363 0 N-CA-C 114.391 1.256 . . . . 63.210000000000001 114.391 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.93 -61.87 0.16 Allowed 'Trans proline' 0 C--N 1.382 2.341 0 C-N-CA 122.519 2.146 . . . . 71.209999999999994 110.509 176.542 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.441 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.8 tp -172.68 144.33 1.39 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.599 1.16 . . . . 74.120000000000005 107.901 172.272 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.653 HD13 HG21 ' A' ' 138' ' ' VAL . 8.9 tp 64.31 -66.36 0.12 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 126.346 1.858 . . . . 61.43 111.828 -169.08 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -59.55 137.47 58.01 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 124.733 1.213 . . . . 71.129999999999995 111.972 178.147 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.54 HG22 HG13 ' A' ' 102' ' ' VAL . 61.2 m -157.66 108.93 1.81 Allowed Pre-proline 0 N--CA 1.475 0.822 0 C-N-CA 124.755 1.222 . . . . 74.200000000000003 109.225 177.358 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -81.42 68.15 8.24 Favored 'Trans proline' 0 C--N 1.371 1.736 0 C-N-CA 122.381 2.054 . . . . 51.039999999999999 112.582 -172.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.54 HG13 HG22 ' A' ' 100' ' ' THR . 9.6 m . . . . . 0 N--CA 1.486 1.333 0 CA-C-N 114.78 -1.1 . . . . 63.229999999999997 112.663 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.566 ' HG3' ' HA3' ' A' ' 166' ' ' GLY . 21.2 ptt180 . . . . . 0 CA--C 1.554 1.108 0 N-CA-C 108.98 -0.748 . . . . 75.310000000000002 108.98 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.475 ' HA ' ' O ' ' A' ' 173' ' ' ASP . 0.1 OUTLIER -101.99 115.06 29.74 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.875 0.87 . . . . 53.409999999999997 110.681 -157.955 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.527 HD22 ' O ' ' A' ' 100' ' ' THR . 13.8 mt -90.86 109.53 20.74 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 106.841 -1.54 . . . . 72.439999999999998 106.841 178.147 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.18 110.64 21.92 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 123.129 0.572 . . . . 75.530000000000001 110.376 -178.233 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.88 138.59 52.73 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.799 -0.815 . . . . 72.0 108.799 177.002 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mp0 -77.82 122.21 25.12 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.51 -0.922 . . . . 73.099999999999994 108.51 176.419 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.56 HD12 HD13 ' A' ' 176' ' ' LEU . 1.0 OUTLIER -99.67 111.05 60.87 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 108.667 -0.864 . . . . 72.409999999999997 108.667 -172.281 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.423 ' HB2' HD11 ' A' ' 181' ' ' LEU . 52.6 Cg_endo -67.89 116.67 4.42 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.06 1.84 . . . . 70.540000000000006 109.788 170.819 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.513 HD21 HD12 ' A' ' 149' ' ' ILE . 23.6 tp -131.45 133.04 44.78 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 108.715 -0.846 . . . . 71.200000000000003 108.715 -172.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 45.1 p -75.48 157.17 34.4 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.36 -0.607 . . . . 63.43 109.36 -178.194 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.54 -31.15 71.89 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.274 0.63 . . . . 64.349999999999994 111.074 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -70.78 -51.64 25.66 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.768 0.827 . . . . 63.439999999999998 110.107 179.458 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -65.45 -34.16 77.64 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.485 0.714 . . . . 72.430000000000007 111.581 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.43 -45.56 86.99 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 124.027 0.829 . . . . 60.140000000000001 110.699 173.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -66.08 -35.75 81.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 124.177 0.991 . . . . 63.009999999999998 111.116 179.596 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -73.65 -43.16 60.2 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.997 0.519 . . . . 65.109999999999999 109.865 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.436 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 67.23 51.37 38.68 Favored Glycine 0 C--N 1.347 1.149 0 CA-C-N 114.877 -1.056 . . . . 41.130000000000003 111.742 -168.887 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.402 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -89.84 -150.55 23.57 Favored Glycine 0 C--N 1.347 1.177 0 CA-C-O 120.841 0.134 . . . . 65.129999999999995 112.971 -177.033 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.418 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 7.5 mp0 -101.36 140.97 34.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.576 -0.898 . . . . 72.549999999999997 108.576 169.754 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 24.4 tpt85 -120.56 121.53 38.6 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.074 0.949 . . . . 70.549999999999997 108.548 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 12.2 p -84.73 117.89 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.784 0.802 . . . . 73.439999999999998 109.769 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.653 HG21 HD13 ' A' ' 98' ' ' LEU . 34.6 m -126.46 160.3 34.41 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 C-N-CA 125.444 1.498 . . . . 72.430000000000007 107.974 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -125.62 112.7 16.46 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-N 118.981 0.809 . . . . 53.130000000000003 111.801 -172.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.514 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.5 p -105.55 105.55 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 C-N-CA 125.608 1.563 . . . . 61.450000000000003 111.004 -176.572 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.25 28.5 15.26 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 124.146 0.978 . . . . 60.409999999999997 112.521 177.111 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.11 -10.49 58.38 Favored Glycine 0 C--N 1.356 1.687 0 CA-C-O 119.79 -0.45 . . . . 64.450000000000003 114.085 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.419 ' HB2' HG13 ' A' ' 140' ' ' VAL . 51.1 mtt180 -90.25 118.32 29.67 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 108.605 -0.887 . . . . 70.109999999999999 108.605 174.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 48.4 ttt85 -98.8 109.74 22.45 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 109.248 -0.649 . . . . 73.450000000000003 109.248 -177.73 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.1 p -130.75 146.07 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.527 1.131 . . . . 71.329999999999998 110.377 -172.272 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.418 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 28.4 m -93.18 119.19 32.09 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 123.693 0.797 . . . . 73.219999999999999 110.464 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -101.26 130.13 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.114 0.966 . . . . 75.400000000000006 109.944 175.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 36.9 ttp180 -75.84 134.77 40.27 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.248 0.547 . . . . 62.43 110.137 178.436 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.513 HD12 HD21 ' A' ' 125' ' ' LEU . 2.8 pt -108.65 145.66 32.07 Favored Pre-proline 0 CA--C 1.564 1.492 0 C-N-CA 125.11 1.364 . . . . 65.329999999999998 108.985 -179.473 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.52 145.99 97.75 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 123.037 2.491 . . . . 72.310000000000002 113.565 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -71.06 117.08 4.97 Favored 'Trans proline' 0 C--N 1.38 2.212 0 C-N-CA 122.709 2.273 . . . . 65.010000000000005 112.294 178.585 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 78.97 31.97 41.57 Favored Glycine 0 CA--C 1.533 1.176 0 CA-C-N 115.738 -0.664 . . . . 71.200000000000003 112.606 -176.218 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.6 p -72.82 146.17 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 123.395 0.678 . . . . 73.25 110.309 179.55 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.52 ' HA ' HD11 ' A' ' 180' ' ' LEU . 92.7 mtt180 -123.23 177.58 5.51 Favored 'General case' 0 N--CA 1.476 0.873 0 CA-C-O 121.808 0.813 . . . . 72.519999999999996 112.851 -171.563 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.0 tp10 -60.09 132.94 55.48 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 113.185 -1.825 . . . . 73.519999999999996 111.325 178.021 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.36 -27.31 15.81 Favored Glycine 0 C--N 1.34 0.775 0 CA-C-O 119.381 -0.677 . . . . 60.399999999999999 112.565 179.225 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.6 m -62.57 121.26 12.88 Favored 'General case' 0 C--N 1.354 0.763 0 C-N-CA 123.433 0.693 . . . . 70.540000000000006 111.004 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.1 126.46 51.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.091 -0.707 . . . . 61.049999999999997 109.091 177.578 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.41 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.4 mt -95.74 103.87 15.18 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 N-CA-C 108.012 -1.107 . . . . 74.510000000000005 108.012 -176.543 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.571 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 53.2 ttp180 -89.02 106.73 18.62 Favored 'General case' 0 C--N 1.355 0.848 0 N-CA-C 110.342 -0.244 . . . . 74.310000000000002 110.342 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.6 t -110.48 96.9 29.44 Favored Pre-proline 0 CA--C 1.553 1.078 0 N-CA-C 108.629 -0.878 . . . . 73.329999999999998 108.629 174.565 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.46 144.19 92.47 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.137 2.558 . . . . 71.439999999999998 112.842 176.548 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.69 -24.33 5.92 Favored Glycine 0 CA--C 1.539 1.584 0 CA-C-O 119.549 -0.584 . . . . 72.230000000000004 114.351 176.688 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 17.2 mmt -90.38 -2.54 57.97 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 117.7 0.75 . . . . 75.430000000000007 111.717 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.12 -115.12 0.54 Allowed Glycine 0 C--N 1.341 0.843 0 N-CA-C 111.346 -0.702 . . . . 64.329999999999998 111.346 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' GLY . . . . . 0.566 ' HA3' ' HG3' ' A' ' 117' ' ' ARG . . . -58.35 107.56 1.16 Allowed Glycine 0 C--N 1.354 1.555 0 CA-C-N 117.165 0.483 . . . . 61.43 113.237 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -80.03 171.57 14.92 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.937 0.895 . . . . 74.140000000000001 110.733 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 106.9 -147.07 16.14 Favored Glycine 0 N--CA 1.473 1.165 0 CA-C-O 119.619 -0.545 . . . . 62.340000000000003 111.819 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 169' ' ' ASN . . . . . 0.415 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 5.6 t-20 -69.82 -52.64 13.16 Favored Pre-proline 0 CA--C 1.566 1.584 0 CA-C-O 118.146 -0.931 . . . . 75.400000000000006 111.303 178.285 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.415 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 88.0 Cg_endo -89.93 108.64 0.39 Allowed 'Trans proline' 0 C--N 1.397 3.079 0 C-N-CA 122.188 1.926 . . . . 64.299999999999997 112.907 178.557 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -66.71 127.67 17.55 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.187 2.591 . . . . 61.219999999999999 112.776 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -110.64 162.67 12.47 Favored Glycine 0 C--N 1.341 0.846 0 CA-C-N 115.542 -0.754 . . . . 61.450000000000003 112.915 -178.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' A' ' 118' ' ' ASP . 4.6 m-20 -80.15 150.3 30.24 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.83 0.852 . . . . 74.230000000000004 110.559 178.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.571 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 62.5 tp -106.58 135.79 47.49 Favored 'General case' 0 C--O 1.216 -0.676 0 N-CA-C 108.302 -0.999 . . . . 75.209999999999994 108.302 173.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.9 mt -128.44 103.31 7.06 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 123.715 0.806 . . . . 74.299999999999997 109.293 179.143 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.564 HD21 HD12 ' A' ' 98' ' ' LEU . 83.4 mt -107.35 103.08 12.34 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 122.684 0.394 . . . . 73.329999999999998 110.92 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.64 96.88 5.72 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.732 -0.667 . . . . 62.049999999999997 109.467 -174.274 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -54.59 130.21 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 C-N-CA 124.888 1.275 . . . . 75.510000000000005 111.848 -177.712 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -123.86 100.24 6.66 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 125.344 1.458 . . . . 72.230000000000004 107.626 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.52 HD11 ' HA ' ' A' ' 154' ' ' ARG . 35.5 mt -70.06 107.91 3.84 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-O 121.168 0.509 . . . . 75.010000000000005 111.151 -176.395 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.423 HD11 ' HB2' ' A' ' 124' ' ' PRO . 48.7 mt -75.98 130.72 77.58 Favored Pre-proline 0 CA--C 1.553 1.083 0 N-CA-C 108.23 -1.026 . . . . 74.200000000000003 108.23 175.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.22 -63.17 0.07 OUTLIER 'Trans proline' 0 CA--C 1.559 1.749 0 C-N-CA 123.074 2.516 . . . . 54.329999999999998 113.207 -176.216 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 . . . . . 0 N--CA 1.489 1.504 0 C-N-CA 123.888 0.875 . . . . 72.340000000000003 108.902 177.684 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pt? . . . . . 0 CA--C 1.566 1.561 0 N-CA-C 111.667 0.247 . . . . 52.210000000000001 111.667 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -74.21 -48.98 0.19 Allowed 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.386 2.058 . . . . 71.0 112.354 176.685 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.504 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.6 tp 168.25 150.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 126.792 2.037 . . . . 74.310000000000002 106.321 -170.553 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.7 HD23 ' HB ' ' A' ' 140' ' ' VAL . 14.2 tp 57.54 -72.51 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 126.108 1.763 . . . . 75.409999999999997 111.587 -173.658 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.61 ' HA ' HD13 ' A' ' 119' ' ' LEU . 87.6 t80 -57.9 123.1 14.62 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.741 1.616 . . . . 72.200000000000003 111.948 172.086 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 98.9 m -145.44 99.17 4.52 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.113 0.965 . . . . 72.25 109.47 175.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -77.4 74.65 5.02 Favored 'Trans proline' 0 C--N 1.371 1.761 0 C-N-CA 122.462 2.108 . . . . 73.219999999999999 113.09 -172.643 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 3.6 m . . . . . 0 CA--C 1.546 0.811 0 CA-C-N 116.102 -0.499 . . . . 72.140000000000001 109.861 176.638 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 38.3 ptt180 . . . . . 0 CA--C 1.536 0.415 0 N-CA-C 108.711 -0.848 . . . . 71.420000000000002 108.711 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -92.59 118.99 31.59 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 106.976 -1.49 . . . . 65.209999999999994 106.976 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.61 HD13 ' HA ' ' A' ' 99' ' ' PHE . 18.4 mt -89.73 108.68 19.83 Favored 'General case' 0 C--O 1.225 -0.228 0 N-CA-C 106.725 -1.584 . . . . 72.25 106.725 -174.241 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -117.42 107.56 14.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.113 -1.069 . . . . 70.439999999999998 108.113 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.61 140.05 50.42 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 108.577 -0.898 . . . . 45.409999999999997 108.577 -179.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.78 129.41 37.0 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 109.189 -0.671 . . . . 64.0 109.189 173.297 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.508 HD12 HD13 ' A' ' 176' ' ' LEU . 2.0 tt -100.02 109.55 56.53 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 108.749 -0.834 . . . . 75.099999999999994 108.749 -173.747 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.03 113.86 2.77 Favored 'Trans proline' 0 C--N 1.378 2.115 0 C-N-CA 122.116 1.877 . . . . 75.129999999999995 110.19 171.095 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.565 HD21 HD12 ' A' ' 149' ' ' ILE . 12.0 tp -133.21 125.91 30.43 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 108.045 -1.095 . . . . 72.310000000000002 108.045 -169.448 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 43.0 p -73.16 171.7 12.46 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 117.975 0.352 . . . . 71.010000000000005 110.69 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 96.7 mt -71.39 -23.83 61.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 123.157 0.583 . . . . 61.310000000000002 111.009 178.758 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -72.03 -50.68 26.5 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.634 -0.876 . . . . 62.340000000000003 108.634 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.664 ' HG3' HH21 ' A' ' 136' ' ' ARG . 29.4 mm-40 -57.55 -40.52 79.04 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.841 1.256 . . . . 72.420000000000002 111.384 176.214 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.56 64.22 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 114.965 -1.016 . . . . 41.530000000000001 111.177 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -60.73 -58.45 8.4 Favored 'General case' 0 C--N 1.349 0.564 0 O-C-N 124.679 1.237 . . . . 74.439999999999998 110.266 -176.713 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.8 m80 -67.66 -38.59 84.0 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 123.958 0.786 . . . . 74.120000000000005 111.047 -175.321 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 73.49 -112.81 4.0 Favored Glycine 0 C--N 1.343 0.947 0 N-CA-C 110.47 -1.052 . . . . 73.519999999999996 110.47 -170.793 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.12 -130.85 22.26 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 111.551 -0.62 . . . . 54.530000000000001 111.551 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 9.3 mp0 -121.43 157.65 30.08 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.975 0.91 . . . . 73.099999999999994 109.452 174.785 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.664 HH21 ' HG3' ' A' ' 129' ' ' GLU . 5.3 tpp180 -135.02 124.03 24.19 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.234 1.414 . . . . 72.329999999999998 107.975 177.374 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.3 p -84.9 127.09 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.091 0 C-N-CA 123.137 0.575 . . . . 72.109999999999999 110.228 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.676 HG23 HD22 ' A' ' 98' ' ' LEU . 30.7 m -140.71 158.01 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.938 1.295 . . . . 71.310000000000002 109.102 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -88.19 135.48 33.42 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 123.162 0.585 . . . . 43.229999999999997 111.284 -174.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.7 ' HB ' HD23 ' A' ' 98' ' ' LEU . 7.2 p -136.86 118.56 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 124.396 1.078 . . . . 43.229999999999997 109.288 168.25 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.39 20.29 11.74 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 123.92 0.888 . . . . 32.119999999999997 112.229 177.256 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.43 -9.47 66.98 Favored Glycine 0 C--N 1.358 1.78 0 C-N-CA 123.051 0.357 . . . . 31.34 113.216 -177.376 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -104.0 128.82 51.57 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.076 0.951 . . . . 75.200000000000003 109.983 -178.331 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.32 141.66 43.35 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.527 -0.545 . . . . 73.519999999999996 109.527 177.735 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.81 126.49 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.64 1.176 . . . . 72.420000000000002 108.619 178.814 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 44.7 m -82.49 109.82 17.05 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.396 0.678 . . . . 75.209999999999994 109.612 175.29 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.5 130.24 47.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 C-N-CA 123.999 0.92 . . . . 65.430000000000007 109.248 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -69.81 118.7 12.99 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.043 0.537 . . . . 75.219999999999999 109.96 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.565 HD12 HD21 ' A' ' 125' ' ' LEU . 17.2 pt -108.02 131.53 21.68 Favored Pre-proline 0 CA--C 1.564 1.508 0 C-N-CA 124.509 1.124 . . . . 73.409999999999997 108.866 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.402 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 18.0 Cg_endo -62.06 140.05 82.11 Favored 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.67 2.247 . . . . 71.140000000000001 113.763 -174.609 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 34.2 Cg_exo -64.61 127.55 19.12 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 123.329 2.686 . . . . 75.030000000000001 112.696 175.568 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 76.76 30.09 56.58 Favored Glycine 0 CA--C 1.528 0.847 0 O-C-N 123.49 0.494 . . . . 43.350000000000001 112.406 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.8 p -73.74 137.36 23.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.78 0 C-N-CA 122.89 0.476 . . . . 75.439999999999998 110.367 -177.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -103.67 173.31 6.36 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.135 0.969 . . . . 75.129999999999995 111.886 -171.176 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.8 tp10 -63.83 122.2 15.86 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-N 113.09 -1.868 . . . . 74.099999999999994 109.346 167.204 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 102.06 -8.39 55.67 Favored Glycine 0 N--CA 1.474 1.215 0 CA-C-O 119.758 -0.468 . . . . 74.409999999999997 113.127 178.745 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.0 m -78.37 121.99 25.19 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.094 0.447 . . . . 73.319999999999993 109.937 177.055 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.8 p -99.15 141.68 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 109.019 -0.734 . . . . 73.219999999999999 109.019 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.518 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 65.4 mt -108.43 104.21 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.344 1.058 . . . . 64.519999999999996 108.724 -176.886 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -88.68 121.12 30.72 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 123.261 0.625 . . . . 61.520000000000003 109.782 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -124.23 106.56 30.64 Favored Pre-proline 0 CA--C 1.557 1.23 0 N-CA-C 107.65 -1.241 . . . . 74.319999999999993 107.65 173.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.91 139.35 36.04 Favored 'Trans proline' 0 C--N 1.373 1.836 0 C-N-CA 122.935 2.423 . . . . 71.519999999999996 113.31 -174.647 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 77.4 0.15 71.12 Favored Glycine 0 C--N 1.352 1.426 0 CA-C-N 115.471 -0.786 . . . . 72.409999999999997 114.264 173.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 93.6 mmm -103.6 15.2 29.49 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.685 0.794 . . . . 75.319999999999993 111.712 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -94.35 -108.24 2.07 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 111.534 -0.626 . . . . 51.409999999999997 111.534 174.029 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 166' ' ' GLY . . . . . 0.424 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -66.1 106.28 1.54 Allowed Glycine 0 C--N 1.344 1.011 0 C-N-CA 123.693 0.663 . . . . 71.420000000000002 112.575 175.407 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -83.8 165.18 19.03 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 123.75 0.82 . . . . 65.120000000000005 109.878 175.541 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 111.79 -141.6 16.71 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 111.184 -0.766 . . . . 54.149999999999999 111.184 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -76.61 -52.37 2.18 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 118.247 -0.882 . . . . 72.430000000000007 111.159 172.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -82.51 118.91 2.93 Favored 'Trans proline' 0 C--N 1.391 2.776 0 C-N-CA 121.627 1.551 . . . . 55.329999999999998 111.657 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_endo -84.9 126.71 3.41 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.718 2.279 . . . . 55.409999999999997 113.593 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' GLY . . . . . 0.424 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -110.2 161.89 12.79 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 115.928 -0.578 . . . . 75.310000000000002 112.021 174.736 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -99.89 162.48 12.96 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 124.676 1.19 . . . . 72.450000000000003 110.009 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.61 HD21 HD11 ' A' ' 98' ' ' LEU . 54.3 tp -116.32 128.38 55.5 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.733 0.813 . . . . 63.539999999999999 109.796 178.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 90.7 mt -128.54 120.51 26.86 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 124.314 1.046 . . . . 61.43 109.729 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.518 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 93.7 mt -118.99 104.17 10.24 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 123.369 0.668 . . . . 73.040000000000006 110.745 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.4 t -86.22 98.5 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.982 0 CA-C-N 115.397 -0.82 . . . . 61.130000000000003 109.404 -172.76 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.3 t -61.29 117.0 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 123.987 0.915 . . . . 63.439999999999998 112.426 -173.735 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -112.88 101.08 9.16 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 126.103 1.761 . . . . 74.319999999999993 108.63 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.418 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 43.5 mt -71.49 114.25 9.37 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.148 -0.478 . . . . 70.340000000000003 110.779 -177.881 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 87.3 mt -61.53 146.73 89.4 Favored Pre-proline 0 CA--C 1.549 0.907 0 CA-C-N 114.752 -1.113 . . . . 61.409999999999997 110.636 178.348 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -64.39 -168.15 0.1 OUTLIER 'Trans proline' 0 C--N 1.378 2.131 0 C-N-CA 123.154 2.569 . . . . 74.219999999999999 113.81 -173.594 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 . . . . . 0 C--O 1.253 1.238 0 CA-C-O 118.014 -0.993 . . . . 64.0 108.664 -179.85 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 94' ' ' MET . . . . . 0.46 ' O ' ' HG ' ' A' ' 95' ' ' LEU . 34.2 tpp . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 110.611 -0.144 . . . . 63.340000000000003 110.611 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.554 HD22 HG23 ' A' ' 100' ' ' THR . 3.2 pp 58.54 111.11 0.02 OUTLIER Pre-proline 0 N--CA 1.482 1.143 0 C-N-CA 127.18 2.192 . . . . 63.420000000000002 111.628 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.656 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 73.6 Cg_endo -73.71 -167.57 0.39 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.685 2.257 . . . . 72.409999999999997 111.377 171.117 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.475 HD12 ' H ' ' A' ' 98' ' ' LEU . 12.7 tp -75.96 142.69 41.91 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.603 -0.517 . . . . 51.43 109.603 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.589 HD13 HG21 ' A' ' 138' ' ' VAL . 6.3 tp 68.89 -57.98 0.5 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 126.95 2.1 . . . . 74.450000000000003 112.02 -167.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.656 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 65.7 t80 -72.65 135.33 45.44 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.697 1.199 . . . . 72.319999999999993 112.534 -173.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.554 HG23 HD22 ' A' ' 95' ' ' LEU . 55.4 m -153.97 101.25 2.49 Favored Pre-proline 0 CA--C 1.544 0.74 0 C-N-CA 123.985 0.914 . . . . 62.149999999999999 109.895 177.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -76.08 83.0 2.06 Favored 'Trans proline' 0 C--N 1.369 1.611 0 C-N-CA 122.128 1.885 . . . . 64.519999999999996 112.304 -173.265 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.529 HG13 HG22 ' A' ' 100' ' ' THR . 30.1 m -88.94 151.28 3.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-N 114.935 -1.03 . . . . 65.549999999999997 109.729 173.317 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -106.54 162.47 13.71 Favored 'General case' 0 C--O 1.242 0.67 0 N-CA-C 109.481 -0.563 . . . . 73.239999999999995 109.481 173.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 22.1 ttmm -145.39 98.82 3.21 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 108.518 -0.919 . . . . 70.340000000000003 108.518 175.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -143.96 7.42 1.89 Allowed Glycine 0 N--CA 1.469 0.899 0 CA-C-N 115.787 -0.642 . . . . 54.509999999999998 112.196 175.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 30.5 p -72.68 96.93 2.08 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 123.193 0.597 . . . . 74.430000000000007 109.699 174.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.16 -178.14 21.01 Favored Glycine 0 C--N 1.344 1.006 0 CA-C-N 115.86 -0.609 . . . . 70.310000000000002 112.055 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -170.3 131.64 2.29 Favored Glycine 0 C--N 1.344 0.973 0 N-CA-C 111.938 -0.465 . . . . 71.109999999999999 111.938 179.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 39.9 t -136.3 -55.54 0.75 Allowed 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.977 -0.749 . . . . 72.439999999999998 108.977 174.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 169.98 45.29 0.03 OUTLIER Glycine 0 C--N 1.349 1.27 0 CA-C-N 115.771 -0.649 . . . . 74.420000000000002 112.132 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 161.8 -170.93 37.63 Favored Glycine 0 C--N 1.344 0.979 0 N-CA-C 112.034 -0.427 . . . . 61.43 112.034 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.2 m -73.53 107.87 6.06 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 122.786 0.434 . . . . 71.040000000000006 110.103 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -94.71 70.65 1.14 Allowed Glycine 0 C--N 1.345 1.053 0 N-CA-C 110.839 -0.904 . . . . 72.010000000000005 110.839 173.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -141.79 32.41 2.03 Favored Glycine 0 C--N 1.347 1.15 0 CA-C-N 115.856 -0.172 . . . . 65.510000000000005 113.513 -175.396 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 41.6 t -73.87 130.11 39.25 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 122.818 0.447 . . . . 75.010000000000005 110.045 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.517 ' H ' ' HB2' ' A' ' 170' ' ' PRO . . . 75.0 104.06 0.1 OUTLIER Glycine 0 C--N 1.345 1.04 0 O-C-N 124.099 0.874 . . . . 63.409999999999997 113.104 176.481 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 -86.1 131.17 34.32 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.948 -0.76 . . . . 63.229999999999997 108.948 175.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -93.31 104.41 16.58 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.561 -1.274 . . . . 64.329999999999998 107.561 -177.018 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.574 HD13 ' HA ' ' A' ' 99' ' ' PHE . 10.3 mt -94.08 109.78 21.52 Favored 'General case' 0 C--N 1.342 0.253 0 N-CA-C 107.093 -1.447 . . . . 71.120000000000005 107.093 -177.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.8 ttt180 -108.63 109.71 20.98 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.702 -0.481 . . . . 73.349999999999994 109.702 176.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -122.95 144.76 49.02 Favored 'General case' 0 C--O 1.242 0.693 0 N-CA-C 109.116 -0.698 . . . . 32.240000000000002 109.116 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -81.81 122.41 27.67 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.957 -1.127 . . . . 74.540000000000006 107.957 177.329 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.457 HD11 ' HG2' ' A' ' 136' ' ' ARG . 47.3 tp -99.32 103.38 20.2 Favored Pre-proline 0 CA--C 1.542 0.645 0 C-N-CA 123.565 0.746 . . . . 72.319999999999993 110.083 -171.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.13 114.39 3.97 Favored 'Trans proline' 0 C--N 1.374 1.894 0 C-N-CA 121.956 1.77 . . . . 72.340000000000003 110.017 176.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.536 HD21 HD12 ' A' ' 149' ' ' ILE . 14.2 tp -136.06 122.45 20.62 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 109.155 -0.683 . . . . 74.430000000000007 109.155 -168.401 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 3.0 m -69.61 162.31 27.87 Favored 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.987 0.915 . . . . 74.239999999999995 111.121 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 69.3 mt -63.93 -36.39 83.79 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.017 0.527 . . . . 73.310000000000002 112.37 -177.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -69.21 -40.19 78.15 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.292 0.637 . . . . 73.219999999999999 109.38 179.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.481 ' HG3' ' NH2' ' A' ' 136' ' ' ARG . 24.6 mm-40 -62.64 -44.27 96.7 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.477 1.111 . . . . 73.129999999999995 110.531 177.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.89 -37.29 78.93 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 115.158 -0.928 . . . . 73.109999999999999 111.408 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.5 t80 -65.84 -49.26 68.82 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.452 1.501 . . . . 71.430000000000007 110.881 -178.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -80.24 -41.22 25.51 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 115.28 -0.873 . . . . 73.209999999999994 111.157 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.528 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.36 58.35 8.83 Favored Glycine 0 C--N 1.345 1.073 0 O-C-N 123.543 0.527 . . . . 65.400000000000006 113.085 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -94.51 -130.69 6.0 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 110.966 -0.854 . . . . 75.310000000000002 110.966 174.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -107.76 160.3 15.83 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.284 0.564 . . . . 64.409999999999997 110.046 169.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.481 ' NH2' ' HG3' ' A' ' 129' ' ' GLU . 5.5 tpp180 -133.02 121.92 23.44 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.495 -1.298 . . . . 73.340000000000003 107.495 172.703 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 62.9 t -72.8 124.34 29.44 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-O 121.082 0.468 . . . . 73.340000000000003 110.084 175.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.589 HG21 HD13 ' A' ' 98' ' ' LEU . 32.9 m -127.33 145.2 35.19 Favored 'Isoleucine or valine' 0 C--O 1.251 1.142 0 C-N-CA 125.08 1.352 . . . . 74.219999999999999 108.105 -177.356 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -104.23 106.28 16.73 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.166 -0.679 . . . . 72.349999999999994 109.166 -176.307 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.609 HG13 ' HB2' ' A' ' 143' ' ' ARG . 2.4 p -106.45 100.18 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.829 0.851 . . . . 50.340000000000003 109.411 -176.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.92 23.91 14.26 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.426 0.691 . . . . 54.340000000000003 111.927 177.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.27 2.91 56.74 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 116.02 -0.537 . . . . 52.340000000000003 112.924 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.609 ' HB2' HG13 ' A' ' 140' ' ' VAL . 48.0 mtp180 -100.56 119.91 39.24 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 108.948 -0.76 . . . . 62.420000000000002 108.948 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.0 tmm_? -81.79 107.37 14.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.002 -0.74 . . . . 52.520000000000003 109.002 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 24.4 m -124.92 156.37 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 C-N-CA 123.701 0.8 . . . . 73.540000000000006 109.776 176.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.6 p -107.96 119.12 38.55 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 123.147 0.579 . . . . 73.450000000000003 110.192 174.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.0 p -99.16 132.28 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.671 -0.492 . . . . 64.25 109.671 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -80.36 120.19 24.07 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.877 0.37 . . . . 74.230000000000004 110.162 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.536 HD12 HD21 ' A' ' 125' ' ' LEU . 7.5 pt -95.08 142.01 24.03 Favored Pre-proline 0 CA--C 1.556 1.182 0 C-N-CA 124.135 0.974 . . . . 71.530000000000001 109.341 179.111 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -72.56 143.86 39.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.267 1.978 . . . . 74.329999999999998 112.5 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.33 133.54 19.43 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 122.633 2.222 . . . . 73.129999999999995 111.915 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.84 30.01 53.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.64 -0.709 . . . . 61.140000000000001 113.253 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 8.2 p -82.72 148.09 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 117.363 0.581 . . . . 72.049999999999997 109.634 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 -126.47 177.71 6.31 Favored 'General case' 0 N--CA 1.479 0.988 0 CA-C-O 121.567 0.699 . . . . 73.510000000000005 112.122 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.6 tp10 -61.37 129.17 39.88 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 113.835 -1.53 . . . . 75.409999999999997 110.78 177.109 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.66 4.66 90.0 Favored Glycine 0 C--N 1.344 0.984 0 O-C-N 123.701 0.626 . . . . 54.130000000000003 113.551 178.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 67.0 m -82.23 119.67 24.38 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 117.444 0.622 . . . . 72.530000000000001 109.457 175.619 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.3 p -98.55 125.29 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-O 121.213 0.53 . . . . 35.299999999999997 110.054 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.8 mt -91.75 104.03 15.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 C-N-CA 124.334 1.053 . . . . 72.549999999999997 108.173 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.464 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 74.8 ttt180 -94.45 114.66 26.72 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 110.139 -0.319 . . . . 73.549999999999997 110.139 -177.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 19.5 t -122.85 98.4 42.77 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 123.59 0.756 . . . . 73.430000000000007 109.092 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.06 125.72 12.86 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.931 2.421 . . . . 72.510000000000005 112.74 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 104.64 -24.49 28.46 Favored Glycine 0 N--CA 1.474 1.19 0 CA-C-O 120.151 -0.25 . . . . 62.310000000000002 113.167 176.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.3 ttm -89.57 -18.92 25.66 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.362 0.665 . . . . 72.340000000000003 111.338 -174.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -69.8 -100.76 0.04 OUTLIER Glycine 0 C--N 1.346 1.103 0 CA-C-O 119.677 -0.513 . . . . 74.109999999999999 113.197 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -53.36 107.78 0.65 Allowed Glycine 0 C--N 1.355 1.59 0 C-N-CA 123.103 0.383 . . . . 70.329999999999998 113.248 179.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 13.0 mm-40 -84.76 169.53 14.13 Favored 'General case' 0 C--O 1.237 0.431 0 C-N-CA 123.602 0.761 . . . . 73.319999999999993 110.096 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 108.33 -138.47 14.67 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.716 -0.675 . . . . 60.030000000000001 111.672 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.437 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 58.0 t30 -77.15 -51.55 2.02 Favored Pre-proline 0 CA--C 1.569 1.706 0 CA-C-O 118.285 -0.864 . . . . 73.349999999999994 111.541 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.517 ' HB2' ' H ' ' A' ' 116' ' ' GLY . 72.8 Cg_endo -95.29 109.79 0.13 Allowed 'Trans proline' 0 C--N 1.394 2.958 0 C-N-CA 122.38 2.053 . . . . 62.219999999999999 112.746 177.239 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -60.45 125.95 18.72 Favored 'Trans proline' 0 C--N 1.381 2.261 0 C-N-CA 122.512 2.141 . . . . 61.119999999999997 111.654 175.072 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -112.27 177.33 18.51 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 116.412 -0.358 . . . . 72.230000000000004 113.88 -176.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.23 146.13 28.75 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.762 0.825 . . . . 72.120000000000005 110.318 -175.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 59.0 tp -113.38 134.51 54.6 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.196 0.598 . . . . 72.0 109.846 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 76.3 mt -129.61 105.2 7.9 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.437 1.095 . . . . 75.439999999999998 109.301 176.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.474 HD21 HD12 ' A' ' 98' ' ' LEU . 68.0 mt -107.55 102.73 11.96 Favored 'General case' 0 N--CA 1.479 1.013 0 O-C-N 122.109 -0.37 . . . . 62.439999999999998 110.009 174.687 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.7 t -85.93 99.04 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 N-CA-C 108.369 -0.974 . . . . 74.150000000000006 108.369 -175.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 87.0 t -56.23 116.81 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.45 1.1 . . . . 73.519999999999996 111.724 -177.078 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -113.07 104.21 12.15 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 125.576 1.551 . . . . 71.209999999999994 107.784 177.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 74.8 mt -69.39 130.38 42.38 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 122.918 0.487 . . . . 60.350000000000001 111.526 -174.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 92.1 mt -84.84 139.02 37.31 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.53 0.732 . . . . 72.439999999999998 110.128 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -65.38 116.54 3.95 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 123.193 2.595 . . . . 54.329999999999998 112.021 -175.059 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.543 -0.741 . . . . 73.319999999999993 109.415 -178.185 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 94' ' ' MET . . . . . 0.438 ' N ' ' SD ' ' A' ' 94' ' ' MET . 1.3 mpt? . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.484 -0.562 . . . . 60.210000000000001 109.484 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.527 ' HB3' ' HA ' ' A' ' 100' ' ' THR . 0.5 OUTLIER -95.09 99.55 4.5 Favored Pre-proline 0 CA--C 1.554 1.116 0 N-CA-C 109.058 -0.719 . . . . 65.239999999999995 109.058 166.736 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -66.62 -49.27 1.73 Allowed 'Trans proline' 0 C--N 1.385 2.498 0 C-N-CA 122.612 2.208 . . . . 70.329999999999998 111.691 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.526 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.4 tp -179.52 154.36 0.61 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.627 1.571 . . . . 74.140000000000001 106.945 -175.261 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.553 HD11 HD21 ' A' ' 174' ' ' LEU . 7.4 tp 53.04 -75.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 125.976 1.71 . . . . 63.229999999999997 111.551 -174.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.74 ' HA ' HD13 ' A' ' 119' ' ' LEU . 85.4 t80 -50.54 129.18 21.84 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.097 1.759 . . . . 74.310000000000002 112.341 171.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.557 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 55.2 m -142.18 105.99 5.65 Favored Pre-proline 0 N--CA 1.471 0.587 0 C-N-CA 124.105 0.962 . . . . 71.030000000000001 108.442 172.436 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -76.85 87.55 1.47 Allowed 'Trans proline' 0 C--N 1.366 1.453 0 C-N-CA 121.517 1.478 . . . . 64.430000000000007 112.42 -170.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.6 m -86.61 147.07 5.6 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-N 114.735 -1.12 . . . . 74.230000000000004 109.995 177.425 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.8 t -79.69 -15.2 58.0 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 122.761 0.424 . . . . 71.319999999999993 111.145 -178.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 56.7 tttm -58.73 121.48 11.17 Favored 'General case' 0 C--N 1.354 0.767 0 C-N-CA 123.671 0.788 . . . . 72.349999999999994 111.213 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -84.38 -124.92 1.22 Allowed Glycine 0 C--N 1.344 0.998 0 CA-C-N 115.298 -0.864 . . . . 74.420000000000002 113.131 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 16.4 m -86.74 -12.31 48.57 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 123.268 0.627 . . . . 62.420000000000002 110.867 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 82.85 -41.98 2.93 Favored Glycine 0 C--N 1.35 1.347 0 C-N-CA 123.12 0.391 . . . . 73.409999999999997 113.67 174.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.56 57.71 3.05 Favored Glycine 0 C--N 1.344 0.986 0 N-CA-C 111.402 -0.679 . . . . 72.450000000000003 111.402 -175.506 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.8 p -70.76 84.79 0.65 Allowed 'General case' 0 C--O 1.245 0.861 0 C-N-CA 123.49 0.716 . . . . 71.230000000000004 110.66 178.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 68.73 -84.06 0.21 Allowed Glycine 0 C--N 1.352 1.457 0 CA-C-N 115.281 -0.872 . . . . 72.329999999999998 111.581 -175.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -174.23 25.37 0.07 OUTLIER Glycine 0 C--N 1.335 0.516 0 N-CA-C 111.248 -0.741 . . . . 54.109999999999999 111.248 173.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 45.4 m -125.83 119.69 28.53 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.884 0.874 . . . . 72.439999999999998 109.859 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 67.58 -100.45 0.61 Allowed Glycine 0 C--N 1.352 1.435 0 O-C-N 124.266 0.978 . . . . 45.420000000000002 112.999 177.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 136.99 129.68 2.8 Favored Glycine 0 C--N 1.341 0.829 0 N-CA-C 111.704 -0.558 . . . . 61.240000000000002 111.704 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 78.9 p -73.91 110.99 8.64 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 123.209 0.603 . . . . 73.430000000000007 109.479 174.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -72.87 -152.62 1.87 Allowed Glycine 0 C--N 1.349 1.278 0 N-CA-C 114.569 0.588 . . . . 54.43 114.569 -172.613 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.431 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 94.2 mtt180 -82.49 131.08 35.22 Favored 'General case' 0 N--CA 1.476 0.862 0 O-C-N 122.461 -0.435 . . . . 73.150000000000006 110.077 -178.092 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.7 105.95 18.17 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 107.345 -1.354 . . . . 65.310000000000002 107.345 -177.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.74 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.5 mt -92.87 108.96 20.4 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 107.26 -1.385 . . . . 71.400000000000006 107.26 -176.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 74.4 ttt180 -119.33 105.87 11.74 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.131 0.972 . . . . 73.140000000000001 108.663 -175.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.58 145.23 40.34 Favored 'General case' 0 C--O 1.242 0.67 0 C-N-CA 123.722 0.809 . . . . 53.100000000000001 109.567 -174.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -76.66 137.59 39.52 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.536 -0.542 . . . . 64.019999999999996 109.536 175.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.411 ' HA ' ' HD2' ' A' ' 124' ' ' PRO . 19.9 tp -101.62 105.36 40.27 Favored Pre-proline 0 CA--C 1.542 0.671 0 C-N-CA 123.992 0.917 . . . . 71.310000000000002 110.201 -178.357 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 123' ' ' LEU . 23.5 Cg_endo -60.64 122.78 11.8 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.488 2.125 . . . . 74.109999999999999 110.342 169.12 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.468 HD21 HD12 ' A' ' 149' ' ' ILE . 25.3 tp -147.83 133.79 19.17 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.889 -0.782 . . . . 73.329999999999998 108.889 -175.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.9 p -81.21 163.66 22.86 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 110.129 -0.323 . . . . 72.120000000000005 110.129 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.0 mt -61.92 -32.7 73.13 Favored 'General case' 0 N--CA 1.482 1.168 0 C-N-CA 123.607 0.763 . . . . 63.210000000000001 110.971 179.537 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -70.72 -50.23 38.51 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 114.987 -1.006 . . . . 75.150000000000006 109.406 -177.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -70.13 -26.65 64.05 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.794 0.837 . . . . 73.219999999999999 111.859 -179.197 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.75 -40.31 69.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.216 0.606 . . . . 75.430000000000007 110.744 174.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -64.43 -46.4 83.36 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.911 0.884 . . . . 64.439999999999998 110.698 175.504 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -63.36 -49.67 72.96 Favored 'General case' 0 C--N 1.351 0.671 0 O-C-N 123.71 0.631 . . . . 73.219999999999999 110.362 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.505 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 56.63 70.39 0.99 Allowed Glycine 0 C--N 1.349 1.276 0 O-C-N 124.128 0.893 . . . . 75.109999999999999 112.771 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -121.06 -121.37 2.81 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.35 -1.1 . . . . 72.400000000000006 110.35 174.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.557 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 7.0 mp0 -99.69 154.96 17.88 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 123.143 0.577 . . . . 42.329999999999998 109.528 172.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.458 ' HB2' HD13 ' A' ' 149' ' ' ILE . 14.0 tpt180 -137.04 122.55 19.61 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 108.162 -1.051 . . . . 75.420000000000002 108.162 178.479 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.1 t -74.34 119.44 21.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 O-C-N 123.577 0.548 . . . . 75.140000000000001 109.886 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.548 HG21 HD13 ' A' ' 98' ' ' LEU . 28.5 m -122.68 147.38 26.89 Favored 'Isoleucine or valine' 0 C--O 1.251 1.147 0 C-N-CA 124.769 1.228 . . . . 55.210000000000001 109.067 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -100.91 127.83 47.22 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.987 0.915 . . . . 74.109999999999999 109.268 -177.178 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.562 HG23 ' HB2' ' A' ' 99' ' ' PHE . 3.1 p -142.66 103.67 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 123.287 0.635 . . . . 72.540000000000006 111.118 -174.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 55.38 29.69 13.55 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 124.448 1.099 . . . . 64.409999999999997 113.14 172.029 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.65 26.34 10.85 Favored Glycine 0 C--N 1.348 1.248 0 CA-C-N 116.36 -0.382 . . . . 41.100000000000001 112.658 179.153 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.496 ' HB2' HG13 ' A' ' 140' ' ' VAL . 54.3 mmt-85 -131.87 136.18 47.25 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.842 0.857 . . . . 72.420000000000002 110.049 -178.417 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 16.1 ttp180 -95.67 105.88 17.92 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 107.917 -1.142 . . . . 75.329999999999998 107.917 171.249 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 33.0 m -125.44 151.37 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 109.915 -0.402 . . . . 31.219999999999999 109.915 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.557 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 34.6 p -106.11 117.65 34.58 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.296 0.638 . . . . 72.340000000000003 109.924 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.2 p -98.8 133.35 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 108.664 -0.865 . . . . 72.219999999999999 108.664 176.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.4 ttt85 -82.4 125.74 31.39 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.203 0.525 . . . . 65.519999999999996 109.754 -178.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.505 HG13 ' HA2' ' A' ' 133' ' ' GLY . 3.3 pt -107.56 145.8 32.04 Favored Pre-proline 0 CA--C 1.557 1.219 0 C-N-CA 124.882 1.273 . . . . 53.420000000000002 108.686 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.43 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 56.7 Cg_endo -71.08 146.56 52.38 Favored 'Trans proline' 0 CA--C 1.566 2.099 0 C-N-CA 122.161 1.907 . . . . 72.310000000000002 112.823 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 23.9 Cg_exo -66.79 134.95 36.57 Favored 'Trans proline' 0 C--N 1.38 2.23 0 C-N-CA 123.172 2.581 . . . . 64.099999999999994 111.962 172.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.16 28.03 62.95 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-N 115.724 -0.671 . . . . 74.109999999999999 113.024 -177.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.43 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 14.7 p -78.19 147.2 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.256 -0.646 . . . . 74.129999999999995 109.256 177.238 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -129.61 177.23 7.37 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 122.011 0.91 . . . . 62.109999999999999 113.085 -167.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.5 tp10 -62.58 121.4 13.23 Favored 'General case' 0 C--O 1.241 0.644 0 CA-C-N 113.463 -1.699 . . . . 74.040000000000006 110.414 174.385 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.73 2.83 69.21 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 115.892 -0.595 . . . . 60.399999999999999 112.822 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 59.5 m -86.39 122.04 29.79 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 109.458 -0.571 . . . . 73.329999999999998 109.458 174.028 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.5 p -101.23 126.35 55.05 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.232 0.539 . . . . 74.409999999999997 110.051 178.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 60.7 mt -93.94 102.92 14.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.941 1.296 . . . . 70.409999999999997 107.914 176.32 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -98.38 121.62 40.53 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.956 -0.387 . . . . 75.329999999999998 109.956 -179.09 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 4.2 t -115.47 99.62 52.64 Favored Pre-proline 0 CA--C 1.556 1.192 0 N-CA-C 107.692 -1.225 . . . . 74.530000000000001 107.692 173.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -68.25 131.39 23.36 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 123.098 2.532 . . . . 60.25 113.63 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 75.87 24.07 70.51 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.085 -0.962 . . . . 45.030000000000001 113.784 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.7 tpt -126.28 -9.2 6.4 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 123.62 0.768 . . . . 71.420000000000002 111.21 -176.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -71.11 -94.7 0.07 OUTLIER Glycine 0 C--N 1.347 1.172 0 CA-C-O 120.175 -0.236 . . . . 74.340000000000003 112.848 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -68.84 106.96 1.91 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.966 -0.352 . . . . 44.420000000000002 112.433 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -72.43 137.46 46.48 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.647 0.779 . . . . 71.230000000000004 111.013 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.2 -163.75 32.55 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 116.006 -0.543 . . . . 75.420000000000002 112.157 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -72.94 -43.95 8.17 Favored Pre-proline 0 CA--C 1.565 1.537 0 CA-C-O 118.968 -0.539 . . . . 73.299999999999997 110.725 174.172 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -93.34 108.37 0.18 Allowed 'Trans proline' 0 C--N 1.386 2.511 0 C-N-CA 122.081 1.854 . . . . 73.319999999999993 111.254 163.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -82.74 137.67 8.99 Favored 'Trans proline' 0 C--N 1.372 1.807 0 C-N-CA 122.361 2.041 . . . . 62.140000000000001 112.243 -178.598 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.431 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -99.04 179.93 31.36 Favored Glycine 0 C--N 1.343 0.935 0 CA-C-N 115.933 -0.576 . . . . 45.420000000000002 113.14 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -87.88 149.03 24.34 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 122.844 0.458 . . . . 74.0 111.239 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.553 HD21 HD11 ' A' ' 98' ' ' LEU . 41.8 tp -112.42 128.64 56.37 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 122.844 0.458 . . . . 74.549999999999997 109.915 177.301 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 74.3 mt -127.46 115.48 18.96 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 124.196 0.998 . . . . 72.510000000000005 109.157 178.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.5 HD21 HD12 ' A' ' 98' ' ' LEU . 72.9 mt -117.07 103.42 10.22 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 123.178 0.591 . . . . 75.319999999999993 110.489 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.6 t -89.79 98.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.072 0 C-N-CA 122.524 0.33 . . . . 73.0 110.331 -173.234 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.8 t -60.09 113.87 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 C-N-CA 124.203 1.001 . . . . 55.539999999999999 112.694 -173.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 22.1 mmm180 -105.0 109.14 21.01 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.126 1.77 . . . . 73.030000000000001 108.649 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 86.6 mt -71.87 119.0 15.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.387 0.275 . . . . 74.140000000000001 110.449 179.152 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 78.4 mt -79.05 147.35 69.63 Favored Pre-proline 0 CA--C 1.545 0.784 0 C-N-CA 123.693 0.797 . . . . 54.32 110.79 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -61.1 110.0 0.79 Allowed 'Trans proline' 0 C--N 1.373 1.82 0 C-N-CA 123.368 2.712 . . . . 75.329999999999998 111.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 77.6 t60 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.733 -0.651 . . . . 63.240000000000002 110.289 178.507 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 96.9 mmm . . . . . 0 N--CA 1.487 1.382 0 N-CA-C 110.171 -0.307 . . . . 70.209999999999994 110.171 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 37.11 89.32 0.08 OUTLIER Pre-proline 0 CA--C 1.562 1.426 0 C-N-CA 126.219 1.808 . . . . 65.040000000000006 114.26 -176.321 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.66 -66.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.388 2.65 0 C-N-CA 122.738 2.292 . . . . 74.120000000000005 111.477 174.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.2 tp -178.89 149.44 0.45 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 125.236 1.414 . . . . 63.130000000000003 107.809 175.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.663 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 13.2 tp 56.99 8.6 0.52 Allowed 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 124.422 1.089 . . . . 74.439999999999998 112.494 -174.678 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.642 ' HA ' HD13 ' A' ' 119' ' ' LEU . 77.2 t80 -150.87 124.49 9.05 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 123.927 0.891 . . . . 74.200000000000003 109.261 -165.608 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.602 ' H ' HD22 ' A' ' 119' ' ' LEU . 95.7 m -150.5 95.24 3.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 C-N-CA 124.639 1.175 . . . . 75.109999999999999 108.155 176.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.6 104.65 1.16 Allowed 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 121.921 1.748 . . . . 55.130000000000003 110.804 -176.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.17 174.04 3.22 Favored 'Isoleucine or valine' 0 C--O 1.244 0.789 0 C-N-CA 123.793 0.837 . . . . 75.510000000000005 109.466 178.307 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 54.0 p -112.47 86.78 2.43 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.41 0.684 . . . . 33.229999999999997 109.283 177.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -79.32 149.64 31.7 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.143 -0.935 . . . . 64.430000000000007 109.676 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 70.36 48.23 38.85 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 111.335 -0.706 . . . . 61.43 111.335 -174.04 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 48.0 t -68.41 -25.41 65.02 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.124 0.97 . . . . 62.420000000000002 112.274 -173.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.49 92.42 0.59 Allowed Glycine 0 C--N 1.353 1.521 0 CA-C-O 120.104 -0.275 . . . . 60.210000000000001 112.813 -178.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 74.41 26.83 66.98 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.894 -0.392 . . . . 73.420000000000002 112.401 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 18.5 m 63.0 14.4 7.53 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 124.654 1.181 . . . . 63.149999999999999 112.36 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -128.12 -59.72 0.12 Allowed Glycine 0 C--N 1.348 1.245 0 N-CA-C 110.416 -1.073 . . . . 72.530000000000001 110.416 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 67.7 -96.31 0.36 Allowed Glycine 0 C--N 1.348 1.218 0 N-CA-C 111.319 -0.712 . . . . 71.230000000000004 111.319 -179.233 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.5 p -84.07 -2.29 56.42 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 124.08 0.952 . . . . 74.129999999999995 111.516 175.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 115.37 -106.46 1.59 Allowed Glycine 0 C--N 1.347 1.185 0 N-CA-C 110.905 -0.878 . . . . 22.239999999999998 110.905 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -112.66 100.6 1.13 Allowed Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.244 -0.742 . . . . 73.450000000000003 111.244 178.524 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 52.9 m -131.64 149.08 52.61 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 123.708 0.803 . . . . 72.329999999999998 110.576 177.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -74.98 -161.75 9.06 Favored Glycine 0 C--N 1.351 1.412 0 O-C-N 123.534 0.521 . . . . 74.120000000000005 111.933 173.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 24.2 ptt180 -97.34 149.33 22.21 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 123.199 0.6 . . . . 64.219999999999999 110.922 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -92.61 114.71 27.34 Favored 'General case' 0 C--N 1.348 0.519 0 N-CA-C 107.686 -1.227 . . . . 72.310000000000002 107.686 175.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.642 HD13 ' HA ' ' A' ' 99' ' ' PHE . 31.2 mt -93.44 107.22 19.1 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 106.991 -1.485 . . . . 64.049999999999997 106.991 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.485 ' H ' ' HB ' ' A' ' 100' ' ' THR . 19.6 ttt180 -116.0 105.83 13.09 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.03 -0.73 . . . . 72.310000000000002 109.03 178.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 141.36 48.17 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.829 0.852 . . . . 45.210000000000001 108.772 -177.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.14 129.6 34.62 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.372 -0.603 . . . . 73.129999999999995 109.372 174.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.483 HD12 HD13 ' A' ' 176' ' ' LEU . 1.7 tt -101.6 109.64 59.75 Favored Pre-proline 0 CA--C 1.55 0.965 0 C-N-CA 123.479 0.712 . . . . 70.439999999999998 109.379 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -67.4 121.82 8.98 Favored 'Trans proline' 0 C--N 1.377 2.079 0 C-N-CA 122.559 2.173 . . . . 71.409999999999997 110.954 172.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.1 tp -140.67 135.09 31.29 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 108.805 -0.813 . . . . 73.120000000000005 108.805 -173.262 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.5 p -76.15 167.12 22.44 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.892 -0.41 . . . . 71.329999999999998 109.892 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.516 HD12 ' HB2' ' A' ' 183' ' ' HIS . 86.6 mt -66.77 -31.11 71.54 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.033 0.533 . . . . 74.140000000000001 110.644 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -71.11 -49.49 43.79 Favored 'General case' 0 C--O 1.22 -0.497 0 CA-C-N 114.701 -1.136 . . . . 71.310000000000002 109.135 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -74.35 -19.6 60.39 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.405 0.682 . . . . 71.340000000000003 111.452 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.54 -45.21 72.78 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.138 0.575 . . . . 52.329999999999998 109.853 167.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.03 -41.37 95.32 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 123.938 0.895 . . . . 75.109999999999999 111.006 176.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -75.48 -39.76 58.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.131 0.572 . . . . 74.329999999999998 110.679 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.25 -114.11 6.26 Favored Glycine 0 C--N 1.345 1.081 0 CA-C-N 115.273 -0.876 . . . . 73.109999999999999 111.207 -172.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.12 -132.71 39.58 Favored Glycine 0 C--N 1.351 1.382 0 CA-C-O 119.668 -0.518 . . . . 75.150000000000006 112.413 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.575 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 10.3 mp0 -105.75 158.22 16.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.847 0.859 . . . . 75.140000000000001 109.958 176.246 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.632 ' HB2' HD13 ' A' ' 149' ' ' ILE . 23.4 tpt85 -133.91 120.87 20.92 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.733 0.813 . . . . 72.519999999999996 109.063 178.452 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.6 t -74.88 109.08 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 C-N-CA 124.165 0.986 . . . . 73.510000000000005 109.626 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.49 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 26.1 m -128.03 149.15 32.68 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 C-N-CA 124.075 0.95 . . . . 72.450000000000003 110.098 -174.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -97.73 103.75 15.72 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 123.649 0.78 . . . . 63.130000000000003 111.322 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.663 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.3 p -103.94 102.26 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.103 0.961 . . . . 71.140000000000001 109.569 -179.03 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.93 27.74 17.16 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 124.321 1.049 . . . . 63.509999999999998 112.201 177.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.54 -13.09 59.78 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-O 119.317 -0.713 . . . . 71.010000000000005 114.227 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.23 152.25 19.32 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 118.164 0.982 . . . . 74.109999999999999 110.093 177.165 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 -100.17 109.01 21.27 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.587 0.755 . . . . 61.140000000000001 109.602 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 86.3 t -122.66 136.84 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 N-CA-C 108.572 -0.899 . . . . 74.140000000000001 108.572 175.746 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.575 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 77.5 p -95.5 113.09 24.72 Favored 'General case' 0 C--O 1.242 0.658 0 N-CA-C 109.168 -0.679 . . . . 60.530000000000001 109.168 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -97.84 136.48 28.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 123.57 0.748 . . . . 53.539999999999999 109.216 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -81.03 127.27 32.41 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.369 0.605 . . . . 64.120000000000005 110.568 -176.439 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.632 HD13 ' HB2' ' A' ' 136' ' ' ARG . 7.5 pt -118.07 145.32 36.62 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.658 1.583 . . . . 73.040000000000006 108.43 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.04 138.2 27.8 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.456 2.104 . . . . 73.5 112.599 178.082 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.73 143.66 51.7 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.336 2.024 . . . . 63.420000000000002 111.544 169.012 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.0 26.48 58.11 Favored Glycine 0 C--N 1.343 0.932 0 CA-C-N 116.278 -0.419 . . . . 53.219999999999999 112.897 -173.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.6 p -87.58 150.85 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 C-N-CA 123.2 0.6 . . . . 71.340000000000003 109.869 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 42.6 mtp180 -123.16 177.86 5.36 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 121.722 0.773 . . . . 75.409999999999997 112.358 -177.104 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -58.37 137.27 57.35 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 113.282 -1.781 . . . . 75.409999999999997 111.038 174.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.76 -14.15 38.55 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-O 119.352 -0.693 . . . . 30.23 113.976 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 63.5 m -71.11 118.37 13.81 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 117.558 0.679 . . . . 74.239999999999995 109.593 -179.104 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.65 132.52 42.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 122.99 0.516 . . . . 64.430000000000007 109.716 -179.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.06 104.65 16.93 Favored 'Isoleucine or valine' 0 C--O 1.241 0.606 0 C-N-CA 124.876 1.27 . . . . 65.040000000000006 107.588 -177.456 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.426 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 64.7 ttt180 -91.61 112.64 24.65 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 109.94 -0.393 . . . . 74.120000000000005 109.94 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 8.6 t -104.11 100.12 19.78 Favored Pre-proline 0 CA--C 1.557 1.219 0 N-CA-C 106.989 -1.485 . . . . 74.209999999999994 106.989 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -66.63 128.83 19.8 Favored 'Trans proline' 0 C--N 1.375 1.943 0 C-N-CA 122.878 2.385 . . . . 70.109999999999999 113.096 -174.364 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.56 22.78 78.13 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.939 -0.573 . . . . 73.540000000000006 114.207 176.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.1 tpt -107.45 -23.96 11.99 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 123.385 0.674 . . . . 51.450000000000003 110.969 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -66.45 -84.14 0.1 OUTLIER Glycine 0 C--N 1.344 1.024 0 CA-C-N 116.359 -0.382 . . . . 73.200000000000003 112.865 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -71.46 93.09 0.52 Allowed Glycine 0 C--N 1.346 1.109 0 N-CA-C 111.466 -0.653 . . . . 61.299999999999997 111.466 173.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 15.3 mm100 -78.78 143.61 35.94 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.757 0.823 . . . . 61.409999999999997 111.756 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.13 -168.24 25.78 Favored Glycine 0 C--O 1.241 0.583 0 CA-C-N 114.8 -1.091 . . . . 65.0 110.377 -177.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 17.3 m120 -62.16 -44.37 88.79 Favored Pre-proline 0 CA--C 1.562 1.416 0 CA-C-O 118.655 -0.688 . . . . 75.430000000000007 110.82 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -82.96 114.43 2.26 Favored 'Trans proline' 0 C--N 1.394 2.972 0 C-N-CA 121.872 1.714 . . . . 74.340000000000003 111.717 167.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -82.94 150.27 14.03 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.222 1.948 . . . . 63.310000000000002 113.059 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -132.84 151.66 20.07 Favored Glycine 0 N--CA 1.473 1.123 0 N-CA-C 110.326 -1.109 . . . . 42.240000000000002 110.326 170.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.58 156.06 39.39 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.489 0.715 . . . . 51.43 112.49 -175.417 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.507 HD21 HD11 ' A' ' 98' ' ' LEU . 65.5 tp -116.22 127.94 55.19 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 108.428 -0.953 . . . . 75.510000000000005 108.428 172.783 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 54.5 mt -128.26 118.34 23.11 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 124.825 1.25 . . . . 63.030000000000001 108.689 -178.088 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.483 HD13 HD12 ' A' ' 123' ' ' LEU . 86.1 mt -120.68 103.31 9.02 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 123.061 0.545 . . . . 71.310000000000002 111.043 -178.298 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.9 t -85.43 96.02 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.587 -0.523 . . . . 74.519999999999996 109.587 -176.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.4 t -55.5 126.76 13.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.921 0.888 . . . . 51.350000000000001 111.807 -178.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -112.48 113.12 25.14 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 125.19 1.396 . . . . 74.340000000000003 107.687 177.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 50.3 mt -74.56 119.53 18.88 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.255 -0.646 . . . . 75.430000000000007 109.255 176.032 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 67.0 mt -82.33 131.24 56.46 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 108.317 -0.994 . . . . 72.25 108.317 176.334 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -68.31 143.03 56.87 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.961 2.441 . . . . 62.409999999999997 112.284 -174.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.516 ' HB2' HD12 ' A' ' 127' ' ' LEU . 47.0 m80 . . . . . 0 N--CA 1.485 1.319 0 C-N-CA 124.03 0.932 . . . . 62.119999999999997 108.806 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 85.2 mtp . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.753 -0.091 . . . . 63.399999999999999 110.753 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.429 ' HB2' ' O ' ' A' ' 99' ' ' PHE . 2.6 pt? -47.57 123.89 9.36 Favored Pre-proline 0 CA--C 1.563 1.452 0 C-N-CA 124.92 1.288 . . . . 70.439999999999998 112.238 178.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.431 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 10.3 Cg_endo -86.75 -79.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 123.009 2.473 . . . . 74.109999999999999 111.248 177.691 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.475 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.5 tp -157.83 142.23 16.18 Favored 'General case' 0 C--N 1.348 0.521 0 N-CA-C 108.292 -1.003 . . . . 63.409999999999997 108.292 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.712 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 5.2 tp 57.09 7.75 0.46 Allowed 'General case' 0 CA--C 1.57 1.713 0 C-N-CA 126.096 1.758 . . . . 53.210000000000001 113.172 -173.099 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.647 ' HA ' HD13 ' A' ' 119' ' ' LEU . 86.7 t80 -139.12 128.79 24.63 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.825 0.85 . . . . 63.310000000000002 109.333 -171.025 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.534 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 86.2 m -153.05 98.62 2.76 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 124.192 0.997 . . . . 74.439999999999998 109.342 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -72.16 83.18 1.23 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.444 2.096 . . . . 75.510000000000005 112.242 -173.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 20.6 m -85.05 173.48 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 CA-C-N 115.406 -0.816 . . . . 75.129999999999995 109.691 175.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 3.7 t -142.57 70.13 1.32 Allowed 'General case' 0 N--CA 1.473 0.684 0 CA-C-O 122.339 1.066 . . . . 73.340000000000003 109.324 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -89.76 97.55 11.26 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 114.63 -1.168 . . . . 64.319999999999993 110.346 -176.52 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -75.08 137.39 22.02 Favored Glycine 0 C--N 1.347 1.173 0 CA-C-N 116.037 -0.528 . . . . 51.140000000000001 111.972 178.598 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.7 m -63.48 -39.36 94.26 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 123.802 0.841 . . . . 55.109999999999999 110.665 176.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 63.11 57.17 16.6 Favored Glycine 0 C--N 1.351 1.396 0 CA-C-N 115.27 -0.877 . . . . 71.530000000000001 112.853 179.068 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.67 151.12 8.43 Favored Glycine 0 C--N 1.345 1.047 0 CA-C-O 119.59 -0.561 . . . . 72.430000000000007 112.111 179.379 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.7 p -69.4 -50.38 46.44 Favored 'General case' 0 N--CA 1.474 0.775 0 C-N-CA 123.82 0.848 . . . . 61.200000000000003 110.544 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -65.93 -23.15 70.91 Favored Glycine 0 C--N 1.354 1.563 0 O-C-N 123.905 0.753 . . . . 44.140000000000001 112.441 175.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -75.99 76.12 1.45 Allowed Glycine 0 C--N 1.348 1.199 0 N-CA-C 111.968 -0.453 . . . . 71.099999999999994 111.968 174.43 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 32.8 t -87.77 83.25 7.17 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 108.39 -0.967 . . . . 61.130000000000003 108.39 177.246 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 74.3 -85.19 0.71 Allowed Glycine 0 C--N 1.347 1.157 0 CA-C-N 115.276 -0.874 . . . . 64.439999999999998 112.12 -178.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.68 -55.29 4.99 Favored Glycine 0 C--N 1.348 1.249 0 N-CA-C 111.482 -0.647 . . . . 73.420000000000002 111.482 -174.206 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 19.8 p -146.49 140.97 26.6 Favored 'General case' 0 C--O 1.242 0.664 0 C-N-CA 125.031 1.333 . . . . 73.140000000000001 108.108 173.398 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.35 -121.31 0.12 Allowed Glycine 0 C--N 1.346 1.112 0 CA-C-O 119.989 -0.34 . . . . 60.340000000000003 112.334 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.503 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.0 OUTLIER -97.54 133.39 42.17 Favored 'General case' 0 N--CA 1.479 0.992 0 CA-C-N 117.591 0.696 . . . . 62.43 110.209 178.708 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -95.35 107.32 19.44 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 107.086 -1.45 . . . . 73.450000000000003 107.086 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.647 HD13 ' HA ' ' A' ' 99' ' ' PHE . 15.7 mt -92.76 108.46 20.0 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 107.593 -1.262 . . . . 64.25 107.593 -174.281 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.518 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 20.8 ttt180 -106.17 104.71 14.47 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 109.049 -0.723 . . . . 65.140000000000001 109.049 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -123.19 134.34 54.17 Favored 'General case' 0 C--O 1.237 0.411 0 N-CA-C 108.929 -0.767 . . . . 51.439999999999998 108.929 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -80.87 121.78 26.39 Favored 'General case' 0 C--O 1.241 0.637 0 N-CA-C 108.254 -1.017 . . . . 61.310000000000002 108.254 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.572 HD21 ' HG2' ' A' ' 136' ' ' ARG . 5.5 tt -99.06 109.74 55.26 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 108.159 -1.052 . . . . 70.109999999999999 108.159 -171.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -72.75 115.23 4.26 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 121.904 1.736 . . . . 62.240000000000002 110.443 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.604 HD21 HD12 ' A' ' 149' ' ' ILE . 29.0 tp -128.81 137.51 51.55 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.601 0.76 . . . . 73.209999999999994 109.498 -173.438 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 74.3 p -79.87 162.62 24.91 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.11 -0.33 . . . . 35.200000000000003 110.11 -178.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.97 -26.95 65.3 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.393 0.677 . . . . 73.239999999999995 110.962 -178.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -68.55 -50.31 52.82 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 114.934 -1.03 . . . . 62.109999999999999 109.093 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 -73.63 -21.23 60.36 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 114.991 -1.004 . . . . 74.349999999999994 112.324 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.09 -44.89 64.76 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.991 0.517 . . . . 72.219999999999999 109.74 170.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -62.13 -42.35 99.16 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.666 1.186 . . . . 72.340000000000003 110.921 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -74.42 -48.8 25.51 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.607 0.363 . . . . 73.519999999999996 110.427 -178.493 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.604 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 62.49 52.34 49.73 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 123.997 0.81 . . . . 74.109999999999999 113.853 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -101.37 -130.49 7.06 Favored Glycine 0 C--N 1.347 1.148 0 N-CA-C 111.452 -0.659 . . . . 62.509999999999998 111.452 177.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -97.28 158.61 15.37 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.072 0.549 . . . . 72.530000000000001 110.149 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.572 ' HG2' HD21 ' A' ' 123' ' ' LEU . 41.0 tpt85 -136.84 119.69 16.3 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.214 -0.903 . . . . 74.519999999999996 108.975 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.8 t -86.39 105.96 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 123.397 0.679 . . . . 70.209999999999994 109.643 -177.143 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.52 HG21 HD13 ' A' ' 98' ' ' LEU . 34.3 m -117.01 162.6 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.001 1.321 . . . . 70.299999999999997 108.345 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -123.98 112.69 17.49 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 122.497 0.319 . . . . 73.450000000000003 111.263 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.712 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.9 p -106.46 105.44 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 124.469 1.107 . . . . 75.400000000000006 109.965 -178.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 58.02 28.74 16.71 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.633 0.773 . . . . 61.130000000000003 112.122 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.25 2.76 55.74 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-O 119.566 -0.574 . . . . 75.239999999999995 114.069 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.6 mtt180 -100.73 121.8 42.27 Favored 'General case' 0 N--CA 1.486 1.349 0 CA-C-N 117.735 0.767 . . . . 64.519999999999996 110.724 -178.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -74.96 126.32 30.75 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.463 0.705 . . . . 74.030000000000001 109.319 172.241 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 3.2 p -148.79 131.0 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.068 0.547 . . . . 70.150000000000006 110.464 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 12.5 p -91.42 105.85 18.07 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 123.547 0.739 . . . . 74.319999999999993 109.647 176.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.8 p -99.35 132.56 44.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 123.906 0.882 . . . . 73.040000000000006 109.036 176.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 58.1 ttt85 -81.92 129.16 34.68 Favored 'General case' 0 C--O 1.242 0.667 0 CA-C-O 121.59 0.709 . . . . 75.349999999999994 110.696 -176.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.604 HD12 HD21 ' A' ' 125' ' ' LEU . 2.4 pt -98.56 145.2 29.48 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.637 1.575 . . . . 60.409999999999997 108.734 174.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.91 143.88 62.44 Favored 'Trans proline' 0 CA--C 1.562 1.906 0 C-N-CA 121.986 1.791 . . . . 74.209999999999994 112.215 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.604 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 30.5 Cg_endo -62.27 130.16 29.45 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.18 2.586 . . . . 54.32 111.787 175.717 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 64.76 46.77 88.76 Favored Glycine 0 C--N 1.344 1.021 0 O-C-N 123.966 0.791 . . . . 72.239999999999995 111.614 -175.541 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 178' ' ' VAL . 8.2 p -75.72 145.6 10.41 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 CA-C-O 121.187 0.517 . . . . 74.420000000000002 110.256 179.262 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.4 mtp180 -104.07 169.78 8.3 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.19 0.996 . . . . 75.120000000000005 111.974 -172.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.6 tp10 -68.19 134.6 50.72 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-N 113.834 -1.53 . . . . 74.219999999999999 110.331 176.489 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.05 2.79 66.81 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-O 118.968 -0.907 . . . . 74.129999999999995 114.395 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.7 m -71.13 117.63 12.89 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 118.213 1.006 . . . . 72.549999999999997 108.869 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.7 p -93.37 132.25 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 109.34 -0.615 . . . . 74.400000000000006 109.34 -178.297 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.546 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 50.0 mt -105.93 104.12 16.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 107.807 -1.183 . . . . 55.200000000000003 107.807 -178.488 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 36.1 ttm180 -91.46 104.74 17.22 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 109.632 -0.507 . . . . 61.25 109.632 177.521 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.4 t -97.12 111.58 58.35 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 107.361 -1.348 . . . . 74.299999999999997 107.361 174.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -69.86 124.62 11.22 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 123.17 2.58 . . . . 72.120000000000005 113.46 -170.343 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 69.38 16.01 70.96 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 114.743 0.657 . . . . 53.43 114.743 173.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.9 mmt -113.83 12.64 18.26 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 123.317 0.647 . . . . 74.030000000000001 111.659 -177.297 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -96.43 -102.17 2.01 Favored Glycine 0 C--N 1.338 0.661 0 O-C-N 123.472 0.483 . . . . 71.140000000000001 112.588 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.503 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -65.48 121.47 20.41 Favored Glycine 0 C--N 1.353 1.523 0 O-C-N 123.948 0.44 . . . . 64.030000000000001 113.587 -173.194 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -71.22 146.95 48.71 Favored 'General case' 0 C--O 1.246 0.92 0 C-N-CA 123.414 0.686 . . . . 73.439999999999998 110.952 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 155.32 -169.38 33.26 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.025 -0.989 . . . . 75.340000000000003 111.093 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -74.34 -48.91 5.46 Favored Pre-proline 0 CA--C 1.566 1.572 0 CA-C-O 118.621 -0.704 . . . . 73.310000000000002 109.378 174.111 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -83.55 111.59 1.79 Allowed 'Trans proline' 0 C--N 1.394 2.962 0 C-N-CA 121.641 1.56 . . . . 62.109999999999999 110.264 164.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -69.52 128.89 16.91 Favored 'Trans proline' 0 C--N 1.369 1.64 0 C-N-CA 122.261 1.974 . . . . 65.010000000000005 111.854 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -90.99 166.78 31.31 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-O 119.873 -0.404 . . . . 73.530000000000001 112.129 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -82.45 158.68 23.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 122.989 0.516 . . . . 75.310000000000002 111.11 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.653 HD21 HD11 ' A' ' 98' ' ' LEU . 40.9 tp -118.29 131.55 56.34 Favored 'General case' 0 C--O 1.223 -0.3 0 C-N-CA 123.69 0.796 . . . . 74.340000000000003 109.463 -178.001 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.518 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 87.0 mt -128.8 125.54 38.0 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.028 0.931 . . . . 55.530000000000001 109.804 -177.617 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.612 HD21 HD12 ' A' ' 98' ' ' LEU . 80.8 mt -125.27 103.03 7.73 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.221 0.609 . . . . 63.119999999999997 111.124 178.549 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 39.4 t -85.59 94.34 4.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.306 -0.998 . . . . 51.43 108.306 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 153' ' ' VAL . 98.7 t -58.49 114.83 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 C-N-CA 123.739 0.816 . . . . 72.120000000000005 111.049 -177.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -106.44 104.41 14.09 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 124.506 1.123 . . . . 74.450000000000003 108.751 178.284 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 72.3 mt -68.94 105.05 2.25 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 109.669 -0.493 . . . . 53.25 109.669 178.785 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.3 mt -60.74 149.66 78.84 Favored Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 124.295 1.038 . . . . 52.020000000000003 111.399 175.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -70.73 165.86 30.68 Favored 'Trans proline' 0 C--N 1.373 1.844 0 C-N-CA 122.314 2.009 . . . . 71.120000000000005 111.311 174.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 . . . . . 0 CA--C 1.552 1.039 0 N-CA-C 108.907 -0.775 . . . . 72.340000000000003 108.907 174.33 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 94' ' ' MET . . . . . 0.437 ' HG3' ' H ' ' A' ' 95' ' ' LEU . 5.6 tpt . . . . . 0 N--CA 1.475 0.779 0 N-CA-C 108.354 -0.98 . . . . 75.0 108.354 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.437 ' H ' ' HG3' ' A' ' 94' ' ' MET . 0.8 OUTLIER -101.45 99.39 11.21 Favored Pre-proline 0 CA--C 1.551 0.996 0 C-N-CA 124.067 0.947 . . . . 74.340000000000003 111.004 178.487 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.1 -67.12 0.03 OUTLIER 'Trans proline' 0 C--N 1.382 2.308 0 C-N-CA 122.055 1.837 . . . . 71.540000000000006 110.969 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.515 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 5.7 tp -171.6 143.62 1.76 Allowed 'General case' 0 C--N 1.35 0.62 0 C-N-CA 124.202 1.001 . . . . 73.519999999999996 108.457 176.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.664 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 6.1 tp 59.36 4.22 0.47 Allowed 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 125.628 1.571 . . . . 72.310000000000002 113.158 -173.031 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.596 ' HB2' HG23 ' A' ' 140' ' ' VAL . 82.7 t80 -139.95 130.43 25.51 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 107.789 -1.189 . . . . 60.32 107.789 -171.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.455 HG22 HG13 ' A' ' 102' ' ' VAL . 75.9 m -149.45 98.02 3.49 Favored Pre-proline 0 N--CA 1.469 0.483 0 O-C-N 124.327 1.017 . . . . 65.519999999999996 109.641 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -70.88 80.8 1.17 Allowed 'Trans proline' 0 C--N 1.367 1.516 0 C-N-CA 122.682 2.255 . . . . 53.32 112.679 -176.089 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.455 HG13 HG22 ' A' ' 100' ' ' THR . 29.9 m -84.81 163.18 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 124.586 1.154 . . . . 71.239999999999995 109.342 171.541 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 16.9 p -146.14 77.92 1.5 Allowed 'General case' 0 C--O 1.243 0.721 0 C-N-CA 123.918 0.887 . . . . 72.129999999999995 109.124 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 19.3 pttm -80.01 121.97 26.15 Favored 'General case' 0 C--N 1.359 1.007 0 N-CA-C 109.244 -0.65 . . . . 74.129999999999995 109.244 177.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 84.38 164.69 38.12 Favored Glycine 0 C--N 1.341 0.814 0 CA-C-N 116.132 -0.485 . . . . 65.200000000000003 112.184 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 38.6 m -103.95 20.06 18.87 Favored 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 124.144 0.978 . . . . 61.439999999999998 111.177 -179.207 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 78.83 -107.25 2.47 Favored Glycine 0 C--N 1.348 1.206 0 N-CA-C 110.399 -1.08 . . . . 54.0 110.399 -173.278 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 59.09 -146.31 43.04 Favored Glycine 0 C--N 1.348 1.201 0 O-C-N 123.811 0.36 . . . . 71.400000000000006 112.781 179.14 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.3 p -74.68 99.28 3.64 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 123.13 0.572 . . . . 63.520000000000003 109.473 172.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -99.49 147.45 18.34 Favored Glycine 0 C--N 1.34 0.792 0 N-CA-C 111.267 -0.733 . . . . 65.239999999999995 111.267 176.469 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -92.61 -140.28 9.61 Favored Glycine 0 C--N 1.345 1.033 0 N-CA-C 111.816 -0.514 . . . . 23.550000000000001 111.816 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 32.0 p -77.87 101.87 7.0 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 109.076 -0.712 . . . . 72.150000000000006 109.076 176.072 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -76.03 76.83 1.38 Allowed Glycine 0 C--N 1.344 1.003 0 CA-C-N 115.999 -0.546 . . . . 52.409999999999997 112.295 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -59.93 -44.9 96.71 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 111.615 -0.594 . . . . 53.509999999999998 111.615 177.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 24.6 m -116.11 112.94 22.45 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.289 1.035 . . . . 75.319999999999993 108.64 171.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.7 -96.24 0.15 Allowed Glycine 0 C--N 1.351 1.387 0 O-C-N 123.431 0.457 . . . . 72.319999999999993 113.037 177.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.51 ' H ' ' HA3' ' A' ' 166' ' ' GLY . 13.7 mtm180 -97.87 130.98 44.74 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 109.323 -0.621 . . . . 62.240000000000002 109.323 175.713 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -103.54 104.24 14.29 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.037 -1.468 . . . . 73.109999999999999 107.037 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.538 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.9 mt -93.55 110.26 21.85 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.846 -1.168 . . . . 74.439999999999998 107.846 -174.557 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.449 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 73.6 ttt-85 -107.49 104.53 14.12 Favored 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 108.732 -0.84 . . . . 73.430000000000007 108.732 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -121.11 126.93 51.02 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.692 0.797 . . . . 42.210000000000001 109.42 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -73.26 118.25 15.99 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 123.54 0.736 . . . . 72.129999999999995 109.563 176.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.422 HD21 ' HG2' ' A' ' 136' ' ' ARG . 5.3 tt -100.83 111.15 62.7 Favored Pre-proline 0 CA--C 1.549 0.934 0 C-N-CA 123.938 0.895 . . . . 54.229999999999997 108.849 -175.17 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.04 126.03 13.27 Favored 'Trans proline' 0 C--N 1.379 2.168 0 C-N-CA 122.555 2.17 . . . . 60.409999999999997 111.43 175.44 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.474 HD21 HD12 ' A' ' 149' ' ' ILE . 15.9 tp -148.15 133.83 18.87 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.231 -0.655 . . . . 72.019999999999996 109.231 -173.347 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.8 p -87.66 171.62 10.32 Favored 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 118.084 0.402 . . . . 62.450000000000003 110.312 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.21 -35.66 81.07 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.595 0.758 . . . . 70.230000000000004 111.362 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -63.96 -50.56 68.13 Favored 'General case' 0 C--N 1.35 0.61 0 CA-C-N 114.718 -1.128 . . . . 64.049999999999997 109.258 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 22.3 mm-40 -73.7 -24.69 59.97 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-N 114.58 -1.191 . . . . 72.530000000000001 111.334 -176.411 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.493 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.42 -38.91 81.66 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.212 -0.904 . . . . 71.400000000000006 110.345 173.779 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -72.66 -39.19 67.33 Favored 'General case' 0 CA--C 1.547 0.84 0 CA-C-N 115.473 -0.785 . . . . 71.310000000000002 110.423 176.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.71 -48.85 67.95 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 122.34 0.256 . . . . 75.400000000000006 111.045 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.588 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.25 59.37 10.98 Favored Glycine 0 C--N 1.345 1.061 0 O-C-N 124.015 0.822 . . . . 35.420000000000002 113.567 175.241 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.426 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -121.69 -155.64 9.51 Favored Glycine 0 C--N 1.34 0.783 0 N-CA-C 111.64 -0.584 . . . . 71.400000000000006 111.64 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.619 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.0 mp0 -75.12 122.74 24.05 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 109.929 -0.397 . . . . 72.430000000000007 109.929 179.07 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.442 ' HB2' HD13 ' A' ' 149' ' ' ILE . 12.8 tpt180 -109.59 119.53 39.7 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.391 -1.337 . . . . 64.329999999999998 107.391 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 50.7 t -83.1 106.63 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.476 0.71 . . . . 72.420000000000002 109.191 -172.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.515 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 33.4 m -116.85 163.24 14.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.887 0 C-N-CA 125.551 1.54 . . . . 64.219999999999999 108.806 -177.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -122.84 111.56 16.82 Favored 'General case' 0 N--CA 1.481 1.097 0 O-C-N 121.748 -0.595 . . . . 63.520000000000003 110.667 -178.654 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.664 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.4 p -104.14 109.74 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 125.015 1.326 . . . . 74.340000000000003 109.471 -177.188 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.94 22.39 13.02 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 123.837 0.855 . . . . 52.229999999999997 112.76 176.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.95 -13.83 58.88 Favored Glycine 0 C--N 1.352 1.439 0 CA-C-O 120.016 -0.325 . . . . 63.219999999999999 113.413 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 26.1 tpt180 -90.72 127.55 36.35 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 123.803 0.841 . . . . 63.119999999999997 109.401 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 15.5 tpp85 -89.2 130.1 35.67 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.577 -0.527 . . . . 74.319999999999993 109.577 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.8 p -147.47 148.98 15.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 C-N-CA 124.193 0.997 . . . . 75.549999999999997 109.555 -179.119 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.619 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 42.9 p -101.17 109.27 21.13 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.371 0.669 . . . . 63.130000000000003 110.156 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.77 124.83 53.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 123.316 0.646 . . . . 63.130000000000003 109.37 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 41.5 ttt180 -71.83 127.93 34.13 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 120.916 0.389 . . . . 74.109999999999999 110.494 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.588 HG13 ' HA2' ' A' ' 133' ' ' GLY . 2.7 pt -100.99 147.66 34.01 Favored Pre-proline 0 CA--C 1.558 1.265 0 C-N-CA 124.956 1.302 . . . . 74.019999999999996 108.223 174.136 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.11 135.61 19.11 Favored 'Trans proline' 0 CA--C 1.558 1.7 0 C-N-CA 122.36 2.04 . . . . 71.030000000000001 112.087 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.81 135.43 48.34 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.407 2.071 . . . . 64.450000000000003 111.81 173.187 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.54 62.56 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-N 115.669 -0.696 . . . . 62.030000000000001 112.42 -174.467 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.493 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 11.0 p -73.4 147.44 9.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 N-CA-C 109.273 -0.64 . . . . 73.120000000000005 109.273 178.162 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 56.1 mtp85 -138.89 178.95 6.78 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.706 0.765 . . . . 64.120000000000005 111.587 -173.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.01 120.0 6.76 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 113.348 -1.751 . . . . 72.349999999999994 110.578 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.23 -10.51 67.51 Favored Glycine 0 C--N 1.341 0.817 0 O-C-N 124.28 0.987 . . . . 50.119999999999997 113.797 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.3 m -70.3 121.54 17.84 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.416 -0.587 . . . . 74.329999999999998 109.416 178.014 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -105.01 122.45 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 109.41 -0.589 . . . . 74.040000000000006 109.41 -178.151 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.625 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 32.3 mt -91.53 101.95 13.02 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 107.782 -1.192 . . . . 64.439999999999998 107.782 -178.103 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.527 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 48.7 ttp85 -96.02 110.25 22.51 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.889 -0.411 . . . . 53.43 109.889 -176.58 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.6 t -103.96 96.46 9.39 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 107.636 -1.246 . . . . 61.020000000000003 107.636 170.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -65.78 127.0 16.96 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.815 2.344 . . . . 72.030000000000001 112.006 -176.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.9 -23.01 37.71 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-O 119.775 -0.459 . . . . 43.229999999999997 113.758 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.0 tpt -76.48 -32.5 58.38 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.255 0.622 . . . . 73.310000000000002 111.94 -174.156 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -65.57 -81.55 0.13 Allowed Glycine 0 CA--C 1.536 1.399 0 O-C-N 123.606 0.566 . . . . 73.120000000000005 113.384 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.51 ' HA3' ' H ' ' A' ' 117' ' ' ARG . . . -65.35 92.68 0.15 Allowed Glycine 0 C--N 1.345 1.077 0 C-N-CA 123.017 0.341 . . . . 73.519999999999996 113.347 174.421 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -91.2 153.08 20.26 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.266 1.027 . . . . 73.549999999999997 110.044 170.557 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 137.44 -62.94 0.58 Allowed Glycine 0 C--N 1.338 0.655 0 N-CA-C 111.203 -0.759 . . . . 54.039999999999999 111.203 178.364 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.531 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 24.3 t-20 -155.89 -56.48 0.02 OUTLIER Pre-proline 0 CA--C 1.567 1.601 0 CA-C-O 118.184 -0.912 . . . . 75.230000000000004 110.643 179.426 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.531 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 57.0 Cg_endo -90.04 113.71 0.52 Allowed 'Trans proline' 0 C--N 1.402 3.38 0 C-N-CA 122.769 2.313 . . . . 74.430000000000007 110.633 174.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 170' ' ' PRO . 22.9 Cg_exo -64.84 123.09 11.13 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 122.417 2.078 . . . . 71.439999999999998 111.059 -176.483 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -111.53 160.84 13.0 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 120.013 -0.326 . . . . 73.400000000000006 112.393 -176.403 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -77.68 139.65 39.47 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.06 0.544 . . . . 63.229999999999997 111.159 -174.464 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.553 HD21 HD11 ' A' ' 98' ' ' LEU . 64.2 tp -101.31 126.99 48.12 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.792 -1.188 . . . . 70.420000000000002 107.792 171.536 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.449 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 75.2 mt -127.16 103.18 7.29 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 124.695 1.198 . . . . 74.030000000000001 109.118 -175.232 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.625 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 88.0 mt -100.23 101.47 12.5 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 122.784 0.434 . . . . 72.239999999999995 110.02 178.33 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.1 t -86.81 99.52 8.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 108.799 -0.815 . . . . 61.210000000000001 108.799 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.91 114.26 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 CA-C-N 115.156 -0.929 . . . . 43.25 111.632 -173.148 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 6.3 mmp_? -99.36 113.16 25.33 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 125.142 1.377 . . . . 53.43 108.528 172.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.429 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 44.3 mt -72.3 127.51 32.78 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.852 -0.425 . . . . 62.130000000000003 109.852 175.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.1 mt -83.92 148.54 54.25 Favored Pre-proline 0 C--O 1.242 0.662 0 C-N-CA 123.883 0.873 . . . . 71.239999999999995 109.883 178.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.8 172.53 9.41 Favored 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 122.827 2.352 . . . . 70.0 111.831 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.533 -0.746 . . . . 75.129999999999995 110.163 -177.415 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 64.1 mtt . . . . . 0 N--CA 1.484 1.228 0 CA-C-O 120.533 0.206 . . . . 65.030000000000001 111.478 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 35.21 93.47 0.05 OUTLIER Pre-proline 0 CA--C 1.558 1.286 0 C-N-CA 126.803 2.041 . . . . 52.420000000000002 114.755 -174.074 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -66.83 -174.3 0.46 Allowed 'Trans proline' 0 C--N 1.369 1.63 0 C-N-CA 122.617 2.211 . . . . 73.510000000000005 111.142 163.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.495 HD11 ' HG ' ' A' ' 123' ' ' LEU . 8.6 tp -72.73 133.47 44.58 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.518 -0.549 . . . . 72.510000000000005 109.518 176.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.685 HD22 HG23 ' A' ' 138' ' ' VAL . 13.4 tp 73.17 -39.98 0.46 Allowed 'General case' 0 N--CA 1.484 1.255 0 C-N-CA 127.268 2.227 . . . . 74.200000000000003 113.077 -176.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -88.12 131.34 34.73 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.141 0.976 . . . . 71.209999999999994 111.528 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.531 HG22 HG13 ' A' ' 102' ' ' VAL . 93.6 m -151.29 92.21 3.78 Favored Pre-proline 0 CA--C 1.55 0.964 0 C-N-CA 123.592 0.757 . . . . 71.109999999999999 109.823 178.668 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -74.06 82.23 1.82 Allowed 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.646 2.23 . . . . 53.130000000000003 113.302 -168.151 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.531 HG13 HG22 ' A' ' 100' ' ' THR . 28.6 m -107.66 -165.6 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 123.985 0.914 . . . . 75.450000000000003 109.972 178.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.9 t -120.54 -30.46 4.52 Favored 'General case' 0 CA--C 1.546 0.788 0 C-N-CA 123.137 0.575 . . . . 73.219999999999999 109.937 171.151 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.0 tppt? -173.48 150.38 1.8 Allowed 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.015 0.926 . . . . 73.319999999999993 109.459 -175.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -164.16 -60.88 0.02 OUTLIER Glycine 0 C--N 1.347 1.17 0 C-N-CA 121.244 -0.503 . . . . 12.33 114.13 -178.51 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 81.8 p -79.32 -50.71 10.45 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 122.793 0.437 . . . . 72.030000000000001 111.32 -173.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -179.39 144.51 6.17 Favored Glycine 0 C--N 1.341 0.837 0 C-N-CA 121.621 -0.323 . . . . 54.509999999999998 112.944 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -164.58 66.98 0.22 Allowed Glycine 0 C--N 1.346 1.13 0 N-CA-C 110.974 -0.85 . . . . 72.219999999999999 110.974 177.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 50.9 m -71.95 98.24 2.01 Favored 'General case' 0 C--O 1.241 0.61 0 C-N-CA 123.502 0.721 . . . . 53.399999999999999 110.599 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -179.8 69.46 0.07 OUTLIER Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.393 -1.083 . . . . 54.310000000000002 110.393 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -80.06 47.42 3.36 Favored Glycine 0 C--N 1.349 1.301 0 C-N-CA 123.18 0.419 . . . . 64.129999999999995 113.704 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.0 m -137.84 21.1 2.86 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.483 1.113 . . . . 44.409999999999997 109.452 176.112 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 164.21 -35.05 0.29 Allowed Glycine 0 C--N 1.352 1.436 0 CA-C-N 115.808 -0.633 . . . . 63.409999999999997 112.141 -177.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 106.94 -155.33 16.43 Favored Glycine 0 C--N 1.346 1.119 0 C-N-CA 123.113 0.387 . . . . 74.140000000000001 112.719 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 50.3 m -151.8 -176.48 5.65 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 123.764 0.826 . . . . 74.310000000000002 110.885 -175.248 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -82.86 173.57 52.48 Favored Glycine 0 C--N 1.354 1.56 0 CA-C-N 116.262 -0.426 . . . . 71.329999999999998 113.181 173.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.508 ' H ' ' HD2' ' A' ' 117' ' ' ARG . 0.0 OUTLIER -82.56 139.33 33.9 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.67 0.788 . . . . 74.400000000000006 111.038 -177.887 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -101.54 108.78 20.45 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.638 -0.875 . . . . 71.200000000000003 108.638 -173.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.429 HD22 ' O ' ' A' ' 100' ' ' THR . 15.2 mt -89.93 110.63 21.58 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.796 -1.186 . . . . 63.439999999999998 107.796 -169.299 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -107.17 109.31 21.1 Favored 'General case' 0 C--N 1.344 0.349 0 N-CA-C 108.997 -0.742 . . . . 54.229999999999997 108.997 173.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -126.5 141.97 51.69 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.277 -1.008 . . . . 74.340000000000003 108.277 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -74.32 135.06 42.54 Favored 'General case' 0 C--O 1.243 0.73 0 N-CA-C 109.051 -0.722 . . . . 72.349999999999994 109.051 173.129 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.495 ' HG ' HD11 ' A' ' 97' ' ' LEU . 1.9 tt -100.83 103.11 22.51 Favored Pre-proline 0 CA--C 1.543 0.708 0 N-CA-C 107.929 -1.138 . . . . 75.409999999999997 107.929 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.423 ' HB2' HD11 ' A' ' 181' ' ' LEU . 52.1 Cg_endo -67.83 115.48 3.79 Favored 'Trans proline' 0 C--N 1.376 2.013 0 C-N-CA 122.49 2.126 . . . . 70.409999999999997 110.052 174.439 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.603 HD21 HD12 ' A' ' 149' ' ' ILE . 17.0 tp -137.6 135.31 36.48 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.074 -0.713 . . . . 71.409999999999997 109.074 -169.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.0 p -77.28 164.58 25.44 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 118.76 0.709 . . . . 54.43 110.581 178.629 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -63.28 -30.91 71.96 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.728 0.811 . . . . 64.219999999999999 111.877 -177.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -75.0 -46.95 31.67 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.561 0.745 . . . . 71.140000000000001 110.13 -178.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 73.3 mm-40 -60.62 -35.69 76.78 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 123.911 0.757 . . . . 73.209999999999994 111.048 176.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.51 -51.63 61.98 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 124.099 0.874 . . . . 34.32 111.21 174.276 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -58.04 -50.82 72.1 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.928 1.291 . . . . 74.329999999999998 111.688 -176.006 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 56.1 m80 -78.18 -41.18 35.46 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.819 -0.628 . . . . 74.329999999999998 109.881 -176.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 73.94 -167.86 54.37 Favored Glycine 0 C--N 1.352 1.451 0 CA-C-N 116.03 -0.532 . . . . 72.150000000000006 112.072 -173.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.472 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 122.85 -165.08 15.57 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 111.766 -0.534 . . . . 44.450000000000003 111.766 177.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.453 ' HA ' ' HA ' ' A' ' 148' ' ' ARG . 1.5 mp0 -84.78 125.71 32.8 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 121.125 0.488 . . . . 75.019999999999996 110.304 178.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 tpp180 -112.88 122.37 47.44 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.929 1.291 . . . . 75.140000000000001 107.92 175.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.4 t -101.86 106.93 20.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 N-CA-C 109.334 -0.617 . . . . 60.219999999999999 109.334 -171.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.685 HG23 HD22 ' A' ' 98' ' ' LEU . 30.0 m -124.46 153.52 31.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.298 1.039 . . . . 74.140000000000001 108.835 -175.645 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -107.03 132.56 52.82 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 122.592 0.357 . . . . 74.549999999999997 111.517 -171.281 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.1 p -113.26 104.8 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 125.21 1.404 . . . . 65.219999999999999 109.881 176.292 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.67 15.54 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 113.187 0.81 . . . . 70.420000000000002 113.187 173.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.0 8.73 47.24 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.908 -0.385 . . . . 45.399999999999999 113.696 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 7.2 tpp180 -115.72 116.39 27.99 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.336 0.655 . . . . 72.420000000000002 109.238 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -87.1 106.38 17.83 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.071 0.548 . . . . 73.530000000000001 109.879 -173.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 78.4 t -112.87 133.96 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.228 1.011 . . . . 71.120000000000005 110.729 -176.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 45.5 t -92.1 104.48 16.87 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.55 0.74 . . . . 75.010000000000005 109.951 175.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.587 HG21 HD12 ' A' ' 176' ' ' LEU . 6.3 p -99.99 122.38 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 123.65 0.78 . . . . 72.400000000000006 110.181 175.799 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 135' ' ' GLU . 61.1 ttt180 -77.09 112.18 13.48 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.673 0.389 . . . . 71.25 110.086 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.603 HD12 HD21 ' A' ' 125' ' ' LEU . 4.4 pt -77.94 138.4 61.43 Favored Pre-proline 0 CA--C 1.56 1.36 0 C-N-CA 123.794 0.838 . . . . 43.200000000000003 109.212 170.665 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -60.0 136.8 71.86 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.911 2.407 . . . . 75.129999999999995 113.271 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -61.59 113.05 1.64 Allowed 'Trans proline' 0 C--N 1.375 1.95 0 C-N-CA 122.776 2.318 . . . . 62.409999999999997 111.585 171.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.89 39.76 16.17 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.051 -0.522 . . . . 73.420000000000002 112.076 -173.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.415 HG21 HG21 ' A' ' 178' ' ' VAL . 12.6 p -75.46 145.32 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 N-CA-C 109.399 -0.593 . . . . 71.140000000000001 109.399 175.64 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -112.62 173.1 6.54 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 121.472 0.653 . . . . 73.200000000000003 112.009 -173.473 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -63.77 133.97 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 113.927 -1.488 . . . . 60.119999999999997 111.107 178.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.36 -21.65 33.99 Favored Glycine 0 C--N 1.349 1.263 0 CA-C-N 115.833 -0.622 . . . . 42.25 113.583 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 72.7 m -63.66 121.52 14.13 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 123.695 0.798 . . . . 73.430000000000007 111.876 -172.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.4 p -95.39 125.29 48.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 CA-C-O 121.302 0.572 . . . . 70.310000000000002 110.268 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.0 mt -93.73 115.23 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.355 1.062 . . . . 71.219999999999999 108.29 -178.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 -101.26 119.94 39.51 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 122.848 0.459 . . . . 72.519999999999996 110.497 -176.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -117.4 99.31 52.52 Favored Pre-proline 0 CA--C 1.552 1.045 0 N-CA-C 107.574 -1.269 . . . . 60.009999999999998 107.574 169.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.77 138.81 81.85 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.791 2.328 . . . . 72.319999999999993 113.913 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.6 5.13 72.58 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 115.07 -0.968 . . . . 63.020000000000003 115.094 175.276 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 13.6 tpt -101.99 -16.0 16.62 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 117.638 0.719 . . . . 70.409999999999997 112.359 -170.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -73.82 -81.72 0.41 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 120.154 -0.248 . . . . 60.200000000000003 112.769 178.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -60.39 93.78 0.07 OUTLIER Glycine 0 C--N 1.352 1.42 0 C-N-CA 123.1 0.381 . . . . 54.229999999999997 112.95 172.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -91.98 171.01 9.4 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.495 1.118 . . . . 73.040000000000006 111.46 175.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 113.76 -65.68 0.27 Allowed Glycine 0 C--N 1.345 1.046 0 CA-C-N 115.579 -0.737 . . . . 43.119999999999997 111.792 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.432 ' H ' ' CD ' ' A' ' 170' ' ' PRO . 3.3 p-10 -168.62 -32.35 0.0 OUTLIER Pre-proline 0 CA--C 1.565 1.554 0 CA-C-O 117.48 -1.248 . . . . 73.310000000000002 112.66 -179.36 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.432 ' CD ' ' H ' ' A' ' 169' ' ' ASN . 62.6 Cg_endo -92.32 106.81 0.22 Allowed 'Trans proline' 0 C--N 1.403 3.442 0 CA-C-N 122.37 1.882 . . . . 73.209999999999994 110.611 168.171 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_exo -66.16 124.85 13.14 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.277 1.984 . . . . 73.019999999999996 111.811 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -120.96 155.95 16.19 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.25 -1.14 . . . . 51.310000000000002 110.25 172.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -76.81 162.69 27.45 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.687 0.795 . . . . 71.129999999999995 111.033 -173.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.515 HD21 HD11 ' A' ' 98' ' ' LEU . 55.9 tp -122.6 130.58 53.16 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.047 0.539 . . . . 74.430000000000007 109.795 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.41 128.77 46.36 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.805 1.242 . . . . 64.200000000000003 109.05 177.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.587 HD12 HG21 ' A' ' 147' ' ' VAL . 88.0 mt -129.17 102.31 6.41 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.198 0.599 . . . . 62.329999999999998 110.948 178.599 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.0 t -85.69 99.32 7.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.66 0 N-CA-C 109.563 -0.532 . . . . 73.310000000000002 109.563 -173.133 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.415 HG21 HG21 ' A' ' 153' ' ' VAL . 96.7 t -56.14 114.51 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.344 1.058 . . . . 71.140000000000001 111.907 -178.103 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -113.09 102.6 10.55 Favored 'General case' 0 C--O 1.239 0.517 0 C-N-CA 124.77 1.228 . . . . 75.400000000000006 108.598 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 68.6 mt -70.28 116.93 11.2 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 115.256 -0.884 . . . . 72.209999999999994 110.962 -177.36 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.423 HD11 ' HB2' ' A' ' 124' ' ' PRO . 58.0 mt -77.26 146.75 75.05 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 115.416 -0.811 . . . . 74.140000000000001 110.378 -177.238 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -60.64 115.05 2.42 Favored 'Trans proline' 0 C--N 1.373 1.817 0 C-N-CA 123.279 2.653 . . . . 72.510000000000005 111.873 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 . . . . . 0 C--O 1.249 1.073 0 N-CA-C 109.331 -0.618 . . . . 63.020000000000003 109.331 -179.856 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 26.6 ptt? . . . . . 0 N--CA 1.484 1.262 0 N-CA-C 110.572 -0.158 . . . . 70.030000000000001 110.572 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 3.4 pp -45.51 130.12 6.31 Favored Pre-proline 0 CA--C 1.566 1.587 0 C-N-CA 124.761 1.224 . . . . 74.239999999999995 112.341 168.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -69.87 -164.05 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 123.611 2.874 . . . . 62.409999999999997 113.433 168.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.73 HD13 ' HD2' ' A' ' 124' ' ' PRO . 0.6 OUTLIER -60.31 -46.56 89.44 Favored 'General case' 0 N--CA 1.483 1.203 0 C-N-CA 124.446 1.098 . . . . 70.340000000000003 112.031 -179.009 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.521 HD22 ' HB ' ' A' ' 140' ' ' VAL . 3.9 tt -139.19 90.04 2.39 Favored 'General case' 0 C--O 1.211 -0.962 0 N-CA-C 108.04 -1.096 . . . . 71.540000000000006 108.04 173.47 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 73.5 t80 172.5 107.05 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 125.518 1.527 . . . . 61.240000000000002 107.373 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.551 HG22 HG13 ' A' ' 102' ' ' VAL . 93.9 m -127.79 94.64 36.77 Favored Pre-proline 0 C--O 1.239 0.511 0 N-CA-C 109.763 -0.458 . . . . 44.329999999999998 109.763 -178.001 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -70.1 85.28 0.67 Allowed 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 122.556 2.17 . . . . 73.209999999999994 112.293 -175.527 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.551 HG13 HG22 ' A' ' 100' ' ' THR . 22.6 m -98.06 150.12 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 C-N-CA 124.001 0.92 . . . . 74.019999999999996 109.582 174.34 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -95.99 143.56 27.06 Favored 'General case' 0 C--O 1.246 0.89 0 N-CA-C 108.327 -0.99 . . . . 74.239999999999995 108.327 171.479 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 17.2 tppt? -77.91 108.83 11.44 Favored 'General case' 0 C--O 1.241 0.625 0 N-CA-C 110.113 -0.328 . . . . 71.040000000000006 110.113 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -70.08 99.48 0.71 Allowed Glycine 0 C--N 1.345 1.08 0 N-CA-C 109.71 -1.356 . . . . 73.0 109.71 168.41 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 21.1 t -66.27 -21.76 66.29 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.635 0.774 . . . . 72.510000000000005 111.605 -174.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -99.72 30.06 10.78 Favored Glycine 0 C--N 1.349 1.291 0 C-N-CA 123.11 0.386 . . . . 75.329999999999998 112.315 173.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -72.82 -71.87 1.03 Allowed Glycine 0 C--N 1.358 1.8 0 CA-C-O 119.972 -0.349 . . . . 72.409999999999997 113.398 -176.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 81.0 p -162.78 15.91 0.08 Allowed 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 123.329 0.652 . . . . 61.5 111.733 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 75.62 86.55 0.31 Allowed Glycine 0 C--N 1.353 1.511 0 CA-C-O 120.039 -0.312 . . . . 54.229999999999997 112.553 -177.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -74.26 91.27 0.73 Allowed Glycine 0 C--N 1.352 1.462 0 N-CA-C 111.553 -0.619 . . . . 63.0 111.553 178.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 17.5 m -63.57 98.9 0.19 Allowed 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 124.592 1.157 . . . . 72.430000000000007 113.035 -171.045 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 80.64 -70.64 2.98 Favored Glycine 0 C--N 1.343 0.966 0 CA-C-N 115.753 -0.658 . . . . 64.310000000000002 113.362 172.295 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -84.13 -150.05 10.63 Favored Glycine 0 N--CA 1.471 1.003 0 CA-C-O 119.937 -0.368 . . . . 62.450000000000003 112.473 177.236 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.1 t 63.09 77.45 0.33 Allowed 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.406 1.082 . . . . 73.319999999999993 111.507 178.519 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.425 ' H ' ' HA2' ' A' ' 172' ' ' GLY . . . -84.79 -102.28 0.63 Allowed Glycine 0 CA--C 1.521 0.437 0 CA-C-N 114.59 -1.186 . . . . 40.340000000000003 111.003 174.13 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.449 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 12.5 mmm-85 -97.63 117.89 32.93 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 107.952 -1.129 . . . . 62.409999999999997 107.952 174.421 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -96.69 104.44 16.43 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.458 -0.941 . . . . 64.129999999999995 108.458 -171.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.453 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.1 mt -92.39 111.48 23.07 Favored 'General case' 0 C--N 1.344 0.344 0 N-CA-C 107.917 -1.142 . . . . 75.239999999999995 107.917 -172.201 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -110.08 105.58 14.75 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 108.686 -0.857 . . . . 43.25 108.686 174.081 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.13 160.92 35.81 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 123.929 0.892 . . . . 70.140000000000001 109.6 -176.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 88.7 mt-10 -99.79 136.39 39.79 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.437 0.695 . . . . 73.099999999999994 110.12 -173.015 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.614 ' HA ' HD13 ' A' ' 97' ' ' LEU . 1.6 tt -105.05 101.33 29.49 Favored Pre-proline 0 CA--C 1.545 0.75 0 C-N-CA 124.247 1.019 . . . . 63.229999999999997 108.759 -176.14 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.73 ' HD2' HD13 ' A' ' 97' ' ' LEU . 30.2 Cg_endo -62.74 120.04 7.38 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.478 2.119 . . . . 74.010000000000005 110.285 170.514 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.624 HD21 HD12 ' A' ' 149' ' ' ILE . 15.2 tp -145.89 135.7 23.43 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.948 0.499 . . . . 54.43 109.664 -172.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.3 p -88.24 168.8 12.41 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.974 0.51 . . . . 64.310000000000002 110.72 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 72.2 mt -63.08 -36.99 85.43 Favored 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 123.395 0.678 . . . . 62.130000000000003 111.928 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -63.55 -54.77 30.93 Favored 'General case' 0 N--CA 1.475 0.811 0 O-C-N 123.953 0.783 . . . . 61.299999999999997 108.983 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -64.19 -34.18 77.5 Favored 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 114.759 -1.109 . . . . 62.439999999999998 111.699 -177.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.41 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -59.9 -49.62 76.96 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.218 0.949 . . . . 65.219999999999999 110.475 175.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -69.61 -34.71 74.47 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 115.008 -0.996 . . . . 73.209999999999994 111.129 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -66.77 -47.08 73.3 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.833 0.453 . . . . 63.409999999999997 110.57 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.52 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.3 41.03 94.85 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 115.532 -0.758 . . . . 73.430000000000007 112.648 -174.595 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -84.39 -163.9 36.87 Favored Glycine 0 C--N 1.347 1.162 0 O-C-N 123.904 0.414 . . . . 42.140000000000001 112.984 -178.137 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.4 mp0 -85.44 144.67 27.85 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.437 -0.579 . . . . 72.349999999999994 109.437 170.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.589 ' HG2' HD21 ' A' ' 123' ' ' LEU . 11.0 tpt180 -125.69 120.32 30.39 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 123.935 0.894 . . . . 61.439999999999998 108.621 -177.153 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.44 123.53 37.94 Favored 'Isoleucine or valine' 0 C--O 1.24 0.573 0 N-CA-C 109.373 -0.602 . . . . 65.239999999999995 109.373 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.441 HG12 HD21 ' A' ' 97' ' ' LEU . 27.2 m -138.25 162.49 30.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 125.02 1.328 . . . . 53.109999999999999 108.54 179.454 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -119.83 129.28 54.35 Favored 'General case' 0 N--CA 1.479 1.019 0 O-C-N 122.053 -0.405 . . . . 74.230000000000004 110.644 -178.519 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.521 ' HB ' HD22 ' A' ' 98' ' ' LEU . 5.3 p -119.89 113.63 41.4 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.599 1.159 . . . . 74.349999999999994 110.045 175.231 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 56.35 33.27 22.03 Favored 'General case' 0 N--CA 1.487 1.425 0 C-N-CA 123.782 0.833 . . . . 64.209999999999994 112.389 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.29 19.28 59.09 Favored Glycine 0 C--N 1.351 1.413 0 CA-C-N 115.858 -0.61 . . . . 41.219999999999999 113.638 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 75.9 mtp180 -125.42 125.61 43.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 123.722 0.809 . . . . 62.210000000000001 110.198 -176.532 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.3 ttp180 -73.51 120.33 18.97 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 122.904 0.482 . . . . 74.109999999999999 110.734 178.118 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 20.5 m -125.24 141.22 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.716 0.807 . . . . 64.239999999999995 109.77 170.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.9 p -106.62 111.71 24.38 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.817 0.847 . . . . 73.530000000000001 109.353 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -101.08 130.75 50.0 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 123.716 0.806 . . . . 62.539999999999999 110.083 178.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 39.0 ttt180 -81.6 114.3 20.2 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.494 -0.928 . . . . 71.319999999999993 108.494 178.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.624 HD12 HD21 ' A' ' 125' ' ' LEU . 5.2 pt -84.51 146.39 47.07 Favored Pre-proline 0 CA--C 1.554 1.132 0 C-N-CA 123.844 0.858 . . . . 65.409999999999997 109.469 177.838 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.433 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 25.1 Cg_exo -66.4 141.76 63.12 Favored 'Trans proline' 0 CA--C 1.562 1.894 0 C-N-CA 122.826 2.351 . . . . 74.340000000000003 112.922 177.565 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 22.4 Cg_exo -67.92 127.95 16.97 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 123.127 2.551 . . . . 61.520000000000003 111.496 172.492 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 74.71 26.34 67.54 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 123.783 0.677 . . . . 45.219999999999999 113.317 -175.317 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.41 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 12.6 p -71.71 146.37 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 117.421 0.61 . . . . 74.439999999999998 110.735 -178.124 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.497 ' HA ' HD11 ' A' ' 180' ' ' LEU . 29.7 mtp-105 -120.99 173.22 7.39 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 121.888 0.851 . . . . 73.239999999999995 112.571 -170.064 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -64.45 120.83 13.03 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 113.292 -1.776 . . . . 73.340000000000003 109.961 174.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 104.34 -23.61 31.28 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-O 119.407 -0.663 . . . . 72.319999999999993 112.965 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 58.5 m -64.25 121.08 13.4 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 123.061 0.544 . . . . 73.400000000000006 110.458 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.2 p -102.39 127.49 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 CA-C-O 121.26 0.552 . . . . 73.030000000000001 110.022 -179.102 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.44 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 54.6 mt -92.64 101.1 12.25 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 107.829 -1.174 . . . . 72.430000000000007 107.829 -179.389 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -86.99 110.04 19.78 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.657 -0.498 . . . . 64.329999999999998 109.657 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.458 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 12.6 t -111.19 93.54 18.57 Favored Pre-proline 0 CA--C 1.555 1.163 0 N-CA-C 107.685 -1.228 . . . . 45.450000000000003 107.685 173.034 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.13 122.29 7.06 Favored 'Trans proline' 0 C--N 1.369 1.618 0 C-N-CA 122.441 2.094 . . . . 71.129999999999995 112.207 -177.255 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.39 -20.91 36.36 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-N 116.537 -0.301 . . . . 63.409999999999997 113.476 177.376 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.41 ' HB2' HG12 ' A' ' 161' ' ' VAL . 86.1 mmm -104.62 16.16 26.59 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 123.398 0.679 . . . . 73.209999999999994 112.081 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.59 -101.93 0.54 Allowed Glycine 0 C--N 1.345 1.061 0 CA-C-O 119.664 -0.52 . . . . 72.319999999999993 111.931 172.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.449 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -68.84 102.78 0.95 Allowed Glycine 0 C--N 1.349 1.299 0 CA-C-N 116.93 0.365 . . . . 74.209999999999994 112.313 177.087 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 7.5 mm-40 -89.27 157.82 18.07 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 124.151 0.981 . . . . 71.140000000000001 110.075 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 147.77 -66.39 0.4 Allowed Glycine 0 C--N 1.344 1.014 0 N-CA-C 110.758 -0.937 . . . . 45.119999999999997 110.758 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.405 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 36.2 t30 -159.12 -54.12 0.01 OUTLIER Pre-proline 0 CA--C 1.562 1.429 0 C-N-CA 124.291 1.036 . . . . 73.150000000000006 110.122 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.405 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 80.5 Cg_endo -85.37 110.54 1.23 Allowed 'Trans proline' 0 C--N 1.399 3.231 0 C-N-CA 121.594 1.53 . . . . 74.109999999999999 110.505 171.485 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.82 123.28 11.12 Favored 'Trans proline' 0 C--N 1.383 2.381 0 C-N-CA 122.163 1.909 . . . . 75.209999999999994 110.996 -174.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.425 ' HA2' ' H ' ' A' ' 116' ' ' GLY . . . -96.1 163.08 23.07 Favored Glycine 0 C--N 1.338 0.642 0 O-C-N 123.649 0.593 . . . . 71.319999999999993 111.912 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -84.36 152.39 24.12 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 108.791 -0.818 . . . . 70.519999999999996 108.791 -179.741 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.458 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 57.6 tp -120.68 132.0 54.86 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.957 0.503 . . . . 71.450000000000003 109.744 178.206 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 84.1 mt -128.39 103.33 7.09 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.189 0.996 . . . . 74.340000000000003 109.153 177.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.473 HD21 ' HG ' ' A' ' 98' ' ' LEU . 86.8 mt -102.51 101.2 11.37 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 121.04 0.447 . . . . 65.420000000000002 110.369 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.1 t -83.96 99.55 6.53 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 108.621 -0.881 . . . . 62.340000000000003 108.621 -176.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.5 t -59.32 117.42 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 123.919 0.888 . . . . 73.219999999999999 111.455 -177.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -100.95 105.23 16.45 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 114.466 -1.243 . . . . 63.350000000000001 108.389 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.497 HD11 ' HA ' ' A' ' 154' ' ' ARG . 30.3 mt -69.28 108.77 3.8 Favored 'General case' 0 C--N 1.348 0.511 0 N-CA-C 109.128 -0.693 . . . . 71.030000000000001 109.128 174.03 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.4 mt -68.56 159.0 83.62 Favored Pre-proline 0 CA--C 1.544 0.72 0 CA-C-N 115.057 -0.974 . . . . 73.049999999999997 110.45 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -74.12 51.91 2.56 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 123.533 2.822 . . . . 61.229999999999997 112.764 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.5 t-80 . . . . . 0 C--O 1.255 1.347 0 C-N-CA 124.697 1.199 . . . . 75.120000000000005 107.962 177.304 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 22.3 ptm . . . . . 0 N--CA 1.483 1.218 0 N-CA-C 110.136 -0.32 . . . . 71.219999999999999 110.136 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -56.57 123.8 59.01 Favored Pre-proline 0 CA--C 1.555 1.145 0 C-N-CA 124.116 0.966 . . . . 71.540000000000006 111.56 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.444 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 97.5 Cg_endo -81.67 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.922 2.414 . . . . 74.439999999999998 111.3 166.579 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.519 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.1 tp -81.83 139.99 34.43 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.261 0.624 . . . . 74.129999999999995 110.254 -179.48 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.676 HD22 HG23 ' A' ' 138' ' ' VAL . 19.3 tp 64.63 -13.06 0.11 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 127.031 2.132 . . . . 75.310000000000002 113.606 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.444 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 47.3 t80 -119.78 122.07 40.57 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 124.376 1.07 . . . . 73.319999999999993 108.91 -173.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.515 HG22 HG13 ' A' ' 102' ' ' VAL . 85.7 m -135.36 90.25 21.07 Favored Pre-proline 0 C--O 1.235 0.329 0 C-N-CA 123.739 0.816 . . . . 72.409999999999997 108.804 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -65.85 93.61 0.27 Allowed 'Trans proline' 0 C--N 1.372 1.769 0 C-N-CA 121.6 1.533 . . . . 63.399999999999999 112.027 -174.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 100' ' ' THR . 27.4 m -123.66 168.5 16.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 C-N-CA 125.266 1.427 . . . . 70.430000000000007 109.375 177.011 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.408 ' OG1' ' HA3' ' A' ' 114' ' ' GLY . 10.0 t -148.88 143.13 26.05 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 107.62 -1.252 . . . . 54.340000000000003 107.62 173.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 21.8 ttmt -81.46 71.41 8.46 Favored 'General case' 0 N--CA 1.48 1.064 0 CA-C-O 121.865 0.841 . . . . 71.239999999999995 109.595 -175.491 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 73.38 -175.22 46.51 Favored Glycine 0 C--N 1.351 1.376 0 CA-C-N 114.622 -1.172 . . . . 72.340000000000003 111.917 -169.179 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 50.5 m -75.4 -34.7 61.08 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 108.963 -0.754 . . . . 71.120000000000005 108.963 167.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -174.01 82.64 0.08 OUTLIER Glycine 0 C--N 1.342 0.903 0 N-CA-C 109.734 -1.347 . . . . 72.439999999999998 109.734 178.447 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -63.38 89.74 0.07 OUTLIER Glycine 0 C--N 1.35 1.341 0 O-C-N 123.921 0.424 . . . . 71.129999999999995 113.333 -174.512 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 23.2 t 54.14 38.12 28.48 Favored 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 124.351 1.06 . . . . 74.519999999999996 110.61 -175.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 98.4 -119.48 6.47 Favored Glycine 0 C--N 1.344 1.015 0 CA-C-N 114.899 -1.046 . . . . 72.230000000000004 110.807 -173.107 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 60.58 35.51 89.43 Favored Glycine 0 C--N 1.356 1.647 0 O-C-N 124.324 0.661 . . . . 73.150000000000006 113.11 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 40.3 m 66.6 -2.83 0.98 Allowed 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 125.029 1.332 . . . . 61.520000000000003 113.735 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 128.42 -143.88 14.8 Favored Glycine 0 C--N 1.342 0.878 0 N-CA-C 110.625 -0.99 . . . . 43.049999999999997 110.625 -169.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.408 ' HA3' ' OG1' ' A' ' 103' ' ' THR . . . -90.3 57.66 3.53 Favored Glycine 0 C--N 1.342 0.908 0 N-CA-C 111.79 -0.524 . . . . 75.409999999999997 111.79 176.525 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 69.8 m -78.38 157.15 29.15 Favored 'General case' 0 C--O 1.24 0.554 0 C-N-CA 123.978 0.911 . . . . 54.420000000000002 112.212 -173.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 64.07 58.74 9.85 Favored Glycine 0 C--N 1.352 1.45 0 O-C-N 123.918 0.761 . . . . 73.219999999999999 112.187 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.614 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 46.7 mtt-85 -69.84 132.08 45.48 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.297 0.639 . . . . 72.120000000000005 109.882 -176.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -99.29 105.02 16.98 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 106.469 -1.678 . . . . 63.450000000000003 106.469 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.494 HD22 ' O ' ' A' ' 100' ' ' THR . 12.6 mt -88.33 106.93 18.55 Favored 'General case' 0 C--N 1.345 0.378 0 N-CA-C 105.78 -1.933 . . . . 70.209999999999994 105.78 -177.309 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.4 ttm-85 -106.91 102.3 11.67 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.824 -1.176 . . . . 75.329999999999998 107.824 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -125.45 136.04 52.97 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.125 -1.065 . . . . 62.32 108.125 -175.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -82.86 129.37 34.99 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.853 -0.612 . . . . 70.140000000000001 109.732 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.52 HD12 HD13 ' A' ' 176' ' ' LEU . 2.2 tt -101.18 105.05 36.93 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 123.681 0.792 . . . . 63.509999999999998 109.558 -172.782 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.579 ' HB2' HD11 ' A' ' 181' ' ' LEU . 33.9 Cg_endo -61.48 116.22 3.27 Favored 'Trans proline' 0 C--N 1.378 2.089 0 C-N-CA 122.958 2.439 . . . . 71.310000000000002 111.213 170.688 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.49 HD21 HD12 ' A' ' 149' ' ' ILE . 30.9 tp -145.61 124.53 12.73 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 123.77 0.828 . . . . 64.219999999999999 109.026 -170.574 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.1 p -75.49 168.24 20.38 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 122.538 0.335 . . . . 74.329999999999998 110.978 -175.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 74.7 mt -63.22 -37.36 86.92 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.642 0.777 . . . . 74.340000000000003 110.901 178.407 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 24.7 mp0 -64.19 -52.36 59.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.95 1.3 . . . . 61.310000000000002 110.136 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -69.75 -32.71 71.39 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.456 -0.793 . . . . 51.539999999999999 111.43 -177.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.57 -45.28 93.64 Favored 'General case' 0 C--N 1.349 0.582 0 O-C-N 123.87 0.731 . . . . 65.420000000000002 110.269 174.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -66.14 -39.35 89.78 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.377 1.071 . . . . 73.219999999999999 110.641 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.0 m80 -61.98 -47.43 84.87 Favored 'General case' 0 C--N 1.358 0.945 0 O-C-N 123.717 0.636 . . . . 72.519999999999996 110.447 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.429 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.08 52.78 47.6 Favored Glycine 0 C--N 1.352 1.427 0 O-C-N 124.046 0.841 . . . . 74.030000000000001 112.516 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -106.41 -141.82 10.52 Favored Glycine 0 C--N 1.339 0.712 0 N-CA-C 111.531 -0.628 . . . . 63.119999999999997 111.531 177.673 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.586 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.9 mp0 -93.68 148.87 21.71 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 108.261 -1.014 . . . . 63.229999999999997 108.261 169.702 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.463 ' HG3' HG13 ' A' ' 138' ' ' VAL . 40.5 tpt85 -123.31 117.68 25.8 Favored 'General case' 0 N--CA 1.463 0.18 0 N-CA-C 107.441 -1.318 . . . . 55.329999999999998 107.441 177.289 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.5 t -86.21 106.0 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 109.165 -0.679 . . . . 74.019999999999996 109.165 -174.435 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.676 HG23 HD22 ' A' ' 98' ' ' LEU . 33.1 m -125.91 157.79 35.51 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 C-N-CA 124.93 1.292 . . . . 74.120000000000005 108.342 -178.138 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -113.65 120.29 40.39 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 118.534 0.606 . . . . 62.450000000000003 111.382 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 6.4 p -105.61 104.6 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.757 0.823 . . . . 74.439999999999998 109.665 173.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.22 29.6 18.81 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.354 0.661 . . . . 53.109999999999999 112.384 172.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.35 -14.23 58.17 Favored Glycine 0 N--CA 1.475 1.287 0 N-CA-C 113.705 0.242 . . . . 54.240000000000002 113.705 -178.296 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -92.78 117.65 30.24 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.027 -0.731 . . . . 70.310000000000002 109.027 -178.624 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 26.5 ttm180 -88.76 105.93 18.02 Favored 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 108.808 -0.812 . . . . 72.150000000000006 108.808 -173.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.57 128.87 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 124.214 1.005 . . . . 73.319999999999993 110.797 -175.42 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.586 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 51.0 p -90.14 107.43 19.13 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 123.841 0.857 . . . . 45.520000000000003 109.699 173.213 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.81 130.1 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 123.721 0.808 . . . . 53.329999999999998 109.995 -178.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 75.8 ttt180 -78.82 113.97 17.35 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.555 0.693 . . . . 73.430000000000007 110.547 -174.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.49 HD12 HD21 ' A' ' 125' ' ' LEU . 4.5 pt -90.25 142.22 28.29 Favored Pre-proline 0 CA--C 1.56 1.358 0 C-N-CA 124.93 1.292 . . . . 62.039999999999999 109.772 178.501 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -69.34 142.91 51.13 Favored 'Trans proline' 0 CA--C 1.564 2.018 0 C-N-CA 122.156 1.904 . . . . 50.340000000000003 112.849 174.489 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.59 127.92 14.58 Favored 'Trans proline' 0 C--N 1.381 2.242 0 C-N-CA 122.832 2.355 . . . . 74.409999999999997 111.475 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 82.72 23.41 56.03 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.657 -0.701 . . . . 72.450000000000003 113.416 -174.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.2 p -74.5 150.22 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.926 0.49 . . . . 73.040000000000006 110.185 178.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -131.64 178.55 6.66 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 121.83 0.824 . . . . 74.010000000000005 112.6 -169.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.82 131.46 50.96 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 113.389 -1.732 . . . . 72.540000000000006 111.412 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.55 -8.05 70.35 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-O 119.464 -0.631 . . . . 23.030000000000001 113.357 177.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 49.3 m -72.43 119.23 16.35 Favored 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.848 -0.797 . . . . 72.25 108.848 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.67 134.27 41.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.286 0.634 . . . . 64.420000000000002 109.747 -175.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.471 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 47.4 mt -106.9 103.43 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.224 1.01 . . . . 74.25 108.35 -176.678 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.455 HH21 HD11 ' A' ' 175' ' ' LEU . 30.2 ttm180 -87.29 111.21 20.82 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 123.134 0.574 . . . . 74.010000000000005 109.959 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.91 102.95 53.96 Favored Pre-proline 0 CA--C 1.554 1.106 0 N-CA-C 108.336 -0.987 . . . . 72.329999999999998 108.336 173.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -68.83 139.43 43.53 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 122.909 2.406 . . . . 72.310000000000002 112.52 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 81.31 -8.41 58.32 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.575 -0.569 . . . . 64.25 114.446 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.0 mtt -113.35 17.58 18.4 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 117.944 0.872 . . . . 75.109999999999999 111.22 -174.112 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -92.96 -107.04 1.76 Allowed Glycine 0 C--N 1.347 1.19 0 CA-C-O 119.508 -0.607 . . . . 72.019999999999996 112.066 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.614 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -64.85 90.48 0.1 OUTLIER Glycine 0 C--N 1.355 1.599 0 CA-C-N 116.937 0.369 . . . . 72.129999999999995 112.78 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -79.66 147.71 31.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.496 0.719 . . . . 74.219999999999999 111.165 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.09 -124.81 1.48 Allowed Glycine 0 C--N 1.342 0.885 0 N-CA-C 110.001 -1.24 . . . . 74.030000000000001 110.001 -176.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.406 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 2.0 m-20 -85.16 -50.61 0.54 Allowed Pre-proline 0 CA--C 1.563 1.463 0 CA-C-O 118.63 -0.7 . . . . 74.099999999999994 110.004 169.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.406 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -99.66 103.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.395 2.995 0 C-N-CA 123.317 2.678 . . . . 53.43 112.434 177.183 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.52 123.19 12.26 Favored 'Trans proline' 0 C--N 1.377 2.056 0 C-N-CA 122.293 1.996 . . . . 74.310000000000002 111.369 -177.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -94.29 -171.63 38.2 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 116.179 -0.464 . . . . 74.549999999999997 112.977 -176.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -99.65 144.85 28.25 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 123.113 0.565 . . . . 70.409999999999997 110.28 -177.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.567 HD21 HD11 ' A' ' 98' ' ' LEU . 46.8 tp -109.9 129.49 55.65 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.425 0.69 . . . . 65.099999999999994 109.174 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.455 HD11 HH21 ' A' ' 160' ' ' ARG . 88.9 mt -128.85 109.33 11.18 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.887 0.875 . . . . 51.5 109.793 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.52 HD13 HD12 ' A' ' 123' ' ' LEU . 83.6 mt -110.19 102.99 11.63 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.056 0.542 . . . . 74.329999999999998 111.713 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.88 94.56 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.941 0 C-N-CA 123.322 0.649 . . . . 75.230000000000004 109.904 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 84.7 t -54.39 114.76 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 124.105 0.962 . . . . 72.340000000000003 112.054 -179.549 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 29.8 mmt180 -98.29 115.24 27.99 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.116 1.366 . . . . 73.040000000000006 108.406 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 66.7 mt -70.31 114.41 8.41 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 120.689 0.281 . . . . 75.310000000000002 110.5 178.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.579 HD11 ' HB2' ' A' ' 124' ' ' PRO . 45.2 mt -89.96 156.9 46.56 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 123.568 0.747 . . . . 55.340000000000003 110.825 175.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -71.18 -162.85 0.11 Allowed 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 123.041 2.494 . . . . 61.200000000000003 112.286 168.131 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 6.7 p80 . . . . . 0 CA--C 1.553 1.091 0 C-N-CA 123.811 0.844 . . . . 71.010000000000005 109.16 -177.868 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 84.4 mtp . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 110.006 -0.368 . . . . 75.209999999999994 110.006 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 37.24 96.33 0.04 OUTLIER Pre-proline 0 CA--C 1.559 1.326 0 C-N-CA 126.285 1.834 . . . . 74.299999999999997 114.168 -178.03 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.455 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 13.0 Cg_exo -70.91 -161.5 0.09 OUTLIER 'Trans proline' 0 C--N 1.375 1.969 0 C-N-CA 122.698 2.265 . . . . 75.420000000000002 111.989 171.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.674 HD13 ' HD2' ' A' ' 124' ' ' PRO . 1.1 tp -58.19 -42.85 87.03 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 124.107 0.963 . . . . 73.420000000000002 112.569 -175.594 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.401 HD22 ' HB ' ' A' ' 140' ' ' VAL . 1.7 tt -141.06 96.52 3.01 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 107.801 -1.185 . . . . 74.310000000000002 107.801 171.762 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.455 ' HB3' ' HD2' ' A' ' 96' ' ' PRO . 53.7 t80 165.36 119.6 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 126.518 1.927 . . . . 72.450000000000003 107.431 172.301 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.574 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 32.7 m -145.54 86.68 7.28 Favored Pre-proline 0 CA--C 1.55 0.961 0 CA-C-N 118.147 0.43 . . . . 63.200000000000003 110.653 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -74.11 86.0 1.32 Allowed 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.371 2.047 . . . . 71.530000000000001 111.623 -177.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.503 HG13 HG22 ' A' ' 100' ' ' THR . 18.0 m -82.07 -174.78 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.585 1.154 . . . . 53.32 112.553 -175.231 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 2.2 t -121.48 92.24 3.7 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.301 1.04 . . . . 64.140000000000001 108.597 175.106 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -118.28 142.6 47.33 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 123.612 0.765 . . . . 74.329999999999998 110.241 178.565 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -153.14 140.75 7.82 Favored Glycine 0 C--N 1.346 1.085 0 N-CA-C 111.721 -0.551 . . . . 71.439999999999998 111.721 178.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 30.2 t -100.45 -170.05 1.81 Allowed 'General case' 0 CA--C 1.552 1.026 0 C-N-CA 123.968 0.907 . . . . 73.349999999999994 109.843 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.23 66.71 3.88 Favored Glycine 0 C--N 1.349 1.279 0 CA-C-O 120.16 -0.245 . . . . 43.140000000000001 113.67 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 57.0 -95.53 0.04 OUTLIER Glycine 0 C--N 1.355 1.627 0 C-N-CA 123.876 0.75 . . . . 64.5 114.063 174.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 44.2 m -94.12 90.75 6.51 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 123.652 0.781 . . . . 71.319999999999993 109.155 176.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 141.68 167.08 11.1 Favored Glycine 0 C--N 1.345 1.061 0 CA-C-N 116.44 -0.346 . . . . 50.310000000000002 112.511 178.143 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -150.78 81.79 0.18 Allowed Glycine 0 C--N 1.346 1.118 0 N-CA-C 111.178 -0.769 . . . . 72.430000000000007 111.178 178.669 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.8 t -69.05 -54.93 12.49 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.144 0.578 . . . . 25.449999999999999 110.45 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -76.17 136.79 20.2 Favored Glycine 0 C--N 1.343 0.923 0 N-CA-C 111.173 -0.771 . . . . 41.439999999999998 111.173 174.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -77.58 72.02 2.24 Favored Glycine 0 C--N 1.347 1.17 0 N-CA-C 111.495 -0.642 . . . . 73.030000000000001 111.495 177.757 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 45.1 m -129.58 102.7 6.49 Favored 'General case' 0 C--O 1.242 0.668 0 C-N-CA 124.197 0.999 . . . . 60.32 110.22 -174.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -85.66 -121.0 1.11 Allowed Glycine 0 C--N 1.345 1.035 0 N-CA-C 110.185 -1.166 . . . . 50.140000000000001 110.185 170.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.668 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.7 mmp_? -96.56 117.85 31.81 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 107.057 -1.46 . . . . 73.349999999999994 107.057 165.649 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.2 105.45 17.8 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 107.578 -1.267 . . . . 64.400000000000006 107.578 -170.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.574 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.8 mt -94.28 110.83 22.55 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 108.244 -1.021 . . . . 74.439999999999998 108.244 -178.688 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.1 ttt180 -110.86 112.76 24.83 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 108.731 -0.841 . . . . 75.239999999999995 108.731 168.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -131.39 153.95 49.14 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.814 -0.81 . . . . 51.210000000000001 108.814 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -92.61 142.22 27.63 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.935 -0.765 . . . . 74.439999999999998 108.935 -176.102 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.648 ' HA ' HD13 ' A' ' 97' ' ' LEU . 12.1 tp -103.14 102.46 28.43 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 124.247 1.019 . . . . 74.25 109.457 -177.734 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.674 ' HD2' HD13 ' A' ' 97' ' ' LEU . 34.6 Cg_endo -65.49 115.71 3.51 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.053 1.835 . . . . 74.430000000000007 109.449 168.465 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.425 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 24.3 tp -145.81 122.1 10.9 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.282 -1.007 . . . . 71.140000000000001 108.282 -174.595 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 80.7 p -75.4 165.31 25.33 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 123.281 0.363 . . . . 73.530000000000001 110.19 -176.235 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.477 HD12 ' HB3' ' A' ' 183' ' ' HIS . 77.6 mt -60.8 -33.31 72.8 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.75 0.82 . . . . 72.349999999999994 111.998 -172.45 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -73.91 -49.58 24.15 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.274 -0.875 . . . . 75.409999999999997 109.272 -178.136 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -68.52 -24.17 64.63 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 115.007 -0.997 . . . . 74.230000000000004 111.374 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.67 -47.34 66.77 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.015 0.926 . . . . 73.319999999999993 109.967 172.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -60.87 -44.09 97.54 Favored 'General case' 0 C--N 1.352 0.677 0 O-C-N 124.637 1.211 . . . . 60.420000000000002 110.867 177.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -71.16 -45.88 62.61 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 123.531 0.519 . . . . 74.239999999999995 111.104 -174.033 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.447 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 71.4 -138.08 27.11 Favored Glycine 0 CA--C 1.53 1.008 0 CA-C-N 116.175 -0.466 . . . . 73.329999999999998 112.275 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.46 -160.19 45.39 Favored Glycine 0 C--N 1.349 1.256 0 CA-C-O 119.882 -0.399 . . . . 62.210000000000001 112.379 178.639 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.567 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 8.9 mp0 -77.46 138.34 39.19 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 117.316 0.558 . . . . 60.240000000000002 109.91 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.501 ' HE ' HD11 ' A' ' 123' ' ' LEU . 23.1 tpt180 -117.69 119.09 33.89 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.392 -0.966 . . . . 73.120000000000005 108.392 -176.166 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 42.9 t -83.51 103.74 11.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 N-CA-C 108.57 -0.9 . . . . 71.109999999999999 108.57 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.443 HG13 ' HG3' ' A' ' 136' ' ' ARG . 18.8 m -123.81 160.83 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 N-CA-C 107.643 -1.243 . . . . 73.349999999999994 107.643 177.551 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -125.95 115.75 20.4 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 119.232 0.923 . . . . 74.239999999999995 111.123 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.401 ' HB ' HD22 ' A' ' 98' ' ' LEU . 2.6 p -105.41 111.16 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 124.378 1.071 . . . . 73.409999999999997 110.771 178.398 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.5 29.83 19.43 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 124.147 0.979 . . . . 72.040000000000006 112.369 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.16 -13.03 62.04 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-N 116.351 -0.386 . . . . 61.409999999999997 113.29 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.66 115.96 28.58 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.309 0.644 . . . . 75.329999999999998 109.817 176.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 32.8 ttm180 -92.49 103.65 16.04 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 108.182 -1.044 . . . . 75.430000000000007 108.182 -176.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 27.0 m -109.57 155.63 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.719 1.208 . . . . 65.129999999999995 111.4 -172.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.567 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 47.9 m -101.73 115.98 31.72 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.859 0.864 . . . . 51.130000000000003 109.708 176.847 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.525 HG11 HD12 ' A' ' 176' ' ' LEU . 74.5 t -99.35 113.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 124.28 1.032 . . . . 64.549999999999997 108.85 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -74.55 102.58 4.57 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 109.145 -0.687 . . . . 64.319999999999993 109.145 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.496 HD13 ' HB2' ' A' ' 136' ' ' ARG . 5.6 pt -96.15 141.93 23.84 Favored Pre-proline 0 CA--C 1.555 1.171 0 C-N-CA 124.418 1.087 . . . . 64.219999999999999 109.51 -178.587 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.428 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 28.8 Cg_endo -64.0 132.83 35.95 Favored 'Trans proline' 0 CA--C 1.564 2.015 0 C-N-CA 122.371 2.047 . . . . 73.140000000000001 112.344 178.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 25.7 Cg_exo -66.98 132.69 28.86 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 122.984 2.456 . . . . 74.409999999999997 112.225 174.004 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.12 34.59 41.14 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.649 -0.705 . . . . 50.210000000000001 112.121 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.419 HG21 HG21 ' A' ' 178' ' ' VAL . 14.6 p -76.44 140.17 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 122.99 0.516 . . . . 73.409999999999997 111.025 -176.162 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 -94.97 177.09 6.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.832 0.825 . . . . 73.0 112.772 -173.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -72.7 129.92 39.33 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.518 -1.674 . . . . 73.430000000000007 110.753 176.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.8 10.33 86.28 Favored Glycine 0 C--N 1.345 1.031 0 CA-C-N 115.45 -0.795 . . . . 74.430000000000007 113.884 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 44.9 m -78.29 118.39 20.45 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.274 -0.639 . . . . 74.530000000000001 109.274 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -94.46 127.28 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-O 121.273 0.558 . . . . 74.099999999999994 110.333 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 51.7 mt -100.97 101.19 11.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 N-CA-C 107.598 -1.26 . . . . 71.109999999999999 107.598 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.493 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 38.9 ttt180 -89.45 113.98 25.41 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 109.92 -0.4 . . . . 73.409999999999997 109.92 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.4 HG11 ' SD ' ' A' ' 164' ' ' MET . 6.5 t -114.49 94.64 37.04 Favored Pre-proline 0 CA--C 1.555 1.149 0 N-CA-C 108.324 -0.991 . . . . 65.230000000000004 108.324 173.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.56 135.2 48.1 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 123.032 2.488 . . . . 71.120000000000005 112.268 177.416 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.95 -7.88 79.84 Favored Glycine 0 C--N 1.345 1.072 0 CA-C-O 119.543 -0.587 . . . . 52.229999999999997 114.2 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.4 ' SD ' HG11 ' A' ' 161' ' ' VAL . 27.6 ttt -100.38 -7.83 23.98 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.636 0.774 . . . . 75.439999999999998 110.772 179.263 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -81.58 -112.94 0.37 Allowed Glycine 0 C--N 1.348 1.207 0 CA-C-N 116.078 -0.51 . . . . 73.230000000000004 112.316 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.668 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -67.0 95.61 0.28 Allowed Glycine 0 C--N 1.347 1.177 0 CA-C-N 116.869 0.334 . . . . 75.310000000000002 113.877 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -71.93 108.54 5.24 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 123.566 0.747 . . . . 72.439999999999998 110.46 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -171.64 -169.85 34.98 Favored Glycine 0 C--N 1.342 0.883 0 CA-C-N 115.861 -0.608 . . . . 65.040000000000006 112.304 178.365 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -61.0 -42.93 89.28 Favored Pre-proline 0 CA--C 1.563 1.442 0 C-N-CA 123.497 0.719 . . . . 73.019999999999996 111.652 176.392 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -88.17 106.67 0.54 Allowed 'Trans proline' 0 C--N 1.387 2.584 0 C-N-CA 121.623 1.549 . . . . 74.299999999999997 110.176 160.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -67.21 125.63 13.81 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 121.994 1.796 . . . . 63.219999999999999 111.858 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -97.14 154.93 20.58 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-N 115.876 -0.602 . . . . 50.310000000000002 111.926 -177.542 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -95.39 163.43 13.25 Favored 'General case' 0 C--O 1.245 0.827 0 C-N-CA 122.899 0.48 . . . . 75.430000000000007 109.931 -178.595 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.2 tp -117.62 139.75 50.57 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 115.088 -0.96 . . . . 61.229999999999997 109.758 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 30.7 mt -128.93 101.6 6.15 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.89 1.276 . . . . 64.340000000000003 108.416 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.525 HD12 HG11 ' A' ' 147' ' ' VAL . 54.5 mt -103.2 101.28 11.22 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 118.318 0.508 . . . . 72.150000000000006 110.162 176.75 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.63 100.6 10.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 115.435 -0.802 . . . . 64.450000000000003 109.138 -174.644 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.543 HG22 HD23 ' A' ' 123' ' ' LEU . 58.2 t -57.76 111.36 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.066 0.946 . . . . 72.420000000000002 112.01 -177.271 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -101.44 111.1 23.23 Favored 'General case' 0 C--O 1.243 0.753 0 C-N-CA 124.388 1.075 . . . . 75.510000000000005 108.914 170.657 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.425 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 62.7 mt -70.5 114.5 8.67 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.389 0.676 . . . . 72.430000000000007 109.846 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.432 HD11 ' HB2' ' A' ' 124' ' ' PRO . 86.5 mt -72.66 155.44 90.92 Favored Pre-proline 0 CA--C 1.548 0.888 0 C-N-CA 123.237 0.615 . . . . 72.430000000000007 110.728 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.66 142.75 60.23 Favored 'Trans proline' 0 C--N 1.375 1.942 0 C-N-CA 123.249 2.633 . . . . 74.409999999999997 112.454 173.072 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.477 ' HB3' HD12 ' A' ' 127' ' ' LEU . 48.1 p-80 . . . . . 0 CA--C 1.555 1.17 0 CA-C-O 118.942 -0.551 . . . . 70.239999999999995 110.986 -179.315 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 25.1 mmt . . . . . 0 N--CA 1.484 1.246 0 N-CA-C 109.81 -0.441 . . . . 72.109999999999999 109.81 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.488 HD22 HG23 ' A' ' 100' ' ' THR . 3.9 pp -91.17 121.94 67.07 Favored Pre-proline 0 CA--C 1.553 1.095 0 N-CA-C 109.96 -0.385 . . . . 64.329999999999998 109.96 178.076 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.4 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 73.8 Cg_endo -85.48 -161.43 0.13 Allowed 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 122.757 2.304 . . . . 61.399999999999999 110.98 164.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.483 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.0 tp -74.25 149.92 40.54 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.262 0.625 . . . . 74.129999999999995 109.412 177.179 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.61 HD11 HD21 ' A' ' 174' ' ' LEU . 8.2 tp 57.74 1.67 0.14 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 125.798 1.639 . . . . 75.5 114.108 -178.228 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.664 ' HA ' HD13 ' A' ' 119' ' ' LEU . 43.3 t80 -139.91 133.7 30.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 123.336 0.655 . . . . 74.319999999999993 109.698 -170.31 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.564 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 85.9 m -152.94 97.05 2.87 Favored Pre-proline 0 CA--C 1.551 1.009 0 C-N-CA 123.8 0.84 . . . . 73.040000000000006 109.476 -177.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.76 77.23 2.29 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 123.02 2.48 . . . . 55.509999999999998 112.799 -170.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.524 HG13 HG22 ' A' ' 100' ' ' THR . 9.0 m -95.93 163.43 2.34 Favored 'Isoleucine or valine' 0 C--O 1.242 0.694 0 CA-C-N 115.494 -0.775 . . . . 75.200000000000003 110.457 178.366 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -119.45 134.48 55.2 Favored 'General case' 0 C--O 1.245 0.819 0 N-CA-C 107.224 -1.398 . . . . 75.409999999999997 107.224 163.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.595 ' HE3' ' HA ' ' A' ' 115' ' ' SER . 25.0 ttmm -73.64 -24.67 60.04 Favored 'General case' 0 CA--C 1.549 0.937 0 C-N-CA 123.006 0.523 . . . . 71.120000000000005 111.115 -175.084 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -155.17 -177.09 28.1 Favored Glycine 0 C--N 1.346 1.089 0 CA-C-N 116.219 -0.446 . . . . 54.039999999999999 112.336 179.255 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 24.0 p -72.86 -54.1 9.66 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 123.52 0.728 . . . . 64.450000000000003 109.611 176.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -93.15 67.04 1.78 Allowed Glycine 0 C--N 1.348 1.195 0 N-CA-C 111.25 -0.74 . . . . 75.129999999999995 111.25 175.212 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -86.13 54.04 4.68 Favored Glycine 0 C--N 1.354 1.536 0 C-N-CA 122.887 0.28 . . . . 63.450000000000003 112.455 -178.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 50.6 m -70.49 98.1 1.4 Allowed 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.532 0.733 . . . . 74.209999999999994 110.427 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 72.25 -97.54 0.77 Allowed Glycine 0 C--N 1.345 1.061 0 CA-C-N 115.798 -0.637 . . . . 62.119999999999997 111.913 -177.054 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 89.83 51.05 2.93 Favored Glycine 0 C--N 1.347 1.147 0 N-CA-C 111.328 -0.709 . . . . 61.240000000000002 111.328 -177.399 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.2 p -70.29 145.35 51.34 Favored 'General case' 0 CA--C 1.553 1.087 0 C-N-CA 123.347 0.659 . . . . 74.430000000000007 110.824 -179.547 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.2 -140.74 15.16 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 111.746 -0.542 . . . . 62.119999999999997 111.746 -175.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.6 50.42 3.78 Favored Glycine 0 C--N 1.346 1.092 0 N-CA-C 111.781 -0.528 . . . . 71.010000000000005 111.781 177.128 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' SER . . . . . 0.595 ' HA ' ' HE3' ' A' ' 104' ' ' LYS . 70.2 m -146.39 22.07 1.34 Allowed 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.655 0.782 . . . . 64.120000000000005 111.116 -172.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -82.01 -152.92 10.7 Favored Glycine 0 C--N 1.344 0.973 0 CA-C-N 116.36 -0.382 . . . . 45.310000000000002 113.778 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.408 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 8.7 mmm-85 -89.24 118.48 28.96 Favored 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 109.133 -0.691 . . . . 73.030000000000001 109.133 -173.04 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.05 106.59 16.64 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 108.691 -0.855 . . . . 73.439999999999998 108.691 -171.314 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.664 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.3 mt -96.43 109.46 22.01 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 107.478 -1.305 . . . . 75.540000000000006 107.478 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 39.8 ttt180 -121.18 106.45 11.53 Favored 'General case' 0 C--O 1.238 0.465 0 N-CA-C 108.557 -0.905 . . . . 71.510000000000005 108.557 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -128.9 141.23 51.35 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.543 -0.91 . . . . 72.450000000000003 108.543 -177.499 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -81.56 130.99 35.26 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 108.895 -0.78 . . . . 64.5 108.895 175.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.597 HD12 HD13 ' A' ' 176' ' ' LEU . 1.6 tt -101.38 108.24 54.37 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 108.103 -1.073 . . . . 75.409999999999997 108.103 -175.633 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.7 113.87 3.33 Favored 'Trans proline' 0 C--N 1.378 2.097 0 C-N-CA 121.775 1.65 . . . . 73.099999999999994 109.42 171.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.566 HD21 HD12 ' A' ' 149' ' ' ILE . 13.5 tp -131.72 122.78 26.44 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.388 -0.968 . . . . 71.129999999999995 108.388 -169.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.9 p -69.71 166.15 19.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.549 0.34 . . . . 64.219999999999999 110.537 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 99.7 mt -62.34 -29.2 70.29 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 122.778 0.431 . . . . 73.200000000000003 110.882 176.065 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -67.8 -57.67 5.91 Favored 'General case' 0 C--N 1.349 0.555 0 C-N-CA 123.907 0.883 . . . . 72.219999999999999 109.263 177.405 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -60.08 -36.49 77.5 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.507 1.123 . . . . 70.219999999999999 111.713 -178.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.407 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.1 -55.72 11.44 Favored 'General case' 0 C--O 1.239 0.551 0 O-C-N 124.061 0.851 . . . . 73.299999999999997 111.212 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.409 ' HA ' ' HA2' ' A' ' 152' ' ' GLY . 65.0 t80 -57.84 -48.28 80.23 Favored 'General case' 0 C--N 1.359 0.99 0 O-C-N 124.554 1.159 . . . . 64.030000000000001 111.399 -177.059 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.9 m80 -72.92 -43.84 61.92 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 116.017 -0.538 . . . . 54.039999999999999 110.19 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.416 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 77.87 -124.01 6.62 Favored Glycine 0 C--N 1.344 0.988 0 CA-C-N 115.762 -0.654 . . . . 70.5 111.566 -176.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 73.49 -129.8 12.67 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 111.151 -0.78 . . . . 72.099999999999994 111.151 -176.562 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.531 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 6.7 mp0 -111.73 161.37 16.36 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.102 0.961 . . . . 72.099999999999994 110.179 176.15 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.626 ' HB2' HD13 ' A' ' 149' ' ' ILE . 20.8 tpt180 -134.01 121.99 22.37 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.212 1.005 . . . . 74.120000000000005 109.401 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 60.9 t -75.14 107.68 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.89 0.876 . . . . 62.420000000000002 109.417 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.528 HG21 HD13 ' A' ' 98' ' ' LEU . 27.0 m -122.96 163.8 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 125.257 1.423 . . . . 65.25 109.354 -179.129 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -120.99 113.02 19.47 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 122.911 0.485 . . . . 63.149999999999999 111.505 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.585 ' HB ' HD23 ' A' ' 98' ' ' LEU . 2.6 p -102.76 102.33 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 C-N-CA 123.649 0.78 . . . . 71.329999999999998 108.972 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.25 25.44 14.87 Favored 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 115.215 -0.902 . . . . 63.329999999999998 110.665 -169.377 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.9 6.17 62.17 Favored Glycine 0 C--N 1.358 1.804 0 CA-C-N 115.63 -0.714 . . . . 53.210000000000001 113.802 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.518 ' HB3' HG13 ' A' ' 140' ' ' VAL . 13.8 tpt180 -92.27 116.98 29.43 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.09 -0.707 . . . . 73.340000000000003 109.09 -179.781 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -80.89 109.8 15.81 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.809 -0.441 . . . . 70.109999999999999 109.809 -174.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 32.1 m -134.11 152.53 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 124.254 1.022 . . . . 43.409999999999997 109.218 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.531 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 45.1 m -104.36 114.86 29.38 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.736 0.414 . . . . 32.420000000000002 110.02 178.034 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.4 p -99.85 133.13 43.84 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 124.289 1.036 . . . . 43.119999999999997 109.9 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 38.9 ttp180 -75.81 115.46 15.53 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.091 0.556 . . . . 72.420000000000002 111.122 -174.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.626 HD13 ' HB2' ' A' ' 136' ' ' ARG . 6.1 pt -99.34 143.26 26.09 Favored Pre-proline 0 CA--C 1.558 1.256 0 C-N-CA 124.864 1.266 . . . . 50.149999999999999 109.315 177.59 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.411 ' HB2' ' HB ' ' A' ' 153' ' ' VAL . 52.7 Cg_exo -57.59 134.74 65.16 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.091 2.527 . . . . 71.239999999999995 113.094 178.616 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -62.72 114.53 2.44 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 70.310000000000002 111.112 172.361 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 131' ' ' PHE . . . 89.98 18.72 49.73 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.577 -0.568 . . . . 74.239999999999995 113.191 -178.628 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.411 ' HB ' ' HB2' ' A' ' 150' ' ' PRO . 13.2 p -64.0 141.68 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 C-N-CA 122.971 0.508 . . . . 64.430000000000007 111.395 -175.126 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -113.12 177.7 4.54 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 123.777 0.831 . . . . 72.420000000000002 112.706 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.69 135.7 57.76 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.535 -1.666 . . . . 73.129999999999995 111.744 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.58 6.66 77.52 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.905 0.753 . . . . 60.409999999999997 114.232 176.667 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.8 m -81.83 119.82 24.39 Favored 'General case' 0 C--N 1.349 0.564 0 N-CA-C 109.179 -0.675 . . . . 62.310000000000002 109.179 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.2 p -97.56 123.39 49.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.903 0 CA-C-O 121.313 0.578 . . . . 61.32 110.366 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.503 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.3 mt -93.29 103.73 14.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 124.379 1.071 . . . . 72.510000000000005 108.619 -175.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.452 ' HE ' HD21 ' A' ' 175' ' ' LEU . 43.0 ttm180 -90.18 111.36 22.49 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 122.767 0.427 . . . . 75.400000000000006 110.025 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 6.3 t -111.18 106.32 57.29 Favored Pre-proline 0 CA--C 1.552 1.05 0 N-CA-C 107.526 -1.287 . . . . 44.109999999999999 107.526 172.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.35 125.35 12.78 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.857 2.372 . . . . 71.400000000000006 112.691 -172.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.9 11.86 85.12 Favored Glycine 0 C--N 1.349 1.291 0 CA-C-O 119.792 -0.449 . . . . 75.120000000000005 114.044 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.2 tpt -100.99 -4.4 27.58 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-N 117.24 0.52 . . . . 74.530000000000001 110.766 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -74.11 -110.58 0.08 OUTLIER Glycine 0 C--N 1.344 0.996 0 CA-C-N 116.073 -0.512 . . . . 74.340000000000003 112.474 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -63.94 108.19 2.12 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 111.777 -0.529 . . . . 70.450000000000003 111.777 178.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.9 mm-40 -88.14 116.84 26.61 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.255 0.622 . . . . 72.040000000000006 110.308 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 169.22 -155.85 26.5 Favored Glycine 0 C--O 1.245 0.816 0 N-CA-C 110.359 -1.097 . . . . 72.030000000000001 110.359 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.457 ' O ' ' HD3' ' A' ' 171' ' ' PRO . 15.0 m120 -65.42 -34.52 9.72 Favored Pre-proline 0 N--CA 1.487 1.398 0 CA-C-O 118.274 -0.869 . . . . 73.099999999999994 112.053 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -90.64 99.6 0.26 Allowed 'Trans proline' 0 C--N 1.394 2.924 0 C-N-CA 122.527 2.152 . . . . 42.310000000000002 111.655 164.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.457 ' HD3' ' O ' ' A' ' 169' ' ' ASN . 10.6 Cg_exo -70.86 123.28 9.6 Favored 'Trans proline' 0 C--N 1.382 2.331 0 C-N-CA 121.683 1.588 . . . . 71.109999999999999 110.613 174.565 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -100.94 156.58 19.23 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.569 -0.613 . . . . 63.009999999999998 111.569 -178.63 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -83.99 143.57 29.7 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 109.849 -0.426 . . . . 74.209999999999994 109.849 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.61 HD21 HD11 ' A' ' 98' ' ' LEU . 64.1 tp -106.98 129.89 54.71 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.179 0.592 . . . . 64.150000000000006 109.851 -179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.452 HD21 ' HE ' ' A' ' 160' ' ' ARG . 98.1 mt -128.75 112.15 13.88 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.448 1.099 . . . . 73.349999999999994 110.025 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.597 HD13 HD12 ' A' ' 123' ' ' LEU . 81.9 mt -108.54 103.83 13.04 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.247 0.619 . . . . 73.310000000000002 110.96 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.52 94.62 4.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 N-CA-C 108.851 -0.796 . . . . 71.430000000000007 108.851 -176.024 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.4 t -57.63 118.68 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.877 0.871 . . . . 50.130000000000003 111.382 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -114.07 107.22 15.36 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 124.648 1.179 . . . . 74.329999999999998 108.22 175.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.05 122.07 18.68 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.526 0.517 . . . . 73.340000000000003 110.857 -176.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 93.0 mt -79.11 141.06 57.74 Favored Pre-proline 0 CA--C 1.544 0.745 0 CA-C-N 115.362 -0.835 . . . . 71.219999999999999 109.556 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.2 166.22 30.33 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.988 2.459 . . . . 72.099999999999994 112.591 -176.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.4 p-80 . . . . . 0 CA--C 1.56 1.327 0 C-N-CA 122.546 0.339 . . . . 71.140000000000001 110.299 178.835 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 20.6 ptp . . . . . 0 CA--C 1.54 0.589 0 CA-C-O 120.196 0.046 . . . . 54.340000000000003 111.102 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 pt? -112.36 103.42 55.4 Favored Pre-proline 0 CA--C 1.562 1.429 0 C-N-CA 123.265 0.626 . . . . 53.299999999999997 110.247 175.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -86.82 -67.79 0.01 OUTLIER 'Trans proline' 0 C--N 1.38 2.19 0 C-N-CA 122.865 2.376 . . . . 72.209999999999994 111.811 175.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.513 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.6 tp -159.74 140.92 12.6 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 108.516 -0.92 . . . . 71.129999999999995 108.516 176.206 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.712 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 11.5 tp 60.58 3.48 0.6 Allowed 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 126.461 1.904 . . . . 73.519999999999996 112.95 -178.207 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.739 ' HA ' HD13 ' A' ' 119' ' ' LEU . 75.0 t80 -135.35 133.25 38.57 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.271 1.028 . . . . 72.430000000000007 108.377 -173.196 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.507 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 89.3 m -153.6 102.17 2.54 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 123.75 0.82 . . . . 74.420000000000002 109.645 177.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -72.94 91.02 0.83 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 122.559 2.173 . . . . 72.030000000000001 111.631 -175.338 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 28.7 m -101.37 167.76 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 124.178 0.991 . . . . 75.299999999999997 110.912 -178.491 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.3 t -88.02 -45.38 10.24 Favored 'General case' 0 CA--C 1.551 0.993 0 N-CA-C 109.485 -0.561 . . . . 62.299999999999997 109.485 172.079 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.453 ' HD2' ' HA3' ' A' ' 110' ' ' GLY . 15.4 tppt? 174.06 115.66 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 125.034 1.334 . . . . 72.420000000000002 109.497 177.781 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -158.02 63.47 0.31 Allowed Glycine 0 C--N 1.34 0.776 0 N-CA-C 110.418 -1.073 . . . . 71.510000000000005 110.418 175.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 14.6 m -72.34 82.43 1.04 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 123.32 0.648 . . . . 74.230000000000004 109.907 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 84.03 -48.72 4.1 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-N 115.85 -0.614 . . . . 52.299999999999997 112.704 -175.31 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -143.78 -48.9 0.04 OUTLIER Glycine 0 C--N 1.343 0.945 0 N-CA-C 110.623 -0.991 . . . . 53.409999999999997 110.623 173.46 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.8 t -154.19 -167.31 2.6 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 124.585 1.154 . . . . 64.109999999999999 108.25 178.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.453 ' HA3' ' HD2' ' A' ' 104' ' ' LYS . . . -162.61 0.31 0.06 OUTLIER Glycine 0 C--N 1.346 1.107 0 CA-C-O 119.562 -0.577 . . . . 53.210000000000001 113.459 174.492 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 75.77 -78.68 1.18 Allowed Glycine 0 C--N 1.349 1.278 0 CA-C-N 116.956 0.378 . . . . 33.210000000000001 112.443 -179.559 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 42.4 t -70.48 100.99 1.88 Allowed 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 123.703 0.801 . . . . 72.409999999999997 109.612 177.267 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -72.38 -39.35 57.24 Favored Glycine 0 C--N 1.348 1.233 0 CA-C-N 114.902 -1.045 . . . . 43.210000000000001 114.631 -172.219 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -90.43 55.96 3.51 Favored Glycine 0 N--CA 1.471 1.024 0 CA-C-N 116.631 0.215 . . . . 61.140000000000001 112.833 -174.816 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 25.7 p -171.92 112.9 0.32 Allowed 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.585 0.754 . . . . 71.319999999999993 109.975 -177.201 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 85.77 106.82 0.72 Allowed Glycine 0 C--N 1.348 1.244 0 CA-C-O 119.872 -0.405 . . . . 75.319999999999993 113.049 177.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.439 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 3.9 mmp_? -86.72 118.45 26.13 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 108.76 -0.83 . . . . 75.530000000000001 108.76 175.588 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -98.12 102.51 14.28 Favored 'General case' 0 CA--C 1.511 -0.542 0 N-CA-C 106.486 -1.672 . . . . 74.540000000000006 106.486 -173.599 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.739 HD13 ' HA ' ' A' ' 99' ' ' PHE . 16.5 mt -93.52 106.33 18.31 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.605 -1.257 . . . . 64.010000000000005 107.605 -169.056 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -111.02 103.24 11.69 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.904 -1.147 . . . . 71.209999999999994 107.904 -179.001 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.46 151.69 51.32 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.583 -0.735 . . . . 75.209999999999994 110.235 -168.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.529 ' HB3' ' HG3' ' A' ' 179' ' ' ARG . 40.4 mt-10 -81.55 124.17 29.27 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 114.6 -1.182 . . . . 72.450000000000003 109.342 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.53 HD12 HD13 ' A' ' 176' ' ' LEU . 3.2 tt -99.52 103.81 23.46 Favored Pre-proline 0 CA--C 1.54 0.583 0 N-CA-C 106.898 -1.519 . . . . 62.43 106.898 178.41 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.3 114.48 3.46 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 121.925 1.75 . . . . 72.340000000000003 110.438 175.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.499 HD21 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -139.23 120.08 14.35 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.039 -1.097 . . . . 71.430000000000007 108.039 -172.709 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 4.9 m -69.73 160.82 30.96 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 123.748 0.819 . . . . 75.129999999999995 111.112 -176.094 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 83.2 mt -56.17 -39.28 72.11 Favored 'General case' 0 N--CA 1.484 1.225 0 C-N-CA 123.894 0.878 . . . . 74.200000000000003 112.13 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -69.12 -44.19 72.91 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.447 0.699 . . . . 73.530000000000001 110.414 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -61.44 -39.15 89.76 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.321 1.048 . . . . 72.530000000000001 111.16 -179.12 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.447 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -72.98 -44.23 61.31 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-N 114.31 -1.314 . . . . 75.439999999999998 111.145 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -56.92 -47.83 79.66 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.803 1.241 . . . . 73.140000000000001 110.913 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -69.83 -48.55 58.53 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.716 -0.675 . . . . 61.399999999999999 110.181 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.549 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 55.65 76.37 0.2 Allowed Glycine 0 C--N 1.356 1.639 0 O-C-N 124.469 1.105 . . . . 25.219999999999999 113.638 176.552 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -112.57 -131.39 5.57 Favored Glycine 0 C--N 1.343 0.922 0 N-CA-C 111.328 -0.709 . . . . 60.039999999999999 111.328 177.193 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -100.96 152.19 20.86 Favored 'General case' 0 C--O 1.245 0.834 0 N-CA-C 108.694 -0.854 . . . . 61.039999999999999 108.694 170.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 tpp85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.003 0.921 . . . . 74.349999999999994 108.867 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.28 131.04 40.46 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 N-CA-C 108.582 -0.896 . . . . 64.319999999999993 108.582 175.546 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 27.1 m -125.14 161.19 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 123.604 0.762 . . . . 75.400000000000006 110.147 -178.419 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -97.56 141.71 30.27 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 124.075 0.95 . . . . 65.049999999999997 108.539 -178.354 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.712 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.0 p -150.1 109.31 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.199 0 C-N-CA 124.733 1.213 . . . . 73.219999999999999 111.394 -177.198 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.13 17.36 8.01 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 114.449 1.277 . . . . 72.519999999999996 114.449 164.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.12 22.34 13.36 Favored Glycine 0 N--CA 1.479 1.561 0 N-CA-C 112.514 -0.235 . . . . 64.25 112.514 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.423 ' HB2' HG13 ' A' ' 140' ' ' VAL . 24.7 mmm180 -134.75 153.86 51.83 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.906 1.282 . . . . 75.099999999999994 107.864 178.144 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -117.69 108.01 14.89 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.034 -0.728 . . . . 72.310000000000002 109.034 175.15 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 63.2 t -116.56 139.19 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 123.477 0.711 . . . . 74.439999999999998 110.174 -174.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.7 p -85.99 140.13 30.58 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 123.733 0.813 . . . . 73.019999999999996 111.087 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.415 HG21 HD12 ' A' ' 176' ' ' LEU . 14.7 p -133.55 157.59 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 124.641 1.176 . . . . 64.049999999999997 108.52 174.696 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 -107.32 128.72 54.7 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.783 -0.451 . . . . 75.239999999999995 109.783 177.484 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.499 HD12 HD21 ' A' ' 125' ' ' LEU . 15.7 pt -101.9 126.84 32.6 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.058 0.943 . . . . 71.150000000000006 108.65 176.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.408 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 27.9 Cg_endo -65.32 147.07 87.3 Favored 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.362 2.042 . . . . 70.540000000000006 113.547 -178.017 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.549 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 38.5 Cg_exo -62.88 121.92 10.0 Favored 'Trans proline' 0 C--N 1.385 2.452 0 C-N-CA 123.821 3.014 . . . . 70.329999999999998 112.159 179.156 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 72.33 40.13 55.83 Favored Glycine 0 C--N 1.339 0.747 0 O-C-N 124.051 0.844 . . . . 73.310000000000002 112.563 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.447 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 14.6 p -76.87 148.93 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 109.872 -0.418 . . . . 54.039999999999999 109.872 178.32 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 68.7 mtp180 -126.51 177.97 6.16 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-O 121.509 0.671 . . . . 60.030000000000001 112.413 -172.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -59.31 133.88 56.49 Favored 'General case' 0 CA--C 1.547 0.851 0 CA-C-N 113.409 -1.723 . . . . 64.209999999999994 111.865 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.31 -16.75 47.06 Favored Glycine 0 C--N 1.345 1.057 0 CA-C-O 119.388 -0.673 . . . . 20.23 113.312 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 48.3 m -67.15 118.72 10.95 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.36 0.58 . . . . 72.129999999999995 110.445 -173.399 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.9 p -94.12 125.0 46.8 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-O 121.528 0.68 . . . . 62.340000000000003 109.923 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 43.4 mt -94.82 99.75 9.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 107.061 -1.459 . . . . 63.100000000000001 107.061 174.319 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 46.6 ttt-85 -83.97 123.42 29.96 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 109.297 -0.631 . . . . 64.010000000000005 109.297 175.508 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.7 t -116.32 111.42 42.24 Favored Pre-proline 0 CA--C 1.555 1.168 0 N-CA-C 106.858 -1.534 . . . . 54.509999999999998 106.858 168.501 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.07 126.08 12.7 Favored 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.673 2.249 . . . . 71.040000000000006 112.25 -175.666 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.92 8.8 86.81 Favored Glycine 0 C--N 1.345 1.042 0 CA-C-N 115.774 -0.648 . . . . 74.549999999999997 114.57 171.466 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 24.0 mmt -114.07 15.35 18.36 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.154 0.582 . . . . 64.019999999999996 111.293 -176.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.21 -96.03 0.98 Allowed Glycine 0 C--N 1.344 0.973 0 N-CA-C 110.377 -1.089 . . . . 42.219999999999999 110.377 169.391 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.439 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -79.12 95.29 1.4 Allowed Glycine 0 C--N 1.346 1.087 0 N-CA-C 112.177 -0.369 . . . . 71.200000000000003 112.177 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.6 mm100 -65.85 131.6 46.68 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.485 0.714 . . . . 70.310000000000002 111.508 -177.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 170.11 174.87 38.61 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.781 -0.928 . . . . 72.140000000000001 110.781 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.456 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 15.3 m120 -59.04 -42.37 93.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.358 0.663 . . . . 72.319999999999993 111.326 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.456 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 1.8 Cg_endo -87.42 101.34 0.5 Allowed 'Trans proline' 0 C--N 1.387 2.596 0 C-N-CA 122.429 2.086 . . . . 75.129999999999995 109.489 158.719 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.48 126.95 12.01 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 121.984 1.789 . . . . 61.329999999999998 111.911 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.99 151.14 21.94 Favored Glycine 0 C--N 1.343 0.946 0 CA-C-N 115.309 -0.859 . . . . 43.100000000000001 111.975 -179.131 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -77.74 159.4 29.1 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.512 0.725 . . . . 61.240000000000002 110.045 -170.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.534 HD21 HD11 ' A' ' 98' ' ' LEU . 47.5 tp -125.05 125.3 43.61 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.52 -0.548 . . . . 75.150000000000006 109.52 176.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 88.6 mt -127.4 101.47 6.47 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.88 0.872 . . . . 65.409999999999997 109.378 179.019 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.53 HD13 HD12 ' A' ' 123' ' ' LEU . 91.1 mt -102.96 102.23 12.28 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.992 0.517 . . . . 72.040000000000006 111.06 -178.147 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.99 107.57 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.011 -0.737 . . . . 71.519999999999996 109.011 -176.544 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.8 t -62.54 117.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.146 0.978 . . . . 73.25 111.078 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' ARG . . . . . 0.529 ' HG3' ' HB3' ' A' ' 122' ' ' GLU . 13.1 mmm180 -110.95 106.48 15.61 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 124.997 1.319 . . . . 71.230000000000004 108.092 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.406 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 65.8 mt -69.16 116.5 9.67 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 123.206 0.602 . . . . 72.310000000000002 110.815 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 81.9 mt -75.07 139.24 72.64 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 115.944 -0.571 . . . . 73.120000000000005 109.67 178.338 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -71.88 179.03 5.16 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.118 2.545 . . . . 72.319999999999993 112.872 177.454 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 . . . . . 0 C--O 1.252 1.234 0 N-CA-C 109.208 -0.664 . . . . 71.530000000000001 109.208 174.592 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 61.3 mtt . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 110.307 -0.257 . . . . 72.530000000000001 110.307 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER 35.03 86.2 0.14 Allowed Pre-proline 0 CA--C 1.559 1.304 0 C-N-CA 126.582 1.953 . . . . 54.140000000000001 113.837 -173.85 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.466 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 22.0 Cg_endo -62.51 178.17 1.01 Allowed 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.58 2.187 . . . . 75.030000000000001 112.473 168.711 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.651 HD13 ' HD2' ' A' ' 124' ' ' PRO . 1.7 tp -43.22 -53.97 4.8 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 125.287 1.435 . . . . 62.399999999999999 112.529 -174.038 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.434 ' O ' ' HB2' ' A' ' 99' ' ' PHE . 12.7 tp -119.3 91.92 3.67 Favored 'General case' 0 C--O 1.215 -0.757 0 N-CA-C 107.619 -1.252 . . . . 63.229999999999997 107.619 172.86 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.524 ' HA ' HD13 ' A' ' 119' ' ' LEU . 62.3 t80 168.52 131.54 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 124.361 1.064 . . . . 61.520000000000003 109.071 173.44 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.557 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 51.5 m -156.68 98.95 2.07 Favored Pre-proline 0 N--CA 1.475 0.787 0 N-CA-C 107.824 -1.176 . . . . 74.219999999999999 107.824 173.626 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -79.51 74.99 5.29 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 122.575 2.184 . . . . 70.120000000000005 112.553 -169.08 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 4.4 m -83.53 172.9 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 CA-C-N 115.541 -0.754 . . . . 52.539999999999999 109.997 179.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 60.6 p -81.88 -76.33 0.26 Allowed 'General case' 0 CA--C 1.547 0.845 0 CA-C-N 116.112 -0.495 . . . . 51.149999999999999 109.791 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.409 ' HB3' ' HA ' ' A' ' 117' ' ' ARG . 4.3 tppp? 42.21 87.03 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 125.397 1.479 . . . . 75.25 112.727 -175.245 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 149.22 -13.56 1.09 Allowed Glycine 0 N--CA 1.463 0.485 0 CA-C-N 115.171 -0.922 . . . . 44.439999999999998 111.445 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 47.7 m -64.15 87.33 0.05 OUTLIER 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 124.157 0.983 . . . . 42.520000000000003 110.592 178.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 59.37 -103.23 0.38 Allowed Glycine 0 C--N 1.347 1.184 0 CA-C-N 115.485 -0.78 . . . . 61.409999999999997 112.699 -179.306 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.05 33.75 6.18 Favored Glycine 0 C--N 1.345 1.069 0 CA-C-O 120.054 -0.303 . . . . 72.040000000000006 112.782 -177.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.4 p -82.67 90.17 6.81 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 109.184 -0.673 . . . . 62.119999999999997 109.184 173.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 69.58 85.4 0.13 Allowed Glycine 0 C--N 1.351 1.396 0 CA-C-N 115.998 -0.546 . . . . 74.439999999999998 111.876 -178.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -75.29 75.05 1.4 Allowed Glycine 0 C--N 1.35 1.348 0 C-N-CA 123.12 0.391 . . . . 61.310000000000002 112.711 -177.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 43.2 m -133.85 129.33 36.31 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 124.538 1.135 . . . . 72.040000000000006 108.419 177.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -65.47 -55.92 18.09 Favored Glycine 0 C--N 1.35 1.336 0 O-C-N 124.098 0.874 . . . . 51.240000000000002 113.236 -173.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -86.12 48.12 3.88 Favored Glycine 0 C--N 1.348 1.204 0 C-N-CA 122.787 0.232 . . . . 51.509999999999998 112.926 -177.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 50.9 m -144.23 103.94 4.05 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.805 0.842 . . . . 42.350000000000001 109.706 -178.638 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -96.13 -161.83 33.02 Favored Glycine 0 C--N 1.338 0.66 0 N-CA-C 111.127 -0.789 . . . . 64.140000000000001 111.127 171.515 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.412 ' HD2' ' H ' ' A' ' 117' ' ' ARG . 0.3 OUTLIER -59.21 123.79 17.83 Favored 'General case' 0 CA--C 1.56 1.348 0 C-N-CA 123.822 0.849 . . . . 75.5 111.065 -179.545 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.57 130.74 40.88 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.228 -1.027 . . . . 74.430000000000007 108.228 -172.413 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.557 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 14.9 mt -100.73 112.83 25.31 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 108.111 -1.07 . . . . 64.239999999999995 108.111 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 75.0 ttt-85 -119.33 108.69 14.91 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 123.883 0.873 . . . . 73.019999999999996 110.208 -179.283 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -146.29 170.26 17.13 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 123.911 0.885 . . . . 74.040000000000006 108.701 179.004 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -97.03 145.21 26.17 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.969 0.414 . . . . 54.310000000000002 110.746 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.62 HD21 ' HG2' ' A' ' 136' ' ' ARG . 1.1 tt -103.01 103.9 36.74 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 124.901 1.28 . . . . 63.130000000000003 109.053 -177.11 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.651 ' HD2' HD13 ' A' ' 97' ' ' LEU . 37.7 Cg_endo -65.17 115.91 3.57 Favored 'Trans proline' 0 C--N 1.38 2.204 0 C-N-CA 122.107 1.871 . . . . 61.420000000000002 109.594 169.163 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.569 HD21 HD12 ' A' ' 149' ' ' ILE . 28.7 tp -137.15 127.02 25.69 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.361 0.664 . . . . 74.099999999999994 110.125 -172.779 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.9 p -78.18 167.91 20.67 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.062 0.545 . . . . 75.400000000000006 111.121 -175.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 76.9 mt -65.58 -37.3 86.25 Favored 'General case' 0 C--O 1.246 0.907 0 C-N-CA 123.981 0.913 . . . . 61.299999999999997 111.366 -173.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.47 -51.74 40.21 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 114.694 -1.139 . . . . 72.209999999999994 108.68 -177.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -62.43 -38.08 88.35 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.771 -1.104 . . . . 41.140000000000001 111.793 -178.123 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.39 -47.23 85.06 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 124.074 0.859 . . . . 73.209999999999994 110.453 176.101 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -66.48 -35.23 79.76 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 124.271 0.982 . . . . 75.530000000000001 111.136 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -67.32 -47.66 69.87 Favored 'General case' 0 C--N 1.363 1.18 0 CA-C-O 120.885 0.374 . . . . 73.030000000000001 110.018 177.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.58 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.19 56.01 24.57 Favored Glycine 0 C--N 1.341 0.852 0 CA-C-N 114.584 -1.189 . . . . 62.340000000000003 112.452 -174.259 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -103.3 -141.09 11.15 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 111.873 -0.491 . . . . 60.240000000000002 111.873 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -98.77 141.65 31.3 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.027 -0.731 . . . . 71.140000000000001 109.027 171.148 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.62 ' HG2' HD21 ' A' ' 123' ' ' LEU . 23.1 tpt180 -115.48 119.72 37.13 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.757 -1.201 . . . . 74.540000000000006 107.757 178.218 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 57.7 t -85.71 109.13 18.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 123.273 0.629 . . . . 61.310000000000002 109.519 -177.058 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.43 HG23 HD22 ' A' ' 98' ' ' LEU . 18.2 m -117.83 164.17 14.35 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 C-N-CA 125.609 1.563 . . . . 73.310000000000002 108.429 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -124.66 138.86 54.28 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 118.655 0.661 . . . . 70.409999999999997 111.413 -178.081 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.488 HG13 ' HB2' ' A' ' 143' ' ' ARG . 5.6 p -128.76 107.21 15.39 Favored 'Isoleucine or valine' 0 C--N 1.359 0.987 0 C-N-CA 124.838 1.255 . . . . 71.349999999999994 110.994 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.98 24.51 11.13 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.482 0.713 . . . . 55.520000000000003 112.166 175.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.39 18.09 29.48 Favored Glycine 0 C--N 1.348 1.246 0 CA-C-N 116.288 -0.415 . . . . 31.219999999999999 113.608 -178.282 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.488 ' HB2' HG13 ' A' ' 140' ' ' VAL . 10.8 mmm180 -117.64 123.09 45.29 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 123.773 0.829 . . . . 72.200000000000003 109.891 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.9 tpt180 -84.25 106.35 15.8 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 108.935 -0.765 . . . . 75.219999999999999 108.935 -176.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 88.4 t -115.98 132.17 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.87 0.868 . . . . 72.319999999999993 109.693 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 30.1 m -98.95 112.55 24.63 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.865 0.866 . . . . 74.409999999999997 109.23 176.121 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.486 HG21 HD12 ' A' ' 176' ' ' LEU . 3.8 p -99.72 121.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 124.023 0.929 . . . . 74.010000000000005 109.382 176.496 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -73.1 119.49 17.41 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.021 0.528 . . . . 74.420000000000002 110.182 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.58 HG13 ' HA2' ' A' ' 133' ' ' GLY . 4.9 pt -92.18 142.64 26.43 Favored Pre-proline 0 CA--C 1.563 1.478 0 C-N-CA 124.331 1.052 . . . . 63.030000000000001 109.948 177.571 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -58.84 148.36 84.24 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 123.555 2.837 . . . . 70.340000000000003 113.84 176.514 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.49 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 59.5 Cg_endo -70.31 113.04 3.33 Favored 'Trans proline' 0 C--N 1.377 2.044 0 C-N-CA 122.829 2.352 . . . . 72.319999999999993 111.414 177.408 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.22 39.01 37.93 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.826 -0.624 . . . . 64.319999999999993 112.34 -175.143 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 8.7 p -71.08 144.75 13.18 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 123.159 0.584 . . . . 74.239999999999995 110.143 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.506 ' HA ' HD11 ' A' ' 180' ' ' LEU . 64.6 mtp180 -119.24 177.13 5.01 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 121.766 0.794 . . . . 75.329999999999998 112.821 -171.376 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -64.89 130.25 42.75 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 113.535 -1.666 . . . . 73.510000000000005 111.121 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.52 -5.55 84.83 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-N 115.95 -0.568 . . . . 34.100000000000001 113.92 179.48 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.9 m -75.48 119.67 19.87 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-N 117.29 0.545 . . . . 72.420000000000002 109.742 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.6 t -98.51 116.63 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.069 0.547 . . . . 61.25 109.858 -174.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 57.5 mt -88.25 101.65 11.88 Favored 'Isoleucine or valine' 0 C--O 1.241 0.609 0 N-CA-C 108.074 -1.084 . . . . 73.310000000000002 108.074 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 13.4 ttp180 -91.79 113.79 26.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 114.821 -1.081 . . . . 74.349999999999994 109.477 178.14 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.0 t -114.85 113.83 44.35 Favored Pre-proline 0 CA--C 1.549 0.925 0 N-CA-C 108.922 -0.77 . . . . 72.140000000000001 108.922 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.04 124.23 12.73 Favored 'Trans proline' 0 C--N 1.377 2.065 0 C-N-CA 122.852 2.368 . . . . 62.420000000000002 112.595 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.41 -3.33 85.2 Favored Glycine 0 C--N 1.344 1.01 0 N-CA-C 114.911 0.724 . . . . 64.329999999999998 114.911 171.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.7 tpt -88.06 -7.62 56.72 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 117.622 0.711 . . . . 71.519999999999996 111.037 -175.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -75.81 -111.67 0.11 Allowed Glycine 0 C--N 1.349 1.278 0 N-CA-C 112.057 -0.417 . . . . 74.099999999999994 112.057 175.709 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.65 103.92 1.52 Allowed Glycine 0 C--N 1.344 1.017 0 CA-C-N 117.134 0.467 . . . . 31.219999999999999 113.304 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -65.98 147.89 52.66 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.483 0.713 . . . . 64.209999999999994 110.935 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 140.07 -171.78 23.73 Favored Glycine 0 N--CA 1.473 1.129 0 C-N-CA 123.136 0.398 . . . . 24.25 112.203 -177.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 45.7 m-80 -61.84 -46.15 92.6 Favored Pre-proline 0 CA--C 1.559 1.32 0 CA-C-O 118.394 -0.812 . . . . 71.349999999999994 111.698 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -88.33 103.66 0.46 Allowed 'Trans proline' 0 C--N 1.391 2.77 0 C-N-CA 121.842 1.695 . . . . 71.049999999999997 110.15 163.642 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -76.58 125.02 7.99 Favored 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 122.211 1.94 . . . . 70.219999999999999 110.723 -177.167 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -81.42 148.82 28.31 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 116.1 -0.5 . . . . 40.119999999999997 112.396 -178.503 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -78.19 151.93 32.93 Favored 'General case' 0 C--O 1.247 0.935 0 CA-C-O 121.102 0.477 . . . . 73.510000000000005 110.102 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.47 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 43.3 tp -114.17 131.89 56.29 Favored 'General case' 0 C--O 1.223 -0.334 0 C-N-CA 122.803 0.441 . . . . 73.099999999999994 110.075 177.162 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 73.1 mt -128.2 104.6 7.84 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 124.495 1.118 . . . . 74.209999999999994 108.902 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.486 HD12 HG21 ' A' ' 147' ' ' VAL . 66.6 mt -113.63 105.53 13.43 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.392 0.677 . . . . 64.430000000000007 110.565 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.8 t -84.72 103.8 12.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 109.239 -0.652 . . . . 64.400000000000006 109.239 -175.365 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.4 t -58.84 125.5 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 O-C-N 123.697 0.623 . . . . 61.219999999999999 111.539 -177.508 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -115.12 107.72 15.7 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 125.144 1.377 . . . . 64.319999999999993 107.499 176.038 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.506 HD11 ' HA ' ' A' ' 154' ' ' ARG . 54.1 mt -69.19 110.09 4.39 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.504 -0.925 . . . . 74.439999999999998 108.504 177.056 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 84.9 mt -68.82 129.84 92.11 Favored Pre-proline 0 CA--C 1.544 0.742 0 CA-C-N 115.715 -0.675 . . . . 75.530000000000001 110.013 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -65.43 158.68 51.5 Favored 'Trans proline' 0 C--N 1.369 1.625 0 C-N-CA 122.978 2.452 . . . . 74.010000000000005 111.825 176.329 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.6 t-80 . . . . . 0 CA--C 1.552 1.028 0 C-N-CA 123.509 0.724 . . . . 75.25 110.239 174.243 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 26.6 ptt? . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 118.929 -0.558 . . . . 64.400000000000006 109.726 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER 29.35 82.29 0.21 Allowed Pre-proline 0 N--CA 1.505 2.319 0 C-N-CA 126.024 1.729 . . . . 74.099999999999994 114.482 -178.639 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -70.32 -43.35 2.24 Favored 'Trans proline' 0 C--N 1.38 2.229 0 C-N-CA 122.514 2.143 . . . . 63.340000000000003 112.153 -173.521 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.561 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.3 tp -175.39 145.43 0.75 Allowed 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.175 1.39 . . . . 65.209999999999994 107.804 -176.301 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.561 ' H ' HD12 ' A' ' 97' ' ' LEU . 4.2 tt 52.77 -78.27 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 126.924 2.09 . . . . 71.450000000000003 111.782 -174.589 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.672 ' HA ' HD13 ' A' ' 119' ' ' LEU . 78.2 t80 -57.01 120.71 8.45 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.909 1.283 . . . . 52.039999999999999 112.444 -178.06 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.555 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 88.8 m -138.62 97.97 9.02 Favored Pre-proline 0 CA--C 1.545 0.778 0 C-N-CA 124.287 1.035 . . . . 74.129999999999995 109.17 176.669 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.92 103.01 1.12 Allowed 'Trans proline' 0 C--N 1.367 1.527 0 C-N-CA 122.447 2.098 . . . . 65.209999999999994 111.708 -176.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.7 m -100.2 177.26 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 C-N-CA 124.249 1.02 . . . . 74.239999999999995 111.378 179.207 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 41.7 p -111.17 -10.25 14.31 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 123.705 0.802 . . . . 74.329999999999998 111.367 177.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 44.9 tttm -67.76 -32.51 73.15 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 123.552 0.741 . . . . 70.040000000000006 112.882 -174.105 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -79.28 19.97 5.25 Favored Glycine 0 CA--C 1.535 1.287 0 CA-C-O 119.62 -0.545 . . . . 71.340000000000003 114.377 -176.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 68.5 p -83.99 -58.51 2.75 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.965 0.906 . . . . 70.319999999999993 110.545 178.07 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -179.04 146.48 7.24 Favored Glycine 0 C--N 1.35 1.357 0 CA-C-N 116.114 -0.494 . . . . 51.43 112.869 -177.244 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.81 -153.26 25.19 Favored Glycine 0 C--N 1.35 1.329 0 N-CA-C 111.714 -0.555 . . . . 60.229999999999997 111.714 176.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 47.5 t -76.32 -30.39 57.67 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 123.643 0.777 . . . . 74.310000000000002 110.583 176.678 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -117.43 20.86 10.99 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-N 115.914 -0.584 . . . . 73.150000000000006 111.879 175.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -137.48 140.64 11.48 Favored Glycine 0 C--N 1.344 1.006 0 N-CA-C 110.766 -0.934 . . . . 55.409999999999997 110.766 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.558 ' HA ' ' HG3' ' A' ' 170' ' ' PRO . 95.8 p 53.75 -78.23 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 125.818 1.647 . . . . 64.519999999999996 112.758 -176.168 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -73.56 86.54 0.62 Allowed Glycine 0 CA--C 1.528 0.902 0 N-CA-C 112.254 -0.338 . . . . 53.229999999999997 112.254 176.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 126.34 -33.96 3.33 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-O 120.023 -0.32 . . . . 51.130000000000003 112.841 174.504 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 64.6 m -151.04 150.23 30.49 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 123.005 0.522 . . . . 73.239999999999995 111.491 -175.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.417 ' HA2' ' HG2' ' A' ' 170' ' ' PRO . . . -95.03 -151.3 28.22 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-N 115.271 -0.877 . . . . 50.549999999999997 112.365 172.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.801 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 68.3 mtt180 -85.55 135.88 33.64 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.545 0.738 . . . . 74.019999999999996 109.722 -178.315 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -99.44 107.43 19.64 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.903 -1.147 . . . . 44.520000000000003 107.903 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.672 HD13 ' HA ' ' A' ' 99' ' ' PHE . 13.5 mt -93.63 109.52 21.15 Favored 'General case' 0 C--O 1.22 -0.454 0 N-CA-C 106.769 -1.567 . . . . 74.409999999999997 106.769 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -121.11 107.94 13.21 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.953 0.901 . . . . 72.540000000000006 108.634 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.23 156.3 47.83 Favored 'General case' 0 C--O 1.24 0.6 0 C-N-CA 123.162 0.585 . . . . 73.349999999999994 110.401 -174.273 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -75.66 125.95 30.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.497 1.119 . . . . 75.150000000000006 108.942 179.11 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.575 HD11 ' HG2' ' A' ' 136' ' ' ARG . 26.1 tp -100.66 101.42 15.35 Favored Pre-proline 0 CA--C 1.543 0.681 0 C-N-CA 123.507 0.723 . . . . 43.25 109.331 178.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.64 114.98 4.17 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.251 1.967 . . . . 64.319999999999993 110.002 175.16 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.515 HD21 HD12 ' A' ' 149' ' ' ILE . 18.6 tp -131.89 135.62 46.79 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 108.223 -1.029 . . . . 74.319999999999993 108.223 -173.405 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 38.8 p -81.84 171.59 14.32 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.588 -0.523 . . . . 71.310000000000002 109.588 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 88.7 mt -68.05 -32.73 73.28 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 122.925 0.49 . . . . 74.299999999999997 110.343 176.14 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -69.48 -49.44 54.7 Favored 'General case' 0 N--CA 1.47 0.56 0 O-C-N 124.013 0.82 . . . . 64.239999999999995 109.433 -177.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -68.66 -34.6 75.98 Favored 'General case' 0 N--CA 1.472 0.648 0 O-C-N 124.016 0.823 . . . . 73.319999999999993 111.127 -178.166 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.51 -48.56 81.25 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.908 0.755 . . . . 54.030000000000001 110.599 173.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -65.09 -37.14 86.55 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 124.464 1.106 . . . . 72.430000000000007 110.905 179.275 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -64.2 -42.32 96.69 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 123.635 0.584 . . . . 71.430000000000007 110.136 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 58.63 35.56 81.57 Favored Glycine 0 C--N 1.349 1.251 0 O-C-N 124.234 0.959 . . . . 71.400000000000006 112.326 -174.712 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -87.71 -136.47 5.12 Favored Glycine 0 C--N 1.342 0.888 0 N-CA-C 112.045 -0.422 . . . . 52.530000000000001 112.045 -175.703 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.602 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 15.3 mp0 -111.43 139.77 46.58 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.052 -1.092 . . . . 43.140000000000001 108.052 173.694 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.575 ' HG2' HD11 ' A' ' 123' ' ' LEU . 37.9 tpt85 -112.81 120.51 41.74 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 124.323 1.049 . . . . 70.209999999999994 108.183 -177.195 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 91.2 t -81.39 106.3 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.79 0.836 . . . . 64.150000000000006 109.395 -176.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.53 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 20.4 m -111.35 159.92 11.0 Favored 'Isoleucine or valine' 0 C--O 1.245 0.839 0 C-N-CA 124.516 1.127 . . . . 74.329999999999998 111.113 -174.595 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -93.72 136.94 33.49 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.624 1.17 . . . . 65.450000000000003 109.056 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 1.5 p -151.9 100.35 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 C-N-CA 124.02 0.928 . . . . 74.430000000000007 110.445 176.043 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.02 21.26 11.63 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 113.526 0.936 . . . . 64.200000000000003 113.526 171.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.55 -7.37 55.89 Favored Glycine 0 N--CA 1.479 1.525 0 C-N-CA 123.162 0.41 . . . . 70.25 113.162 -176.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.04 150.2 21.52 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.83 0.852 . . . . 73.099999999999994 109.461 173.749 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 55.7 ttp180 -113.36 108.84 17.77 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 107.282 -1.377 . . . . 72.049999999999997 107.282 176.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.407 ' O ' HG22 ' A' ' 138' ' ' VAL . 70.1 t -121.77 134.48 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 C-N-CA 123.379 0.672 . . . . 72.329999999999998 110.619 -173.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.602 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 29.1 p -95.37 109.21 21.41 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 123.483 0.713 . . . . 41.149999999999999 109.165 176.488 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -98.91 128.24 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.508 0.723 . . . . 71.319999999999993 109.338 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -70.43 122.91 20.52 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 109.287 -0.634 . . . . 72.420000000000002 109.287 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.515 HD12 HD21 ' A' ' 125' ' ' LEU . 4.3 pt -98.69 149.49 35.79 Favored Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 124.875 1.27 . . . . 53.229999999999997 109.623 176.576 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -63.82 143.41 85.98 Favored 'Trans proline' 0 C--N 1.377 2.062 0 C-N-CA 122.77 2.313 . . . . 71.230000000000004 112.755 176.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.35 123.53 10.66 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 122.755 2.303 . . . . 40.509999999999998 111.91 174.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.48 26.71 64.95 Favored Glycine 0 C--N 1.347 1.179 0 CA-C-N 115.849 -0.614 . . . . 71.230000000000004 113.101 -178.444 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 7.4 p -67.68 145.9 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 C-N-CA 123.658 0.783 . . . . 63.119999999999997 111.363 -177.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.505 ' HA ' HD11 ' A' ' 180' ' ' LEU . 60.5 mtp180 -120.13 169.42 10.24 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-O 121.855 0.836 . . . . 75.099999999999994 112.832 -172.158 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -61.12 119.85 9.16 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 113.062 -1.881 . . . . 64.150000000000006 109.623 173.077 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 116.23 -25.4 9.33 Favored Glycine 0 N--CA 1.477 1.377 0 O-C-N 123.325 0.391 . . . . 61.149999999999999 112.583 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.6 m -69.88 123.92 22.71 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.479 0.712 . . . . 54.310000000000002 110.924 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.0 p -100.94 131.08 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 108.666 -0.864 . . . . 71.140000000000001 108.666 172.374 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 34.9 mt -100.05 102.15 13.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 107.859 -1.163 . . . . 71.150000000000006 107.859 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.489 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 51.1 ttp85 -87.73 106.43 18.05 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.538 -0.541 . . . . 72.230000000000004 109.538 175.182 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.1 t -100.48 96.44 5.29 Favored Pre-proline 0 CA--C 1.555 1.173 0 N-CA-C 107.481 -1.303 . . . . 73.299999999999997 107.481 173.361 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.66 143.67 42.58 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.958 2.438 . . . . 71.340000000000003 111.564 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' GLY . . . . . 0.713 ' HA2' ' HB2' ' A' ' 171' ' ' PRO . . . 85.47 -24.79 6.93 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-N 116.068 -0.514 . . . . 63.399999999999999 113.595 177.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.7 mmt -98.73 14.76 27.54 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.956 0.902 . . . . 71.209999999999994 111.013 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.86 -119.94 1.72 Allowed Glycine 0 C--N 1.348 1.21 0 N-CA-C 111.758 -0.537 . . . . 60.049999999999997 111.758 175.648 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.801 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.94 112.8 3.57 Favored Glycine 0 C--N 1.348 1.231 0 CA-C-N 117.11 0.455 . . . . 72.439999999999998 112.453 -177.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -81.53 139.3 35.2 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.581 0.752 . . . . 70.549999999999997 110.502 -177.185 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -173.37 -142.64 3.94 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.509 -1.037 . . . . 75.519999999999996 110.509 -179.187 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.411 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 39.3 t30 -73.81 -49.41 6.11 Favored Pre-proline 0 CA--C 1.563 1.471 0 N-CA-C 109.151 -0.685 . . . . 64.299999999999997 109.151 169.318 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.558 ' HG3' ' HA ' ' A' ' 112' ' ' SER . 93.1 Cg_endo -91.8 135.14 1.58 Allowed 'Trans proline' 0 C--N 1.389 2.709 0 C-N-CA 121.935 1.757 . . . . 72.439999999999998 111.748 165.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.713 ' HB2' ' HA2' ' A' ' 163' ' ' GLY . 55.8 Cg_endo -67.56 128.35 17.99 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.406 2.071 . . . . 61.140000000000001 111.599 172.307 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.27 162.84 32.47 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-N 116.095 -0.502 . . . . 43.340000000000003 113.108 -179.127 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -86.73 145.81 26.51 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.67 0.788 . . . . 65.400000000000006 110.532 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.489 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 42.8 tp -111.21 135.1 52.24 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.835 0.854 . . . . 62.210000000000001 109.288 173.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 66.7 mt -127.67 102.18 6.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.062 1.345 . . . . 54.420000000000002 108.813 178.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 98.1 mt -102.41 101.41 11.63 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.406 0.682 . . . . 73.150000000000006 109.481 177.738 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.7 t -85.66 97.87 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 109.043 -0.725 . . . . 75.129999999999995 109.043 -174.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 86.7 t -57.96 104.87 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 124.415 1.086 . . . . 71.129999999999995 111.47 -176.161 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -98.35 101.64 13.15 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-N 113.803 -1.544 . . . . 74.219999999999999 108.375 170.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.505 HD11 ' HA ' ' A' ' 154' ' ' ARG . 47.3 mt -69.64 126.77 30.73 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.634 -0.506 . . . . 73.129999999999995 109.634 176.509 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 59.5 mt -77.01 140.46 66.56 Favored Pre-proline 0 CA--C 1.548 0.865 0 N-CA-C 108.772 -0.825 . . . . 75.219999999999999 108.772 178.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -49.23 -73.54 0.04 OUTLIER 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 123.994 3.129 . . . . 54.229999999999997 113.165 -174.164 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 . . . . . 0 C--O 1.252 1.192 0 C-N-CA 124.538 1.135 . . . . 73.450000000000003 108.382 177.855 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 11.3 ttt . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 110.222 -0.288 . . . . 64.25 110.222 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.449 ' HG ' ' HA ' ' A' ' 100' ' ' THR . 2.7 tt 66.73 70.89 0.47 Allowed Pre-proline 0 CA--C 1.556 1.21 0 C-N-CA 124.316 1.046 . . . . 62.5 109.601 172.676 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -75.4 -60.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.385 2.495 0 C-N-CA 121.951 1.768 . . . . 74.109999999999999 111.828 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.47 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.2 tp -169.32 135.96 1.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.696 -1.594 . . . . 73.420000000000002 106.696 -173.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.547 HD13 HD11 ' A' ' 176' ' ' LEU . 14.8 tp 70.67 -60.42 0.5 Allowed 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.89 2.076 . . . . 72.019999999999996 112.511 -173.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.706 ' HB2' ' HA ' ' A' ' 140' ' ' VAL . 32.7 t80 -61.45 113.29 2.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.201 1.0 . . . . 72.530000000000001 111.782 179.111 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.449 ' HA ' ' HG ' ' A' ' 95' ' ' LEU . 98.2 m -133.4 95.3 18.29 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 124.045 0.938 . . . . 73.540000000000006 109.575 175.471 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.47 84.25 1.41 Allowed 'Trans proline' 0 C--N 1.369 1.658 0 C-N-CA 122.317 2.011 . . . . 73.230000000000004 112.802 -175.591 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.43 HG13 HG22 ' A' ' 100' ' ' THR . 23.3 m -86.55 167.09 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-N 115.062 -0.972 . . . . 64.409999999999997 110.57 177.325 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.4 t -115.79 37.59 3.57 Favored 'General case' 0 CA--C 1.553 1.072 0 C-N-CA 123.205 0.602 . . . . 71.219999999999999 109.568 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.452 ' HA ' ' HE3' ' A' ' 104' ' ' LYS . 0.5 OUTLIER 72.18 -70.46 0.16 Allowed 'General case' 0 N--CA 1.49 1.539 0 C-N-CA 125.018 1.327 . . . . 64.540000000000006 109.946 -172.838 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 176.82 156.93 16.75 Favored Glycine 0 C--N 1.343 0.933 0 O-C-N 123.041 0.213 . . . . 75.230000000000004 112.83 176.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 67.4 m -80.97 -26.84 36.27 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 123.735 0.814 . . . . 74.049999999999997 110.732 172.304 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.21 158.71 51.96 Favored Glycine 0 C--N 1.348 1.228 0 O-C-N 124.071 0.857 . . . . 63.030000000000001 112.271 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -55.93 113.31 3.86 Favored Glycine 0 C--N 1.347 1.193 0 O-C-N 124.299 0.647 . . . . 41.049999999999997 112.404 178.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 12.1 m -77.11 -10.21 59.24 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 123.307 0.643 . . . . 71.219999999999999 111.314 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 80.18 -70.9 2.86 Favored Glycine 0 C--N 1.357 1.718 0 C-N-CA 123.174 0.416 . . . . 62.5 112.416 178.392 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -165.81 -137.78 2.28 Favored Glycine 0 C--N 1.341 0.814 0 N-CA-C 110.547 -1.021 . . . . 72.019999999999996 110.547 176.245 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 63.2 p -76.67 -5.76 49.28 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.168 0.587 . . . . 71.150000000000006 112.249 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -83.46 60.97 4.82 Favored Glycine 0 C--N 1.355 1.624 0 O-C-N 123.534 0.521 . . . . 55.329999999999998 113.189 -176.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -144.9 154.67 26.03 Favored Glycine 0 C--N 1.34 0.803 0 N-CA-C 110.372 -1.091 . . . . 73.140000000000001 110.372 176.785 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 27.2 m -93.8 -167.29 1.66 Allowed 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 123.215 0.606 . . . . 64.129999999999995 110.447 178.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -80.73 -159.88 22.29 Favored Glycine 0 C--N 1.344 0.974 0 N-CA-C 115.253 0.861 . . . . 70.439999999999998 115.253 -173.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 -68.89 128.55 37.08 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 108.64 -0.874 . . . . 71.430000000000007 108.64 -177.055 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -96.87 106.19 18.46 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 106.801 -1.555 . . . . 60.119999999999997 106.801 -178.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 15.7 mt -92.71 107.13 18.98 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 106.297 -1.742 . . . . 71.0 106.297 -172.127 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.504 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 59.6 ttt-85 -114.99 105.97 13.6 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.008 -1.108 . . . . 74.049999999999997 108.008 -176.685 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.52 146.67 50.43 Favored 'General case' 0 C--O 1.24 0.601 0 N-CA-C 108.742 -0.836 . . . . 61.030000000000001 108.742 -179.094 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -71.84 131.35 42.91 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 108.621 -0.881 . . . . 70.409999999999997 108.621 173.049 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.544 HD21 ' HG2' ' A' ' 136' ' ' ARG . 1.5 tt -98.4 103.27 17.41 Favored Pre-proline 0 CA--C 1.532 0.275 0 N-CA-C 106.352 -1.721 . . . . 73.230000000000004 106.352 176.431 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.474 ' HB2' HD11 ' A' ' 181' ' ' LEU . 50.5 Cg_endo -65.61 116.0 3.69 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 121.935 1.757 . . . . 74.349999999999994 109.786 174.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.464 HD21 HD12 ' A' ' 149' ' ' ILE . 15.6 tp -147.75 120.32 8.55 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.395 -0.595 . . . . 60.119999999999997 109.395 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.455 HG22 ' HB2' ' A' ' 181' ' ' LEU . 71.4 p -77.13 168.04 20.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.807 0.443 . . . . 51.43 111.724 -177.288 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.3 mt -55.64 -47.2 77.02 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 123.872 0.869 . . . . 74.129999999999995 112.137 -177.388 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -66.71 -41.4 88.02 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 115.959 -0.564 . . . . 74.299999999999997 111.279 -178.576 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -68.31 -31.86 71.59 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 122.91 0.484 . . . . 52.329999999999998 111.592 178.165 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -72.21 -39.38 68.59 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 123.337 0.655 . . . . 61.439999999999998 111.07 177.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -63.21 -56.52 15.93 Favored 'General case' 0 N--CA 1.472 0.628 0 O-C-N 124.619 1.199 . . . . 61.229999999999997 110.011 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 50.3 m80 -70.24 -34.96 73.49 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.469 -0.787 . . . . 71.010000000000005 111.16 -177.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 68.94 -135.35 28.07 Favored Glycine 0 C--N 1.353 1.513 0 N-CA-C 111.949 -0.46 . . . . 33.520000000000003 111.949 -177.29 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.49 -143.28 16.5 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 112.201 -0.36 . . . . 62.439999999999998 112.201 178.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -104.44 148.36 26.52 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.237 0.541 . . . . 71.310000000000002 111.31 -178.604 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.544 ' HG2' HD21 ' A' ' 123' ' ' LEU . 2.2 tpp180 -137.16 119.1 15.28 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 106.741 -1.577 . . . . 74.430000000000007 106.741 175.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.59 115.97 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.704 0 CA-C-O 121.864 0.84 . . . . 75.409999999999997 109.801 -174.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 11.4 m -122.7 164.33 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.981 1.312 . . . . 74.030000000000001 108.828 -171.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -123.16 125.42 45.1 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 118.457 0.571 . . . . 74.409999999999997 111.936 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.706 ' HA ' ' HB2' ' A' ' 99' ' ' PHE . 4.0 p -113.52 111.37 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.368 1.067 . . . . 62.119999999999997 110.17 175.888 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.34 26.3 14.97 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 123.807 0.843 . . . . 61.520000000000003 112.854 172.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.86 -12.03 60.84 Favored Glycine 0 C--N 1.352 1.421 0 CA-C-N 116.51 -0.314 . . . . 53.450000000000003 113.104 -177.249 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.1 tpp180 -92.22 115.86 28.44 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.637 0.775 . . . . 75.409999999999997 110.03 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 3.1 tpp180 -87.0 106.95 18.19 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.934 -0.765 . . . . 65.239999999999995 108.934 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 34.4 m -116.22 156.35 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 C-N-CA 123.911 0.884 . . . . 73.140000000000001 110.923 -178.785 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.0 p -91.32 141.95 28.22 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.53 0.732 . . . . 61.0 110.099 175.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 43.2 t -128.38 111.51 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 C-N-CA 124.747 1.219 . . . . 74.239999999999995 108.855 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -80.07 102.32 9.26 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.446 0.641 . . . . 60.420000000000002 109.417 178.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.464 HD12 HD21 ' A' ' 125' ' ' LEU . 16.5 pt -82.74 131.66 53.99 Favored Pre-proline 0 CA--C 1.559 1.296 0 CA-C-N 114.81 -1.086 . . . . 75.430000000000007 109.907 178.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 37.1 Cg_exo -64.22 135.86 48.87 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 122.656 2.237 . . . . 55.130000000000003 113.437 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -67.04 121.32 8.48 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 122.345 2.03 . . . . 52.310000000000002 110.742 168.63 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 87.82 27.47 26.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 115.549 -0.75 . . . . 73.230000000000004 113.22 -172.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.66 142.88 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 117.443 0.622 . . . . 64.409999999999997 109.74 176.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -112.7 177.6 4.58 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 121.635 0.731 . . . . 72.409999999999997 112.407 -172.149 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -65.02 133.49 51.79 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 113.56 -1.654 . . . . 62.439999999999998 110.644 176.612 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 83.8 -14.02 44.96 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-O 119.24 -0.755 . . . . 53.340000000000003 113.353 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 68.4 m -66.28 117.79 9.05 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 117.422 0.611 . . . . 63.310000000000002 109.667 -175.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.21 133.57 33.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 CA-C-O 121.362 0.601 . . . . 75.319999999999993 110.001 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.538 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 94.0 mt -99.95 102.3 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 N-CA-C 106.519 -1.66 . . . . 72.040000000000006 106.519 177.145 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.536 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 61.1 ttp85 -99.31 110.18 22.73 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.354 -0.385 . . . . 70.439999999999998 110.184 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.93 100.55 10.05 Favored Pre-proline 0 CA--C 1.557 1.241 0 N-CA-C 107.525 -1.287 . . . . 72.409999999999997 107.525 170.23 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.45 136.7 29.17 Favored 'Trans proline' 0 C--N 1.376 1.976 0 C-N-CA 122.937 2.424 . . . . 75.409999999999997 112.637 -173.073 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.15 -21.82 11.37 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.889 -0.596 . . . . 64.219999999999999 113.883 177.146 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 56.8 mtt -100.52 16.42 24.74 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 123.563 0.745 . . . . 74.209999999999994 111.402 -173.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' GLY . . . . . 0.584 ' HA2' HD13 ' A' ' 174' ' ' LEU . . . -85.27 -103.45 0.67 Allowed Glycine 0 C--N 1.351 1.407 0 CA-C-N 116.196 -0.457 . . . . 74.230000000000004 112.236 176.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -66.86 103.18 0.86 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.807 -0.517 . . . . 25.219999999999999 111.807 175.529 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -88.61 152.7 21.67 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.704 0.801 . . . . 73.099999999999994 110.419 -179.115 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 134.17 -137.0 8.96 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.462 -1.055 . . . . 74.25 110.462 -172.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.533 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 14.9 m120 -71.97 -56.48 4.55 Favored Pre-proline 0 CA--C 1.563 1.479 0 CA-C-N 117.704 0.752 . . . . 73.25 111.243 176.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.533 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -93.82 119.64 0.34 Allowed 'Trans proline' 0 C--N 1.396 3.041 0 C-N-CA 122.443 2.095 . . . . 53.200000000000003 112.434 178.388 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -63.03 125.2 15.36 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.82 2.347 . . . . 73.430000000000007 112.271 174.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.83 173.77 23.89 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 116.576 -0.284 . . . . 74.319999999999993 112.472 177.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -95.05 134.93 37.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.082 0.553 . . . . 62.43 109.878 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.584 HD13 ' HA2' ' A' ' 165' ' ' GLY . 17.1 tp -97.79 119.36 36.25 Favored 'General case' 0 C--O 1.216 -0.673 0 N-CA-C 107.989 -1.115 . . . . 73.420000000000002 107.989 -178.533 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 65.6 mt -123.48 120.15 32.06 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.761 0.824 . . . . 71.340000000000003 109.598 -170.108 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.547 HD11 HD13 ' A' ' 98' ' ' LEU . 41.9 mt -123.0 101.12 7.24 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 123.254 0.622 . . . . 74.340000000000003 110.937 177.323 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.1 t -85.84 96.38 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 108.409 -0.96 . . . . 70.239999999999995 108.409 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.8 t -56.02 126.51 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.199 1.0 . . . . 53.149999999999999 111.721 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.8 mmm-85 -112.87 110.01 19.83 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.786 -1.191 . . . . 75.030000000000001 107.786 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 46.0 mt -70.67 96.04 1.17 Allowed 'General case' 0 C--O 1.238 0.481 0 N-CA-C 109.408 -0.59 . . . . 71.439999999999998 109.408 178.374 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.474 HD11 ' HB2' ' A' ' 124' ' ' PRO . 80.4 mt -71.56 149.3 93.4 Favored Pre-proline 0 C--O 1.246 0.873 0 CA-C-N 114.711 -1.131 . . . . 62.340000000000003 110.445 -179.284 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -57.86 142.86 96.52 Favored 'Trans proline' 0 C--N 1.372 1.801 0 C-N-CA 122.557 2.171 . . . . 71.530000000000001 111.656 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 27.9 p80 . . . . . 0 CA--C 1.558 1.265 0 C-N-CA 123.543 0.737 . . . . 74.310000000000002 111.328 179.228 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 120.951 0.405 . . . . 63.32 110.377 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.454 ' H ' HD23 ' A' ' 95' ' ' LEU . 1.3 pt? -107.7 112.59 62.05 Favored Pre-proline 0 CA--C 1.545 0.776 0 CA-C-N 115.237 -0.892 . . . . 73.109999999999999 110.251 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_exo -73.34 -160.9 0.1 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 122.8 2.333 . . . . 72.510000000000005 111.25 167.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.541 HD12 ' H ' ' A' ' 98' ' ' LEU . 9.1 tp -72.04 141.47 49.28 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.819 -0.808 . . . . 71.230000000000004 108.819 171.532 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.677 HD13 HG21 ' A' ' 138' ' ' VAL . 6.0 tp 65.58 -68.16 0.12 Allowed 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 126.83 2.052 . . . . 45.310000000000002 111.579 -174.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.592 ' HA ' HD13 ' A' ' 119' ' ' LEU . 59.8 t80 -59.78 127.83 33.91 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.213 1.005 . . . . 70.409999999999997 111.708 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.502 HG22 HG13 ' A' ' 102' ' ' VAL . 56.3 m -141.75 104.61 5.81 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 124.086 0.954 . . . . 74.099999999999994 109.228 175.116 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.1 87.1 1.05 Allowed 'Trans proline' 0 C--N 1.362 1.278 0 C-N-CA 122.299 2.0 . . . . 60.310000000000002 112.97 -170.284 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.502 HG13 HG22 ' A' ' 100' ' ' THR . 22.8 m -113.37 170.81 4.18 Favored 'Isoleucine or valine' 0 C--O 1.239 0.525 0 CA-C-N 114.451 -1.25 . . . . 73.319999999999993 109.846 174.608 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.8 t -159.59 146.67 16.71 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 123.933 0.893 . . . . 52.350000000000001 109.392 173.105 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 32.0 mtmm -122.28 98.37 5.9 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.561 -0.903 . . . . 74.430000000000007 108.561 177.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -100.88 -114.21 3.71 Favored Glycine 0 N--CA 1.477 1.395 0 CA-C-O 119.185 -0.786 . . . . 62.25 111.558 177.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 78.0 p 48.16 55.12 9.19 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 125.646 1.578 . . . . 63.32 111.963 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 72.24 -93.6 0.61 Allowed Glycine 0 C--N 1.342 0.875 0 N-CA-C 110.439 -1.064 . . . . 70.019999999999996 110.439 -169.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 64.35 73.9 0.52 Allowed Glycine 0 C--N 1.351 1.379 0 O-C-N 123.83 0.371 . . . . 43.310000000000002 112.867 176.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.3 m -65.14 -45.73 83.83 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.839 0.855 . . . . 75.319999999999993 111.893 -173.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 75.78 -95.18 1.0 Allowed Glycine 0 C--N 1.347 1.139 0 CA-C-N 115.703 -0.68 . . . . 41.420000000000002 112.782 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 88.57 -7.85 80.7 Favored Glycine 0 C--N 1.346 1.107 0 N-CA-C 114.054 0.382 . . . . 40.340000000000003 114.054 179.204 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.6 t -158.17 137.45 11.7 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.299 0.64 . . . . 72.230000000000004 110.256 -176.522 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.68 -174.78 41.99 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 123.574 0.546 . . . . 72.549999999999997 113.877 176.039 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.01 -87.51 1.15 Allowed Glycine 0 C--N 1.342 0.9 0 CA-C-O 119.653 -0.526 . . . . 21.449999999999999 111.971 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.0 m 59.78 47.8 9.88 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 124.211 1.004 . . . . 71.239999999999995 111.436 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -68.85 -112.6 0.02 OUTLIER Glycine 0 CA--C 1.528 0.888 0 CA-C-N 115.035 -0.984 . . . . 74.439999999999998 112.598 176.321 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 42.9 mtt180 -98.26 135.29 40.1 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.072 0.549 . . . . 74.239999999999995 109.775 174.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -98.91 104.17 16.19 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.873 -1.529 . . . . 71.230000000000004 106.873 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.592 HD13 ' HA ' ' A' ' 99' ' ' PHE . 11.5 mt -92.71 110.44 21.88 Favored 'General case' 0 C--N 1.343 0.323 0 N-CA-C 106.633 -1.617 . . . . 65.209999999999994 106.633 -173.402 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -117.76 108.55 15.52 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 108.975 -0.75 . . . . 75.340000000000003 108.975 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.48 154.02 51.15 Favored 'General case' 0 C--O 1.24 0.592 0 C-N-CA 123.193 0.597 . . . . 32.439999999999998 110.682 -171.601 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -72.13 131.58 43.0 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.291 -0.868 . . . . 60.229999999999997 109.109 173.207 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.627 HD21 ' HG2' ' A' ' 136' ' ' ARG . 2.4 tt -101.47 102.61 22.59 Favored Pre-proline 0 CA--C 1.544 0.733 0 N-CA-C 107.949 -1.13 . . . . 73.430000000000007 107.949 176.047 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.74 115.79 3.94 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 121.928 1.752 . . . . 71.510000000000005 110.019 173.143 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 46.3 tp -142.75 131.52 22.73 Favored 'General case' 0 C--O 1.225 -0.194 0 C-N-CA 123.648 0.779 . . . . 71.129999999999995 109.012 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 55.0 p -80.13 163.61 23.98 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 122.865 0.466 . . . . 74.230000000000004 111.286 -176.745 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.9 mt -58.77 -51.82 68.35 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.666 0.787 . . . . 74.299999999999997 112.826 -171.204 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -64.83 -40.13 94.68 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 122.742 0.417 . . . . 74.019999999999996 111.109 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -69.49 -26.04 64.35 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 112.288 0.477 . . . . 74.030000000000001 112.288 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -69.11 -46.68 67.1 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 123.619 0.768 . . . . 63.210000000000001 109.743 172.096 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -61.93 -42.03 98.63 Favored 'General case' 0 CA--C 1.546 0.801 0 CA-C-N 114.614 -1.176 . . . . 64.409999999999997 111.039 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.4 m80 -72.97 -42.2 63.6 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 122.804 0.442 . . . . 72.340000000000003 110.317 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.85 -128.76 9.79 Favored Glycine 0 C--N 1.345 1.032 0 CA-C-N 115.309 -0.86 . . . . 53.130000000000003 111.308 -172.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.416 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 80.38 -158.5 41.79 Favored Glycine 0 C--N 1.348 1.24 0 CA-C-N 116.834 0.317 . . . . 43.530000000000001 112.805 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -84.0 147.16 27.59 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 117.329 0.564 . . . . 71.129999999999995 109.763 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.627 ' HG2' HD21 ' A' ' 123' ' ' LEU . 27.0 tpt180 -128.33 121.2 28.63 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.433 0.693 . . . . 73.219999999999999 109.178 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.416 HG13 ' HG3' ' A' ' 144' ' ' ARG . 93.1 t -79.22 106.87 10.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.455 0 C-N-CA 123.975 0.91 . . . . 73.030000000000001 109.265 178.055 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.677 HG21 HD13 ' A' ' 98' ' ' LEU . 20.7 m -111.13 159.64 10.97 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 123.863 0.865 . . . . 74.129999999999995 109.377 176.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -116.79 138.12 51.72 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 107.703 -1.221 . . . . 73.239999999999995 107.703 -176.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.572 HG13 ' HB2' ' A' ' 143' ' ' ARG . 3.7 p -150.15 107.12 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 C-N-CA 123.212 0.605 . . . . 60.530000000000001 111.498 -176.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.18 20.6 8.63 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 113.359 0.874 . . . . 44.5 113.359 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.9 28.31 7.87 Favored Glycine 0 C--N 1.344 0.976 0 C-N-CA 122.903 0.287 . . . . 73.120000000000005 112.582 -175.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.572 ' HB2' HG13 ' A' ' 140' ' ' VAL . 82.3 mtt85 -133.68 156.64 47.55 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 123.533 0.733 . . . . 74.129999999999995 110.095 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.416 ' HG3' HG13 ' A' ' 137' ' ' VAL . 31.6 ttm180 -109.86 119.77 40.39 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.754 0.822 . . . . 75.439999999999998 109.169 170.457 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.404 ' O ' HG22 ' A' ' 138' ' ' VAL . 69.8 t -115.69 135.63 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 108.421 -0.955 . . . . 53.240000000000002 108.421 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 28.9 p -103.2 104.78 14.96 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 109.141 -0.688 . . . . 72.030000000000001 109.141 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 4.7 p -98.3 120.29 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 109.172 -0.677 . . . . 74.319999999999993 109.172 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 47.3 ttp180 -78.21 100.37 6.62 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-O 121.415 0.626 . . . . 74.200000000000003 109.33 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.562 HD13 ' HB2' ' A' ' 136' ' ' ARG . 3.1 pt -79.55 144.9 62.03 Favored Pre-proline 0 CA--C 1.563 1.449 0 CA-C-N 114.639 -1.164 . . . . 72.329999999999998 109.766 178.444 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -61.93 136.82 63.71 Favored 'Trans proline' 0 CA--C 1.562 1.891 0 C-N-CA 123.005 2.47 . . . . 52.43 113.393 -179.033 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -62.18 113.12 1.76 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.948 2.432 . . . . 55.219999999999999 111.179 172.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.47 35.51 8.59 Favored Glycine 0 C--N 1.34 0.765 0 O-C-N 123.616 0.573 . . . . 72.409999999999997 112.379 -176.241 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.415 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 12.6 p -76.65 145.85 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 N-CA-C 109.818 -0.438 . . . . 70.239999999999995 109.818 176.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -118.39 177.15 4.92 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.651 0.739 . . . . 75.140000000000001 112.636 -171.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -64.68 135.05 55.47 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 113.989 -1.459 . . . . 63.420000000000002 110.974 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.22 -6.13 64.73 Favored Glycine 0 C--N 1.343 0.959 0 CA-C-N 115.767 -0.652 . . . . 75.099999999999994 113.646 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 56.0 m -74.85 118.89 18.31 Favored 'General case' 0 C--N 1.351 0.647 0 CA-C-N 117.502 0.651 . . . . 72.430000000000007 109.506 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.0 p -99.05 134.25 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 123.087 0.555 . . . . 64.010000000000005 110.413 -177.136 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 67.7 mt -105.94 105.87 19.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 C-N-CA 124.328 1.051 . . . . 73.140000000000001 108.71 -175.125 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 58.0 ttm-85 -87.96 111.86 21.94 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.81 0.444 . . . . 74.409999999999997 110.405 -178.318 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -123.95 98.95 38.66 Favored Pre-proline 0 CA--C 1.554 1.124 0 C-N-CA 123.942 0.897 . . . . 72.439999999999998 109.0 179.308 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.28 131.75 21.13 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.488 2.126 . . . . 75.319999999999993 112.22 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.89 -23.17 37.07 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.761 -0.654 . . . . 52.509999999999998 113.56 176.099 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.2 mpt? -89.57 6.56 40.55 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.107 0.563 . . . . 74.239999999999995 111.288 178.004 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -85.51 -108.37 0.7 Allowed Glycine 0 C--N 1.344 1.001 0 N-CA-C 111.556 -0.617 . . . . 74.319999999999993 111.556 174.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.6 108.93 2.64 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 112.286 -0.326 . . . . 74.349999999999994 112.286 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 15.1 mm-40 -88.36 148.46 24.24 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.194 0.598 . . . . 63.100000000000001 110.885 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.48 -138.51 8.49 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 111.062 -0.815 . . . . 73.510000000000005 111.062 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.457 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 3.4 m-20 -78.41 -49.16 1.82 Allowed Pre-proline 0 CA--C 1.566 1.578 0 CA-C-O 118.29 -0.862 . . . . 44.340000000000003 110.644 175.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.457 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -94.97 106.41 0.12 Allowed 'Trans proline' 0 C--N 1.396 3.034 0 C-N-CA 122.658 2.238 . . . . 63.229999999999997 111.905 172.09 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.37 125.23 13.63 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 122.025 1.817 . . . . 70.510000000000005 111.456 174.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -99.97 173.96 26.06 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 116.041 -0.527 . . . . 72.120000000000005 111.975 175.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -92.48 152.57 19.6 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 123.309 0.644 . . . . 72.310000000000002 110.663 -174.076 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.463 HD21 HD11 ' A' ' 98' ' ' LEU . 59.3 tp -114.23 133.76 55.4 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.901 0.88 . . . . 53.43 109.75 179.011 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.3 mt -129.85 103.46 6.82 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.021 0.928 . . . . 63.240000000000002 110.428 176.56 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.602 HD21 HD12 ' A' ' 98' ' ' LEU . 82.8 mt -101.77 103.18 13.9 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 123.072 0.549 . . . . 72.299999999999997 111.212 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.9 t -84.11 97.68 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 N-CA-C 108.954 -0.758 . . . . 64.310000000000002 108.954 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 89.5 t -57.03 130.26 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 124.024 0.93 . . . . 71.510000000000005 111.436 -178.199 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -121.4 105.32 10.4 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 125.068 1.347 . . . . 63.399999999999999 107.912 -177.21 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 24.1 mt -70.32 109.8 4.92 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.377 -0.601 . . . . 63.229999999999997 109.377 178.337 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.8 mt -72.27 149.97 91.82 Favored Pre-proline 0 CA--C 1.549 0.942 0 C-N-CA 123.062 0.545 . . . . 75.219999999999999 110.097 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -58.93 97.49 0.09 OUTLIER 'Trans proline' 0 C--N 1.376 2.005 0 C-N-CA 122.898 2.399 . . . . 61.329999999999998 110.98 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 124.772 1.229 . . . . 64.239999999999995 109.702 -172.574 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 22.6 ptt? . . . . . 0 N--CA 1.482 1.139 0 CA-C-O 120.432 0.158 . . . . 71.329999999999998 111.019 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 tt 63.26 74.08 0.47 Allowed Pre-proline 0 CA--C 1.556 1.202 0 C-N-CA 124.858 1.263 . . . . 71.239999999999995 111.664 166.429 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -90.81 -152.04 0.04 OUTLIER 'Trans proline' 0 CA--C 1.553 1.434 0 C-N-CA 122.827 2.351 . . . . 73.439999999999998 111.101 168.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.584 HD12 ' H ' ' A' ' 98' ' ' LEU . 12.1 tp -74.69 144.52 43.71 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.961 0.905 . . . . 73.239999999999995 109.41 175.24 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.603 HD13 HG21 ' A' ' 138' ' ' VAL . 9.0 tp 64.4 -67.79 0.11 Allowed 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.731 2.412 . . . . 74.209999999999994 112.002 -171.422 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.713 ' HA ' HD13 ' A' ' 119' ' ' LEU . 60.7 t80 -64.58 130.01 42.01 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.411 1.084 . . . . 75.310000000000002 111.531 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.473 HG22 HG13 ' A' ' 102' ' ' VAL . 39.7 m -146.09 98.29 4.39 Favored Pre-proline 0 CA--C 1.54 0.58 0 C-N-CA 124.679 1.192 . . . . 75.140000000000001 108.766 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.26 87.11 0.92 Allowed 'Trans proline' 0 C--N 1.366 1.471 0 C-N-CA 122.192 1.928 . . . . 72.010000000000005 112.554 -171.538 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.473 HG13 HG22 ' A' ' 100' ' ' THR . 14.7 m -98.42 152.12 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 C-N-CA 124.332 1.053 . . . . 71.329999999999998 108.745 173.362 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -102.81 -24.62 13.7 Favored 'General case' 0 C--O 1.244 0.781 0 C-N-CA 123.275 0.63 . . . . 61.409999999999997 111.341 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.8 pptp? -85.56 162.64 18.79 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-O 121.386 0.612 . . . . 73.200000000000003 110.818 -171.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 175.14 171.08 38.86 Favored Glycine 0 C--N 1.337 0.638 0 CA-C-N 115.029 -0.987 . . . . 53.340000000000003 111.375 176.611 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 44.7 t -74.13 -7.16 51.58 Favored 'General case' 0 CA--C 1.553 1.078 0 C-N-CA 123.553 0.741 . . . . 50.310000000000002 111.38 178.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.13 54.25 4.71 Favored Glycine 0 C--N 1.356 1.647 0 C-N-CA 123.142 0.401 . . . . 64.030000000000001 113.126 177.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.8 24.25 0.42 Allowed Glycine 0 C--N 1.341 0.826 0 N-CA-C 109.88 -1.288 . . . . 71.540000000000006 109.88 173.349 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.8 t -157.63 -43.39 0.07 Allowed 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 124.788 1.235 . . . . 65.129999999999995 109.138 -176.712 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 156.22 -169.78 33.79 Favored Glycine 0 C--N 1.355 1.633 0 CA-C-N 115.959 -0.564 . . . . 72.329999999999998 112.408 177.584 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 151.92 165.12 12.79 Favored Glycine 0 CA--C 1.529 0.915 0 C-N-CA 122.686 0.184 . . . . 71.310000000000002 112.914 176.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.3 m -71.01 90.41 0.83 Allowed 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.6 0.76 . . . . 64.239999999999995 109.668 174.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 88.72 -43.66 3.1 Favored Glycine 0 C--N 1.349 1.261 0 CA-C-N 115.929 -0.578 . . . . 74.439999999999998 111.719 -171.029 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 135.01 -167.37 24.09 Favored Glycine 0 C--N 1.343 0.945 0 N-CA-C 110.471 -1.051 . . . . 75.150000000000006 110.471 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 46.8 m -148.95 125.52 11.02 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.088 -0.708 . . . . 53.409999999999997 109.088 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -83.62 -140.16 4.11 Favored Glycine 0 CA--C 1.531 1.051 0 N-CA-C 112.199 -0.36 . . . . 62.109999999999999 112.199 175.305 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.651 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 37.5 mtm180 -90.08 141.27 28.85 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 123.672 0.789 . . . . 61.340000000000003 109.495 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -99.8 107.49 19.54 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 108.188 -1.041 . . . . 62.100000000000001 108.188 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.713 HD13 ' HA ' ' A' ' 99' ' ' PHE . 16.4 mt -93.63 111.05 22.66 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 107.64 -1.244 . . . . 60.140000000000001 107.64 -175.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.3 ttp85 -114.6 105.61 13.28 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 108.896 -0.779 . . . . 73.340000000000003 108.896 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 145.66 50.96 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 123.68 0.792 . . . . 45.399999999999999 109.633 -175.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.504 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 3.2 mp0 -74.16 131.73 41.55 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 123.667 0.787 . . . . 54.25 109.225 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.532 HD11 ' HG2' ' A' ' 136' ' ' ARG . 40.9 tp -100.12 102.89 19.57 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 124.29 1.036 . . . . 71.099999999999994 109.134 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -67.86 114.56 3.39 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 122.274 1.982 . . . . 70.140000000000001 109.956 176.415 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.538 HD21 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -143.86 131.43 21.15 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.066 -0.716 . . . . 74.099999999999994 109.066 -171.339 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.8 p -80.52 170.51 16.25 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 110.296 -0.261 . . . . 62.119999999999997 110.296 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 84.8 mt -61.37 -34.74 75.83 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.837 0.855 . . . . 72.409999999999997 111.157 -178.257 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -72.79 -51.67 18.07 Favored 'General case' 0 C--N 1.345 0.379 0 CA-C-N 114.776 -1.102 . . . . 75.340000000000003 108.803 -176.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -66.94 -26.72 66.98 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.01 -0.996 . . . . 61.009999999999998 111.575 -176.272 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.447 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -74.87 -50.47 16.89 Favored 'General case' 0 C--N 1.348 0.521 0 C-N-CA 123.901 0.88 . . . . 55.0 111.375 176.102 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -58.61 -46.15 87.66 Favored 'General case' 0 C--N 1.361 1.068 0 O-C-N 124.308 1.005 . . . . 72.049999999999997 110.664 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -77.78 -40.63 40.11 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.279 -0.873 . . . . 74.420000000000002 111.033 -176.418 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.58 -164.53 50.9 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 111.828 -0.509 . . . . 63.130000000000003 111.828 -175.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.471 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 119.49 -161.11 14.18 Favored Glycine 0 N--CA 1.473 1.12 0 N-CA-C 111.774 -0.53 . . . . 62.119999999999997 111.774 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -81.52 141.63 33.63 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.046 0.539 . . . . 75.230000000000004 110.253 177.356 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.532 ' HG2' HD11 ' A' ' 123' ' ' LEU . 19.4 tpp180 -126.75 121.28 31.56 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.969 0.908 . . . . 60.439999999999998 108.768 178.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 56.0 t -81.28 107.63 13.72 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 C-N-CA 123.339 0.656 . . . . 75.230000000000004 109.614 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.603 HG21 HD13 ' A' ' 98' ' ' LEU . 25.5 m -116.37 164.63 12.53 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 C-N-CA 125.297 1.439 . . . . 72.200000000000003 109.318 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -122.41 131.48 53.9 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 123.446 0.699 . . . . 64.420000000000002 109.575 -171.33 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.415 ' HB ' HD23 ' A' ' 98' ' ' LEU . 5.2 p -142.54 102.41 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.321 0 C-N-CA 124.211 1.004 . . . . 72.219999999999999 111.656 -174.002 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.55 25.93 14.86 Favored 'General case' 0 N--CA 1.493 1.681 0 C-N-CA 124.229 1.012 . . . . 74.510000000000005 112.759 175.139 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.56 -0.8 53.01 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 123.901 0.762 . . . . 55.509999999999998 113.438 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.4 ' HB2' HG13 ' A' ' 140' ' ' VAL . 31.5 mmm180 -104.07 141.89 35.42 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.421 0.689 . . . . 64.340000000000003 110.367 -177.458 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -97.81 113.89 25.8 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.753 0.821 . . . . 73.150000000000006 109.284 178.306 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 73.6 t -118.51 129.6 74.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 123.859 0.864 . . . . 74.010000000000005 109.561 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 33.5 p -97.39 106.58 18.92 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 109.063 -0.717 . . . . 73.329999999999998 109.063 174.155 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.3 p -98.7 125.9 51.99 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 123.494 0.717 . . . . 71.409999999999997 109.76 -177.349 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.2 ttt180 -81.99 105.06 12.79 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.379 0.672 . . . . 70.219999999999999 109.62 -177.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.538 HD12 HD21 ' A' ' 125' ' ' LEU . 4.8 pt -87.24 146.03 39.18 Favored Pre-proline 0 C--O 1.253 1.265 0 C-N-CA 124.68 1.192 . . . . 74.420000000000002 109.343 176.493 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.455 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 57.0 Cg_endo -72.04 143.09 39.69 Favored 'Trans proline' 0 CA--C 1.56 1.799 0 C-N-CA 122.441 2.094 . . . . 72.239999999999995 112.76 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.39 130.49 22.53 Favored 'Trans proline' 0 C--N 1.375 1.941 0 C-N-CA 122.493 2.129 . . . . 52.340000000000003 111.262 171.34 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.82 27.57 45.73 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 115.548 -0.751 . . . . 51.409999999999997 112.243 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.455 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 12.4 p -76.62 147.71 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 108.989 -0.745 . . . . 51.030000000000001 108.989 176.737 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.0 mtp180 -125.12 176.06 6.96 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-O 121.993 0.901 . . . . 72.319999999999993 112.591 -166.171 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -64.42 123.9 20.38 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-N 113.292 -1.776 . . . . 71.400000000000006 110.332 175.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.54 89.55 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.798 0.686 . . . . 33.420000000000002 113.611 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.3 m -76.54 118.49 19.25 Favored 'General case' 0 C--N 1.35 0.614 0 N-CA-C 108.778 -0.823 . . . . 71.439999999999998 108.778 176.312 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.12 124.7 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 CA-C-O 121.437 0.637 . . . . 71.329999999999998 109.677 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.5 mt -95.14 102.85 14.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 C-N-CA 124.324 1.05 . . . . 73.25 108.23 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.503 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 35.1 ttm180 -87.28 107.91 18.72 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 109.49 -0.559 . . . . 74.310000000000002 109.49 174.578 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.9 t -105.7 107.69 59.92 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 107.428 -1.323 . . . . 71.109999999999999 107.428 173.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -66.02 135.4 40.61 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.484 2.123 . . . . 74.519999999999996 112.043 -177.131 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 80.39 -5.33 64.19 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 114.723 0.649 . . . . 73.120000000000005 114.723 174.722 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 96.3 mmm -103.9 16.58 26.01 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 117.807 0.803 . . . . 61.32 111.842 -176.224 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -90.88 -142.29 10.07 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 116.149 -0.478 . . . . 54.210000000000001 111.983 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.651 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.69 127.93 8.58 Favored Glycine 0 C--N 1.343 0.965 0 N-CA-C 111.638 -0.585 . . . . 63.509999999999998 111.638 -177.638 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.9 mm-40 -83.61 151.64 25.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 123.46 0.704 . . . . 75.5 110.513 -175.476 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -148.75 -125.85 1.48 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 109.559 -1.417 . . . . 74.120000000000005 109.559 177.707 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.558 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 23.2 t30 -74.63 -51.26 4.14 Favored Pre-proline 0 CA--C 1.564 1.493 0 N-CA-C 108.118 -1.067 . . . . 71.549999999999997 108.118 161.265 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.558 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 49.4 Cg_endo -100.13 164.45 0.47 Allowed 'Trans proline' 0 C--N 1.39 2.731 0 C-N-CA 122.74 2.294 . . . . 72.120000000000005 111.689 165.324 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.21 136.68 14.61 Favored 'Trans proline' 0 CA--C 1.557 1.67 0 C-N-CA 121.794 1.662 . . . . 73.239999999999995 112.182 174.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -86.78 179.7 48.89 Favored Glycine 0 C--N 1.348 1.218 0 CA-C-O 119.999 -0.334 . . . . 24.420000000000002 112.552 175.16 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -97.48 148.53 23.13 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.043 0.537 . . . . 74.319999999999993 110.956 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.503 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 56.8 tp -107.01 132.73 52.62 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.052 0.941 . . . . 72.200000000000003 110.368 -178.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 93.6 mt -129.37 104.02 7.25 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 125.023 1.329 . . . . 73.209999999999994 109.609 176.26 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.524 HD21 HD12 ' A' ' 98' ' ' LEU . 65.9 mt -104.54 103.44 13.12 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 122.98 0.512 . . . . 54.329999999999998 110.518 176.476 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.5 t -84.83 93.6 3.57 Favored 'Isoleucine or valine' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 71.040000000000006 108.603 -177.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.499 HG22 HD23 ' A' ' 123' ' ' LEU . 97.3 t -56.7 127.66 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.098 0.959 . . . . 75.540000000000006 111.264 -178.429 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 179' ' ' ARG . . . . . 0.504 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.9 mmt180 -121.57 114.49 21.27 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 124.546 1.138 . . . . 70.510000000000005 108.435 -179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 75.1 mt -72.48 106.16 4.46 Favored 'General case' 0 C--O 1.241 0.648 0 O-C-N 123.826 0.704 . . . . 53.100000000000001 110.132 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 72.1 mt -66.22 153.77 91.6 Favored Pre-proline 0 CA--C 1.546 0.807 0 CA-C-N 115.868 -0.605 . . . . 64.200000000000003 110.522 179.026 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -56.99 140.79 93.39 Favored 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 122.899 2.4 . . . . 62.109999999999999 111.218 173.362 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 . . . . . 0 C--O 1.251 1.159 0 N-CA-C 109.329 -0.619 . . . . 72.299999999999997 109.329 -179.098 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 62.4 mtt . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 110.0 -0.37 . . . . 64.5 110.0 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.3 pt? 37.16 75.21 0.54 Allowed Pre-proline 0 N--CA 1.488 1.464 0 C-N-CA 125.757 1.623 . . . . 65.510000000000005 113.346 -173.011 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.69 -44.63 7.87 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 122.074 1.849 . . . . 62.140000000000001 110.832 176.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.562 HD12 ' H ' ' A' ' 98' ' ' LEU . 5.6 tp -177.99 144.52 0.34 Allowed 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.495 1.518 . . . . 50.439999999999998 107.807 177.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.888 HD23 ' HB ' ' A' ' 140' ' ' VAL . 18.2 tp 62.68 -70.16 0.06 Allowed 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 126.779 2.031 . . . . 75.230000000000004 112.226 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.563 ' HA ' HD13 ' A' ' 119' ' ' LEU . 76.8 t80 -63.23 130.76 45.93 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.335 1.054 . . . . 75.349999999999994 110.785 174.37 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.487 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 52.3 m -139.65 102.55 7.12 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 124.2 1.0 . . . . 61.119999999999997 109.475 177.049 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.87 89.68 0.86 Allowed 'Trans proline' 0 C--N 1.359 1.106 0 C-N-CA 121.676 1.584 . . . . 73.430000000000007 111.159 -177.419 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.5 m -85.55 172.17 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 CA-C-N 115.789 -0.641 . . . . 74.129999999999995 109.601 170.628 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.9 t -128.77 119.02 23.8 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 108.461 -0.94 . . . . 61.43 108.461 177.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 14.7 mmmm -95.2 85.69 4.36 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-O 121.066 0.46 . . . . 71.099999999999994 110.651 -174.144 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -116.91 24.97 9.16 Favored Glycine 0 C--N 1.344 1.004 0 N-CA-C 110.748 -0.941 . . . . 62.030000000000001 110.748 170.789 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 16.7 p -70.13 93.35 0.81 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 123.64 0.776 . . . . 71.109999999999999 110.74 -178.206 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.94 -43.1 3.2 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-N 115.625 -0.716 . . . . 73.530000000000001 113.27 178.629 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.9 -123.53 5.84 Favored Glycine 0 C--N 1.348 1.209 0 N-CA-C 110.483 -1.047 . . . . 74.049999999999997 110.483 -178.141 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 30.3 t -79.11 83.41 5.18 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 123.424 0.689 . . . . 52.32 110.193 -179.226 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -128.89 100.92 0.53 Allowed Glycine 0 C--N 1.342 0.916 0 N-CA-C 110.525 -1.03 . . . . 45.109999999999999 110.525 -177.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -67.84 83.89 0.16 Allowed Glycine 0 C--N 1.346 1.088 0 O-C-N 124.302 0.648 . . . . 71.239999999999995 112.806 -178.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.0 m -97.28 22.23 8.95 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 124.418 1.087 . . . . 53.32 110.667 -178.046 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 92.47 -107.05 3.47 Favored Glycine 0 C--N 1.349 1.294 0 N-CA-C 111.321 -0.712 . . . . 51.240000000000002 111.321 -174.363 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.53 -51.48 16.28 Favored Glycine 0 C--N 1.351 1.381 0 N-CA-C 111.753 -0.539 . . . . 64.099999999999994 111.753 177.826 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 13.1 m 60.51 15.12 5.34 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 124.542 1.137 . . . . 71.120000000000005 112.747 174.739 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -79.08 -163.36 25.24 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 115.535 0.974 . . . . 72.310000000000002 115.535 -168.73 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 -80.06 117.62 21.05 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 108.144 -1.058 . . . . 74.040000000000006 108.144 -173.401 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -94.44 104.87 16.84 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 107.314 -1.365 . . . . 75.219999999999999 107.314 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.563 HD13 ' HA ' ' A' ' 99' ' ' PHE . 11.8 mt -92.53 111.83 23.55 Favored 'General case' 0 C--N 1.345 0.384 0 N-CA-C 107.785 -1.191 . . . . 71.5 107.785 -172.079 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 68.6 ttt180 -120.13 107.82 13.5 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.253 1.021 . . . . 74.239999999999995 108.724 -177.581 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.19 148.16 50.85 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.066 0.546 . . . . 73.239999999999995 111.531 -171.371 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.593 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.5 mp0 -68.3 125.06 25.24 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.403 1.081 . . . . 63.25 109.443 170.338 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.45 HD12 HD13 ' A' ' 176' ' ' LEU . 2.5 tt -101.67 102.9 24.78 Favored Pre-proline 0 CA--C 1.543 0.687 0 N-CA-C 108.104 -1.073 . . . . 64.239999999999995 108.104 175.142 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.39 115.54 3.57 Favored 'Trans proline' 0 C--N 1.378 2.107 0 C-N-CA 121.689 1.592 . . . . 74.340000000000003 109.636 171.241 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.585 HD21 HD12 ' A' ' 149' ' ' ILE . 14.0 tp -137.64 123.11 19.6 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.6 -0.889 . . . . 61.399999999999999 108.6 -170.166 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.9 p -73.81 169.99 16.23 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 117.785 0.266 . . . . 62.219999999999999 110.705 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.1 mt -62.76 -33.43 75.14 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.575 0.75 . . . . 73.420000000000002 111.042 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -71.76 -45.51 61.45 Favored 'General case' 0 C--N 1.352 0.683 0 O-C-N 123.783 0.677 . . . . 73.129999999999995 109.312 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -64.18 -35.46 80.88 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 123.695 0.798 . . . . 72.209999999999994 111.634 176.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.43 -42.91 67.67 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.46 0.704 . . . . 75.420000000000002 111.867 -179.573 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.1 t80 -68.39 -50.88 49.8 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-N 114.884 -1.053 . . . . 71.400000000000006 110.102 -179.09 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -75.06 -42.0 57.86 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 115.669 -0.696 . . . . 74.310000000000002 111.213 -174.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.31 -134.5 16.82 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.564 0.54 . . . . 64.219999999999999 111.844 -177.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 76.27 -146.69 33.53 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-O 119.658 -0.523 . . . . 71.409999999999997 111.856 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.42 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 1.4 mp0 -85.18 146.69 26.98 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 117.83 0.815 . . . . 74.030000000000001 110.412 178.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.596 ' HB2' HD13 ' A' ' 149' ' ' ILE . 24.7 tpt180 -129.05 121.55 28.11 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.244 1.018 . . . . 73.239999999999995 108.936 177.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.5 t -82.18 108.72 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 C-N-CA 123.499 0.72 . . . . 73.019999999999996 109.736 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.574 HG23 HD22 ' A' ' 98' ' ' LEU . 33.6 m -128.11 162.15 34.92 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.012 0 C-N-CA 124.995 1.318 . . . . 42.25 108.825 178.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -107.32 138.09 44.16 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 122.882 0.473 . . . . 73.420000000000002 110.191 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.888 ' HB ' HD23 ' A' ' 98' ' ' LEU . 3.0 p -123.27 105.87 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 124.564 1.146 . . . . 74.239999999999995 109.06 171.727 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.11 14.87 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.744 0.818 . . . . 72.549999999999997 112.863 174.67 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.28 11.03 43.32 Favored Glycine 0 C--N 1.35 1.349 0 CA-C-O 119.901 -0.388 . . . . 64.549999999999997 113.843 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -115.31 118.38 33.09 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 117.429 0.615 . . . . 71.540000000000006 110.192 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -82.51 106.14 14.13 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.43 0.692 . . . . 72.120000000000005 109.956 -178.19 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 25.9 m -121.44 155.6 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.6 0.76 . . . . 62.420000000000002 110.342 -179.246 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.42 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 14.1 p -106.61 110.15 22.26 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.635 0.774 . . . . 53.210000000000001 109.646 175.053 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -99.22 128.99 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 124.061 0.944 . . . . 62.210000000000001 109.205 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -77.95 109.2 11.79 Favored 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.051 0.453 . . . . 63.350000000000001 110.506 -175.152 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.596 HD13 ' HB2' ' A' ' 136' ' ' ARG . 5.0 pt -86.55 142.74 35.25 Favored Pre-proline 0 CA--C 1.558 1.253 0 C-N-CA 124.484 1.113 . . . . 75.540000000000006 108.775 173.397 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.411 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 73.0 Cg_endo -75.47 137.24 20.47 Favored 'Trans proline' 0 CA--C 1.562 1.902 0 C-N-CA 122.191 1.927 . . . . 65.340000000000003 111.822 177.353 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 35.9 Cg_exo -63.44 135.9 52.11 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 122.761 2.308 . . . . 72.049999999999997 112.327 174.7 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.51 14.6 61.41 Favored Glycine 0 CA--C 1.534 1.253 0 O-C-N 123.636 0.585 . . . . 65.25 113.401 -176.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.18 143.26 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.324 0.649 . . . . 63.409999999999997 110.374 -177.134 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -118.49 177.5 4.8 Favored 'General case' 0 N--CA 1.484 1.24 0 CA-C-O 121.651 0.738 . . . . 55.039999999999999 112.894 -169.626 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -63.49 126.69 28.32 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 113.855 -1.52 . . . . 71.439999999999998 110.11 174.807 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -10.15 65.46 Favored Glycine 0 CA--C 1.532 1.129 0 O-C-N 124.111 0.882 . . . . 21.210000000000001 113.968 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.1 m -69.86 120.33 15.43 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-N 117.861 0.83 . . . . 74.140000000000001 109.989 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.61 139.86 17.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 C-N-CA 122.817 0.447 . . . . 71.319999999999993 110.077 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 44.6 mt -110.94 102.23 13.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 N-CA-C 106.85 -1.537 . . . . 55.509999999999998 106.85 178.359 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 6.0 ttp180 -88.15 102.17 14.53 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 108.961 -0.755 . . . . 65.140000000000001 108.961 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -95.2 113.05 60.66 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 107.746 -1.205 . . . . 54.240000000000002 107.746 175.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.39 128.45 15.47 Favored 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 122.847 2.365 . . . . 64.150000000000006 112.688 -169.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 63.49 23.42 66.74 Favored Glycine 0 C--N 1.351 1.392 0 O-C-N 123.592 0.558 . . . . 62.219999999999999 114.371 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.8 tpp -100.62 -18.4 16.58 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.487 0.715 . . . . 72.540000000000006 111.066 -177.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -72.45 -95.9 0.08 OUTLIER Glycine 0 C--N 1.345 1.035 0 CA-C-N 115.832 -0.622 . . . . 45.340000000000003 113.256 -175.376 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -72.36 86.75 0.5 Allowed Glycine 0 C--N 1.346 1.117 0 N-CA-C 112.252 -0.339 . . . . 71.450000000000003 112.252 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.8 mm-40 -81.93 121.64 26.75 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.376 0.67 . . . . 62.329999999999998 109.978 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 162.31 -142.12 7.72 Favored Glycine 0 C--O 1.241 0.591 0 N-CA-C 111.282 -0.727 . . . . 71.329999999999998 111.282 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.513 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 19.3 m120 -67.43 -49.43 42.25 Favored Pre-proline 0 CA--C 1.566 1.56 0 CA-C-O 118.271 -0.871 . . . . 72.219999999999999 110.886 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.513 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -96.48 106.69 0.1 OUTLIER 'Trans proline' 0 C--N 1.395 3.023 0 C-N-CA 123.125 2.55 . . . . 73.439999999999998 111.485 170.51 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.01 129.87 24.28 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.641 2.227 . . . . 34.229999999999997 111.778 178.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -117.97 157.33 15.22 Favored Glycine 0 C--N 1.338 0.642 0 N-CA-C 111.501 -0.64 . . . . 54.329999999999998 111.501 178.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -89.7 158.85 17.38 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 123.603 0.761 . . . . 72.329999999999998 110.558 -177.433 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.432 HD21 HD11 ' A' ' 98' ' ' LEU . 67.0 tp -115.7 132.64 56.57 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.834 0.853 . . . . 74.319999999999993 109.948 -177.675 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.7 mt -127.84 101.41 6.33 Favored 'General case' 0 CA--C 1.549 0.925 0 C-N-CA 125.35 1.46 . . . . 55.119999999999997 109.236 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.528 HD21 HD12 ' A' ' 98' ' ' LEU . 75.7 mt -101.46 100.83 11.33 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 123.11 0.564 . . . . 71.420000000000002 110.923 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 4.7 t -85.53 95.26 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 N-CA-C 108.409 -0.96 . . . . 75.019999999999996 108.409 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 73.9 t -54.67 135.03 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.695 1.198 . . . . 71.239999999999995 111.629 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' ARG . . . . . 0.593 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.3 mmt180 -128.27 107.68 9.97 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.312 -1.366 . . . . 63.329999999999998 107.312 -177.669 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 53.3 mt -69.98 121.62 17.75 Favored 'General case' 0 N--CA 1.47 0.534 0 O-C-N 123.438 0.461 . . . . 73.230000000000004 109.943 -177.443 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 83.8 mt -85.46 140.64 36.2 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.894 -0.594 . . . . 72.019999999999996 110.268 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.56 -15.9 34.14 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.667 2.245 . . . . 75.219999999999999 111.872 172.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 35.9 m80 . . . . . 0 C--N 1.356 0.849 0 C-N-CA 124.308 1.043 . . . . 64.519999999999996 108.264 176.994 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 84.3 mtp . . . . . 0 N--CA 1.488 1.448 0 N-CA-C 109.663 -0.495 . . . . 61.140000000000001 109.663 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 40.88 81.85 0.24 Allowed Pre-proline 0 N--CA 1.491 1.586 0 C-N-CA 125.906 1.683 . . . . 60.140000000000001 113.688 -177.311 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -64.71 -55.93 0.47 Allowed 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.494 2.129 . . . . 61.329999999999998 112.0 177.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.485 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.2 tp -177.55 134.88 0.18 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.785 1.234 . . . . 74.420000000000002 108.18 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.526 HD22 HG23 ' A' ' 138' ' ' VAL . 15.4 tp 66.86 -63.57 0.26 Allowed 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 126.89 2.076 . . . . 73.340000000000003 111.379 -174.797 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -69.43 126.02 28.49 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.696 1.198 . . . . 73.099999999999994 111.433 176.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.543 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 87.1 m -138.77 88.45 13.88 Favored Pre-proline 0 N--CA 1.47 0.57 0 C-N-CA 124.444 1.098 . . . . 65.010000000000005 108.657 176.076 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.4 83.96 0.61 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 122.461 2.107 . . . . 74.200000000000003 112.615 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 100' ' ' THR . 21.2 m -96.22 -179.31 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 CA-C-N 114.612 -1.176 . . . . 63.310000000000002 108.857 172.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.4 t -132.27 151.16 51.96 Favored 'General case' 0 C--O 1.244 0.78 0 N-CA-C 108.833 -0.803 . . . . 70.140000000000001 108.833 174.263 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 36.8 ttmt -134.34 107.41 7.61 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 120.932 0.396 . . . . 51.119999999999997 110.47 178.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -162.5 27.11 0.24 Allowed Glycine 0 C--N 1.339 0.749 0 CA-C-N 114.854 -1.067 . . . . 45.399999999999999 110.561 172.66 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 49.2 m -81.95 72.39 9.0 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 123.958 0.903 . . . . 71.140000000000001 109.859 -178.557 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 74.94 174.05 33.05 Favored Glycine 0 C--N 1.35 1.311 0 CA-C-N 115.374 -0.83 . . . . 75.319999999999993 112.927 -176.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.19 153.99 10.77 Favored Glycine 0 CA--C 1.533 1.217 0 N-CA-C 113.703 0.241 . . . . 71.349999999999994 113.703 177.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 46.7 t -166.06 169.36 14.64 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.097 0.959 . . . . 65.450000000000003 109.633 -177.777 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 160.86 162.76 12.94 Favored Glycine 0 C--N 1.344 0.982 0 N-CA-C 112.219 -0.352 . . . . 73.299999999999997 112.219 177.244 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -65.05 -56.21 17.36 Favored Glycine 0 C--N 1.349 1.295 0 N-CA-C 111.626 -0.59 . . . . 32.25 111.626 177.361 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.8 m -97.27 -27.63 14.42 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 123.603 0.761 . . . . 51.219999999999999 109.793 171.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -72.78 85.57 0.55 Allowed Glycine 0 C--N 1.358 1.757 0 O-C-N 123.645 0.591 . . . . 40.25 114.145 -172.069 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -175.15 91.84 0.09 OUTLIER Glycine 0 C--N 1.34 0.77 0 N-CA-C 110.49 -1.044 . . . . 71.140000000000001 110.49 179.24 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 40.5 m -66.37 154.22 40.67 Favored 'General case' 0 C--O 1.243 0.728 0 C-N-CA 123.749 0.82 . . . . 73.099999999999994 110.699 176.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.03 -168.62 22.9 Favored Glycine 0 C--N 1.344 1.01 0 CA-C-N 116.329 -0.396 . . . . 70.120000000000005 112.72 172.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.412 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 45.2 mtt180 -73.57 153.35 40.27 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 123.579 0.752 . . . . 71.519999999999996 110.432 -175.278 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -98.05 109.17 21.97 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 107.491 -1.3 . . . . 75.349999999999994 107.491 177.413 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.543 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 15.0 mt -91.47 108.04 19.62 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 106.165 -1.791 . . . . 74.219999999999999 106.165 177.848 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 34.7 ttt180 -118.89 106.16 12.21 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.104 -1.073 . . . . 71.030000000000001 108.104 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -131.0 144.54 51.55 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.165 0.586 . . . . 74.329999999999998 109.54 -175.573 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.644 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.2 mp0 -72.8 129.01 37.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 114.88 -1.055 . . . . 75.150000000000006 108.536 173.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.543 HD21 ' HG2' ' A' ' 136' ' ' ARG . 3.0 tt -99.76 102.39 16.97 Favored Pre-proline 0 CA--C 1.536 0.438 0 N-CA-C 106.609 -1.626 . . . . 54.25 106.609 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -65.93 113.86 2.75 Favored 'Trans proline' 0 C--N 1.376 2.026 0 C-N-CA 121.839 1.693 . . . . 73.140000000000001 110.271 174.638 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.523 HD21 HD12 ' A' ' 149' ' ' ILE . 17.8 tp -144.36 121.9 11.75 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.796 -1.187 . . . . 72.340000000000003 107.796 -173.812 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.3 p -73.96 168.34 19.67 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 117.761 0.255 . . . . 75.209999999999994 110.478 -177.331 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.8 mt -57.58 -36.43 71.7 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.249 0.619 . . . . 74.420000000000002 110.918 176.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 21.2 mp0 -71.88 -46.75 56.78 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 124.611 1.165 . . . . 60.020000000000003 110.386 -176.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -72.06 -27.49 62.72 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.601 0.76 . . . . 74.450000000000003 111.911 -179.051 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -69.41 -46.02 67.82 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.426 0.69 . . . . 64.340000000000003 109.926 173.352 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -58.96 -41.56 87.77 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 124.718 1.207 . . . . 61.049999999999997 110.849 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.45 -49.1 67.83 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.59 0.556 . . . . 71.340000000000003 109.541 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.49 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.01 56.93 22.41 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.062 -0.972 . . . . 24.329999999999998 113.106 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -92.0 -148.17 21.91 Favored Glycine 0 C--N 1.345 1.033 0 O-C-N 123.491 0.171 . . . . 61.119999999999997 112.808 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -95.4 132.32 40.59 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 107.757 -1.201 . . . . 73.430000000000007 107.757 169.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.543 ' HG2' HD21 ' A' ' 123' ' ' LEU . 12.8 tpp180 -111.62 116.94 31.65 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 107.678 -1.23 . . . . 72.540000000000006 107.678 -178.405 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 144' ' ' ARG . 12.1 p -98.76 118.12 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 N-CA-C 108.133 -1.062 . . . . 72.239999999999995 108.133 -176.746 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.526 HG23 HD22 ' A' ' 98' ' ' LEU . 35.6 m -134.22 161.84 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.849 0.86 . . . . 60.119999999999997 110.008 -173.825 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -96.97 136.88 36.91 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 123.679 0.792 . . . . 65.329999999999998 110.093 -173.596 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.433 ' HB ' HD23 ' A' ' 98' ' ' LEU . 5.4 p -144.49 111.59 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.607 1.163 . . . . 74.530000000000001 109.631 177.111 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.4 22.01 12.95 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 123.684 0.794 . . . . 51.020000000000003 113.025 173.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.92 -16.12 58.76 Favored Glycine 0 C--N 1.345 1.049 0 C-N-CA 123.827 0.727 . . . . 52.200000000000003 112.653 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 19.4 tpp180 -95.72 123.92 39.51 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.249 1.02 . . . . 72.310000000000002 109.551 178.42 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.522 ' HG2' HG22 ' A' ' 137' ' ' VAL . 22.6 ttp180 -89.51 107.05 18.85 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 108.728 -0.841 . . . . 74.310000000000002 108.728 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 70.0 t -112.7 136.79 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 C-N-CA 124.112 0.965 . . . . 75.310000000000002 110.508 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 31.9 p -96.18 120.83 37.17 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.279 0.632 . . . . 72.540000000000006 110.669 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.5 p -106.37 131.02 57.14 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.943 1.297 . . . . 51.049999999999997 109.345 174.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 46.7 ttp180 -79.02 122.34 26.07 Favored 'General case' 0 C--O 1.243 0.72 0 CA-C-O 120.969 0.414 . . . . 62.149999999999999 109.98 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.523 HD12 HD21 ' A' ' 125' ' ' LEU . 10.3 pt -96.5 140.71 22.32 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 124.26 1.024 . . . . 71.310000000000002 109.823 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 20.5 Cg_exo -66.18 142.66 68.13 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.058 2.505 . . . . 71.140000000000001 113.045 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -66.17 130.91 25.29 Favored 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 122.327 2.018 . . . . 72.239999999999995 110.802 170.144 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 70.81 26.29 74.26 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 115.532 -0.758 . . . . 62.420000000000002 113.945 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.0 p -68.77 137.37 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-N 117.201 0.5 . . . . 74.120000000000005 110.755 -178.672 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -98.37 175.77 5.93 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.875 0.845 . . . . 75.519999999999996 112.963 -168.256 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -69.65 134.0 48.21 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 113.547 -1.661 . . . . 74.109999999999999 110.669 177.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 73.89 10.17 80.27 Favored Glycine 0 C--N 1.342 0.914 0 CA-C-N 116.062 -0.517 . . . . 72.430000000000007 113.452 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.5 m -81.32 118.9 23.02 Favored 'General case' 0 C--N 1.347 0.473 0 N-CA-C 108.626 -0.879 . . . . 74.120000000000005 108.626 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 3.3 p -99.91 115.03 40.08 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.351 0.596 . . . . 54.020000000000003 109.796 -175.064 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 55.5 mt -90.05 104.49 15.24 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 124.516 1.126 . . . . 71.010000000000005 108.212 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.52 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 24.8 ttp180 -90.32 117.9 29.4 Favored 'General case' 0 C--N 1.344 0.355 0 N-CA-C 110.548 -0.168 . . . . 72.430000000000007 110.548 -179.655 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.0 t -109.11 95.28 17.29 Favored Pre-proline 0 CA--C 1.555 1.157 0 N-CA-C 107.5 -1.296 . . . . 64.120000000000005 107.5 166.711 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -70.26 136.29 31.33 Favored 'Trans proline' 0 C--N 1.373 1.857 0 C-N-CA 122.888 2.392 . . . . 72.25 111.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.39 2.24 82.92 Favored Glycine 0 CA--C 1.531 1.089 0 CA-C-O 119.635 -0.536 . . . . 65.319999999999993 114.118 178.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 41.4 tpp -128.51 12.99 6.48 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 117.872 0.836 . . . . 74.450000000000003 110.726 -177.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.38 -106.74 0.78 Allowed Glycine 0 C--N 1.344 1.021 0 CA-C-N 115.866 -0.606 . . . . 73.109999999999999 111.896 178.516 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -61.38 105.11 0.8 Allowed Glycine 0 C--N 1.347 1.179 0 C-N-CA 123.018 0.342 . . . . 74.310000000000002 113.502 -177.248 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -89.69 134.7 34.02 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.862 0.865 . . . . 54.439999999999998 109.176 173.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -178.9 -51.14 0.08 OUTLIER Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.031 -1.228 . . . . 74.340000000000003 110.031 177.445 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.458 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 25.1 t-20 -166.25 -54.76 0.01 OUTLIER Pre-proline 0 CA--C 1.556 1.192 0 C-N-CA 124.952 1.301 . . . . 65.420000000000002 108.173 169.544 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.458 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 82.1 Cg_endo -82.54 134.49 7.63 Favored 'Trans proline' 0 C--N 1.399 3.196 0 C-N-CA 121.721 1.614 . . . . 74.420000000000002 110.411 170.004 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.76 125.84 10.87 Favored 'Trans proline' 0 C--N 1.367 1.537 0 C-N-CA 122.228 1.952 . . . . 74.549999999999997 111.824 178.031 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -95.13 -172.18 37.03 Favored Glycine 0 C--N 1.349 1.273 0 CA-C-N 116.182 -0.463 . . . . 63.140000000000001 113.416 175.495 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.6 144.33 28.02 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.417 0.687 . . . . 70.420000000000002 110.5 178.241 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.52 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.6 tp -107.99 129.68 55.1 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-N 115.312 -0.858 . . . . 74.319999999999993 108.879 178.315 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.4 mt -128.27 102.56 6.73 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 124.472 1.109 . . . . 75.530000000000001 109.187 -178.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.436 HD21 HD12 ' A' ' 98' ' ' LEU . 89.4 mt -104.08 101.36 11.12 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 121.0 0.428 . . . . 73.129999999999995 110.486 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.46 95.75 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.47 -0.937 . . . . 62.049999999999997 108.47 -176.195 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.7 t -55.63 124.11 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 124.142 0.977 . . . . 70.409999999999997 111.355 -179.229 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 179' ' ' ARG . . . . . 0.644 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 28.2 mmt180 -116.38 104.48 11.51 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.383 1.073 . . . . 74.129999999999995 108.459 -179.323 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.46 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 60.8 mt -70.05 111.05 5.44 Favored 'General case' 0 C--N 1.343 0.323 0 C-N-CA 123.685 0.794 . . . . 75.430000000000007 110.732 -178.028 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 63.3 mt -94.73 144.22 27.51 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.324 0.65 . . . . 54.100000000000001 110.044 -179.284 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.93 -33.23 4.84 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 122.425 2.083 . . . . 73.209999999999994 110.773 167.17 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 . . . . . 0 N--CA 1.48 1.069 0 C-N-CA 124.82 1.248 . . . . 73.299999999999997 108.15 175.829 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 110.275 -0.268 . . . . 70.219999999999999 110.275 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pp 36.7 81.06 0.25 Allowed Pre-proline 0 CA--C 1.56 1.363 0 C-N-CA 126.057 1.743 . . . . 63.210000000000001 114.391 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.93 -61.87 0.16 Allowed 'Trans proline' 0 C--N 1.382 2.341 0 C-N-CA 122.519 2.146 . . . . 71.209999999999994 110.509 176.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.441 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.8 tp -172.68 144.33 1.39 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.599 1.16 . . . . 74.120000000000005 107.901 172.272 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.653 HD13 HG21 ' A' ' 138' ' ' VAL . 8.9 tp 64.31 -66.36 0.12 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 126.346 1.858 . . . . 61.43 111.828 -169.08 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -59.55 137.47 58.01 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 124.733 1.213 . . . . 71.129999999999995 111.972 178.147 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.54 HG22 HG13 ' A' ' 102' ' ' VAL . 61.2 m -157.66 108.93 1.81 Allowed Pre-proline 0 N--CA 1.475 0.822 0 C-N-CA 124.755 1.222 . . . . 74.200000000000003 109.225 177.358 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -81.42 68.15 8.24 Favored 'Trans proline' 0 C--N 1.371 1.736 0 C-N-CA 122.381 2.054 . . . . 51.039999999999999 112.582 -172.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.54 HG13 HG22 ' A' ' 100' ' ' THR . 9.6 m -62.06 -29.34 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 CA-C-N 114.78 -1.1 . . . . 63.229999999999997 112.663 -179.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.6 t 44.44 33.03 0.81 Allowed 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 125.69 1.596 . . . . 74.219999999999999 113.824 176.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.2 164.86 11.59 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 124.517 1.127 . . . . 53.299999999999997 110.981 -175.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 177.97 -51.74 0.1 OUTLIER Glycine 0 C--N 1.339 0.697 0 N-CA-C 110.564 -1.014 . . . . 74.319999999999993 110.564 178.503 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.4 m 61.06 20.07 10.54 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 124.643 1.177 . . . . 65.209999999999994 112.759 176.262 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 158.13 156.43 7.97 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 112.048 -0.421 . . . . 64.109999999999999 112.048 -177.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.41 -23.09 57.46 Favored Glycine 0 C--N 1.348 1.195 0 C-N-CA 122.974 0.321 . . . . 62.229999999999997 112.843 177.727 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 59.8 p -137.73 154.31 49.64 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.655 0.782 . . . . 61.219999999999999 110.738 -178.1 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -152.62 167.18 31.46 Favored Glycine 0 C--N 1.353 1.523 0 C-N-CA 123.537 0.589 . . . . 75.219999999999999 111.887 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -68.34 -47.85 55.47 Favored Glycine 0 C--N 1.348 1.236 0 C-N-CA 123.034 0.349 . . . . 74.219999999999999 113.536 -173.072 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 22.7 t -76.97 -38.56 52.99 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.402 0.681 . . . . 55.32 109.553 177.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -173.69 146.57 8.9 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 115.023 -0.99 . . . . 65.450000000000003 111.631 -179.628 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.61 -39.01 30.83 Favored Glycine 0 C--N 1.342 0.908 0 O-C-N 123.724 0.308 . . . . 62.119999999999997 112.96 177.747 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 51.4 m -102.14 150.2 23.51 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.811 0.844 . . . . 75.319999999999993 110.064 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.735 ' HA2' ' HA2' ' A' ' 172' ' ' GLY . . . 149.67 75.22 0.02 OUTLIER Glycine 0 C--N 1.347 1.185 0 O-C-N 123.207 0.317 . . . . 53.240000000000002 113.053 175.465 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.566 ' HG3' ' HA3' ' A' ' 166' ' ' GLY . 21.2 ptt180 -95.8 124.28 39.75 Favored 'General case' 0 CA--C 1.554 1.108 0 N-CA-C 108.98 -0.748 . . . . 75.310000000000002 108.98 170.843 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.475 ' HA ' ' O ' ' A' ' 173' ' ' ASP . 0.1 OUTLIER -101.99 115.06 29.74 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.875 0.87 . . . . 53.409999999999997 110.681 -157.955 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.527 HD22 ' O ' ' A' ' 100' ' ' THR . 13.8 mt -90.86 109.53 20.74 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 106.841 -1.54 . . . . 72.439999999999998 106.841 178.147 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.18 110.64 21.92 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 123.129 0.572 . . . . 75.530000000000001 110.376 -178.233 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.88 138.59 52.73 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.799 -0.815 . . . . 72.0 108.799 177.002 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mp0 -77.82 122.21 25.12 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.51 -0.922 . . . . 73.099999999999994 108.51 176.419 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.56 HD12 HD13 ' A' ' 176' ' ' LEU . 1.0 OUTLIER -99.67 111.05 60.87 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 108.667 -0.864 . . . . 72.409999999999997 108.667 -172.281 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.423 ' HB2' HD11 ' A' ' 181' ' ' LEU . 52.6 Cg_endo -67.89 116.67 4.42 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.06 1.84 . . . . 70.540000000000006 109.788 170.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.513 HD21 HD12 ' A' ' 149' ' ' ILE . 23.6 tp -131.45 133.04 44.78 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 108.715 -0.846 . . . . 71.200000000000003 108.715 -172.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 45.1 p -75.48 157.17 34.4 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.36 -0.607 . . . . 63.43 109.36 -178.194 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.54 -31.15 71.89 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.274 0.63 . . . . 64.349999999999994 111.074 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -70.78 -51.64 25.66 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.768 0.827 . . . . 63.439999999999998 110.107 179.458 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -65.45 -34.16 77.64 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.485 0.714 . . . . 72.430000000000007 111.581 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.43 -45.56 86.99 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 124.027 0.829 . . . . 60.140000000000001 110.699 173.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -66.08 -35.75 81.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 124.177 0.991 . . . . 63.009999999999998 111.116 179.596 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -73.65 -43.16 60.2 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.997 0.519 . . . . 65.109999999999999 109.865 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.436 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 67.23 51.37 38.68 Favored Glycine 0 C--N 1.347 1.149 0 CA-C-N 114.877 -1.056 . . . . 41.130000000000003 111.742 -168.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.402 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -89.84 -150.55 23.57 Favored Glycine 0 C--N 1.347 1.177 0 CA-C-O 120.841 0.134 . . . . 65.129999999999995 112.971 -177.033 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.418 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 7.5 mp0 -101.36 140.97 34.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.576 -0.898 . . . . 72.549999999999997 108.576 169.754 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 24.4 tpt85 -120.56 121.53 38.6 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.074 0.949 . . . . 70.549999999999997 108.548 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 12.2 p -84.73 117.89 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.784 0.802 . . . . 73.439999999999998 109.769 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.653 HG21 HD13 ' A' ' 98' ' ' LEU . 34.6 m -126.46 160.3 34.41 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 C-N-CA 125.444 1.498 . . . . 72.430000000000007 107.974 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -125.62 112.7 16.46 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-N 118.981 0.809 . . . . 53.130000000000003 111.801 -172.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.514 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.5 p -105.55 105.55 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 C-N-CA 125.608 1.563 . . . . 61.450000000000003 111.004 -176.572 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.25 28.5 15.26 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 124.146 0.978 . . . . 60.409999999999997 112.521 177.111 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.11 -10.49 58.38 Favored Glycine 0 C--N 1.356 1.687 0 CA-C-O 119.79 -0.45 . . . . 64.450000000000003 114.085 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.419 ' HB2' HG13 ' A' ' 140' ' ' VAL . 51.1 mtt180 -90.25 118.32 29.67 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 108.605 -0.887 . . . . 70.109999999999999 108.605 174.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 48.4 ttt85 -98.8 109.74 22.45 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 109.248 -0.649 . . . . 73.450000000000003 109.248 -177.73 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.1 p -130.75 146.07 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.527 1.131 . . . . 71.329999999999998 110.377 -172.272 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.418 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 28.4 m -93.18 119.19 32.09 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 123.693 0.797 . . . . 73.219999999999999 110.464 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -101.26 130.13 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.114 0.966 . . . . 75.400000000000006 109.944 175.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 36.9 ttp180 -75.84 134.77 40.27 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.248 0.547 . . . . 62.43 110.137 178.436 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.513 HD12 HD21 ' A' ' 125' ' ' LEU . 2.8 pt -108.65 145.66 32.07 Favored Pre-proline 0 CA--C 1.564 1.492 0 C-N-CA 125.11 1.364 . . . . 65.329999999999998 108.985 -179.473 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.52 145.99 97.75 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 123.037 2.491 . . . . 72.310000000000002 113.565 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -71.06 117.08 4.97 Favored 'Trans proline' 0 C--N 1.38 2.212 0 C-N-CA 122.709 2.273 . . . . 65.010000000000005 112.294 178.585 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 78.97 31.97 41.57 Favored Glycine 0 CA--C 1.533 1.176 0 CA-C-N 115.738 -0.664 . . . . 71.200000000000003 112.606 -176.218 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.6 p -72.82 146.17 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 123.395 0.678 . . . . 73.25 110.309 179.55 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.52 ' HA ' HD11 ' A' ' 180' ' ' LEU . 92.7 mtt180 -123.23 177.58 5.51 Favored 'General case' 0 N--CA 1.476 0.873 0 CA-C-O 121.808 0.813 . . . . 72.519999999999996 112.851 -171.563 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.0 tp10 -60.09 132.94 55.48 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 113.185 -1.825 . . . . 73.519999999999996 111.325 178.021 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.36 -27.31 15.81 Favored Glycine 0 C--N 1.34 0.775 0 CA-C-O 119.381 -0.677 . . . . 60.399999999999999 112.565 179.225 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.6 m -62.57 121.26 12.88 Favored 'General case' 0 C--N 1.354 0.763 0 C-N-CA 123.433 0.693 . . . . 70.540000000000006 111.004 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.1 126.46 51.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.091 -0.707 . . . . 61.049999999999997 109.091 177.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.41 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.4 mt -95.74 103.87 15.18 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 N-CA-C 108.012 -1.107 . . . . 74.510000000000005 108.012 -176.543 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.571 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 53.2 ttp180 -89.02 106.73 18.62 Favored 'General case' 0 C--N 1.355 0.848 0 N-CA-C 110.342 -0.244 . . . . 74.310000000000002 110.342 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.6 t -110.48 96.9 29.44 Favored Pre-proline 0 CA--C 1.553 1.078 0 N-CA-C 108.629 -0.878 . . . . 73.329999999999998 108.629 174.565 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.46 144.19 92.47 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.137 2.558 . . . . 71.439999999999998 112.842 176.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.69 -24.33 5.92 Favored Glycine 0 CA--C 1.539 1.584 0 CA-C-O 119.549 -0.584 . . . . 72.230000000000004 114.351 176.688 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 17.2 mmt -90.38 -2.54 57.97 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 117.7 0.75 . . . . 75.430000000000007 111.717 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.12 -115.12 0.54 Allowed Glycine 0 C--N 1.341 0.843 0 N-CA-C 111.346 -0.702 . . . . 64.329999999999998 111.346 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.566 ' HA3' ' HG3' ' A' ' 117' ' ' ARG . . . -58.35 107.56 1.16 Allowed Glycine 0 C--N 1.354 1.555 0 CA-C-N 117.165 0.483 . . . . 61.43 113.237 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -80.03 171.57 14.92 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.937 0.895 . . . . 74.140000000000001 110.733 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 106.9 -147.07 16.14 Favored Glycine 0 N--CA 1.473 1.165 0 CA-C-O 119.619 -0.545 . . . . 62.340000000000003 111.819 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.415 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 5.6 t-20 -69.82 -52.64 13.16 Favored Pre-proline 0 CA--C 1.566 1.584 0 CA-C-O 118.146 -0.931 . . . . 75.400000000000006 111.303 178.285 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.415 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 88.0 Cg_endo -89.93 108.64 0.39 Allowed 'Trans proline' 0 C--N 1.397 3.079 0 C-N-CA 122.188 1.926 . . . . 64.299999999999997 112.907 178.557 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -66.71 127.67 17.55 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.187 2.591 . . . . 61.219999999999999 112.776 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.735 ' HA2' ' HA2' ' A' ' 116' ' ' GLY . . . -110.64 162.67 12.47 Favored Glycine 0 C--N 1.341 0.846 0 CA-C-N 115.542 -0.754 . . . . 61.450000000000003 112.915 -178.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' A' ' 118' ' ' ASP . 4.6 m-20 -80.15 150.3 30.24 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.83 0.852 . . . . 74.230000000000004 110.559 178.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.571 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 62.5 tp -106.58 135.79 47.49 Favored 'General case' 0 C--O 1.216 -0.676 0 N-CA-C 108.302 -0.999 . . . . 75.209999999999994 108.302 173.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.9 mt -128.44 103.31 7.06 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 123.715 0.806 . . . . 74.299999999999997 109.293 179.143 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.564 HD21 HD12 ' A' ' 98' ' ' LEU . 83.4 mt -107.35 103.08 12.34 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 122.684 0.394 . . . . 73.329999999999998 110.92 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.64 96.88 5.72 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.732 -0.667 . . . . 62.049999999999997 109.467 -174.274 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -54.59 130.21 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 C-N-CA 124.888 1.275 . . . . 75.510000000000005 111.848 -177.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -123.86 100.24 6.66 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 125.344 1.458 . . . . 72.230000000000004 107.626 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.52 HD11 ' HA ' ' A' ' 154' ' ' ARG . 35.5 mt -70.06 107.91 3.84 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-O 121.168 0.509 . . . . 75.010000000000005 111.151 -176.395 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.423 HD11 ' HB2' ' A' ' 124' ' ' PRO . 48.7 mt -75.98 130.72 77.58 Favored Pre-proline 0 CA--C 1.553 1.083 0 N-CA-C 108.23 -1.026 . . . . 74.200000000000003 108.23 175.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.22 -63.17 0.07 OUTLIER 'Trans proline' 0 CA--C 1.559 1.749 0 C-N-CA 123.074 2.516 . . . . 54.329999999999998 113.207 -176.216 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 . . . . . 0 N--CA 1.489 1.504 0 C-N-CA 123.888 0.875 . . . . 72.340000000000003 108.902 177.684 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 27.2 ptt? . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 119.317 -0.373 . . . . 60.100000000000001 110.366 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -51.98 115.19 6.28 Favored Pre-proline 0 CA--C 1.566 1.561 0 C-N-CA 124.302 1.041 . . . . 52.210000000000001 111.667 179.306 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -74.21 -48.98 0.19 Allowed 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.386 2.058 . . . . 71.0 112.354 176.685 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.504 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.6 tp 168.25 150.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 126.792 2.037 . . . . 74.310000000000002 106.321 -170.553 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.7 HD23 ' HB ' ' A' ' 140' ' ' VAL . 14.2 tp 57.54 -72.51 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 126.108 1.763 . . . . 75.409999999999997 111.587 -173.658 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.61 ' HA ' HD13 ' A' ' 119' ' ' LEU . 87.6 t80 -57.9 123.1 14.62 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.741 1.616 . . . . 72.200000000000003 111.948 172.086 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 98.9 m -145.44 99.17 4.52 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.113 0.965 . . . . 72.25 109.47 175.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -77.4 74.65 5.02 Favored 'Trans proline' 0 C--N 1.371 1.761 0 C-N-CA 122.462 2.108 . . . . 73.219999999999999 113.09 -172.643 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 3.6 m -78.62 176.82 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.811 0 CA-C-N 116.102 -0.499 . . . . 72.140000000000001 109.861 176.638 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 2.0 t -121.67 127.71 51.07 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.498 0.719 . . . . 51.210000000000001 109.144 176.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.475 ' HE2' ' HB2' ' A' ' 115' ' ' SER . 0.0 OUTLIER -77.8 90.75 4.07 Favored 'General case' 0 C--O 1.241 0.638 0 N-CA-C 108.536 -0.913 . . . . 73.030000000000001 108.536 173.293 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -71.25 130.75 19.25 Favored Glycine 0 CA--C 1.524 0.65 0 CA-C-N 114.373 -1.285 . . . . 73.219999999999999 111.81 175.611 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 40.0 t -163.65 -66.0 0.04 OUTLIER 'General case' 0 C--O 1.242 0.677 0 N-CA-C 107.071 -1.455 . . . . 43.420000000000002 107.071 176.127 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.19 -98.4 0.04 OUTLIER Glycine 0 C--N 1.355 1.622 0 CA-C-N 114.844 -1.071 . . . . 72.439999999999998 113.662 176.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 70.44 -82.45 0.37 Allowed Glycine 0 C--N 1.353 1.473 0 C-N-CA 123.943 0.782 . . . . 64.329999999999998 111.926 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 31.9 t -143.07 97.2 3.05 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.678 -1.23 . . . . 71.120000000000005 107.678 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 91.68 -109.45 3.73 Favored Glycine 0 C--N 1.343 0.956 0 N-CA-C 111.062 -0.815 . . . . 53.399999999999999 111.062 -173.742 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 76.4 77.39 0.76 Allowed Glycine 0 C--N 1.347 1.162 0 N-CA-C 111.818 -0.513 . . . . 73.109999999999999 111.818 -177.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 25.8 m -62.27 -31.55 72.14 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 123.782 0.833 . . . . 72.019999999999996 112.044 -179.089 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 163.06 -62.47 0.26 Allowed Glycine 0 C--N 1.337 0.613 0 N-CA-C 111.264 -0.734 . . . . 34.409999999999997 111.264 177.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.14 -88.68 0.4 Allowed Glycine 0 C--N 1.346 1.109 0 O-C-N 124.3 0.647 . . . . 24.100000000000001 111.899 -176.335 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' SER . . . . . 0.475 ' HB2' ' HE2' ' A' ' 104' ' ' LYS . 12.7 m -96.16 152.99 18.04 Favored 'General case' 0 C--O 1.244 0.766 0 C-N-CA 123.745 0.818 . . . . 72.230000000000004 108.816 177.018 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -84.3 -165.31 39.04 Favored Glycine 0 N--CA 1.465 0.627 0 CA-C-N 116.1 -0.5 . . . . 72.019999999999996 113.697 -175.573 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 38.3 ptt180 -87.47 130.93 34.51 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 108.711 -0.848 . . . . 71.420000000000002 108.711 174.335 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -92.59 118.99 31.59 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 106.976 -1.49 . . . . 65.209999999999994 106.976 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.61 HD13 ' HA ' ' A' ' 99' ' ' PHE . 18.4 mt -89.73 108.68 19.83 Favored 'General case' 0 C--O 1.225 -0.228 0 N-CA-C 106.725 -1.584 . . . . 72.25 106.725 -174.241 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -117.42 107.56 14.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.113 -1.069 . . . . 70.439999999999998 108.113 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.61 140.05 50.42 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 108.577 -0.898 . . . . 45.409999999999997 108.577 -179.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.78 129.41 37.0 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 109.189 -0.671 . . . . 64.0 109.189 173.297 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.508 HD12 HD13 ' A' ' 176' ' ' LEU . 2.0 tt -100.02 109.55 56.53 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 108.749 -0.834 . . . . 75.099999999999994 108.749 -173.747 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.03 113.86 2.77 Favored 'Trans proline' 0 C--N 1.378 2.115 0 C-N-CA 122.116 1.877 . . . . 75.129999999999995 110.19 171.095 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.565 HD21 HD12 ' A' ' 149' ' ' ILE . 12.0 tp -133.21 125.91 30.43 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 108.045 -1.095 . . . . 72.310000000000002 108.045 -169.448 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 43.0 p -73.16 171.7 12.46 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 117.975 0.352 . . . . 71.010000000000005 110.69 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 96.7 mt -71.39 -23.83 61.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 123.157 0.583 . . . . 61.310000000000002 111.009 178.758 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -72.03 -50.68 26.5 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.634 -0.876 . . . . 62.340000000000003 108.634 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.664 ' HG3' HH21 ' A' ' 136' ' ' ARG . 29.4 mm-40 -57.55 -40.52 79.04 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.841 1.256 . . . . 72.420000000000002 111.384 176.214 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.56 64.22 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 114.965 -1.016 . . . . 41.530000000000001 111.177 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -60.73 -58.45 8.4 Favored 'General case' 0 C--N 1.349 0.564 0 O-C-N 124.679 1.237 . . . . 74.439999999999998 110.266 -176.713 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.8 m80 -67.66 -38.59 84.0 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 123.958 0.786 . . . . 74.120000000000005 111.047 -175.321 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 73.49 -112.81 4.0 Favored Glycine 0 C--N 1.343 0.947 0 N-CA-C 110.47 -1.052 . . . . 73.519999999999996 110.47 -170.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.12 -130.85 22.26 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 111.551 -0.62 . . . . 54.530000000000001 111.551 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 9.3 mp0 -121.43 157.65 30.08 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.975 0.91 . . . . 73.099999999999994 109.452 174.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.664 HH21 ' HG3' ' A' ' 129' ' ' GLU . 5.3 tpp180 -135.02 124.03 24.19 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.234 1.414 . . . . 72.329999999999998 107.975 177.374 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.3 p -84.9 127.09 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.091 0 C-N-CA 123.137 0.575 . . . . 72.109999999999999 110.228 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.676 HG23 HD22 ' A' ' 98' ' ' LEU . 30.7 m -140.71 158.01 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.938 1.295 . . . . 71.310000000000002 109.102 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -88.19 135.48 33.42 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 123.162 0.585 . . . . 43.229999999999997 111.284 -174.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.7 ' HB ' HD23 ' A' ' 98' ' ' LEU . 7.2 p -136.86 118.56 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 124.396 1.078 . . . . 43.229999999999997 109.288 168.25 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.39 20.29 11.74 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 123.92 0.888 . . . . 32.119999999999997 112.229 177.256 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.43 -9.47 66.98 Favored Glycine 0 C--N 1.358 1.78 0 C-N-CA 123.051 0.357 . . . . 31.34 113.216 -177.376 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -104.0 128.82 51.57 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.076 0.951 . . . . 75.200000000000003 109.983 -178.331 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.32 141.66 43.35 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.527 -0.545 . . . . 73.519999999999996 109.527 177.735 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.81 126.49 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.64 1.176 . . . . 72.420000000000002 108.619 178.814 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 44.7 m -82.49 109.82 17.05 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.396 0.678 . . . . 75.209999999999994 109.612 175.29 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.5 130.24 47.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 C-N-CA 123.999 0.92 . . . . 65.430000000000007 109.248 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -69.81 118.7 12.99 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.043 0.537 . . . . 75.219999999999999 109.96 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.565 HD12 HD21 ' A' ' 125' ' ' LEU . 17.2 pt -108.02 131.53 21.68 Favored Pre-proline 0 CA--C 1.564 1.508 0 C-N-CA 124.509 1.124 . . . . 73.409999999999997 108.866 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.402 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 18.0 Cg_endo -62.06 140.05 82.11 Favored 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.67 2.247 . . . . 71.140000000000001 113.763 -174.609 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 34.2 Cg_exo -64.61 127.55 19.12 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 123.329 2.686 . . . . 75.030000000000001 112.696 175.568 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 76.76 30.09 56.58 Favored Glycine 0 CA--C 1.528 0.847 0 O-C-N 123.49 0.494 . . . . 43.350000000000001 112.406 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.8 p -73.74 137.36 23.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.78 0 C-N-CA 122.89 0.476 . . . . 75.439999999999998 110.367 -177.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -103.67 173.31 6.36 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.135 0.969 . . . . 75.129999999999995 111.886 -171.176 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.8 tp10 -63.83 122.2 15.86 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-N 113.09 -1.868 . . . . 74.099999999999994 109.346 167.204 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 102.06 -8.39 55.67 Favored Glycine 0 N--CA 1.474 1.215 0 CA-C-O 119.758 -0.468 . . . . 74.409999999999997 113.127 178.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.0 m -78.37 121.99 25.19 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.094 0.447 . . . . 73.319999999999993 109.937 177.055 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.8 p -99.15 141.68 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 109.019 -0.734 . . . . 73.219999999999999 109.019 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.518 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 65.4 mt -108.43 104.21 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.344 1.058 . . . . 64.519999999999996 108.724 -176.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -88.68 121.12 30.72 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 123.261 0.625 . . . . 61.520000000000003 109.782 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -124.23 106.56 30.64 Favored Pre-proline 0 CA--C 1.557 1.23 0 N-CA-C 107.65 -1.241 . . . . 74.319999999999993 107.65 173.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.91 139.35 36.04 Favored 'Trans proline' 0 C--N 1.373 1.836 0 C-N-CA 122.935 2.423 . . . . 71.519999999999996 113.31 -174.647 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 77.4 0.15 71.12 Favored Glycine 0 C--N 1.352 1.426 0 CA-C-N 115.471 -0.786 . . . . 72.409999999999997 114.264 173.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 93.6 mmm -103.6 15.2 29.49 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.685 0.794 . . . . 75.319999999999993 111.712 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -94.35 -108.24 2.07 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 111.534 -0.626 . . . . 51.409999999999997 111.534 174.029 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.424 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -66.1 106.28 1.54 Allowed Glycine 0 C--N 1.344 1.011 0 C-N-CA 123.693 0.663 . . . . 71.420000000000002 112.575 175.407 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -83.8 165.18 19.03 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 123.75 0.82 . . . . 65.120000000000005 109.878 175.541 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 111.79 -141.6 16.71 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 111.184 -0.766 . . . . 54.149999999999999 111.184 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -76.61 -52.37 2.18 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 118.247 -0.882 . . . . 72.430000000000007 111.159 172.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -82.51 118.91 2.93 Favored 'Trans proline' 0 C--N 1.391 2.776 0 C-N-CA 121.627 1.551 . . . . 55.329999999999998 111.657 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_endo -84.9 126.71 3.41 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.718 2.279 . . . . 55.409999999999997 113.593 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.424 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -110.2 161.89 12.79 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 115.928 -0.578 . . . . 75.310000000000002 112.021 174.736 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -99.89 162.48 12.96 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 124.676 1.19 . . . . 72.450000000000003 110.009 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.61 HD21 HD11 ' A' ' 98' ' ' LEU . 54.3 tp -116.32 128.38 55.5 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.733 0.813 . . . . 63.539999999999999 109.796 178.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 90.7 mt -128.54 120.51 26.86 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 124.314 1.046 . . . . 61.43 109.729 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.518 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 93.7 mt -118.99 104.17 10.24 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 123.369 0.668 . . . . 73.040000000000006 110.745 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.4 t -86.22 98.5 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.982 0 CA-C-N 115.397 -0.82 . . . . 61.130000000000003 109.404 -172.76 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.3 t -61.29 117.0 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 123.987 0.915 . . . . 63.439999999999998 112.426 -173.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -112.88 101.08 9.16 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 126.103 1.761 . . . . 74.319999999999993 108.63 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.418 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 43.5 mt -71.49 114.25 9.37 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.148 -0.478 . . . . 70.340000000000003 110.779 -177.881 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 87.3 mt -61.53 146.73 89.4 Favored Pre-proline 0 CA--C 1.549 0.907 0 CA-C-N 114.752 -1.113 . . . . 61.409999999999997 110.636 178.348 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -64.39 -168.15 0.1 OUTLIER 'Trans proline' 0 C--N 1.378 2.131 0 C-N-CA 123.154 2.569 . . . . 74.219999999999999 113.81 -173.594 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 . . . . . 0 C--O 1.253 1.238 0 CA-C-O 118.014 -0.993 . . . . 64.0 108.664 -179.85 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.554 HD22 HG23 ' A' ' 100' ' ' THR . 3.2 pp . . . . . 0 N--CA 1.482 1.143 0 N-CA-C 111.628 0.233 . . . . 63.42 111.628 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.656 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 73.6 Cg_endo -73.71 -167.57 0.39 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.685 2.257 . . . . 72.41 111.377 171.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.475 HD12 ' H ' ' A' ' 98' ' ' LEU . 12.7 tp -75.96 142.69 41.91 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.603 -0.517 . . . . 51.43 109.603 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.589 HD13 HG21 ' A' ' 138' ' ' VAL . 6.3 tp 68.89 -57.98 0.5 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 126.95 2.1 . . . . 74.45 112.02 -167.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.656 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 65.7 t80 -72.65 135.33 45.44 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.697 1.199 . . . . 72.32 112.534 -173.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.554 HG23 HD22 ' A' ' 95' ' ' LEU . 55.4 m -153.97 101.25 2.49 Favored Pre-proline 0 CA--C 1.544 0.74 0 C-N-CA 123.985 0.914 . . . . 62.15 109.895 177.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -76.08 83.0 2.06 Favored 'Trans proline' 0 C--N 1.369 1.611 0 C-N-CA 122.128 1.885 . . . . 64.52 112.304 -173.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.529 HG13 HG22 ' A' ' 100' ' ' THR . 30.1 m . . . . . 0 CA--C 1.538 0.497 0 CA-C-N 114.935 -1.03 . . . . 65.55 109.729 173.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 . . . . . 0 N--CA 1.472 0.653 0 N-CA-C 108.948 -0.76 . . . . 63.23 108.948 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -93.31 104.41 16.58 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.561 -1.274 . . . . 64.33 107.561 -177.018 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.574 HD13 ' HA ' ' A' ' 99' ' ' PHE . 10.3 mt -94.08 109.78 21.52 Favored 'General case' 0 C--N 1.342 0.253 0 N-CA-C 107.093 -1.447 . . . . 71.12 107.093 -177.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.8 ttt180 -108.63 109.71 20.98 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.702 -0.481 . . . . 73.35 109.702 176.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -122.95 144.76 49.02 Favored 'General case' 0 C--O 1.242 0.693 0 N-CA-C 109.116 -0.698 . . . . 32.24 109.116 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -81.81 122.41 27.67 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.957 -1.127 . . . . 74.54 107.957 177.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.457 HD11 ' HG2' ' A' ' 136' ' ' ARG . 47.3 tp -99.32 103.38 20.2 Favored Pre-proline 0 CA--C 1.542 0.645 0 C-N-CA 123.565 0.746 . . . . 72.32 110.083 -171.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.13 114.39 3.97 Favored 'Trans proline' 0 C--N 1.374 1.894 0 C-N-CA 121.956 1.77 . . . . 72.34 110.017 176.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.536 HD21 HD12 ' A' ' 149' ' ' ILE . 14.2 tp -136.06 122.45 20.62 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 109.155 -0.683 . . . . 74.43 109.155 -168.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 3.0 m -69.61 162.31 27.87 Favored 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.987 0.915 . . . . 74.24 111.121 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 69.3 mt -63.93 -36.39 83.79 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.017 0.527 . . . . 73.31 112.37 -177.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -69.21 -40.19 78.15 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.292 0.637 . . . . 73.22 109.38 179.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.481 ' HG3' ' NH2' ' A' ' 136' ' ' ARG . 24.6 mm-40 -62.64 -44.27 96.7 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.477 1.111 . . . . 73.13 110.531 177.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.89 -37.29 78.93 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 115.158 -0.928 . . . . 73.11 111.408 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.5 t80 -65.84 -49.26 68.82 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.452 1.501 . . . . 71.43 110.881 -178.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -80.24 -41.22 25.51 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 115.28 -0.873 . . . . 73.21 111.157 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.528 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.36 58.35 8.83 Favored Glycine 0 C--N 1.345 1.073 0 O-C-N 123.543 0.527 . . . . 65.4 113.085 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -94.51 -130.69 6.0 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 110.966 -0.854 . . . . 75.31 110.966 174.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -107.76 160.3 15.83 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.284 0.564 . . . . 64.41 110.046 169.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.481 ' NH2' ' HG3' ' A' ' 129' ' ' GLU . 5.5 tpp180 -133.02 121.92 23.44 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.495 -1.298 . . . . 73.34 107.495 172.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 62.9 t -72.8 124.34 29.44 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-O 121.082 0.468 . . . . 73.34 110.084 175.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.589 HG21 HD13 ' A' ' 98' ' ' LEU . 32.9 m -127.33 145.2 35.19 Favored 'Isoleucine or valine' 0 C--O 1.251 1.142 0 C-N-CA 125.08 1.352 . . . . 74.22 108.105 -177.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -104.23 106.28 16.73 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.166 -0.679 . . . . 72.35 109.166 -176.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.609 HG13 ' HB2' ' A' ' 143' ' ' ARG . 2.4 p -106.45 100.18 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.829 0.851 . . . . 50.34 109.411 -176.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.92 23.91 14.26 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.426 0.691 . . . . 54.34 111.927 177.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.27 2.91 56.74 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 116.02 -0.537 . . . . 52.34 112.924 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.609 ' HB2' HG13 ' A' ' 140' ' ' VAL . 48.0 mtp180 -100.56 119.91 39.24 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 108.948 -0.76 . . . . 62.42 108.948 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.0 tmm_? -81.79 107.37 14.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.002 -0.74 . . . . 52.52 109.002 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 24.4 m -124.92 156.37 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 C-N-CA 123.701 0.8 . . . . 73.54 109.776 176.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.6 p -107.96 119.12 38.55 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 123.147 0.579 . . . . 73.45 110.192 174.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.0 p -99.16 132.28 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.671 -0.492 . . . . 64.25 109.671 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -80.36 120.19 24.07 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.877 0.37 . . . . 74.23 110.162 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.536 HD12 HD21 ' A' ' 125' ' ' LEU . 7.5 pt -95.08 142.01 24.03 Favored Pre-proline 0 CA--C 1.556 1.182 0 C-N-CA 124.135 0.974 . . . . 71.53 109.341 179.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -72.56 143.86 39.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.267 1.978 . . . . 74.33 112.5 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.33 133.54 19.43 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 122.633 2.222 . . . . 73.13 111.915 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.84 30.01 53.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.64 -0.709 . . . . 61.14 113.253 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 8.2 p -82.72 148.09 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 117.363 0.581 . . . . 72.05 109.634 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 -126.47 177.71 6.31 Favored 'General case' 0 N--CA 1.479 0.988 0 CA-C-O 121.567 0.699 . . . . 73.51 112.122 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.6 tp10 -61.37 129.17 39.88 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 113.835 -1.53 . . . . 75.41 110.78 177.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.66 4.66 90.0 Favored Glycine 0 C--N 1.344 0.984 0 O-C-N 123.701 0.626 . . . . 54.13 113.551 178.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 67.0 m -82.23 119.67 24.38 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 117.444 0.622 . . . . 72.53 109.457 175.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.3 p -98.55 125.29 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-O 121.213 0.53 . . . . 35.3 110.054 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.8 mt -91.75 104.03 15.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 C-N-CA 124.334 1.053 . . . . 72.55 108.173 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.464 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 74.8 ttt180 -94.45 114.66 26.72 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 110.139 -0.319 . . . . 73.55 110.139 -177.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 19.5 t -122.85 98.4 42.77 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 123.59 0.756 . . . . 73.43 109.092 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.06 125.72 12.86 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.931 2.421 . . . . 72.51 112.74 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 104.64 -24.49 28.46 Favored Glycine 0 N--CA 1.474 1.19 0 CA-C-O 120.151 -0.25 . . . . 62.31 113.167 176.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.3 ttm -89.57 -18.92 25.66 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.362 0.665 . . . . 72.34 111.338 -174.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -69.8 -100.76 0.04 OUTLIER Glycine 0 C--N 1.346 1.103 0 CA-C-O 119.677 -0.513 . . . . 74.11 113.197 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -53.36 107.78 0.65 Allowed Glycine 0 C--N 1.355 1.59 0 C-N-CA 123.103 0.383 . . . . 70.33 113.248 179.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 13.0 mm-40 -84.76 169.53 14.13 Favored 'General case' 0 C--O 1.237 0.431 0 C-N-CA 123.602 0.761 . . . . 73.32 110.096 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 108.33 -138.47 14.67 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.716 -0.675 . . . . 60.03 111.672 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.437 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 58.0 t30 -77.15 -51.55 2.02 Favored Pre-proline 0 CA--C 1.569 1.706 0 CA-C-O 118.285 -0.864 . . . . 73.35 111.541 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.437 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 72.8 Cg_endo -95.29 109.79 0.13 Allowed 'Trans proline' 0 C--N 1.394 2.958 0 C-N-CA 122.38 2.053 . . . . 62.22 112.746 177.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -60.45 125.95 18.72 Favored 'Trans proline' 0 C--N 1.381 2.261 0 C-N-CA 122.512 2.141 . . . . 61.12 111.654 175.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -112.27 177.33 18.51 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 116.412 -0.358 . . . . 72.23 113.88 -176.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.23 146.13 28.75 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.762 0.825 . . . . 72.12 110.318 -175.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 59.0 tp -113.38 134.51 54.6 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.196 0.598 . . . . 72.0 109.846 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 76.3 mt -129.61 105.2 7.9 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.437 1.095 . . . . 75.44 109.301 176.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.474 HD21 HD12 ' A' ' 98' ' ' LEU . 68.0 mt -107.55 102.73 11.96 Favored 'General case' 0 N--CA 1.479 1.013 0 O-C-N 122.109 -0.37 . . . . 62.44 110.009 174.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.7 t -85.93 99.04 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 N-CA-C 108.369 -0.974 . . . . 74.15 108.369 -175.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 87.0 t -56.23 116.81 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.45 1.1 . . . . 73.52 111.724 -177.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -113.07 104.21 12.15 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 125.576 1.551 . . . . 71.21 107.784 177.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 74.8 mt -69.39 130.38 42.38 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 122.918 0.487 . . . . 60.35 111.526 -174.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 92.1 mt -84.84 139.02 37.31 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.53 0.732 . . . . 72.44 110.128 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -65.38 116.54 3.95 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 123.193 2.595 . . . . 54.33 112.021 -175.059 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.543 -0.741 . . . . 73.32 109.415 -178.185 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.527 ' HB3' ' HA ' ' A' ' 100' ' ' THR . 0.5 OUTLIER . . . . . 0 CA--C 1.554 1.116 0 N-CA-C 109.058 -0.719 . . . . 65.24 109.058 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -66.62 -49.27 1.73 Allowed 'Trans proline' 0 C--N 1.385 2.498 0 C-N-CA 122.612 2.208 . . . . 70.33 111.691 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.526 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.4 tp -179.52 154.36 0.61 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.627 1.571 . . . . 74.14 106.945 -175.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.553 HD11 HD21 ' A' ' 174' ' ' LEU . 7.4 tp 53.04 -75.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 125.976 1.71 . . . . 63.23 111.551 -174.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.74 ' HA ' HD13 ' A' ' 119' ' ' LEU . 85.4 t80 -50.54 129.18 21.84 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.097 1.759 . . . . 74.31 112.341 171.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.557 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 55.2 m -142.18 105.99 5.65 Favored Pre-proline 0 N--CA 1.471 0.587 0 C-N-CA 124.105 0.962 . . . . 71.03 108.442 172.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -76.85 87.55 1.47 Allowed 'Trans proline' 0 C--N 1.366 1.453 0 C-N-CA 121.517 1.478 . . . . 64.43 112.42 -170.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 CA--C 1.546 0.791 0 CA-C-N 114.735 -1.12 . . . . 74.23 109.995 177.425 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.431 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 94.2 mtt180 . . . . . 0 N--CA 1.476 0.862 0 N-CA-C 110.077 -0.342 . . . . 73.15 110.077 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.7 105.95 18.17 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 107.345 -1.354 . . . . 65.31 107.345 -177.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.74 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.5 mt -92.87 108.96 20.4 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 107.26 -1.385 . . . . 71.4 107.26 -176.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 74.4 ttt180 -119.33 105.87 11.74 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.131 0.972 . . . . 73.14 108.663 -175.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.58 145.23 40.34 Favored 'General case' 0 C--O 1.242 0.67 0 C-N-CA 123.722 0.809 . . . . 53.1 109.567 -174.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -76.66 137.59 39.52 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.536 -0.542 . . . . 64.02 109.536 175.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.411 ' HA ' ' HD2' ' A' ' 124' ' ' PRO . 19.9 tp -101.62 105.36 40.27 Favored Pre-proline 0 CA--C 1.542 0.671 0 C-N-CA 123.992 0.917 . . . . 71.31 110.201 -178.357 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 123' ' ' LEU . 23.5 Cg_endo -60.64 122.78 11.8 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.488 2.125 . . . . 74.11 110.342 169.12 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.468 HD21 HD12 ' A' ' 149' ' ' ILE . 25.3 tp -147.83 133.79 19.17 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.889 -0.782 . . . . 73.33 108.889 -175.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.9 p -81.21 163.66 22.86 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 110.129 -0.323 . . . . 72.12 110.129 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.0 mt -61.92 -32.7 73.13 Favored 'General case' 0 N--CA 1.482 1.168 0 C-N-CA 123.607 0.763 . . . . 63.21 110.971 179.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -70.72 -50.23 38.51 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 114.987 -1.006 . . . . 75.15 109.406 -177.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -70.13 -26.65 64.05 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.794 0.837 . . . . 73.22 111.859 -179.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.75 -40.31 69.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.216 0.606 . . . . 75.43 110.744 174.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -64.43 -46.4 83.36 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.911 0.884 . . . . 64.44 110.698 175.504 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -63.36 -49.67 72.96 Favored 'General case' 0 C--N 1.351 0.671 0 O-C-N 123.71 0.631 . . . . 73.22 110.362 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.505 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 56.63 70.39 0.99 Allowed Glycine 0 C--N 1.349 1.276 0 O-C-N 124.128 0.893 . . . . 75.11 112.771 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -121.06 -121.37 2.81 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.35 -1.1 . . . . 72.4 110.35 174.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.557 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 7.0 mp0 -99.69 154.96 17.88 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 123.143 0.577 . . . . 42.33 109.528 172.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.458 ' HB2' HD13 ' A' ' 149' ' ' ILE . 14.0 tpt180 -137.04 122.55 19.61 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 108.162 -1.051 . . . . 75.42 108.162 178.479 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.1 t -74.34 119.44 21.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 O-C-N 123.577 0.548 . . . . 75.14 109.886 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.548 HG21 HD13 ' A' ' 98' ' ' LEU . 28.5 m -122.68 147.38 26.89 Favored 'Isoleucine or valine' 0 C--O 1.251 1.147 0 C-N-CA 124.769 1.228 . . . . 55.21 109.067 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -100.91 127.83 47.22 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.987 0.915 . . . . 74.11 109.268 -177.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.562 HG23 ' HB2' ' A' ' 99' ' ' PHE . 3.1 p -142.66 103.67 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 123.287 0.635 . . . . 72.54 111.118 -174.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 55.38 29.69 13.55 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 124.448 1.099 . . . . 64.41 113.14 172.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.65 26.34 10.85 Favored Glycine 0 C--N 1.348 1.248 0 CA-C-N 116.36 -0.382 . . . . 41.1 112.658 179.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.496 ' HB2' HG13 ' A' ' 140' ' ' VAL . 54.3 mmt-85 -131.87 136.18 47.25 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.842 0.857 . . . . 72.42 110.049 -178.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 16.1 ttp180 -95.67 105.88 17.92 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 107.917 -1.142 . . . . 75.33 107.917 171.249 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 33.0 m -125.44 151.37 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 109.915 -0.402 . . . . 31.22 109.915 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.557 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 34.6 p -106.11 117.65 34.58 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.296 0.638 . . . . 72.34 109.924 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.2 p -98.8 133.35 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 108.664 -0.865 . . . . 72.22 108.664 176.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.4 ttt85 -82.4 125.74 31.39 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.203 0.525 . . . . 65.52 109.754 -178.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.505 HG13 ' HA2' ' A' ' 133' ' ' GLY . 3.3 pt -107.56 145.8 32.04 Favored Pre-proline 0 CA--C 1.557 1.219 0 C-N-CA 124.882 1.273 . . . . 53.42 108.686 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.43 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 56.7 Cg_endo -71.08 146.56 52.38 Favored 'Trans proline' 0 CA--C 1.566 2.099 0 C-N-CA 122.161 1.907 . . . . 72.31 112.823 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 23.9 Cg_exo -66.79 134.95 36.57 Favored 'Trans proline' 0 C--N 1.38 2.23 0 C-N-CA 123.172 2.581 . . . . 64.1 111.962 172.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.16 28.03 62.95 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-N 115.724 -0.671 . . . . 74.11 113.024 -177.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.43 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 14.7 p -78.19 147.2 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.256 -0.646 . . . . 74.13 109.256 177.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -129.61 177.23 7.37 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 122.011 0.91 . . . . 62.11 113.085 -167.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.5 tp10 -62.58 121.4 13.23 Favored 'General case' 0 C--O 1.241 0.644 0 CA-C-N 113.463 -1.699 . . . . 74.04 110.414 174.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.73 2.83 69.21 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 115.892 -0.595 . . . . 60.4 112.822 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 59.5 m -86.39 122.04 29.79 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 109.458 -0.571 . . . . 73.33 109.458 174.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.5 p -101.23 126.35 55.05 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.232 0.539 . . . . 74.41 110.051 178.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 60.7 mt -93.94 102.92 14.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.941 1.296 . . . . 70.41 107.914 176.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -98.38 121.62 40.53 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.956 -0.387 . . . . 75.33 109.956 -179.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 4.2 t -115.47 99.62 52.64 Favored Pre-proline 0 CA--C 1.556 1.192 0 N-CA-C 107.692 -1.225 . . . . 74.53 107.692 173.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -68.25 131.39 23.36 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 123.098 2.532 . . . . 60.25 113.63 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 75.87 24.07 70.51 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.085 -0.962 . . . . 45.03 113.784 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.7 tpt -126.28 -9.2 6.4 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 123.62 0.768 . . . . 71.42 111.21 -176.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -71.11 -94.7 0.07 OUTLIER Glycine 0 C--N 1.347 1.172 0 CA-C-O 120.175 -0.236 . . . . 74.34 112.848 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -68.84 106.96 1.91 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.966 -0.352 . . . . 44.42 112.433 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -72.43 137.46 46.48 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.647 0.779 . . . . 71.23 111.013 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.2 -163.75 32.55 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 116.006 -0.543 . . . . 75.42 112.157 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -72.94 -43.95 8.17 Favored Pre-proline 0 CA--C 1.565 1.537 0 CA-C-O 118.968 -0.539 . . . . 73.3 110.725 174.172 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -93.34 108.37 0.18 Allowed 'Trans proline' 0 C--N 1.386 2.511 0 C-N-CA 122.081 1.854 . . . . 73.32 111.254 163.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -82.74 137.67 8.99 Favored 'Trans proline' 0 C--N 1.372 1.807 0 C-N-CA 122.361 2.041 . . . . 62.14 112.243 -178.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . 0.431 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -99.04 179.93 31.36 Favored Glycine 0 C--N 1.343 0.935 0 CA-C-N 115.933 -0.576 . . . . 45.42 113.14 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -87.88 149.03 24.34 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 122.844 0.458 . . . . 74.0 111.239 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.553 HD21 HD11 ' A' ' 98' ' ' LEU . 41.8 tp -112.42 128.64 56.37 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 122.844 0.458 . . . . 74.55 109.915 177.301 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 74.3 mt -127.46 115.48 18.96 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 124.196 0.998 . . . . 72.51 109.157 178.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.5 HD21 HD12 ' A' ' 98' ' ' LEU . 72.9 mt -117.07 103.42 10.22 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 123.178 0.591 . . . . 75.32 110.489 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.6 t -89.79 98.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.072 0 C-N-CA 122.524 0.33 . . . . 73.0 110.331 -173.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.8 t -60.09 113.87 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 C-N-CA 124.203 1.001 . . . . 55.54 112.694 -173.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 22.1 mmm180 -105.0 109.14 21.01 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.126 1.77 . . . . 73.03 108.649 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 86.6 mt -71.87 119.0 15.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.387 0.275 . . . . 74.14 110.449 179.152 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 78.4 mt -79.05 147.35 69.63 Favored Pre-proline 0 CA--C 1.545 0.784 0 C-N-CA 123.693 0.797 . . . . 54.32 110.79 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -61.1 110.0 0.79 Allowed 'Trans proline' 0 C--N 1.373 1.82 0 C-N-CA 123.368 2.712 . . . . 75.33 111.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 77.6 t60 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.733 -0.651 . . . . 63.24 110.289 178.507 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.562 1.426 0 N-CA-C 114.26 1.207 . . . . 65.04 114.26 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.66 -66.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.388 2.65 0 C-N-CA 122.738 2.292 . . . . 74.12 111.477 174.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.2 tp -178.89 149.44 0.45 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 125.236 1.414 . . . . 63.13 107.809 175.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.663 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 13.2 tp 56.99 8.6 0.52 Allowed 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 124.422 1.089 . . . . 74.44 112.494 -174.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.642 ' HA ' HD13 ' A' ' 119' ' ' LEU . 77.2 t80 -150.87 124.49 9.05 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 123.927 0.891 . . . . 74.2 109.261 -165.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.602 ' H ' HD22 ' A' ' 119' ' ' LEU . 95.7 m -150.5 95.24 3.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 C-N-CA 124.639 1.175 . . . . 75.11 108.155 176.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.6 104.65 1.16 Allowed 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 121.921 1.748 . . . . 55.13 110.804 -176.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.8 m . . . . . 0 C--O 1.244 0.789 0 C-N-CA 123.793 0.837 . . . . 75.51 109.466 178.307 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 24.2 ptt180 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.687 0.279 . . . . 64.22 110.922 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -92.61 114.71 27.34 Favored 'General case' 0 C--N 1.348 0.519 0 N-CA-C 107.686 -1.227 . . . . 72.31 107.686 175.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.642 HD13 ' HA ' ' A' ' 99' ' ' PHE . 31.2 mt -93.44 107.22 19.1 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 106.991 -1.485 . . . . 64.05 106.991 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.485 ' H ' ' HB ' ' A' ' 100' ' ' THR . 19.6 ttt180 -116.0 105.83 13.09 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.03 -0.73 . . . . 72.31 109.03 178.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 141.36 48.17 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.829 0.852 . . . . 45.21 108.772 -177.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.14 129.6 34.62 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.372 -0.603 . . . . 73.13 109.372 174.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.483 HD12 HD13 ' A' ' 176' ' ' LEU . 1.7 tt -101.6 109.64 59.75 Favored Pre-proline 0 CA--C 1.55 0.965 0 C-N-CA 123.479 0.712 . . . . 70.44 109.379 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -67.4 121.82 8.98 Favored 'Trans proline' 0 C--N 1.377 2.079 0 C-N-CA 122.559 2.173 . . . . 71.41 110.954 172.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.1 tp -140.67 135.09 31.29 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 108.805 -0.813 . . . . 73.12 108.805 -173.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.5 p -76.15 167.12 22.44 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.892 -0.41 . . . . 71.33 109.892 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.516 HD12 ' HB2' ' A' ' 183' ' ' HIS . 86.6 mt -66.77 -31.11 71.54 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.033 0.533 . . . . 74.14 110.644 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -71.11 -49.49 43.79 Favored 'General case' 0 C--O 1.22 -0.497 0 CA-C-N 114.701 -1.136 . . . . 71.31 109.135 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -74.35 -19.6 60.39 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.405 0.682 . . . . 71.34 111.452 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.54 -45.21 72.78 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.138 0.575 . . . . 52.33 109.853 167.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.03 -41.37 95.32 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 123.938 0.895 . . . . 75.11 111.006 176.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -75.48 -39.76 58.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.131 0.572 . . . . 74.33 110.679 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.25 -114.11 6.26 Favored Glycine 0 C--N 1.345 1.081 0 CA-C-N 115.273 -0.876 . . . . 73.11 111.207 -172.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.12 -132.71 39.58 Favored Glycine 0 C--N 1.351 1.382 0 CA-C-O 119.668 -0.518 . . . . 75.15 112.413 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.575 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 10.3 mp0 -105.75 158.22 16.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.847 0.859 . . . . 75.14 109.958 176.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.632 ' HB2' HD13 ' A' ' 149' ' ' ILE . 23.4 tpt85 -133.91 120.87 20.92 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.733 0.813 . . . . 72.52 109.063 178.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.6 t -74.88 109.08 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 C-N-CA 124.165 0.986 . . . . 73.51 109.626 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.49 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 26.1 m -128.03 149.15 32.68 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 C-N-CA 124.075 0.95 . . . . 72.45 110.098 -174.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -97.73 103.75 15.72 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 123.649 0.78 . . . . 63.13 111.322 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.663 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.3 p -103.94 102.26 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.103 0.961 . . . . 71.14 109.569 -179.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.93 27.74 17.16 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 124.321 1.049 . . . . 63.51 112.201 177.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.54 -13.09 59.78 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-O 119.317 -0.713 . . . . 71.01 114.227 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.23 152.25 19.32 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 118.164 0.982 . . . . 74.11 110.093 177.165 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 -100.17 109.01 21.27 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.587 0.755 . . . . 61.14 109.602 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 86.3 t -122.66 136.84 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 N-CA-C 108.572 -0.899 . . . . 74.14 108.572 175.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.575 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 77.5 p -95.5 113.09 24.72 Favored 'General case' 0 C--O 1.242 0.658 0 N-CA-C 109.168 -0.679 . . . . 60.53 109.168 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -97.84 136.48 28.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 123.57 0.748 . . . . 53.54 109.216 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -81.03 127.27 32.41 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.369 0.605 . . . . 64.12 110.568 -176.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.632 HD13 ' HB2' ' A' ' 136' ' ' ARG . 7.5 pt -118.07 145.32 36.62 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.658 1.583 . . . . 73.04 108.43 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.04 138.2 27.8 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.456 2.104 . . . . 73.5 112.599 178.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.73 143.66 51.7 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.336 2.024 . . . . 63.42 111.544 169.012 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.0 26.48 58.11 Favored Glycine 0 C--N 1.343 0.932 0 CA-C-N 116.278 -0.419 . . . . 53.22 112.897 -173.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.6 p -87.58 150.85 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 C-N-CA 123.2 0.6 . . . . 71.34 109.869 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 42.6 mtp180 -123.16 177.86 5.36 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 121.722 0.773 . . . . 75.41 112.358 -177.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -58.37 137.27 57.35 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 113.282 -1.781 . . . . 75.41 111.038 174.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.76 -14.15 38.55 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-O 119.352 -0.693 . . . . 30.23 113.976 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 63.5 m -71.11 118.37 13.81 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 117.558 0.679 . . . . 74.24 109.593 -179.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.65 132.52 42.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 122.99 0.516 . . . . 64.43 109.716 -179.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.06 104.65 16.93 Favored 'Isoleucine or valine' 0 C--O 1.241 0.606 0 C-N-CA 124.876 1.27 . . . . 65.04 107.588 -177.456 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.426 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 64.7 ttt180 -91.61 112.64 24.65 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 109.94 -0.393 . . . . 74.12 109.94 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 8.6 t -104.11 100.12 19.78 Favored Pre-proline 0 CA--C 1.557 1.219 0 N-CA-C 106.989 -1.485 . . . . 74.21 106.989 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -66.63 128.83 19.8 Favored 'Trans proline' 0 C--N 1.375 1.943 0 C-N-CA 122.878 2.385 . . . . 70.11 113.096 -174.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.56 22.78 78.13 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.939 -0.573 . . . . 73.54 114.207 176.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.1 tpt -107.45 -23.96 11.99 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 123.385 0.674 . . . . 51.45 110.969 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -66.45 -84.14 0.1 OUTLIER Glycine 0 C--N 1.344 1.024 0 CA-C-N 116.359 -0.382 . . . . 73.2 112.865 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -71.46 93.09 0.52 Allowed Glycine 0 C--N 1.346 1.109 0 N-CA-C 111.466 -0.653 . . . . 61.3 111.466 173.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.4 mm-40 -78.78 143.61 35.94 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.757 0.823 . . . . 61.41 111.756 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.13 -168.24 25.78 Favored Glycine 0 C--O 1.241 0.583 0 CA-C-N 114.8 -1.091 . . . . 65.0 110.377 -177.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 17.3 m120 -62.16 -44.37 88.79 Favored Pre-proline 0 CA--C 1.562 1.416 0 CA-C-O 118.655 -0.688 . . . . 75.43 110.82 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -82.96 114.43 2.26 Favored 'Trans proline' 0 C--N 1.394 2.972 0 C-N-CA 121.872 1.714 . . . . 74.34 111.717 167.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -82.94 150.27 14.03 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.222 1.948 . . . . 63.31 113.059 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -132.84 151.66 20.07 Favored Glycine 0 N--CA 1.473 1.123 0 N-CA-C 110.326 -1.109 . . . . 42.24 110.326 170.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.58 156.06 39.39 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.489 0.715 . . . . 51.43 112.49 -175.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.507 HD21 HD11 ' A' ' 98' ' ' LEU . 65.5 tp -116.22 127.94 55.19 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 108.428 -0.953 . . . . 75.51 108.428 172.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 54.5 mt -128.26 118.34 23.11 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 124.825 1.25 . . . . 63.03 108.689 -178.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.483 HD13 HD12 ' A' ' 123' ' ' LEU . 86.1 mt -120.68 103.31 9.02 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 123.061 0.545 . . . . 71.31 111.043 -178.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.9 t -85.43 96.02 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.587 -0.523 . . . . 74.52 109.587 -176.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.4 t -55.5 126.76 13.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.921 0.888 . . . . 51.35 111.807 -178.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -112.48 113.12 25.14 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 125.19 1.396 . . . . 74.34 107.687 177.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 50.3 mt -74.56 119.53 18.88 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.255 -0.646 . . . . 75.43 109.255 176.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 67.0 mt -82.33 131.24 56.46 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 108.317 -0.994 . . . . 72.25 108.317 176.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -68.31 143.03 56.87 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.961 2.441 . . . . 62.41 112.284 -174.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.516 ' HB2' HD12 ' A' ' 127' ' ' LEU . 47.0 m80 . . . . . 0 N--CA 1.485 1.319 0 C-N-CA 124.03 0.932 . . . . 62.12 108.806 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.429 ' HB2' ' O ' ' A' ' 99' ' ' PHE . 2.6 pt? . . . . . 0 CA--C 1.563 1.452 0 N-CA-C 112.238 0.459 . . . . 70.44 112.238 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.431 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 10.3 Cg_endo -86.75 -79.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 123.009 2.473 . . . . 74.11 111.248 177.691 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.475 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.5 tp -157.83 142.23 16.18 Favored 'General case' 0 C--N 1.348 0.521 0 N-CA-C 108.292 -1.003 . . . . 63.41 108.292 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.712 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 5.2 tp 57.09 7.75 0.46 Allowed 'General case' 0 CA--C 1.57 1.713 0 C-N-CA 126.096 1.758 . . . . 53.21 113.172 -173.099 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.647 ' HA ' HD13 ' A' ' 119' ' ' LEU . 86.7 t80 -139.12 128.79 24.63 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.825 0.85 . . . . 63.31 109.333 -171.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.534 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 86.2 m -153.05 98.62 2.76 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 124.192 0.997 . . . . 74.44 109.342 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -72.16 83.18 1.23 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.444 2.096 . . . . 75.51 112.242 -173.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 20.6 m . . . . . 0 N--CA 1.474 0.75 0 CA-C-N 115.406 -0.816 . . . . 75.13 109.691 175.385 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.503 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.0 OUTLIER . . . . . 0 N--CA 1.479 0.992 0 N-CA-C 110.209 -0.293 . . . . 62.43 110.209 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -95.35 107.32 19.44 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 107.086 -1.45 . . . . 73.45 107.086 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.647 HD13 ' HA ' ' A' ' 99' ' ' PHE . 15.7 mt -92.76 108.46 20.0 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 107.593 -1.262 . . . . 64.25 107.593 -174.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.518 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 20.8 ttt180 -106.17 104.71 14.47 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 109.049 -0.723 . . . . 65.14 109.049 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -123.19 134.34 54.17 Favored 'General case' 0 C--O 1.237 0.411 0 N-CA-C 108.929 -0.767 . . . . 51.44 108.929 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -80.87 121.78 26.39 Favored 'General case' 0 C--O 1.241 0.637 0 N-CA-C 108.254 -1.017 . . . . 61.31 108.254 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.572 HD21 ' HG2' ' A' ' 136' ' ' ARG . 5.5 tt -99.06 109.74 55.26 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 108.159 -1.052 . . . . 70.11 108.159 -171.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -72.75 115.23 4.26 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 121.904 1.736 . . . . 62.24 110.443 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.604 HD21 HD12 ' A' ' 149' ' ' ILE . 29.0 tp -128.81 137.51 51.55 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.601 0.76 . . . . 73.21 109.498 -173.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 74.3 p -79.87 162.62 24.91 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.11 -0.33 . . . . 35.2 110.11 -178.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.97 -26.95 65.3 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.393 0.677 . . . . 73.24 110.962 -178.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -68.55 -50.31 52.82 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 114.934 -1.03 . . . . 62.11 109.093 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 -73.63 -21.23 60.36 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 114.991 -1.004 . . . . 74.35 112.324 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.09 -44.89 64.76 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.991 0.517 . . . . 72.22 109.74 170.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -62.13 -42.35 99.16 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.666 1.186 . . . . 72.34 110.921 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -74.42 -48.8 25.51 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.607 0.363 . . . . 73.52 110.427 -178.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.604 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 62.49 52.34 49.73 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 123.997 0.81 . . . . 74.11 113.853 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -101.37 -130.49 7.06 Favored Glycine 0 C--N 1.347 1.148 0 N-CA-C 111.452 -0.659 . . . . 62.51 111.452 177.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -97.28 158.61 15.37 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.072 0.549 . . . . 72.53 110.149 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.572 ' HG2' HD21 ' A' ' 123' ' ' LEU . 41.0 tpt85 -136.84 119.69 16.3 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.214 -0.903 . . . . 74.52 108.975 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.8 t -86.39 105.96 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 123.397 0.679 . . . . 70.21 109.643 -177.143 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.52 HG21 HD13 ' A' ' 98' ' ' LEU . 34.3 m -117.01 162.6 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.001 1.321 . . . . 70.3 108.345 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -123.98 112.69 17.49 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 122.497 0.319 . . . . 73.45 111.263 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.712 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.9 p -106.46 105.44 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 124.469 1.107 . . . . 75.4 109.965 -178.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 58.02 28.74 16.71 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.633 0.773 . . . . 61.13 112.122 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.25 2.76 55.74 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-O 119.566 -0.574 . . . . 75.24 114.069 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.6 mtt180 -100.73 121.8 42.27 Favored 'General case' 0 N--CA 1.486 1.349 0 CA-C-N 117.735 0.767 . . . . 64.52 110.724 -178.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -74.96 126.32 30.75 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.463 0.705 . . . . 74.03 109.319 172.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 3.2 p -148.79 131.0 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.068 0.547 . . . . 70.15 110.464 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 12.5 p -91.42 105.85 18.07 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 123.547 0.739 . . . . 74.32 109.647 176.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.8 p -99.35 132.56 44.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 123.906 0.882 . . . . 73.04 109.036 176.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 58.1 ttt85 -81.92 129.16 34.68 Favored 'General case' 0 C--O 1.242 0.667 0 CA-C-O 121.59 0.709 . . . . 75.35 110.696 -176.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.604 HD12 HD21 ' A' ' 125' ' ' LEU . 2.4 pt -98.56 145.2 29.48 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.637 1.575 . . . . 60.41 108.734 174.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.91 143.88 62.44 Favored 'Trans proline' 0 CA--C 1.562 1.906 0 C-N-CA 121.986 1.791 . . . . 74.21 112.215 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.604 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 30.5 Cg_endo -62.27 130.16 29.45 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.18 2.586 . . . . 54.32 111.787 175.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 64.76 46.77 88.76 Favored Glycine 0 C--N 1.344 1.021 0 O-C-N 123.966 0.791 . . . . 72.24 111.614 -175.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 178' ' ' VAL . 8.2 p -75.72 145.6 10.41 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 CA-C-O 121.187 0.517 . . . . 74.42 110.256 179.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.4 mtp180 -104.07 169.78 8.3 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.19 0.996 . . . . 75.12 111.974 -172.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.6 tp10 -68.19 134.6 50.72 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-N 113.834 -1.53 . . . . 74.22 110.331 176.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.05 2.79 66.81 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-O 118.968 -0.907 . . . . 74.13 114.395 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.7 m -71.13 117.63 12.89 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 118.213 1.006 . . . . 72.55 108.869 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.7 p -93.37 132.25 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 109.34 -0.615 . . . . 74.4 109.34 -178.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.546 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 50.0 mt -105.93 104.12 16.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 107.807 -1.183 . . . . 55.2 107.807 -178.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 36.1 ttm180 -91.46 104.74 17.22 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 109.632 -0.507 . . . . 61.25 109.632 177.521 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.4 t -97.12 111.58 58.35 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 107.361 -1.348 . . . . 74.3 107.361 174.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -69.86 124.62 11.22 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 123.17 2.58 . . . . 72.12 113.46 -170.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 69.38 16.01 70.96 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 114.743 0.657 . . . . 53.43 114.743 173.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.9 mmt -113.83 12.64 18.26 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 123.317 0.647 . . . . 74.03 111.659 -177.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -96.43 -102.17 2.01 Favored Glycine 0 C--N 1.338 0.661 0 O-C-N 123.472 0.483 . . . . 71.14 112.588 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . 0.503 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -65.48 121.47 20.41 Favored Glycine 0 C--N 1.353 1.523 0 O-C-N 123.948 0.44 . . . . 64.03 113.587 -173.194 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -71.22 146.95 48.71 Favored 'General case' 0 C--O 1.246 0.92 0 C-N-CA 123.414 0.686 . . . . 73.44 110.952 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 155.32 -169.38 33.26 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.025 -0.989 . . . . 75.34 111.093 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -74.34 -48.91 5.46 Favored Pre-proline 0 CA--C 1.566 1.572 0 CA-C-O 118.621 -0.704 . . . . 73.31 109.378 174.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -83.55 111.59 1.79 Allowed 'Trans proline' 0 C--N 1.394 2.962 0 C-N-CA 121.641 1.56 . . . . 62.11 110.264 164.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -69.52 128.89 16.91 Favored 'Trans proline' 0 C--N 1.369 1.64 0 C-N-CA 122.261 1.974 . . . . 65.01 111.854 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -90.99 166.78 31.31 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-O 119.873 -0.404 . . . . 73.53 112.129 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -82.45 158.68 23.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 122.989 0.516 . . . . 75.31 111.11 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.653 HD21 HD11 ' A' ' 98' ' ' LEU . 40.9 tp -118.29 131.55 56.34 Favored 'General case' 0 C--O 1.223 -0.3 0 C-N-CA 123.69 0.796 . . . . 74.34 109.463 -178.001 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.518 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 87.0 mt -128.8 125.54 38.0 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.028 0.931 . . . . 55.53 109.804 -177.617 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.612 HD21 HD12 ' A' ' 98' ' ' LEU . 80.8 mt -125.27 103.03 7.73 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.221 0.609 . . . . 63.12 111.124 178.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 39.4 t -85.59 94.34 4.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.306 -0.998 . . . . 51.43 108.306 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 153' ' ' VAL . 98.7 t -58.49 114.83 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 C-N-CA 123.739 0.816 . . . . 72.12 111.049 -177.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -106.44 104.41 14.09 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 124.506 1.123 . . . . 74.45 108.751 178.284 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 72.3 mt -68.94 105.05 2.25 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 109.669 -0.493 . . . . 53.25 109.669 178.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.3 mt -60.74 149.66 78.84 Favored Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 124.295 1.038 . . . . 52.02 111.399 175.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -70.73 165.86 30.68 Favored 'Trans proline' 0 C--N 1.373 1.844 0 C-N-CA 122.314 2.009 . . . . 71.12 111.311 174.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 . . . . . 0 CA--C 1.552 1.039 0 N-CA-C 108.907 -0.775 . . . . 72.34 108.907 174.33 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.407 ' HB3' ' HA ' ' A' ' 100' ' ' THR . 0.8 OUTLIER . . . . . 0 CA--C 1.551 0.996 0 CA-C-O 119.822 -0.132 . . . . 74.34 111.004 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.1 -67.12 0.03 OUTLIER 'Trans proline' 0 C--N 1.382 2.308 0 C-N-CA 122.055 1.837 . . . . 71.54 110.969 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.515 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 5.7 tp -171.6 143.62 1.76 Allowed 'General case' 0 C--N 1.35 0.62 0 C-N-CA 124.202 1.001 . . . . 73.52 108.457 176.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.664 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 6.1 tp 59.36 4.22 0.47 Allowed 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 125.628 1.571 . . . . 72.31 113.158 -173.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.596 ' HB2' HG23 ' A' ' 140' ' ' VAL . 82.7 t80 -139.95 130.43 25.51 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 107.789 -1.189 . . . . 60.32 107.789 -171.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.455 HG22 HG13 ' A' ' 102' ' ' VAL . 75.9 m -149.45 98.02 3.49 Favored Pre-proline 0 N--CA 1.469 0.483 0 O-C-N 124.327 1.017 . . . . 65.52 109.641 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -70.88 80.8 1.17 Allowed 'Trans proline' 0 C--N 1.367 1.516 0 C-N-CA 122.682 2.255 . . . . 53.32 112.679 -176.089 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.455 HG13 HG22 ' A' ' 100' ' ' THR . 29.9 m . . . . . 0 N--CA 1.474 0.726 0 C-N-CA 124.586 1.154 . . . . 71.24 109.342 171.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 13.7 mtm180 . . . . . 0 N--CA 1.478 0.957 0 N-CA-C 109.323 -0.621 . . . . 62.24 109.323 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -103.54 104.24 14.29 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.037 -1.468 . . . . 73.11 107.037 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.538 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.9 mt -93.55 110.26 21.85 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.846 -1.168 . . . . 74.44 107.846 -174.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.449 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 73.6 ttt-85 -107.49 104.53 14.12 Favored 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 108.732 -0.84 . . . . 73.43 108.732 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -121.11 126.93 51.02 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.692 0.797 . . . . 42.21 109.42 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -73.26 118.25 15.99 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 123.54 0.736 . . . . 72.13 109.563 176.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.422 HD21 ' HG2' ' A' ' 136' ' ' ARG . 5.3 tt -100.83 111.15 62.7 Favored Pre-proline 0 CA--C 1.549 0.934 0 C-N-CA 123.938 0.895 . . . . 54.23 108.849 -175.17 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.04 126.03 13.27 Favored 'Trans proline' 0 C--N 1.379 2.168 0 C-N-CA 122.555 2.17 . . . . 60.41 111.43 175.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.474 HD21 HD12 ' A' ' 149' ' ' ILE . 15.9 tp -148.15 133.83 18.87 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.231 -0.655 . . . . 72.02 109.231 -173.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.8 p -87.66 171.62 10.32 Favored 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 118.084 0.402 . . . . 62.45 110.312 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.21 -35.66 81.07 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.595 0.758 . . . . 70.23 111.362 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -63.96 -50.56 68.13 Favored 'General case' 0 C--N 1.35 0.61 0 CA-C-N 114.718 -1.128 . . . . 64.05 109.258 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 22.3 mm-40 -73.7 -24.69 59.97 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-N 114.58 -1.191 . . . . 72.53 111.334 -176.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.493 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.42 -38.91 81.66 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.212 -0.904 . . . . 71.4 110.345 173.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -72.66 -39.19 67.33 Favored 'General case' 0 CA--C 1.547 0.84 0 CA-C-N 115.473 -0.785 . . . . 71.31 110.423 176.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.71 -48.85 67.95 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 122.34 0.256 . . . . 75.4 111.045 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.588 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.25 59.37 10.98 Favored Glycine 0 C--N 1.345 1.061 0 O-C-N 124.015 0.822 . . . . 35.42 113.567 175.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.426 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -121.69 -155.64 9.51 Favored Glycine 0 C--N 1.34 0.783 0 N-CA-C 111.64 -0.584 . . . . 71.4 111.64 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.619 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.0 mp0 -75.12 122.74 24.05 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 109.929 -0.397 . . . . 72.43 109.929 179.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.442 ' HB2' HD13 ' A' ' 149' ' ' ILE . 12.8 tpt180 -109.59 119.53 39.7 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.391 -1.337 . . . . 64.33 107.391 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 50.7 t -83.1 106.63 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.476 0.71 . . . . 72.42 109.191 -172.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.515 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 33.4 m -116.85 163.24 14.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.887 0 C-N-CA 125.551 1.54 . . . . 64.22 108.806 -177.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -122.84 111.56 16.82 Favored 'General case' 0 N--CA 1.481 1.097 0 O-C-N 121.748 -0.595 . . . . 63.52 110.667 -178.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.664 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.4 p -104.14 109.74 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 125.015 1.326 . . . . 74.34 109.471 -177.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.94 22.39 13.02 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 123.837 0.855 . . . . 52.23 112.76 176.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.95 -13.83 58.88 Favored Glycine 0 C--N 1.352 1.439 0 CA-C-O 120.016 -0.325 . . . . 63.22 113.413 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 26.1 tpt180 -90.72 127.55 36.35 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 123.803 0.841 . . . . 63.12 109.401 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 15.5 tpp85 -89.2 130.1 35.67 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.577 -0.527 . . . . 74.32 109.577 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.8 p -147.47 148.98 15.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 C-N-CA 124.193 0.997 . . . . 75.55 109.555 -179.119 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.619 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 42.9 p -101.17 109.27 21.13 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.371 0.669 . . . . 63.13 110.156 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.77 124.83 53.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 123.316 0.646 . . . . 63.13 109.37 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 41.5 ttt180 -71.83 127.93 34.13 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 120.916 0.389 . . . . 74.11 110.494 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.588 HG13 ' HA2' ' A' ' 133' ' ' GLY . 2.7 pt -100.99 147.66 34.01 Favored Pre-proline 0 CA--C 1.558 1.265 0 C-N-CA 124.956 1.302 . . . . 74.02 108.223 174.136 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.11 135.61 19.11 Favored 'Trans proline' 0 CA--C 1.558 1.7 0 C-N-CA 122.36 2.04 . . . . 71.03 112.087 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.81 135.43 48.34 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.407 2.071 . . . . 64.45 111.81 173.187 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.54 62.56 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-N 115.669 -0.696 . . . . 62.03 112.42 -174.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.493 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 11.0 p -73.4 147.44 9.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 N-CA-C 109.273 -0.64 . . . . 73.12 109.273 178.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 56.1 mtp85 -138.89 178.95 6.78 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.706 0.765 . . . . 64.12 111.587 -173.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.01 120.0 6.76 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 113.348 -1.751 . . . . 72.35 110.578 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.23 -10.51 67.51 Favored Glycine 0 C--N 1.341 0.817 0 O-C-N 124.28 0.987 . . . . 50.12 113.797 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.3 m -70.3 121.54 17.84 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.416 -0.587 . . . . 74.33 109.416 178.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -105.01 122.45 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 109.41 -0.589 . . . . 74.04 109.41 -178.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.625 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 32.3 mt -91.53 101.95 13.02 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 107.782 -1.192 . . . . 64.44 107.782 -178.103 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.527 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 48.7 ttp85 -96.02 110.25 22.51 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.889 -0.411 . . . . 53.43 109.889 -176.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.6 t -103.96 96.46 9.39 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 107.636 -1.246 . . . . 61.02 107.636 170.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -65.78 127.0 16.96 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.815 2.344 . . . . 72.03 112.006 -176.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.9 -23.01 37.71 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-O 119.775 -0.459 . . . . 43.23 113.758 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.0 tpt -76.48 -32.5 58.38 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.255 0.622 . . . . 73.31 111.94 -174.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -65.57 -81.55 0.13 Allowed Glycine 0 CA--C 1.536 1.399 0 O-C-N 123.606 0.566 . . . . 73.12 113.384 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -65.35 92.68 0.15 Allowed Glycine 0 C--N 1.345 1.077 0 C-N-CA 123.017 0.341 . . . . 73.52 113.347 174.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.9 mm-40 -91.2 153.08 20.26 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.266 1.027 . . . . 73.55 110.044 170.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 137.44 -62.94 0.58 Allowed Glycine 0 C--N 1.338 0.655 0 N-CA-C 111.203 -0.759 . . . . 54.04 111.203 178.364 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.531 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 24.3 t-20 -155.89 -56.48 0.02 OUTLIER Pre-proline 0 CA--C 1.567 1.601 0 CA-C-O 118.184 -0.912 . . . . 75.23 110.643 179.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.531 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 57.0 Cg_endo -90.04 113.71 0.52 Allowed 'Trans proline' 0 C--N 1.402 3.38 0 C-N-CA 122.769 2.313 . . . . 74.43 110.633 174.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 170' ' ' PRO . 22.9 Cg_exo -64.84 123.09 11.13 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 122.417 2.078 . . . . 71.44 111.059 -176.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -111.53 160.84 13.0 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 120.013 -0.326 . . . . 73.4 112.393 -176.403 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -77.68 139.65 39.47 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.06 0.544 . . . . 63.23 111.159 -174.464 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.553 HD21 HD11 ' A' ' 98' ' ' LEU . 64.2 tp -101.31 126.99 48.12 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.792 -1.188 . . . . 70.42 107.792 171.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.449 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 75.2 mt -127.16 103.18 7.29 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 124.695 1.198 . . . . 74.03 109.118 -175.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.625 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 88.0 mt -100.23 101.47 12.5 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 122.784 0.434 . . . . 72.24 110.02 178.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.1 t -86.81 99.52 8.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 108.799 -0.815 . . . . 61.21 108.799 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.91 114.26 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 CA-C-N 115.156 -0.929 . . . . 43.25 111.632 -173.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 6.3 mmp_? -99.36 113.16 25.33 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 125.142 1.377 . . . . 53.43 108.528 172.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.429 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 44.3 mt -72.3 127.51 32.78 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.852 -0.425 . . . . 62.13 109.852 175.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.1 mt -83.92 148.54 54.25 Favored Pre-proline 0 C--O 1.242 0.662 0 C-N-CA 123.883 0.873 . . . . 71.24 109.883 178.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.8 172.53 9.41 Favored 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 122.827 2.352 . . . . 70.0 111.831 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.533 -0.746 . . . . 75.13 110.163 -177.415 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.558 1.286 0 N-CA-C 114.755 1.391 . . . . 52.42 114.755 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -66.83 -174.3 0.46 Allowed 'Trans proline' 0 C--N 1.369 1.63 0 C-N-CA 122.617 2.211 . . . . 73.51 111.142 163.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.495 HD11 ' HG ' ' A' ' 123' ' ' LEU . 8.6 tp -72.73 133.47 44.58 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.518 -0.549 . . . . 72.51 109.518 176.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.685 HD22 HG23 ' A' ' 138' ' ' VAL . 13.4 tp 73.17 -39.98 0.46 Allowed 'General case' 0 N--CA 1.484 1.255 0 C-N-CA 127.268 2.227 . . . . 74.2 113.077 -176.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -88.12 131.34 34.73 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.141 0.976 . . . . 71.21 111.528 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.531 HG22 HG13 ' A' ' 102' ' ' VAL . 93.6 m -151.29 92.21 3.78 Favored Pre-proline 0 CA--C 1.55 0.964 0 C-N-CA 123.592 0.757 . . . . 71.11 109.823 178.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -74.06 82.23 1.82 Allowed 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.646 2.23 . . . . 53.13 113.302 -168.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.531 HG13 HG22 ' A' ' 100' ' ' THR . 28.6 m . . . . . 0 N--CA 1.474 0.731 0 C-N-CA 123.985 0.914 . . . . 75.45 109.972 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.474 0.75 0 CA-C-O 121.19 0.519 . . . . 74.4 111.038 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -101.54 108.78 20.45 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.638 -0.875 . . . . 71.2 108.638 -173.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.429 HD22 ' O ' ' A' ' 100' ' ' THR . 15.2 mt -89.93 110.63 21.58 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.796 -1.186 . . . . 63.44 107.796 -169.299 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -107.17 109.31 21.1 Favored 'General case' 0 C--N 1.344 0.349 0 N-CA-C 108.997 -0.742 . . . . 54.23 108.997 173.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -126.5 141.97 51.69 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.277 -1.008 . . . . 74.34 108.277 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -74.32 135.06 42.54 Favored 'General case' 0 C--O 1.243 0.73 0 N-CA-C 109.051 -0.722 . . . . 72.35 109.051 173.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.495 ' HG ' HD11 ' A' ' 97' ' ' LEU . 1.9 tt -100.83 103.11 22.51 Favored Pre-proline 0 CA--C 1.543 0.708 0 N-CA-C 107.929 -1.138 . . . . 75.41 107.929 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.423 ' HB2' HD11 ' A' ' 181' ' ' LEU . 52.1 Cg_endo -67.83 115.48 3.79 Favored 'Trans proline' 0 C--N 1.376 2.013 0 C-N-CA 122.49 2.126 . . . . 70.41 110.052 174.439 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.603 HD21 HD12 ' A' ' 149' ' ' ILE . 17.0 tp -137.6 135.31 36.48 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.074 -0.713 . . . . 71.41 109.074 -169.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.0 p -77.28 164.58 25.44 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 118.76 0.709 . . . . 54.43 110.581 178.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -63.28 -30.91 71.96 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.728 0.811 . . . . 64.22 111.877 -177.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -75.0 -46.95 31.67 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.561 0.745 . . . . 71.14 110.13 -178.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 73.3 mm-40 -60.62 -35.69 76.78 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 123.911 0.757 . . . . 73.21 111.048 176.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.51 -51.63 61.98 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 124.099 0.874 . . . . 34.32 111.21 174.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -58.04 -50.82 72.1 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.928 1.291 . . . . 74.33 111.688 -176.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 56.1 m80 -78.18 -41.18 35.46 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.819 -0.628 . . . . 74.33 109.881 -176.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 73.94 -167.86 54.37 Favored Glycine 0 C--N 1.352 1.451 0 CA-C-N 116.03 -0.532 . . . . 72.15 112.072 -173.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.472 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 122.85 -165.08 15.57 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 111.766 -0.534 . . . . 44.45 111.766 177.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.453 ' HA ' ' HA ' ' A' ' 148' ' ' ARG . 1.5 mp0 -84.78 125.71 32.8 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 121.125 0.488 . . . . 75.02 110.304 178.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 tpp180 -112.88 122.37 47.44 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.929 1.291 . . . . 75.14 107.92 175.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.4 t -101.86 106.93 20.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 N-CA-C 109.334 -0.617 . . . . 60.22 109.334 -171.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.685 HG23 HD22 ' A' ' 98' ' ' LEU . 30.0 m -124.46 153.52 31.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.298 1.039 . . . . 74.14 108.835 -175.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -107.03 132.56 52.82 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 122.592 0.357 . . . . 74.55 111.517 -171.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.1 p -113.26 104.8 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 125.21 1.404 . . . . 65.22 109.881 176.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.67 15.54 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 113.187 0.81 . . . . 70.42 113.187 173.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.0 8.73 47.24 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.908 -0.385 . . . . 45.4 113.696 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 7.2 tpp180 -115.72 116.39 27.99 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.336 0.655 . . . . 72.42 109.238 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -87.1 106.38 17.83 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.071 0.548 . . . . 73.53 109.879 -173.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 78.4 t -112.87 133.96 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.228 1.011 . . . . 71.12 110.729 -176.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 45.5 t -92.1 104.48 16.87 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.55 0.74 . . . . 75.01 109.951 175.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.587 HG21 HD12 ' A' ' 176' ' ' LEU . 6.3 p -99.99 122.38 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 123.65 0.78 . . . . 72.4 110.181 175.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 135' ' ' GLU . 61.1 ttt180 -77.09 112.18 13.48 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.673 0.389 . . . . 71.25 110.086 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.603 HD12 HD21 ' A' ' 125' ' ' LEU . 4.4 pt -77.94 138.4 61.43 Favored Pre-proline 0 CA--C 1.56 1.36 0 C-N-CA 123.794 0.838 . . . . 43.2 109.212 170.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -60.0 136.8 71.86 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.911 2.407 . . . . 75.13 113.271 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -61.59 113.05 1.64 Allowed 'Trans proline' 0 C--N 1.375 1.95 0 C-N-CA 122.776 2.318 . . . . 62.41 111.585 171.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.89 39.76 16.17 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.051 -0.522 . . . . 73.42 112.076 -173.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.415 HG21 HG21 ' A' ' 178' ' ' VAL . 12.6 p -75.46 145.32 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 N-CA-C 109.399 -0.593 . . . . 71.14 109.399 175.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -112.62 173.1 6.54 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 121.472 0.653 . . . . 73.2 112.009 -173.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -63.77 133.97 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 113.927 -1.488 . . . . 60.12 111.107 178.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.36 -21.65 33.99 Favored Glycine 0 C--N 1.349 1.263 0 CA-C-N 115.833 -0.622 . . . . 42.25 113.583 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 72.7 m -63.66 121.52 14.13 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 123.695 0.798 . . . . 73.43 111.876 -172.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.4 p -95.39 125.29 48.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 CA-C-O 121.302 0.572 . . . . 70.31 110.268 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.0 mt -93.73 115.23 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.355 1.062 . . . . 71.22 108.29 -178.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 -101.26 119.94 39.51 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 122.848 0.459 . . . . 72.52 110.497 -176.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -117.4 99.31 52.52 Favored Pre-proline 0 CA--C 1.552 1.045 0 N-CA-C 107.574 -1.269 . . . . 60.01 107.574 169.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.77 138.81 81.85 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.791 2.328 . . . . 72.32 113.913 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.6 5.13 72.58 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 115.07 -0.968 . . . . 63.02 115.094 175.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 13.6 tpt -101.99 -16.0 16.62 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 117.638 0.719 . . . . 70.41 112.359 -170.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -73.82 -81.72 0.41 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 120.154 -0.248 . . . . 60.2 112.769 178.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -60.39 93.78 0.07 OUTLIER Glycine 0 C--N 1.352 1.42 0 C-N-CA 123.1 0.381 . . . . 54.23 112.95 172.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -91.98 171.01 9.4 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.495 1.118 . . . . 73.04 111.46 175.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 113.76 -65.68 0.27 Allowed Glycine 0 C--N 1.345 1.046 0 CA-C-N 115.579 -0.737 . . . . 43.12 111.792 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.432 ' H ' ' CD ' ' A' ' 170' ' ' PRO . 3.3 p-10 -168.62 -32.35 0.0 OUTLIER Pre-proline 0 CA--C 1.565 1.554 0 CA-C-O 117.48 -1.248 . . . . 73.31 112.66 -179.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.432 ' CD ' ' H ' ' A' ' 169' ' ' ASN . 62.6 Cg_endo -92.32 106.81 0.22 Allowed 'Trans proline' 0 C--N 1.403 3.442 0 CA-C-N 122.37 1.882 . . . . 73.21 110.611 168.171 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_exo -66.16 124.85 13.14 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.277 1.984 . . . . 73.02 111.811 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -120.96 155.95 16.19 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.25 -1.14 . . . . 51.31 110.25 172.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -76.81 162.69 27.45 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.687 0.795 . . . . 71.13 111.033 -173.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.515 HD21 HD11 ' A' ' 98' ' ' LEU . 55.9 tp -122.6 130.58 53.16 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.047 0.539 . . . . 74.43 109.795 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.41 128.77 46.36 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.805 1.242 . . . . 64.2 109.05 177.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.587 HD12 HG21 ' A' ' 147' ' ' VAL . 88.0 mt -129.17 102.31 6.41 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.198 0.599 . . . . 62.33 110.948 178.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.0 t -85.69 99.32 7.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.66 0 N-CA-C 109.563 -0.532 . . . . 73.31 109.563 -173.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.415 HG21 HG21 ' A' ' 153' ' ' VAL . 96.7 t -56.14 114.51 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.344 1.058 . . . . 71.14 111.907 -178.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -113.09 102.6 10.55 Favored 'General case' 0 C--O 1.239 0.517 0 C-N-CA 124.77 1.228 . . . . 75.4 108.598 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 68.6 mt -70.28 116.93 11.2 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 115.256 -0.884 . . . . 72.21 110.962 -177.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.423 HD11 ' HB2' ' A' ' 124' ' ' PRO . 58.0 mt -77.26 146.75 75.05 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 115.416 -0.811 . . . . 74.14 110.378 -177.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -60.64 115.05 2.42 Favored 'Trans proline' 0 C--N 1.373 1.817 0 C-N-CA 123.279 2.653 . . . . 72.51 111.873 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 . . . . . 0 C--O 1.249 1.073 0 N-CA-C 109.331 -0.618 . . . . 63.02 109.331 -179.856 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 3.4 pp . . . . . 0 CA--C 1.566 1.587 0 N-CA-C 112.341 0.497 . . . . 74.24 112.341 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -69.87 -164.05 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 123.611 2.874 . . . . 62.41 113.433 168.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.73 HD13 ' HD2' ' A' ' 124' ' ' PRO . 0.6 OUTLIER -60.31 -46.56 89.44 Favored 'General case' 0 N--CA 1.483 1.203 0 C-N-CA 124.446 1.098 . . . . 70.34 112.031 -179.009 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.521 HD22 ' HB ' ' A' ' 140' ' ' VAL . 3.9 tt -139.19 90.04 2.39 Favored 'General case' 0 C--O 1.211 -0.962 0 N-CA-C 108.04 -1.096 . . . . 71.54 108.04 173.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 73.5 t80 172.5 107.05 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 125.518 1.527 . . . . 61.24 107.373 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.551 HG22 HG13 ' A' ' 102' ' ' VAL . 93.9 m -127.79 94.64 36.77 Favored Pre-proline 0 C--O 1.239 0.511 0 N-CA-C 109.763 -0.458 . . . . 44.33 109.763 -178.001 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -70.1 85.28 0.67 Allowed 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 122.556 2.17 . . . . 73.21 112.293 -175.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.551 HG13 HG22 ' A' ' 100' ' ' THR . 22.6 m . . . . . 0 N--CA 1.47 0.541 0 C-N-CA 124.001 0.92 . . . . 74.02 109.582 174.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.449 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 12.5 mmm-85 . . . . . 0 N--CA 1.474 0.743 0 N-CA-C 107.952 -1.129 . . . . 62.41 107.952 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -96.69 104.44 16.43 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.458 -0.941 . . . . 64.13 108.458 -171.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.453 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.1 mt -92.39 111.48 23.07 Favored 'General case' 0 C--N 1.344 0.344 0 N-CA-C 107.917 -1.142 . . . . 75.24 107.917 -172.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -110.08 105.58 14.75 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 108.686 -0.857 . . . . 43.25 108.686 174.081 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.13 160.92 35.81 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 123.929 0.892 . . . . 70.14 109.6 -176.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 88.7 mt-10 -99.79 136.39 39.79 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.437 0.695 . . . . 73.1 110.12 -173.015 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.614 ' HA ' HD13 ' A' ' 97' ' ' LEU . 1.6 tt -105.05 101.33 29.49 Favored Pre-proline 0 CA--C 1.545 0.75 0 C-N-CA 124.247 1.019 . . . . 63.23 108.759 -176.14 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.73 ' HD2' HD13 ' A' ' 97' ' ' LEU . 30.2 Cg_endo -62.74 120.04 7.38 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.478 2.119 . . . . 74.01 110.285 170.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.624 HD21 HD12 ' A' ' 149' ' ' ILE . 15.2 tp -145.89 135.7 23.43 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.948 0.499 . . . . 54.43 109.664 -172.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.3 p -88.24 168.8 12.41 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.974 0.51 . . . . 64.31 110.72 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 72.2 mt -63.08 -36.99 85.43 Favored 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 123.395 0.678 . . . . 62.13 111.928 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -63.55 -54.77 30.93 Favored 'General case' 0 N--CA 1.475 0.811 0 O-C-N 123.953 0.783 . . . . 61.3 108.983 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -64.19 -34.18 77.5 Favored 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 114.759 -1.109 . . . . 62.44 111.699 -177.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.41 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -59.9 -49.62 76.96 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.218 0.949 . . . . 65.22 110.475 175.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -69.61 -34.71 74.47 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 115.008 -0.996 . . . . 73.21 111.129 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -66.77 -47.08 73.3 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.833 0.453 . . . . 63.41 110.57 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.52 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.3 41.03 94.85 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 115.532 -0.758 . . . . 73.43 112.648 -174.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -84.39 -163.9 36.87 Favored Glycine 0 C--N 1.347 1.162 0 O-C-N 123.904 0.414 . . . . 42.14 112.984 -178.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.4 mp0 -85.44 144.67 27.85 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.437 -0.579 . . . . 72.35 109.437 170.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.589 ' HG2' HD21 ' A' ' 123' ' ' LEU . 11.0 tpt180 -125.69 120.32 30.39 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 123.935 0.894 . . . . 61.44 108.621 -177.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.44 123.53 37.94 Favored 'Isoleucine or valine' 0 C--O 1.24 0.573 0 N-CA-C 109.373 -0.602 . . . . 65.24 109.373 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.441 HG12 HD21 ' A' ' 97' ' ' LEU . 27.2 m -138.25 162.49 30.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 125.02 1.328 . . . . 53.11 108.54 179.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -119.83 129.28 54.35 Favored 'General case' 0 N--CA 1.479 1.019 0 O-C-N 122.053 -0.405 . . . . 74.23 110.644 -178.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.521 ' HB ' HD22 ' A' ' 98' ' ' LEU . 5.3 p -119.89 113.63 41.4 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.599 1.159 . . . . 74.35 110.045 175.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 56.35 33.27 22.03 Favored 'General case' 0 N--CA 1.487 1.425 0 C-N-CA 123.782 0.833 . . . . 64.21 112.389 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.29 19.28 59.09 Favored Glycine 0 C--N 1.351 1.413 0 CA-C-N 115.858 -0.61 . . . . 41.22 113.638 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 75.9 mtp180 -125.42 125.61 43.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 123.722 0.809 . . . . 62.21 110.198 -176.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.3 ttp180 -73.51 120.33 18.97 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 122.904 0.482 . . . . 74.11 110.734 178.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 20.5 m -125.24 141.22 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.716 0.807 . . . . 64.24 109.77 170.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.9 p -106.62 111.71 24.38 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.817 0.847 . . . . 73.53 109.353 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -101.08 130.75 50.0 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 123.716 0.806 . . . . 62.54 110.083 178.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 39.0 ttt180 -81.6 114.3 20.2 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.494 -0.928 . . . . 71.32 108.494 178.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.624 HD12 HD21 ' A' ' 125' ' ' LEU . 5.2 pt -84.51 146.39 47.07 Favored Pre-proline 0 CA--C 1.554 1.132 0 C-N-CA 123.844 0.858 . . . . 65.41 109.469 177.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.433 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 25.1 Cg_exo -66.4 141.76 63.12 Favored 'Trans proline' 0 CA--C 1.562 1.894 0 C-N-CA 122.826 2.351 . . . . 74.34 112.922 177.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 22.4 Cg_exo -67.92 127.95 16.97 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 123.127 2.551 . . . . 61.52 111.496 172.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 74.71 26.34 67.54 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 123.783 0.677 . . . . 45.22 113.317 -175.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.41 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 12.6 p -71.71 146.37 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 117.421 0.61 . . . . 74.44 110.735 -178.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.497 ' HA ' HD11 ' A' ' 180' ' ' LEU . 29.7 mtp-105 -120.99 173.22 7.39 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 121.888 0.851 . . . . 73.24 112.571 -170.064 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -64.45 120.83 13.03 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 113.292 -1.776 . . . . 73.34 109.961 174.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 104.34 -23.61 31.28 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-O 119.407 -0.663 . . . . 72.32 112.965 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 58.5 m -64.25 121.08 13.4 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 123.061 0.544 . . . . 73.4 110.458 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.2 p -102.39 127.49 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 CA-C-O 121.26 0.552 . . . . 73.03 110.022 -179.102 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.44 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 54.6 mt -92.64 101.1 12.25 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 107.829 -1.174 . . . . 72.43 107.829 -179.389 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -86.99 110.04 19.78 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.657 -0.498 . . . . 64.33 109.657 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.458 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 12.6 t -111.19 93.54 18.57 Favored Pre-proline 0 CA--C 1.555 1.163 0 N-CA-C 107.685 -1.228 . . . . 45.45 107.685 173.034 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.13 122.29 7.06 Favored 'Trans proline' 0 C--N 1.369 1.618 0 C-N-CA 122.441 2.094 . . . . 71.13 112.207 -177.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.39 -20.91 36.36 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-N 116.537 -0.301 . . . . 63.41 113.476 177.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.41 ' HB2' HG12 ' A' ' 161' ' ' VAL . 86.1 mmm -104.62 16.16 26.59 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 123.398 0.679 . . . . 73.21 112.081 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.59 -101.93 0.54 Allowed Glycine 0 C--N 1.345 1.061 0 CA-C-O 119.664 -0.52 . . . . 72.32 111.931 172.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . 0.449 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -68.84 102.78 0.95 Allowed Glycine 0 C--N 1.349 1.299 0 CA-C-N 116.93 0.365 . . . . 74.21 112.313 177.087 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 7.5 mm-40 -89.27 157.82 18.07 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 124.151 0.981 . . . . 71.14 110.075 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 147.77 -66.39 0.4 Allowed Glycine 0 C--N 1.344 1.014 0 N-CA-C 110.758 -0.937 . . . . 45.12 110.758 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.405 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 36.2 t30 -159.12 -54.12 0.01 OUTLIER Pre-proline 0 CA--C 1.562 1.429 0 C-N-CA 124.291 1.036 . . . . 73.15 110.122 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.405 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 80.5 Cg_endo -85.37 110.54 1.23 Allowed 'Trans proline' 0 C--N 1.399 3.231 0 C-N-CA 121.594 1.53 . . . . 74.11 110.505 171.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.82 123.28 11.12 Favored 'Trans proline' 0 C--N 1.383 2.381 0 C-N-CA 122.163 1.909 . . . . 75.21 110.996 -174.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -96.1 163.08 23.07 Favored Glycine 0 C--N 1.338 0.642 0 O-C-N 123.649 0.593 . . . . 71.32 111.912 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -84.36 152.39 24.12 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 108.791 -0.818 . . . . 70.52 108.791 -179.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.458 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 57.6 tp -120.68 132.0 54.86 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.957 0.503 . . . . 71.45 109.744 178.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 84.1 mt -128.39 103.33 7.09 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.189 0.996 . . . . 74.34 109.153 177.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.473 HD21 ' HG ' ' A' ' 98' ' ' LEU . 86.8 mt -102.51 101.2 11.37 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 121.04 0.447 . . . . 65.42 110.369 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.1 t -83.96 99.55 6.53 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 108.621 -0.881 . . . . 62.34 108.621 -176.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.5 t -59.32 117.42 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 123.919 0.888 . . . . 73.22 111.455 -177.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -100.95 105.23 16.45 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 114.466 -1.243 . . . . 63.35 108.389 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.497 HD11 ' HA ' ' A' ' 154' ' ' ARG . 30.3 mt -69.28 108.77 3.8 Favored 'General case' 0 C--N 1.348 0.511 0 N-CA-C 109.128 -0.693 . . . . 71.03 109.128 174.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.4 mt -68.56 159.0 83.62 Favored Pre-proline 0 CA--C 1.544 0.72 0 CA-C-N 115.057 -0.974 . . . . 73.05 110.45 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -74.12 51.91 2.56 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 123.533 2.822 . . . . 61.23 112.764 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.5 t-80 . . . . . 0 C--O 1.255 1.347 0 C-N-CA 124.697 1.199 . . . . 75.12 107.962 177.304 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.6 pt? . . . . . 0 CA--C 1.555 1.145 0 N-CA-C 111.56 0.207 . . . . 71.54 111.56 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.444 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 97.5 Cg_endo -81.67 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.922 2.414 . . . . 74.44 111.3 166.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.519 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.1 tp -81.83 139.99 34.43 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.261 0.624 . . . . 74.13 110.254 -179.48 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.676 HD22 HG23 ' A' ' 138' ' ' VAL . 19.3 tp 64.63 -13.06 0.11 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 127.031 2.132 . . . . 75.31 113.606 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.444 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 47.3 t80 -119.78 122.07 40.57 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 124.376 1.07 . . . . 73.32 108.91 -173.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.515 HG22 HG13 ' A' ' 102' ' ' VAL . 85.7 m -135.36 90.25 21.07 Favored Pre-proline 0 C--O 1.235 0.329 0 C-N-CA 123.739 0.816 . . . . 72.41 108.804 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -65.85 93.61 0.27 Allowed 'Trans proline' 0 C--N 1.372 1.769 0 C-N-CA 121.6 1.533 . . . . 63.4 112.027 -174.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 100' ' ' THR . 27.4 m . . . . . 0 N--CA 1.465 0.32 0 C-N-CA 125.266 1.427 . . . . 70.43 109.375 177.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.614 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 46.7 mtt-85 . . . . . 0 N--CA 1.476 0.854 0 N-CA-C 109.882 -0.414 . . . . 72.12 109.882 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -99.29 105.02 16.98 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 106.469 -1.678 . . . . 63.45 106.469 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.494 HD22 ' O ' ' A' ' 100' ' ' THR . 12.6 mt -88.33 106.93 18.55 Favored 'General case' 0 C--N 1.345 0.378 0 N-CA-C 105.78 -1.933 . . . . 70.21 105.78 -177.309 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.4 ttm-85 -106.91 102.3 11.67 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.824 -1.176 . . . . 75.33 107.824 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -125.45 136.04 52.97 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.125 -1.065 . . . . 62.32 108.125 -175.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -82.86 129.37 34.99 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.853 -0.612 . . . . 70.14 109.732 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.52 HD12 HD13 ' A' ' 176' ' ' LEU . 2.2 tt -101.18 105.05 36.93 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 123.681 0.792 . . . . 63.51 109.558 -172.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.579 ' HB2' HD11 ' A' ' 181' ' ' LEU . 33.9 Cg_endo -61.48 116.22 3.27 Favored 'Trans proline' 0 C--N 1.378 2.089 0 C-N-CA 122.958 2.439 . . . . 71.31 111.213 170.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.49 HD21 HD12 ' A' ' 149' ' ' ILE . 30.9 tp -145.61 124.53 12.73 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 123.77 0.828 . . . . 64.22 109.026 -170.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.1 p -75.49 168.24 20.38 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 122.538 0.335 . . . . 74.33 110.978 -175.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 74.7 mt -63.22 -37.36 86.92 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.642 0.777 . . . . 74.34 110.901 178.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 24.7 mp0 -64.19 -52.36 59.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.95 1.3 . . . . 61.31 110.136 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -69.75 -32.71 71.39 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.456 -0.793 . . . . 51.54 111.43 -177.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.57 -45.28 93.64 Favored 'General case' 0 C--N 1.349 0.582 0 O-C-N 123.87 0.731 . . . . 65.42 110.269 174.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -66.14 -39.35 89.78 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.377 1.071 . . . . 73.22 110.641 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.0 m80 -61.98 -47.43 84.87 Favored 'General case' 0 C--N 1.358 0.945 0 O-C-N 123.717 0.636 . . . . 72.52 110.447 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.429 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.08 52.78 47.6 Favored Glycine 0 C--N 1.352 1.427 0 O-C-N 124.046 0.841 . . . . 74.03 112.516 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -106.41 -141.82 10.52 Favored Glycine 0 C--N 1.339 0.712 0 N-CA-C 111.531 -0.628 . . . . 63.12 111.531 177.673 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.586 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.9 mp0 -93.68 148.87 21.71 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 108.261 -1.014 . . . . 63.23 108.261 169.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.463 ' HG3' HG13 ' A' ' 138' ' ' VAL . 40.5 tpt85 -123.31 117.68 25.8 Favored 'General case' 0 N--CA 1.463 0.18 0 N-CA-C 107.441 -1.318 . . . . 55.33 107.441 177.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.5 t -86.21 106.0 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 109.165 -0.679 . . . . 74.02 109.165 -174.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.676 HG23 HD22 ' A' ' 98' ' ' LEU . 33.1 m -125.91 157.79 35.51 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 C-N-CA 124.93 1.292 . . . . 74.12 108.342 -178.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -113.65 120.29 40.39 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 118.534 0.606 . . . . 62.45 111.382 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 6.4 p -105.61 104.6 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.757 0.823 . . . . 74.44 109.665 173.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.22 29.6 18.81 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.354 0.661 . . . . 53.11 112.384 172.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.35 -14.23 58.17 Favored Glycine 0 N--CA 1.475 1.287 0 N-CA-C 113.705 0.242 . . . . 54.24 113.705 -178.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -92.78 117.65 30.24 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.027 -0.731 . . . . 70.31 109.027 -178.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 26.5 ttm180 -88.76 105.93 18.02 Favored 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 108.808 -0.812 . . . . 72.15 108.808 -173.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.57 128.87 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 124.214 1.005 . . . . 73.32 110.797 -175.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.586 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 51.0 p -90.14 107.43 19.13 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 123.841 0.857 . . . . 45.52 109.699 173.213 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.81 130.1 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 123.721 0.808 . . . . 53.33 109.995 -178.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 75.8 ttt180 -78.82 113.97 17.35 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.555 0.693 . . . . 73.43 110.547 -174.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.49 HD12 HD21 ' A' ' 125' ' ' LEU . 4.5 pt -90.25 142.22 28.29 Favored Pre-proline 0 CA--C 1.56 1.358 0 C-N-CA 124.93 1.292 . . . . 62.04 109.772 178.501 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -69.34 142.91 51.13 Favored 'Trans proline' 0 CA--C 1.564 2.018 0 C-N-CA 122.156 1.904 . . . . 50.34 112.849 174.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.59 127.92 14.58 Favored 'Trans proline' 0 C--N 1.381 2.242 0 C-N-CA 122.832 2.355 . . . . 74.41 111.475 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 82.72 23.41 56.03 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.657 -0.701 . . . . 72.45 113.416 -174.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.2 p -74.5 150.22 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.926 0.49 . . . . 73.04 110.185 178.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -131.64 178.55 6.66 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 121.83 0.824 . . . . 74.01 112.6 -169.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.82 131.46 50.96 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 113.389 -1.732 . . . . 72.54 111.412 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.55 -8.05 70.35 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-O 119.464 -0.631 . . . . 23.03 113.357 177.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 49.3 m -72.43 119.23 16.35 Favored 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.848 -0.797 . . . . 72.25 108.848 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.67 134.27 41.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.286 0.634 . . . . 64.42 109.747 -175.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.471 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 47.4 mt -106.9 103.43 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.224 1.01 . . . . 74.25 108.35 -176.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.455 HH21 HD11 ' A' ' 175' ' ' LEU . 30.2 ttm180 -87.29 111.21 20.82 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 123.134 0.574 . . . . 74.01 109.959 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.91 102.95 53.96 Favored Pre-proline 0 CA--C 1.554 1.106 0 N-CA-C 108.336 -0.987 . . . . 72.33 108.336 173.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -68.83 139.43 43.53 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 122.909 2.406 . . . . 72.31 112.52 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 81.31 -8.41 58.32 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.575 -0.569 . . . . 64.25 114.446 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.0 mtt -113.35 17.58 18.4 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 117.944 0.872 . . . . 75.11 111.22 -174.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -92.96 -107.04 1.76 Allowed Glycine 0 C--N 1.347 1.19 0 CA-C-O 119.508 -0.607 . . . . 72.02 112.066 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . 0.614 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -64.85 90.48 0.1 OUTLIER Glycine 0 C--N 1.355 1.599 0 CA-C-N 116.937 0.369 . . . . 72.13 112.78 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -79.66 147.71 31.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.496 0.719 . . . . 74.22 111.165 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.09 -124.81 1.48 Allowed Glycine 0 C--N 1.342 0.885 0 N-CA-C 110.001 -1.24 . . . . 74.03 110.001 -176.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.406 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 2.0 m-20 -85.16 -50.61 0.54 Allowed Pre-proline 0 CA--C 1.563 1.463 0 CA-C-O 118.63 -0.7 . . . . 74.1 110.004 169.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.406 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -99.66 103.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.395 2.995 0 C-N-CA 123.317 2.678 . . . . 53.43 112.434 177.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.52 123.19 12.26 Favored 'Trans proline' 0 C--N 1.377 2.056 0 C-N-CA 122.293 1.996 . . . . 74.31 111.369 -177.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -94.29 -171.63 38.2 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 116.179 -0.464 . . . . 74.55 112.977 -176.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -99.65 144.85 28.25 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 123.113 0.565 . . . . 70.41 110.28 -177.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.567 HD21 HD11 ' A' ' 98' ' ' LEU . 46.8 tp -109.9 129.49 55.65 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.425 0.69 . . . . 65.1 109.174 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.455 HD11 HH21 ' A' ' 160' ' ' ARG . 88.9 mt -128.85 109.33 11.18 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.887 0.875 . . . . 51.5 109.793 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.52 HD13 HD12 ' A' ' 123' ' ' LEU . 83.6 mt -110.19 102.99 11.63 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.056 0.542 . . . . 74.33 111.713 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.88 94.56 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.941 0 C-N-CA 123.322 0.649 . . . . 75.23 109.904 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 84.7 t -54.39 114.76 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 124.105 0.962 . . . . 72.34 112.054 -179.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 29.8 mmt180 -98.29 115.24 27.99 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.116 1.366 . . . . 73.04 108.406 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 66.7 mt -70.31 114.41 8.41 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 120.689 0.281 . . . . 75.31 110.5 178.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.579 HD11 ' HB2' ' A' ' 124' ' ' PRO . 45.2 mt -89.96 156.9 46.56 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 123.568 0.747 . . . . 55.34 110.825 175.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -71.18 -162.85 0.11 Allowed 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 123.041 2.494 . . . . 61.2 112.286 168.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 6.7 p80 . . . . . 0 CA--C 1.553 1.091 0 C-N-CA 123.811 0.844 . . . . 71.01 109.16 -177.868 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.559 1.326 0 N-CA-C 114.168 1.173 . . . . 74.3 114.168 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.455 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 13.0 Cg_exo -70.91 -161.5 0.09 OUTLIER 'Trans proline' 0 C--N 1.375 1.969 0 C-N-CA 122.698 2.265 . . . . 75.42 111.989 171.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.674 HD13 ' HD2' ' A' ' 124' ' ' PRO . 1.1 tp -58.19 -42.85 87.03 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 124.107 0.963 . . . . 73.42 112.569 -175.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.401 HD22 ' HB ' ' A' ' 140' ' ' VAL . 1.7 tt -141.06 96.52 3.01 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 107.801 -1.185 . . . . 74.31 107.801 171.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.455 ' HB3' ' HD2' ' A' ' 96' ' ' PRO . 53.7 t80 165.36 119.6 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 126.518 1.927 . . . . 72.45 107.431 172.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.574 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 32.7 m -145.54 86.68 7.28 Favored Pre-proline 0 CA--C 1.55 0.961 0 CA-C-N 118.147 0.43 . . . . 63.2 110.653 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -74.11 86.0 1.32 Allowed 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.371 2.047 . . . . 71.53 111.623 -177.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.503 HG13 HG22 ' A' ' 100' ' ' THR . 18.0 m . . . . . 0 N--CA 1.481 1.094 0 C-N-CA 124.585 1.154 . . . . 53.32 112.553 -175.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.668 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.7 mmp_? . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 107.057 -1.46 . . . . 73.35 107.057 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.2 105.45 17.8 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 107.578 -1.267 . . . . 64.4 107.578 -170.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.574 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.8 mt -94.28 110.83 22.55 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 108.244 -1.021 . . . . 74.44 108.244 -178.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.1 ttt180 -110.86 112.76 24.83 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 108.731 -0.841 . . . . 75.24 108.731 168.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -131.39 153.95 49.14 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.814 -0.81 . . . . 51.21 108.814 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -92.61 142.22 27.63 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.935 -0.765 . . . . 74.44 108.935 -176.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.648 ' HA ' HD13 ' A' ' 97' ' ' LEU . 12.1 tp -103.14 102.46 28.43 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 124.247 1.019 . . . . 74.25 109.457 -177.734 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.674 ' HD2' HD13 ' A' ' 97' ' ' LEU . 34.6 Cg_endo -65.49 115.71 3.51 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.053 1.835 . . . . 74.43 109.449 168.465 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.425 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 24.3 tp -145.81 122.1 10.9 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.282 -1.007 . . . . 71.14 108.282 -174.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 80.7 p -75.4 165.31 25.33 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 123.281 0.363 . . . . 73.53 110.19 -176.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.477 HD12 ' HB3' ' A' ' 183' ' ' HIS . 77.6 mt -60.8 -33.31 72.8 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.75 0.82 . . . . 72.35 111.998 -172.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -73.91 -49.58 24.15 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.274 -0.875 . . . . 75.41 109.272 -178.136 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -68.52 -24.17 64.63 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 115.007 -0.997 . . . . 74.23 111.374 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.67 -47.34 66.77 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.015 0.926 . . . . 73.32 109.967 172.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -60.87 -44.09 97.54 Favored 'General case' 0 C--N 1.352 0.677 0 O-C-N 124.637 1.211 . . . . 60.42 110.867 177.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -71.16 -45.88 62.61 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 123.531 0.519 . . . . 74.24 111.104 -174.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.447 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 71.4 -138.08 27.11 Favored Glycine 0 CA--C 1.53 1.008 0 CA-C-N 116.175 -0.466 . . . . 73.33 112.275 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.46 -160.19 45.39 Favored Glycine 0 C--N 1.349 1.256 0 CA-C-O 119.882 -0.399 . . . . 62.21 112.379 178.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.567 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 8.9 mp0 -77.46 138.34 39.19 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 117.316 0.558 . . . . 60.24 109.91 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.501 ' HE ' HD11 ' A' ' 123' ' ' LEU . 23.1 tpt180 -117.69 119.09 33.89 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.392 -0.966 . . . . 73.12 108.392 -176.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 42.9 t -83.51 103.74 11.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 N-CA-C 108.57 -0.9 . . . . 71.11 108.57 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.443 HG13 ' HG3' ' A' ' 136' ' ' ARG . 18.8 m -123.81 160.83 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 N-CA-C 107.643 -1.243 . . . . 73.35 107.643 177.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -125.95 115.75 20.4 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 119.232 0.923 . . . . 74.24 111.123 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.401 ' HB ' HD22 ' A' ' 98' ' ' LEU . 2.6 p -105.41 111.16 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 124.378 1.071 . . . . 73.41 110.771 178.398 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.5 29.83 19.43 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 124.147 0.979 . . . . 72.04 112.369 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.16 -13.03 62.04 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-N 116.351 -0.386 . . . . 61.41 113.29 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.66 115.96 28.58 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.309 0.644 . . . . 75.33 109.817 176.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 32.8 ttm180 -92.49 103.65 16.04 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 108.182 -1.044 . . . . 75.43 108.182 -176.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 27.0 m -109.57 155.63 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.719 1.208 . . . . 65.13 111.4 -172.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.567 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 47.9 m -101.73 115.98 31.72 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.859 0.864 . . . . 51.13 109.708 176.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.525 HG11 HD12 ' A' ' 176' ' ' LEU . 74.5 t -99.35 113.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 124.28 1.032 . . . . 64.55 108.85 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -74.55 102.58 4.57 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 109.145 -0.687 . . . . 64.32 109.145 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.496 HD13 ' HB2' ' A' ' 136' ' ' ARG . 5.6 pt -96.15 141.93 23.84 Favored Pre-proline 0 CA--C 1.555 1.171 0 C-N-CA 124.418 1.087 . . . . 64.22 109.51 -178.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.428 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 28.8 Cg_endo -64.0 132.83 35.95 Favored 'Trans proline' 0 CA--C 1.564 2.015 0 C-N-CA 122.371 2.047 . . . . 73.14 112.344 178.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 25.7 Cg_exo -66.98 132.69 28.86 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 122.984 2.456 . . . . 74.41 112.225 174.004 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.12 34.59 41.14 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.649 -0.705 . . . . 50.21 112.121 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.419 HG21 HG21 ' A' ' 178' ' ' VAL . 14.6 p -76.44 140.17 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 122.99 0.516 . . . . 73.41 111.025 -176.162 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 -94.97 177.09 6.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.832 0.825 . . . . 73.0 112.772 -173.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -72.7 129.92 39.33 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.518 -1.674 . . . . 73.43 110.753 176.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.8 10.33 86.28 Favored Glycine 0 C--N 1.345 1.031 0 CA-C-N 115.45 -0.795 . . . . 74.43 113.884 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 44.9 m -78.29 118.39 20.45 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.274 -0.639 . . . . 74.53 109.274 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -94.46 127.28 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-O 121.273 0.558 . . . . 74.1 110.333 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 51.7 mt -100.97 101.19 11.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 N-CA-C 107.598 -1.26 . . . . 71.11 107.598 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.493 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 38.9 ttt180 -89.45 113.98 25.41 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 109.92 -0.4 . . . . 73.41 109.92 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.4 HG11 ' SD ' ' A' ' 164' ' ' MET . 6.5 t -114.49 94.64 37.04 Favored Pre-proline 0 CA--C 1.555 1.149 0 N-CA-C 108.324 -0.991 . . . . 65.23 108.324 173.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.56 135.2 48.1 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 123.032 2.488 . . . . 71.12 112.268 177.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.95 -7.88 79.84 Favored Glycine 0 C--N 1.345 1.072 0 CA-C-O 119.543 -0.587 . . . . 52.23 114.2 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.4 ' SD ' HG11 ' A' ' 161' ' ' VAL . 27.6 ttt -100.38 -7.83 23.98 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.636 0.774 . . . . 75.44 110.772 179.263 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -81.58 -112.94 0.37 Allowed Glycine 0 C--N 1.348 1.207 0 CA-C-N 116.078 -0.51 . . . . 73.23 112.316 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . 0.668 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -67.0 95.61 0.28 Allowed Glycine 0 C--N 1.347 1.177 0 CA-C-N 116.869 0.334 . . . . 75.31 113.877 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -71.93 108.54 5.24 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 123.566 0.747 . . . . 72.44 110.46 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -171.64 -169.85 34.98 Favored Glycine 0 C--N 1.342 0.883 0 CA-C-N 115.861 -0.608 . . . . 65.04 112.304 178.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -61.0 -42.93 89.28 Favored Pre-proline 0 CA--C 1.563 1.442 0 C-N-CA 123.497 0.719 . . . . 73.02 111.652 176.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -88.17 106.67 0.54 Allowed 'Trans proline' 0 C--N 1.387 2.584 0 C-N-CA 121.623 1.549 . . . . 74.3 110.176 160.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -67.21 125.63 13.81 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 121.994 1.796 . . . . 63.22 111.858 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -97.14 154.93 20.58 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-N 115.876 -0.602 . . . . 50.31 111.926 -177.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -95.39 163.43 13.25 Favored 'General case' 0 C--O 1.245 0.827 0 C-N-CA 122.899 0.48 . . . . 75.43 109.931 -178.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.2 tp -117.62 139.75 50.57 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 115.088 -0.96 . . . . 61.23 109.758 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 30.7 mt -128.93 101.6 6.15 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.89 1.276 . . . . 64.34 108.416 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.525 HD12 HG11 ' A' ' 147' ' ' VAL . 54.5 mt -103.2 101.28 11.22 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 118.318 0.508 . . . . 72.15 110.162 176.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.63 100.6 10.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 115.435 -0.802 . . . . 64.45 109.138 -174.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.543 HG22 HD23 ' A' ' 123' ' ' LEU . 58.2 t -57.76 111.36 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.066 0.946 . . . . 72.42 112.01 -177.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -101.44 111.1 23.23 Favored 'General case' 0 C--O 1.243 0.753 0 C-N-CA 124.388 1.075 . . . . 75.51 108.914 170.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.425 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 62.7 mt -70.5 114.5 8.67 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.389 0.676 . . . . 72.43 109.846 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.432 HD11 ' HB2' ' A' ' 124' ' ' PRO . 86.5 mt -72.66 155.44 90.92 Favored Pre-proline 0 CA--C 1.548 0.888 0 C-N-CA 123.237 0.615 . . . . 72.43 110.728 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.66 142.75 60.23 Favored 'Trans proline' 0 C--N 1.375 1.942 0 C-N-CA 123.249 2.633 . . . . 74.41 112.454 173.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.477 ' HB3' HD12 ' A' ' 127' ' ' LEU . 48.1 p-80 . . . . . 0 CA--C 1.555 1.17 0 CA-C-O 118.942 -0.551 . . . . 70.24 110.986 -179.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.488 HD22 HG23 ' A' ' 100' ' ' THR . 3.9 pp . . . . . 0 CA--C 1.553 1.095 0 N-CA-C 109.96 -0.385 . . . . 64.33 109.96 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.4 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 73.8 Cg_endo -85.48 -161.43 0.13 Allowed 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 122.757 2.304 . . . . 61.4 110.98 164.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.483 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.0 tp -74.25 149.92 40.54 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.262 0.625 . . . . 74.13 109.412 177.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.61 HD11 HD21 ' A' ' 174' ' ' LEU . 8.2 tp 57.74 1.67 0.14 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 125.798 1.639 . . . . 75.5 114.108 -178.228 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.664 ' HA ' HD13 ' A' ' 119' ' ' LEU . 43.3 t80 -139.91 133.7 30.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 123.336 0.655 . . . . 74.32 109.698 -170.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.564 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 85.9 m -152.94 97.05 2.87 Favored Pre-proline 0 CA--C 1.551 1.009 0 C-N-CA 123.8 0.84 . . . . 73.04 109.476 -177.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.76 77.23 2.29 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 123.02 2.48 . . . . 55.51 112.799 -170.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.524 HG13 HG22 ' A' ' 100' ' ' THR . 9.0 m . . . . . 0 C--O 1.242 0.694 0 CA-C-N 115.494 -0.775 . . . . 75.2 110.457 178.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.408 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 8.7 mmm-85 . . . . . 0 N--CA 1.48 1.049 0 N-CA-C 109.133 -0.691 . . . . 73.03 109.133 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.05 106.59 16.64 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 108.691 -0.855 . . . . 73.44 108.691 -171.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.664 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.3 mt -96.43 109.46 22.01 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 107.478 -1.305 . . . . 75.54 107.478 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 39.8 ttt180 -121.18 106.45 11.53 Favored 'General case' 0 C--O 1.238 0.465 0 N-CA-C 108.557 -0.905 . . . . 71.51 108.557 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -128.9 141.23 51.35 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.543 -0.91 . . . . 72.45 108.543 -177.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -81.56 130.99 35.26 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 108.895 -0.78 . . . . 64.5 108.895 175.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.597 HD12 HD13 ' A' ' 176' ' ' LEU . 1.6 tt -101.38 108.24 54.37 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 108.103 -1.073 . . . . 75.41 108.103 -175.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.7 113.87 3.33 Favored 'Trans proline' 0 C--N 1.378 2.097 0 C-N-CA 121.775 1.65 . . . . 73.1 109.42 171.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.566 HD21 HD12 ' A' ' 149' ' ' ILE . 13.5 tp -131.72 122.78 26.44 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.388 -0.968 . . . . 71.13 108.388 -169.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.9 p -69.71 166.15 19.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.549 0.34 . . . . 64.22 110.537 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 99.7 mt -62.34 -29.2 70.29 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 122.778 0.431 . . . . 73.2 110.882 176.065 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -67.8 -57.67 5.91 Favored 'General case' 0 C--N 1.349 0.555 0 C-N-CA 123.907 0.883 . . . . 72.22 109.263 177.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -60.08 -36.49 77.5 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.507 1.123 . . . . 70.22 111.713 -178.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.407 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.1 -55.72 11.44 Favored 'General case' 0 C--O 1.239 0.551 0 O-C-N 124.061 0.851 . . . . 73.3 111.212 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.409 ' HA ' ' HA2' ' A' ' 152' ' ' GLY . 65.0 t80 -57.84 -48.28 80.23 Favored 'General case' 0 C--N 1.359 0.99 0 O-C-N 124.554 1.159 . . . . 64.03 111.399 -177.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.9 m80 -72.92 -43.84 61.92 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 116.017 -0.538 . . . . 54.04 110.19 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.416 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 77.87 -124.01 6.62 Favored Glycine 0 C--N 1.344 0.988 0 CA-C-N 115.762 -0.654 . . . . 70.5 111.566 -176.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 73.49 -129.8 12.67 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 111.151 -0.78 . . . . 72.1 111.151 -176.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.531 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 6.7 mp0 -111.73 161.37 16.36 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.102 0.961 . . . . 72.1 110.179 176.15 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.626 ' HB2' HD13 ' A' ' 149' ' ' ILE . 20.8 tpt180 -134.01 121.99 22.37 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.212 1.005 . . . . 74.12 109.401 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 60.9 t -75.14 107.68 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.89 0.876 . . . . 62.42 109.417 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.528 HG21 HD13 ' A' ' 98' ' ' LEU . 27.0 m -122.96 163.8 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 125.257 1.423 . . . . 65.25 109.354 -179.129 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -120.99 113.02 19.47 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 122.911 0.485 . . . . 63.15 111.505 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.585 ' HB ' HD23 ' A' ' 98' ' ' LEU . 2.6 p -102.76 102.33 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 C-N-CA 123.649 0.78 . . . . 71.33 108.972 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.25 25.44 14.87 Favored 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 115.215 -0.902 . . . . 63.33 110.665 -169.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.9 6.17 62.17 Favored Glycine 0 C--N 1.358 1.804 0 CA-C-N 115.63 -0.714 . . . . 53.21 113.802 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.518 ' HB3' HG13 ' A' ' 140' ' ' VAL . 13.8 tpt180 -92.27 116.98 29.43 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.09 -0.707 . . . . 73.34 109.09 -179.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -80.89 109.8 15.81 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.809 -0.441 . . . . 70.11 109.809 -174.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 32.1 m -134.11 152.53 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 124.254 1.022 . . . . 43.41 109.218 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.531 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 45.1 m -104.36 114.86 29.38 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.736 0.414 . . . . 32.42 110.02 178.034 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.4 p -99.85 133.13 43.84 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 124.289 1.036 . . . . 43.12 109.9 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 38.9 ttp180 -75.81 115.46 15.53 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.091 0.556 . . . . 72.42 111.122 -174.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.626 HD13 ' HB2' ' A' ' 136' ' ' ARG . 6.1 pt -99.34 143.26 26.09 Favored Pre-proline 0 CA--C 1.558 1.256 0 C-N-CA 124.864 1.266 . . . . 50.15 109.315 177.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.411 ' HB2' ' HB ' ' A' ' 153' ' ' VAL . 52.7 Cg_exo -57.59 134.74 65.16 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.091 2.527 . . . . 71.24 113.094 178.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -62.72 114.53 2.44 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 70.31 111.112 172.361 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 131' ' ' PHE . . . 89.98 18.72 49.73 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.577 -0.568 . . . . 74.24 113.191 -178.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.411 ' HB ' ' HB2' ' A' ' 150' ' ' PRO . 13.2 p -64.0 141.68 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 C-N-CA 122.971 0.508 . . . . 64.43 111.395 -175.126 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -113.12 177.7 4.54 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 123.777 0.831 . . . . 72.42 112.706 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.69 135.7 57.76 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.535 -1.666 . . . . 73.13 111.744 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.58 6.66 77.52 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.905 0.753 . . . . 60.41 114.232 176.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.8 m -81.83 119.82 24.39 Favored 'General case' 0 C--N 1.349 0.564 0 N-CA-C 109.179 -0.675 . . . . 62.31 109.179 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.2 p -97.56 123.39 49.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.903 0 CA-C-O 121.313 0.578 . . . . 61.32 110.366 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.503 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.3 mt -93.29 103.73 14.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 124.379 1.071 . . . . 72.51 108.619 -175.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.452 ' HE ' HD21 ' A' ' 175' ' ' LEU . 43.0 ttm180 -90.18 111.36 22.49 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 122.767 0.427 . . . . 75.4 110.025 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 6.3 t -111.18 106.32 57.29 Favored Pre-proline 0 CA--C 1.552 1.05 0 N-CA-C 107.526 -1.287 . . . . 44.11 107.526 172.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.35 125.35 12.78 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.857 2.372 . . . . 71.4 112.691 -172.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.9 11.86 85.12 Favored Glycine 0 C--N 1.349 1.291 0 CA-C-O 119.792 -0.449 . . . . 75.12 114.044 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.2 tpt -100.99 -4.4 27.58 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-N 117.24 0.52 . . . . 74.53 110.766 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -74.11 -110.58 0.08 OUTLIER Glycine 0 C--N 1.344 0.996 0 CA-C-N 116.073 -0.512 . . . . 74.34 112.474 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -63.94 108.19 2.12 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 111.777 -0.529 . . . . 70.45 111.777 178.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.9 mm-40 -88.14 116.84 26.61 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.255 0.622 . . . . 72.04 110.308 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 169.22 -155.85 26.5 Favored Glycine 0 C--O 1.245 0.816 0 N-CA-C 110.359 -1.097 . . . . 72.03 110.359 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.457 ' O ' ' HD3' ' A' ' 171' ' ' PRO . 15.0 m120 -65.42 -34.52 9.72 Favored Pre-proline 0 N--CA 1.487 1.398 0 CA-C-O 118.274 -0.869 . . . . 73.1 112.053 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -90.64 99.6 0.26 Allowed 'Trans proline' 0 C--N 1.394 2.924 0 C-N-CA 122.527 2.152 . . . . 42.31 111.655 164.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.457 ' HD3' ' O ' ' A' ' 169' ' ' ASN . 10.6 Cg_exo -70.86 123.28 9.6 Favored 'Trans proline' 0 C--N 1.382 2.331 0 C-N-CA 121.683 1.588 . . . . 71.11 110.613 174.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -100.94 156.58 19.23 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.569 -0.613 . . . . 63.01 111.569 -178.63 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -83.99 143.57 29.7 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 109.849 -0.426 . . . . 74.21 109.849 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.61 HD21 HD11 ' A' ' 98' ' ' LEU . 64.1 tp -106.98 129.89 54.71 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.179 0.592 . . . . 64.15 109.851 -179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.452 HD21 ' HE ' ' A' ' 160' ' ' ARG . 98.1 mt -128.75 112.15 13.88 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.448 1.099 . . . . 73.35 110.025 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.597 HD13 HD12 ' A' ' 123' ' ' LEU . 81.9 mt -108.54 103.83 13.04 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.247 0.619 . . . . 73.31 110.96 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.52 94.62 4.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 N-CA-C 108.851 -0.796 . . . . 71.43 108.851 -176.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.4 t -57.63 118.68 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.877 0.871 . . . . 50.13 111.382 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -114.07 107.22 15.36 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 124.648 1.179 . . . . 74.33 108.22 175.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.05 122.07 18.68 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.526 0.517 . . . . 73.34 110.857 -176.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 93.0 mt -79.11 141.06 57.74 Favored Pre-proline 0 CA--C 1.544 0.745 0 CA-C-N 115.362 -0.835 . . . . 71.22 109.556 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.2 166.22 30.33 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.988 2.459 . . . . 72.1 112.591 -176.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.4 p-80 . . . . . 0 CA--C 1.56 1.327 0 C-N-CA 122.546 0.339 . . . . 71.14 110.299 178.835 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 pt? . . . . . 0 CA--C 1.562 1.429 0 N-CA-C 110.247 -0.279 . . . . 53.3 110.247 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -86.82 -67.79 0.01 OUTLIER 'Trans proline' 0 C--N 1.38 2.19 0 C-N-CA 122.865 2.376 . . . . 72.21 111.811 175.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.513 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.6 tp -159.74 140.92 12.6 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 108.516 -0.92 . . . . 71.13 108.516 176.206 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.712 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 11.5 tp 60.58 3.48 0.6 Allowed 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 126.461 1.904 . . . . 73.52 112.95 -178.207 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.739 ' HA ' HD13 ' A' ' 119' ' ' LEU . 75.0 t80 -135.35 133.25 38.57 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.271 1.028 . . . . 72.43 108.377 -173.196 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.507 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 89.3 m -153.6 102.17 2.54 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 123.75 0.82 . . . . 74.42 109.645 177.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -72.94 91.02 0.83 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 122.559 2.173 . . . . 72.03 111.631 -175.338 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 28.7 m . . . . . 0 N--CA 1.48 1.042 0 C-N-CA 124.178 0.991 . . . . 75.3 110.912 -178.491 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.439 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 3.9 mmp_? . . . . . 0 N--CA 1.484 1.238 0 N-CA-C 108.76 -0.83 . . . . 75.53 108.76 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -98.12 102.51 14.28 Favored 'General case' 0 CA--C 1.511 -0.542 0 N-CA-C 106.486 -1.672 . . . . 74.54 106.486 -173.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.739 HD13 ' HA ' ' A' ' 99' ' ' PHE . 16.5 mt -93.52 106.33 18.31 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.605 -1.257 . . . . 64.01 107.605 -169.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -111.02 103.24 11.69 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.904 -1.147 . . . . 71.21 107.904 -179.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.46 151.69 51.32 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.583 -0.735 . . . . 75.21 110.235 -168.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.529 ' HB3' ' HG3' ' A' ' 179' ' ' ARG . 40.4 mt-10 -81.55 124.17 29.27 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 114.6 -1.182 . . . . 72.45 109.342 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.53 HD12 HD13 ' A' ' 176' ' ' LEU . 3.2 tt -99.52 103.81 23.46 Favored Pre-proline 0 CA--C 1.54 0.583 0 N-CA-C 106.898 -1.519 . . . . 62.43 106.898 178.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.3 114.48 3.46 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 121.925 1.75 . . . . 72.34 110.438 175.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.499 HD21 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -139.23 120.08 14.35 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.039 -1.097 . . . . 71.43 108.039 -172.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 4.9 m -69.73 160.82 30.96 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 123.748 0.819 . . . . 75.13 111.112 -176.094 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 83.2 mt -56.17 -39.28 72.11 Favored 'General case' 0 N--CA 1.484 1.225 0 C-N-CA 123.894 0.878 . . . . 74.2 112.13 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -69.12 -44.19 72.91 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.447 0.699 . . . . 73.53 110.414 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -61.44 -39.15 89.76 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.321 1.048 . . . . 72.53 111.16 -179.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.447 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -72.98 -44.23 61.31 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-N 114.31 -1.314 . . . . 75.44 111.145 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -56.92 -47.83 79.66 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.803 1.241 . . . . 73.14 110.913 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -69.83 -48.55 58.53 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.716 -0.675 . . . . 61.4 110.181 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.549 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 55.65 76.37 0.2 Allowed Glycine 0 C--N 1.356 1.639 0 O-C-N 124.469 1.105 . . . . 25.22 113.638 176.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -112.57 -131.39 5.57 Favored Glycine 0 C--N 1.343 0.922 0 N-CA-C 111.328 -0.709 . . . . 60.04 111.328 177.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -100.96 152.19 20.86 Favored 'General case' 0 C--O 1.245 0.834 0 N-CA-C 108.694 -0.854 . . . . 61.04 108.694 170.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 tpp85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.003 0.921 . . . . 74.35 108.867 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.28 131.04 40.46 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 N-CA-C 108.582 -0.896 . . . . 64.32 108.582 175.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 27.1 m -125.14 161.19 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 123.604 0.762 . . . . 75.4 110.147 -178.419 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -97.56 141.71 30.27 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 124.075 0.95 . . . . 65.05 108.539 -178.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.712 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.0 p -150.1 109.31 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.199 0 C-N-CA 124.733 1.213 . . . . 73.22 111.394 -177.198 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.13 17.36 8.01 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 114.449 1.277 . . . . 72.52 114.449 164.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.12 22.34 13.36 Favored Glycine 0 N--CA 1.479 1.561 0 N-CA-C 112.514 -0.235 . . . . 64.25 112.514 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.423 ' HB2' HG13 ' A' ' 140' ' ' VAL . 24.7 mmm180 -134.75 153.86 51.83 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.906 1.282 . . . . 75.1 107.864 178.144 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -117.69 108.01 14.89 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.034 -0.728 . . . . 72.31 109.034 175.15 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 63.2 t -116.56 139.19 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 123.477 0.711 . . . . 74.44 110.174 -174.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.7 p -85.99 140.13 30.58 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 123.733 0.813 . . . . 73.02 111.087 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.415 HG21 HD12 ' A' ' 176' ' ' LEU . 14.7 p -133.55 157.59 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 124.641 1.176 . . . . 64.05 108.52 174.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 -107.32 128.72 54.7 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.783 -0.451 . . . . 75.24 109.783 177.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.499 HD12 HD21 ' A' ' 125' ' ' LEU . 15.7 pt -101.9 126.84 32.6 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.058 0.943 . . . . 71.15 108.65 176.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.408 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 27.9 Cg_endo -65.32 147.07 87.3 Favored 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.362 2.042 . . . . 70.54 113.547 -178.017 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.549 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 38.5 Cg_exo -62.88 121.92 10.0 Favored 'Trans proline' 0 C--N 1.385 2.452 0 C-N-CA 123.821 3.014 . . . . 70.33 112.159 179.156 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 72.33 40.13 55.83 Favored Glycine 0 C--N 1.339 0.747 0 O-C-N 124.051 0.844 . . . . 73.31 112.563 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.447 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 14.6 p -76.87 148.93 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 109.872 -0.418 . . . . 54.04 109.872 178.32 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 68.7 mtp180 -126.51 177.97 6.16 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-O 121.509 0.671 . . . . 60.03 112.413 -172.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -59.31 133.88 56.49 Favored 'General case' 0 CA--C 1.547 0.851 0 CA-C-N 113.409 -1.723 . . . . 64.21 111.865 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.31 -16.75 47.06 Favored Glycine 0 C--N 1.345 1.057 0 CA-C-O 119.388 -0.673 . . . . 20.23 113.312 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 48.3 m -67.15 118.72 10.95 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.36 0.58 . . . . 72.13 110.445 -173.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.9 p -94.12 125.0 46.8 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-O 121.528 0.68 . . . . 62.34 109.923 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 43.4 mt -94.82 99.75 9.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 107.061 -1.459 . . . . 63.1 107.061 174.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 46.6 ttt-85 -83.97 123.42 29.96 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 109.297 -0.631 . . . . 64.01 109.297 175.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.7 t -116.32 111.42 42.24 Favored Pre-proline 0 CA--C 1.555 1.168 0 N-CA-C 106.858 -1.534 . . . . 54.51 106.858 168.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.07 126.08 12.7 Favored 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.673 2.249 . . . . 71.04 112.25 -175.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.92 8.8 86.81 Favored Glycine 0 C--N 1.345 1.042 0 CA-C-N 115.774 -0.648 . . . . 74.55 114.57 171.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.452 ' HA ' HE22 ' A' ' 167' ' ' GLN . 24.0 mmt -114.07 15.35 18.36 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.154 0.582 . . . . 64.02 111.293 -176.685 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.21 -96.03 0.98 Allowed Glycine 0 C--N 1.344 0.973 0 N-CA-C 110.377 -1.089 . . . . 42.22 110.377 169.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . 0.439 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -79.12 95.29 1.4 Allowed Glycine 0 C--N 1.346 1.087 0 N-CA-C 112.177 -0.369 . . . . 71.2 112.177 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.452 HE22 ' HA ' ' A' ' 164' ' ' MET . 11.3 mm-40 -65.85 131.6 46.68 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.485 0.714 . . . . 70.31 111.508 -177.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 170.11 174.87 38.61 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.781 -0.928 . . . . 72.14 110.781 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.456 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 15.3 m120 -59.04 -42.37 93.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.358 0.663 . . . . 72.32 111.326 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.456 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 1.8 Cg_endo -87.42 101.34 0.5 Allowed 'Trans proline' 0 C--N 1.387 2.596 0 C-N-CA 122.429 2.086 . . . . 75.13 109.489 158.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.48 126.95 12.01 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 121.984 1.789 . . . . 61.33 111.911 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.99 151.14 21.94 Favored Glycine 0 C--N 1.343 0.946 0 CA-C-N 115.309 -0.859 . . . . 43.1 111.975 -179.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -77.74 159.4 29.1 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.512 0.725 . . . . 61.24 110.045 -170.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.534 HD21 HD11 ' A' ' 98' ' ' LEU . 47.5 tp -125.05 125.3 43.61 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.52 -0.548 . . . . 75.15 109.52 176.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 88.6 mt -127.4 101.47 6.47 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.88 0.872 . . . . 65.41 109.378 179.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.53 HD13 HD12 ' A' ' 123' ' ' LEU . 91.1 mt -102.96 102.23 12.28 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.992 0.517 . . . . 72.04 111.06 -178.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.99 107.57 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.011 -0.737 . . . . 71.52 109.011 -176.544 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.8 t -62.54 117.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.146 0.978 . . . . 73.25 111.078 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . 0.529 ' HG3' ' HB3' ' A' ' 122' ' ' GLU . 13.1 mmm180 -110.95 106.48 15.61 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 124.997 1.319 . . . . 71.23 108.092 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.406 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 65.8 mt -69.16 116.5 9.67 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 123.206 0.602 . . . . 72.31 110.815 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 81.9 mt -75.07 139.24 72.64 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 115.944 -0.571 . . . . 73.12 109.67 178.338 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -71.88 179.03 5.16 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.118 2.545 . . . . 72.32 112.872 177.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 . . . . . 0 C--O 1.252 1.234 0 N-CA-C 109.208 -0.664 . . . . 71.53 109.208 174.592 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.559 1.304 0 N-CA-C 113.837 1.051 . . . . 54.14 113.837 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.466 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 22.0 Cg_endo -62.51 178.17 1.01 Allowed 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.58 2.187 . . . . 75.03 112.473 168.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.651 HD13 ' HD2' ' A' ' 124' ' ' PRO . 1.7 tp -43.22 -53.97 4.8 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 125.287 1.435 . . . . 62.4 112.529 -174.038 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.434 ' O ' ' HB2' ' A' ' 99' ' ' PHE . 12.7 tp -119.3 91.92 3.67 Favored 'General case' 0 C--O 1.215 -0.757 0 N-CA-C 107.619 -1.252 . . . . 63.23 107.619 172.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.524 ' HA ' HD13 ' A' ' 119' ' ' LEU . 62.3 t80 168.52 131.54 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 124.361 1.064 . . . . 61.52 109.071 173.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.557 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 51.5 m -156.68 98.95 2.07 Favored Pre-proline 0 N--CA 1.475 0.787 0 N-CA-C 107.824 -1.176 . . . . 74.22 107.824 173.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -79.51 74.99 5.29 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 122.575 2.184 . . . . 70.12 112.553 -169.08 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 4.4 m . . . . . 0 CA--C 1.545 0.783 0 CA-C-N 115.541 -0.754 . . . . 52.54 109.997 179.448 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.56 1.348 0 CA-C-O 121.217 0.532 . . . . 75.5 111.065 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.57 130.74 40.88 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.228 -1.027 . . . . 74.43 108.228 -172.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.557 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 14.9 mt -100.73 112.83 25.31 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 108.111 -1.07 . . . . 64.24 108.111 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 75.0 ttt-85 -119.33 108.69 14.91 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 123.883 0.873 . . . . 73.02 110.208 -179.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -146.29 170.26 17.13 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 123.911 0.885 . . . . 74.04 108.701 179.004 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -97.03 145.21 26.17 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.969 0.414 . . . . 54.31 110.746 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.62 HD21 ' HG2' ' A' ' 136' ' ' ARG . 1.1 tt -103.01 103.9 36.74 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 124.901 1.28 . . . . 63.13 109.053 -177.11 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.651 ' HD2' HD13 ' A' ' 97' ' ' LEU . 37.7 Cg_endo -65.17 115.91 3.57 Favored 'Trans proline' 0 C--N 1.38 2.204 0 C-N-CA 122.107 1.871 . . . . 61.42 109.594 169.163 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.569 HD21 HD12 ' A' ' 149' ' ' ILE . 28.7 tp -137.15 127.02 25.69 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.361 0.664 . . . . 74.1 110.125 -172.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.9 p -78.18 167.91 20.67 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.062 0.545 . . . . 75.4 111.121 -175.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 76.9 mt -65.58 -37.3 86.25 Favored 'General case' 0 C--O 1.246 0.907 0 C-N-CA 123.981 0.913 . . . . 61.3 111.366 -173.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.47 -51.74 40.21 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 114.694 -1.139 . . . . 72.21 108.68 -177.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -62.43 -38.08 88.35 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.771 -1.104 . . . . 41.14 111.793 -178.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.39 -47.23 85.06 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 124.074 0.859 . . . . 73.21 110.453 176.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -66.48 -35.23 79.76 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 124.271 0.982 . . . . 75.53 111.136 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -67.32 -47.66 69.87 Favored 'General case' 0 C--N 1.363 1.18 0 CA-C-O 120.885 0.374 . . . . 73.03 110.018 177.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.58 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.19 56.01 24.57 Favored Glycine 0 C--N 1.341 0.852 0 CA-C-N 114.584 -1.189 . . . . 62.34 112.452 -174.259 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -103.3 -141.09 11.15 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 111.873 -0.491 . . . . 60.24 111.873 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -98.77 141.65 31.3 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.027 -0.731 . . . . 71.14 109.027 171.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.62 ' HG2' HD21 ' A' ' 123' ' ' LEU . 23.1 tpt180 -115.48 119.72 37.13 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.757 -1.201 . . . . 74.54 107.757 178.218 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 57.7 t -85.71 109.13 18.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 123.273 0.629 . . . . 61.31 109.519 -177.058 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.43 HG23 HD22 ' A' ' 98' ' ' LEU . 18.2 m -117.83 164.17 14.35 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 C-N-CA 125.609 1.563 . . . . 73.31 108.429 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -124.66 138.86 54.28 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 118.655 0.661 . . . . 70.41 111.413 -178.081 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.488 HG13 ' HB2' ' A' ' 143' ' ' ARG . 5.6 p -128.76 107.21 15.39 Favored 'Isoleucine or valine' 0 C--N 1.359 0.987 0 C-N-CA 124.838 1.255 . . . . 71.35 110.994 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.98 24.51 11.13 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.482 0.713 . . . . 55.52 112.166 175.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.39 18.09 29.48 Favored Glycine 0 C--N 1.348 1.246 0 CA-C-N 116.288 -0.415 . . . . 31.22 113.608 -178.282 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.488 ' HB2' HG13 ' A' ' 140' ' ' VAL . 10.8 mmm180 -117.64 123.09 45.29 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 123.773 0.829 . . . . 72.2 109.891 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.9 tpt180 -84.25 106.35 15.8 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 108.935 -0.765 . . . . 75.22 108.935 -176.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 88.4 t -115.98 132.17 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.87 0.868 . . . . 72.32 109.693 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 30.1 m -98.95 112.55 24.63 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.865 0.866 . . . . 74.41 109.23 176.121 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.486 HG21 HD12 ' A' ' 176' ' ' LEU . 3.8 p -99.72 121.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 124.023 0.929 . . . . 74.01 109.382 176.496 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -73.1 119.49 17.41 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.021 0.528 . . . . 74.42 110.182 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.58 HG13 ' HA2' ' A' ' 133' ' ' GLY . 4.9 pt -92.18 142.64 26.43 Favored Pre-proline 0 CA--C 1.563 1.478 0 C-N-CA 124.331 1.052 . . . . 63.03 109.948 177.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -58.84 148.36 84.24 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 123.555 2.837 . . . . 70.34 113.84 176.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.49 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 59.5 Cg_endo -70.31 113.04 3.33 Favored 'Trans proline' 0 C--N 1.377 2.044 0 C-N-CA 122.829 2.352 . . . . 72.32 111.414 177.408 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.22 39.01 37.93 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.826 -0.624 . . . . 64.32 112.34 -175.143 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 8.7 p -71.08 144.75 13.18 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 123.159 0.584 . . . . 74.24 110.143 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.506 ' HA ' HD11 ' A' ' 180' ' ' LEU . 64.6 mtp180 -119.24 177.13 5.01 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 121.766 0.794 . . . . 75.33 112.821 -171.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -64.89 130.25 42.75 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 113.535 -1.666 . . . . 73.51 111.121 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.52 -5.55 84.83 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-N 115.95 -0.568 . . . . 34.1 113.92 179.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.9 m -75.48 119.67 19.87 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-N 117.29 0.545 . . . . 72.42 109.742 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.6 t -98.51 116.63 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.069 0.547 . . . . 61.25 109.858 -174.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 57.5 mt -88.25 101.65 11.88 Favored 'Isoleucine or valine' 0 C--O 1.241 0.609 0 N-CA-C 108.074 -1.084 . . . . 73.31 108.074 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 13.4 ttp180 -91.79 113.79 26.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 114.821 -1.081 . . . . 74.35 109.477 178.14 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.0 t -114.85 113.83 44.35 Favored Pre-proline 0 CA--C 1.549 0.925 0 N-CA-C 108.922 -0.77 . . . . 72.14 108.922 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.04 124.23 12.73 Favored 'Trans proline' 0 C--N 1.377 2.065 0 C-N-CA 122.852 2.368 . . . . 62.42 112.595 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.41 -3.33 85.2 Favored Glycine 0 C--N 1.344 1.01 0 N-CA-C 114.911 0.724 . . . . 64.33 114.911 171.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.7 tpt -88.06 -7.62 56.72 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 117.622 0.711 . . . . 71.52 111.037 -175.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -75.81 -111.67 0.11 Allowed Glycine 0 C--N 1.349 1.278 0 N-CA-C 112.057 -0.417 . . . . 74.1 112.057 175.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.65 103.92 1.52 Allowed Glycine 0 C--N 1.344 1.017 0 CA-C-N 117.134 0.467 . . . . 31.22 113.304 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -65.98 147.89 52.66 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.483 0.713 . . . . 64.21 110.935 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 140.07 -171.78 23.73 Favored Glycine 0 N--CA 1.473 1.129 0 C-N-CA 123.136 0.398 . . . . 24.25 112.203 -177.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 45.7 m-80 -61.84 -46.15 92.6 Favored Pre-proline 0 CA--C 1.559 1.32 0 CA-C-O 118.394 -0.812 . . . . 71.35 111.698 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -88.33 103.66 0.46 Allowed 'Trans proline' 0 C--N 1.391 2.77 0 C-N-CA 121.842 1.695 . . . . 71.05 110.15 163.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -76.58 125.02 7.99 Favored 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 122.211 1.94 . . . . 70.22 110.723 -177.167 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -81.42 148.82 28.31 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 116.1 -0.5 . . . . 40.12 112.396 -178.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -78.19 151.93 32.93 Favored 'General case' 0 C--O 1.247 0.935 0 CA-C-O 121.102 0.477 . . . . 73.51 110.102 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.47 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 43.3 tp -114.17 131.89 56.29 Favored 'General case' 0 C--O 1.223 -0.334 0 C-N-CA 122.803 0.441 . . . . 73.1 110.075 177.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 73.1 mt -128.2 104.6 7.84 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 124.495 1.118 . . . . 74.21 108.902 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.486 HD12 HG21 ' A' ' 147' ' ' VAL . 66.6 mt -113.63 105.53 13.43 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.392 0.677 . . . . 64.43 110.565 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.8 t -84.72 103.8 12.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 109.239 -0.652 . . . . 64.4 109.239 -175.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.4 t -58.84 125.5 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 O-C-N 123.697 0.623 . . . . 61.22 111.539 -177.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -115.12 107.72 15.7 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 125.144 1.377 . . . . 64.32 107.499 176.038 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.506 HD11 ' HA ' ' A' ' 154' ' ' ARG . 54.1 mt -69.19 110.09 4.39 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.504 -0.925 . . . . 74.44 108.504 177.056 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 84.9 mt -68.82 129.84 92.11 Favored Pre-proline 0 CA--C 1.544 0.742 0 CA-C-N 115.715 -0.675 . . . . 75.53 110.013 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -65.43 158.68 51.5 Favored 'Trans proline' 0 C--N 1.369 1.625 0 C-N-CA 122.978 2.452 . . . . 74.01 111.825 176.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.6 t-80 . . . . . 0 CA--C 1.552 1.028 0 C-N-CA 123.509 0.724 . . . . 75.25 110.239 174.243 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.505 2.319 0 N-CA-C 114.482 1.29 . . . . 74.1 114.482 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -70.32 -43.35 2.24 Favored 'Trans proline' 0 C--N 1.38 2.229 0 C-N-CA 122.514 2.143 . . . . 63.34 112.153 -173.521 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.561 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.3 tp -175.39 145.43 0.75 Allowed 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.175 1.39 . . . . 65.21 107.804 -176.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.561 ' H ' HD12 ' A' ' 97' ' ' LEU . 4.2 tt 52.77 -78.27 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 126.924 2.09 . . . . 71.45 111.782 -174.589 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.672 ' HA ' HD13 ' A' ' 119' ' ' LEU . 78.2 t80 -57.01 120.71 8.45 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.909 1.283 . . . . 52.04 112.444 -178.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.555 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 88.8 m -138.62 97.97 9.02 Favored Pre-proline 0 CA--C 1.545 0.778 0 C-N-CA 124.287 1.035 . . . . 74.13 109.17 176.669 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.92 103.01 1.12 Allowed 'Trans proline' 0 C--N 1.367 1.527 0 C-N-CA 122.447 2.098 . . . . 65.21 111.708 -176.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.473 0.712 0 C-N-CA 124.249 1.02 . . . . 74.24 111.378 179.207 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.801 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 68.3 mtt180 . . . . . 0 N--CA 1.477 0.901 0 N-CA-C 109.722 -0.474 . . . . 74.02 109.722 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -99.44 107.43 19.64 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.903 -1.147 . . . . 44.52 107.903 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.672 HD13 ' HA ' ' A' ' 99' ' ' PHE . 13.5 mt -93.63 109.52 21.15 Favored 'General case' 0 C--O 1.22 -0.454 0 N-CA-C 106.769 -1.567 . . . . 74.41 106.769 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -121.11 107.94 13.21 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.953 0.901 . . . . 72.54 108.634 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.23 156.3 47.83 Favored 'General case' 0 C--O 1.24 0.6 0 C-N-CA 123.162 0.585 . . . . 73.35 110.401 -174.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -75.66 125.95 30.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.497 1.119 . . . . 75.15 108.942 179.11 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.575 HD11 ' HG2' ' A' ' 136' ' ' ARG . 26.1 tp -100.66 101.42 15.35 Favored Pre-proline 0 CA--C 1.543 0.681 0 C-N-CA 123.507 0.723 . . . . 43.25 109.331 178.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.64 114.98 4.17 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.251 1.967 . . . . 64.32 110.002 175.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.515 HD21 HD12 ' A' ' 149' ' ' ILE . 18.6 tp -131.89 135.62 46.79 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 108.223 -1.029 . . . . 74.32 108.223 -173.405 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 38.8 p -81.84 171.59 14.32 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.588 -0.523 . . . . 71.31 109.588 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 88.7 mt -68.05 -32.73 73.28 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 122.925 0.49 . . . . 74.3 110.343 176.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -69.48 -49.44 54.7 Favored 'General case' 0 N--CA 1.47 0.56 0 O-C-N 124.013 0.82 . . . . 64.24 109.433 -177.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -68.66 -34.6 75.98 Favored 'General case' 0 N--CA 1.472 0.648 0 O-C-N 124.016 0.823 . . . . 73.32 111.127 -178.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.51 -48.56 81.25 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.908 0.755 . . . . 54.03 110.599 173.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -65.09 -37.14 86.55 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 124.464 1.106 . . . . 72.43 110.905 179.275 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -64.2 -42.32 96.69 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 123.635 0.584 . . . . 71.43 110.136 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 58.63 35.56 81.57 Favored Glycine 0 C--N 1.349 1.251 0 O-C-N 124.234 0.959 . . . . 71.4 112.326 -174.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -87.71 -136.47 5.12 Favored Glycine 0 C--N 1.342 0.888 0 N-CA-C 112.045 -0.422 . . . . 52.53 112.045 -175.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.602 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 15.3 mp0 -111.43 139.77 46.58 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.052 -1.092 . . . . 43.14 108.052 173.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.575 ' HG2' HD11 ' A' ' 123' ' ' LEU . 37.9 tpt85 -112.81 120.51 41.74 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 124.323 1.049 . . . . 70.21 108.183 -177.195 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 91.2 t -81.39 106.3 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.79 0.836 . . . . 64.15 109.395 -176.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.53 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 20.4 m -111.35 159.92 11.0 Favored 'Isoleucine or valine' 0 C--O 1.245 0.839 0 C-N-CA 124.516 1.127 . . . . 74.33 111.113 -174.595 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -93.72 136.94 33.49 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.624 1.17 . . . . 65.45 109.056 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 1.5 p -151.9 100.35 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 C-N-CA 124.02 0.928 . . . . 74.43 110.445 176.043 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.02 21.26 11.63 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 113.526 0.936 . . . . 64.2 113.526 171.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.55 -7.37 55.89 Favored Glycine 0 N--CA 1.479 1.525 0 C-N-CA 123.162 0.41 . . . . 70.25 113.162 -176.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.04 150.2 21.52 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.83 0.852 . . . . 73.1 109.461 173.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 55.7 ttp180 -113.36 108.84 17.77 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 107.282 -1.377 . . . . 72.05 107.282 176.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.407 ' O ' HG22 ' A' ' 138' ' ' VAL . 70.1 t -121.77 134.48 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 C-N-CA 123.379 0.672 . . . . 72.33 110.619 -173.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.602 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 29.1 p -95.37 109.21 21.41 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 123.483 0.713 . . . . 41.15 109.165 176.488 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -98.91 128.24 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.508 0.723 . . . . 71.32 109.338 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -70.43 122.91 20.52 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 109.287 -0.634 . . . . 72.42 109.287 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.515 HD12 HD21 ' A' ' 125' ' ' LEU . 4.3 pt -98.69 149.49 35.79 Favored Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 124.875 1.27 . . . . 53.23 109.623 176.576 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -63.82 143.41 85.98 Favored 'Trans proline' 0 C--N 1.377 2.062 0 C-N-CA 122.77 2.313 . . . . 71.23 112.755 176.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.35 123.53 10.66 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 122.755 2.303 . . . . 40.51 111.91 174.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.48 26.71 64.95 Favored Glycine 0 C--N 1.347 1.179 0 CA-C-N 115.849 -0.614 . . . . 71.23 113.101 -178.444 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 7.4 p -67.68 145.9 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 C-N-CA 123.658 0.783 . . . . 63.12 111.363 -177.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.505 ' HA ' HD11 ' A' ' 180' ' ' LEU . 60.5 mtp180 -120.13 169.42 10.24 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-O 121.855 0.836 . . . . 75.1 112.832 -172.158 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -61.12 119.85 9.16 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 113.062 -1.881 . . . . 64.15 109.623 173.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 116.23 -25.4 9.33 Favored Glycine 0 N--CA 1.477 1.377 0 O-C-N 123.325 0.391 . . . . 61.15 112.583 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.6 m -69.88 123.92 22.71 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.479 0.712 . . . . 54.31 110.924 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.0 p -100.94 131.08 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 108.666 -0.864 . . . . 71.14 108.666 172.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 34.9 mt -100.05 102.15 13.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 107.859 -1.163 . . . . 71.15 107.859 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.489 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 51.1 ttp85 -87.73 106.43 18.05 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.538 -0.541 . . . . 72.23 109.538 175.182 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.1 t -100.48 96.44 5.29 Favored Pre-proline 0 CA--C 1.555 1.173 0 N-CA-C 107.481 -1.303 . . . . 73.3 107.481 173.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.66 143.67 42.58 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.958 2.438 . . . . 71.34 111.564 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . 0.713 ' HA2' ' HB2' ' A' ' 171' ' ' PRO . . . 85.47 -24.79 6.93 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-N 116.068 -0.514 . . . . 63.4 113.595 177.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.7 mmt -98.73 14.76 27.54 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.956 0.902 . . . . 71.21 111.013 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.86 -119.94 1.72 Allowed Glycine 0 C--N 1.348 1.21 0 N-CA-C 111.758 -0.537 . . . . 60.05 111.758 175.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . 0.801 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.94 112.8 3.57 Favored Glycine 0 C--N 1.348 1.231 0 CA-C-N 117.11 0.455 . . . . 72.44 112.453 -177.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -81.53 139.3 35.2 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.581 0.752 . . . . 70.55 110.502 -177.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -173.37 -142.64 3.94 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.509 -1.037 . . . . 75.52 110.509 -179.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.411 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 39.3 t30 -73.81 -49.41 6.11 Favored Pre-proline 0 CA--C 1.563 1.471 0 N-CA-C 109.151 -0.685 . . . . 64.3 109.151 169.318 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.411 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 93.1 Cg_endo -91.8 135.14 1.58 Allowed 'Trans proline' 0 C--N 1.389 2.709 0 C-N-CA 121.935 1.757 . . . . 72.44 111.748 165.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.713 ' HB2' ' HA2' ' A' ' 163' ' ' GLY . 55.8 Cg_endo -67.56 128.35 17.99 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.406 2.071 . . . . 61.14 111.599 172.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.27 162.84 32.47 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-N 116.095 -0.502 . . . . 43.34 113.108 -179.127 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -86.73 145.81 26.51 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.67 0.788 . . . . 65.4 110.532 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.489 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 42.8 tp -111.21 135.1 52.24 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.835 0.854 . . . . 62.21 109.288 173.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 66.7 mt -127.67 102.18 6.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.062 1.345 . . . . 54.42 108.813 178.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 98.1 mt -102.41 101.41 11.63 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.406 0.682 . . . . 73.15 109.481 177.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.7 t -85.66 97.87 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 109.043 -0.725 . . . . 75.13 109.043 -174.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 86.7 t -57.96 104.87 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 124.415 1.086 . . . . 71.13 111.47 -176.161 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -98.35 101.64 13.15 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-N 113.803 -1.544 . . . . 74.22 108.375 170.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.505 HD11 ' HA ' ' A' ' 154' ' ' ARG . 47.3 mt -69.64 126.77 30.73 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.634 -0.506 . . . . 73.13 109.634 176.509 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 59.5 mt -77.01 140.46 66.56 Favored Pre-proline 0 CA--C 1.548 0.865 0 N-CA-C 108.772 -0.825 . . . . 75.22 108.772 178.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -49.23 -73.54 0.04 OUTLIER 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 123.994 3.129 . . . . 54.23 113.165 -174.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 . . . . . 0 C--O 1.252 1.192 0 C-N-CA 124.538 1.135 . . . . 73.45 108.382 177.855 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.449 ' HG ' ' HA ' ' A' ' 100' ' ' THR . 2.7 tt . . . . . 0 CA--C 1.556 1.21 0 N-CA-C 109.601 -0.518 . . . . 62.5 109.601 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -75.4 -60.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.385 2.495 0 C-N-CA 121.951 1.768 . . . . 74.11 111.828 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.47 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.2 tp -169.32 135.96 1.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.696 -1.594 . . . . 73.42 106.696 -173.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.547 HD13 HD11 ' A' ' 176' ' ' LEU . 14.8 tp 70.67 -60.42 0.5 Allowed 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.89 2.076 . . . . 72.02 112.511 -173.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.706 ' HB2' ' HA ' ' A' ' 140' ' ' VAL . 32.7 t80 -61.45 113.29 2.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.201 1.0 . . . . 72.53 111.782 179.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.449 ' HA ' ' HG ' ' A' ' 95' ' ' LEU . 98.2 m -133.4 95.3 18.29 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 124.045 0.938 . . . . 73.54 109.575 175.471 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.47 84.25 1.41 Allowed 'Trans proline' 0 C--N 1.369 1.658 0 C-N-CA 122.317 2.011 . . . . 73.23 112.802 -175.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.43 HG13 HG22 ' A' ' 100' ' ' THR . 23.3 m . . . . . 0 N--CA 1.472 0.633 0 CA-C-N 115.062 -0.972 . . . . 64.41 110.57 177.325 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 . . . . . 0 N--CA 1.477 0.891 0 N-CA-C 108.64 -0.874 . . . . 71.43 108.64 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -96.87 106.19 18.46 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 106.801 -1.555 . . . . 60.12 106.801 -178.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 15.7 mt -92.71 107.13 18.98 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 106.297 -1.742 . . . . 71.0 106.297 -172.127 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.504 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 59.6 ttt-85 -114.99 105.97 13.6 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.008 -1.108 . . . . 74.05 108.008 -176.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.52 146.67 50.43 Favored 'General case' 0 C--O 1.24 0.601 0 N-CA-C 108.742 -0.836 . . . . 61.03 108.742 -179.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -71.84 131.35 42.91 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 108.621 -0.881 . . . . 70.41 108.621 173.049 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.544 HD21 ' HG2' ' A' ' 136' ' ' ARG . 1.5 tt -98.4 103.27 17.41 Favored Pre-proline 0 CA--C 1.532 0.275 0 N-CA-C 106.352 -1.721 . . . . 73.23 106.352 176.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.474 ' HB2' HD11 ' A' ' 181' ' ' LEU . 50.5 Cg_endo -65.61 116.0 3.69 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 121.935 1.757 . . . . 74.35 109.786 174.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.464 HD21 HD12 ' A' ' 149' ' ' ILE . 15.6 tp -147.75 120.32 8.55 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.395 -0.595 . . . . 60.12 109.395 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.455 HG22 ' HB2' ' A' ' 181' ' ' LEU . 71.4 p -77.13 168.04 20.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.807 0.443 . . . . 51.43 111.724 -177.288 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.3 mt -55.64 -47.2 77.02 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 123.872 0.869 . . . . 74.13 112.137 -177.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -66.71 -41.4 88.02 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 115.959 -0.564 . . . . 74.3 111.279 -178.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -68.31 -31.86 71.59 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 122.91 0.484 . . . . 52.33 111.592 178.165 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -72.21 -39.38 68.59 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 123.337 0.655 . . . . 61.44 111.07 177.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -63.21 -56.52 15.93 Favored 'General case' 0 N--CA 1.472 0.628 0 O-C-N 124.619 1.199 . . . . 61.23 110.011 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 50.3 m80 -70.24 -34.96 73.49 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.469 -0.787 . . . . 71.01 111.16 -177.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 68.94 -135.35 28.07 Favored Glycine 0 C--N 1.353 1.513 0 N-CA-C 111.949 -0.46 . . . . 33.52 111.949 -177.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.49 -143.28 16.5 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 112.201 -0.36 . . . . 62.44 112.201 178.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -104.44 148.36 26.52 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.237 0.541 . . . . 71.31 111.31 -178.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.544 ' HG2' HD21 ' A' ' 123' ' ' LEU . 2.2 tpp180 -137.16 119.1 15.28 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 106.741 -1.577 . . . . 74.43 106.741 175.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.59 115.97 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.704 0 CA-C-O 121.864 0.84 . . . . 75.41 109.801 -174.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 11.4 m -122.7 164.33 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.981 1.312 . . . . 74.03 108.828 -171.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -123.16 125.42 45.1 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 118.457 0.571 . . . . 74.41 111.936 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.706 ' HA ' ' HB2' ' A' ' 99' ' ' PHE . 4.0 p -113.52 111.37 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.368 1.067 . . . . 62.12 110.17 175.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.34 26.3 14.97 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 123.807 0.843 . . . . 61.52 112.854 172.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.86 -12.03 60.84 Favored Glycine 0 C--N 1.352 1.421 0 CA-C-N 116.51 -0.314 . . . . 53.45 113.104 -177.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.1 tpp180 -92.22 115.86 28.44 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.637 0.775 . . . . 75.41 110.03 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 3.1 tpp180 -87.0 106.95 18.19 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.934 -0.765 . . . . 65.24 108.934 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 34.4 m -116.22 156.35 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 C-N-CA 123.911 0.884 . . . . 73.14 110.923 -178.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.0 p -91.32 141.95 28.22 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.53 0.732 . . . . 61.0 110.099 175.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 43.2 t -128.38 111.51 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 C-N-CA 124.747 1.219 . . . . 74.24 108.855 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -80.07 102.32 9.26 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.446 0.641 . . . . 60.42 109.417 178.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.464 HD12 HD21 ' A' ' 125' ' ' LEU . 16.5 pt -82.74 131.66 53.99 Favored Pre-proline 0 CA--C 1.559 1.296 0 CA-C-N 114.81 -1.086 . . . . 75.43 109.907 178.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 37.1 Cg_exo -64.22 135.86 48.87 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 122.656 2.237 . . . . 55.13 113.437 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -67.04 121.32 8.48 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 122.345 2.03 . . . . 52.31 110.742 168.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 87.82 27.47 26.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 115.549 -0.75 . . . . 73.23 113.22 -172.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.66 142.88 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 117.443 0.622 . . . . 64.41 109.74 176.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -112.7 177.6 4.58 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 121.635 0.731 . . . . 72.41 112.407 -172.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -65.02 133.49 51.79 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 113.56 -1.654 . . . . 62.44 110.644 176.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 83.8 -14.02 44.96 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-O 119.24 -0.755 . . . . 53.34 113.353 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 68.4 m -66.28 117.79 9.05 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 117.422 0.611 . . . . 63.31 109.667 -175.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.21 133.57 33.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 CA-C-O 121.362 0.601 . . . . 75.32 110.001 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.538 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 94.0 mt -99.95 102.3 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 N-CA-C 106.519 -1.66 . . . . 72.04 106.519 177.145 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.536 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 61.1 ttp85 -99.31 110.18 22.73 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.354 -0.385 . . . . 70.44 110.184 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.93 100.55 10.05 Favored Pre-proline 0 CA--C 1.557 1.241 0 N-CA-C 107.525 -1.287 . . . . 72.41 107.525 170.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.45 136.7 29.17 Favored 'Trans proline' 0 C--N 1.376 1.976 0 C-N-CA 122.937 2.424 . . . . 75.41 112.637 -173.073 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.15 -21.82 11.37 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.889 -0.596 . . . . 64.22 113.883 177.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 56.8 mtt -100.52 16.42 24.74 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 123.563 0.745 . . . . 74.21 111.402 -173.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . 0.584 ' HA2' HD13 ' A' ' 174' ' ' LEU . . . -85.27 -103.45 0.67 Allowed Glycine 0 C--N 1.351 1.407 0 CA-C-N 116.196 -0.457 . . . . 74.23 112.236 176.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -66.86 103.18 0.86 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.807 -0.517 . . . . 25.22 111.807 175.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -88.61 152.7 21.67 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.704 0.801 . . . . 73.1 110.419 -179.115 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 134.17 -137.0 8.96 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.462 -1.055 . . . . 74.25 110.462 -172.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.533 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 14.9 m120 -71.97 -56.48 4.55 Favored Pre-proline 0 CA--C 1.563 1.479 0 CA-C-N 117.704 0.752 . . . . 73.25 111.243 176.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.533 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -93.82 119.64 0.34 Allowed 'Trans proline' 0 C--N 1.396 3.041 0 C-N-CA 122.443 2.095 . . . . 53.2 112.434 178.388 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -63.03 125.2 15.36 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.82 2.347 . . . . 73.43 112.271 174.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.83 173.77 23.89 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 116.576 -0.284 . . . . 74.32 112.472 177.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -95.05 134.93 37.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.082 0.553 . . . . 62.43 109.878 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.584 HD13 ' HA2' ' A' ' 165' ' ' GLY . 17.1 tp -97.79 119.36 36.25 Favored 'General case' 0 C--O 1.216 -0.673 0 N-CA-C 107.989 -1.115 . . . . 73.42 107.989 -178.533 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 65.6 mt -123.48 120.15 32.06 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.761 0.824 . . . . 71.34 109.598 -170.108 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.547 HD11 HD13 ' A' ' 98' ' ' LEU . 41.9 mt -123.0 101.12 7.24 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 123.254 0.622 . . . . 74.34 110.937 177.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.1 t -85.84 96.38 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 108.409 -0.96 . . . . 70.24 108.409 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.8 t -56.02 126.51 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.199 1.0 . . . . 53.15 111.721 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.8 mmm-85 -112.87 110.01 19.83 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.786 -1.191 . . . . 75.03 107.786 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 46.0 mt -70.67 96.04 1.17 Allowed 'General case' 0 C--O 1.238 0.481 0 N-CA-C 109.408 -0.59 . . . . 71.44 109.408 178.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.474 HD11 ' HB2' ' A' ' 124' ' ' PRO . 80.4 mt -71.56 149.3 93.4 Favored Pre-proline 0 C--O 1.246 0.873 0 CA-C-N 114.711 -1.131 . . . . 62.34 110.445 -179.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -57.86 142.86 96.52 Favored 'Trans proline' 0 C--N 1.372 1.801 0 C-N-CA 122.557 2.171 . . . . 71.53 111.656 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 27.9 p80 . . . . . 0 CA--C 1.558 1.265 0 C-N-CA 123.543 0.737 . . . . 74.31 111.328 179.228 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.3 pt? . . . . . 0 CA--C 1.545 0.776 0 N-CA-C 110.251 -0.277 . . . . 73.11 110.251 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_exo -73.34 -160.9 0.1 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 122.8 2.333 . . . . 72.51 111.25 167.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.541 HD12 ' H ' ' A' ' 98' ' ' LEU . 9.1 tp -72.04 141.47 49.28 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.819 -0.808 . . . . 71.23 108.819 171.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.677 HD13 HG21 ' A' ' 138' ' ' VAL . 6.0 tp 65.58 -68.16 0.12 Allowed 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 126.83 2.052 . . . . 45.31 111.579 -174.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.592 ' HA ' HD13 ' A' ' 119' ' ' LEU . 59.8 t80 -59.78 127.83 33.91 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.213 1.005 . . . . 70.41 111.708 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.502 HG22 HG13 ' A' ' 102' ' ' VAL . 56.3 m -141.75 104.61 5.81 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 124.086 0.954 . . . . 74.1 109.228 175.116 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.1 87.1 1.05 Allowed 'Trans proline' 0 C--N 1.362 1.278 0 C-N-CA 122.299 2.0 . . . . 60.31 112.97 -170.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.502 HG13 HG22 ' A' ' 100' ' ' THR . 22.8 m . . . . . 0 C--O 1.239 0.525 0 CA-C-N 114.451 -1.25 . . . . 73.32 109.846 174.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 42.9 mtt180 . . . . . 0 N--CA 1.473 0.693 0 N-CA-C 109.775 -0.454 . . . . 74.24 109.775 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -98.91 104.17 16.19 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.873 -1.529 . . . . 71.23 106.873 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.592 HD13 ' HA ' ' A' ' 99' ' ' PHE . 11.5 mt -92.71 110.44 21.88 Favored 'General case' 0 C--N 1.343 0.323 0 N-CA-C 106.633 -1.617 . . . . 65.21 106.633 -173.402 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -117.76 108.55 15.52 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 108.975 -0.75 . . . . 75.34 108.975 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.48 154.02 51.15 Favored 'General case' 0 C--O 1.24 0.592 0 C-N-CA 123.193 0.597 . . . . 32.44 110.682 -171.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -72.13 131.58 43.0 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.291 -0.868 . . . . 60.23 109.109 173.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.627 HD21 ' HG2' ' A' ' 136' ' ' ARG . 2.4 tt -101.47 102.61 22.59 Favored Pre-proline 0 CA--C 1.544 0.733 0 N-CA-C 107.949 -1.13 . . . . 73.43 107.949 176.047 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.74 115.79 3.94 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 121.928 1.752 . . . . 71.51 110.019 173.143 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 46.3 tp -142.75 131.52 22.73 Favored 'General case' 0 C--O 1.225 -0.194 0 C-N-CA 123.648 0.779 . . . . 71.13 109.012 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 55.0 p -80.13 163.61 23.98 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 122.865 0.466 . . . . 74.23 111.286 -176.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.9 mt -58.77 -51.82 68.35 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.666 0.787 . . . . 74.3 112.826 -171.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -64.83 -40.13 94.68 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 122.742 0.417 . . . . 74.02 111.109 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -69.49 -26.04 64.35 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 112.288 0.477 . . . . 74.03 112.288 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -69.11 -46.68 67.1 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 123.619 0.768 . . . . 63.21 109.743 172.096 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -61.93 -42.03 98.63 Favored 'General case' 0 CA--C 1.546 0.801 0 CA-C-N 114.614 -1.176 . . . . 64.41 111.039 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.4 m80 -72.97 -42.2 63.6 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 122.804 0.442 . . . . 72.34 110.317 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.85 -128.76 9.79 Favored Glycine 0 C--N 1.345 1.032 0 CA-C-N 115.309 -0.86 . . . . 53.13 111.308 -172.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.416 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 80.38 -158.5 41.79 Favored Glycine 0 C--N 1.348 1.24 0 CA-C-N 116.834 0.317 . . . . 43.53 112.805 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -84.0 147.16 27.59 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 117.329 0.564 . . . . 71.13 109.763 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.627 ' HG2' HD21 ' A' ' 123' ' ' LEU . 27.0 tpt180 -128.33 121.2 28.63 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.433 0.693 . . . . 73.22 109.178 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.416 HG13 ' HG3' ' A' ' 144' ' ' ARG . 93.1 t -79.22 106.87 10.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.455 0 C-N-CA 123.975 0.91 . . . . 73.03 109.265 178.055 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.677 HG21 HD13 ' A' ' 98' ' ' LEU . 20.7 m -111.13 159.64 10.97 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 123.863 0.865 . . . . 74.13 109.377 176.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -116.79 138.12 51.72 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 107.703 -1.221 . . . . 73.24 107.703 -176.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.572 HG13 ' HB2' ' A' ' 143' ' ' ARG . 3.7 p -150.15 107.12 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 C-N-CA 123.212 0.605 . . . . 60.53 111.498 -176.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.18 20.6 8.63 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 113.359 0.874 . . . . 44.5 113.359 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.9 28.31 7.87 Favored Glycine 0 C--N 1.344 0.976 0 C-N-CA 122.903 0.287 . . . . 73.12 112.582 -175.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.572 ' HB2' HG13 ' A' ' 140' ' ' VAL . 82.3 mtt85 -133.68 156.64 47.55 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 123.533 0.733 . . . . 74.13 110.095 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.416 ' HG3' HG13 ' A' ' 137' ' ' VAL . 31.6 ttm180 -109.86 119.77 40.39 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.754 0.822 . . . . 75.44 109.169 170.457 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.404 ' O ' HG22 ' A' ' 138' ' ' VAL . 69.8 t -115.69 135.63 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 108.421 -0.955 . . . . 53.24 108.421 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 28.9 p -103.2 104.78 14.96 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 109.141 -0.688 . . . . 72.03 109.141 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 4.7 p -98.3 120.29 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 109.172 -0.677 . . . . 74.32 109.172 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 47.3 ttp180 -78.21 100.37 6.62 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-O 121.415 0.626 . . . . 74.2 109.33 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.562 HD13 ' HB2' ' A' ' 136' ' ' ARG . 3.1 pt -79.55 144.9 62.03 Favored Pre-proline 0 CA--C 1.563 1.449 0 CA-C-N 114.639 -1.164 . . . . 72.33 109.766 178.444 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -61.93 136.82 63.71 Favored 'Trans proline' 0 CA--C 1.562 1.891 0 C-N-CA 123.005 2.47 . . . . 52.43 113.393 -179.033 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -62.18 113.12 1.76 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.948 2.432 . . . . 55.22 111.179 172.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.47 35.51 8.59 Favored Glycine 0 C--N 1.34 0.765 0 O-C-N 123.616 0.573 . . . . 72.41 112.379 -176.241 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.415 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 12.6 p -76.65 145.85 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 N-CA-C 109.818 -0.438 . . . . 70.24 109.818 176.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -118.39 177.15 4.92 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.651 0.739 . . . . 75.14 112.636 -171.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -64.68 135.05 55.47 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 113.989 -1.459 . . . . 63.42 110.974 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.22 -6.13 64.73 Favored Glycine 0 C--N 1.343 0.959 0 CA-C-N 115.767 -0.652 . . . . 75.1 113.646 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 56.0 m -74.85 118.89 18.31 Favored 'General case' 0 C--N 1.351 0.647 0 CA-C-N 117.502 0.651 . . . . 72.43 109.506 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.0 p -99.05 134.25 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 123.087 0.555 . . . . 64.01 110.413 -177.136 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 67.7 mt -105.94 105.87 19.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 C-N-CA 124.328 1.051 . . . . 73.14 108.71 -175.125 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 58.0 ttm-85 -87.96 111.86 21.94 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.81 0.444 . . . . 74.41 110.405 -178.318 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -123.95 98.95 38.66 Favored Pre-proline 0 CA--C 1.554 1.124 0 C-N-CA 123.942 0.897 . . . . 72.44 109.0 179.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.28 131.75 21.13 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.488 2.126 . . . . 75.32 112.22 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.89 -23.17 37.07 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.761 -0.654 . . . . 52.51 113.56 176.099 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.2 mpt? -89.57 6.56 40.55 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.107 0.563 . . . . 74.24 111.288 178.004 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -85.51 -108.37 0.7 Allowed Glycine 0 C--N 1.344 1.001 0 N-CA-C 111.556 -0.617 . . . . 74.32 111.556 174.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.6 108.93 2.64 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 112.286 -0.326 . . . . 74.35 112.286 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.577 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -88.36 148.46 24.24 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.194 0.598 . . . . 63.1 110.885 -179.493 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.48 -138.51 8.49 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 111.062 -0.815 . . . . 73.51 111.062 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.457 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 3.4 m-20 -78.41 -49.16 1.82 Allowed Pre-proline 0 CA--C 1.566 1.578 0 CA-C-O 118.29 -0.862 . . . . 44.34 110.644 175.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.457 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -94.97 106.41 0.12 Allowed 'Trans proline' 0 C--N 1.396 3.034 0 C-N-CA 122.658 2.238 . . . . 63.23 111.905 172.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.37 125.23 13.63 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 122.025 1.817 . . . . 70.51 111.456 174.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -99.97 173.96 26.06 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 116.041 -0.527 . . . . 72.12 111.975 175.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -92.48 152.57 19.6 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 123.309 0.644 . . . . 72.31 110.663 -174.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.463 HD21 HD11 ' A' ' 98' ' ' LEU . 59.3 tp -114.23 133.76 55.4 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.901 0.88 . . . . 53.43 109.75 179.011 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.3 mt -129.85 103.46 6.82 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.021 0.928 . . . . 63.24 110.428 176.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.602 HD21 HD12 ' A' ' 98' ' ' LEU . 82.8 mt -101.77 103.18 13.9 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 123.072 0.549 . . . . 72.3 111.212 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.9 t -84.11 97.68 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 N-CA-C 108.954 -0.758 . . . . 64.31 108.954 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 89.5 t -57.03 130.26 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 124.024 0.93 . . . . 71.51 111.436 -178.199 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -121.4 105.32 10.4 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 125.068 1.347 . . . . 63.4 107.912 -177.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 24.1 mt -70.32 109.8 4.92 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.377 -0.601 . . . . 63.23 109.377 178.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.8 mt -72.27 149.97 91.82 Favored Pre-proline 0 CA--C 1.549 0.942 0 C-N-CA 123.062 0.545 . . . . 75.22 110.097 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -58.93 97.49 0.09 OUTLIER 'Trans proline' 0 C--N 1.376 2.005 0 C-N-CA 122.898 2.399 . . . . 61.33 110.98 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 124.772 1.229 . . . . 64.24 109.702 -172.574 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 tt . . . . . 0 CA--C 1.556 1.202 0 N-CA-C 111.664 0.246 . . . . 71.24 111.664 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -90.81 -152.04 0.04 OUTLIER 'Trans proline' 0 CA--C 1.553 1.434 0 C-N-CA 122.827 2.351 . . . . 73.44 111.101 168.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.584 HD12 ' H ' ' A' ' 98' ' ' LEU . 12.1 tp -74.69 144.52 43.71 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.961 0.905 . . . . 73.24 109.41 175.24 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.603 HD13 HG21 ' A' ' 138' ' ' VAL . 9.0 tp 64.4 -67.79 0.11 Allowed 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.731 2.412 . . . . 74.21 112.002 -171.422 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.713 ' HA ' HD13 ' A' ' 119' ' ' LEU . 60.7 t80 -64.58 130.01 42.01 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.411 1.084 . . . . 75.31 111.531 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.473 HG22 HG13 ' A' ' 102' ' ' VAL . 39.7 m -146.09 98.29 4.39 Favored Pre-proline 0 CA--C 1.54 0.58 0 C-N-CA 124.679 1.192 . . . . 75.14 108.766 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.26 87.11 0.92 Allowed 'Trans proline' 0 C--N 1.366 1.471 0 C-N-CA 122.192 1.928 . . . . 72.01 112.554 -171.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.473 HG13 HG22 ' A' ' 100' ' ' THR . 14.7 m . . . . . 0 CA--C 1.541 0.621 0 C-N-CA 124.332 1.053 . . . . 71.33 108.745 173.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.651 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 37.5 mtm180 . . . . . 0 N--CA 1.476 0.875 0 N-CA-C 109.495 -0.558 . . . . 61.34 109.495 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -99.8 107.49 19.54 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 108.188 -1.041 . . . . 62.1 108.188 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.713 HD13 ' HA ' ' A' ' 99' ' ' PHE . 16.4 mt -93.63 111.05 22.66 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 107.64 -1.244 . . . . 60.14 107.64 -175.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.3 ttp85 -114.6 105.61 13.28 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 108.896 -0.779 . . . . 73.34 108.896 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 145.66 50.96 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 123.68 0.792 . . . . 45.4 109.633 -175.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.504 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 3.2 mp0 -74.16 131.73 41.55 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 123.667 0.787 . . . . 54.25 109.225 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.532 HD11 ' HG2' ' A' ' 136' ' ' ARG . 40.9 tp -100.12 102.89 19.57 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 124.29 1.036 . . . . 71.1 109.134 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -67.86 114.56 3.39 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 122.274 1.982 . . . . 70.14 109.956 176.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.538 HD21 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -143.86 131.43 21.15 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.066 -0.716 . . . . 74.1 109.066 -171.339 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.8 p -80.52 170.51 16.25 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 110.296 -0.261 . . . . 62.12 110.296 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 84.8 mt -61.37 -34.74 75.83 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.837 0.855 . . . . 72.41 111.157 -178.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -72.79 -51.67 18.07 Favored 'General case' 0 C--N 1.345 0.379 0 CA-C-N 114.776 -1.102 . . . . 75.34 108.803 -176.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -66.94 -26.72 66.98 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.01 -0.996 . . . . 61.01 111.575 -176.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.447 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -74.87 -50.47 16.89 Favored 'General case' 0 C--N 1.348 0.521 0 C-N-CA 123.901 0.88 . . . . 55.0 111.375 176.102 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -58.61 -46.15 87.66 Favored 'General case' 0 C--N 1.361 1.068 0 O-C-N 124.308 1.005 . . . . 72.05 110.664 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -77.78 -40.63 40.11 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.279 -0.873 . . . . 74.42 111.033 -176.418 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.58 -164.53 50.9 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 111.828 -0.509 . . . . 63.13 111.828 -175.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.471 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 119.49 -161.11 14.18 Favored Glycine 0 N--CA 1.473 1.12 0 N-CA-C 111.774 -0.53 . . . . 62.12 111.774 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -81.52 141.63 33.63 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.046 0.539 . . . . 75.23 110.253 177.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.532 ' HG2' HD11 ' A' ' 123' ' ' LEU . 19.4 tpp180 -126.75 121.28 31.56 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.969 0.908 . . . . 60.44 108.768 178.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 56.0 t -81.28 107.63 13.72 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 C-N-CA 123.339 0.656 . . . . 75.23 109.614 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.603 HG21 HD13 ' A' ' 98' ' ' LEU . 25.5 m -116.37 164.63 12.53 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 C-N-CA 125.297 1.439 . . . . 72.2 109.318 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -122.41 131.48 53.9 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 123.446 0.699 . . . . 64.42 109.575 -171.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.415 ' HB ' HD23 ' A' ' 98' ' ' LEU . 5.2 p -142.54 102.41 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.321 0 C-N-CA 124.211 1.004 . . . . 72.22 111.656 -174.002 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.55 25.93 14.86 Favored 'General case' 0 N--CA 1.493 1.681 0 C-N-CA 124.229 1.012 . . . . 74.51 112.759 175.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.56 -0.8 53.01 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 123.901 0.762 . . . . 55.51 113.438 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.4 ' HB2' HG13 ' A' ' 140' ' ' VAL . 31.5 mmm180 -104.07 141.89 35.42 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.421 0.689 . . . . 64.34 110.367 -177.458 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -97.81 113.89 25.8 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.753 0.821 . . . . 73.15 109.284 178.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 73.6 t -118.51 129.6 74.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 123.859 0.864 . . . . 74.01 109.561 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 33.5 p -97.39 106.58 18.92 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 109.063 -0.717 . . . . 73.33 109.063 174.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.3 p -98.7 125.9 51.99 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 123.494 0.717 . . . . 71.41 109.76 -177.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.2 ttt180 -81.99 105.06 12.79 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.379 0.672 . . . . 70.22 109.62 -177.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.538 HD12 HD21 ' A' ' 125' ' ' LEU . 4.8 pt -87.24 146.03 39.18 Favored Pre-proline 0 C--O 1.253 1.265 0 C-N-CA 124.68 1.192 . . . . 74.42 109.343 176.493 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.455 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 57.0 Cg_endo -72.04 143.09 39.69 Favored 'Trans proline' 0 CA--C 1.56 1.799 0 C-N-CA 122.441 2.094 . . . . 72.24 112.76 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.39 130.49 22.53 Favored 'Trans proline' 0 C--N 1.375 1.941 0 C-N-CA 122.493 2.129 . . . . 52.34 111.262 171.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.82 27.57 45.73 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 115.548 -0.751 . . . . 51.41 112.243 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.455 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 12.4 p -76.62 147.71 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 108.989 -0.745 . . . . 51.03 108.989 176.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.0 mtp180 -125.12 176.06 6.96 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-O 121.993 0.901 . . . . 72.32 112.591 -166.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -64.42 123.9 20.38 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-N 113.292 -1.776 . . . . 71.4 110.332 175.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.54 89.55 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.798 0.686 . . . . 33.42 113.611 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.3 m -76.54 118.49 19.25 Favored 'General case' 0 C--N 1.35 0.614 0 N-CA-C 108.778 -0.823 . . . . 71.44 108.778 176.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.12 124.7 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 CA-C-O 121.437 0.637 . . . . 71.33 109.677 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.5 mt -95.14 102.85 14.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 C-N-CA 124.324 1.05 . . . . 73.25 108.23 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.503 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 35.1 ttm180 -87.28 107.91 18.72 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 109.49 -0.559 . . . . 74.31 109.49 174.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.9 t -105.7 107.69 59.92 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 107.428 -1.323 . . . . 71.11 107.428 173.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -66.02 135.4 40.61 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.484 2.123 . . . . 74.52 112.043 -177.131 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 80.39 -5.33 64.19 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 114.723 0.649 . . . . 73.12 114.723 174.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 96.3 mmm -103.9 16.58 26.01 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 117.807 0.803 . . . . 61.32 111.842 -176.224 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -90.88 -142.29 10.07 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 116.149 -0.478 . . . . 54.21 111.983 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . 0.651 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.69 127.93 8.58 Favored Glycine 0 C--N 1.343 0.965 0 N-CA-C 111.638 -0.585 . . . . 63.51 111.638 -177.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.9 mm-40 -83.61 151.64 25.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 123.46 0.704 . . . . 75.5 110.513 -175.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -148.75 -125.85 1.48 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 109.559 -1.417 . . . . 74.12 109.559 177.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.558 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 23.2 t30 -74.63 -51.26 4.14 Favored Pre-proline 0 CA--C 1.564 1.493 0 N-CA-C 108.118 -1.067 . . . . 71.55 108.118 161.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.558 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 49.4 Cg_endo -100.13 164.45 0.47 Allowed 'Trans proline' 0 C--N 1.39 2.731 0 C-N-CA 122.74 2.294 . . . . 72.12 111.689 165.324 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.21 136.68 14.61 Favored 'Trans proline' 0 CA--C 1.557 1.67 0 C-N-CA 121.794 1.662 . . . . 73.24 112.182 174.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -86.78 179.7 48.89 Favored Glycine 0 C--N 1.348 1.218 0 CA-C-O 119.999 -0.334 . . . . 24.42 112.552 175.16 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -97.48 148.53 23.13 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.043 0.537 . . . . 74.32 110.956 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.503 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 56.8 tp -107.01 132.73 52.62 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.052 0.941 . . . . 72.2 110.368 -178.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 93.6 mt -129.37 104.02 7.25 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 125.023 1.329 . . . . 73.21 109.609 176.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.524 HD21 HD12 ' A' ' 98' ' ' LEU . 65.9 mt -104.54 103.44 13.12 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 122.98 0.512 . . . . 54.33 110.518 176.476 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.5 t -84.83 93.6 3.57 Favored 'Isoleucine or valine' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 71.04 108.603 -177.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.499 HG22 HD23 ' A' ' 123' ' ' LEU . 97.3 t -56.7 127.66 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.098 0.959 . . . . 75.54 111.264 -178.429 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . 0.504 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.9 mmt180 -121.57 114.49 21.27 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 124.546 1.138 . . . . 70.51 108.435 -179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 75.1 mt -72.48 106.16 4.46 Favored 'General case' 0 C--O 1.241 0.648 0 O-C-N 123.826 0.704 . . . . 53.1 110.132 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 72.1 mt -66.22 153.77 91.6 Favored Pre-proline 0 CA--C 1.546 0.807 0 CA-C-N 115.868 -0.605 . . . . 64.2 110.522 179.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -56.99 140.79 93.39 Favored 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 122.899 2.4 . . . . 62.11 111.218 173.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 . . . . . 0 C--O 1.251 1.159 0 N-CA-C 109.329 -0.619 . . . . 72.3 109.329 -179.098 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.3 pt? . . . . . 0 N--CA 1.488 1.464 0 N-CA-C 113.346 0.869 . . . . 65.51 113.346 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.69 -44.63 7.87 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 122.074 1.849 . . . . 62.14 110.832 176.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.562 HD12 ' H ' ' A' ' 98' ' ' LEU . 5.6 tp -177.99 144.52 0.34 Allowed 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.495 1.518 . . . . 50.44 107.807 177.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.888 HD23 ' HB ' ' A' ' 140' ' ' VAL . 18.2 tp 62.68 -70.16 0.06 Allowed 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 126.779 2.031 . . . . 75.23 112.226 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.563 ' HA ' HD13 ' A' ' 119' ' ' LEU . 76.8 t80 -63.23 130.76 45.93 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.335 1.054 . . . . 75.35 110.785 174.37 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.487 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 52.3 m -139.65 102.55 7.12 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 124.2 1.0 . . . . 61.12 109.475 177.049 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.87 89.68 0.86 Allowed 'Trans proline' 0 C--N 1.359 1.106 0 C-N-CA 121.676 1.584 . . . . 73.43 111.159 -177.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.474 0.755 0 CA-C-N 115.789 -0.641 . . . . 74.13 109.601 170.628 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 . . . . . 0 CA--C 1.537 0.451 0 N-CA-C 108.144 -1.058 . . . . 74.04 108.144 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -94.44 104.87 16.84 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 107.314 -1.365 . . . . 75.22 107.314 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.563 HD13 ' HA ' ' A' ' 99' ' ' PHE . 11.8 mt -92.53 111.83 23.55 Favored 'General case' 0 C--N 1.345 0.384 0 N-CA-C 107.785 -1.191 . . . . 71.5 107.785 -172.079 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 68.6 ttt180 -120.13 107.82 13.5 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.253 1.021 . . . . 74.24 108.724 -177.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.19 148.16 50.85 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.066 0.546 . . . . 73.24 111.531 -171.371 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.593 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.5 mp0 -68.3 125.06 25.24 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.403 1.081 . . . . 63.25 109.443 170.338 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.45 HD12 HD13 ' A' ' 176' ' ' LEU . 2.5 tt -101.67 102.9 24.78 Favored Pre-proline 0 CA--C 1.543 0.687 0 N-CA-C 108.104 -1.073 . . . . 64.24 108.104 175.142 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.39 115.54 3.57 Favored 'Trans proline' 0 C--N 1.378 2.107 0 C-N-CA 121.689 1.592 . . . . 74.34 109.636 171.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.585 HD21 HD12 ' A' ' 149' ' ' ILE . 14.0 tp -137.64 123.11 19.6 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.6 -0.889 . . . . 61.4 108.6 -170.166 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.9 p -73.81 169.99 16.23 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 117.785 0.266 . . . . 62.22 110.705 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.1 mt -62.76 -33.43 75.14 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.575 0.75 . . . . 73.42 111.042 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -71.76 -45.51 61.45 Favored 'General case' 0 C--N 1.352 0.683 0 O-C-N 123.783 0.677 . . . . 73.13 109.312 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -64.18 -35.46 80.88 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 123.695 0.798 . . . . 72.21 111.634 176.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.43 -42.91 67.67 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.46 0.704 . . . . 75.42 111.867 -179.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.1 t80 -68.39 -50.88 49.8 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-N 114.884 -1.053 . . . . 71.4 110.102 -179.09 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -75.06 -42.0 57.86 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 115.669 -0.696 . . . . 74.31 111.213 -174.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.31 -134.5 16.82 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.564 0.54 . . . . 64.22 111.844 -177.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 76.27 -146.69 33.53 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-O 119.658 -0.523 . . . . 71.41 111.856 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.42 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 1.4 mp0 -85.18 146.69 26.98 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 117.83 0.815 . . . . 74.03 110.412 178.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.596 ' HB2' HD13 ' A' ' 149' ' ' ILE . 24.7 tpt180 -129.05 121.55 28.11 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.244 1.018 . . . . 73.24 108.936 177.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.5 t -82.18 108.72 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 C-N-CA 123.499 0.72 . . . . 73.02 109.736 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.574 HG23 HD22 ' A' ' 98' ' ' LEU . 33.6 m -128.11 162.15 34.92 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.012 0 C-N-CA 124.995 1.318 . . . . 42.25 108.825 178.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -107.32 138.09 44.16 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 122.882 0.473 . . . . 73.42 110.191 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.888 ' HB ' HD23 ' A' ' 98' ' ' LEU . 3.0 p -123.27 105.87 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 124.564 1.146 . . . . 74.24 109.06 171.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.11 14.87 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.744 0.818 . . . . 72.55 112.863 174.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.28 11.03 43.32 Favored Glycine 0 C--N 1.35 1.349 0 CA-C-O 119.901 -0.388 . . . . 64.55 113.843 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -115.31 118.38 33.09 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 117.429 0.615 . . . . 71.54 110.192 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -82.51 106.14 14.13 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.43 0.692 . . . . 72.12 109.956 -178.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 25.9 m -121.44 155.6 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.6 0.76 . . . . 62.42 110.342 -179.246 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.42 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 14.1 p -106.61 110.15 22.26 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.635 0.774 . . . . 53.21 109.646 175.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -99.22 128.99 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 124.061 0.944 . . . . 62.21 109.205 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -77.95 109.2 11.79 Favored 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.051 0.453 . . . . 63.35 110.506 -175.152 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.596 HD13 ' HB2' ' A' ' 136' ' ' ARG . 5.0 pt -86.55 142.74 35.25 Favored Pre-proline 0 CA--C 1.558 1.253 0 C-N-CA 124.484 1.113 . . . . 75.54 108.775 173.397 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.411 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 73.0 Cg_endo -75.47 137.24 20.47 Favored 'Trans proline' 0 CA--C 1.562 1.902 0 C-N-CA 122.191 1.927 . . . . 65.34 111.822 177.353 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 35.9 Cg_exo -63.44 135.9 52.11 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 122.761 2.308 . . . . 72.05 112.327 174.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.51 14.6 61.41 Favored Glycine 0 CA--C 1.534 1.253 0 O-C-N 123.636 0.585 . . . . 65.25 113.401 -176.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.18 143.26 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.324 0.649 . . . . 63.41 110.374 -177.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -118.49 177.5 4.8 Favored 'General case' 0 N--CA 1.484 1.24 0 CA-C-O 121.651 0.738 . . . . 55.04 112.894 -169.626 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -63.49 126.69 28.32 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 113.855 -1.52 . . . . 71.44 110.11 174.807 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -10.15 65.46 Favored Glycine 0 CA--C 1.532 1.129 0 O-C-N 124.111 0.882 . . . . 21.21 113.968 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.1 m -69.86 120.33 15.43 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-N 117.861 0.83 . . . . 74.14 109.989 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.61 139.86 17.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 C-N-CA 122.817 0.447 . . . . 71.32 110.077 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 44.6 mt -110.94 102.23 13.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 N-CA-C 106.85 -1.537 . . . . 55.51 106.85 178.359 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 6.0 ttp180 -88.15 102.17 14.53 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 108.961 -0.755 . . . . 65.14 108.961 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -95.2 113.05 60.66 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 107.746 -1.205 . . . . 54.24 107.746 175.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.39 128.45 15.47 Favored 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 122.847 2.365 . . . . 64.15 112.688 -169.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 63.49 23.42 66.74 Favored Glycine 0 C--N 1.351 1.392 0 O-C-N 123.592 0.558 . . . . 62.22 114.371 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.8 tpp -100.62 -18.4 16.58 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.487 0.715 . . . . 72.54 111.066 -177.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -72.45 -95.9 0.08 OUTLIER Glycine 0 C--N 1.345 1.035 0 CA-C-N 115.832 -0.622 . . . . 45.34 113.256 -175.376 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -72.36 86.75 0.5 Allowed Glycine 0 C--N 1.346 1.117 0 N-CA-C 112.252 -0.339 . . . . 71.45 112.252 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . 0.65 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -81.93 121.64 26.75 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.376 0.67 . . . . 62.33 109.978 179.654 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 162.31 -142.12 7.72 Favored Glycine 0 C--O 1.241 0.591 0 N-CA-C 111.282 -0.727 . . . . 71.33 111.282 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.513 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 19.3 m120 -67.43 -49.43 42.25 Favored Pre-proline 0 CA--C 1.566 1.56 0 CA-C-O 118.271 -0.871 . . . . 72.22 110.886 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.513 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -96.48 106.69 0.1 OUTLIER 'Trans proline' 0 C--N 1.395 3.023 0 C-N-CA 123.125 2.55 . . . . 73.44 111.485 170.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.01 129.87 24.28 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.641 2.227 . . . . 34.23 111.778 178.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -117.97 157.33 15.22 Favored Glycine 0 C--N 1.338 0.642 0 N-CA-C 111.501 -0.64 . . . . 54.33 111.501 178.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -89.7 158.85 17.38 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 123.603 0.761 . . . . 72.33 110.558 -177.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.432 HD21 HD11 ' A' ' 98' ' ' LEU . 67.0 tp -115.7 132.64 56.57 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.834 0.853 . . . . 74.32 109.948 -177.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.7 mt -127.84 101.41 6.33 Favored 'General case' 0 CA--C 1.549 0.925 0 C-N-CA 125.35 1.46 . . . . 55.12 109.236 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.528 HD21 HD12 ' A' ' 98' ' ' LEU . 75.7 mt -101.46 100.83 11.33 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 123.11 0.564 . . . . 71.42 110.923 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 4.7 t -85.53 95.26 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 N-CA-C 108.409 -0.96 . . . . 75.02 108.409 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 73.9 t -54.67 135.03 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.695 1.198 . . . . 71.24 111.629 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . 0.593 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.3 mmt180 -128.27 107.68 9.97 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.312 -1.366 . . . . 63.33 107.312 -177.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 53.3 mt -69.98 121.62 17.75 Favored 'General case' 0 N--CA 1.47 0.534 0 O-C-N 123.438 0.461 . . . . 73.23 109.943 -177.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 83.8 mt -85.46 140.64 36.2 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.894 -0.594 . . . . 72.02 110.268 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.56 -15.9 34.14 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.667 2.245 . . . . 75.22 111.872 172.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 35.9 m80 . . . . . 0 C--N 1.356 0.849 0 C-N-CA 124.308 1.043 . . . . 64.52 108.264 176.994 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 113.688 0.996 . . . . 60.14 113.688 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -64.71 -55.93 0.47 Allowed 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.494 2.129 . . . . 61.33 112.0 177.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.485 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.2 tp -177.55 134.88 0.18 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.785 1.234 . . . . 74.42 108.18 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.526 HD22 HG23 ' A' ' 138' ' ' VAL . 15.4 tp 66.86 -63.57 0.26 Allowed 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 126.89 2.076 . . . . 73.34 111.379 -174.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -69.43 126.02 28.49 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.696 1.198 . . . . 73.1 111.433 176.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.543 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 87.1 m -138.77 88.45 13.88 Favored Pre-proline 0 N--CA 1.47 0.57 0 C-N-CA 124.444 1.098 . . . . 65.01 108.657 176.076 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.4 83.96 0.61 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 122.461 2.107 . . . . 74.2 112.615 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 100' ' ' THR . 21.2 m . . . . . 0 CA--C 1.538 0.506 0 CA-C-N 114.612 -1.176 . . . . 63.31 108.857 172.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.412 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 45.2 mtt180 . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 110.432 -0.21 . . . . 71.52 110.432 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -98.05 109.17 21.97 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 107.491 -1.3 . . . . 75.35 107.491 177.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.543 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 15.0 mt -91.47 108.04 19.62 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 106.165 -1.791 . . . . 74.22 106.165 177.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 34.7 ttt180 -118.89 106.16 12.21 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.104 -1.073 . . . . 71.03 108.104 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -131.0 144.54 51.55 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.165 0.586 . . . . 74.33 109.54 -175.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.644 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.2 mp0 -72.8 129.01 37.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 114.88 -1.055 . . . . 75.15 108.536 173.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.543 HD21 ' HG2' ' A' ' 136' ' ' ARG . 3.0 tt -99.76 102.39 16.97 Favored Pre-proline 0 CA--C 1.536 0.438 0 N-CA-C 106.609 -1.626 . . . . 54.25 106.609 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -65.93 113.86 2.75 Favored 'Trans proline' 0 C--N 1.376 2.026 0 C-N-CA 121.839 1.693 . . . . 73.14 110.271 174.638 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.523 HD21 HD12 ' A' ' 149' ' ' ILE . 17.8 tp -144.36 121.9 11.75 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.796 -1.187 . . . . 72.34 107.796 -173.812 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.3 p -73.96 168.34 19.67 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 117.761 0.255 . . . . 75.21 110.478 -177.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.8 mt -57.58 -36.43 71.7 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.249 0.619 . . . . 74.42 110.918 176.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 21.2 mp0 -71.88 -46.75 56.78 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 124.611 1.165 . . . . 60.02 110.386 -176.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -72.06 -27.49 62.72 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.601 0.76 . . . . 74.45 111.911 -179.051 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -69.41 -46.02 67.82 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.426 0.69 . . . . 64.34 109.926 173.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -58.96 -41.56 87.77 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 124.718 1.207 . . . . 61.05 110.849 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.45 -49.1 67.83 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.59 0.556 . . . . 71.34 109.541 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.49 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.01 56.93 22.41 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.062 -0.972 . . . . 24.33 113.106 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -92.0 -148.17 21.91 Favored Glycine 0 C--N 1.345 1.033 0 O-C-N 123.491 0.171 . . . . 61.12 112.808 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -95.4 132.32 40.59 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 107.757 -1.201 . . . . 73.43 107.757 169.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.543 ' HG2' HD21 ' A' ' 123' ' ' LEU . 12.8 tpp180 -111.62 116.94 31.65 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 107.678 -1.23 . . . . 72.54 107.678 -178.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 144' ' ' ARG . 12.1 p -98.76 118.12 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 N-CA-C 108.133 -1.062 . . . . 72.24 108.133 -176.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.526 HG23 HD22 ' A' ' 98' ' ' LEU . 35.6 m -134.22 161.84 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.849 0.86 . . . . 60.12 110.008 -173.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -96.97 136.88 36.91 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 123.679 0.792 . . . . 65.33 110.093 -173.596 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.433 ' HB ' HD23 ' A' ' 98' ' ' LEU . 5.4 p -144.49 111.59 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.607 1.163 . . . . 74.53 109.631 177.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.4 22.01 12.95 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 123.684 0.794 . . . . 51.02 113.025 173.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.92 -16.12 58.76 Favored Glycine 0 C--N 1.345 1.049 0 C-N-CA 123.827 0.727 . . . . 52.2 112.653 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 19.4 tpp180 -95.72 123.92 39.51 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.249 1.02 . . . . 72.31 109.551 178.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.522 ' HG2' HG22 ' A' ' 137' ' ' VAL . 22.6 ttp180 -89.51 107.05 18.85 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 108.728 -0.841 . . . . 74.31 108.728 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 70.0 t -112.7 136.79 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 C-N-CA 124.112 0.965 . . . . 75.31 110.508 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 31.9 p -96.18 120.83 37.17 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.279 0.632 . . . . 72.54 110.669 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.5 p -106.37 131.02 57.14 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.943 1.297 . . . . 51.05 109.345 174.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 46.7 ttp180 -79.02 122.34 26.07 Favored 'General case' 0 C--O 1.243 0.72 0 CA-C-O 120.969 0.414 . . . . 62.15 109.98 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.523 HD12 HD21 ' A' ' 125' ' ' LEU . 10.3 pt -96.5 140.71 22.32 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 124.26 1.024 . . . . 71.31 109.823 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 20.5 Cg_exo -66.18 142.66 68.13 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.058 2.505 . . . . 71.14 113.045 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -66.17 130.91 25.29 Favored 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 122.327 2.018 . . . . 72.24 110.802 170.144 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 70.81 26.29 74.26 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 115.532 -0.758 . . . . 62.42 113.945 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.0 p -68.77 137.37 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-N 117.201 0.5 . . . . 74.12 110.755 -178.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -98.37 175.77 5.93 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.875 0.845 . . . . 75.52 112.963 -168.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -69.65 134.0 48.21 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 113.547 -1.661 . . . . 74.11 110.669 177.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 73.89 10.17 80.27 Favored Glycine 0 C--N 1.342 0.914 0 CA-C-N 116.062 -0.517 . . . . 72.43 113.452 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.5 m -81.32 118.9 23.02 Favored 'General case' 0 C--N 1.347 0.473 0 N-CA-C 108.626 -0.879 . . . . 74.12 108.626 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 3.3 p -99.91 115.03 40.08 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.351 0.596 . . . . 54.02 109.796 -175.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 55.5 mt -90.05 104.49 15.24 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 124.516 1.126 . . . . 71.01 108.212 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.52 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 24.8 ttp180 -90.32 117.9 29.4 Favored 'General case' 0 C--N 1.344 0.355 0 N-CA-C 110.548 -0.168 . . . . 72.43 110.548 -179.655 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.0 t -109.11 95.28 17.29 Favored Pre-proline 0 CA--C 1.555 1.157 0 N-CA-C 107.5 -1.296 . . . . 64.12 107.5 166.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -70.26 136.29 31.33 Favored 'Trans proline' 0 C--N 1.373 1.857 0 C-N-CA 122.888 2.392 . . . . 72.25 111.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.39 2.24 82.92 Favored Glycine 0 CA--C 1.531 1.089 0 CA-C-O 119.635 -0.536 . . . . 65.32 114.118 178.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 41.4 tpp -128.51 12.99 6.48 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 117.872 0.836 . . . . 74.45 110.726 -177.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.38 -106.74 0.78 Allowed Glycine 0 C--N 1.344 1.021 0 CA-C-N 115.866 -0.606 . . . . 73.11 111.896 178.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -61.38 105.11 0.8 Allowed Glycine 0 C--N 1.347 1.179 0 C-N-CA 123.018 0.342 . . . . 74.31 113.502 -177.248 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -89.69 134.7 34.02 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.862 0.865 . . . . 54.44 109.176 173.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -178.9 -51.14 0.08 OUTLIER Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.031 -1.228 . . . . 74.34 110.031 177.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.458 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 25.1 t-20 -166.25 -54.76 0.01 OUTLIER Pre-proline 0 CA--C 1.556 1.192 0 C-N-CA 124.952 1.301 . . . . 65.42 108.173 169.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.458 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 82.1 Cg_endo -82.54 134.49 7.63 Favored 'Trans proline' 0 C--N 1.399 3.196 0 C-N-CA 121.721 1.614 . . . . 74.42 110.411 170.004 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.76 125.84 10.87 Favored 'Trans proline' 0 C--N 1.367 1.537 0 C-N-CA 122.228 1.952 . . . . 74.55 111.824 178.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -95.13 -172.18 37.03 Favored Glycine 0 C--N 1.349 1.273 0 CA-C-N 116.182 -0.463 . . . . 63.14 113.416 175.495 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.6 144.33 28.02 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.417 0.687 . . . . 70.42 110.5 178.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.52 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.6 tp -107.99 129.68 55.1 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-N 115.312 -0.858 . . . . 74.32 108.879 178.315 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.4 mt -128.27 102.56 6.73 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 124.472 1.109 . . . . 75.53 109.187 -178.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.436 HD21 HD12 ' A' ' 98' ' ' LEU . 89.4 mt -104.08 101.36 11.12 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 121.0 0.428 . . . . 73.13 110.486 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.46 95.75 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.47 -0.937 . . . . 62.05 108.47 -176.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.7 t -55.63 124.11 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 124.142 0.977 . . . . 70.41 111.355 -179.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . 0.644 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 28.2 mmt180 -116.38 104.48 11.51 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.383 1.073 . . . . 74.13 108.459 -179.323 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.46 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 60.8 mt -70.05 111.05 5.44 Favored 'General case' 0 C--N 1.343 0.323 0 C-N-CA 123.685 0.794 . . . . 75.43 110.732 -178.028 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 63.3 mt -94.73 144.22 27.51 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.324 0.65 . . . . 54.1 110.044 -179.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.93 -33.23 4.84 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 122.425 2.083 . . . . 73.21 110.773 167.17 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 . . . . . 0 N--CA 1.48 1.069 0 C-N-CA 124.82 1.248 . . . . 73.3 108.15 175.829 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pp . . . . . 0 CA--C 1.56 1.363 0 N-CA-C 114.391 1.256 . . . . 63.21 114.391 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.93 -61.87 0.16 Allowed 'Trans proline' 0 C--N 1.382 2.341 0 C-N-CA 122.519 2.146 . . . . 71.21 110.509 176.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.441 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.8 tp -172.68 144.33 1.39 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.599 1.16 . . . . 74.12 107.901 172.272 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.653 HD13 HG21 ' A' ' 138' ' ' VAL . 8.9 tp 64.31 -66.36 0.12 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 126.346 1.858 . . . . 61.43 111.828 -169.08 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -59.55 137.47 58.01 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 124.733 1.213 . . . . 71.13 111.972 178.147 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.54 HG22 HG13 ' A' ' 102' ' ' VAL . 61.2 m -157.66 108.93 1.81 Allowed Pre-proline 0 N--CA 1.475 0.822 0 C-N-CA 124.755 1.222 . . . . 74.2 109.225 177.358 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -81.42 68.15 8.24 Favored 'Trans proline' 0 C--N 1.371 1.736 0 C-N-CA 122.381 2.054 . . . . 51.04 112.582 -172.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.54 HG13 HG22 ' A' ' 100' ' ' THR . 9.6 m . . . . . 0 N--CA 1.486 1.333 0 CA-C-N 114.78 -1.1 . . . . 63.23 112.663 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.566 ' HG3' ' HA3' ' A' ' 166' ' ' GLY . 21.2 ptt180 . . . . . 0 CA--C 1.554 1.108 0 N-CA-C 108.98 -0.748 . . . . 75.31 108.98 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.475 ' HA ' ' O ' ' A' ' 173' ' ' ASP . 0.1 OUTLIER -101.99 115.06 29.74 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.875 0.87 . . . . 53.41 110.681 -157.955 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.527 HD22 ' O ' ' A' ' 100' ' ' THR . 13.8 mt -90.86 109.53 20.74 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 106.841 -1.54 . . . . 72.44 106.841 178.147 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.18 110.64 21.92 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 123.129 0.572 . . . . 75.53 110.376 -178.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.88 138.59 52.73 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.799 -0.815 . . . . 72.0 108.799 177.002 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mp0 -77.82 122.21 25.12 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.51 -0.922 . . . . 73.1 108.51 176.419 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.56 HD12 HD13 ' A' ' 176' ' ' LEU . 1.0 OUTLIER -99.67 111.05 60.87 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 108.667 -0.864 . . . . 72.41 108.667 -172.281 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.423 ' HB2' HD11 ' A' ' 181' ' ' LEU . 52.6 Cg_endo -67.89 116.67 4.42 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.06 1.84 . . . . 70.54 109.788 170.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.513 HD21 HD12 ' A' ' 149' ' ' ILE . 23.6 tp -131.45 133.04 44.78 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 108.715 -0.846 . . . . 71.2 108.715 -172.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 45.1 p -75.48 157.17 34.4 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.36 -0.607 . . . . 63.43 109.36 -178.194 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.54 -31.15 71.89 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.274 0.63 . . . . 64.35 111.074 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -70.78 -51.64 25.66 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.768 0.827 . . . . 63.44 110.107 179.458 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -65.45 -34.16 77.64 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.485 0.714 . . . . 72.43 111.581 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.43 -45.56 86.99 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 124.027 0.829 . . . . 60.14 110.699 173.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -66.08 -35.75 81.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 124.177 0.991 . . . . 63.01 111.116 179.596 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -73.65 -43.16 60.2 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.997 0.519 . . . . 65.11 109.865 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.436 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 67.23 51.37 38.68 Favored Glycine 0 C--N 1.347 1.149 0 CA-C-N 114.877 -1.056 . . . . 41.13 111.742 -168.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.402 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -89.84 -150.55 23.57 Favored Glycine 0 C--N 1.347 1.177 0 CA-C-O 120.841 0.134 . . . . 65.13 112.971 -177.033 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.418 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 7.5 mp0 -101.36 140.97 34.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.576 -0.898 . . . . 72.55 108.576 169.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 24.4 tpt85 -120.56 121.53 38.6 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.074 0.949 . . . . 70.55 108.548 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 12.2 p -84.73 117.89 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.784 0.802 . . . . 73.44 109.769 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.653 HG21 HD13 ' A' ' 98' ' ' LEU . 34.6 m -126.46 160.3 34.41 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 C-N-CA 125.444 1.498 . . . . 72.43 107.974 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -125.62 112.7 16.46 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-N 118.981 0.809 . . . . 53.13 111.801 -172.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.514 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.5 p -105.55 105.55 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 C-N-CA 125.608 1.563 . . . . 61.45 111.004 -176.572 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.25 28.5 15.26 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 124.146 0.978 . . . . 60.41 112.521 177.111 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.11 -10.49 58.38 Favored Glycine 0 C--N 1.356 1.687 0 CA-C-O 119.79 -0.45 . . . . 64.45 114.085 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.419 ' HB2' HG13 ' A' ' 140' ' ' VAL . 51.1 mtt180 -90.25 118.32 29.67 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 108.605 -0.887 . . . . 70.11 108.605 174.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 48.4 ttt85 -98.8 109.74 22.45 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 109.248 -0.649 . . . . 73.45 109.248 -177.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.1 p -130.75 146.07 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.527 1.131 . . . . 71.33 110.377 -172.272 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.418 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 28.4 m -93.18 119.19 32.09 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 123.693 0.797 . . . . 73.22 110.464 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -101.26 130.13 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.114 0.966 . . . . 75.4 109.944 175.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 36.9 ttp180 -75.84 134.77 40.27 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.248 0.547 . . . . 62.43 110.137 178.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.513 HD12 HD21 ' A' ' 125' ' ' LEU . 2.8 pt -108.65 145.66 32.07 Favored Pre-proline 0 CA--C 1.564 1.492 0 C-N-CA 125.11 1.364 . . . . 65.33 108.985 -179.473 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.52 145.99 97.75 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 123.037 2.491 . . . . 72.31 113.565 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -71.06 117.08 4.97 Favored 'Trans proline' 0 C--N 1.38 2.212 0 C-N-CA 122.709 2.273 . . . . 65.01 112.294 178.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 78.97 31.97 41.57 Favored Glycine 0 CA--C 1.533 1.176 0 CA-C-N 115.738 -0.664 . . . . 71.2 112.606 -176.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.6 p -72.82 146.17 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 123.395 0.678 . . . . 73.25 110.309 179.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.52 ' HA ' HD11 ' A' ' 180' ' ' LEU . 92.7 mtt180 -123.23 177.58 5.51 Favored 'General case' 0 N--CA 1.476 0.873 0 CA-C-O 121.808 0.813 . . . . 72.52 112.851 -171.563 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.0 tp10 -60.09 132.94 55.48 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 113.185 -1.825 . . . . 73.52 111.325 178.021 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.36 -27.31 15.81 Favored Glycine 0 C--N 1.34 0.775 0 CA-C-O 119.381 -0.677 . . . . 60.4 112.565 179.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.6 m -62.57 121.26 12.88 Favored 'General case' 0 C--N 1.354 0.763 0 C-N-CA 123.433 0.693 . . . . 70.54 111.004 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.1 126.46 51.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.091 -0.707 . . . . 61.05 109.091 177.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.41 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.4 mt -95.74 103.87 15.18 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 N-CA-C 108.012 -1.107 . . . . 74.51 108.012 -176.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.571 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 53.2 ttp180 -89.02 106.73 18.62 Favored 'General case' 0 C--N 1.355 0.848 0 N-CA-C 110.342 -0.244 . . . . 74.31 110.342 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.6 t -110.48 96.9 29.44 Favored Pre-proline 0 CA--C 1.553 1.078 0 N-CA-C 108.629 -0.878 . . . . 73.33 108.629 174.565 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.46 144.19 92.47 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.137 2.558 . . . . 71.44 112.842 176.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.69 -24.33 5.92 Favored Glycine 0 CA--C 1.539 1.584 0 CA-C-O 119.549 -0.584 . . . . 72.23 114.351 176.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 17.2 mmt -90.38 -2.54 57.97 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 117.7 0.75 . . . . 75.43 111.717 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.12 -115.12 0.54 Allowed Glycine 0 C--N 1.341 0.843 0 N-CA-C 111.346 -0.702 . . . . 64.33 111.346 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . 0.566 ' HA3' ' HG3' ' A' ' 117' ' ' ARG . . . -58.35 107.56 1.16 Allowed Glycine 0 C--N 1.354 1.555 0 CA-C-N 117.165 0.483 . . . . 61.43 113.237 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -80.03 171.57 14.92 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.937 0.895 . . . . 74.14 110.733 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 106.9 -147.07 16.14 Favored Glycine 0 N--CA 1.473 1.165 0 CA-C-O 119.619 -0.545 . . . . 62.34 111.819 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . 0.415 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 5.6 t-20 -69.82 -52.64 13.16 Favored Pre-proline 0 CA--C 1.566 1.584 0 CA-C-O 118.146 -0.931 . . . . 75.4 111.303 178.285 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.415 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 88.0 Cg_endo -89.93 108.64 0.39 Allowed 'Trans proline' 0 C--N 1.397 3.079 0 C-N-CA 122.188 1.926 . . . . 64.3 112.907 178.557 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -66.71 127.67 17.55 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.187 2.591 . . . . 61.22 112.776 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -110.64 162.67 12.47 Favored Glycine 0 C--N 1.341 0.846 0 CA-C-N 115.542 -0.754 . . . . 61.45 112.915 -178.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' A' ' 118' ' ' ASP . 4.6 m-20 -80.15 150.3 30.24 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.83 0.852 . . . . 74.23 110.559 178.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.571 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 62.5 tp -106.58 135.79 47.49 Favored 'General case' 0 C--O 1.216 -0.676 0 N-CA-C 108.302 -0.999 . . . . 75.21 108.302 173.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.9 mt -128.44 103.31 7.06 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 123.715 0.806 . . . . 74.3 109.293 179.143 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.564 HD21 HD12 ' A' ' 98' ' ' LEU . 83.4 mt -107.35 103.08 12.34 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 122.684 0.394 . . . . 73.33 110.92 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.64 96.88 5.72 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.732 -0.667 . . . . 62.05 109.467 -174.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -54.59 130.21 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 C-N-CA 124.888 1.275 . . . . 75.51 111.848 -177.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -123.86 100.24 6.66 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 125.344 1.458 . . . . 72.23 107.626 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.52 HD11 ' HA ' ' A' ' 154' ' ' ARG . 35.5 mt -70.06 107.91 3.84 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-O 121.168 0.509 . . . . 75.01 111.151 -176.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.423 HD11 ' HB2' ' A' ' 124' ' ' PRO . 48.7 mt -75.98 130.72 77.58 Favored Pre-proline 0 CA--C 1.553 1.083 0 N-CA-C 108.23 -1.026 . . . . 74.2 108.23 175.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.22 -63.17 0.07 OUTLIER 'Trans proline' 0 CA--C 1.559 1.749 0 C-N-CA 123.074 2.516 . . . . 54.33 113.207 -176.216 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 . . . . . 0 N--CA 1.489 1.504 0 C-N-CA 123.888 0.875 . . . . 72.34 108.902 177.684 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pt? . . . . . 0 CA--C 1.566 1.561 0 N-CA-C 111.667 0.247 . . . . 52.21 111.667 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -74.21 -48.98 0.19 Allowed 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.386 2.058 . . . . 71.0 112.354 176.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.504 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.6 tp 168.25 150.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 126.792 2.037 . . . . 74.31 106.321 -170.553 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.7 HD23 ' HB ' ' A' ' 140' ' ' VAL . 14.2 tp 57.54 -72.51 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 126.108 1.763 . . . . 75.41 111.587 -173.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.61 ' HA ' HD13 ' A' ' 119' ' ' LEU . 87.6 t80 -57.9 123.1 14.62 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.741 1.616 . . . . 72.2 111.948 172.086 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 98.9 m -145.44 99.17 4.52 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.113 0.965 . . . . 72.25 109.47 175.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -77.4 74.65 5.02 Favored 'Trans proline' 0 C--N 1.371 1.761 0 C-N-CA 122.462 2.108 . . . . 73.22 113.09 -172.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 3.6 m . . . . . 0 CA--C 1.546 0.811 0 CA-C-N 116.102 -0.499 . . . . 72.14 109.861 176.638 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 38.3 ptt180 . . . . . 0 CA--C 1.536 0.415 0 N-CA-C 108.711 -0.848 . . . . 71.42 108.711 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -92.59 118.99 31.59 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 106.976 -1.49 . . . . 65.21 106.976 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.61 HD13 ' HA ' ' A' ' 99' ' ' PHE . 18.4 mt -89.73 108.68 19.83 Favored 'General case' 0 C--O 1.225 -0.228 0 N-CA-C 106.725 -1.584 . . . . 72.25 106.725 -174.241 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -117.42 107.56 14.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.113 -1.069 . . . . 70.44 108.113 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.61 140.05 50.42 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 108.577 -0.898 . . . . 45.41 108.577 -179.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.78 129.41 37.0 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 109.189 -0.671 . . . . 64.0 109.189 173.297 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.508 HD12 HD13 ' A' ' 176' ' ' LEU . 2.0 tt -100.02 109.55 56.53 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 108.749 -0.834 . . . . 75.1 108.749 -173.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.03 113.86 2.77 Favored 'Trans proline' 0 C--N 1.378 2.115 0 C-N-CA 122.116 1.877 . . . . 75.13 110.19 171.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.565 HD21 HD12 ' A' ' 149' ' ' ILE . 12.0 tp -133.21 125.91 30.43 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 108.045 -1.095 . . . . 72.31 108.045 -169.448 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 43.0 p -73.16 171.7 12.46 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 117.975 0.352 . . . . 71.01 110.69 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 96.7 mt -71.39 -23.83 61.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 123.157 0.583 . . . . 61.31 111.009 178.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -72.03 -50.68 26.5 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.634 -0.876 . . . . 62.34 108.634 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.664 ' HG3' HH21 ' A' ' 136' ' ' ARG . 29.4 mm-40 -57.55 -40.52 79.04 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.841 1.256 . . . . 72.42 111.384 176.214 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.56 64.22 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 114.965 -1.016 . . . . 41.53 111.177 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -60.73 -58.45 8.4 Favored 'General case' 0 C--N 1.349 0.564 0 O-C-N 124.679 1.237 . . . . 74.44 110.266 -176.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.8 m80 -67.66 -38.59 84.0 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 123.958 0.786 . . . . 74.12 111.047 -175.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 73.49 -112.81 4.0 Favored Glycine 0 C--N 1.343 0.947 0 N-CA-C 110.47 -1.052 . . . . 73.52 110.47 -170.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.12 -130.85 22.26 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 111.551 -0.62 . . . . 54.53 111.551 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 9.3 mp0 -121.43 157.65 30.08 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.975 0.91 . . . . 73.1 109.452 174.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.664 HH21 ' HG3' ' A' ' 129' ' ' GLU . 5.3 tpp180 -135.02 124.03 24.19 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.234 1.414 . . . . 72.33 107.975 177.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.3 p -84.9 127.09 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.091 0 C-N-CA 123.137 0.575 . . . . 72.11 110.228 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.676 HG23 HD22 ' A' ' 98' ' ' LEU . 30.7 m -140.71 158.01 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.938 1.295 . . . . 71.31 109.102 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -88.19 135.48 33.42 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 123.162 0.585 . . . . 43.23 111.284 -174.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.7 ' HB ' HD23 ' A' ' 98' ' ' LEU . 7.2 p -136.86 118.56 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 124.396 1.078 . . . . 43.23 109.288 168.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.39 20.29 11.74 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 123.92 0.888 . . . . 32.12 112.229 177.256 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.43 -9.47 66.98 Favored Glycine 0 C--N 1.358 1.78 0 C-N-CA 123.051 0.357 . . . . 31.34 113.216 -177.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -104.0 128.82 51.57 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.076 0.951 . . . . 75.2 109.983 -178.331 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.32 141.66 43.35 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.527 -0.545 . . . . 73.52 109.527 177.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.81 126.49 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.64 1.176 . . . . 72.42 108.619 178.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 44.7 m -82.49 109.82 17.05 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.396 0.678 . . . . 75.21 109.612 175.29 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.5 130.24 47.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 C-N-CA 123.999 0.92 . . . . 65.43 109.248 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -69.81 118.7 12.99 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.043 0.537 . . . . 75.22 109.96 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.565 HD12 HD21 ' A' ' 125' ' ' LEU . 17.2 pt -108.02 131.53 21.68 Favored Pre-proline 0 CA--C 1.564 1.508 0 C-N-CA 124.509 1.124 . . . . 73.41 108.866 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.402 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 18.0 Cg_endo -62.06 140.05 82.11 Favored 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.67 2.247 . . . . 71.14 113.763 -174.609 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 34.2 Cg_exo -64.61 127.55 19.12 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 123.329 2.686 . . . . 75.03 112.696 175.568 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 76.76 30.09 56.58 Favored Glycine 0 CA--C 1.528 0.847 0 O-C-N 123.49 0.494 . . . . 43.35 112.406 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.8 p -73.74 137.36 23.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.78 0 C-N-CA 122.89 0.476 . . . . 75.44 110.367 -177.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -103.67 173.31 6.36 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.135 0.969 . . . . 75.13 111.886 -171.176 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.8 tp10 -63.83 122.2 15.86 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-N 113.09 -1.868 . . . . 74.1 109.346 167.204 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 102.06 -8.39 55.67 Favored Glycine 0 N--CA 1.474 1.215 0 CA-C-O 119.758 -0.468 . . . . 74.41 113.127 178.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.0 m -78.37 121.99 25.19 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.094 0.447 . . . . 73.32 109.937 177.055 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.8 p -99.15 141.68 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 109.019 -0.734 . . . . 73.22 109.019 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.518 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 65.4 mt -108.43 104.21 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.344 1.058 . . . . 64.52 108.724 -176.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -88.68 121.12 30.72 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 123.261 0.625 . . . . 61.52 109.782 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -124.23 106.56 30.64 Favored Pre-proline 0 CA--C 1.557 1.23 0 N-CA-C 107.65 -1.241 . . . . 74.32 107.65 173.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.91 139.35 36.04 Favored 'Trans proline' 0 C--N 1.373 1.836 0 C-N-CA 122.935 2.423 . . . . 71.52 113.31 -174.647 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 77.4 0.15 71.12 Favored Glycine 0 C--N 1.352 1.426 0 CA-C-N 115.471 -0.786 . . . . 72.41 114.264 173.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 93.6 mmm -103.6 15.2 29.49 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.685 0.794 . . . . 75.32 111.712 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -94.35 -108.24 2.07 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 111.534 -0.626 . . . . 51.41 111.534 174.029 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' GLY . . . . . 0.424 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -66.1 106.28 1.54 Allowed Glycine 0 C--N 1.344 1.011 0 C-N-CA 123.693 0.663 . . . . 71.42 112.575 175.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -83.8 165.18 19.03 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 123.75 0.82 . . . . 65.12 109.878 175.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 111.79 -141.6 16.71 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 111.184 -0.766 . . . . 54.15 111.184 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -76.61 -52.37 2.18 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 118.247 -0.882 . . . . 72.43 111.159 172.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -82.51 118.91 2.93 Favored 'Trans proline' 0 C--N 1.391 2.776 0 C-N-CA 121.627 1.551 . . . . 55.33 111.657 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_endo -84.9 126.71 3.41 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.718 2.279 . . . . 55.41 113.593 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . 0.424 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -110.2 161.89 12.79 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 115.928 -0.578 . . . . 75.31 112.021 174.736 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -99.89 162.48 12.96 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 124.676 1.19 . . . . 72.45 110.009 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.61 HD21 HD11 ' A' ' 98' ' ' LEU . 54.3 tp -116.32 128.38 55.5 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.733 0.813 . . . . 63.54 109.796 178.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 90.7 mt -128.54 120.51 26.86 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 124.314 1.046 . . . . 61.43 109.729 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.518 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 93.7 mt -118.99 104.17 10.24 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 123.369 0.668 . . . . 73.04 110.745 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.4 t -86.22 98.5 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.982 0 CA-C-N 115.397 -0.82 . . . . 61.13 109.404 -172.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.3 t -61.29 117.0 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 123.987 0.915 . . . . 63.44 112.426 -173.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -112.88 101.08 9.16 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 126.103 1.761 . . . . 74.32 108.63 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.418 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 43.5 mt -71.49 114.25 9.37 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.148 -0.478 . . . . 70.34 110.779 -177.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 87.3 mt -61.53 146.73 89.4 Favored Pre-proline 0 CA--C 1.549 0.907 0 CA-C-N 114.752 -1.113 . . . . 61.41 110.636 178.348 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -64.39 -168.15 0.1 OUTLIER 'Trans proline' 0 C--N 1.378 2.131 0 C-N-CA 123.154 2.569 . . . . 74.22 113.81 -173.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 . . . . . 0 C--O 1.253 1.238 0 CA-C-O 118.014 -0.993 . . . . 64.0 108.664 -179.85 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . 0.46 ' O ' ' HG ' ' A' ' 95' ' ' LEU . 34.2 tpp . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 110.611 -0.144 . . . . 63.34 110.611 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.554 HD22 HG23 ' A' ' 100' ' ' THR . 3.2 pp 58.54 111.11 0.02 OUTLIER Pre-proline 0 N--CA 1.482 1.143 0 C-N-CA 127.18 2.192 . . . . 63.42 111.628 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.656 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 73.6 Cg_endo -73.71 -167.57 0.39 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.685 2.257 . . . . 72.41 111.377 171.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.475 HD12 ' H ' ' A' ' 98' ' ' LEU . 12.7 tp -75.96 142.69 41.91 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.603 -0.517 . . . . 51.43 109.603 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.589 HD13 HG21 ' A' ' 138' ' ' VAL . 6.3 tp 68.89 -57.98 0.5 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 126.95 2.1 . . . . 74.45 112.02 -167.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.656 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 65.7 t80 -72.65 135.33 45.44 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.697 1.199 . . . . 72.32 112.534 -173.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.554 HG23 HD22 ' A' ' 95' ' ' LEU . 55.4 m -153.97 101.25 2.49 Favored Pre-proline 0 CA--C 1.544 0.74 0 C-N-CA 123.985 0.914 . . . . 62.15 109.895 177.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -76.08 83.0 2.06 Favored 'Trans proline' 0 C--N 1.369 1.611 0 C-N-CA 122.128 1.885 . . . . 64.52 112.304 -173.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.529 HG13 HG22 ' A' ' 100' ' ' THR . 30.1 m -88.94 151.28 3.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-N 114.935 -1.03 . . . . 65.55 109.729 173.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -106.54 162.47 13.71 Favored 'General case' 0 C--O 1.242 0.67 0 N-CA-C 109.481 -0.563 . . . . 73.24 109.481 173.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 22.1 ttmm -145.39 98.82 3.21 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 108.518 -0.919 . . . . 70.34 108.518 175.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -143.96 7.42 1.89 Allowed Glycine 0 N--CA 1.469 0.899 0 CA-C-N 115.787 -0.642 . . . . 54.51 112.196 175.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 30.5 p -72.68 96.93 2.08 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 123.193 0.597 . . . . 74.43 109.699 174.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.16 -178.14 21.01 Favored Glycine 0 C--N 1.344 1.006 0 CA-C-N 115.86 -0.609 . . . . 70.31 112.055 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -170.3 131.64 2.29 Favored Glycine 0 C--N 1.344 0.973 0 N-CA-C 111.938 -0.465 . . . . 71.11 111.938 179.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 39.9 t -136.3 -55.54 0.75 Allowed 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.977 -0.749 . . . . 72.44 108.977 174.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 169.98 45.29 0.03 OUTLIER Glycine 0 C--N 1.349 1.27 0 CA-C-N 115.771 -0.649 . . . . 74.42 112.132 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 161.8 -170.93 37.63 Favored Glycine 0 C--N 1.344 0.979 0 N-CA-C 112.034 -0.427 . . . . 61.43 112.034 -179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.2 m -73.53 107.87 6.06 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 122.786 0.434 . . . . 71.04 110.103 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -94.71 70.65 1.14 Allowed Glycine 0 C--N 1.345 1.053 0 N-CA-C 110.839 -0.904 . . . . 72.01 110.839 173.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -141.79 32.41 2.03 Favored Glycine 0 C--N 1.347 1.15 0 CA-C-N 115.856 -0.172 . . . . 65.51 113.513 -175.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 41.6 t -73.87 130.11 39.25 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 122.818 0.447 . . . . 75.01 110.045 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.517 ' H ' ' HB2' ' A' ' 170' ' ' PRO . . . 75.0 104.06 0.1 OUTLIER Glycine 0 C--N 1.345 1.04 0 O-C-N 124.099 0.874 . . . . 63.41 113.104 176.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 -86.1 131.17 34.32 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.948 -0.76 . . . . 63.23 108.948 175.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -93.31 104.41 16.58 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.561 -1.274 . . . . 64.33 107.561 -177.018 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.574 HD13 ' HA ' ' A' ' 99' ' ' PHE . 10.3 mt -94.08 109.78 21.52 Favored 'General case' 0 C--N 1.342 0.253 0 N-CA-C 107.093 -1.447 . . . . 71.12 107.093 -177.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.8 ttt180 -108.63 109.71 20.98 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.702 -0.481 . . . . 73.35 109.702 176.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -122.95 144.76 49.02 Favored 'General case' 0 C--O 1.242 0.693 0 N-CA-C 109.116 -0.698 . . . . 32.24 109.116 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -81.81 122.41 27.67 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 107.957 -1.127 . . . . 74.54 107.957 177.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.457 HD11 ' HG2' ' A' ' 136' ' ' ARG . 47.3 tp -99.32 103.38 20.2 Favored Pre-proline 0 CA--C 1.542 0.645 0 C-N-CA 123.565 0.746 . . . . 72.32 110.083 -171.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.13 114.39 3.97 Favored 'Trans proline' 0 C--N 1.374 1.894 0 C-N-CA 121.956 1.77 . . . . 72.34 110.017 176.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.536 HD21 HD12 ' A' ' 149' ' ' ILE . 14.2 tp -136.06 122.45 20.62 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 109.155 -0.683 . . . . 74.43 109.155 -168.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 3.0 m -69.61 162.31 27.87 Favored 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.987 0.915 . . . . 74.24 111.121 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 69.3 mt -63.93 -36.39 83.79 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.017 0.527 . . . . 73.31 112.37 -177.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -69.21 -40.19 78.15 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.292 0.637 . . . . 73.22 109.38 179.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.481 ' HG3' ' NH2' ' A' ' 136' ' ' ARG . 24.6 mm-40 -62.64 -44.27 96.7 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 124.477 1.111 . . . . 73.13 110.531 177.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.89 -37.29 78.93 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 115.158 -0.928 . . . . 73.11 111.408 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.5 t80 -65.84 -49.26 68.82 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.452 1.501 . . . . 71.43 110.881 -178.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -80.24 -41.22 25.51 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 115.28 -0.873 . . . . 73.21 111.157 -174.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.528 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.36 58.35 8.83 Favored Glycine 0 C--N 1.345 1.073 0 O-C-N 123.543 0.527 . . . . 65.4 113.085 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -94.51 -130.69 6.0 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 110.966 -0.854 . . . . 75.31 110.966 174.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -107.76 160.3 15.83 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.284 0.564 . . . . 64.41 110.046 169.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.481 ' NH2' ' HG3' ' A' ' 129' ' ' GLU . 5.5 tpp180 -133.02 121.92 23.44 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.495 -1.298 . . . . 73.34 107.495 172.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 62.9 t -72.8 124.34 29.44 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-O 121.082 0.468 . . . . 73.34 110.084 175.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.589 HG21 HD13 ' A' ' 98' ' ' LEU . 32.9 m -127.33 145.2 35.19 Favored 'Isoleucine or valine' 0 C--O 1.251 1.142 0 C-N-CA 125.08 1.352 . . . . 74.22 108.105 -177.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -104.23 106.28 16.73 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.166 -0.679 . . . . 72.35 109.166 -176.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.609 HG13 ' HB2' ' A' ' 143' ' ' ARG . 2.4 p -106.45 100.18 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.829 0.851 . . . . 50.34 109.411 -176.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.92 23.91 14.26 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.426 0.691 . . . . 54.34 111.927 177.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.27 2.91 56.74 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 116.02 -0.537 . . . . 52.34 112.924 -179.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.609 ' HB2' HG13 ' A' ' 140' ' ' VAL . 48.0 mtp180 -100.56 119.91 39.24 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 108.948 -0.76 . . . . 62.42 108.948 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.0 tmm_? -81.79 107.37 14.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.002 -0.74 . . . . 52.52 109.002 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 24.4 m -124.92 156.37 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 C-N-CA 123.701 0.8 . . . . 73.54 109.776 176.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.6 p -107.96 119.12 38.55 Favored 'General case' 0 C--O 1.241 0.607 0 C-N-CA 123.147 0.579 . . . . 73.45 110.192 174.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.0 p -99.16 132.28 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.671 -0.492 . . . . 64.25 109.671 176.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.4 ttp180 -80.36 120.19 24.07 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.877 0.37 . . . . 74.23 110.162 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.536 HD12 HD21 ' A' ' 125' ' ' LEU . 7.5 pt -95.08 142.01 24.03 Favored Pre-proline 0 CA--C 1.556 1.182 0 C-N-CA 124.135 0.974 . . . . 71.53 109.341 179.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -72.56 143.86 39.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.267 1.978 . . . . 74.33 112.5 178.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -73.33 133.54 19.43 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 122.633 2.222 . . . . 73.13 111.915 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.84 30.01 53.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.64 -0.709 . . . . 61.14 113.253 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 8.2 p -82.72 148.09 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 117.363 0.581 . . . . 72.05 109.634 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 -126.47 177.71 6.31 Favored 'General case' 0 N--CA 1.479 0.988 0 CA-C-O 121.567 0.699 . . . . 73.51 112.122 -171.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.6 tp10 -61.37 129.17 39.88 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 113.835 -1.53 . . . . 75.41 110.78 177.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.66 4.66 90.0 Favored Glycine 0 C--N 1.344 0.984 0 O-C-N 123.701 0.626 . . . . 54.13 113.551 178.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 67.0 m -82.23 119.67 24.38 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 117.444 0.622 . . . . 72.53 109.457 175.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.3 p -98.55 125.29 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-O 121.213 0.53 . . . . 35.3 110.054 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.8 mt -91.75 104.03 15.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 C-N-CA 124.334 1.053 . . . . 72.55 108.173 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.464 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 74.8 ttt180 -94.45 114.66 26.72 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 110.139 -0.319 . . . . 73.55 110.139 -177.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 19.5 t -122.85 98.4 42.77 Favored Pre-proline 0 CA--C 1.56 1.365 0 C-N-CA 123.59 0.756 . . . . 73.43 109.092 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.06 125.72 12.86 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.931 2.421 . . . . 72.51 112.74 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 104.64 -24.49 28.46 Favored Glycine 0 N--CA 1.474 1.19 0 CA-C-O 120.151 -0.25 . . . . 62.31 113.167 176.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.3 ttm -89.57 -18.92 25.66 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.362 0.665 . . . . 72.34 111.338 -174.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -69.8 -100.76 0.04 OUTLIER Glycine 0 C--N 1.346 1.103 0 CA-C-O 119.677 -0.513 . . . . 74.11 113.197 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -53.36 107.78 0.65 Allowed Glycine 0 C--N 1.355 1.59 0 C-N-CA 123.103 0.383 . . . . 70.33 113.248 179.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 13.0 mm-40 -84.76 169.53 14.13 Favored 'General case' 0 C--O 1.237 0.431 0 C-N-CA 123.602 0.761 . . . . 73.32 110.096 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 108.33 -138.47 14.67 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.716 -0.675 . . . . 60.03 111.672 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.437 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 58.0 t30 -77.15 -51.55 2.02 Favored Pre-proline 0 CA--C 1.569 1.706 0 CA-C-O 118.285 -0.864 . . . . 73.35 111.541 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.517 ' HB2' ' H ' ' A' ' 116' ' ' GLY . 72.8 Cg_endo -95.29 109.79 0.13 Allowed 'Trans proline' 0 C--N 1.394 2.958 0 C-N-CA 122.38 2.053 . . . . 62.22 112.746 177.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -60.45 125.95 18.72 Favored 'Trans proline' 0 C--N 1.381 2.261 0 C-N-CA 122.512 2.141 . . . . 61.12 111.654 175.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -112.27 177.33 18.51 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 116.412 -0.358 . . . . 72.23 113.88 -176.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -83.23 146.13 28.75 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.762 0.825 . . . . 72.12 110.318 -175.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 59.0 tp -113.38 134.51 54.6 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.196 0.598 . . . . 72.0 109.846 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 76.3 mt -129.61 105.2 7.9 Favored 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 124.437 1.095 . . . . 75.44 109.301 176.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.474 HD21 HD12 ' A' ' 98' ' ' LEU . 68.0 mt -107.55 102.73 11.96 Favored 'General case' 0 N--CA 1.479 1.013 0 O-C-N 122.109 -0.37 . . . . 62.44 110.009 174.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.7 t -85.93 99.04 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 N-CA-C 108.369 -0.974 . . . . 74.15 108.369 -175.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 87.0 t -56.23 116.81 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.45 1.1 . . . . 73.52 111.724 -177.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.1 mmt180 -113.07 104.21 12.15 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 125.576 1.551 . . . . 71.21 107.784 177.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 74.8 mt -69.39 130.38 42.38 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 122.918 0.487 . . . . 60.35 111.526 -174.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 92.1 mt -84.84 139.02 37.31 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.53 0.732 . . . . 72.44 110.128 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -65.38 116.54 3.95 Favored 'Trans proline' 0 C--N 1.378 2.099 0 C-N-CA 123.193 2.595 . . . . 54.33 112.021 -175.059 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.543 -0.741 . . . . 73.32 109.415 -178.185 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . 0.438 ' N ' ' SD ' ' A' ' 94' ' ' MET . 1.3 mpt? . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.484 -0.562 . . . . 60.21 109.484 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.527 ' HB3' ' HA ' ' A' ' 100' ' ' THR . 0.5 OUTLIER -95.09 99.55 4.5 Favored Pre-proline 0 CA--C 1.554 1.116 0 N-CA-C 109.058 -0.719 . . . . 65.24 109.058 166.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -66.62 -49.27 1.73 Allowed 'Trans proline' 0 C--N 1.385 2.498 0 C-N-CA 122.612 2.208 . . . . 70.33 111.691 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.526 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.4 tp -179.52 154.36 0.61 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 125.627 1.571 . . . . 74.14 106.945 -175.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.553 HD11 HD21 ' A' ' 174' ' ' LEU . 7.4 tp 53.04 -75.98 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 125.976 1.71 . . . . 63.23 111.551 -174.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.74 ' HA ' HD13 ' A' ' 119' ' ' LEU . 85.4 t80 -50.54 129.18 21.84 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 126.097 1.759 . . . . 74.31 112.341 171.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.557 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 55.2 m -142.18 105.99 5.65 Favored Pre-proline 0 N--CA 1.471 0.587 0 C-N-CA 124.105 0.962 . . . . 71.03 108.442 172.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -76.85 87.55 1.47 Allowed 'Trans proline' 0 C--N 1.366 1.453 0 C-N-CA 121.517 1.478 . . . . 64.43 112.42 -170.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.6 m -86.61 147.07 5.6 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-N 114.735 -1.12 . . . . 74.23 109.995 177.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.8 t -79.69 -15.2 58.0 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 122.761 0.424 . . . . 71.32 111.145 -178.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 56.7 tttm -58.73 121.48 11.17 Favored 'General case' 0 C--N 1.354 0.767 0 C-N-CA 123.671 0.788 . . . . 72.35 111.213 177.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -84.38 -124.92 1.22 Allowed Glycine 0 C--N 1.344 0.998 0 CA-C-N 115.298 -0.864 . . . . 74.42 113.131 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 16.4 m -86.74 -12.31 48.57 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 123.268 0.627 . . . . 62.42 110.867 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 82.85 -41.98 2.93 Favored Glycine 0 C--N 1.35 1.347 0 C-N-CA 123.12 0.391 . . . . 73.41 113.67 174.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.56 57.71 3.05 Favored Glycine 0 C--N 1.344 0.986 0 N-CA-C 111.402 -0.679 . . . . 72.45 111.402 -175.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.8 p -70.76 84.79 0.65 Allowed 'General case' 0 C--O 1.245 0.861 0 C-N-CA 123.49 0.716 . . . . 71.23 110.66 178.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 68.73 -84.06 0.21 Allowed Glycine 0 C--N 1.352 1.457 0 CA-C-N 115.281 -0.872 . . . . 72.33 111.581 -175.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -174.23 25.37 0.07 OUTLIER Glycine 0 C--N 1.335 0.516 0 N-CA-C 111.248 -0.741 . . . . 54.11 111.248 173.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 45.4 m -125.83 119.69 28.53 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.884 0.874 . . . . 72.44 109.859 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 67.58 -100.45 0.61 Allowed Glycine 0 C--N 1.352 1.435 0 O-C-N 124.266 0.978 . . . . 45.42 112.999 177.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 136.99 129.68 2.8 Favored Glycine 0 C--N 1.341 0.829 0 N-CA-C 111.704 -0.558 . . . . 61.24 111.704 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 78.9 p -73.91 110.99 8.64 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 123.209 0.603 . . . . 73.43 109.479 174.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -72.87 -152.62 1.87 Allowed Glycine 0 C--N 1.349 1.278 0 N-CA-C 114.569 0.588 . . . . 54.43 114.569 -172.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.431 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 94.2 mtt180 -82.49 131.08 35.22 Favored 'General case' 0 N--CA 1.476 0.862 0 O-C-N 122.461 -0.435 . . . . 73.15 110.077 -178.092 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.7 105.95 18.17 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 107.345 -1.354 . . . . 65.31 107.345 -177.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.74 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.5 mt -92.87 108.96 20.4 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 107.26 -1.385 . . . . 71.4 107.26 -176.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 74.4 ttt180 -119.33 105.87 11.74 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.131 0.972 . . . . 73.14 108.663 -175.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.58 145.23 40.34 Favored 'General case' 0 C--O 1.242 0.67 0 C-N-CA 123.722 0.809 . . . . 53.1 109.567 -174.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -76.66 137.59 39.52 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.536 -0.542 . . . . 64.02 109.536 175.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.411 ' HA ' ' HD2' ' A' ' 124' ' ' PRO . 19.9 tp -101.62 105.36 40.27 Favored Pre-proline 0 CA--C 1.542 0.671 0 C-N-CA 123.992 0.917 . . . . 71.31 110.201 -178.357 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 123' ' ' LEU . 23.5 Cg_endo -60.64 122.78 11.8 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.488 2.125 . . . . 74.11 110.342 169.12 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.468 HD21 HD12 ' A' ' 149' ' ' ILE . 25.3 tp -147.83 133.79 19.17 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.889 -0.782 . . . . 73.33 108.889 -175.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.9 p -81.21 163.66 22.86 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 110.129 -0.323 . . . . 72.12 110.129 179.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.0 mt -61.92 -32.7 73.13 Favored 'General case' 0 N--CA 1.482 1.168 0 C-N-CA 123.607 0.763 . . . . 63.21 110.971 179.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -70.72 -50.23 38.51 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 114.987 -1.006 . . . . 75.15 109.406 -177.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -70.13 -26.65 64.05 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.794 0.837 . . . . 73.22 111.859 -179.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.75 -40.31 69.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.216 0.606 . . . . 75.43 110.744 174.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -64.43 -46.4 83.36 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.911 0.884 . . . . 64.44 110.698 175.504 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -63.36 -49.67 72.96 Favored 'General case' 0 C--N 1.351 0.671 0 O-C-N 123.71 0.631 . . . . 73.22 110.362 -177.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.505 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 56.63 70.39 0.99 Allowed Glycine 0 C--N 1.349 1.276 0 O-C-N 124.128 0.893 . . . . 75.11 112.771 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -121.06 -121.37 2.81 Favored Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.35 -1.1 . . . . 72.4 110.35 174.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.557 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 7.0 mp0 -99.69 154.96 17.88 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 123.143 0.577 . . . . 42.33 109.528 172.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.458 ' HB2' HD13 ' A' ' 149' ' ' ILE . 14.0 tpt180 -137.04 122.55 19.61 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 108.162 -1.051 . . . . 75.42 108.162 178.479 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.1 t -74.34 119.44 21.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 O-C-N 123.577 0.548 . . . . 75.14 109.886 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.548 HG21 HD13 ' A' ' 98' ' ' LEU . 28.5 m -122.68 147.38 26.89 Favored 'Isoleucine or valine' 0 C--O 1.251 1.147 0 C-N-CA 124.769 1.228 . . . . 55.21 109.067 179.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -100.91 127.83 47.22 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.987 0.915 . . . . 74.11 109.268 -177.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.562 HG23 ' HB2' ' A' ' 99' ' ' PHE . 3.1 p -142.66 103.67 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 C-N-CA 123.287 0.635 . . . . 72.54 111.118 -174.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 55.38 29.69 13.55 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 124.448 1.099 . . . . 64.41 113.14 172.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.65 26.34 10.85 Favored Glycine 0 C--N 1.348 1.248 0 CA-C-N 116.36 -0.382 . . . . 41.1 112.658 179.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.496 ' HB2' HG13 ' A' ' 140' ' ' VAL . 54.3 mmt-85 -131.87 136.18 47.25 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.842 0.857 . . . . 72.42 110.049 -178.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 16.1 ttp180 -95.67 105.88 17.92 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 107.917 -1.142 . . . . 75.33 107.917 171.249 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 33.0 m -125.44 151.37 31.3 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 N-CA-C 109.915 -0.402 . . . . 31.22 109.915 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.557 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 34.6 p -106.11 117.65 34.58 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.296 0.638 . . . . 72.34 109.924 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.2 p -98.8 133.35 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 N-CA-C 108.664 -0.865 . . . . 72.22 108.664 176.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.4 ttt85 -82.4 125.74 31.39 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.203 0.525 . . . . 65.52 109.754 -178.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.505 HG13 ' HA2' ' A' ' 133' ' ' GLY . 3.3 pt -107.56 145.8 32.04 Favored Pre-proline 0 CA--C 1.557 1.219 0 C-N-CA 124.882 1.273 . . . . 53.42 108.686 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.43 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 56.7 Cg_endo -71.08 146.56 52.38 Favored 'Trans proline' 0 CA--C 1.566 2.099 0 C-N-CA 122.161 1.907 . . . . 72.31 112.823 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 23.9 Cg_exo -66.79 134.95 36.57 Favored 'Trans proline' 0 C--N 1.38 2.23 0 C-N-CA 123.172 2.581 . . . . 64.1 111.962 172.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.16 28.03 62.95 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-N 115.724 -0.671 . . . . 74.11 113.024 -177.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.43 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 14.7 p -78.19 147.2 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.256 -0.646 . . . . 74.13 109.256 177.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -129.61 177.23 7.37 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 122.011 0.91 . . . . 62.11 113.085 -167.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.5 tp10 -62.58 121.4 13.23 Favored 'General case' 0 C--O 1.241 0.644 0 CA-C-N 113.463 -1.699 . . . . 74.04 110.414 174.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.73 2.83 69.21 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 115.892 -0.595 . . . . 60.4 112.822 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 59.5 m -86.39 122.04 29.79 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 109.458 -0.571 . . . . 73.33 109.458 174.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.5 p -101.23 126.35 55.05 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.232 0.539 . . . . 74.41 110.051 178.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 60.7 mt -93.94 102.92 14.13 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.941 1.296 . . . . 70.41 107.914 176.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -98.38 121.62 40.53 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.956 -0.387 . . . . 75.33 109.956 -179.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 4.2 t -115.47 99.62 52.64 Favored Pre-proline 0 CA--C 1.556 1.192 0 N-CA-C 107.692 -1.225 . . . . 74.53 107.692 173.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -68.25 131.39 23.36 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 123.098 2.532 . . . . 60.25 113.63 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 75.87 24.07 70.51 Favored Glycine 0 CA--C 1.529 0.922 0 CA-C-N 115.085 -0.962 . . . . 45.03 113.784 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.7 tpt -126.28 -9.2 6.4 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 123.62 0.768 . . . . 71.42 111.21 -176.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -71.11 -94.7 0.07 OUTLIER Glycine 0 C--N 1.347 1.172 0 CA-C-O 120.175 -0.236 . . . . 74.34 112.848 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -68.84 106.96 1.91 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.966 -0.352 . . . . 44.42 112.433 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -72.43 137.46 46.48 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.647 0.779 . . . . 71.23 111.013 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.2 -163.75 32.55 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 116.006 -0.543 . . . . 75.42 112.157 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -72.94 -43.95 8.17 Favored Pre-proline 0 CA--C 1.565 1.537 0 CA-C-O 118.968 -0.539 . . . . 73.3 110.725 174.172 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -93.34 108.37 0.18 Allowed 'Trans proline' 0 C--N 1.386 2.511 0 C-N-CA 122.081 1.854 . . . . 73.32 111.254 163.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_endo -82.74 137.67 8.99 Favored 'Trans proline' 0 C--N 1.372 1.807 0 C-N-CA 122.361 2.041 . . . . 62.14 112.243 -178.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.431 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -99.04 179.93 31.36 Favored Glycine 0 C--N 1.343 0.935 0 CA-C-N 115.933 -0.576 . . . . 45.42 113.14 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -87.88 149.03 24.34 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 122.844 0.458 . . . . 74.0 111.239 -175.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.553 HD21 HD11 ' A' ' 98' ' ' LEU . 41.8 tp -112.42 128.64 56.37 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 122.844 0.458 . . . . 74.55 109.915 177.301 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 74.3 mt -127.46 115.48 18.96 Favored 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 124.196 0.998 . . . . 72.51 109.157 178.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.5 HD21 HD12 ' A' ' 98' ' ' LEU . 72.9 mt -117.07 103.42 10.22 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 123.178 0.591 . . . . 75.32 110.489 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.6 t -89.79 98.59 8.32 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.072 0 C-N-CA 122.524 0.33 . . . . 73.0 110.331 -173.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.8 t -60.09 113.87 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 C-N-CA 124.203 1.001 . . . . 55.54 112.694 -173.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 22.1 mmm180 -105.0 109.14 21.01 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 126.126 1.77 . . . . 73.03 108.649 176.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 86.6 mt -71.87 119.0 15.42 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 122.387 0.275 . . . . 74.14 110.449 179.152 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 78.4 mt -79.05 147.35 69.63 Favored Pre-proline 0 CA--C 1.545 0.784 0 C-N-CA 123.693 0.797 . . . . 54.32 110.79 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -61.1 110.0 0.79 Allowed 'Trans proline' 0 C--N 1.373 1.82 0 C-N-CA 123.368 2.712 . . . . 75.33 111.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 77.6 t60 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.733 -0.651 . . . . 63.24 110.289 178.507 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 96.9 mmm . . . . . 0 N--CA 1.487 1.382 0 N-CA-C 110.171 -0.307 . . . . 70.21 110.171 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 37.11 89.32 0.08 OUTLIER Pre-proline 0 CA--C 1.562 1.426 0 C-N-CA 126.219 1.808 . . . . 65.04 114.26 -176.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.66 -66.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.388 2.65 0 C-N-CA 122.738 2.292 . . . . 74.12 111.477 174.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.2 tp -178.89 149.44 0.45 Allowed 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 125.236 1.414 . . . . 63.13 107.809 175.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.663 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 13.2 tp 56.99 8.6 0.52 Allowed 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 124.422 1.089 . . . . 74.44 112.494 -174.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.642 ' HA ' HD13 ' A' ' 119' ' ' LEU . 77.2 t80 -150.87 124.49 9.05 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 123.927 0.891 . . . . 74.2 109.261 -165.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.602 ' H ' HD22 ' A' ' 119' ' ' LEU . 95.7 m -150.5 95.24 3.54 Favored Pre-proline 0 CA--C 1.541 0.606 0 C-N-CA 124.639 1.175 . . . . 75.11 108.155 176.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.6 104.65 1.16 Allowed 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 121.921 1.748 . . . . 55.13 110.804 -176.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.17 174.04 3.22 Favored 'Isoleucine or valine' 0 C--O 1.244 0.789 0 C-N-CA 123.793 0.837 . . . . 75.51 109.466 178.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 54.0 p -112.47 86.78 2.43 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.41 0.684 . . . . 33.23 109.283 177.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -79.32 149.64 31.7 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.143 -0.935 . . . . 64.43 109.676 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 70.36 48.23 38.85 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 111.335 -0.706 . . . . 61.43 111.335 -174.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 48.0 t -68.41 -25.41 65.02 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.124 0.97 . . . . 62.42 112.274 -173.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -72.49 92.42 0.59 Allowed Glycine 0 C--N 1.353 1.521 0 CA-C-O 120.104 -0.275 . . . . 60.21 112.813 -178.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 74.41 26.83 66.98 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.894 -0.392 . . . . 73.42 112.401 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 18.5 m 63.0 14.4 7.53 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 124.654 1.181 . . . . 63.15 112.36 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -128.12 -59.72 0.12 Allowed Glycine 0 C--N 1.348 1.245 0 N-CA-C 110.416 -1.073 . . . . 72.53 110.416 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 67.7 -96.31 0.36 Allowed Glycine 0 C--N 1.348 1.218 0 N-CA-C 111.319 -0.712 . . . . 71.23 111.319 -179.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.5 p -84.07 -2.29 56.42 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 124.08 0.952 . . . . 74.13 111.516 175.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 115.37 -106.46 1.59 Allowed Glycine 0 C--N 1.347 1.185 0 N-CA-C 110.905 -0.878 . . . . 22.24 110.905 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -112.66 100.6 1.13 Allowed Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.244 -0.742 . . . . 73.45 111.244 178.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 52.9 m -131.64 149.08 52.61 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 123.708 0.803 . . . . 72.33 110.576 177.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -74.98 -161.75 9.06 Favored Glycine 0 C--N 1.351 1.412 0 O-C-N 123.534 0.521 . . . . 74.12 111.933 173.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 24.2 ptt180 -97.34 149.33 22.21 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 123.199 0.6 . . . . 64.22 110.922 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -92.61 114.71 27.34 Favored 'General case' 0 C--N 1.348 0.519 0 N-CA-C 107.686 -1.227 . . . . 72.31 107.686 175.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.642 HD13 ' HA ' ' A' ' 99' ' ' PHE . 31.2 mt -93.44 107.22 19.1 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 106.991 -1.485 . . . . 64.05 106.991 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.485 ' H ' ' HB ' ' A' ' 100' ' ' THR . 19.6 ttt180 -116.0 105.83 13.09 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.03 -0.73 . . . . 72.31 109.03 178.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 141.36 48.17 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.829 0.852 . . . . 45.21 108.772 -177.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.14 129.6 34.62 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.372 -0.603 . . . . 73.13 109.372 174.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.483 HD12 HD13 ' A' ' 176' ' ' LEU . 1.7 tt -101.6 109.64 59.75 Favored Pre-proline 0 CA--C 1.55 0.965 0 C-N-CA 123.479 0.712 . . . . 70.44 109.379 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -67.4 121.82 8.98 Favored 'Trans proline' 0 C--N 1.377 2.079 0 C-N-CA 122.559 2.173 . . . . 71.41 110.954 172.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.1 tp -140.67 135.09 31.29 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 108.805 -0.813 . . . . 73.12 108.805 -173.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.5 p -76.15 167.12 22.44 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.892 -0.41 . . . . 71.33 109.892 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.516 HD12 ' HB2' ' A' ' 183' ' ' HIS . 86.6 mt -66.77 -31.11 71.54 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.033 0.533 . . . . 74.14 110.644 178.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -71.11 -49.49 43.79 Favored 'General case' 0 C--O 1.22 -0.497 0 CA-C-N 114.701 -1.136 . . . . 71.31 109.135 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -74.35 -19.6 60.39 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.405 0.682 . . . . 71.34 111.452 -179.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.54 -45.21 72.78 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.138 0.575 . . . . 52.33 109.853 167.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -65.03 -41.37 95.32 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 123.938 0.895 . . . . 75.11 111.006 176.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -75.48 -39.76 58.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.131 0.572 . . . . 74.33 110.679 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.25 -114.11 6.26 Favored Glycine 0 C--N 1.345 1.081 0 CA-C-N 115.273 -0.876 . . . . 73.11 111.207 -172.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.12 -132.71 39.58 Favored Glycine 0 C--N 1.351 1.382 0 CA-C-O 119.668 -0.518 . . . . 75.15 112.413 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.575 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 10.3 mp0 -105.75 158.22 16.89 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.847 0.859 . . . . 75.14 109.958 176.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.632 ' HB2' HD13 ' A' ' 149' ' ' ILE . 23.4 tpt85 -133.91 120.87 20.92 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.733 0.813 . . . . 72.52 109.063 178.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.6 t -74.88 109.08 7.22 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 C-N-CA 124.165 0.986 . . . . 73.51 109.626 -179.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.49 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 26.1 m -128.03 149.15 32.68 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 C-N-CA 124.075 0.95 . . . . 72.45 110.098 -174.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -97.73 103.75 15.72 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 123.649 0.78 . . . . 63.13 111.322 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.663 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.3 p -103.94 102.26 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.103 0.961 . . . . 71.14 109.569 -179.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.93 27.74 17.16 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 124.321 1.049 . . . . 63.51 112.201 177.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.54 -13.09 59.78 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-O 119.317 -0.713 . . . . 71.01 114.227 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.23 152.25 19.32 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 118.164 0.982 . . . . 74.11 110.093 177.165 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 -100.17 109.01 21.27 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.587 0.755 . . . . 61.14 109.602 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 86.3 t -122.66 136.84 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 N-CA-C 108.572 -0.899 . . . . 74.14 108.572 175.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.575 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 77.5 p -95.5 113.09 24.72 Favored 'General case' 0 C--O 1.242 0.658 0 N-CA-C 109.168 -0.679 . . . . 60.53 109.168 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -97.84 136.48 28.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 123.57 0.748 . . . . 53.54 109.216 -178.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -81.03 127.27 32.41 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 121.369 0.605 . . . . 64.12 110.568 -176.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.632 HD13 ' HB2' ' A' ' 136' ' ' ARG . 7.5 pt -118.07 145.32 36.62 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.658 1.583 . . . . 73.04 108.43 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -73.04 138.2 27.8 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.456 2.104 . . . . 73.5 112.599 178.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.73 143.66 51.7 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.336 2.024 . . . . 63.42 111.544 169.012 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.0 26.48 58.11 Favored Glycine 0 C--N 1.343 0.932 0 CA-C-N 116.278 -0.419 . . . . 53.22 112.897 -173.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.6 p -87.58 150.85 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 C-N-CA 123.2 0.6 . . . . 71.34 109.869 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 42.6 mtp180 -123.16 177.86 5.36 Favored 'General case' 0 N--CA 1.483 1.178 0 CA-C-O 121.722 0.773 . . . . 75.41 112.358 -177.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -58.37 137.27 57.35 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 113.282 -1.781 . . . . 75.41 111.038 174.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.76 -14.15 38.55 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-O 119.352 -0.693 . . . . 30.23 113.976 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 63.5 m -71.11 118.37 13.81 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 117.558 0.679 . . . . 74.24 109.593 -179.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.2 p -97.65 132.52 42.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 122.99 0.516 . . . . 64.43 109.716 -179.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.5 mt -103.06 104.65 16.93 Favored 'Isoleucine or valine' 0 C--O 1.241 0.606 0 C-N-CA 124.876 1.27 . . . . 65.04 107.588 -177.456 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.426 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 64.7 ttt180 -91.61 112.64 24.65 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 109.94 -0.393 . . . . 74.12 109.94 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 8.6 t -104.11 100.12 19.78 Favored Pre-proline 0 CA--C 1.557 1.219 0 N-CA-C 106.989 -1.485 . . . . 74.21 106.989 167.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -66.63 128.83 19.8 Favored 'Trans proline' 0 C--N 1.375 1.943 0 C-N-CA 122.878 2.385 . . . . 70.11 113.096 -174.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.56 22.78 78.13 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.939 -0.573 . . . . 73.54 114.207 176.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.1 tpt -107.45 -23.96 11.99 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 123.385 0.674 . . . . 51.45 110.969 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -66.45 -84.14 0.1 OUTLIER Glycine 0 C--N 1.344 1.024 0 CA-C-N 116.359 -0.382 . . . . 73.2 112.865 179.393 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -71.46 93.09 0.52 Allowed Glycine 0 C--N 1.346 1.109 0 N-CA-C 111.466 -0.653 . . . . 61.3 111.466 173.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.4 mm-40 -78.78 143.61 35.94 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.757 0.823 . . . . 61.41 111.756 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.13 -168.24 25.78 Favored Glycine 0 C--O 1.241 0.583 0 CA-C-N 114.8 -1.091 . . . . 65.0 110.377 -177.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 17.3 m120 -62.16 -44.37 88.79 Favored Pre-proline 0 CA--C 1.562 1.416 0 CA-C-O 118.655 -0.688 . . . . 75.43 110.82 169.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -82.96 114.43 2.26 Favored 'Trans proline' 0 C--N 1.394 2.972 0 C-N-CA 121.872 1.714 . . . . 74.34 111.717 167.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -82.94 150.27 14.03 Favored 'Trans proline' 0 C--N 1.378 2.13 0 C-N-CA 122.222 1.948 . . . . 63.31 113.059 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -132.84 151.66 20.07 Favored Glycine 0 N--CA 1.473 1.123 0 N-CA-C 110.326 -1.109 . . . . 42.24 110.326 170.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.58 156.06 39.39 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.489 0.715 . . . . 51.43 112.49 -175.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.507 HD21 HD11 ' A' ' 98' ' ' LEU . 65.5 tp -116.22 127.94 55.19 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 108.428 -0.953 . . . . 75.51 108.428 172.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 54.5 mt -128.26 118.34 23.11 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 124.825 1.25 . . . . 63.03 108.689 -178.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.483 HD13 HD12 ' A' ' 123' ' ' LEU . 86.1 mt -120.68 103.31 9.02 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 123.061 0.545 . . . . 71.31 111.043 -178.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.9 t -85.43 96.02 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.587 -0.523 . . . . 74.52 109.587 -176.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.4 t -55.5 126.76 13.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.921 0.888 . . . . 51.35 111.807 -178.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -112.48 113.12 25.14 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 125.19 1.396 . . . . 74.34 107.687 177.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 50.3 mt -74.56 119.53 18.88 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 109.255 -0.646 . . . . 75.43 109.255 176.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 67.0 mt -82.33 131.24 56.46 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 108.317 -0.994 . . . . 72.25 108.317 176.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -68.31 143.03 56.87 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.961 2.441 . . . . 62.41 112.284 -174.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.516 ' HB2' HD12 ' A' ' 127' ' ' LEU . 47.0 m80 . . . . . 0 N--CA 1.485 1.319 0 C-N-CA 124.03 0.932 . . . . 62.12 108.806 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 85.2 mtp . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.753 -0.091 . . . . 63.4 110.753 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.429 ' HB2' ' O ' ' A' ' 99' ' ' PHE . 2.6 pt? -47.57 123.89 9.36 Favored Pre-proline 0 CA--C 1.563 1.452 0 C-N-CA 124.92 1.288 . . . . 70.44 112.238 178.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.431 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 10.3 Cg_endo -86.75 -79.99 0.0 OUTLIER 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 123.009 2.473 . . . . 74.11 111.248 177.691 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.475 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 6.5 tp -157.83 142.23 16.18 Favored 'General case' 0 C--N 1.348 0.521 0 N-CA-C 108.292 -1.003 . . . . 63.41 108.292 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.712 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 5.2 tp 57.09 7.75 0.46 Allowed 'General case' 0 CA--C 1.57 1.713 0 C-N-CA 126.096 1.758 . . . . 53.21 113.172 -173.099 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.647 ' HA ' HD13 ' A' ' 119' ' ' LEU . 86.7 t80 -139.12 128.79 24.63 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.825 0.85 . . . . 63.31 109.333 -171.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.534 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 86.2 m -153.05 98.62 2.76 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 124.192 0.997 . . . . 74.44 109.342 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -72.16 83.18 1.23 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.444 2.096 . . . . 75.51 112.242 -173.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 20.6 m -85.05 173.48 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 CA-C-N 115.406 -0.816 . . . . 75.13 109.691 175.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 3.7 t -142.57 70.13 1.32 Allowed 'General case' 0 N--CA 1.473 0.684 0 CA-C-O 122.339 1.066 . . . . 73.34 109.324 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -89.76 97.55 11.26 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 114.63 -1.168 . . . . 64.32 110.346 -176.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -75.08 137.39 22.02 Favored Glycine 0 C--N 1.347 1.173 0 CA-C-N 116.037 -0.528 . . . . 51.14 111.972 178.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.7 m -63.48 -39.36 94.26 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 123.802 0.841 . . . . 55.11 110.665 176.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 63.11 57.17 16.6 Favored Glycine 0 C--N 1.351 1.396 0 CA-C-N 115.27 -0.877 . . . . 71.53 112.853 179.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.67 151.12 8.43 Favored Glycine 0 C--N 1.345 1.047 0 CA-C-O 119.59 -0.561 . . . . 72.43 112.111 179.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.7 p -69.4 -50.38 46.44 Favored 'General case' 0 N--CA 1.474 0.775 0 C-N-CA 123.82 0.848 . . . . 61.2 110.544 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -65.93 -23.15 70.91 Favored Glycine 0 C--N 1.354 1.563 0 O-C-N 123.905 0.753 . . . . 44.14 112.441 175.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -75.99 76.12 1.45 Allowed Glycine 0 C--N 1.348 1.199 0 N-CA-C 111.968 -0.453 . . . . 71.1 111.968 174.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 32.8 t -87.77 83.25 7.17 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 108.39 -0.967 . . . . 61.13 108.39 177.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 74.3 -85.19 0.71 Allowed Glycine 0 C--N 1.347 1.157 0 CA-C-N 115.276 -0.874 . . . . 64.44 112.12 -178.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.68 -55.29 4.99 Favored Glycine 0 C--N 1.348 1.249 0 N-CA-C 111.482 -0.647 . . . . 73.42 111.482 -174.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 19.8 p -146.49 140.97 26.6 Favored 'General case' 0 C--O 1.242 0.664 0 C-N-CA 125.031 1.333 . . . . 73.14 108.108 173.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.35 -121.31 0.12 Allowed Glycine 0 C--N 1.346 1.112 0 CA-C-O 119.989 -0.34 . . . . 60.34 112.334 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.503 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.0 OUTLIER -97.54 133.39 42.17 Favored 'General case' 0 N--CA 1.479 0.992 0 CA-C-N 117.591 0.696 . . . . 62.43 110.209 178.708 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -95.35 107.32 19.44 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 107.086 -1.45 . . . . 73.45 107.086 177.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.647 HD13 ' HA ' ' A' ' 99' ' ' PHE . 15.7 mt -92.76 108.46 20.0 Favored 'General case' 0 C--N 1.342 0.272 0 N-CA-C 107.593 -1.262 . . . . 64.25 107.593 -174.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.518 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 20.8 ttt180 -106.17 104.71 14.47 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 109.049 -0.723 . . . . 65.14 109.049 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -123.19 134.34 54.17 Favored 'General case' 0 C--O 1.237 0.411 0 N-CA-C 108.929 -0.767 . . . . 51.44 108.929 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -80.87 121.78 26.39 Favored 'General case' 0 C--O 1.241 0.637 0 N-CA-C 108.254 -1.017 . . . . 61.31 108.254 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.572 HD21 ' HG2' ' A' ' 136' ' ' ARG . 5.5 tt -99.06 109.74 55.26 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 108.159 -1.052 . . . . 70.11 108.159 -171.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -72.75 115.23 4.26 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 121.904 1.736 . . . . 62.24 110.443 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.604 HD21 HD12 ' A' ' 149' ' ' ILE . 29.0 tp -128.81 137.51 51.55 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.601 0.76 . . . . 73.21 109.498 -173.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 74.3 p -79.87 162.62 24.91 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.11 -0.33 . . . . 35.2 110.11 -178.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.97 -26.95 65.3 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.393 0.677 . . . . 73.24 110.962 -178.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -68.55 -50.31 52.82 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 114.934 -1.03 . . . . 62.11 109.093 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 14.5 mm-40 -73.63 -21.23 60.36 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 114.991 -1.004 . . . . 74.35 112.324 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.09 -44.89 64.76 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.991 0.517 . . . . 72.22 109.74 170.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -62.13 -42.35 99.16 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.666 1.186 . . . . 72.34 110.921 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.7 m80 -74.42 -48.8 25.51 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.607 0.363 . . . . 73.52 110.427 -178.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.604 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 62.49 52.34 49.73 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 123.997 0.81 . . . . 74.11 113.853 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -101.37 -130.49 7.06 Favored Glycine 0 C--N 1.347 1.148 0 N-CA-C 111.452 -0.659 . . . . 62.51 111.452 177.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -97.28 158.61 15.37 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.072 0.549 . . . . 72.53 110.149 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.572 ' HG2' HD21 ' A' ' 123' ' ' LEU . 41.0 tpt85 -136.84 119.69 16.3 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.214 -0.903 . . . . 74.52 108.975 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.8 t -86.39 105.96 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 123.397 0.679 . . . . 70.21 109.643 -177.143 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.52 HG21 HD13 ' A' ' 98' ' ' LEU . 34.3 m -117.01 162.6 14.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 125.001 1.321 . . . . 70.3 108.345 -178.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 45.5 tt0 -123.98 112.69 17.49 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 122.497 0.319 . . . . 73.45 111.263 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.712 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 2.9 p -106.46 105.44 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 124.469 1.107 . . . . 75.4 109.965 -178.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 58.02 28.74 16.71 Favored 'General case' 0 N--CA 1.491 1.583 0 C-N-CA 123.633 0.773 . . . . 61.13 112.122 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.25 2.76 55.74 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-O 119.566 -0.574 . . . . 75.24 114.069 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.6 mtt180 -100.73 121.8 42.27 Favored 'General case' 0 N--CA 1.486 1.349 0 CA-C-N 117.735 0.767 . . . . 64.52 110.724 -178.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -74.96 126.32 30.75 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.463 0.705 . . . . 74.03 109.319 172.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 3.2 p -148.79 131.0 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.068 0.547 . . . . 70.15 110.464 178.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 12.5 p -91.42 105.85 18.07 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 123.547 0.739 . . . . 74.32 109.647 176.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.8 p -99.35 132.56 44.53 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 123.906 0.882 . . . . 73.04 109.036 176.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 58.1 ttt85 -81.92 129.16 34.68 Favored 'General case' 0 C--O 1.242 0.667 0 CA-C-O 121.59 0.709 . . . . 75.35 110.696 -176.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.604 HD12 HD21 ' A' ' 125' ' ' LEU . 2.4 pt -98.56 145.2 29.48 Favored Pre-proline 0 CA--C 1.557 1.244 0 C-N-CA 125.637 1.575 . . . . 60.41 108.734 174.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.91 143.88 62.44 Favored 'Trans proline' 0 CA--C 1.562 1.906 0 C-N-CA 121.986 1.791 . . . . 74.21 112.215 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.604 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 30.5 Cg_endo -62.27 130.16 29.45 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.18 2.586 . . . . 54.32 111.787 175.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 64.76 46.77 88.76 Favored Glycine 0 C--N 1.344 1.021 0 O-C-N 123.966 0.791 . . . . 72.24 111.614 -175.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 178' ' ' VAL . 8.2 p -75.72 145.6 10.41 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 CA-C-O 121.187 0.517 . . . . 74.42 110.256 179.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.4 mtp180 -104.07 169.78 8.3 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 124.19 0.996 . . . . 75.12 111.974 -172.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.6 tp10 -68.19 134.6 50.72 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-N 113.834 -1.53 . . . . 74.22 110.331 176.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.05 2.79 66.81 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-O 118.968 -0.907 . . . . 74.13 114.395 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.7 m -71.13 117.63 12.89 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 118.213 1.006 . . . . 72.55 108.869 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.7 p -93.37 132.25 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 109.34 -0.615 . . . . 74.4 109.34 -178.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.546 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 50.0 mt -105.93 104.12 16.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 107.807 -1.183 . . . . 55.2 107.807 -178.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 36.1 ttm180 -91.46 104.74 17.22 Favored 'General case' 0 C--O 1.236 0.394 0 N-CA-C 109.632 -0.507 . . . . 61.25 109.632 177.521 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.4 t -97.12 111.58 58.35 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 107.361 -1.348 . . . . 74.3 107.361 174.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -69.86 124.62 11.22 Favored 'Trans proline' 0 C--N 1.374 1.873 0 C-N-CA 123.17 2.58 . . . . 72.12 113.46 -170.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 69.38 16.01 70.96 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 114.743 0.657 . . . . 53.43 114.743 173.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.9 mmt -113.83 12.64 18.26 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 123.317 0.647 . . . . 74.03 111.659 -177.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -96.43 -102.17 2.01 Favored Glycine 0 C--N 1.338 0.661 0 O-C-N 123.472 0.483 . . . . 71.14 112.588 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.503 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -65.48 121.47 20.41 Favored Glycine 0 C--N 1.353 1.523 0 O-C-N 123.948 0.44 . . . . 64.03 113.587 -173.194 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -71.22 146.95 48.71 Favored 'General case' 0 C--O 1.246 0.92 0 C-N-CA 123.414 0.686 . . . . 73.44 110.952 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 155.32 -169.38 33.26 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.025 -0.989 . . . . 75.34 111.093 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -74.34 -48.91 5.46 Favored Pre-proline 0 CA--C 1.566 1.572 0 CA-C-O 118.621 -0.704 . . . . 73.31 109.378 174.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -83.55 111.59 1.79 Allowed 'Trans proline' 0 C--N 1.394 2.962 0 C-N-CA 121.641 1.56 . . . . 62.11 110.264 164.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -69.52 128.89 16.91 Favored 'Trans proline' 0 C--N 1.369 1.64 0 C-N-CA 122.261 1.974 . . . . 65.01 111.854 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -90.99 166.78 31.31 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-O 119.873 -0.404 . . . . 73.53 112.129 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -82.45 158.68 23.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 122.989 0.516 . . . . 75.31 111.11 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.653 HD21 HD11 ' A' ' 98' ' ' LEU . 40.9 tp -118.29 131.55 56.34 Favored 'General case' 0 C--O 1.223 -0.3 0 C-N-CA 123.69 0.796 . . . . 74.34 109.463 -178.001 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.518 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 87.0 mt -128.8 125.54 38.0 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.028 0.931 . . . . 55.53 109.804 -177.617 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.612 HD21 HD12 ' A' ' 98' ' ' LEU . 80.8 mt -125.27 103.03 7.73 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.221 0.609 . . . . 63.12 111.124 178.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 39.4 t -85.59 94.34 4.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.306 -0.998 . . . . 51.43 108.306 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 153' ' ' VAL . 98.7 t -58.49 114.83 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 C-N-CA 123.739 0.816 . . . . 72.12 111.049 -177.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -106.44 104.41 14.09 Favored 'General case' 0 C--O 1.237 0.43 0 C-N-CA 124.506 1.123 . . . . 74.45 108.751 178.284 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 72.3 mt -68.94 105.05 2.25 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 109.669 -0.493 . . . . 53.25 109.669 178.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.3 mt -60.74 149.66 78.84 Favored Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 124.295 1.038 . . . . 52.02 111.399 175.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -70.73 165.86 30.68 Favored 'Trans proline' 0 C--N 1.373 1.844 0 C-N-CA 122.314 2.009 . . . . 71.12 111.311 174.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 . . . . . 0 CA--C 1.552 1.039 0 N-CA-C 108.907 -0.775 . . . . 72.34 108.907 174.33 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . 0.437 ' HG3' ' H ' ' A' ' 95' ' ' LEU . 5.6 tpt . . . . . 0 N--CA 1.475 0.779 0 N-CA-C 108.354 -0.98 . . . . 75.0 108.354 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.437 ' H ' ' HG3' ' A' ' 94' ' ' MET . 0.8 OUTLIER -101.45 99.39 11.21 Favored Pre-proline 0 CA--C 1.551 0.996 0 C-N-CA 124.067 0.947 . . . . 74.34 111.004 178.487 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.1 -67.12 0.03 OUTLIER 'Trans proline' 0 C--N 1.382 2.308 0 C-N-CA 122.055 1.837 . . . . 71.54 110.969 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.515 ' HG ' ' HB ' ' A' ' 138' ' ' VAL . 5.7 tp -171.6 143.62 1.76 Allowed 'General case' 0 C--N 1.35 0.62 0 C-N-CA 124.202 1.001 . . . . 73.52 108.457 176.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.664 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 6.1 tp 59.36 4.22 0.47 Allowed 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 125.628 1.571 . . . . 72.31 113.158 -173.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.596 ' HB2' HG23 ' A' ' 140' ' ' VAL . 82.7 t80 -139.95 130.43 25.51 Favored 'General case' 0 CA--C 1.512 -0.505 0 N-CA-C 107.789 -1.189 . . . . 60.32 107.789 -171.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.455 HG22 HG13 ' A' ' 102' ' ' VAL . 75.9 m -149.45 98.02 3.49 Favored Pre-proline 0 N--CA 1.469 0.483 0 O-C-N 124.327 1.017 . . . . 65.52 109.641 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -70.88 80.8 1.17 Allowed 'Trans proline' 0 C--N 1.367 1.516 0 C-N-CA 122.682 2.255 . . . . 53.32 112.679 -176.089 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.455 HG13 HG22 ' A' ' 100' ' ' THR . 29.9 m -84.81 163.18 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 124.586 1.154 . . . . 71.24 109.342 171.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 16.9 p -146.14 77.92 1.5 Allowed 'General case' 0 C--O 1.243 0.721 0 C-N-CA 123.918 0.887 . . . . 72.13 109.124 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 19.3 pttm -80.01 121.97 26.15 Favored 'General case' 0 C--N 1.359 1.007 0 N-CA-C 109.244 -0.65 . . . . 74.13 109.244 177.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 84.38 164.69 38.12 Favored Glycine 0 C--N 1.341 0.814 0 CA-C-N 116.132 -0.485 . . . . 65.2 112.184 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 38.6 m -103.95 20.06 18.87 Favored 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 124.144 0.978 . . . . 61.44 111.177 -179.207 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 78.83 -107.25 2.47 Favored Glycine 0 C--N 1.348 1.206 0 N-CA-C 110.399 -1.08 . . . . 54.0 110.399 -173.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 59.09 -146.31 43.04 Favored Glycine 0 C--N 1.348 1.201 0 O-C-N 123.811 0.36 . . . . 71.4 112.781 179.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 35.3 p -74.68 99.28 3.64 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 123.13 0.572 . . . . 63.52 109.473 172.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -99.49 147.45 18.34 Favored Glycine 0 C--N 1.34 0.792 0 N-CA-C 111.267 -0.733 . . . . 65.24 111.267 176.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -92.61 -140.28 9.61 Favored Glycine 0 C--N 1.345 1.033 0 N-CA-C 111.816 -0.514 . . . . 23.55 111.816 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 32.0 p -77.87 101.87 7.0 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 109.076 -0.712 . . . . 72.15 109.076 176.072 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -76.03 76.83 1.38 Allowed Glycine 0 C--N 1.344 1.003 0 CA-C-N 115.999 -0.546 . . . . 52.41 112.295 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -59.93 -44.9 96.71 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 111.615 -0.594 . . . . 53.51 111.615 177.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 24.6 m -116.11 112.94 22.45 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.289 1.035 . . . . 75.32 108.64 171.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.7 -96.24 0.15 Allowed Glycine 0 C--N 1.351 1.387 0 O-C-N 123.431 0.457 . . . . 72.32 113.037 177.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.51 ' H ' ' HA3' ' A' ' 166' ' ' GLY . 13.7 mtm180 -97.87 130.98 44.74 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 109.323 -0.621 . . . . 62.24 109.323 175.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -103.54 104.24 14.29 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.037 -1.468 . . . . 73.11 107.037 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.538 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.9 mt -93.55 110.26 21.85 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.846 -1.168 . . . . 74.44 107.846 -174.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.449 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 73.6 ttt-85 -107.49 104.53 14.12 Favored 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 108.732 -0.84 . . . . 73.43 108.732 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -121.11 126.93 51.02 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.692 0.797 . . . . 42.21 109.42 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -73.26 118.25 15.99 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 123.54 0.736 . . . . 72.13 109.563 176.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.422 HD21 ' HG2' ' A' ' 136' ' ' ARG . 5.3 tt -100.83 111.15 62.7 Favored Pre-proline 0 CA--C 1.549 0.934 0 C-N-CA 123.938 0.895 . . . . 54.23 108.849 -175.17 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.04 126.03 13.27 Favored 'Trans proline' 0 C--N 1.379 2.168 0 C-N-CA 122.555 2.17 . . . . 60.41 111.43 175.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.474 HD21 HD12 ' A' ' 149' ' ' ILE . 15.9 tp -148.15 133.83 18.87 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.231 -0.655 . . . . 72.02 109.231 -173.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.8 p -87.66 171.62 10.32 Favored 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 118.084 0.402 . . . . 62.45 110.312 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.21 -35.66 81.07 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.595 0.758 . . . . 70.23 111.362 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -63.96 -50.56 68.13 Favored 'General case' 0 C--N 1.35 0.61 0 CA-C-N 114.718 -1.128 . . . . 64.05 109.258 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 22.3 mm-40 -73.7 -24.69 59.97 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-N 114.58 -1.191 . . . . 72.53 111.334 -176.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.493 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.42 -38.91 81.66 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-N 115.212 -0.904 . . . . 71.4 110.345 173.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -72.66 -39.19 67.33 Favored 'General case' 0 CA--C 1.547 0.84 0 CA-C-N 115.473 -0.785 . . . . 71.31 110.423 176.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.71 -48.85 67.95 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 122.34 0.256 . . . . 75.4 111.045 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.588 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.25 59.37 10.98 Favored Glycine 0 C--N 1.345 1.061 0 O-C-N 124.015 0.822 . . . . 35.42 113.567 175.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.426 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -121.69 -155.64 9.51 Favored Glycine 0 C--N 1.34 0.783 0 N-CA-C 111.64 -0.584 . . . . 71.4 111.64 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.619 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.0 mp0 -75.12 122.74 24.05 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 109.929 -0.397 . . . . 72.43 109.929 179.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.442 ' HB2' HD13 ' A' ' 149' ' ' ILE . 12.8 tpt180 -109.59 119.53 39.7 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.391 -1.337 . . . . 64.33 107.391 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 50.7 t -83.1 106.63 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.476 0.71 . . . . 72.42 109.191 -172.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.515 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 33.4 m -116.85 163.24 14.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.887 0 C-N-CA 125.551 1.54 . . . . 64.22 108.806 -177.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -122.84 111.56 16.82 Favored 'General case' 0 N--CA 1.481 1.097 0 O-C-N 121.748 -0.595 . . . . 63.52 110.667 -178.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.664 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.4 p -104.14 109.74 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 125.015 1.326 . . . . 74.34 109.471 -177.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.94 22.39 13.02 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 123.837 0.855 . . . . 52.23 112.76 176.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.95 -13.83 58.88 Favored Glycine 0 C--N 1.352 1.439 0 CA-C-O 120.016 -0.325 . . . . 63.22 113.413 -177.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 26.1 tpt180 -90.72 127.55 36.35 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 123.803 0.841 . . . . 63.12 109.401 177.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 15.5 tpp85 -89.2 130.1 35.67 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.577 -0.527 . . . . 74.32 109.577 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.8 p -147.47 148.98 15.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 C-N-CA 124.193 0.997 . . . . 75.55 109.555 -179.119 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.619 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 42.9 p -101.17 109.27 21.13 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 123.371 0.669 . . . . 63.13 110.156 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.1 p -99.77 124.83 53.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 123.316 0.646 . . . . 63.13 109.37 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 41.5 ttt180 -71.83 127.93 34.13 Favored 'General case' 0 CA--C 1.548 0.892 0 CA-C-O 120.916 0.389 . . . . 74.11 110.494 -178.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.588 HG13 ' HA2' ' A' ' 133' ' ' GLY . 2.7 pt -100.99 147.66 34.01 Favored Pre-proline 0 CA--C 1.558 1.265 0 C-N-CA 124.956 1.302 . . . . 74.02 108.223 174.136 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.11 135.61 19.11 Favored 'Trans proline' 0 CA--C 1.558 1.7 0 C-N-CA 122.36 2.04 . . . . 71.03 112.087 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.81 135.43 48.34 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.407 2.071 . . . . 64.45 111.81 173.187 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 85.19 17.54 62.56 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-N 115.669 -0.696 . . . . 62.03 112.42 -174.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.493 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 11.0 p -73.4 147.44 9.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 N-CA-C 109.273 -0.64 . . . . 73.12 109.273 178.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 56.1 mtp85 -138.89 178.95 6.78 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-O 121.706 0.765 . . . . 64.12 111.587 -173.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.01 120.0 6.76 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 113.348 -1.751 . . . . 72.35 110.578 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 96.23 -10.51 67.51 Favored Glycine 0 C--N 1.341 0.817 0 O-C-N 124.28 0.987 . . . . 50.12 113.797 178.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.3 m -70.3 121.54 17.84 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.416 -0.587 . . . . 74.33 109.416 178.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -105.01 122.45 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 109.41 -0.589 . . . . 74.04 109.41 -178.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.625 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 32.3 mt -91.53 101.95 13.02 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 N-CA-C 107.782 -1.192 . . . . 64.44 107.782 -178.103 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.527 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 48.7 ttp85 -96.02 110.25 22.51 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.889 -0.411 . . . . 53.43 109.889 -176.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.6 t -103.96 96.46 9.39 Favored Pre-proline 0 CA--C 1.552 1.041 0 N-CA-C 107.636 -1.246 . . . . 61.02 107.636 170.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -65.78 127.0 16.96 Favored 'Trans proline' 0 C--N 1.374 1.903 0 C-N-CA 122.815 2.344 . . . . 72.03 112.006 -176.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.9 -23.01 37.71 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-O 119.775 -0.459 . . . . 43.23 113.758 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.0 tpt -76.48 -32.5 58.38 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.255 0.622 . . . . 73.31 111.94 -174.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -65.57 -81.55 0.13 Allowed Glycine 0 CA--C 1.536 1.399 0 O-C-N 123.606 0.566 . . . . 73.12 113.384 -175.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.51 ' HA3' ' H ' ' A' ' 117' ' ' ARG . . . -65.35 92.68 0.15 Allowed Glycine 0 C--N 1.345 1.077 0 C-N-CA 123.017 0.341 . . . . 73.52 113.347 174.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.9 mm-40 -91.2 153.08 20.26 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 124.266 1.027 . . . . 73.55 110.044 170.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 137.44 -62.94 0.58 Allowed Glycine 0 C--N 1.338 0.655 0 N-CA-C 111.203 -0.759 . . . . 54.04 111.203 178.364 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.531 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 24.3 t-20 -155.89 -56.48 0.02 OUTLIER Pre-proline 0 CA--C 1.567 1.601 0 CA-C-O 118.184 -0.912 . . . . 75.23 110.643 179.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.531 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 57.0 Cg_endo -90.04 113.71 0.52 Allowed 'Trans proline' 0 C--N 1.402 3.38 0 C-N-CA 122.769 2.313 . . . . 74.43 110.633 174.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 170' ' ' PRO . 22.9 Cg_exo -64.84 123.09 11.13 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 122.417 2.078 . . . . 71.44 111.059 -176.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -111.53 160.84 13.0 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 120.013 -0.326 . . . . 73.4 112.393 -176.403 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -77.68 139.65 39.47 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.06 0.544 . . . . 63.23 111.159 -174.464 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.553 HD21 HD11 ' A' ' 98' ' ' LEU . 64.2 tp -101.31 126.99 48.12 Favored 'General case' 0 C--O 1.22 -0.458 0 N-CA-C 107.792 -1.188 . . . . 70.42 107.792 171.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.449 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 75.2 mt -127.16 103.18 7.29 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 124.695 1.198 . . . . 74.03 109.118 -175.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.625 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 88.0 mt -100.23 101.47 12.5 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 122.784 0.434 . . . . 72.24 110.02 178.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.1 t -86.81 99.52 8.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 N-CA-C 108.799 -0.815 . . . . 61.21 108.799 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.91 114.26 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 CA-C-N 115.156 -0.929 . . . . 43.25 111.632 -173.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 6.3 mmp_? -99.36 113.16 25.33 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 125.142 1.377 . . . . 53.43 108.528 172.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.429 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 44.3 mt -72.3 127.51 32.78 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.852 -0.425 . . . . 62.13 109.852 175.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.1 mt -83.92 148.54 54.25 Favored Pre-proline 0 C--O 1.242 0.662 0 C-N-CA 123.883 0.873 . . . . 71.24 109.883 178.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.8 172.53 9.41 Favored 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 122.827 2.352 . . . . 70.0 111.831 174.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.533 -0.746 . . . . 75.13 110.163 -177.415 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 64.1 mtt . . . . . 0 N--CA 1.484 1.228 0 CA-C-O 120.533 0.206 . . . . 65.03 111.478 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 35.21 93.47 0.05 OUTLIER Pre-proline 0 CA--C 1.558 1.286 0 C-N-CA 126.803 2.041 . . . . 52.42 114.755 -174.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -66.83 -174.3 0.46 Allowed 'Trans proline' 0 C--N 1.369 1.63 0 C-N-CA 122.617 2.211 . . . . 73.51 111.142 163.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.495 HD11 ' HG ' ' A' ' 123' ' ' LEU . 8.6 tp -72.73 133.47 44.58 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 109.518 -0.549 . . . . 72.51 109.518 176.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.685 HD22 HG23 ' A' ' 138' ' ' VAL . 13.4 tp 73.17 -39.98 0.46 Allowed 'General case' 0 N--CA 1.484 1.255 0 C-N-CA 127.268 2.227 . . . . 74.2 113.077 -176.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -88.12 131.34 34.73 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.141 0.976 . . . . 71.21 111.528 -178.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.531 HG22 HG13 ' A' ' 102' ' ' VAL . 93.6 m -151.29 92.21 3.78 Favored Pre-proline 0 CA--C 1.55 0.964 0 C-N-CA 123.592 0.757 . . . . 71.11 109.823 178.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -74.06 82.23 1.82 Allowed 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.646 2.23 . . . . 53.13 113.302 -168.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.531 HG13 HG22 ' A' ' 100' ' ' THR . 28.6 m -107.66 -165.6 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 123.985 0.914 . . . . 75.45 109.972 178.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.9 t -120.54 -30.46 4.52 Favored 'General case' 0 CA--C 1.546 0.788 0 C-N-CA 123.137 0.575 . . . . 73.22 109.937 171.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.0 tppt? -173.48 150.38 1.8 Allowed 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.015 0.926 . . . . 73.32 109.459 -175.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -164.16 -60.88 0.02 OUTLIER Glycine 0 C--N 1.347 1.17 0 C-N-CA 121.244 -0.503 . . . . 12.33 114.13 -178.51 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 81.8 p -79.32 -50.71 10.45 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 122.793 0.437 . . . . 72.03 111.32 -173.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -179.39 144.51 6.17 Favored Glycine 0 C--N 1.341 0.837 0 C-N-CA 121.621 -0.323 . . . . 54.51 112.944 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -164.58 66.98 0.22 Allowed Glycine 0 C--N 1.346 1.13 0 N-CA-C 110.974 -0.85 . . . . 72.22 110.974 177.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 50.9 m -71.95 98.24 2.01 Favored 'General case' 0 C--O 1.241 0.61 0 C-N-CA 123.502 0.721 . . . . 53.4 110.599 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -179.8 69.46 0.07 OUTLIER Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.393 -1.083 . . . . 54.31 110.393 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -80.06 47.42 3.36 Favored Glycine 0 C--N 1.349 1.301 0 C-N-CA 123.18 0.419 . . . . 64.13 113.704 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.0 m -137.84 21.1 2.86 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 124.483 1.113 . . . . 44.41 109.452 176.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 164.21 -35.05 0.29 Allowed Glycine 0 C--N 1.352 1.436 0 CA-C-N 115.808 -0.633 . . . . 63.41 112.141 -177.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 106.94 -155.33 16.43 Favored Glycine 0 C--N 1.346 1.119 0 C-N-CA 123.113 0.387 . . . . 74.14 112.719 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 50.3 m -151.8 -176.48 5.65 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 123.764 0.826 . . . . 74.31 110.885 -175.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -82.86 173.57 52.48 Favored Glycine 0 C--N 1.354 1.56 0 CA-C-N 116.262 -0.426 . . . . 71.33 113.181 173.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.508 ' HD2' ' H ' ' A' ' 117' ' ' ARG . 0.0 OUTLIER -82.56 139.33 33.9 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.67 0.788 . . . . 74.4 111.038 -177.887 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -101.54 108.78 20.45 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.638 -0.875 . . . . 71.2 108.638 -173.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.429 HD22 ' O ' ' A' ' 100' ' ' THR . 15.2 mt -89.93 110.63 21.58 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 107.796 -1.186 . . . . 63.44 107.796 -169.299 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.2 ttt180 -107.17 109.31 21.1 Favored 'General case' 0 C--N 1.344 0.349 0 N-CA-C 108.997 -0.742 . . . . 54.23 108.997 173.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -126.5 141.97 51.69 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.277 -1.008 . . . . 74.34 108.277 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -74.32 135.06 42.54 Favored 'General case' 0 C--O 1.243 0.73 0 N-CA-C 109.051 -0.722 . . . . 72.35 109.051 173.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.495 ' HG ' HD11 ' A' ' 97' ' ' LEU . 1.9 tt -100.83 103.11 22.51 Favored Pre-proline 0 CA--C 1.543 0.708 0 N-CA-C 107.929 -1.138 . . . . 75.41 107.929 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.423 ' HB2' HD11 ' A' ' 181' ' ' LEU . 52.1 Cg_endo -67.83 115.48 3.79 Favored 'Trans proline' 0 C--N 1.376 2.013 0 C-N-CA 122.49 2.126 . . . . 70.41 110.052 174.439 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.603 HD21 HD12 ' A' ' 149' ' ' ILE . 17.0 tp -137.6 135.31 36.48 Favored 'General case' 0 N--CA 1.468 0.442 0 N-CA-C 109.074 -0.713 . . . . 71.41 109.074 -169.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.0 p -77.28 164.58 25.44 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 118.76 0.709 . . . . 54.43 110.581 178.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.5 mt -63.28 -30.91 71.96 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 123.728 0.811 . . . . 64.22 111.877 -177.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -75.0 -46.95 31.67 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.561 0.745 . . . . 71.14 110.13 -178.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 73.3 mm-40 -60.62 -35.69 76.78 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 123.911 0.757 . . . . 73.21 111.048 176.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.51 -51.63 61.98 Favored 'General case' 0 CA--C 1.54 0.575 0 O-C-N 124.099 0.874 . . . . 34.32 111.21 174.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -58.04 -50.82 72.1 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.928 1.291 . . . . 74.33 111.688 -176.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 56.1 m80 -78.18 -41.18 35.46 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.819 -0.628 . . . . 74.33 109.881 -176.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 73.94 -167.86 54.37 Favored Glycine 0 C--N 1.352 1.451 0 CA-C-N 116.03 -0.532 . . . . 72.15 112.072 -173.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.472 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 122.85 -165.08 15.57 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 111.766 -0.534 . . . . 44.45 111.766 177.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.453 ' HA ' ' HA ' ' A' ' 148' ' ' ARG . 1.5 mp0 -84.78 125.71 32.8 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 121.125 0.488 . . . . 75.02 110.304 178.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 tpp180 -112.88 122.37 47.44 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.929 1.291 . . . . 75.14 107.92 175.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.4 t -101.86 106.93 20.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 N-CA-C 109.334 -0.617 . . . . 60.22 109.334 -171.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.685 HG23 HD22 ' A' ' 98' ' ' LEU . 30.0 m -124.46 153.52 31.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 124.298 1.039 . . . . 74.14 108.835 -175.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -107.03 132.56 52.82 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 122.592 0.357 . . . . 74.55 111.517 -171.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.1 p -113.26 104.8 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 125.21 1.404 . . . . 65.22 109.881 176.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.67 15.54 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 113.187 0.81 . . . . 70.42 113.187 173.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.0 8.73 47.24 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.908 -0.385 . . . . 45.4 113.696 -178.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 7.2 tpp180 -115.72 116.39 27.99 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.336 0.655 . . . . 72.42 109.238 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -87.1 106.38 17.83 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.071 0.548 . . . . 73.53 109.879 -173.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 78.4 t -112.87 133.96 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 C-N-CA 124.228 1.011 . . . . 71.12 110.729 -176.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 45.5 t -92.1 104.48 16.87 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.55 0.74 . . . . 75.01 109.951 175.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.587 HG21 HD12 ' A' ' 176' ' ' LEU . 6.3 p -99.99 122.38 51.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 123.65 0.78 . . . . 72.4 110.181 175.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 135' ' ' GLU . 61.1 ttt180 -77.09 112.18 13.48 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.673 0.389 . . . . 71.25 110.086 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.603 HD12 HD21 ' A' ' 125' ' ' LEU . 4.4 pt -77.94 138.4 61.43 Favored Pre-proline 0 CA--C 1.56 1.36 0 C-N-CA 123.794 0.838 . . . . 43.2 109.212 170.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -60.0 136.8 71.86 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.911 2.407 . . . . 75.13 113.271 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -61.59 113.05 1.64 Allowed 'Trans proline' 0 C--N 1.375 1.95 0 C-N-CA 122.776 2.318 . . . . 62.41 111.585 171.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 79.89 39.76 16.17 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.051 -0.522 . . . . 73.42 112.076 -173.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.415 HG21 HG21 ' A' ' 178' ' ' VAL . 12.6 p -75.46 145.32 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 N-CA-C 109.399 -0.593 . . . . 71.14 109.399 175.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -112.62 173.1 6.54 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 121.472 0.653 . . . . 73.2 112.009 -173.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -63.77 133.97 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 113.927 -1.488 . . . . 60.12 111.107 178.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 91.36 -21.65 33.99 Favored Glycine 0 C--N 1.349 1.263 0 CA-C-N 115.833 -0.622 . . . . 42.25 113.583 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 72.7 m -63.66 121.52 14.13 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 123.695 0.798 . . . . 73.43 111.876 -172.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.4 p -95.39 125.29 48.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 CA-C-O 121.302 0.572 . . . . 70.31 110.268 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 54.0 mt -93.73 115.23 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 124.355 1.062 . . . . 71.22 108.29 -178.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 80.4 ttt180 -101.26 119.94 39.51 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 122.848 0.459 . . . . 72.52 110.497 -176.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -117.4 99.31 52.52 Favored Pre-proline 0 CA--C 1.552 1.045 0 N-CA-C 107.574 -1.269 . . . . 60.01 107.574 169.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -60.77 138.81 81.85 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 122.791 2.328 . . . . 72.32 113.913 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.6 5.13 72.58 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 115.07 -0.968 . . . . 63.02 115.094 175.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 13.6 tpt -101.99 -16.0 16.62 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-N 117.638 0.719 . . . . 70.41 112.359 -170.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -73.82 -81.72 0.41 Allowed Glycine 0 CA--C 1.529 0.938 0 CA-C-O 120.154 -0.248 . . . . 60.2 112.769 178.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -60.39 93.78 0.07 OUTLIER Glycine 0 C--N 1.352 1.42 0 C-N-CA 123.1 0.381 . . . . 54.23 112.95 172.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -91.98 171.01 9.4 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.495 1.118 . . . . 73.04 111.46 175.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 113.76 -65.68 0.27 Allowed Glycine 0 C--N 1.345 1.046 0 CA-C-N 115.579 -0.737 . . . . 43.12 111.792 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.432 ' H ' ' CD ' ' A' ' 170' ' ' PRO . 3.3 p-10 -168.62 -32.35 0.0 OUTLIER Pre-proline 0 CA--C 1.565 1.554 0 CA-C-O 117.48 -1.248 . . . . 73.31 112.66 -179.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.432 ' CD ' ' H ' ' A' ' 169' ' ' ASN . 62.6 Cg_endo -92.32 106.81 0.22 Allowed 'Trans proline' 0 C--N 1.403 3.442 0 CA-C-N 122.37 1.882 . . . . 73.21 110.611 168.171 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_exo -66.16 124.85 13.14 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.277 1.984 . . . . 73.02 111.811 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -120.96 155.95 16.19 Favored Glycine 0 C--N 1.335 0.508 0 N-CA-C 110.25 -1.14 . . . . 51.31 110.25 172.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -76.81 162.69 27.45 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.687 0.795 . . . . 71.13 111.033 -173.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.515 HD21 HD11 ' A' ' 98' ' ' LEU . 55.9 tp -122.6 130.58 53.16 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.047 0.539 . . . . 74.43 109.795 177.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.2 mt -127.41 128.77 46.36 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 124.805 1.242 . . . . 64.2 109.05 177.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.587 HD12 HG21 ' A' ' 147' ' ' VAL . 88.0 mt -129.17 102.31 6.41 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.198 0.599 . . . . 62.33 110.948 178.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.0 t -85.69 99.32 7.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.66 0 N-CA-C 109.563 -0.532 . . . . 73.31 109.563 -173.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.415 HG21 HG21 ' A' ' 153' ' ' VAL . 96.7 t -56.14 114.51 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 124.344 1.058 . . . . 71.14 111.907 -178.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.4 mmt180 -113.09 102.6 10.55 Favored 'General case' 0 C--O 1.239 0.517 0 C-N-CA 124.77 1.228 . . . . 75.4 108.598 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 68.6 mt -70.28 116.93 11.2 Favored 'General case' 0 C--O 1.239 0.522 0 CA-C-N 115.256 -0.884 . . . . 72.21 110.962 -177.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.423 HD11 ' HB2' ' A' ' 124' ' ' PRO . 58.0 mt -77.26 146.75 75.05 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 115.416 -0.811 . . . . 74.14 110.378 -177.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -60.64 115.05 2.42 Favored 'Trans proline' 0 C--N 1.373 1.817 0 C-N-CA 123.279 2.653 . . . . 72.51 111.873 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 . . . . . 0 C--O 1.249 1.073 0 N-CA-C 109.331 -0.618 . . . . 63.02 109.331 -179.856 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 26.6 ptt? . . . . . 0 N--CA 1.484 1.262 0 N-CA-C 110.572 -0.158 . . . . 70.03 110.572 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 3.4 pp -45.51 130.12 6.31 Favored Pre-proline 0 CA--C 1.566 1.587 0 C-N-CA 124.761 1.224 . . . . 74.24 112.341 168.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -69.87 -164.05 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 123.611 2.874 . . . . 62.41 113.433 168.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.73 HD13 ' HD2' ' A' ' 124' ' ' PRO . 0.6 OUTLIER -60.31 -46.56 89.44 Favored 'General case' 0 N--CA 1.483 1.203 0 C-N-CA 124.446 1.098 . . . . 70.34 112.031 -179.009 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.521 HD22 ' HB ' ' A' ' 140' ' ' VAL . 3.9 tt -139.19 90.04 2.39 Favored 'General case' 0 C--O 1.211 -0.962 0 N-CA-C 108.04 -1.096 . . . . 71.54 108.04 173.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 73.5 t80 172.5 107.05 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 125.518 1.527 . . . . 61.24 107.373 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.551 HG22 HG13 ' A' ' 102' ' ' VAL . 93.9 m -127.79 94.64 36.77 Favored Pre-proline 0 C--O 1.239 0.511 0 N-CA-C 109.763 -0.458 . . . . 44.33 109.763 -178.001 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -70.1 85.28 0.67 Allowed 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 122.556 2.17 . . . . 73.21 112.293 -175.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.551 HG13 HG22 ' A' ' 100' ' ' THR . 22.6 m -98.06 150.12 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 C-N-CA 124.001 0.92 . . . . 74.02 109.582 174.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -95.99 143.56 27.06 Favored 'General case' 0 C--O 1.246 0.89 0 N-CA-C 108.327 -0.99 . . . . 74.24 108.327 171.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 17.2 tppt? -77.91 108.83 11.44 Favored 'General case' 0 C--O 1.241 0.625 0 N-CA-C 110.113 -0.328 . . . . 71.04 110.113 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -70.08 99.48 0.71 Allowed Glycine 0 C--N 1.345 1.08 0 N-CA-C 109.71 -1.356 . . . . 73.0 109.71 168.41 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 21.1 t -66.27 -21.76 66.29 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.635 0.774 . . . . 72.51 111.605 -174.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -99.72 30.06 10.78 Favored Glycine 0 C--N 1.349 1.291 0 C-N-CA 123.11 0.386 . . . . 75.33 112.315 173.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -72.82 -71.87 1.03 Allowed Glycine 0 C--N 1.358 1.8 0 CA-C-O 119.972 -0.349 . . . . 72.41 113.398 -176.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 81.0 p -162.78 15.91 0.08 Allowed 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 123.329 0.652 . . . . 61.5 111.733 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 75.62 86.55 0.31 Allowed Glycine 0 C--N 1.353 1.511 0 CA-C-O 120.039 -0.312 . . . . 54.23 112.553 -177.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -74.26 91.27 0.73 Allowed Glycine 0 C--N 1.352 1.462 0 N-CA-C 111.553 -0.619 . . . . 63.0 111.553 178.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 17.5 m -63.57 98.9 0.19 Allowed 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 124.592 1.157 . . . . 72.43 113.035 -171.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 80.64 -70.64 2.98 Favored Glycine 0 C--N 1.343 0.966 0 CA-C-N 115.753 -0.658 . . . . 64.31 113.362 172.295 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -84.13 -150.05 10.63 Favored Glycine 0 N--CA 1.471 1.003 0 CA-C-O 119.937 -0.368 . . . . 62.45 112.473 177.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.1 t 63.09 77.45 0.33 Allowed 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.406 1.082 . . . . 73.32 111.507 178.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.425 ' H ' ' HA2' ' A' ' 172' ' ' GLY . . . -84.79 -102.28 0.63 Allowed Glycine 0 CA--C 1.521 0.437 0 CA-C-N 114.59 -1.186 . . . . 40.34 111.003 174.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.449 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 12.5 mmm-85 -97.63 117.89 32.93 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 107.952 -1.129 . . . . 62.41 107.952 174.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.7 m-20 -96.69 104.44 16.43 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.458 -0.941 . . . . 64.13 108.458 -171.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.453 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.1 mt -92.39 111.48 23.07 Favored 'General case' 0 C--N 1.344 0.344 0 N-CA-C 107.917 -1.142 . . . . 75.24 107.917 -172.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -110.08 105.58 14.75 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 108.686 -0.857 . . . . 43.25 108.686 174.081 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.13 160.92 35.81 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 123.929 0.892 . . . . 70.14 109.6 -176.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 88.7 mt-10 -99.79 136.39 39.79 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 123.437 0.695 . . . . 73.1 110.12 -173.015 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.614 ' HA ' HD13 ' A' ' 97' ' ' LEU . 1.6 tt -105.05 101.33 29.49 Favored Pre-proline 0 CA--C 1.545 0.75 0 C-N-CA 124.247 1.019 . . . . 63.23 108.759 -176.14 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.73 ' HD2' HD13 ' A' ' 97' ' ' LEU . 30.2 Cg_endo -62.74 120.04 7.38 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.478 2.119 . . . . 74.01 110.285 170.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.624 HD21 HD12 ' A' ' 149' ' ' ILE . 15.2 tp -145.89 135.7 23.43 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.948 0.499 . . . . 54.43 109.664 -172.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.3 p -88.24 168.8 12.41 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.974 0.51 . . . . 64.31 110.72 -178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 72.2 mt -63.08 -36.99 85.43 Favored 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 123.395 0.678 . . . . 62.13 111.928 -177.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -63.55 -54.77 30.93 Favored 'General case' 0 N--CA 1.475 0.811 0 O-C-N 123.953 0.783 . . . . 61.3 108.983 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -64.19 -34.18 77.5 Favored 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 114.759 -1.109 . . . . 62.44 111.699 -177.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.41 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -59.9 -49.62 76.96 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 124.218 0.949 . . . . 65.22 110.475 175.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -69.61 -34.71 74.47 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 115.008 -0.996 . . . . 73.21 111.129 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.5 m80 -66.77 -47.08 73.3 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.833 0.453 . . . . 63.41 110.57 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.52 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 66.3 41.03 94.85 Favored Glycine 0 C--N 1.343 0.926 0 CA-C-N 115.532 -0.758 . . . . 73.43 112.648 -174.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -84.39 -163.9 36.87 Favored Glycine 0 C--N 1.347 1.162 0 O-C-N 123.904 0.414 . . . . 42.14 112.984 -178.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 6.4 mp0 -85.44 144.67 27.85 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.437 -0.579 . . . . 72.35 109.437 170.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.589 ' HG2' HD21 ' A' ' 123' ' ' LEU . 11.0 tpt180 -125.69 120.32 30.39 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 123.935 0.894 . . . . 61.44 108.621 -177.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.4 p -81.44 123.53 37.94 Favored 'Isoleucine or valine' 0 C--O 1.24 0.573 0 N-CA-C 109.373 -0.602 . . . . 65.24 109.373 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.441 HG12 HD21 ' A' ' 97' ' ' LEU . 27.2 m -138.25 162.49 30.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 C-N-CA 125.02 1.328 . . . . 53.11 108.54 179.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -119.83 129.28 54.35 Favored 'General case' 0 N--CA 1.479 1.019 0 O-C-N 122.053 -0.405 . . . . 74.23 110.644 -178.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.521 ' HB ' HD22 ' A' ' 98' ' ' LEU . 5.3 p -119.89 113.63 41.4 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.599 1.159 . . . . 74.35 110.045 175.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 56.35 33.27 22.03 Favored 'General case' 0 N--CA 1.487 1.425 0 C-N-CA 123.782 0.833 . . . . 64.21 112.389 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.29 19.28 59.09 Favored Glycine 0 C--N 1.351 1.413 0 CA-C-N 115.858 -0.61 . . . . 41.22 113.638 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 75.9 mtp180 -125.42 125.61 43.65 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 123.722 0.809 . . . . 62.21 110.198 -176.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.3 ttp180 -73.51 120.33 18.97 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 122.904 0.482 . . . . 74.11 110.734 178.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 20.5 m -125.24 141.22 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.716 0.807 . . . . 64.24 109.77 170.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.9 p -106.62 111.71 24.38 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.817 0.847 . . . . 73.53 109.353 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -101.08 130.75 50.0 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 123.716 0.806 . . . . 62.54 110.083 178.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 39.0 ttt180 -81.6 114.3 20.2 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.494 -0.928 . . . . 71.32 108.494 178.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.624 HD12 HD21 ' A' ' 125' ' ' LEU . 5.2 pt -84.51 146.39 47.07 Favored Pre-proline 0 CA--C 1.554 1.132 0 C-N-CA 123.844 0.858 . . . . 65.41 109.469 177.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.433 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 25.1 Cg_exo -66.4 141.76 63.12 Favored 'Trans proline' 0 CA--C 1.562 1.894 0 C-N-CA 122.826 2.351 . . . . 74.34 112.922 177.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 22.4 Cg_exo -67.92 127.95 16.97 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 123.127 2.551 . . . . 61.52 111.496 172.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 74.71 26.34 67.54 Favored Glycine 0 CA--C 1.53 1.009 0 O-C-N 123.783 0.677 . . . . 45.22 113.317 -175.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.41 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 12.6 p -71.71 146.37 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 117.421 0.61 . . . . 74.44 110.735 -178.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.497 ' HA ' HD11 ' A' ' 180' ' ' LEU . 29.7 mtp-105 -120.99 173.22 7.39 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 121.888 0.851 . . . . 73.24 112.571 -170.064 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -64.45 120.83 13.03 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 113.292 -1.776 . . . . 73.34 109.961 174.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 104.34 -23.61 31.28 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-O 119.407 -0.663 . . . . 72.32 112.965 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 58.5 m -64.25 121.08 13.4 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 123.061 0.544 . . . . 73.4 110.458 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.2 p -102.39 127.49 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 CA-C-O 121.26 0.552 . . . . 73.03 110.022 -179.102 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.44 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 54.6 mt -92.64 101.1 12.25 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 107.829 -1.174 . . . . 72.43 107.829 -179.389 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -86.99 110.04 19.78 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.657 -0.498 . . . . 64.33 109.657 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.458 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 12.6 t -111.19 93.54 18.57 Favored Pre-proline 0 CA--C 1.555 1.163 0 N-CA-C 107.685 -1.228 . . . . 45.45 107.685 173.034 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.13 122.29 7.06 Favored 'Trans proline' 0 C--N 1.369 1.618 0 C-N-CA 122.441 2.094 . . . . 71.13 112.207 -177.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.39 -20.91 36.36 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-N 116.537 -0.301 . . . . 63.41 113.476 177.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.41 ' HB2' HG12 ' A' ' 161' ' ' VAL . 86.1 mmm -104.62 16.16 26.59 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 123.398 0.679 . . . . 73.21 112.081 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.59 -101.93 0.54 Allowed Glycine 0 C--N 1.345 1.061 0 CA-C-O 119.664 -0.52 . . . . 72.32 111.931 172.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.449 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -68.84 102.78 0.95 Allowed Glycine 0 C--N 1.349 1.299 0 CA-C-N 116.93 0.365 . . . . 74.21 112.313 177.087 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 7.5 mm-40 -89.27 157.82 18.07 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 124.151 0.981 . . . . 71.14 110.075 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 147.77 -66.39 0.4 Allowed Glycine 0 C--N 1.344 1.014 0 N-CA-C 110.758 -0.937 . . . . 45.12 110.758 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.405 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 36.2 t30 -159.12 -54.12 0.01 OUTLIER Pre-proline 0 CA--C 1.562 1.429 0 C-N-CA 124.291 1.036 . . . . 73.15 110.122 178.653 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.405 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 80.5 Cg_endo -85.37 110.54 1.23 Allowed 'Trans proline' 0 C--N 1.399 3.231 0 C-N-CA 121.594 1.53 . . . . 74.11 110.505 171.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.82 123.28 11.12 Favored 'Trans proline' 0 C--N 1.383 2.381 0 C-N-CA 122.163 1.909 . . . . 75.21 110.996 -174.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.425 ' HA2' ' H ' ' A' ' 116' ' ' GLY . . . -96.1 163.08 23.07 Favored Glycine 0 C--N 1.338 0.642 0 O-C-N 123.649 0.593 . . . . 71.32 111.912 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -84.36 152.39 24.12 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 108.791 -0.818 . . . . 70.52 108.791 -179.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.458 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 57.6 tp -120.68 132.0 54.86 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.957 0.503 . . . . 71.45 109.744 178.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 84.1 mt -128.39 103.33 7.09 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 124.189 0.996 . . . . 74.34 109.153 177.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.473 HD21 ' HG ' ' A' ' 98' ' ' LEU . 86.8 mt -102.51 101.2 11.37 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 121.04 0.447 . . . . 65.42 110.369 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.1 t -83.96 99.55 6.53 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 108.621 -0.881 . . . . 62.34 108.621 -176.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 97.5 t -59.32 117.42 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 123.919 0.888 . . . . 73.22 111.455 -177.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -100.95 105.23 16.45 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-N 114.466 -1.243 . . . . 63.35 108.389 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.497 HD11 ' HA ' ' A' ' 154' ' ' ARG . 30.3 mt -69.28 108.77 3.8 Favored 'General case' 0 C--N 1.348 0.511 0 N-CA-C 109.128 -0.693 . . . . 71.03 109.128 174.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.4 mt -68.56 159.0 83.62 Favored Pre-proline 0 CA--C 1.544 0.72 0 CA-C-N 115.057 -0.974 . . . . 73.05 110.45 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -74.12 51.91 2.56 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 123.533 2.822 . . . . 61.23 112.764 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.5 t-80 . . . . . 0 C--O 1.255 1.347 0 C-N-CA 124.697 1.199 . . . . 75.12 107.962 177.304 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 22.3 ptm . . . . . 0 N--CA 1.483 1.218 0 N-CA-C 110.136 -0.32 . . . . 71.22 110.136 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -56.57 123.8 59.01 Favored Pre-proline 0 CA--C 1.555 1.145 0 C-N-CA 124.116 0.966 . . . . 71.54 111.56 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.444 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 97.5 Cg_endo -81.67 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.922 2.414 . . . . 74.44 111.3 166.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.519 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.1 tp -81.83 139.99 34.43 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.261 0.624 . . . . 74.13 110.254 -179.48 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.676 HD22 HG23 ' A' ' 138' ' ' VAL . 19.3 tp 64.63 -13.06 0.11 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 127.031 2.132 . . . . 75.31 113.606 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.444 ' HB3' ' HG2' ' A' ' 96' ' ' PRO . 47.3 t80 -119.78 122.07 40.57 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 124.376 1.07 . . . . 73.32 108.91 -173.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.515 HG22 HG13 ' A' ' 102' ' ' VAL . 85.7 m -135.36 90.25 21.07 Favored Pre-proline 0 C--O 1.235 0.329 0 C-N-CA 123.739 0.816 . . . . 72.41 108.804 -178.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -65.85 93.61 0.27 Allowed 'Trans proline' 0 C--N 1.372 1.769 0 C-N-CA 121.6 1.533 . . . . 63.4 112.027 -174.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 100' ' ' THR . 27.4 m -123.66 168.5 16.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 C-N-CA 125.266 1.427 . . . . 70.43 109.375 177.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.408 ' OG1' ' HA3' ' A' ' 114' ' ' GLY . 10.0 t -148.88 143.13 26.05 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 107.62 -1.252 . . . . 54.34 107.62 173.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 21.8 ttmt -81.46 71.41 8.46 Favored 'General case' 0 N--CA 1.48 1.064 0 CA-C-O 121.865 0.841 . . . . 71.24 109.595 -175.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 73.38 -175.22 46.51 Favored Glycine 0 C--N 1.351 1.376 0 CA-C-N 114.622 -1.172 . . . . 72.34 111.917 -169.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 50.5 m -75.4 -34.7 61.08 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 108.963 -0.754 . . . . 71.12 108.963 167.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -174.01 82.64 0.08 OUTLIER Glycine 0 C--N 1.342 0.903 0 N-CA-C 109.734 -1.347 . . . . 72.44 109.734 178.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -63.38 89.74 0.07 OUTLIER Glycine 0 C--N 1.35 1.341 0 O-C-N 123.921 0.424 . . . . 71.13 113.333 -174.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 23.2 t 54.14 38.12 28.48 Favored 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 124.351 1.06 . . . . 74.52 110.61 -175.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 98.4 -119.48 6.47 Favored Glycine 0 C--N 1.344 1.015 0 CA-C-N 114.899 -1.046 . . . . 72.23 110.807 -173.107 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 60.58 35.51 89.43 Favored Glycine 0 C--N 1.356 1.647 0 O-C-N 124.324 0.661 . . . . 73.15 113.11 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 40.3 m 66.6 -2.83 0.98 Allowed 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 125.029 1.332 . . . . 61.52 113.735 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 128.42 -143.88 14.8 Favored Glycine 0 C--N 1.342 0.878 0 N-CA-C 110.625 -0.99 . . . . 43.05 110.625 -169.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.408 ' HA3' ' OG1' ' A' ' 103' ' ' THR . . . -90.3 57.66 3.53 Favored Glycine 0 C--N 1.342 0.908 0 N-CA-C 111.79 -0.524 . . . . 75.41 111.79 176.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 69.8 m -78.38 157.15 29.15 Favored 'General case' 0 C--O 1.24 0.554 0 C-N-CA 123.978 0.911 . . . . 54.42 112.212 -173.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 64.07 58.74 9.85 Favored Glycine 0 C--N 1.352 1.45 0 O-C-N 123.918 0.761 . . . . 73.22 112.187 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.614 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 46.7 mtt-85 -69.84 132.08 45.48 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.297 0.639 . . . . 72.12 109.882 -176.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -99.29 105.02 16.98 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 106.469 -1.678 . . . . 63.45 106.469 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.494 HD22 ' O ' ' A' ' 100' ' ' THR . 12.6 mt -88.33 106.93 18.55 Favored 'General case' 0 C--N 1.345 0.378 0 N-CA-C 105.78 -1.933 . . . . 70.21 105.78 -177.309 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.4 ttm-85 -106.91 102.3 11.67 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.824 -1.176 . . . . 75.33 107.824 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -125.45 136.04 52.97 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 108.125 -1.065 . . . . 62.32 108.125 -175.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -82.86 129.37 34.99 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.853 -0.612 . . . . 70.14 109.732 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.52 HD12 HD13 ' A' ' 176' ' ' LEU . 2.2 tt -101.18 105.05 36.93 Favored Pre-proline 0 CA--C 1.55 0.949 0 C-N-CA 123.681 0.792 . . . . 63.51 109.558 -172.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.579 ' HB2' HD11 ' A' ' 181' ' ' LEU . 33.9 Cg_endo -61.48 116.22 3.27 Favored 'Trans proline' 0 C--N 1.378 2.089 0 C-N-CA 122.958 2.439 . . . . 71.31 111.213 170.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.49 HD21 HD12 ' A' ' 149' ' ' ILE . 30.9 tp -145.61 124.53 12.73 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 123.77 0.828 . . . . 64.22 109.026 -170.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.1 p -75.49 168.24 20.38 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 122.538 0.335 . . . . 74.33 110.978 -175.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 74.7 mt -63.22 -37.36 86.92 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.642 0.777 . . . . 74.34 110.901 178.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 24.7 mp0 -64.19 -52.36 59.29 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.95 1.3 . . . . 61.31 110.136 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 44.7 mm-40 -69.75 -32.71 71.39 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.456 -0.793 . . . . 51.54 111.43 -177.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.57 -45.28 93.64 Favored 'General case' 0 C--N 1.349 0.582 0 O-C-N 123.87 0.731 . . . . 65.42 110.269 174.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -66.14 -39.35 89.78 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.377 1.071 . . . . 73.22 110.641 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 30.0 m80 -61.98 -47.43 84.87 Favored 'General case' 0 C--N 1.358 0.945 0 O-C-N 123.717 0.636 . . . . 72.52 110.447 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.429 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.08 52.78 47.6 Favored Glycine 0 C--N 1.352 1.427 0 O-C-N 124.046 0.841 . . . . 74.03 112.516 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -106.41 -141.82 10.52 Favored Glycine 0 C--N 1.339 0.712 0 N-CA-C 111.531 -0.628 . . . . 63.12 111.531 177.673 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.586 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 3.9 mp0 -93.68 148.87 21.71 Favored 'General case' 0 C--O 1.24 0.577 0 N-CA-C 108.261 -1.014 . . . . 63.23 108.261 169.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.463 ' HG3' HG13 ' A' ' 138' ' ' VAL . 40.5 tpt85 -123.31 117.68 25.8 Favored 'General case' 0 N--CA 1.463 0.18 0 N-CA-C 107.441 -1.318 . . . . 55.33 107.441 177.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.5 t -86.21 106.0 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 109.165 -0.679 . . . . 74.02 109.165 -174.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.676 HG23 HD22 ' A' ' 98' ' ' LEU . 33.1 m -125.91 157.79 35.51 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 C-N-CA 124.93 1.292 . . . . 74.12 108.342 -178.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -113.65 120.29 40.39 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 118.534 0.606 . . . . 62.45 111.382 -173.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 6.4 p -105.61 104.6 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.757 0.823 . . . . 74.44 109.665 173.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.22 29.6 18.81 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.354 0.661 . . . . 53.11 112.384 172.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.35 -14.23 58.17 Favored Glycine 0 N--CA 1.475 1.287 0 N-CA-C 113.705 0.242 . . . . 54.24 113.705 -178.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -92.78 117.65 30.24 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.027 -0.731 . . . . 70.31 109.027 -178.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 26.5 ttm180 -88.76 105.93 18.02 Favored 'General case' 0 CA--C 1.547 0.845 0 N-CA-C 108.808 -0.812 . . . . 72.15 108.808 -173.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.57 128.87 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 124.214 1.005 . . . . 73.32 110.797 -175.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.586 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 51.0 p -90.14 107.43 19.13 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 123.841 0.857 . . . . 45.52 109.699 173.213 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.81 130.1 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 C-N-CA 123.721 0.808 . . . . 53.33 109.995 -178.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 75.8 ttt180 -78.82 113.97 17.35 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-O 121.555 0.693 . . . . 73.43 110.547 -174.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.49 HD12 HD21 ' A' ' 125' ' ' LEU . 4.5 pt -90.25 142.22 28.29 Favored Pre-proline 0 CA--C 1.56 1.358 0 C-N-CA 124.93 1.292 . . . . 62.04 109.772 178.501 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -69.34 142.91 51.13 Favored 'Trans proline' 0 CA--C 1.564 2.018 0 C-N-CA 122.156 1.904 . . . . 50.34 112.849 174.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -70.59 127.92 14.58 Favored 'Trans proline' 0 C--N 1.381 2.242 0 C-N-CA 122.832 2.355 . . . . 74.41 111.475 174.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 82.72 23.41 56.03 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.657 -0.701 . . . . 72.45 113.416 -174.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.2 p -74.5 150.22 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.926 0.49 . . . . 73.04 110.185 178.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -131.64 178.55 6.66 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 121.83 0.824 . . . . 74.01 112.6 -169.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.82 131.46 50.96 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 113.389 -1.732 . . . . 72.54 111.412 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.55 -8.05 70.35 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-O 119.464 -0.631 . . . . 23.03 113.357 177.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 49.3 m -72.43 119.23 16.35 Favored 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.848 -0.797 . . . . 72.25 108.848 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -100.67 134.27 41.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.286 0.634 . . . . 64.42 109.747 -175.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.471 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 47.4 mt -106.9 103.43 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 124.224 1.01 . . . . 74.25 108.35 -176.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.455 HH21 HD11 ' A' ' 175' ' ' LEU . 30.2 ttm180 -87.29 111.21 20.82 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 123.134 0.574 . . . . 74.01 109.959 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.91 102.95 53.96 Favored Pre-proline 0 CA--C 1.554 1.106 0 N-CA-C 108.336 -0.987 . . . . 72.33 108.336 173.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -68.83 139.43 43.53 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 122.909 2.406 . . . . 72.31 112.52 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 81.31 -8.41 58.32 Favored Glycine 0 CA--C 1.534 1.254 0 CA-C-O 119.575 -0.569 . . . . 64.25 114.446 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.0 mtt -113.35 17.58 18.4 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 117.944 0.872 . . . . 75.11 111.22 -174.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -92.96 -107.04 1.76 Allowed Glycine 0 C--N 1.347 1.19 0 CA-C-O 119.508 -0.607 . . . . 72.02 112.066 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.614 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -64.85 90.48 0.1 OUTLIER Glycine 0 C--N 1.355 1.599 0 CA-C-N 116.937 0.369 . . . . 72.13 112.78 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -79.66 147.71 31.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.496 0.719 . . . . 74.22 111.165 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 157.09 -124.81 1.48 Allowed Glycine 0 C--N 1.342 0.885 0 N-CA-C 110.001 -1.24 . . . . 74.03 110.001 -176.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.406 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 2.0 m-20 -85.16 -50.61 0.54 Allowed Pre-proline 0 CA--C 1.563 1.463 0 CA-C-O 118.63 -0.7 . . . . 74.1 110.004 169.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.406 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -99.66 103.76 0.05 OUTLIER 'Trans proline' 0 C--N 1.395 2.995 0 C-N-CA 123.317 2.678 . . . . 53.43 112.434 177.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -61.52 123.19 12.26 Favored 'Trans proline' 0 C--N 1.377 2.056 0 C-N-CA 122.293 1.996 . . . . 74.31 111.369 -177.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -94.29 -171.63 38.2 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 116.179 -0.464 . . . . 74.55 112.977 -176.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -99.65 144.85 28.25 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 123.113 0.565 . . . . 70.41 110.28 -177.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.567 HD21 HD11 ' A' ' 98' ' ' LEU . 46.8 tp -109.9 129.49 55.65 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.425 0.69 . . . . 65.1 109.174 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.455 HD11 HH21 ' A' ' 160' ' ' ARG . 88.9 mt -128.85 109.33 11.18 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.887 0.875 . . . . 51.5 109.793 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.52 HD13 HD12 ' A' ' 123' ' ' LEU . 83.6 mt -110.19 102.99 11.63 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.056 0.542 . . . . 74.33 111.713 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.88 94.56 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.941 0 C-N-CA 123.322 0.649 . . . . 75.23 109.904 -176.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 84.7 t -54.39 114.76 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 124.105 0.962 . . . . 72.34 112.054 -179.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 29.8 mmt180 -98.29 115.24 27.99 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.116 1.366 . . . . 73.04 108.406 172.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 66.7 mt -70.31 114.41 8.41 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 120.689 0.281 . . . . 75.31 110.5 178.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.579 HD11 ' HB2' ' A' ' 124' ' ' PRO . 45.2 mt -89.96 156.9 46.56 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 123.568 0.747 . . . . 55.34 110.825 175.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -71.18 -162.85 0.11 Allowed 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 123.041 2.494 . . . . 61.2 112.286 168.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 6.7 p80 . . . . . 0 CA--C 1.553 1.091 0 C-N-CA 123.811 0.844 . . . . 71.01 109.16 -177.868 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 84.4 mtp . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 110.006 -0.368 . . . . 75.21 110.006 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 37.24 96.33 0.04 OUTLIER Pre-proline 0 CA--C 1.559 1.326 0 C-N-CA 126.285 1.834 . . . . 74.3 114.168 -178.03 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.455 ' HD2' ' HB3' ' A' ' 99' ' ' PHE . 13.0 Cg_exo -70.91 -161.5 0.09 OUTLIER 'Trans proline' 0 C--N 1.375 1.969 0 C-N-CA 122.698 2.265 . . . . 75.42 111.989 171.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.674 HD13 ' HD2' ' A' ' 124' ' ' PRO . 1.1 tp -58.19 -42.85 87.03 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 124.107 0.963 . . . . 73.42 112.569 -175.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.401 HD22 ' HB ' ' A' ' 140' ' ' VAL . 1.7 tt -141.06 96.52 3.01 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 107.801 -1.185 . . . . 74.31 107.801 171.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.455 ' HB3' ' HD2' ' A' ' 96' ' ' PRO . 53.7 t80 165.36 119.6 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 126.518 1.927 . . . . 72.45 107.431 172.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.574 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 32.7 m -145.54 86.68 7.28 Favored Pre-proline 0 CA--C 1.55 0.961 0 CA-C-N 118.147 0.43 . . . . 63.2 110.653 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -74.11 86.0 1.32 Allowed 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.371 2.047 . . . . 71.53 111.623 -177.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.503 HG13 HG22 ' A' ' 100' ' ' THR . 18.0 m -82.07 -174.78 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.585 1.154 . . . . 53.32 112.553 -175.231 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 2.2 t -121.48 92.24 3.7 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.301 1.04 . . . . 64.14 108.597 175.106 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -118.28 142.6 47.33 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 123.612 0.765 . . . . 74.33 110.241 178.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -153.14 140.75 7.82 Favored Glycine 0 C--N 1.346 1.085 0 N-CA-C 111.721 -0.551 . . . . 71.44 111.721 178.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 30.2 t -100.45 -170.05 1.81 Allowed 'General case' 0 CA--C 1.552 1.026 0 C-N-CA 123.968 0.907 . . . . 73.35 109.843 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -83.23 66.71 3.88 Favored Glycine 0 C--N 1.349 1.279 0 CA-C-O 120.16 -0.245 . . . . 43.14 113.67 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 57.0 -95.53 0.04 OUTLIER Glycine 0 C--N 1.355 1.627 0 C-N-CA 123.876 0.75 . . . . 64.5 114.063 174.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 44.2 m -94.12 90.75 6.51 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 123.652 0.781 . . . . 71.32 109.155 176.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 141.68 167.08 11.1 Favored Glycine 0 C--N 1.345 1.061 0 CA-C-N 116.44 -0.346 . . . . 50.31 112.511 178.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -150.78 81.79 0.18 Allowed Glycine 0 C--N 1.346 1.118 0 N-CA-C 111.178 -0.769 . . . . 72.43 111.178 178.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.8 t -69.05 -54.93 12.49 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.144 0.578 . . . . 25.45 110.45 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -76.17 136.79 20.2 Favored Glycine 0 C--N 1.343 0.923 0 N-CA-C 111.173 -0.771 . . . . 41.44 111.173 174.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -77.58 72.02 2.24 Favored Glycine 0 C--N 1.347 1.17 0 N-CA-C 111.495 -0.642 . . . . 73.03 111.495 177.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 45.1 m -129.58 102.7 6.49 Favored 'General case' 0 C--O 1.242 0.668 0 C-N-CA 124.197 0.999 . . . . 60.32 110.22 -174.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -85.66 -121.0 1.11 Allowed Glycine 0 C--N 1.345 1.035 0 N-CA-C 110.185 -1.166 . . . . 50.14 110.185 170.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.668 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 1.7 mmp_? -96.56 117.85 31.81 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 107.057 -1.46 . . . . 73.35 107.057 165.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.2 105.45 17.8 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 107.578 -1.267 . . . . 64.4 107.578 -170.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.574 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 11.8 mt -94.28 110.83 22.55 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 108.244 -1.021 . . . . 74.44 108.244 -178.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.1 ttt180 -110.86 112.76 24.83 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 108.731 -0.841 . . . . 75.24 108.731 168.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -131.39 153.95 49.14 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.814 -0.81 . . . . 51.21 108.814 176.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -92.61 142.22 27.63 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.935 -0.765 . . . . 74.44 108.935 -176.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.648 ' HA ' HD13 ' A' ' 97' ' ' LEU . 12.1 tp -103.14 102.46 28.43 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 124.247 1.019 . . . . 74.25 109.457 -177.734 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.674 ' HD2' HD13 ' A' ' 97' ' ' LEU . 34.6 Cg_endo -65.49 115.71 3.51 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.053 1.835 . . . . 74.43 109.449 168.465 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.425 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 24.3 tp -145.81 122.1 10.9 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.282 -1.007 . . . . 71.14 108.282 -174.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 80.7 p -75.4 165.31 25.33 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 123.281 0.363 . . . . 73.53 110.19 -176.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.477 HD12 ' HB3' ' A' ' 183' ' ' HIS . 77.6 mt -60.8 -33.31 72.8 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.75 0.82 . . . . 72.35 111.998 -172.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -73.91 -49.58 24.15 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.274 -0.875 . . . . 75.41 109.272 -178.136 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -68.52 -24.17 64.63 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 115.007 -0.997 . . . . 74.23 111.374 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.67 -47.34 66.77 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 124.015 0.926 . . . . 73.32 109.967 172.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.5 t80 -60.87 -44.09 97.54 Favored 'General case' 0 C--N 1.352 0.677 0 O-C-N 124.637 1.211 . . . . 60.42 110.867 177.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -71.16 -45.88 62.61 Favored 'General case' 0 N--CA 1.477 0.899 0 O-C-N 123.531 0.519 . . . . 74.24 111.104 -174.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.447 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 71.4 -138.08 27.11 Favored Glycine 0 CA--C 1.53 1.008 0 CA-C-N 116.175 -0.466 . . . . 73.33 112.275 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.46 -160.19 45.39 Favored Glycine 0 C--N 1.349 1.256 0 CA-C-O 119.882 -0.399 . . . . 62.21 112.379 178.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.567 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 8.9 mp0 -77.46 138.34 39.19 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 117.316 0.558 . . . . 60.24 109.91 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.501 ' HE ' HD11 ' A' ' 123' ' ' LEU . 23.1 tpt180 -117.69 119.09 33.89 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.392 -0.966 . . . . 73.12 108.392 -176.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 42.9 t -83.51 103.74 11.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 N-CA-C 108.57 -0.9 . . . . 71.11 108.57 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.443 HG13 ' HG3' ' A' ' 136' ' ' ARG . 18.8 m -123.81 160.83 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 N-CA-C 107.643 -1.243 . . . . 73.35 107.643 177.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -125.95 115.75 20.4 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 119.232 0.923 . . . . 74.24 111.123 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.401 ' HB ' HD22 ' A' ' 98' ' ' LEU . 2.6 p -105.41 111.16 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 C-N-CA 124.378 1.071 . . . . 73.41 110.771 178.398 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.5 29.83 19.43 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 124.147 0.979 . . . . 72.04 112.369 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.16 -13.03 62.04 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-N 116.351 -0.386 . . . . 61.41 113.29 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.66 115.96 28.58 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.309 0.644 . . . . 75.33 109.817 176.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 32.8 ttm180 -92.49 103.65 16.04 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 108.182 -1.044 . . . . 75.43 108.182 -176.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 27.0 m -109.57 155.63 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 124.719 1.208 . . . . 65.13 111.4 -172.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.567 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 47.9 m -101.73 115.98 31.72 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.859 0.864 . . . . 51.13 109.708 176.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.525 HG11 HD12 ' A' ' 176' ' ' LEU . 74.5 t -99.35 113.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 124.28 1.032 . . . . 64.55 108.85 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.0 ttt180 -74.55 102.58 4.57 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 109.145 -0.687 . . . . 64.32 109.145 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.496 HD13 ' HB2' ' A' ' 136' ' ' ARG . 5.6 pt -96.15 141.93 23.84 Favored Pre-proline 0 CA--C 1.555 1.171 0 C-N-CA 124.418 1.087 . . . . 64.22 109.51 -178.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.428 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 28.8 Cg_endo -64.0 132.83 35.95 Favored 'Trans proline' 0 CA--C 1.564 2.015 0 C-N-CA 122.371 2.047 . . . . 73.14 112.344 178.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 25.7 Cg_exo -66.98 132.69 28.86 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 122.984 2.456 . . . . 74.41 112.225 174.004 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.12 34.59 41.14 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.649 -0.705 . . . . 50.21 112.121 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.419 HG21 HG21 ' A' ' 178' ' ' VAL . 14.6 p -76.44 140.17 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 122.99 0.516 . . . . 73.41 111.025 -176.162 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 -94.97 177.09 6.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.832 0.825 . . . . 73.0 112.772 -173.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -72.7 129.92 39.33 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.518 -1.674 . . . . 73.43 110.753 176.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.8 10.33 86.28 Favored Glycine 0 C--N 1.345 1.031 0 CA-C-N 115.45 -0.795 . . . . 74.43 113.884 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 44.9 m -78.29 118.39 20.45 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.274 -0.639 . . . . 74.53 109.274 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.6 p -94.46 127.28 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-O 121.273 0.558 . . . . 74.1 110.333 -177.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 51.7 mt -100.97 101.19 11.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 N-CA-C 107.598 -1.26 . . . . 71.11 107.598 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.493 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 38.9 ttt180 -89.45 113.98 25.41 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 109.92 -0.4 . . . . 73.41 109.92 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.4 HG11 ' SD ' ' A' ' 164' ' ' MET . 6.5 t -114.49 94.64 37.04 Favored Pre-proline 0 CA--C 1.555 1.149 0 N-CA-C 108.324 -0.991 . . . . 65.23 108.324 173.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.56 135.2 48.1 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 123.032 2.488 . . . . 71.12 112.268 177.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.95 -7.88 79.84 Favored Glycine 0 C--N 1.345 1.072 0 CA-C-O 119.543 -0.587 . . . . 52.23 114.2 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.4 ' SD ' HG11 ' A' ' 161' ' ' VAL . 27.6 ttt -100.38 -7.83 23.98 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.636 0.774 . . . . 75.44 110.772 179.263 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -81.58 -112.94 0.37 Allowed Glycine 0 C--N 1.348 1.207 0 CA-C-N 116.078 -0.51 . . . . 73.23 112.316 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.668 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -67.0 95.61 0.28 Allowed Glycine 0 C--N 1.347 1.177 0 CA-C-N 116.869 0.334 . . . . 75.31 113.877 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -71.93 108.54 5.24 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 123.566 0.747 . . . . 72.44 110.46 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -171.64 -169.85 34.98 Favored Glycine 0 C--N 1.342 0.883 0 CA-C-N 115.861 -0.608 . . . . 65.04 112.304 178.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 -61.0 -42.93 89.28 Favored Pre-proline 0 CA--C 1.563 1.442 0 C-N-CA 123.497 0.719 . . . . 73.02 111.652 176.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 78.7 Cg_endo -88.17 106.67 0.54 Allowed 'Trans proline' 0 C--N 1.387 2.584 0 C-N-CA 121.623 1.549 . . . . 74.3 110.176 160.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -67.21 125.63 13.81 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 121.994 1.796 . . . . 63.22 111.858 -177.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -97.14 154.93 20.58 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-N 115.876 -0.602 . . . . 50.31 111.926 -177.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -95.39 163.43 13.25 Favored 'General case' 0 C--O 1.245 0.827 0 C-N-CA 122.899 0.48 . . . . 75.43 109.931 -178.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.2 tp -117.62 139.75 50.57 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 115.088 -0.96 . . . . 61.23 109.758 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 30.7 mt -128.93 101.6 6.15 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.89 1.276 . . . . 64.34 108.416 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.525 HD12 HG11 ' A' ' 147' ' ' VAL . 54.5 mt -103.2 101.28 11.22 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 118.318 0.508 . . . . 72.15 110.162 176.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.63 100.6 10.36 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 115.435 -0.802 . . . . 64.45 109.138 -174.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.543 HG22 HD23 ' A' ' 123' ' ' LEU . 58.2 t -57.76 111.36 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 124.066 0.946 . . . . 72.42 112.01 -177.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -101.44 111.1 23.23 Favored 'General case' 0 C--O 1.243 0.753 0 C-N-CA 124.388 1.075 . . . . 75.51 108.914 170.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.425 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 62.7 mt -70.5 114.5 8.67 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.389 0.676 . . . . 72.43 109.846 179.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.432 HD11 ' HB2' ' A' ' 124' ' ' PRO . 86.5 mt -72.66 155.44 90.92 Favored Pre-proline 0 CA--C 1.548 0.888 0 C-N-CA 123.237 0.615 . . . . 72.43 110.728 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.66 142.75 60.23 Favored 'Trans proline' 0 C--N 1.375 1.942 0 C-N-CA 123.249 2.633 . . . . 74.41 112.454 173.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.477 ' HB3' HD12 ' A' ' 127' ' ' LEU . 48.1 p-80 . . . . . 0 CA--C 1.555 1.17 0 CA-C-O 118.942 -0.551 . . . . 70.24 110.986 -179.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 25.1 mmt . . . . . 0 N--CA 1.484 1.246 0 N-CA-C 109.81 -0.441 . . . . 72.11 109.81 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.488 HD22 HG23 ' A' ' 100' ' ' THR . 3.9 pp -91.17 121.94 67.07 Favored Pre-proline 0 CA--C 1.553 1.095 0 N-CA-C 109.96 -0.385 . . . . 64.33 109.96 178.076 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.4 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 73.8 Cg_endo -85.48 -161.43 0.13 Allowed 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 122.757 2.304 . . . . 61.4 110.98 164.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.483 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.0 tp -74.25 149.92 40.54 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.262 0.625 . . . . 74.13 109.412 177.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.61 HD11 HD21 ' A' ' 174' ' ' LEU . 8.2 tp 57.74 1.67 0.14 Allowed 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 125.798 1.639 . . . . 75.5 114.108 -178.228 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.664 ' HA ' HD13 ' A' ' 119' ' ' LEU . 43.3 t80 -139.91 133.7 30.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 123.336 0.655 . . . . 74.32 109.698 -170.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.564 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 85.9 m -152.94 97.05 2.87 Favored Pre-proline 0 CA--C 1.551 1.009 0 C-N-CA 123.8 0.84 . . . . 73.04 109.476 -177.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -72.76 77.23 2.29 Favored 'Trans proline' 0 C--N 1.374 1.887 0 C-N-CA 123.02 2.48 . . . . 55.51 112.799 -170.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.524 HG13 HG22 ' A' ' 100' ' ' THR . 9.0 m -95.93 163.43 2.34 Favored 'Isoleucine or valine' 0 C--O 1.242 0.694 0 CA-C-N 115.494 -0.775 . . . . 75.2 110.457 178.366 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -119.45 134.48 55.2 Favored 'General case' 0 C--O 1.245 0.819 0 N-CA-C 107.224 -1.398 . . . . 75.41 107.224 163.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.595 ' HE3' ' HA ' ' A' ' 115' ' ' SER . 25.0 ttmm -73.64 -24.67 60.04 Favored 'General case' 0 CA--C 1.549 0.937 0 C-N-CA 123.006 0.523 . . . . 71.12 111.115 -175.084 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -155.17 -177.09 28.1 Favored Glycine 0 C--N 1.346 1.089 0 CA-C-N 116.219 -0.446 . . . . 54.04 112.336 179.255 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 24.0 p -72.86 -54.1 9.66 Favored 'General case' 0 CA--C 1.544 0.733 0 C-N-CA 123.52 0.728 . . . . 64.45 109.611 176.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -93.15 67.04 1.78 Allowed Glycine 0 C--N 1.348 1.195 0 N-CA-C 111.25 -0.74 . . . . 75.13 111.25 175.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -86.13 54.04 4.68 Favored Glycine 0 C--N 1.354 1.536 0 C-N-CA 122.887 0.28 . . . . 63.45 112.455 -178.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 50.6 m -70.49 98.1 1.4 Allowed 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.532 0.733 . . . . 74.21 110.427 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 72.25 -97.54 0.77 Allowed Glycine 0 C--N 1.345 1.061 0 CA-C-N 115.798 -0.637 . . . . 62.12 111.913 -177.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 89.83 51.05 2.93 Favored Glycine 0 C--N 1.347 1.147 0 N-CA-C 111.328 -0.709 . . . . 61.24 111.328 -177.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.2 p -70.29 145.35 51.34 Favored 'General case' 0 CA--C 1.553 1.087 0 C-N-CA 123.347 0.659 . . . . 74.43 110.824 -179.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.2 -140.74 15.16 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 111.746 -0.542 . . . . 62.12 111.746 -175.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.6 50.42 3.78 Favored Glycine 0 C--N 1.346 1.092 0 N-CA-C 111.781 -0.528 . . . . 71.01 111.781 177.128 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . 0.595 ' HA ' ' HE3' ' A' ' 104' ' ' LYS . 70.2 m -146.39 22.07 1.34 Allowed 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.655 0.782 . . . . 64.12 111.116 -172.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -82.01 -152.92 10.7 Favored Glycine 0 C--N 1.344 0.973 0 CA-C-N 116.36 -0.382 . . . . 45.31 113.778 -178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.408 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 8.7 mmm-85 -89.24 118.48 28.96 Favored 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 109.133 -0.691 . . . . 73.03 109.133 -173.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.05 106.59 16.64 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 108.691 -0.855 . . . . 73.44 108.691 -171.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.664 HD13 ' HA ' ' A' ' 99' ' ' PHE . 12.3 mt -96.43 109.46 22.01 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 107.478 -1.305 . . . . 75.54 107.478 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 39.8 ttt180 -121.18 106.45 11.53 Favored 'General case' 0 C--O 1.238 0.465 0 N-CA-C 108.557 -0.905 . . . . 71.51 108.557 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -128.9 141.23 51.35 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.543 -0.91 . . . . 72.45 108.543 -177.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -81.56 130.99 35.26 Favored 'General case' 0 C--O 1.237 0.435 0 N-CA-C 108.895 -0.78 . . . . 64.5 108.895 175.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.597 HD12 HD13 ' A' ' 176' ' ' LEU . 1.6 tt -101.38 108.24 54.37 Favored Pre-proline 0 CA--C 1.54 0.568 0 N-CA-C 108.103 -1.073 . . . . 75.41 108.103 -175.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.7 113.87 3.33 Favored 'Trans proline' 0 C--N 1.378 2.097 0 C-N-CA 121.775 1.65 . . . . 73.1 109.42 171.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.566 HD21 HD12 ' A' ' 149' ' ' ILE . 13.5 tp -131.72 122.78 26.44 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.388 -0.968 . . . . 71.13 108.388 -169.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.9 p -69.71 166.15 19.8 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.549 0.34 . . . . 64.22 110.537 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 99.7 mt -62.34 -29.2 70.29 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 122.778 0.431 . . . . 73.2 110.882 176.065 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -67.8 -57.67 5.91 Favored 'General case' 0 C--N 1.349 0.555 0 C-N-CA 123.907 0.883 . . . . 72.22 109.263 177.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -60.08 -36.49 77.5 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.507 1.123 . . . . 70.22 111.713 -178.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.407 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -68.1 -55.72 11.44 Favored 'General case' 0 C--O 1.239 0.551 0 O-C-N 124.061 0.851 . . . . 73.3 111.212 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.409 ' HA ' ' HA2' ' A' ' 152' ' ' GLY . 65.0 t80 -57.84 -48.28 80.23 Favored 'General case' 0 C--N 1.359 0.99 0 O-C-N 124.554 1.159 . . . . 64.03 111.399 -177.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.9 m80 -72.92 -43.84 61.92 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 116.017 -0.538 . . . . 54.04 110.19 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.416 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 77.87 -124.01 6.62 Favored Glycine 0 C--N 1.344 0.988 0 CA-C-N 115.762 -0.654 . . . . 70.5 111.566 -176.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 73.49 -129.8 12.67 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 111.151 -0.78 . . . . 72.1 111.151 -176.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.531 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 6.7 mp0 -111.73 161.37 16.36 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 124.102 0.961 . . . . 72.1 110.179 176.15 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.626 ' HB2' HD13 ' A' ' 149' ' ' ILE . 20.8 tpt180 -134.01 121.99 22.37 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 124.212 1.005 . . . . 74.12 109.401 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 60.9 t -75.14 107.68 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 C-N-CA 123.89 0.876 . . . . 62.42 109.417 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.528 HG21 HD13 ' A' ' 98' ' ' LEU . 27.0 m -122.96 163.8 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 125.257 1.423 . . . . 65.25 109.354 -179.129 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -120.99 113.02 19.47 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 122.911 0.485 . . . . 63.15 111.505 -177.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.585 ' HB ' HD23 ' A' ' 98' ' ' LEU . 2.6 p -102.76 102.33 13.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 C-N-CA 123.649 0.78 . . . . 71.33 108.972 -176.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.25 25.44 14.87 Favored 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 115.215 -0.902 . . . . 63.33 110.665 -169.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.9 6.17 62.17 Favored Glycine 0 C--N 1.358 1.804 0 CA-C-N 115.63 -0.714 . . . . 53.21 113.802 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.518 ' HB3' HG13 ' A' ' 140' ' ' VAL . 13.8 tpt180 -92.27 116.98 29.43 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.09 -0.707 . . . . 73.34 109.09 -179.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -80.89 109.8 15.81 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.809 -0.441 . . . . 70.11 109.809 -174.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 32.1 m -134.11 152.53 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 124.254 1.022 . . . . 43.41 109.218 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.531 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 45.1 m -104.36 114.86 29.38 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.736 0.414 . . . . 32.42 110.02 178.034 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.4 p -99.85 133.13 43.84 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 124.289 1.036 . . . . 43.12 109.9 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 38.9 ttp180 -75.81 115.46 15.53 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.091 0.556 . . . . 72.42 111.122 -174.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.626 HD13 ' HB2' ' A' ' 136' ' ' ARG . 6.1 pt -99.34 143.26 26.09 Favored Pre-proline 0 CA--C 1.558 1.256 0 C-N-CA 124.864 1.266 . . . . 50.15 109.315 177.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.411 ' HB2' ' HB ' ' A' ' 153' ' ' VAL . 52.7 Cg_exo -57.59 134.74 65.16 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.091 2.527 . . . . 71.24 113.094 178.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -62.72 114.53 2.44 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 70.31 111.112 172.361 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 131' ' ' PHE . . . 89.98 18.72 49.73 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.577 -0.568 . . . . 74.24 113.191 -178.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.411 ' HB ' ' HB2' ' A' ' 150' ' ' PRO . 13.2 p -64.0 141.68 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 C-N-CA 122.971 0.508 . . . . 64.43 111.395 -175.126 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 60.8 mtp180 -113.12 177.7 4.54 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 123.777 0.831 . . . . 72.42 112.706 -170.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -59.69 135.7 57.76 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.535 -1.666 . . . . 73.13 111.744 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.58 6.66 77.52 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.905 0.753 . . . . 60.41 114.232 176.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.8 m -81.83 119.82 24.39 Favored 'General case' 0 C--N 1.349 0.564 0 N-CA-C 109.179 -0.675 . . . . 62.31 109.179 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.2 p -97.56 123.39 49.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.903 0 CA-C-O 121.313 0.578 . . . . 61.32 110.366 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.503 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.3 mt -93.29 103.73 14.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 124.379 1.071 . . . . 72.51 108.619 -175.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.452 ' HE ' HD21 ' A' ' 175' ' ' LEU . 43.0 ttm180 -90.18 111.36 22.49 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 122.767 0.427 . . . . 75.4 110.025 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 6.3 t -111.18 106.32 57.29 Favored Pre-proline 0 CA--C 1.552 1.05 0 N-CA-C 107.526 -1.287 . . . . 44.11 107.526 172.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.35 125.35 12.78 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.857 2.372 . . . . 71.4 112.691 -172.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.9 11.86 85.12 Favored Glycine 0 C--N 1.349 1.291 0 CA-C-O 119.792 -0.449 . . . . 75.12 114.044 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.2 tpt -100.99 -4.4 27.58 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-N 117.24 0.52 . . . . 74.53 110.766 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -74.11 -110.58 0.08 OUTLIER Glycine 0 C--N 1.344 0.996 0 CA-C-N 116.073 -0.512 . . . . 74.34 112.474 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -63.94 108.19 2.12 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 111.777 -0.529 . . . . 70.45 111.777 178.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.9 mm-40 -88.14 116.84 26.61 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.255 0.622 . . . . 72.04 110.308 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 169.22 -155.85 26.5 Favored Glycine 0 C--O 1.245 0.816 0 N-CA-C 110.359 -1.097 . . . . 72.03 110.359 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.457 ' O ' ' HD3' ' A' ' 171' ' ' PRO . 15.0 m120 -65.42 -34.52 9.72 Favored Pre-proline 0 N--CA 1.487 1.398 0 CA-C-O 118.274 -0.869 . . . . 73.1 112.053 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -90.64 99.6 0.26 Allowed 'Trans proline' 0 C--N 1.394 2.924 0 C-N-CA 122.527 2.152 . . . . 42.31 111.655 164.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.457 ' HD3' ' O ' ' A' ' 169' ' ' ASN . 10.6 Cg_exo -70.86 123.28 9.6 Favored 'Trans proline' 0 C--N 1.382 2.331 0 C-N-CA 121.683 1.588 . . . . 71.11 110.613 174.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -100.94 156.58 19.23 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.569 -0.613 . . . . 63.01 111.569 -178.63 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -83.99 143.57 29.7 Favored 'General case' 0 C--O 1.243 0.735 0 N-CA-C 109.849 -0.426 . . . . 74.21 109.849 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.61 HD21 HD11 ' A' ' 98' ' ' LEU . 64.1 tp -106.98 129.89 54.71 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 123.179 0.592 . . . . 64.15 109.851 -179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.452 HD21 ' HE ' ' A' ' 160' ' ' ARG . 98.1 mt -128.75 112.15 13.88 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.448 1.099 . . . . 73.35 110.025 178.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.597 HD13 HD12 ' A' ' 123' ' ' LEU . 81.9 mt -108.54 103.83 13.04 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.247 0.619 . . . . 73.31 110.96 178.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.52 94.62 4.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 N-CA-C 108.851 -0.796 . . . . 71.43 108.851 -176.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.4 t -57.63 118.68 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.877 0.871 . . . . 50.13 111.382 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -114.07 107.22 15.36 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 124.648 1.179 . . . . 74.33 108.22 175.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.05 122.07 18.68 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.526 0.517 . . . . 73.34 110.857 -176.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 93.0 mt -79.11 141.06 57.74 Favored Pre-proline 0 CA--C 1.544 0.745 0 CA-C-N 115.362 -0.835 . . . . 71.22 109.556 176.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -72.2 166.22 30.33 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.988 2.459 . . . . 72.1 112.591 -176.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.4 p-80 . . . . . 0 CA--C 1.56 1.327 0 C-N-CA 122.546 0.339 . . . . 71.14 110.299 178.835 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 20.6 ptp . . . . . 0 CA--C 1.54 0.589 0 CA-C-O 120.196 0.046 . . . . 54.34 111.102 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 pt? -112.36 103.42 55.4 Favored Pre-proline 0 CA--C 1.562 1.429 0 C-N-CA 123.265 0.626 . . . . 53.3 110.247 175.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -86.82 -67.79 0.01 OUTLIER 'Trans proline' 0 C--N 1.38 2.19 0 C-N-CA 122.865 2.376 . . . . 72.21 111.811 175.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.513 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.6 tp -159.74 140.92 12.6 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 108.516 -0.92 . . . . 71.13 108.516 176.206 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.712 ' HB3' ' HB ' ' A' ' 140' ' ' VAL . 11.5 tp 60.58 3.48 0.6 Allowed 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 126.461 1.904 . . . . 73.52 112.95 -178.207 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.739 ' HA ' HD13 ' A' ' 119' ' ' LEU . 75.0 t80 -135.35 133.25 38.57 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 124.271 1.028 . . . . 72.43 108.377 -173.196 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.507 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 89.3 m -153.6 102.17 2.54 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 123.75 0.82 . . . . 74.42 109.645 177.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -72.94 91.02 0.83 Allowed 'Trans proline' 0 CA--C 1.551 1.372 0 C-N-CA 122.559 2.173 . . . . 72.03 111.631 -175.338 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 28.7 m -101.37 167.76 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 124.178 0.991 . . . . 75.3 110.912 -178.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.3 t -88.02 -45.38 10.24 Favored 'General case' 0 CA--C 1.551 0.993 0 N-CA-C 109.485 -0.561 . . . . 62.3 109.485 172.079 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.453 ' HD2' ' HA3' ' A' ' 110' ' ' GLY . 15.4 tppt? 174.06 115.66 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 125.034 1.334 . . . . 72.42 109.497 177.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -158.02 63.47 0.31 Allowed Glycine 0 C--N 1.34 0.776 0 N-CA-C 110.418 -1.073 . . . . 71.51 110.418 175.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 14.6 m -72.34 82.43 1.04 Allowed 'General case' 0 CA--C 1.547 0.855 0 C-N-CA 123.32 0.648 . . . . 74.23 109.907 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 84.03 -48.72 4.1 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-N 115.85 -0.614 . . . . 52.3 112.704 -175.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -143.78 -48.9 0.04 OUTLIER Glycine 0 C--N 1.343 0.945 0 N-CA-C 110.623 -0.991 . . . . 53.41 110.623 173.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.8 t -154.19 -167.31 2.6 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 124.585 1.154 . . . . 64.11 108.25 178.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.453 ' HA3' ' HD2' ' A' ' 104' ' ' LYS . . . -162.61 0.31 0.06 OUTLIER Glycine 0 C--N 1.346 1.107 0 CA-C-O 119.562 -0.577 . . . . 53.21 113.459 174.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 75.77 -78.68 1.18 Allowed Glycine 0 C--N 1.349 1.278 0 CA-C-N 116.956 0.378 . . . . 33.21 112.443 -179.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 42.4 t -70.48 100.99 1.88 Allowed 'General case' 0 CA--C 1.548 0.896 0 C-N-CA 123.703 0.801 . . . . 72.41 109.612 177.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -72.38 -39.35 57.24 Favored Glycine 0 C--N 1.348 1.233 0 CA-C-N 114.902 -1.045 . . . . 43.21 114.631 -172.219 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -90.43 55.96 3.51 Favored Glycine 0 N--CA 1.471 1.024 0 CA-C-N 116.631 0.215 . . . . 61.14 112.833 -174.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 25.7 p -171.92 112.9 0.32 Allowed 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.585 0.754 . . . . 71.32 109.975 -177.201 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 85.77 106.82 0.72 Allowed Glycine 0 C--N 1.348 1.244 0 CA-C-O 119.872 -0.405 . . . . 75.32 113.049 177.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.439 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 3.9 mmp_? -86.72 118.45 26.13 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 108.76 -0.83 . . . . 75.53 108.76 175.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -98.12 102.51 14.28 Favored 'General case' 0 CA--C 1.511 -0.542 0 N-CA-C 106.486 -1.672 . . . . 74.54 106.486 -173.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.739 HD13 ' HA ' ' A' ' 99' ' ' PHE . 16.5 mt -93.52 106.33 18.31 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 107.605 -1.257 . . . . 64.01 107.605 -169.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -111.02 103.24 11.69 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.904 -1.147 . . . . 71.21 107.904 -179.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.46 151.69 51.32 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.583 -0.735 . . . . 75.21 110.235 -168.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.529 ' HB3' ' HG3' ' A' ' 179' ' ' ARG . 40.4 mt-10 -81.55 124.17 29.27 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-N 114.6 -1.182 . . . . 72.45 109.342 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.53 HD12 HD13 ' A' ' 176' ' ' LEU . 3.2 tt -99.52 103.81 23.46 Favored Pre-proline 0 CA--C 1.54 0.583 0 N-CA-C 106.898 -1.519 . . . . 62.43 106.898 178.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.3 114.48 3.46 Favored 'Trans proline' 0 C--N 1.38 2.205 0 C-N-CA 121.925 1.75 . . . . 72.34 110.438 175.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.499 HD21 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -139.23 120.08 14.35 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.039 -1.097 . . . . 71.43 108.039 -172.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 4.9 m -69.73 160.82 30.96 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 123.748 0.819 . . . . 75.13 111.112 -176.094 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 83.2 mt -56.17 -39.28 72.11 Favored 'General case' 0 N--CA 1.484 1.225 0 C-N-CA 123.894 0.878 . . . . 74.2 112.13 -179.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -69.12 -44.19 72.91 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.447 0.699 . . . . 73.53 110.414 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -61.44 -39.15 89.76 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.321 1.048 . . . . 72.53 111.16 -179.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.447 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -72.98 -44.23 61.31 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-N 114.31 -1.314 . . . . 75.44 111.145 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 72.3 t80 -56.92 -47.83 79.66 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.803 1.241 . . . . 73.14 110.913 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -69.83 -48.55 58.53 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.716 -0.675 . . . . 61.4 110.181 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.549 ' HA3' ' HA ' ' A' ' 151' ' ' PRO . . . 55.65 76.37 0.2 Allowed Glycine 0 C--N 1.356 1.639 0 O-C-N 124.469 1.105 . . . . 25.22 113.638 176.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -112.57 -131.39 5.57 Favored Glycine 0 C--N 1.343 0.922 0 N-CA-C 111.328 -0.709 . . . . 60.04 111.328 177.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -100.96 152.19 20.86 Favored 'General case' 0 C--O 1.245 0.834 0 N-CA-C 108.694 -0.854 . . . . 61.04 108.694 170.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 tpp85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.003 0.921 . . . . 74.35 108.867 -179.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.28 131.04 40.46 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 N-CA-C 108.582 -0.896 . . . . 64.32 108.582 175.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 27.1 m -125.14 161.19 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.869 0 C-N-CA 123.604 0.762 . . . . 75.4 110.147 -178.419 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.9 tm-20 -97.56 141.71 30.27 Favored 'General case' 0 CA--C 1.55 0.97 0 C-N-CA 124.075 0.95 . . . . 65.05 108.539 -178.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.712 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.0 p -150.1 109.31 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.199 0 C-N-CA 124.733 1.213 . . . . 73.22 111.394 -177.198 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.13 17.36 8.01 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 114.449 1.277 . . . . 72.52 114.449 164.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.12 22.34 13.36 Favored Glycine 0 N--CA 1.479 1.561 0 N-CA-C 112.514 -0.235 . . . . 64.25 112.514 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.423 ' HB2' HG13 ' A' ' 140' ' ' VAL . 24.7 mmm180 -134.75 153.86 51.83 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.906 1.282 . . . . 75.1 107.864 178.144 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -117.69 108.01 14.89 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.034 -0.728 . . . . 72.31 109.034 175.15 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 63.2 t -116.56 139.19 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 123.477 0.711 . . . . 74.44 110.174 -174.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.7 p -85.99 140.13 30.58 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 123.733 0.813 . . . . 73.02 111.087 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.415 HG21 HD12 ' A' ' 176' ' ' LEU . 14.7 p -133.55 157.59 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 C-N-CA 124.641 1.176 . . . . 64.05 108.52 174.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 -107.32 128.72 54.7 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.783 -0.451 . . . . 75.24 109.783 177.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.499 HD12 HD21 ' A' ' 125' ' ' LEU . 15.7 pt -101.9 126.84 32.6 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.058 0.943 . . . . 71.15 108.65 176.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.408 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 27.9 Cg_endo -65.32 147.07 87.3 Favored 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.362 2.042 . . . . 70.54 113.547 -178.017 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.549 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 38.5 Cg_exo -62.88 121.92 10.0 Favored 'Trans proline' 0 C--N 1.385 2.452 0 C-N-CA 123.821 3.014 . . . . 70.33 112.159 179.156 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 72.33 40.13 55.83 Favored Glycine 0 C--N 1.339 0.747 0 O-C-N 124.051 0.844 . . . . 73.31 112.563 -179.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.447 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 14.6 p -76.87 148.93 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 109.872 -0.418 . . . . 54.04 109.872 178.32 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 68.7 mtp180 -126.51 177.97 6.16 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-O 121.509 0.671 . . . . 60.03 112.413 -172.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -59.31 133.88 56.49 Favored 'General case' 0 CA--C 1.547 0.851 0 CA-C-N 113.409 -1.723 . . . . 64.21 111.865 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.31 -16.75 47.06 Favored Glycine 0 C--N 1.345 1.057 0 CA-C-O 119.388 -0.673 . . . . 20.23 113.312 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 48.3 m -67.15 118.72 10.95 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 117.36 0.58 . . . . 72.13 110.445 -173.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.9 p -94.12 125.0 46.8 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-O 121.528 0.68 . . . . 62.34 109.923 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 43.4 mt -94.82 99.75 9.94 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 107.061 -1.459 . . . . 63.1 107.061 174.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 46.6 ttt-85 -83.97 123.42 29.96 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 109.297 -0.631 . . . . 64.01 109.297 175.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.7 t -116.32 111.42 42.24 Favored Pre-proline 0 CA--C 1.555 1.168 0 N-CA-C 106.858 -1.534 . . . . 54.51 106.858 168.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.07 126.08 12.7 Favored 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.673 2.249 . . . . 71.04 112.25 -175.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 76.92 8.8 86.81 Favored Glycine 0 C--N 1.345 1.042 0 CA-C-N 115.774 -0.648 . . . . 74.55 114.57 171.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.452 ' HA ' HE22 ' A' ' 167' ' ' GLN . 24.0 mmt -114.07 15.35 18.36 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.154 0.582 . . . . 64.02 111.293 -176.685 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.21 -96.03 0.98 Allowed Glycine 0 C--N 1.344 0.973 0 N-CA-C 110.377 -1.089 . . . . 42.22 110.377 169.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.439 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -79.12 95.29 1.4 Allowed Glycine 0 C--N 1.346 1.087 0 N-CA-C 112.177 -0.369 . . . . 71.2 112.177 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.452 HE22 ' HA ' ' A' ' 164' ' ' MET . 11.3 mm-40 -65.85 131.6 46.68 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.485 0.714 . . . . 70.31 111.508 -177.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 170.11 174.87 38.61 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.781 -0.928 . . . . 72.14 110.781 -176.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.456 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 15.3 m120 -59.04 -42.37 93.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.358 0.663 . . . . 72.32 111.326 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.456 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 1.8 Cg_endo -87.42 101.34 0.5 Allowed 'Trans proline' 0 C--N 1.387 2.596 0 C-N-CA 122.429 2.086 . . . . 75.13 109.489 158.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.48 126.95 12.01 Favored 'Trans proline' 0 C--N 1.377 2.073 0 C-N-CA 121.984 1.789 . . . . 61.33 111.911 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.99 151.14 21.94 Favored Glycine 0 C--N 1.343 0.946 0 CA-C-N 115.309 -0.859 . . . . 43.1 111.975 -179.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -77.74 159.4 29.1 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.512 0.725 . . . . 61.24 110.045 -170.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.534 HD21 HD11 ' A' ' 98' ' ' LEU . 47.5 tp -125.05 125.3 43.61 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.52 -0.548 . . . . 75.15 109.52 176.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 88.6 mt -127.4 101.47 6.47 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.88 0.872 . . . . 65.41 109.378 179.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.53 HD13 HD12 ' A' ' 123' ' ' LEU . 91.1 mt -102.96 102.23 12.28 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.992 0.517 . . . . 72.04 111.06 -178.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.99 107.57 16.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.011 -0.737 . . . . 71.52 109.011 -176.544 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.8 t -62.54 117.84 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.975 0 C-N-CA 124.146 0.978 . . . . 73.25 111.078 -179.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . 0.529 ' HG3' ' HB3' ' A' ' 122' ' ' GLU . 13.1 mmm180 -110.95 106.48 15.61 Favored 'General case' 0 C--O 1.239 0.524 0 C-N-CA 124.997 1.319 . . . . 71.23 108.092 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.406 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 65.8 mt -69.16 116.5 9.67 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 123.206 0.602 . . . . 72.31 110.815 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 81.9 mt -75.07 139.24 72.64 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 115.944 -0.571 . . . . 73.12 109.67 178.338 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -71.88 179.03 5.16 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 123.118 2.545 . . . . 72.32 112.872 177.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 . . . . . 0 C--O 1.252 1.234 0 N-CA-C 109.208 -0.664 . . . . 71.53 109.208 174.592 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 61.3 mtt . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 110.307 -0.257 . . . . 72.53 110.307 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER 35.03 86.2 0.14 Allowed Pre-proline 0 CA--C 1.559 1.304 0 C-N-CA 126.582 1.953 . . . . 54.14 113.837 -173.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.466 ' HG2' ' HB3' ' A' ' 99' ' ' PHE . 22.0 Cg_endo -62.51 178.17 1.01 Allowed 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.58 2.187 . . . . 75.03 112.473 168.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.651 HD13 ' HD2' ' A' ' 124' ' ' PRO . 1.7 tp -43.22 -53.97 4.8 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 125.287 1.435 . . . . 62.4 112.529 -174.038 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.434 ' O ' ' HB2' ' A' ' 99' ' ' PHE . 12.7 tp -119.3 91.92 3.67 Favored 'General case' 0 C--O 1.215 -0.757 0 N-CA-C 107.619 -1.252 . . . . 63.23 107.619 172.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.524 ' HA ' HD13 ' A' ' 119' ' ' LEU . 62.3 t80 168.52 131.54 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 124.361 1.064 . . . . 61.52 109.071 173.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.557 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 51.5 m -156.68 98.95 2.07 Favored Pre-proline 0 N--CA 1.475 0.787 0 N-CA-C 107.824 -1.176 . . . . 74.22 107.824 173.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -79.51 74.99 5.29 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 122.575 2.184 . . . . 70.12 112.553 -169.08 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 4.4 m -83.53 172.9 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 CA-C-N 115.541 -0.754 . . . . 52.54 109.997 179.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 60.6 p -81.88 -76.33 0.26 Allowed 'General case' 0 CA--C 1.547 0.845 0 CA-C-N 116.112 -0.495 . . . . 51.15 109.791 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.409 ' HB3' ' HA ' ' A' ' 117' ' ' ARG . 4.3 tppp? 42.21 87.03 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 125.397 1.479 . . . . 75.25 112.727 -175.245 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 149.22 -13.56 1.09 Allowed Glycine 0 N--CA 1.463 0.485 0 CA-C-N 115.171 -0.922 . . . . 44.44 111.445 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 47.7 m -64.15 87.33 0.05 OUTLIER 'General case' 0 CA--C 1.548 0.894 0 C-N-CA 124.157 0.983 . . . . 42.52 110.592 178.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 59.37 -103.23 0.38 Allowed Glycine 0 C--N 1.347 1.184 0 CA-C-N 115.485 -0.78 . . . . 61.41 112.699 -179.306 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.05 33.75 6.18 Favored Glycine 0 C--N 1.345 1.069 0 CA-C-O 120.054 -0.303 . . . . 72.04 112.782 -177.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.4 p -82.67 90.17 6.81 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 109.184 -0.673 . . . . 62.12 109.184 173.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 69.58 85.4 0.13 Allowed Glycine 0 C--N 1.351 1.396 0 CA-C-N 115.998 -0.546 . . . . 74.44 111.876 -178.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -75.29 75.05 1.4 Allowed Glycine 0 C--N 1.35 1.348 0 C-N-CA 123.12 0.391 . . . . 61.31 112.711 -177.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 43.2 m -133.85 129.33 36.31 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 124.538 1.135 . . . . 72.04 108.419 177.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -65.47 -55.92 18.09 Favored Glycine 0 C--N 1.35 1.336 0 O-C-N 124.098 0.874 . . . . 51.24 113.236 -173.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -86.12 48.12 3.88 Favored Glycine 0 C--N 1.348 1.204 0 C-N-CA 122.787 0.232 . . . . 51.51 112.926 -177.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 50.9 m -144.23 103.94 4.05 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.805 0.842 . . . . 42.35 109.706 -178.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -96.13 -161.83 33.02 Favored Glycine 0 C--N 1.338 0.66 0 N-CA-C 111.127 -0.789 . . . . 64.14 111.127 171.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.412 ' HD2' ' H ' ' A' ' 117' ' ' ARG . 0.3 OUTLIER -59.21 123.79 17.83 Favored 'General case' 0 CA--C 1.56 1.348 0 C-N-CA 123.822 0.849 . . . . 75.5 111.065 -179.545 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -94.57 130.74 40.88 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.228 -1.027 . . . . 74.43 108.228 -172.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.557 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 14.9 mt -100.73 112.83 25.31 Favored 'General case' 0 CA--C 1.537 0.471 0 N-CA-C 108.111 -1.07 . . . . 64.24 108.111 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 75.0 ttt-85 -119.33 108.69 14.91 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 123.883 0.873 . . . . 73.02 110.208 -179.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -146.29 170.26 17.13 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 123.911 0.885 . . . . 74.04 108.701 179.004 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -97.03 145.21 26.17 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.969 0.414 . . . . 54.31 110.746 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.62 HD21 ' HG2' ' A' ' 136' ' ' ARG . 1.1 tt -103.01 103.9 36.74 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 124.901 1.28 . . . . 63.13 109.053 -177.11 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.651 ' HD2' HD13 ' A' ' 97' ' ' LEU . 37.7 Cg_endo -65.17 115.91 3.57 Favored 'Trans proline' 0 C--N 1.38 2.204 0 C-N-CA 122.107 1.871 . . . . 61.42 109.594 169.163 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.569 HD21 HD12 ' A' ' 149' ' ' ILE . 28.7 tp -137.15 127.02 25.69 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.361 0.664 . . . . 74.1 110.125 -172.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.9 p -78.18 167.91 20.67 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 123.062 0.545 . . . . 75.4 111.121 -175.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 76.9 mt -65.58 -37.3 86.25 Favored 'General case' 0 C--O 1.246 0.907 0 C-N-CA 123.981 0.913 . . . . 61.3 111.366 -173.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.47 -51.74 40.21 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 114.694 -1.139 . . . . 72.21 108.68 -177.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -62.43 -38.08 88.35 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.771 -1.104 . . . . 41.14 111.793 -178.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.39 -47.23 85.06 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 124.074 0.859 . . . . 73.21 110.453 176.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 57.1 t80 -66.48 -35.23 79.76 Favored 'General case' 0 CA--C 1.548 0.868 0 O-C-N 124.271 0.982 . . . . 75.53 111.136 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -67.32 -47.66 69.87 Favored 'General case' 0 C--N 1.363 1.18 0 CA-C-O 120.885 0.374 . . . . 73.03 110.018 177.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.58 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 62.19 56.01 24.57 Favored Glycine 0 C--N 1.341 0.852 0 CA-C-N 114.584 -1.189 . . . . 62.34 112.452 -174.259 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -103.3 -141.09 11.15 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 111.873 -0.491 . . . . 60.24 111.873 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -98.77 141.65 31.3 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.027 -0.731 . . . . 71.14 109.027 171.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.62 ' HG2' HD21 ' A' ' 123' ' ' LEU . 23.1 tpt180 -115.48 119.72 37.13 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.757 -1.201 . . . . 74.54 107.757 178.218 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 57.7 t -85.71 109.13 18.08 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 123.273 0.629 . . . . 61.31 109.519 -177.058 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.43 HG23 HD22 ' A' ' 98' ' ' LEU . 18.2 m -117.83 164.17 14.35 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 C-N-CA 125.609 1.563 . . . . 73.31 108.429 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -124.66 138.86 54.28 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 118.655 0.661 . . . . 70.41 111.413 -178.081 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.488 HG13 ' HB2' ' A' ' 143' ' ' ARG . 5.6 p -128.76 107.21 15.39 Favored 'Isoleucine or valine' 0 C--N 1.359 0.987 0 C-N-CA 124.838 1.255 . . . . 71.35 110.994 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.98 24.51 11.13 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.482 0.713 . . . . 55.52 112.166 175.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.39 18.09 29.48 Favored Glycine 0 C--N 1.348 1.246 0 CA-C-N 116.288 -0.415 . . . . 31.22 113.608 -178.282 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.488 ' HB2' HG13 ' A' ' 140' ' ' VAL . 10.8 mmm180 -117.64 123.09 45.29 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 123.773 0.829 . . . . 72.2 109.891 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 6.9 tpt180 -84.25 106.35 15.8 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 108.935 -0.765 . . . . 75.22 108.935 -176.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 88.4 t -115.98 132.17 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.87 0.868 . . . . 72.32 109.693 -178.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 30.1 m -98.95 112.55 24.63 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 123.865 0.866 . . . . 74.41 109.23 176.121 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.486 HG21 HD12 ' A' ' 176' ' ' LEU . 3.8 p -99.72 121.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 C-N-CA 124.023 0.929 . . . . 74.01 109.382 176.496 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -73.1 119.49 17.41 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.021 0.528 . . . . 74.42 110.182 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.58 HG13 ' HA2' ' A' ' 133' ' ' GLY . 4.9 pt -92.18 142.64 26.43 Favored Pre-proline 0 CA--C 1.563 1.478 0 C-N-CA 124.331 1.052 . . . . 63.03 109.948 177.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -58.84 148.36 84.24 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 123.555 2.837 . . . . 70.34 113.84 176.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.49 ' HA ' ' HA3' ' A' ' 133' ' ' GLY . 59.5 Cg_endo -70.31 113.04 3.33 Favored 'Trans proline' 0 C--N 1.377 2.044 0 C-N-CA 122.829 2.352 . . . . 72.32 111.414 177.408 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.22 39.01 37.93 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.826 -0.624 . . . . 64.32 112.34 -175.143 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 8.7 p -71.08 144.75 13.18 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 123.159 0.584 . . . . 74.24 110.143 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.506 ' HA ' HD11 ' A' ' 180' ' ' LEU . 64.6 mtp180 -119.24 177.13 5.01 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 121.766 0.794 . . . . 75.33 112.821 -171.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -64.89 130.25 42.75 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 113.535 -1.666 . . . . 73.51 111.121 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 87.52 -5.55 84.83 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-N 115.95 -0.568 . . . . 34.1 113.92 179.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.9 m -75.48 119.67 19.87 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-N 117.29 0.545 . . . . 72.42 109.742 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.6 t -98.51 116.63 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.069 0.547 . . . . 61.25 109.858 -174.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 57.5 mt -88.25 101.65 11.88 Favored 'Isoleucine or valine' 0 C--O 1.241 0.609 0 N-CA-C 108.074 -1.084 . . . . 73.31 108.074 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 13.4 ttp180 -91.79 113.79 26.15 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 114.821 -1.081 . . . . 74.35 109.477 178.14 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.0 t -114.85 113.83 44.35 Favored Pre-proline 0 CA--C 1.549 0.925 0 N-CA-C 108.922 -0.77 . . . . 72.14 108.922 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.04 124.23 12.73 Favored 'Trans proline' 0 C--N 1.377 2.065 0 C-N-CA 122.852 2.368 . . . . 62.42 112.595 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.41 -3.33 85.2 Favored Glycine 0 C--N 1.344 1.01 0 N-CA-C 114.911 0.724 . . . . 64.33 114.911 171.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.7 tpt -88.06 -7.62 56.72 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 117.622 0.711 . . . . 71.52 111.037 -175.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -75.81 -111.67 0.11 Allowed Glycine 0 C--N 1.349 1.278 0 N-CA-C 112.057 -0.417 . . . . 74.1 112.057 175.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.65 103.92 1.52 Allowed Glycine 0 C--N 1.344 1.017 0 CA-C-N 117.134 0.467 . . . . 31.22 113.304 179.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.6 mm-40 -65.98 147.89 52.66 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.483 0.713 . . . . 64.21 110.935 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 140.07 -171.78 23.73 Favored Glycine 0 N--CA 1.473 1.129 0 C-N-CA 123.136 0.398 . . . . 24.25 112.203 -177.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 45.7 m-80 -61.84 -46.15 92.6 Favored Pre-proline 0 CA--C 1.559 1.32 0 CA-C-O 118.394 -0.812 . . . . 71.35 111.698 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -88.33 103.66 0.46 Allowed 'Trans proline' 0 C--N 1.391 2.77 0 C-N-CA 121.842 1.695 . . . . 71.05 110.15 163.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -76.58 125.02 7.99 Favored 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 122.211 1.94 . . . . 70.22 110.723 -177.167 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -81.42 148.82 28.31 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 116.1 -0.5 . . . . 40.12 112.396 -178.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -78.19 151.93 32.93 Favored 'General case' 0 C--O 1.247 0.935 0 CA-C-O 121.102 0.477 . . . . 73.51 110.102 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.47 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 43.3 tp -114.17 131.89 56.29 Favored 'General case' 0 C--O 1.223 -0.334 0 C-N-CA 122.803 0.441 . . . . 73.1 110.075 177.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 73.1 mt -128.2 104.6 7.84 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 124.495 1.118 . . . . 74.21 108.902 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.486 HD12 HG21 ' A' ' 147' ' ' VAL . 66.6 mt -113.63 105.53 13.43 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.392 0.677 . . . . 64.43 110.565 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.8 t -84.72 103.8 12.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 109.239 -0.652 . . . . 64.4 109.239 -175.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.4 t -58.84 125.5 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 O-C-N 123.697 0.623 . . . . 61.22 111.539 -177.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -115.12 107.72 15.7 Favored 'General case' 0 C--O 1.239 0.514 0 C-N-CA 125.144 1.377 . . . . 64.32 107.499 176.038 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.506 HD11 ' HA ' ' A' ' 154' ' ' ARG . 54.1 mt -69.19 110.09 4.39 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.504 -0.925 . . . . 74.44 108.504 177.056 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 84.9 mt -68.82 129.84 92.11 Favored Pre-proline 0 CA--C 1.544 0.742 0 CA-C-N 115.715 -0.675 . . . . 75.53 110.013 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -65.43 158.68 51.5 Favored 'Trans proline' 0 C--N 1.369 1.625 0 C-N-CA 122.978 2.452 . . . . 74.01 111.825 176.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 31.6 t-80 . . . . . 0 CA--C 1.552 1.028 0 C-N-CA 123.509 0.724 . . . . 75.25 110.239 174.243 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 26.6 ptt? . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 118.929 -0.558 . . . . 64.4 109.726 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER 29.35 82.29 0.21 Allowed Pre-proline 0 N--CA 1.505 2.319 0 C-N-CA 126.024 1.729 . . . . 74.1 114.482 -178.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -70.32 -43.35 2.24 Favored 'Trans proline' 0 C--N 1.38 2.229 0 C-N-CA 122.514 2.143 . . . . 63.34 112.153 -173.521 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.561 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.3 tp -175.39 145.43 0.75 Allowed 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 125.175 1.39 . . . . 65.21 107.804 -176.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.561 ' H ' HD12 ' A' ' 97' ' ' LEU . 4.2 tt 52.77 -78.27 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.261 0 C-N-CA 126.924 2.09 . . . . 71.45 111.782 -174.589 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.672 ' HA ' HD13 ' A' ' 119' ' ' LEU . 78.2 t80 -57.01 120.71 8.45 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.909 1.283 . . . . 52.04 112.444 -178.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.555 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 88.8 m -138.62 97.97 9.02 Favored Pre-proline 0 CA--C 1.545 0.778 0 C-N-CA 124.287 1.035 . . . . 74.13 109.17 176.669 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -69.92 103.01 1.12 Allowed 'Trans proline' 0 C--N 1.367 1.527 0 C-N-CA 122.447 2.098 . . . . 65.21 111.708 -176.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.7 m -100.2 177.26 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 C-N-CA 124.249 1.02 . . . . 74.24 111.378 179.207 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 41.7 p -111.17 -10.25 14.31 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 123.705 0.802 . . . . 74.33 111.367 177.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 44.9 tttm -67.76 -32.51 73.15 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 123.552 0.741 . . . . 70.04 112.882 -174.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -79.28 19.97 5.25 Favored Glycine 0 CA--C 1.535 1.287 0 CA-C-O 119.62 -0.545 . . . . 71.34 114.377 -176.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 68.5 p -83.99 -58.51 2.75 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.965 0.906 . . . . 70.32 110.545 178.07 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -179.04 146.48 7.24 Favored Glycine 0 C--N 1.35 1.357 0 CA-C-N 116.114 -0.494 . . . . 51.43 112.869 -177.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.81 -153.26 25.19 Favored Glycine 0 C--N 1.35 1.329 0 N-CA-C 111.714 -0.555 . . . . 60.23 111.714 176.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 47.5 t -76.32 -30.39 57.67 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 123.643 0.777 . . . . 74.31 110.583 176.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -117.43 20.86 10.99 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-N 115.914 -0.584 . . . . 73.15 111.879 175.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -137.48 140.64 11.48 Favored Glycine 0 C--N 1.344 1.006 0 N-CA-C 110.766 -0.934 . . . . 55.41 110.766 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.558 ' HA ' ' HG3' ' A' ' 170' ' ' PRO . 95.8 p 53.75 -78.23 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 125.818 1.647 . . . . 64.52 112.758 -176.168 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -73.56 86.54 0.62 Allowed Glycine 0 CA--C 1.528 0.902 0 N-CA-C 112.254 -0.338 . . . . 53.23 112.254 176.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 126.34 -33.96 3.33 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-O 120.023 -0.32 . . . . 51.13 112.841 174.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 64.6 m -151.04 150.23 30.49 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 123.005 0.522 . . . . 73.24 111.491 -175.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.417 ' HA2' ' HG2' ' A' ' 170' ' ' PRO . . . -95.03 -151.3 28.22 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-N 115.271 -0.877 . . . . 50.55 112.365 172.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.801 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 68.3 mtt180 -85.55 135.88 33.64 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.545 0.738 . . . . 74.02 109.722 -178.315 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -99.44 107.43 19.64 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.903 -1.147 . . . . 44.52 107.903 -174.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.672 HD13 ' HA ' ' A' ' 99' ' ' PHE . 13.5 mt -93.63 109.52 21.15 Favored 'General case' 0 C--O 1.22 -0.454 0 N-CA-C 106.769 -1.567 . . . . 74.41 106.769 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.8 ttt180 -121.11 107.94 13.21 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.953 0.901 . . . . 72.54 108.634 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.23 156.3 47.83 Favored 'General case' 0 C--O 1.24 0.6 0 C-N-CA 123.162 0.585 . . . . 73.35 110.401 -174.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -75.66 125.95 30.05 Favored 'General case' 0 N--CA 1.469 0.507 0 C-N-CA 124.497 1.119 . . . . 75.15 108.942 179.11 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.575 HD11 ' HG2' ' A' ' 136' ' ' ARG . 26.1 tp -100.66 101.42 15.35 Favored Pre-proline 0 CA--C 1.543 0.681 0 C-N-CA 123.507 0.723 . . . . 43.25 109.331 178.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.64 114.98 4.17 Favored 'Trans proline' 0 C--N 1.377 2.038 0 C-N-CA 122.251 1.967 . . . . 64.32 110.002 175.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.515 HD21 HD12 ' A' ' 149' ' ' ILE . 18.6 tp -131.89 135.62 46.79 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 108.223 -1.029 . . . . 74.32 108.223 -173.405 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 38.8 p -81.84 171.59 14.32 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.588 -0.523 . . . . 71.31 109.588 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 88.7 mt -68.05 -32.73 73.28 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 122.925 0.49 . . . . 74.3 110.343 176.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -69.48 -49.44 54.7 Favored 'General case' 0 N--CA 1.47 0.56 0 O-C-N 124.013 0.82 . . . . 64.24 109.433 -177.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 17.5 mm-40 -68.66 -34.6 75.98 Favored 'General case' 0 N--CA 1.472 0.648 0 O-C-N 124.016 0.823 . . . . 73.32 111.127 -178.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.51 -48.56 81.25 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.908 0.755 . . . . 54.03 110.599 173.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -65.09 -37.14 86.55 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 124.464 1.106 . . . . 72.43 110.905 179.275 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -64.2 -42.32 96.69 Favored 'General case' 0 N--CA 1.474 0.747 0 O-C-N 123.635 0.584 . . . . 71.43 110.136 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 58.63 35.56 81.57 Favored Glycine 0 C--N 1.349 1.251 0 O-C-N 124.234 0.959 . . . . 71.4 112.326 -174.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -87.71 -136.47 5.12 Favored Glycine 0 C--N 1.342 0.888 0 N-CA-C 112.045 -0.422 . . . . 52.53 112.045 -175.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.602 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 15.3 mp0 -111.43 139.77 46.58 Favored 'General case' 0 C--O 1.239 0.502 0 N-CA-C 108.052 -1.092 . . . . 43.14 108.052 173.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.575 ' HG2' HD11 ' A' ' 123' ' ' LEU . 37.9 tpt85 -112.81 120.51 41.74 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 124.323 1.049 . . . . 70.21 108.183 -177.195 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 91.2 t -81.39 106.3 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.79 0.836 . . . . 64.15 109.395 -176.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.53 ' HB ' ' HG ' ' A' ' 97' ' ' LEU . 20.4 m -111.35 159.92 11.0 Favored 'Isoleucine or valine' 0 C--O 1.245 0.839 0 C-N-CA 124.516 1.127 . . . . 74.33 111.113 -174.595 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -93.72 136.94 33.49 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.624 1.17 . . . . 65.45 109.056 174.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 1.5 p -151.9 100.35 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 C-N-CA 124.02 0.928 . . . . 74.43 110.445 176.043 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.02 21.26 11.63 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 113.526 0.936 . . . . 64.2 113.526 171.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.55 -7.37 55.89 Favored Glycine 0 N--CA 1.479 1.525 0 C-N-CA 123.162 0.41 . . . . 70.25 113.162 -176.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.04 150.2 21.52 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.83 0.852 . . . . 73.1 109.461 173.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 55.7 ttp180 -113.36 108.84 17.77 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 107.282 -1.377 . . . . 72.05 107.282 176.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.407 ' O ' HG22 ' A' ' 138' ' ' VAL . 70.1 t -121.77 134.48 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 C-N-CA 123.379 0.672 . . . . 72.33 110.619 -173.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.602 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 29.1 p -95.37 109.21 21.41 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 123.483 0.713 . . . . 41.15 109.165 176.488 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.9 p -98.91 128.24 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 C-N-CA 123.508 0.723 . . . . 71.32 109.338 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -70.43 122.91 20.52 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 109.287 -0.634 . . . . 72.42 109.287 179.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.515 HD12 HD21 ' A' ' 125' ' ' LEU . 4.3 pt -98.69 149.49 35.79 Favored Pre-proline 0 CA--C 1.559 1.324 0 C-N-CA 124.875 1.27 . . . . 53.23 109.623 176.576 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -63.82 143.41 85.98 Favored 'Trans proline' 0 C--N 1.377 2.062 0 C-N-CA 122.77 2.313 . . . . 71.23 112.755 176.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.35 123.53 10.66 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 122.755 2.303 . . . . 40.51 111.91 174.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 75.48 26.71 64.95 Favored Glycine 0 C--N 1.347 1.179 0 CA-C-N 115.849 -0.614 . . . . 71.23 113.101 -178.444 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 7.4 p -67.68 145.9 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 C-N-CA 123.658 0.783 . . . . 63.12 111.363 -177.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.505 ' HA ' HD11 ' A' ' 180' ' ' LEU . 60.5 mtp180 -120.13 169.42 10.24 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-O 121.855 0.836 . . . . 75.1 112.832 -172.158 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -61.12 119.85 9.16 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 113.062 -1.881 . . . . 64.15 109.623 173.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 116.23 -25.4 9.33 Favored Glycine 0 N--CA 1.477 1.377 0 O-C-N 123.325 0.391 . . . . 61.15 112.583 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.6 m -69.88 123.92 22.71 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.479 0.712 . . . . 54.31 110.924 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 4.0 p -100.94 131.08 49.28 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 N-CA-C 108.666 -0.864 . . . . 71.14 108.666 172.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 34.9 mt -100.05 102.15 13.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.596 0 N-CA-C 107.859 -1.163 . . . . 71.15 107.859 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.489 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 51.1 ttp85 -87.73 106.43 18.05 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.538 -0.541 . . . . 72.23 109.538 175.182 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.1 t -100.48 96.44 5.29 Favored Pre-proline 0 CA--C 1.555 1.173 0 N-CA-C 107.481 -1.303 . . . . 73.3 107.481 173.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.66 143.67 42.58 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.958 2.438 . . . . 71.34 111.564 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . 0.713 ' HA2' ' HB2' ' A' ' 171' ' ' PRO . . . 85.47 -24.79 6.93 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-N 116.068 -0.514 . . . . 63.4 113.595 177.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 25.7 mmt -98.73 14.76 27.54 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.956 0.902 . . . . 71.21 111.013 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -88.86 -119.94 1.72 Allowed Glycine 0 C--N 1.348 1.21 0 N-CA-C 111.758 -0.537 . . . . 60.05 111.758 175.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.801 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.94 112.8 3.57 Favored Glycine 0 C--N 1.348 1.231 0 CA-C-N 117.11 0.455 . . . . 72.44 112.453 -177.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.7 mm-40 -81.53 139.3 35.2 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.581 0.752 . . . . 70.55 110.502 -177.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -173.37 -142.64 3.94 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.509 -1.037 . . . . 75.52 110.509 -179.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.411 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 39.3 t30 -73.81 -49.41 6.11 Favored Pre-proline 0 CA--C 1.563 1.471 0 N-CA-C 109.151 -0.685 . . . . 64.3 109.151 169.318 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.558 ' HG3' ' HA ' ' A' ' 112' ' ' SER . 93.1 Cg_endo -91.8 135.14 1.58 Allowed 'Trans proline' 0 C--N 1.389 2.709 0 C-N-CA 121.935 1.757 . . . . 72.44 111.748 165.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.713 ' HB2' ' HA2' ' A' ' 163' ' ' GLY . 55.8 Cg_endo -67.56 128.35 17.99 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.406 2.071 . . . . 61.14 111.599 172.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -88.27 162.84 32.47 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-N 116.095 -0.502 . . . . 43.34 113.108 -179.127 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -86.73 145.81 26.51 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.67 0.788 . . . . 65.4 110.532 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.489 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 42.8 tp -111.21 135.1 52.24 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.835 0.854 . . . . 62.21 109.288 173.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 66.7 mt -127.67 102.18 6.71 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.062 1.345 . . . . 54.42 108.813 178.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 98.1 mt -102.41 101.41 11.63 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.406 0.682 . . . . 73.15 109.481 177.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.7 t -85.66 97.87 6.09 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 109.043 -0.725 . . . . 75.13 109.043 -174.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 86.7 t -57.96 104.87 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 124.415 1.086 . . . . 71.13 111.47 -176.161 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -98.35 101.64 13.15 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-N 113.803 -1.544 . . . . 74.22 108.375 170.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.505 HD11 ' HA ' ' A' ' 154' ' ' ARG . 47.3 mt -69.64 126.77 30.73 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.634 -0.506 . . . . 73.13 109.634 176.509 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 59.5 mt -77.01 140.46 66.56 Favored Pre-proline 0 CA--C 1.548 0.865 0 N-CA-C 108.772 -0.825 . . . . 75.22 108.772 178.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -49.23 -73.54 0.04 OUTLIER 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 123.994 3.129 . . . . 54.23 113.165 -174.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 . . . . . 0 C--O 1.252 1.192 0 C-N-CA 124.538 1.135 . . . . 73.45 108.382 177.855 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 11.3 ttt . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 110.222 -0.288 . . . . 64.25 110.222 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.449 ' HG ' ' HA ' ' A' ' 100' ' ' THR . 2.7 tt 66.73 70.89 0.47 Allowed Pre-proline 0 CA--C 1.556 1.21 0 C-N-CA 124.316 1.046 . . . . 62.5 109.601 172.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -75.4 -60.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.385 2.495 0 C-N-CA 121.951 1.768 . . . . 74.11 111.828 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.47 HD12 ' H ' ' A' ' 98' ' ' LEU . 6.2 tp -169.32 135.96 1.69 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 106.696 -1.594 . . . . 73.42 106.696 -173.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.547 HD13 HD11 ' A' ' 176' ' ' LEU . 14.8 tp 70.67 -60.42 0.5 Allowed 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 126.89 2.076 . . . . 72.02 112.511 -173.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.706 ' HB2' ' HA ' ' A' ' 140' ' ' VAL . 32.7 t80 -61.45 113.29 2.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.201 1.0 . . . . 72.53 111.782 179.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.449 ' HA ' ' HG ' ' A' ' 95' ' ' LEU . 98.2 m -133.4 95.3 18.29 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 124.045 0.938 . . . . 73.54 109.575 175.471 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.47 84.25 1.41 Allowed 'Trans proline' 0 C--N 1.369 1.658 0 C-N-CA 122.317 2.011 . . . . 73.23 112.802 -175.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.43 HG13 HG22 ' A' ' 100' ' ' THR . 23.3 m -86.55 167.09 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-N 115.062 -0.972 . . . . 64.41 110.57 177.325 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.4 t -115.79 37.59 3.57 Favored 'General case' 0 CA--C 1.553 1.072 0 C-N-CA 123.205 0.602 . . . . 71.22 109.568 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.452 ' HE3' ' HA ' ' A' ' 104' ' ' LYS . 0.5 OUTLIER 72.18 -70.46 0.16 Allowed 'General case' 0 N--CA 1.49 1.539 0 C-N-CA 125.018 1.327 . . . . 64.54 109.946 -172.838 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 176.82 156.93 16.75 Favored Glycine 0 C--N 1.343 0.933 0 O-C-N 123.041 0.213 . . . . 75.23 112.83 176.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 67.4 m -80.97 -26.84 36.27 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 123.735 0.814 . . . . 74.05 110.732 172.304 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -68.21 158.71 51.96 Favored Glycine 0 C--N 1.348 1.228 0 O-C-N 124.071 0.857 . . . . 63.03 112.271 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -55.93 113.31 3.86 Favored Glycine 0 C--N 1.347 1.193 0 O-C-N 124.299 0.647 . . . . 41.05 112.404 178.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 12.1 m -77.11 -10.21 59.24 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 123.307 0.643 . . . . 71.22 111.314 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 80.18 -70.9 2.86 Favored Glycine 0 C--N 1.357 1.718 0 C-N-CA 123.174 0.416 . . . . 62.5 112.416 178.392 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -165.81 -137.78 2.28 Favored Glycine 0 C--N 1.341 0.814 0 N-CA-C 110.547 -1.021 . . . . 72.02 110.547 176.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 63.2 p -76.67 -5.76 49.28 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.168 0.587 . . . . 71.15 112.249 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -83.46 60.97 4.82 Favored Glycine 0 C--N 1.355 1.624 0 O-C-N 123.534 0.521 . . . . 55.33 113.189 -176.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -144.9 154.67 26.03 Favored Glycine 0 C--N 1.34 0.803 0 N-CA-C 110.372 -1.091 . . . . 73.14 110.372 176.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 27.2 m -93.8 -167.29 1.66 Allowed 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 123.215 0.606 . . . . 64.13 110.447 178.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -80.73 -159.88 22.29 Favored Glycine 0 C--N 1.344 0.974 0 N-CA-C 115.253 0.861 . . . . 70.44 115.253 -173.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 -68.89 128.55 37.08 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 108.64 -0.874 . . . . 71.43 108.64 -177.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -96.87 106.19 18.46 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 106.801 -1.555 . . . . 60.12 106.801 -178.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 15.7 mt -92.71 107.13 18.98 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 106.297 -1.742 . . . . 71.0 106.297 -172.127 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.504 ' HA ' ' HB2' ' A' ' 175' ' ' LEU . 59.6 ttt-85 -114.99 105.97 13.6 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 108.008 -1.108 . . . . 74.05 108.008 -176.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.52 146.67 50.43 Favored 'General case' 0 C--O 1.24 0.601 0 N-CA-C 108.742 -0.836 . . . . 61.03 108.742 -179.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -71.84 131.35 42.91 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 108.621 -0.881 . . . . 70.41 108.621 173.049 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.544 HD21 ' HG2' ' A' ' 136' ' ' ARG . 1.5 tt -98.4 103.27 17.41 Favored Pre-proline 0 CA--C 1.532 0.275 0 N-CA-C 106.352 -1.721 . . . . 73.23 106.352 176.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.474 ' HB2' HD11 ' A' ' 181' ' ' LEU . 50.5 Cg_endo -65.61 116.0 3.69 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 121.935 1.757 . . . . 74.35 109.786 174.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.464 HD21 HD12 ' A' ' 149' ' ' ILE . 15.6 tp -147.75 120.32 8.55 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.395 -0.595 . . . . 60.12 109.395 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.455 HG22 ' HB2' ' A' ' 181' ' ' LEU . 71.4 p -77.13 168.04 20.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.807 0.443 . . . . 51.43 111.724 -177.288 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.3 mt -55.64 -47.2 77.02 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 123.872 0.869 . . . . 74.13 112.137 -177.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -66.71 -41.4 88.02 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 115.959 -0.564 . . . . 74.3 111.279 -178.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -68.31 -31.86 71.59 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 122.91 0.484 . . . . 52.33 111.592 178.165 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -72.21 -39.38 68.59 Favored 'General case' 0 N--CA 1.47 0.548 0 C-N-CA 123.337 0.655 . . . . 61.44 111.07 177.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -63.21 -56.52 15.93 Favored 'General case' 0 N--CA 1.472 0.628 0 O-C-N 124.619 1.199 . . . . 61.23 110.011 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 50.3 m80 -70.24 -34.96 73.49 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.469 -0.787 . . . . 71.01 111.16 -177.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 68.94 -135.35 28.07 Favored Glycine 0 C--N 1.353 1.513 0 N-CA-C 111.949 -0.46 . . . . 33.52 111.949 -177.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.49 -143.28 16.5 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 112.201 -0.36 . . . . 62.44 112.201 178.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -104.44 148.36 26.52 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.237 0.541 . . . . 71.31 111.31 -178.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.544 ' HG2' HD21 ' A' ' 123' ' ' LEU . 2.2 tpp180 -137.16 119.1 15.28 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 106.741 -1.577 . . . . 74.43 106.741 175.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.59 115.97 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.704 0 CA-C-O 121.864 0.84 . . . . 75.41 109.801 -174.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 11.4 m -122.7 164.33 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.981 1.312 . . . . 74.03 108.828 -171.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -123.16 125.42 45.1 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 118.457 0.571 . . . . 74.41 111.936 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.706 ' HA ' ' HB2' ' A' ' 99' ' ' PHE . 4.0 p -113.52 111.37 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 C-N-CA 124.368 1.067 . . . . 62.12 110.17 175.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.34 26.3 14.97 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 123.807 0.843 . . . . 61.52 112.854 172.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.86 -12.03 60.84 Favored Glycine 0 C--N 1.352 1.421 0 CA-C-N 116.51 -0.314 . . . . 53.45 113.104 -177.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 20.1 tpp180 -92.22 115.86 28.44 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.637 0.775 . . . . 75.41 110.03 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 3.1 tpp180 -87.0 106.95 18.19 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.934 -0.765 . . . . 65.24 108.934 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 34.4 m -116.22 156.35 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 C-N-CA 123.911 0.884 . . . . 73.14 110.923 -178.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.0 p -91.32 141.95 28.22 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.53 0.732 . . . . 61.0 110.099 175.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 43.2 t -128.38 111.51 24.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.273 0 C-N-CA 124.747 1.219 . . . . 74.24 108.855 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -80.07 102.32 9.26 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.446 0.641 . . . . 60.42 109.417 178.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.464 HD12 HD21 ' A' ' 125' ' ' LEU . 16.5 pt -82.74 131.66 53.99 Favored Pre-proline 0 CA--C 1.559 1.296 0 CA-C-N 114.81 -1.086 . . . . 75.43 109.907 178.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 37.1 Cg_exo -64.22 135.86 48.87 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 122.656 2.237 . . . . 55.13 113.437 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -67.04 121.32 8.48 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 122.345 2.03 . . . . 52.31 110.742 168.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 87.82 27.47 26.47 Favored Glycine 0 CA--C 1.536 1.367 0 CA-C-N 115.549 -0.75 . . . . 73.23 113.22 -172.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.66 142.88 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 117.443 0.622 . . . . 64.41 109.74 176.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -112.7 177.6 4.58 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 121.635 0.731 . . . . 72.41 112.407 -172.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -65.02 133.49 51.79 Favored 'General case' 0 CA--C 1.54 0.585 0 CA-C-N 113.56 -1.654 . . . . 62.44 110.644 176.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 83.8 -14.02 44.96 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-O 119.24 -0.755 . . . . 53.34 113.353 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 68.4 m -66.28 117.79 9.05 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 117.422 0.611 . . . . 63.31 109.667 -175.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.21 133.57 33.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 CA-C-O 121.362 0.601 . . . . 75.32 110.001 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.538 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 94.0 mt -99.95 102.3 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 N-CA-C 106.519 -1.66 . . . . 72.04 106.519 177.145 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.536 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 61.1 ttp85 -99.31 110.18 22.73 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 116.354 -0.385 . . . . 70.44 110.184 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.93 100.55 10.05 Favored Pre-proline 0 CA--C 1.557 1.241 0 N-CA-C 107.525 -1.287 . . . . 72.41 107.525 170.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.45 136.7 29.17 Favored 'Trans proline' 0 C--N 1.376 1.976 0 C-N-CA 122.937 2.424 . . . . 75.41 112.637 -173.073 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.15 -21.82 11.37 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.889 -0.596 . . . . 64.22 113.883 177.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 56.8 mtt -100.52 16.42 24.74 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 123.563 0.745 . . . . 74.21 111.402 -173.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . 0.584 ' HA2' HD13 ' A' ' 174' ' ' LEU . . . -85.27 -103.45 0.67 Allowed Glycine 0 C--N 1.351 1.407 0 CA-C-N 116.196 -0.457 . . . . 74.23 112.236 176.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -66.86 103.18 0.86 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.807 -0.517 . . . . 25.22 111.807 175.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.5 mm-40 -88.61 152.7 21.67 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.704 0.801 . . . . 73.1 110.419 -179.115 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 134.17 -137.0 8.96 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.462 -1.055 . . . . 74.25 110.462 -172.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.533 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 14.9 m120 -71.97 -56.48 4.55 Favored Pre-proline 0 CA--C 1.563 1.479 0 CA-C-N 117.704 0.752 . . . . 73.25 111.243 176.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.533 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -93.82 119.64 0.34 Allowed 'Trans proline' 0 C--N 1.396 3.041 0 C-N-CA 122.443 2.095 . . . . 53.2 112.434 178.388 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -63.03 125.2 15.36 Favored 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.82 2.347 . . . . 73.43 112.271 174.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.83 173.77 23.89 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-N 116.576 -0.284 . . . . 74.32 112.472 177.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -95.05 134.93 37.21 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.082 0.553 . . . . 62.43 109.878 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.584 HD13 ' HA2' ' A' ' 165' ' ' GLY . 17.1 tp -97.79 119.36 36.25 Favored 'General case' 0 C--O 1.216 -0.673 0 N-CA-C 107.989 -1.115 . . . . 73.42 107.989 -178.533 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' A' ' 120' ' ' ARG . 65.6 mt -123.48 120.15 32.06 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.761 0.824 . . . . 71.34 109.598 -170.108 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.547 HD11 HD13 ' A' ' 98' ' ' LEU . 41.9 mt -123.0 101.12 7.24 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 123.254 0.622 . . . . 74.34 110.937 177.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.1 t -85.84 96.38 5.11 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 108.409 -0.96 . . . . 70.24 108.409 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 94.8 t -56.02 126.51 13.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 124.199 1.0 . . . . 53.15 111.721 -178.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.8 mmm-85 -112.87 110.01 19.83 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.786 -1.191 . . . . 75.03 107.786 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 46.0 mt -70.67 96.04 1.17 Allowed 'General case' 0 C--O 1.238 0.481 0 N-CA-C 109.408 -0.59 . . . . 71.44 109.408 178.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.474 HD11 ' HB2' ' A' ' 124' ' ' PRO . 80.4 mt -71.56 149.3 93.4 Favored Pre-proline 0 C--O 1.246 0.873 0 CA-C-N 114.711 -1.131 . . . . 62.34 110.445 -179.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -57.86 142.86 96.52 Favored 'Trans proline' 0 C--N 1.372 1.801 0 C-N-CA 122.557 2.171 . . . . 71.53 111.656 172.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 27.9 p80 . . . . . 0 CA--C 1.558 1.265 0 C-N-CA 123.543 0.737 . . . . 74.31 111.328 179.228 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 120.951 0.405 . . . . 63.32 110.377 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.454 ' H ' HD23 ' A' ' 95' ' ' LEU . 1.3 pt? -107.7 112.59 62.05 Favored Pre-proline 0 CA--C 1.545 0.776 0 CA-C-N 115.237 -0.892 . . . . 73.11 110.251 179.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_exo -73.34 -160.9 0.1 Allowed 'Trans proline' 0 C--N 1.368 1.56 0 C-N-CA 122.8 2.333 . . . . 72.51 111.25 167.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.541 HD12 ' H ' ' A' ' 98' ' ' LEU . 9.1 tp -72.04 141.47 49.28 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.819 -0.808 . . . . 71.23 108.819 171.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.677 HD13 HG21 ' A' ' 138' ' ' VAL . 6.0 tp 65.58 -68.16 0.12 Allowed 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 126.83 2.052 . . . . 45.31 111.579 -174.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.592 ' HA ' HD13 ' A' ' 119' ' ' LEU . 59.8 t80 -59.78 127.83 33.91 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 124.213 1.005 . . . . 70.41 111.708 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.502 HG22 HG13 ' A' ' 102' ' ' VAL . 56.3 m -141.75 104.61 5.81 Favored Pre-proline 0 N--CA 1.469 0.488 0 C-N-CA 124.086 0.954 . . . . 74.1 109.228 175.116 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.1 87.1 1.05 Allowed 'Trans proline' 0 C--N 1.362 1.278 0 C-N-CA 122.299 2.0 . . . . 60.31 112.97 -170.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.502 HG13 HG22 ' A' ' 100' ' ' THR . 22.8 m -113.37 170.81 4.18 Favored 'Isoleucine or valine' 0 C--O 1.239 0.525 0 CA-C-N 114.451 -1.25 . . . . 73.32 109.846 174.608 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.8 t -159.59 146.67 16.71 Favored 'General case' 0 C--O 1.24 0.586 0 C-N-CA 123.933 0.893 . . . . 52.35 109.392 173.105 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 32.0 mtmm -122.28 98.37 5.9 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.561 -0.903 . . . . 74.43 108.561 177.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -100.88 -114.21 3.71 Favored Glycine 0 N--CA 1.477 1.395 0 CA-C-O 119.185 -0.786 . . . . 62.25 111.558 177.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 78.0 p 48.16 55.12 9.19 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 125.646 1.578 . . . . 63.32 111.963 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 72.24 -93.6 0.61 Allowed Glycine 0 C--N 1.342 0.875 0 N-CA-C 110.439 -1.064 . . . . 70.02 110.439 -169.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 64.35 73.9 0.52 Allowed Glycine 0 C--N 1.351 1.379 0 O-C-N 123.83 0.371 . . . . 43.31 112.867 176.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.3 m -65.14 -45.73 83.83 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.839 0.855 . . . . 75.32 111.893 -173.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 75.78 -95.18 1.0 Allowed Glycine 0 C--N 1.347 1.139 0 CA-C-N 115.703 -0.68 . . . . 41.42 112.782 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 88.57 -7.85 80.7 Favored Glycine 0 C--N 1.346 1.107 0 N-CA-C 114.054 0.382 . . . . 40.34 114.054 179.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.6 t -158.17 137.45 11.7 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.299 0.64 . . . . 72.23 110.256 -176.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.68 -174.78 41.99 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 123.574 0.546 . . . . 72.55 113.877 176.039 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -88.01 -87.51 1.15 Allowed Glycine 0 C--N 1.342 0.9 0 CA-C-O 119.653 -0.526 . . . . 21.45 111.971 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.0 m 59.78 47.8 9.88 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 124.211 1.004 . . . . 71.24 111.436 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -68.85 -112.6 0.02 OUTLIER Glycine 0 CA--C 1.528 0.888 0 CA-C-N 115.035 -0.984 . . . . 74.44 112.598 176.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 42.9 mtt180 -98.26 135.29 40.1 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.072 0.549 . . . . 74.24 109.775 174.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -98.91 104.17 16.19 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 106.873 -1.529 . . . . 71.23 106.873 177.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.592 HD13 ' HA ' ' A' ' 99' ' ' PHE . 11.5 mt -92.71 110.44 21.88 Favored 'General case' 0 C--N 1.343 0.323 0 N-CA-C 106.633 -1.617 . . . . 65.21 106.633 -173.402 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -117.76 108.55 15.52 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 108.975 -0.75 . . . . 75.34 108.975 -178.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.48 154.02 51.15 Favored 'General case' 0 C--O 1.24 0.592 0 C-N-CA 123.193 0.597 . . . . 32.44 110.682 -171.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -72.13 131.58 43.0 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.291 -0.868 . . . . 60.23 109.109 173.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.627 HD21 ' HG2' ' A' ' 136' ' ' ARG . 2.4 tt -101.47 102.61 22.59 Favored Pre-proline 0 CA--C 1.544 0.733 0 N-CA-C 107.949 -1.13 . . . . 73.43 107.949 176.047 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.74 115.79 3.94 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 121.928 1.752 . . . . 71.51 110.019 173.143 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 46.3 tp -142.75 131.52 22.73 Favored 'General case' 0 C--O 1.225 -0.194 0 C-N-CA 123.648 0.779 . . . . 71.13 109.012 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 55.0 p -80.13 163.61 23.98 Favored 'General case' 0 CA--C 1.547 0.84 0 C-N-CA 122.865 0.466 . . . . 74.23 111.286 -176.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.9 mt -58.77 -51.82 68.35 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.666 0.787 . . . . 74.3 112.826 -171.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -64.83 -40.13 94.68 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 122.742 0.417 . . . . 74.02 111.109 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 15.3 mm-40 -69.49 -26.04 64.35 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 112.288 0.477 . . . . 74.03 112.288 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -69.11 -46.68 67.1 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 123.619 0.768 . . . . 63.21 109.743 172.096 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -61.93 -42.03 98.63 Favored 'General case' 0 CA--C 1.546 0.801 0 CA-C-N 114.614 -1.176 . . . . 64.41 111.039 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.4 m80 -72.97 -42.2 63.6 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 122.804 0.442 . . . . 72.34 110.317 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.85 -128.76 9.79 Favored Glycine 0 C--N 1.345 1.032 0 CA-C-N 115.309 -0.86 . . . . 53.13 111.308 -172.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.416 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 80.38 -158.5 41.79 Favored Glycine 0 C--N 1.348 1.24 0 CA-C-N 116.834 0.317 . . . . 43.53 112.805 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -84.0 147.16 27.59 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 117.329 0.564 . . . . 71.13 109.763 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.627 ' HG2' HD21 ' A' ' 123' ' ' LEU . 27.0 tpt180 -128.33 121.2 28.63 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 123.433 0.693 . . . . 73.22 109.178 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.416 HG13 ' HG3' ' A' ' 144' ' ' ARG . 93.1 t -79.22 106.87 10.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.455 0 C-N-CA 123.975 0.91 . . . . 73.03 109.265 178.055 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.677 HG21 HD13 ' A' ' 98' ' ' LEU . 20.7 m -111.13 159.64 10.97 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 123.863 0.865 . . . . 74.13 109.377 176.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -116.79 138.12 51.72 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 107.703 -1.221 . . . . 73.24 107.703 -176.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.572 HG13 ' HB2' ' A' ' 143' ' ' ARG . 3.7 p -150.15 107.12 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 C-N-CA 123.212 0.605 . . . . 60.53 111.498 -176.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.18 20.6 8.63 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 113.359 0.874 . . . . 44.5 113.359 169.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.9 28.31 7.87 Favored Glycine 0 C--N 1.344 0.976 0 C-N-CA 122.903 0.287 . . . . 73.12 112.582 -175.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.572 ' HB2' HG13 ' A' ' 140' ' ' VAL . 82.3 mtt85 -133.68 156.64 47.55 Favored 'General case' 0 N--CA 1.486 1.352 0 C-N-CA 123.533 0.733 . . . . 74.13 110.095 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.416 ' HG3' HG13 ' A' ' 137' ' ' VAL . 31.6 ttm180 -109.86 119.77 40.39 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.754 0.822 . . . . 75.44 109.169 170.457 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.404 ' O ' HG22 ' A' ' 138' ' ' VAL . 69.8 t -115.69 135.63 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 108.421 -0.955 . . . . 53.24 108.421 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 28.9 p -103.2 104.78 14.96 Favored 'General case' 0 CA--C 1.539 0.542 0 N-CA-C 109.141 -0.688 . . . . 72.03 109.141 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 4.7 p -98.3 120.29 47.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 109.172 -0.677 . . . . 74.32 109.172 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 47.3 ttp180 -78.21 100.37 6.62 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-O 121.415 0.626 . . . . 74.2 109.33 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.562 HD13 ' HB2' ' A' ' 136' ' ' ARG . 3.1 pt -79.55 144.9 62.03 Favored Pre-proline 0 CA--C 1.563 1.449 0 CA-C-N 114.639 -1.164 . . . . 72.33 109.766 178.444 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -61.93 136.82 63.71 Favored 'Trans proline' 0 CA--C 1.562 1.891 0 C-N-CA 123.005 2.47 . . . . 52.43 113.393 -179.033 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -62.18 113.12 1.76 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.948 2.432 . . . . 55.22 111.179 172.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.47 35.51 8.59 Favored Glycine 0 C--N 1.34 0.765 0 O-C-N 123.616 0.573 . . . . 72.41 112.379 -176.241 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.415 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 12.6 p -76.65 145.85 9.69 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 N-CA-C 109.818 -0.438 . . . . 70.24 109.818 176.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -118.39 177.15 4.92 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.651 0.739 . . . . 75.14 112.636 -171.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -64.68 135.05 55.47 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 113.989 -1.459 . . . . 63.42 110.974 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.22 -6.13 64.73 Favored Glycine 0 C--N 1.343 0.959 0 CA-C-N 115.767 -0.652 . . . . 75.1 113.646 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 56.0 m -74.85 118.89 18.31 Favored 'General case' 0 C--N 1.351 0.647 0 CA-C-N 117.502 0.651 . . . . 72.43 109.506 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.0 p -99.05 134.25 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 C-N-CA 123.087 0.555 . . . . 64.01 110.413 -177.136 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 67.7 mt -105.94 105.87 19.51 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 C-N-CA 124.328 1.051 . . . . 73.14 108.71 -175.125 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 58.0 ttm-85 -87.96 111.86 21.94 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.81 0.444 . . . . 74.41 110.405 -178.318 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.4 t -123.95 98.95 38.66 Favored Pre-proline 0 CA--C 1.554 1.124 0 C-N-CA 123.942 0.897 . . . . 72.44 109.0 179.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.28 131.75 21.13 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.488 2.126 . . . . 75.32 112.22 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 99.89 -23.17 37.07 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.761 -0.654 . . . . 52.51 113.56 176.099 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.2 mpt? -89.57 6.56 40.55 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.107 0.563 . . . . 74.24 111.288 178.004 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -85.51 -108.37 0.7 Allowed Glycine 0 C--N 1.344 1.001 0 N-CA-C 111.556 -0.617 . . . . 74.32 111.556 174.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -73.6 108.93 2.64 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 112.286 -0.326 . . . . 74.35 112.286 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.577 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -88.36 148.46 24.24 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.194 0.598 . . . . 63.1 110.885 -179.493 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 142.48 -138.51 8.49 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 111.062 -0.815 . . . . 73.51 111.062 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.457 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 3.4 m-20 -78.41 -49.16 1.82 Allowed Pre-proline 0 CA--C 1.566 1.578 0 CA-C-O 118.29 -0.862 . . . . 44.34 110.644 175.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.457 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 72.6 Cg_endo -94.97 106.41 0.12 Allowed 'Trans proline' 0 C--N 1.396 3.034 0 C-N-CA 122.658 2.238 . . . . 63.23 111.905 172.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.37 125.23 13.63 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 122.025 1.817 . . . . 70.51 111.456 174.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -99.97 173.96 26.06 Favored Glycine 0 C--N 1.34 0.797 0 CA-C-N 116.041 -0.527 . . . . 72.12 111.975 175.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -92.48 152.57 19.6 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 123.309 0.644 . . . . 72.31 110.663 -174.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.463 HD21 HD11 ' A' ' 98' ' ' LEU . 59.3 tp -114.23 133.76 55.4 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 123.901 0.88 . . . . 53.43 109.75 179.011 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.3 mt -129.85 103.46 6.82 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.021 0.928 . . . . 63.24 110.428 176.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.602 HD21 HD12 ' A' ' 98' ' ' LEU . 82.8 mt -101.77 103.18 13.9 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 123.072 0.549 . . . . 72.3 111.212 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.9 t -84.11 97.68 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 N-CA-C 108.954 -0.758 . . . . 64.31 108.954 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 89.5 t -57.03 130.26 19.67 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 124.024 0.93 . . . . 71.51 111.436 -178.199 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 27.0 mmt180 -121.4 105.32 10.4 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 125.068 1.347 . . . . 63.4 107.912 -177.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 24.1 mt -70.32 109.8 4.92 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.377 -0.601 . . . . 63.23 109.377 178.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.8 mt -72.27 149.97 91.82 Favored Pre-proline 0 CA--C 1.549 0.942 0 C-N-CA 123.062 0.545 . . . . 75.22 110.097 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -58.93 97.49 0.09 OUTLIER 'Trans proline' 0 C--N 1.376 2.005 0 C-N-CA 122.898 2.399 . . . . 61.33 110.98 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 . . . . . 0 C--O 1.249 1.078 0 C-N-CA 124.772 1.229 . . . . 64.24 109.702 -172.574 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 22.6 ptt? . . . . . 0 N--CA 1.482 1.139 0 CA-C-O 120.432 0.158 . . . . 71.33 111.019 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 tt 63.26 74.08 0.47 Allowed Pre-proline 0 CA--C 1.556 1.202 0 C-N-CA 124.858 1.263 . . . . 71.24 111.664 166.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -90.81 -152.04 0.04 OUTLIER 'Trans proline' 0 CA--C 1.553 1.434 0 C-N-CA 122.827 2.351 . . . . 73.44 111.101 168.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.584 HD12 ' H ' ' A' ' 98' ' ' LEU . 12.1 tp -74.69 144.52 43.71 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.961 0.905 . . . . 73.24 109.41 175.24 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.603 HD13 HG21 ' A' ' 138' ' ' VAL . 9.0 tp 64.4 -67.79 0.11 Allowed 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 127.731 2.412 . . . . 74.21 112.002 -171.422 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.713 ' HA ' HD13 ' A' ' 119' ' ' LEU . 60.7 t80 -64.58 130.01 42.01 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.411 1.084 . . . . 75.31 111.531 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.473 HG22 HG13 ' A' ' 102' ' ' VAL . 39.7 m -146.09 98.29 4.39 Favored Pre-proline 0 CA--C 1.54 0.58 0 C-N-CA 124.679 1.192 . . . . 75.14 108.766 178.01 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -72.26 87.11 0.92 Allowed 'Trans proline' 0 C--N 1.366 1.471 0 C-N-CA 122.192 1.928 . . . . 72.01 112.554 -171.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.473 HG13 HG22 ' A' ' 100' ' ' THR . 14.7 m -98.42 152.12 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 C-N-CA 124.332 1.053 . . . . 71.33 108.745 173.362 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 8.8 t -102.81 -24.62 13.7 Favored 'General case' 0 C--O 1.244 0.781 0 C-N-CA 123.275 0.63 . . . . 61.41 111.341 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.8 pptp? -85.56 162.64 18.79 Favored 'General case' 0 N--CA 1.481 1.108 0 CA-C-O 121.386 0.612 . . . . 73.2 110.818 -171.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 175.14 171.08 38.86 Favored Glycine 0 C--N 1.337 0.638 0 CA-C-N 115.029 -0.987 . . . . 53.34 111.375 176.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 44.7 t -74.13 -7.16 51.58 Favored 'General case' 0 CA--C 1.553 1.078 0 C-N-CA 123.553 0.741 . . . . 50.31 111.38 178.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -81.13 54.25 4.71 Favored Glycine 0 C--N 1.356 1.647 0 C-N-CA 123.142 0.401 . . . . 64.03 113.126 177.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.8 24.25 0.42 Allowed Glycine 0 C--N 1.341 0.826 0 N-CA-C 109.88 -1.288 . . . . 71.54 109.88 173.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 32.8 t -157.63 -43.39 0.07 Allowed 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 124.788 1.235 . . . . 65.13 109.138 -176.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 156.22 -169.78 33.79 Favored Glycine 0 C--N 1.355 1.633 0 CA-C-N 115.959 -0.564 . . . . 72.33 112.408 177.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 151.92 165.12 12.79 Favored Glycine 0 CA--C 1.529 0.915 0 C-N-CA 122.686 0.184 . . . . 71.31 112.914 176.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.3 m -71.01 90.41 0.83 Allowed 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 123.6 0.76 . . . . 64.24 109.668 174.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 88.72 -43.66 3.1 Favored Glycine 0 C--N 1.349 1.261 0 CA-C-N 115.929 -0.578 . . . . 74.44 111.719 -171.029 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 135.01 -167.37 24.09 Favored Glycine 0 C--N 1.343 0.945 0 N-CA-C 110.471 -1.051 . . . . 75.15 110.471 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 46.8 m -148.95 125.52 11.02 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.088 -0.708 . . . . 53.41 109.088 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -83.62 -140.16 4.11 Favored Glycine 0 CA--C 1.531 1.051 0 N-CA-C 112.199 -0.36 . . . . 62.11 112.199 175.305 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.651 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 37.5 mtm180 -90.08 141.27 28.85 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 123.672 0.789 . . . . 61.34 109.495 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -99.8 107.49 19.54 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 108.188 -1.041 . . . . 62.1 108.188 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.713 HD13 ' HA ' ' A' ' 99' ' ' PHE . 16.4 mt -93.63 111.05 22.66 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 107.64 -1.244 . . . . 60.14 107.64 -175.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 49.3 ttp85 -114.6 105.61 13.28 Favored 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 108.896 -0.779 . . . . 73.34 108.896 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -133.08 145.66 50.96 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 123.68 0.792 . . . . 45.4 109.633 -175.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.504 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 3.2 mp0 -74.16 131.73 41.55 Favored 'General case' 0 C--O 1.237 0.44 0 C-N-CA 123.667 0.787 . . . . 54.25 109.225 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.532 HD11 ' HG2' ' A' ' 136' ' ' ARG . 40.9 tp -100.12 102.89 19.57 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 124.29 1.036 . . . . 71.1 109.134 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -67.86 114.56 3.39 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 122.274 1.982 . . . . 70.14 109.956 176.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.538 HD21 HD12 ' A' ' 149' ' ' ILE . 15.3 tp -143.86 131.43 21.15 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.066 -0.716 . . . . 74.1 109.066 -171.339 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.8 p -80.52 170.51 16.25 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 110.296 -0.261 . . . . 62.12 110.296 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 84.8 mt -61.37 -34.74 75.83 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 123.837 0.855 . . . . 72.41 111.157 -178.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -72.79 -51.67 18.07 Favored 'General case' 0 C--N 1.345 0.379 0 CA-C-N 114.776 -1.102 . . . . 75.34 108.803 -176.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -66.94 -26.72 66.98 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.01 -0.996 . . . . 61.01 111.575 -176.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.447 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -74.87 -50.47 16.89 Favored 'General case' 0 C--N 1.348 0.521 0 C-N-CA 123.901 0.88 . . . . 55.0 111.375 176.102 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -58.61 -46.15 87.66 Favored 'General case' 0 C--N 1.361 1.068 0 O-C-N 124.308 1.005 . . . . 72.05 110.664 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -77.78 -40.63 40.11 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.279 -0.873 . . . . 74.42 111.033 -176.418 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.58 -164.53 50.9 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 111.828 -0.509 . . . . 63.13 111.828 -175.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.471 ' O ' HG12 ' A' ' 149' ' ' ILE . . . 119.49 -161.11 14.18 Favored Glycine 0 N--CA 1.473 1.12 0 N-CA-C 111.774 -0.53 . . . . 62.12 111.774 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 15.6 mp0 -81.52 141.63 33.63 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.046 0.539 . . . . 75.23 110.253 177.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.532 ' HG2' HD11 ' A' ' 123' ' ' LEU . 19.4 tpp180 -126.75 121.28 31.56 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.969 0.908 . . . . 60.44 108.768 178.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 56.0 t -81.28 107.63 13.72 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 C-N-CA 123.339 0.656 . . . . 75.23 109.614 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.603 HG21 HD13 ' A' ' 98' ' ' LEU . 25.5 m -116.37 164.63 12.53 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 C-N-CA 125.297 1.439 . . . . 72.2 109.318 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -122.41 131.48 53.9 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 123.446 0.699 . . . . 64.42 109.575 -171.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.415 ' HB ' HD23 ' A' ' 98' ' ' LEU . 5.2 p -142.54 102.41 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.321 0 C-N-CA 124.211 1.004 . . . . 72.22 111.656 -174.002 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.55 25.93 14.86 Favored 'General case' 0 N--CA 1.493 1.681 0 C-N-CA 124.229 1.012 . . . . 74.51 112.759 175.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.56 -0.8 53.01 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 123.901 0.762 . . . . 55.51 113.438 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.4 ' HB2' HG13 ' A' ' 140' ' ' VAL . 31.5 mmm180 -104.07 141.89 35.42 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.421 0.689 . . . . 64.34 110.367 -177.458 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -97.81 113.89 25.8 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.753 0.821 . . . . 73.15 109.284 178.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 73.6 t -118.51 129.6 74.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 123.859 0.864 . . . . 74.01 109.561 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 33.5 p -97.39 106.58 18.92 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 109.063 -0.717 . . . . 73.33 109.063 174.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.3 p -98.7 125.9 51.99 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 123.494 0.717 . . . . 71.41 109.76 -177.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.2 ttt180 -81.99 105.06 12.79 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.379 0.672 . . . . 70.22 109.62 -177.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.538 HD12 HD21 ' A' ' 125' ' ' LEU . 4.8 pt -87.24 146.03 39.18 Favored Pre-proline 0 C--O 1.253 1.265 0 C-N-CA 124.68 1.192 . . . . 74.42 109.343 176.493 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.455 ' HG2' ' HB ' ' A' ' 153' ' ' VAL . 57.0 Cg_endo -72.04 143.09 39.69 Favored 'Trans proline' 0 CA--C 1.56 1.799 0 C-N-CA 122.441 2.094 . . . . 72.24 112.76 -179.732 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.39 130.49 22.53 Favored 'Trans proline' 0 C--N 1.375 1.941 0 C-N-CA 122.493 2.129 . . . . 52.34 111.262 171.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.82 27.57 45.73 Favored Glycine 0 CA--C 1.525 0.719 0 CA-C-N 115.548 -0.751 . . . . 51.41 112.243 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.455 ' HB ' ' HG2' ' A' ' 150' ' ' PRO . 12.4 p -76.62 147.71 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 108.989 -0.745 . . . . 51.03 108.989 176.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.0 mtp180 -125.12 176.06 6.96 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-O 121.993 0.901 . . . . 72.32 112.591 -166.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -64.42 123.9 20.38 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-N 113.292 -1.776 . . . . 71.4 110.332 175.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.54 89.55 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.798 0.686 . . . . 33.42 113.611 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.3 m -76.54 118.49 19.25 Favored 'General case' 0 C--N 1.35 0.614 0 N-CA-C 108.778 -0.823 . . . . 71.44 108.778 176.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 6.7 p -99.12 124.7 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 CA-C-O 121.437 0.637 . . . . 71.33 109.677 179.229 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.5 mt -95.14 102.85 14.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 C-N-CA 124.324 1.05 . . . . 73.25 108.23 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.503 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 35.1 ttm180 -87.28 107.91 18.72 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 109.49 -0.559 . . . . 74.31 109.49 174.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.9 t -105.7 107.69 59.92 Favored Pre-proline 0 CA--C 1.55 0.956 0 N-CA-C 107.428 -1.323 . . . . 71.11 107.428 173.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -66.02 135.4 40.61 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.484 2.123 . . . . 74.52 112.043 -177.131 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 80.39 -5.33 64.19 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 114.723 0.649 . . . . 73.12 114.723 174.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 96.3 mmm -103.9 16.58 26.01 Favored 'General case' 0 N--CA 1.489 1.476 0 CA-C-N 117.807 0.803 . . . . 61.32 111.842 -176.224 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -90.88 -142.29 10.07 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 116.149 -0.478 . . . . 54.21 111.983 175.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.651 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -77.69 127.93 8.58 Favored Glycine 0 C--N 1.343 0.965 0 N-CA-C 111.638 -0.585 . . . . 63.51 111.638 -177.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.9 mm-40 -83.61 151.64 25.23 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 123.46 0.704 . . . . 75.5 110.513 -175.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -148.75 -125.85 1.48 Allowed Glycine 0 N--CA 1.468 0.828 0 N-CA-C 109.559 -1.417 . . . . 74.12 109.559 177.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.558 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 23.2 t30 -74.63 -51.26 4.14 Favored Pre-proline 0 CA--C 1.564 1.493 0 N-CA-C 108.118 -1.067 . . . . 71.55 108.118 161.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.558 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 49.4 Cg_endo -100.13 164.45 0.47 Allowed 'Trans proline' 0 C--N 1.39 2.731 0 C-N-CA 122.74 2.294 . . . . 72.12 111.689 165.324 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.21 136.68 14.61 Favored 'Trans proline' 0 CA--C 1.557 1.67 0 C-N-CA 121.794 1.662 . . . . 73.24 112.182 174.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -86.78 179.7 48.89 Favored Glycine 0 C--N 1.348 1.218 0 CA-C-O 119.999 -0.334 . . . . 24.42 112.552 175.16 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -97.48 148.53 23.13 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.043 0.537 . . . . 74.32 110.956 -173.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.503 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 56.8 tp -107.01 132.73 52.62 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.052 0.941 . . . . 72.2 110.368 -178.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 93.6 mt -129.37 104.02 7.25 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 125.023 1.329 . . . . 73.21 109.609 176.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.524 HD21 HD12 ' A' ' 98' ' ' LEU . 65.9 mt -104.54 103.44 13.12 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 122.98 0.512 . . . . 54.33 110.518 176.476 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.5 t -84.83 93.6 3.57 Favored 'Isoleucine or valine' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 71.04 108.603 -177.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.499 HG22 HD23 ' A' ' 123' ' ' LEU . 97.3 t -56.7 127.66 16.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 124.098 0.959 . . . . 75.54 111.264 -178.429 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . 0.504 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.9 mmt180 -121.57 114.49 21.27 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 124.546 1.138 . . . . 70.51 108.435 -179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 75.1 mt -72.48 106.16 4.46 Favored 'General case' 0 C--O 1.241 0.648 0 O-C-N 123.826 0.704 . . . . 53.1 110.132 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 72.1 mt -66.22 153.77 91.6 Favored Pre-proline 0 CA--C 1.546 0.807 0 CA-C-N 115.868 -0.605 . . . . 64.2 110.522 179.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -56.99 140.79 93.39 Favored 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 122.899 2.4 . . . . 62.11 111.218 173.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 . . . . . 0 C--O 1.251 1.159 0 N-CA-C 109.329 -0.619 . . . . 72.3 109.329 -179.098 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 62.4 mtt . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 110.0 -0.37 . . . . 64.5 110.0 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.3 pt? 37.16 75.21 0.54 Allowed Pre-proline 0 N--CA 1.488 1.464 0 C-N-CA 125.757 1.623 . . . . 65.51 113.346 -173.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.69 -44.63 7.87 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 122.074 1.849 . . . . 62.14 110.832 176.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.562 HD12 ' H ' ' A' ' 98' ' ' LEU . 5.6 tp -177.99 144.52 0.34 Allowed 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 125.495 1.518 . . . . 50.44 107.807 177.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.888 HD23 ' HB ' ' A' ' 140' ' ' VAL . 18.2 tp 62.68 -70.16 0.06 Allowed 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 126.779 2.031 . . . . 75.23 112.226 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.563 ' HA ' HD13 ' A' ' 119' ' ' LEU . 76.8 t80 -63.23 130.76 45.93 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.335 1.054 . . . . 75.35 110.785 174.37 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.487 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 52.3 m -139.65 102.55 7.12 Favored Pre-proline 0 N--CA 1.468 0.446 0 C-N-CA 124.2 1.0 . . . . 61.12 109.475 177.049 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_endo -72.87 89.68 0.86 Allowed 'Trans proline' 0 C--N 1.359 1.106 0 C-N-CA 121.676 1.584 . . . . 73.43 111.159 -177.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.5 m -85.55 172.17 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 CA-C-N 115.789 -0.641 . . . . 74.13 109.601 170.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.9 t -128.77 119.02 23.8 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 108.461 -0.94 . . . . 61.43 108.461 177.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 14.7 mmmm -95.2 85.69 4.36 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-O 121.066 0.46 . . . . 71.1 110.651 -174.144 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -116.91 24.97 9.16 Favored Glycine 0 C--N 1.344 1.004 0 N-CA-C 110.748 -0.941 . . . . 62.03 110.748 170.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 16.7 p -70.13 93.35 0.81 Allowed 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 123.64 0.776 . . . . 71.11 110.74 -178.206 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.94 -43.1 3.2 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-N 115.625 -0.716 . . . . 73.53 113.27 178.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.9 -123.53 5.84 Favored Glycine 0 C--N 1.348 1.209 0 N-CA-C 110.483 -1.047 . . . . 74.05 110.483 -178.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 30.3 t -79.11 83.41 5.18 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 123.424 0.689 . . . . 52.32 110.193 -179.226 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -128.89 100.92 0.53 Allowed Glycine 0 C--N 1.342 0.916 0 N-CA-C 110.525 -1.03 . . . . 45.11 110.525 -177.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -67.84 83.89 0.16 Allowed Glycine 0 C--N 1.346 1.088 0 O-C-N 124.302 0.648 . . . . 71.24 112.806 -178.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.0 m -97.28 22.23 8.95 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 124.418 1.087 . . . . 53.32 110.667 -178.046 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 92.47 -107.05 3.47 Favored Glycine 0 C--N 1.349 1.294 0 N-CA-C 111.321 -0.712 . . . . 51.24 111.321 -174.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.53 -51.48 16.28 Favored Glycine 0 C--N 1.351 1.381 0 N-CA-C 111.753 -0.539 . . . . 64.1 111.753 177.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 13.1 m 60.51 15.12 5.34 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 124.542 1.137 . . . . 71.12 112.747 174.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -79.08 -163.36 25.24 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 115.535 0.974 . . . . 72.31 115.535 -168.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 -80.06 117.62 21.05 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 108.144 -1.058 . . . . 74.04 108.144 -173.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -94.44 104.87 16.84 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 107.314 -1.365 . . . . 75.22 107.314 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.563 HD13 ' HA ' ' A' ' 99' ' ' PHE . 11.8 mt -92.53 111.83 23.55 Favored 'General case' 0 C--N 1.345 0.384 0 N-CA-C 107.785 -1.191 . . . . 71.5 107.785 -172.079 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 68.6 ttt180 -120.13 107.82 13.5 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.253 1.021 . . . . 74.24 108.724 -177.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.19 148.16 50.85 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.066 0.546 . . . . 73.24 111.531 -171.371 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.593 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.5 mp0 -68.3 125.06 25.24 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 124.403 1.081 . . . . 63.25 109.443 170.338 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.45 HD12 HD13 ' A' ' 176' ' ' LEU . 2.5 tt -101.67 102.9 24.78 Favored Pre-proline 0 CA--C 1.543 0.687 0 N-CA-C 108.104 -1.073 . . . . 64.24 108.104 175.142 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.39 115.54 3.57 Favored 'Trans proline' 0 C--N 1.378 2.107 0 C-N-CA 121.689 1.592 . . . . 74.34 109.636 171.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.585 HD21 HD12 ' A' ' 149' ' ' ILE . 14.0 tp -137.64 123.11 19.6 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.6 -0.889 . . . . 61.4 108.6 -170.166 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.9 p -73.81 169.99 16.23 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 117.785 0.266 . . . . 62.22 110.705 -178.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 97.1 mt -62.76 -33.43 75.14 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.575 0.75 . . . . 73.42 111.042 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -71.76 -45.51 61.45 Favored 'General case' 0 C--N 1.352 0.683 0 O-C-N 123.783 0.677 . . . . 73.13 109.312 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -64.18 -35.46 80.88 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 123.695 0.798 . . . . 72.21 111.634 176.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -71.43 -42.91 67.67 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.46 0.704 . . . . 75.42 111.867 -179.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.1 t80 -68.39 -50.88 49.8 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-N 114.884 -1.053 . . . . 71.4 110.102 -179.09 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -75.06 -42.0 57.86 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 115.669 -0.696 . . . . 74.31 111.213 -174.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 75.31 -134.5 16.82 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.564 0.54 . . . . 64.22 111.844 -177.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 76.27 -146.69 33.53 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-O 119.658 -0.523 . . . . 71.41 111.856 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.42 ' HB3' ' HB2' ' A' ' 146' ' ' SER . 1.4 mp0 -85.18 146.69 26.98 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 117.83 0.815 . . . . 74.03 110.412 178.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.596 ' HB2' HD13 ' A' ' 149' ' ' ILE . 24.7 tpt180 -129.05 121.55 28.11 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 124.244 1.018 . . . . 73.24 108.936 177.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 83.5 t -82.18 108.72 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 C-N-CA 123.499 0.72 . . . . 73.02 109.736 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.574 HG23 HD22 ' A' ' 98' ' ' LEU . 33.6 m -128.11 162.15 34.92 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.012 0 C-N-CA 124.995 1.318 . . . . 42.25 108.825 178.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -107.32 138.09 44.16 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 122.882 0.473 . . . . 73.42 110.191 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.888 ' HB ' HD23 ' A' ' 98' ' ' LEU . 3.0 p -123.27 105.87 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 124.564 1.146 . . . . 74.24 109.06 171.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.29 26.11 14.87 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.744 0.818 . . . . 72.55 112.863 174.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 100.28 11.03 43.32 Favored Glycine 0 C--N 1.35 1.349 0 CA-C-O 119.901 -0.388 . . . . 64.55 113.843 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -115.31 118.38 33.09 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 117.429 0.615 . . . . 71.54 110.192 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -82.51 106.14 14.13 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.43 0.692 . . . . 72.12 109.956 -178.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 25.9 m -121.44 155.6 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.6 0.76 . . . . 62.42 110.342 -179.246 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.42 ' HB2' ' HB3' ' A' ' 135' ' ' GLU . 14.1 p -106.61 110.15 22.26 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.635 0.774 . . . . 53.21 109.646 175.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.6 p -99.22 128.99 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 124.061 0.944 . . . . 62.21 109.205 177.219 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 42.9 ttp180 -77.95 109.2 11.79 Favored 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.051 0.453 . . . . 63.35 110.506 -175.152 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.596 HD13 ' HB2' ' A' ' 136' ' ' ARG . 5.0 pt -86.55 142.74 35.25 Favored Pre-proline 0 CA--C 1.558 1.253 0 C-N-CA 124.484 1.113 . . . . 75.54 108.775 173.397 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.411 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 73.0 Cg_endo -75.47 137.24 20.47 Favored 'Trans proline' 0 CA--C 1.562 1.902 0 C-N-CA 122.191 1.927 . . . . 65.34 111.822 177.353 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 35.9 Cg_exo -63.44 135.9 52.11 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 122.761 2.308 . . . . 72.05 112.327 174.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.51 14.6 61.41 Favored Glycine 0 CA--C 1.534 1.253 0 O-C-N 123.636 0.585 . . . . 65.25 113.401 -176.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.18 143.26 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.324 0.649 . . . . 63.41 110.374 -177.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -118.49 177.5 4.8 Favored 'General case' 0 N--CA 1.484 1.24 0 CA-C-O 121.651 0.738 . . . . 55.04 112.894 -169.626 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -63.49 126.69 28.32 Favored 'General case' 0 CA--C 1.543 0.71 0 CA-C-N 113.855 -1.52 . . . . 71.44 110.11 174.807 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -10.15 65.46 Favored Glycine 0 CA--C 1.532 1.129 0 O-C-N 124.111 0.882 . . . . 21.21 113.968 -177.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.1 m -69.86 120.33 15.43 Favored 'General case' 0 C--N 1.356 0.888 0 CA-C-N 117.861 0.83 . . . . 74.14 109.989 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.61 139.86 17.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 C-N-CA 122.817 0.447 . . . . 71.32 110.077 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 44.6 mt -110.94 102.23 13.68 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 N-CA-C 106.85 -1.537 . . . . 55.51 106.85 178.359 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 6.0 ttp180 -88.15 102.17 14.53 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 108.961 -0.755 . . . . 65.14 108.961 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 14.5 t -95.2 113.05 60.66 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 107.746 -1.205 . . . . 54.24 107.746 175.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -70.39 128.45 15.47 Favored 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 122.847 2.365 . . . . 64.15 112.688 -169.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 63.49 23.42 66.74 Favored Glycine 0 C--N 1.351 1.392 0 O-C-N 123.592 0.558 . . . . 62.22 114.371 175.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 51.8 tpp -100.62 -18.4 16.58 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 123.487 0.715 . . . . 72.54 111.066 -177.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -72.45 -95.9 0.08 OUTLIER Glycine 0 C--N 1.345 1.035 0 CA-C-N 115.832 -0.622 . . . . 45.34 113.256 -175.376 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -72.36 86.75 0.5 Allowed Glycine 0 C--N 1.346 1.117 0 N-CA-C 112.252 -0.339 . . . . 71.45 112.252 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.65 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -81.93 121.64 26.75 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.376 0.67 . . . . 62.33 109.978 179.654 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 162.31 -142.12 7.72 Favored Glycine 0 C--O 1.241 0.591 0 N-CA-C 111.282 -0.727 . . . . 71.33 111.282 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.513 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 19.3 m120 -67.43 -49.43 42.25 Favored Pre-proline 0 CA--C 1.566 1.56 0 CA-C-O 118.271 -0.871 . . . . 72.22 110.886 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.513 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 74.5 Cg_endo -96.48 106.69 0.1 OUTLIER 'Trans proline' 0 C--N 1.395 3.023 0 C-N-CA 123.125 2.55 . . . . 73.44 111.485 170.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.01 129.87 24.28 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.641 2.227 . . . . 34.23 111.778 178.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -117.97 157.33 15.22 Favored Glycine 0 C--N 1.338 0.642 0 N-CA-C 111.501 -0.64 . . . . 54.33 111.501 178.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -89.7 158.85 17.38 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 123.603 0.761 . . . . 72.33 110.558 -177.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.432 HD21 HD11 ' A' ' 98' ' ' LEU . 67.0 tp -115.7 132.64 56.57 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.834 0.853 . . . . 74.32 109.948 -177.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.7 mt -127.84 101.41 6.33 Favored 'General case' 0 CA--C 1.549 0.925 0 C-N-CA 125.35 1.46 . . . . 55.12 109.236 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.528 HD21 HD12 ' A' ' 98' ' ' LEU . 75.7 mt -101.46 100.83 11.33 Favored 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 123.11 0.564 . . . . 71.42 110.923 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 4.7 t -85.53 95.26 4.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 N-CA-C 108.409 -0.96 . . . . 75.02 108.409 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 73.9 t -54.67 135.03 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 124.695 1.198 . . . . 71.24 111.629 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . 0.593 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 30.3 mmt180 -128.27 107.68 9.97 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.312 -1.366 . . . . 63.33 107.312 -177.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 53.3 mt -69.98 121.62 17.75 Favored 'General case' 0 N--CA 1.47 0.534 0 O-C-N 123.438 0.461 . . . . 73.23 109.943 -177.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 83.8 mt -85.46 140.64 36.2 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.894 -0.594 . . . . 72.02 110.268 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.56 -15.9 34.14 Favored 'Trans proline' 0 C--N 1.372 1.774 0 C-N-CA 122.667 2.245 . . . . 75.22 111.872 172.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 35.9 m80 . . . . . 0 C--N 1.356 0.849 0 C-N-CA 124.308 1.043 . . . . 64.52 108.264 176.994 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 84.3 mtp . . . . . 0 N--CA 1.488 1.448 0 N-CA-C 109.663 -0.495 . . . . 61.14 109.663 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 40.88 81.85 0.24 Allowed Pre-proline 0 N--CA 1.491 1.586 0 C-N-CA 125.906 1.683 . . . . 60.14 113.688 -177.311 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -64.71 -55.93 0.47 Allowed 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 122.494 2.129 . . . . 61.33 112.0 177.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.485 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.2 tp -177.55 134.88 0.18 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 124.785 1.234 . . . . 74.42 108.18 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.526 HD22 HG23 ' A' ' 138' ' ' VAL . 15.4 tp 66.86 -63.57 0.26 Allowed 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 126.89 2.076 . . . . 73.34 111.379 -174.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -69.43 126.02 28.49 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 124.696 1.198 . . . . 73.1 111.433 176.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.543 ' HB ' ' HA ' ' A' ' 119' ' ' LEU . 87.1 m -138.77 88.45 13.88 Favored Pre-proline 0 N--CA 1.47 0.57 0 C-N-CA 124.444 1.098 . . . . 65.01 108.657 176.076 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -69.4 83.96 0.61 Allowed 'Trans proline' 0 C--N 1.368 1.601 0 C-N-CA 122.461 2.107 . . . . 74.2 112.615 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 100' ' ' THR . 21.2 m -96.22 -179.31 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 CA-C-N 114.612 -1.176 . . . . 63.31 108.857 172.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.4 t -132.27 151.16 51.96 Favored 'General case' 0 C--O 1.244 0.78 0 N-CA-C 108.833 -0.803 . . . . 70.14 108.833 174.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 36.8 ttmt -134.34 107.41 7.61 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 120.932 0.396 . . . . 51.12 110.47 178.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -162.5 27.11 0.24 Allowed Glycine 0 C--N 1.339 0.749 0 CA-C-N 114.854 -1.067 . . . . 45.4 110.561 172.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 49.2 m -81.95 72.39 9.0 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 123.958 0.903 . . . . 71.14 109.859 -178.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 74.94 174.05 33.05 Favored Glycine 0 C--N 1.35 1.311 0 CA-C-N 115.374 -0.83 . . . . 75.32 112.927 -176.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.19 153.99 10.77 Favored Glycine 0 CA--C 1.533 1.217 0 N-CA-C 113.703 0.241 . . . . 71.35 113.703 177.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 46.7 t -166.06 169.36 14.64 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.097 0.959 . . . . 65.45 109.633 -177.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 160.86 162.76 12.94 Favored Glycine 0 C--N 1.344 0.982 0 N-CA-C 112.219 -0.352 . . . . 73.3 112.219 177.244 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -65.05 -56.21 17.36 Favored Glycine 0 C--N 1.349 1.295 0 N-CA-C 111.626 -0.59 . . . . 32.25 111.626 177.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.8 m -97.27 -27.63 14.42 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 123.603 0.761 . . . . 51.22 109.793 171.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -72.78 85.57 0.55 Allowed Glycine 0 C--N 1.358 1.757 0 O-C-N 123.645 0.591 . . . . 40.25 114.145 -172.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -175.15 91.84 0.09 OUTLIER Glycine 0 C--N 1.34 0.77 0 N-CA-C 110.49 -1.044 . . . . 71.14 110.49 179.24 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 40.5 m -66.37 154.22 40.67 Favored 'General case' 0 C--O 1.243 0.728 0 C-N-CA 123.749 0.82 . . . . 73.1 110.699 176.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.03 -168.62 22.9 Favored Glycine 0 C--N 1.344 1.01 0 CA-C-N 116.329 -0.396 . . . . 70.12 112.72 172.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.412 ' O ' ' HA3' ' A' ' 172' ' ' GLY . 45.2 mtt180 -73.57 153.35 40.27 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 123.579 0.752 . . . . 71.52 110.432 -175.278 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -98.05 109.17 21.97 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 107.491 -1.3 . . . . 75.35 107.491 177.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.543 ' HA ' ' HB ' ' A' ' 100' ' ' THR . 15.0 mt -91.47 108.04 19.62 Favored 'General case' 0 C--N 1.347 0.484 0 N-CA-C 106.165 -1.791 . . . . 74.22 106.165 177.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 34.7 ttt180 -118.89 106.16 12.21 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.104 -1.073 . . . . 71.03 108.104 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -131.0 144.54 51.55 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.165 0.586 . . . . 74.33 109.54 -175.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.644 ' HG3' ' HE ' ' A' ' 179' ' ' ARG . 1.2 mp0 -72.8 129.01 37.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 114.88 -1.055 . . . . 75.15 108.536 173.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.543 HD21 ' HG2' ' A' ' 136' ' ' ARG . 3.0 tt -99.76 102.39 16.97 Favored Pre-proline 0 CA--C 1.536 0.438 0 N-CA-C 106.609 -1.626 . . . . 54.25 106.609 -179.535 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -65.93 113.86 2.75 Favored 'Trans proline' 0 C--N 1.376 2.026 0 C-N-CA 121.839 1.693 . . . . 73.14 110.271 174.638 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.523 HD21 HD12 ' A' ' 149' ' ' ILE . 17.8 tp -144.36 121.9 11.75 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.796 -1.187 . . . . 72.34 107.796 -173.812 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 68.3 p -73.96 168.34 19.67 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 117.761 0.255 . . . . 75.21 110.478 -177.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.8 mt -57.58 -36.43 71.7 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.249 0.619 . . . . 74.42 110.918 176.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 21.2 mp0 -71.88 -46.75 56.78 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 124.611 1.165 . . . . 60.02 110.386 -176.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -72.06 -27.49 62.72 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.601 0.76 . . . . 74.45 111.911 -179.051 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -69.41 -46.02 67.82 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.426 0.69 . . . . 64.34 109.926 173.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -58.96 -41.56 87.77 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 124.718 1.207 . . . . 61.05 110.849 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -66.45 -49.1 67.83 Favored 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.59 0.556 . . . . 71.34 109.541 177.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.49 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 57.01 56.93 22.41 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.062 -0.972 . . . . 24.33 113.106 -178.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -92.0 -148.17 21.91 Favored Glycine 0 C--N 1.345 1.033 0 O-C-N 123.491 0.171 . . . . 61.12 112.808 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -95.4 132.32 40.59 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 107.757 -1.201 . . . . 73.43 107.757 169.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.543 ' HG2' HD21 ' A' ' 123' ' ' LEU . 12.8 tpp180 -111.62 116.94 31.65 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 107.678 -1.23 . . . . 72.54 107.678 -178.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 144' ' ' ARG . 12.1 p -98.76 118.12 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 N-CA-C 108.133 -1.062 . . . . 72.24 108.133 -176.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.526 HG23 HD22 ' A' ' 98' ' ' LEU . 35.6 m -134.22 161.84 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.849 0.86 . . . . 60.12 110.008 -173.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -96.97 136.88 36.91 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 123.679 0.792 . . . . 65.33 110.093 -173.596 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.433 ' HB ' HD23 ' A' ' 98' ' ' LEU . 5.4 p -144.49 111.59 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.607 1.163 . . . . 74.53 109.631 177.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.4 22.01 12.95 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 123.684 0.794 . . . . 51.02 113.025 173.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 99.92 -16.12 58.76 Favored Glycine 0 C--N 1.345 1.049 0 C-N-CA 123.827 0.727 . . . . 52.2 112.653 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 19.4 tpp180 -95.72 123.92 39.51 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 124.249 1.02 . . . . 72.31 109.551 178.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.522 ' HG2' HG22 ' A' ' 137' ' ' VAL . 22.6 ttp180 -89.51 107.05 18.85 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 108.728 -0.841 . . . . 74.31 108.728 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 70.0 t -112.7 136.79 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 C-N-CA 124.112 0.965 . . . . 75.31 110.508 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 31.9 p -96.18 120.83 37.17 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.279 0.632 . . . . 72.54 110.669 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 6.5 p -106.37 131.02 57.14 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.943 1.297 . . . . 51.05 109.345 174.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 46.7 ttp180 -79.02 122.34 26.07 Favored 'General case' 0 C--O 1.243 0.72 0 CA-C-O 120.969 0.414 . . . . 62.15 109.98 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.523 HD12 HD21 ' A' ' 125' ' ' LEU . 10.3 pt -96.5 140.71 22.32 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 124.26 1.024 . . . . 71.31 109.823 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 20.5 Cg_exo -66.18 142.66 68.13 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.058 2.505 . . . . 71.14 113.045 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -66.17 130.91 25.29 Favored 'Trans proline' 0 C--N 1.378 2.087 0 C-N-CA 122.327 2.018 . . . . 72.24 110.802 170.144 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 70.81 26.29 74.26 Favored Glycine 0 CA--C 1.534 1.227 0 CA-C-N 115.532 -0.758 . . . . 62.42 113.945 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.0 p -68.77 137.37 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-N 117.201 0.5 . . . . 74.12 110.755 -178.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 88.5 mtt180 -98.37 175.77 5.93 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 121.875 0.845 . . . . 75.52 112.963 -168.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -69.65 134.0 48.21 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 113.547 -1.661 . . . . 74.11 110.669 177.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 73.89 10.17 80.27 Favored Glycine 0 C--N 1.342 0.914 0 CA-C-N 116.062 -0.517 . . . . 72.43 113.452 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.5 m -81.32 118.9 23.02 Favored 'General case' 0 C--N 1.347 0.473 0 N-CA-C 108.626 -0.879 . . . . 74.12 108.626 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 3.3 p -99.91 115.03 40.08 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.351 0.596 . . . . 54.02 109.796 -175.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 55.5 mt -90.05 104.49 15.24 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 124.516 1.126 . . . . 71.01 108.212 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.52 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 24.8 ttp180 -90.32 117.9 29.4 Favored 'General case' 0 C--N 1.344 0.355 0 N-CA-C 110.548 -0.168 . . . . 72.43 110.548 -179.655 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.0 t -109.11 95.28 17.29 Favored Pre-proline 0 CA--C 1.555 1.157 0 N-CA-C 107.5 -1.296 . . . . 64.12 107.5 166.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -70.26 136.29 31.33 Favored 'Trans proline' 0 C--N 1.373 1.857 0 C-N-CA 122.888 2.392 . . . . 72.25 111.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 87.39 2.24 82.92 Favored Glycine 0 CA--C 1.531 1.089 0 CA-C-O 119.635 -0.536 . . . . 65.32 114.118 178.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 41.4 tpp -128.51 12.99 6.48 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 117.872 0.836 . . . . 74.45 110.726 -177.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.38 -106.74 0.78 Allowed Glycine 0 C--N 1.344 1.021 0 CA-C-N 115.866 -0.606 . . . . 73.11 111.896 178.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -61.38 105.11 0.8 Allowed Glycine 0 C--N 1.347 1.179 0 C-N-CA 123.018 0.342 . . . . 74.31 113.502 -177.248 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -89.69 134.7 34.02 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 123.862 0.865 . . . . 54.44 109.176 173.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -178.9 -51.14 0.08 OUTLIER Glycine 0 C--N 1.337 0.591 0 N-CA-C 110.031 -1.228 . . . . 74.34 110.031 177.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.458 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 25.1 t-20 -166.25 -54.76 0.01 OUTLIER Pre-proline 0 CA--C 1.556 1.192 0 C-N-CA 124.952 1.301 . . . . 65.42 108.173 169.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.458 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 82.1 Cg_endo -82.54 134.49 7.63 Favored 'Trans proline' 0 C--N 1.399 3.196 0 C-N-CA 121.721 1.614 . . . . 74.42 110.411 170.004 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -72.76 125.84 10.87 Favored 'Trans proline' 0 C--N 1.367 1.537 0 C-N-CA 122.228 1.952 . . . . 74.55 111.824 178.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 117' ' ' ARG . . . -95.13 -172.18 37.03 Favored Glycine 0 C--N 1.349 1.273 0 CA-C-N 116.182 -0.463 . . . . 63.14 113.416 175.495 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.6 144.33 28.02 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.417 0.687 . . . . 70.42 110.5 178.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.52 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 55.6 tp -107.99 129.68 55.1 Favored 'General case' 0 C--O 1.219 -0.533 0 CA-C-N 115.312 -0.858 . . . . 74.32 108.879 178.315 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.4 mt -128.27 102.56 6.73 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 124.472 1.109 . . . . 75.53 109.187 -178.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.436 HD21 HD12 ' A' ' 98' ' ' LEU . 89.4 mt -104.08 101.36 11.12 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 121.0 0.428 . . . . 73.13 110.486 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 20.6 t -85.46 95.75 4.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.47 -0.937 . . . . 62.05 108.47 -176.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.7 t -55.63 124.11 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 C-N-CA 124.142 0.977 . . . . 70.41 111.355 -179.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . 0.644 ' HE ' ' HG3' ' A' ' 122' ' ' GLU . 28.2 mmt180 -116.38 104.48 11.51 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.383 1.073 . . . . 74.13 108.459 -179.323 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.46 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 60.8 mt -70.05 111.05 5.44 Favored 'General case' 0 C--N 1.343 0.323 0 C-N-CA 123.685 0.794 . . . . 75.43 110.732 -178.028 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 63.3 mt -94.73 144.22 27.51 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.324 0.65 . . . . 54.1 110.044 -179.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.93 -33.23 4.84 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 122.425 2.083 . . . . 73.21 110.773 167.17 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 . . . . . 0 N--CA 1.48 1.069 0 C-N-CA 124.82 1.248 . . . . 73.3 108.15 175.829 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 110.275 -0.268 . . . . 70.22 110.275 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pp 36.7 81.06 0.25 Allowed Pre-proline 0 CA--C 1.56 1.363 0 C-N-CA 126.057 1.743 . . . . 63.21 114.391 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.93 -61.87 0.16 Allowed 'Trans proline' 0 C--N 1.382 2.341 0 C-N-CA 122.519 2.146 . . . . 71.21 110.509 176.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.441 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.8 tp -172.68 144.33 1.39 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.599 1.16 . . . . 74.12 107.901 172.272 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.653 HD13 HG21 ' A' ' 138' ' ' VAL . 8.9 tp 64.31 -66.36 0.12 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 126.346 1.858 . . . . 61.43 111.828 -169.08 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -59.55 137.47 58.01 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 124.733 1.213 . . . . 71.13 111.972 178.147 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.54 HG22 HG13 ' A' ' 102' ' ' VAL . 61.2 m -157.66 108.93 1.81 Allowed Pre-proline 0 N--CA 1.475 0.822 0 C-N-CA 124.755 1.222 . . . . 74.2 109.225 177.358 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -81.42 68.15 8.24 Favored 'Trans proline' 0 C--N 1.371 1.736 0 C-N-CA 122.381 2.054 . . . . 51.04 112.582 -172.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.54 HG13 HG22 ' A' ' 100' ' ' THR . 9.6 m -62.06 -29.34 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 CA-C-N 114.78 -1.1 . . . . 63.23 112.663 -179.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.6 t 44.44 33.03 0.81 Allowed 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 125.69 1.596 . . . . 74.22 113.824 176.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.2 164.86 11.59 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 124.517 1.127 . . . . 53.3 110.981 -175.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 177.97 -51.74 0.1 OUTLIER Glycine 0 C--N 1.339 0.697 0 N-CA-C 110.564 -1.014 . . . . 74.32 110.564 178.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.4 m 61.06 20.07 10.54 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 124.643 1.177 . . . . 65.21 112.759 176.262 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 158.13 156.43 7.97 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 112.048 -0.421 . . . . 64.11 112.048 -177.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -82.41 -23.09 57.46 Favored Glycine 0 C--N 1.348 1.195 0 C-N-CA 122.974 0.321 . . . . 62.23 112.843 177.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 59.8 p -137.73 154.31 49.64 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.655 0.782 . . . . 61.22 110.738 -178.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -152.62 167.18 31.46 Favored Glycine 0 C--N 1.353 1.523 0 C-N-CA 123.537 0.589 . . . . 75.22 111.887 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -68.34 -47.85 55.47 Favored Glycine 0 C--N 1.348 1.236 0 C-N-CA 123.034 0.349 . . . . 74.22 113.536 -173.072 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 22.7 t -76.97 -38.56 52.99 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.402 0.681 . . . . 55.32 109.553 177.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -173.69 146.57 8.9 Favored Glycine 0 C--N 1.345 1.044 0 CA-C-N 115.023 -0.99 . . . . 65.45 111.631 -179.628 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.61 -39.01 30.83 Favored Glycine 0 C--N 1.342 0.908 0 O-C-N 123.724 0.308 . . . . 62.12 112.96 177.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 51.4 m -102.14 150.2 23.51 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.811 0.844 . . . . 75.32 110.064 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.735 ' HA2' ' HA2' ' A' ' 172' ' ' GLY . . . 149.67 75.22 0.02 OUTLIER Glycine 0 C--N 1.347 1.185 0 O-C-N 123.207 0.317 . . . . 53.24 113.053 175.465 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.566 ' HG3' ' HA3' ' A' ' 166' ' ' GLY . 21.2 ptt180 -95.8 124.28 39.75 Favored 'General case' 0 CA--C 1.554 1.108 0 N-CA-C 108.98 -0.748 . . . . 75.31 108.98 170.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.475 ' HA ' ' O ' ' A' ' 173' ' ' ASP . 0.1 OUTLIER -101.99 115.06 29.74 Favored 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.875 0.87 . . . . 53.41 110.681 -157.955 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.527 HD22 ' O ' ' A' ' 100' ' ' THR . 13.8 mt -90.86 109.53 20.74 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 106.841 -1.54 . . . . 72.44 106.841 178.147 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.18 110.64 21.92 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 123.129 0.572 . . . . 75.53 110.376 -178.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -127.88 138.59 52.73 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.799 -0.815 . . . . 72.0 108.799 177.002 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mp0 -77.82 122.21 25.12 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.51 -0.922 . . . . 73.1 108.51 176.419 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.56 HD12 HD13 ' A' ' 176' ' ' LEU . 1.0 OUTLIER -99.67 111.05 60.87 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 108.667 -0.864 . . . . 72.41 108.667 -172.281 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.423 ' HB2' HD11 ' A' ' 181' ' ' LEU . 52.6 Cg_endo -67.89 116.67 4.42 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.06 1.84 . . . . 70.54 109.788 170.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.513 HD21 HD12 ' A' ' 149' ' ' ILE . 23.6 tp -131.45 133.04 44.78 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 108.715 -0.846 . . . . 71.2 108.715 -172.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 45.1 p -75.48 157.17 34.4 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.36 -0.607 . . . . 63.43 109.36 -178.194 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 95.1 mt -62.54 -31.15 71.89 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.274 0.63 . . . . 64.35 111.074 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -70.78 -51.64 25.66 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 123.768 0.827 . . . . 63.44 110.107 179.458 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -65.45 -34.16 77.64 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.485 0.714 . . . . 72.43 111.581 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.43 -45.56 86.99 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 124.027 0.829 . . . . 60.14 110.699 173.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -66.08 -35.75 81.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 124.177 0.991 . . . . 63.01 111.116 179.596 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -73.65 -43.16 60.2 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.997 0.519 . . . . 65.11 109.865 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.436 ' HA2' HG13 ' A' ' 149' ' ' ILE . . . 67.23 51.37 38.68 Favored Glycine 0 C--N 1.347 1.149 0 CA-C-N 114.877 -1.056 . . . . 41.13 111.742 -168.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.402 ' O ' HG12 ' A' ' 149' ' ' ILE . . . -89.84 -150.55 23.57 Favored Glycine 0 C--N 1.347 1.177 0 CA-C-O 120.841 0.134 . . . . 65.13 112.971 -177.033 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.418 ' HB3' ' HB3' ' A' ' 146' ' ' SER . 7.5 mp0 -101.36 140.97 34.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.576 -0.898 . . . . 72.55 108.576 169.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 24.4 tpt85 -120.56 121.53 38.6 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.074 0.949 . . . . 70.55 108.548 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 12.2 p -84.73 117.89 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.784 0.802 . . . . 73.44 109.769 -177.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.653 HG21 HD13 ' A' ' 98' ' ' LEU . 34.6 m -126.46 160.3 34.41 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 C-N-CA 125.444 1.498 . . . . 72.43 107.974 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -125.62 112.7 16.46 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-N 118.981 0.809 . . . . 53.13 111.801 -172.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.514 ' HB ' ' HB3' ' A' ' 98' ' ' LEU . 3.5 p -105.55 105.55 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 C-N-CA 125.608 1.563 . . . . 61.45 111.004 -176.572 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 57.25 28.5 15.26 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 124.146 0.978 . . . . 60.41 112.521 177.111 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 101.11 -10.49 58.38 Favored Glycine 0 C--N 1.356 1.687 0 CA-C-O 119.79 -0.45 . . . . 64.45 114.085 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.419 ' HB2' HG13 ' A' ' 140' ' ' VAL . 51.1 mtt180 -90.25 118.32 29.67 Favored 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 108.605 -0.887 . . . . 70.11 108.605 174.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 48.4 ttt85 -98.8 109.74 22.45 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 109.248 -0.649 . . . . 73.45 109.248 -177.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 6.1 p -130.75 146.07 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 C-N-CA 124.527 1.131 . . . . 71.33 110.377 -172.272 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.418 ' HB3' ' HB3' ' A' ' 135' ' ' GLU . 28.4 m -93.18 119.19 32.09 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 123.693 0.797 . . . . 73.22 110.464 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -101.26 130.13 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.114 0.966 . . . . 75.4 109.944 175.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 36.9 ttp180 -75.84 134.77 40.27 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.248 0.547 . . . . 62.43 110.137 178.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.513 HD12 HD21 ' A' ' 125' ' ' LEU . 2.8 pt -108.65 145.66 32.07 Favored Pre-proline 0 CA--C 1.564 1.492 0 C-N-CA 125.11 1.364 . . . . 65.33 108.985 -179.473 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.52 145.99 97.75 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 123.037 2.491 . . . . 72.31 113.565 178.261 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -71.06 117.08 4.97 Favored 'Trans proline' 0 C--N 1.38 2.212 0 C-N-CA 122.709 2.273 . . . . 65.01 112.294 178.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 78.97 31.97 41.57 Favored Glycine 0 CA--C 1.533 1.176 0 CA-C-N 115.738 -0.664 . . . . 71.2 112.606 -176.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 14.6 p -72.82 146.17 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 123.395 0.678 . . . . 73.25 110.309 179.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.52 ' HA ' HD11 ' A' ' 180' ' ' LEU . 92.7 mtt180 -123.23 177.58 5.51 Favored 'General case' 0 N--CA 1.476 0.873 0 CA-C-O 121.808 0.813 . . . . 72.52 112.851 -171.563 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.0 tp10 -60.09 132.94 55.48 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 113.185 -1.825 . . . . 73.52 111.325 178.021 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 95.36 -27.31 15.81 Favored Glycine 0 C--N 1.34 0.775 0 CA-C-O 119.381 -0.677 . . . . 60.4 112.565 179.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 50.6 m -62.57 121.26 12.88 Favored 'General case' 0 C--N 1.354 0.763 0 C-N-CA 123.433 0.693 . . . . 70.54 111.004 -175.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.1 126.46 51.11 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.091 -0.707 . . . . 61.05 109.091 177.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.41 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 49.4 mt -95.74 103.87 15.18 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 N-CA-C 108.012 -1.107 . . . . 74.51 108.012 -176.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.571 ' HA ' ' O ' ' A' ' 174' ' ' LEU . 53.2 ttp180 -89.02 106.73 18.62 Favored 'General case' 0 C--N 1.355 0.848 0 N-CA-C 110.342 -0.244 . . . . 74.31 110.342 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.6 t -110.48 96.9 29.44 Favored Pre-proline 0 CA--C 1.553 1.078 0 N-CA-C 108.629 -0.878 . . . . 73.33 108.629 174.565 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.46 144.19 92.47 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.137 2.558 . . . . 71.44 112.842 176.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.69 -24.33 5.92 Favored Glycine 0 CA--C 1.539 1.584 0 CA-C-O 119.549 -0.584 . . . . 72.23 114.351 176.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 17.2 mmt -90.38 -2.54 57.97 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 117.7 0.75 . . . . 75.43 111.717 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.12 -115.12 0.54 Allowed Glycine 0 C--N 1.341 0.843 0 N-CA-C 111.346 -0.702 . . . . 64.33 111.346 174.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.566 ' HA3' ' HG3' ' A' ' 117' ' ' ARG . . . -58.35 107.56 1.16 Allowed Glycine 0 C--N 1.354 1.555 0 CA-C-N 117.165 0.483 . . . . 61.43 113.237 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.1 mm-40 -80.03 171.57 14.92 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.937 0.895 . . . . 74.14 110.733 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 106.9 -147.07 16.14 Favored Glycine 0 N--CA 1.473 1.165 0 CA-C-O 119.619 -0.545 . . . . 62.34 111.819 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.415 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 5.6 t-20 -69.82 -52.64 13.16 Favored Pre-proline 0 CA--C 1.566 1.584 0 CA-C-O 118.146 -0.931 . . . . 75.4 111.303 178.285 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.415 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 88.0 Cg_endo -89.93 108.64 0.39 Allowed 'Trans proline' 0 C--N 1.397 3.079 0 C-N-CA 122.188 1.926 . . . . 64.3 112.907 178.557 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -66.71 127.67 17.55 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.187 2.591 . . . . 61.22 112.776 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.735 ' HA2' ' HA2' ' A' ' 116' ' ' GLY . . . -110.64 162.67 12.47 Favored Glycine 0 C--N 1.341 0.846 0 CA-C-N 115.542 -0.754 . . . . 61.45 112.915 -178.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' A' ' 118' ' ' ASP . 4.6 m-20 -80.15 150.3 30.24 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.83 0.852 . . . . 74.23 110.559 178.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.571 ' O ' ' HA ' ' A' ' 160' ' ' ARG . 62.5 tp -106.58 135.79 47.49 Favored 'General case' 0 C--O 1.216 -0.676 0 N-CA-C 108.302 -0.999 . . . . 75.21 108.302 173.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 95.9 mt -128.44 103.31 7.06 Favored 'General case' 0 CA--C 1.548 0.901 0 C-N-CA 123.715 0.806 . . . . 74.3 109.293 179.143 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.564 HD21 HD12 ' A' ' 98' ' ' LEU . 83.4 mt -107.35 103.08 12.34 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 122.684 0.394 . . . . 73.33 110.92 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.64 96.88 5.72 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.732 -0.667 . . . . 62.05 109.467 -174.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -54.59 130.21 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 C-N-CA 124.888 1.275 . . . . 75.51 111.848 -177.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -123.86 100.24 6.66 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 125.344 1.458 . . . . 72.23 107.626 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.52 HD11 ' HA ' ' A' ' 154' ' ' ARG . 35.5 mt -70.06 107.91 3.84 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-O 121.168 0.509 . . . . 75.01 111.151 -176.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.423 HD11 ' HB2' ' A' ' 124' ' ' PRO . 48.7 mt -75.98 130.72 77.58 Favored Pre-proline 0 CA--C 1.553 1.083 0 N-CA-C 108.23 -1.026 . . . . 74.2 108.23 175.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.22 -63.17 0.07 OUTLIER 'Trans proline' 0 CA--C 1.559 1.749 0 C-N-CA 123.074 2.516 . . . . 54.33 113.207 -176.216 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 76.8 m-70 . . . . . 0 N--CA 1.489 1.504 0 C-N-CA 123.888 0.875 . . . . 72.34 108.902 177.684 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' MET . . . . . . . . . . . . . 27.2 ptt? . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 119.317 -0.373 . . . . 60.1 110.366 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -51.98 115.19 6.28 Favored Pre-proline 0 CA--C 1.566 1.561 0 C-N-CA 124.302 1.041 . . . . 52.21 111.667 179.306 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -74.21 -48.98 0.19 Allowed 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.386 2.058 . . . . 71.0 112.354 176.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.504 HD12 ' H ' ' A' ' 98' ' ' LEU . 7.6 tp 168.25 150.34 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 126.792 2.037 . . . . 74.31 106.321 -170.553 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.7 HD23 ' HB ' ' A' ' 140' ' ' VAL . 14.2 tp 57.54 -72.51 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 126.108 1.763 . . . . 75.41 111.587 -173.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.61 ' HA ' HD13 ' A' ' 119' ' ' LEU . 87.6 t80 -57.9 123.1 14.62 Favored 'General case' 0 CA--C 1.55 0.967 0 C-N-CA 125.741 1.616 . . . . 72.2 111.948 172.086 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 98.9 m -145.44 99.17 4.52 Favored Pre-proline 0 CA--C 1.545 0.766 0 C-N-CA 124.113 0.965 . . . . 72.25 109.47 175.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -77.4 74.65 5.02 Favored 'Trans proline' 0 C--N 1.371 1.761 0 C-N-CA 122.462 2.108 . . . . 73.22 113.09 -172.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 3.6 m -78.62 176.82 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.811 0 CA-C-N 116.102 -0.499 . . . . 72.14 109.861 176.638 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 2.0 t -121.67 127.71 51.07 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.498 0.719 . . . . 51.21 109.144 176.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.475 ' HE2' ' HB2' ' A' ' 115' ' ' SER . 0.0 OUTLIER -77.8 90.75 4.07 Favored 'General case' 0 C--O 1.241 0.638 0 N-CA-C 108.536 -0.913 . . . . 73.03 108.536 173.293 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -71.25 130.75 19.25 Favored Glycine 0 CA--C 1.524 0.65 0 CA-C-N 114.373 -1.285 . . . . 73.22 111.81 175.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 40.0 t -163.65 -66.0 0.04 OUTLIER 'General case' 0 C--O 1.242 0.677 0 N-CA-C 107.071 -1.455 . . . . 43.42 107.071 176.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.19 -98.4 0.04 OUTLIER Glycine 0 C--N 1.355 1.622 0 CA-C-N 114.844 -1.071 . . . . 72.44 113.662 176.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 70.44 -82.45 0.37 Allowed Glycine 0 C--N 1.353 1.473 0 C-N-CA 123.943 0.782 . . . . 64.33 111.926 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 31.9 t -143.07 97.2 3.05 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.678 -1.23 . . . . 71.12 107.678 174.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 91.68 -109.45 3.73 Favored Glycine 0 C--N 1.343 0.956 0 N-CA-C 111.062 -0.815 . . . . 53.4 111.062 -173.742 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 76.4 77.39 0.76 Allowed Glycine 0 C--N 1.347 1.162 0 N-CA-C 111.818 -0.513 . . . . 73.11 111.818 -177.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 25.8 m -62.27 -31.55 72.14 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 123.782 0.833 . . . . 72.02 112.044 -179.089 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 163.06 -62.47 0.26 Allowed Glycine 0 C--N 1.337 0.613 0 N-CA-C 111.264 -0.734 . . . . 34.41 111.264 177.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.14 -88.68 0.4 Allowed Glycine 0 C--N 1.346 1.109 0 O-C-N 124.3 0.647 . . . . 24.1 111.899 -176.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . 0.475 ' HB2' ' HE2' ' A' ' 104' ' ' LYS . 12.7 m -96.16 152.99 18.04 Favored 'General case' 0 C--O 1.244 0.766 0 C-N-CA 123.745 0.818 . . . . 72.23 108.816 177.018 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -84.3 -165.31 39.04 Favored Glycine 0 N--CA 1.465 0.627 0 CA-C-N 116.1 -0.5 . . . . 72.02 113.697 -175.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 38.3 ptt180 -87.47 130.93 34.51 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 108.711 -0.848 . . . . 71.42 108.711 174.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -92.59 118.99 31.59 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 106.976 -1.49 . . . . 65.21 106.976 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.61 HD13 ' HA ' ' A' ' 99' ' ' PHE . 18.4 mt -89.73 108.68 19.83 Favored 'General case' 0 C--O 1.225 -0.228 0 N-CA-C 106.725 -1.584 . . . . 72.25 106.725 -174.241 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 18.4 ttm180 -117.42 107.56 14.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.113 -1.069 . . . . 70.44 108.113 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.61 140.05 50.42 Favored 'General case' 0 C--O 1.238 0.47 0 N-CA-C 108.577 -0.898 . . . . 45.41 108.577 -179.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.78 129.41 37.0 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 109.189 -0.671 . . . . 64.0 109.189 173.297 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.508 HD12 HD13 ' A' ' 176' ' ' LEU . 2.0 tt -100.02 109.55 56.53 Favored Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 108.749 -0.834 . . . . 75.1 108.749 -173.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.03 113.86 2.77 Favored 'Trans proline' 0 C--N 1.378 2.115 0 C-N-CA 122.116 1.877 . . . . 75.13 110.19 171.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.565 HD21 HD12 ' A' ' 149' ' ' ILE . 12.0 tp -133.21 125.91 30.43 Favored 'General case' 0 CA--C 1.531 0.242 0 N-CA-C 108.045 -1.095 . . . . 72.31 108.045 -169.448 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 43.0 p -73.16 171.7 12.46 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 117.975 0.352 . . . . 71.01 110.69 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 96.7 mt -71.39 -23.83 61.95 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 123.157 0.583 . . . . 61.31 111.009 178.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -72.03 -50.68 26.5 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.634 -0.876 . . . . 62.34 108.634 175.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.664 ' HG3' HH21 ' A' ' 136' ' ' ARG . 29.4 mm-40 -57.55 -40.52 79.04 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 124.841 1.256 . . . . 72.42 111.384 176.214 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.56 64.22 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 114.965 -1.016 . . . . 41.53 111.177 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -60.73 -58.45 8.4 Favored 'General case' 0 C--N 1.349 0.564 0 O-C-N 124.679 1.237 . . . . 74.44 110.266 -176.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.8 m80 -67.66 -38.59 84.0 Favored 'General case' 0 N--CA 1.475 0.801 0 O-C-N 123.958 0.786 . . . . 74.12 111.047 -175.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 73.49 -112.81 4.0 Favored Glycine 0 C--N 1.343 0.947 0 N-CA-C 110.47 -1.052 . . . . 73.52 110.47 -170.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.12 -130.85 22.26 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 111.551 -0.62 . . . . 54.53 111.551 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 9.3 mp0 -121.43 157.65 30.08 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.975 0.91 . . . . 73.1 109.452 174.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.664 HH21 ' HG3' ' A' ' 129' ' ' GLU . 5.3 tpp180 -135.02 124.03 24.19 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.234 1.414 . . . . 72.33 107.975 177.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.3 p -84.9 127.09 40.2 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.091 0 C-N-CA 123.137 0.575 . . . . 72.11 110.228 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.676 HG23 HD22 ' A' ' 98' ' ' LEU . 30.7 m -140.71 158.01 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.938 1.295 . . . . 71.31 109.102 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -88.19 135.48 33.42 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 123.162 0.585 . . . . 43.23 111.284 -174.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.7 ' HB ' HD23 ' A' ' 98' ' ' LEU . 7.2 p -136.86 118.56 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 124.396 1.078 . . . . 43.23 109.288 168.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.39 20.29 11.74 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 123.92 0.888 . . . . 32.12 112.229 177.256 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 96.43 -9.47 66.98 Favored Glycine 0 C--N 1.358 1.78 0 C-N-CA 123.051 0.357 . . . . 31.34 113.216 -177.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -104.0 128.82 51.57 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.076 0.951 . . . . 75.2 109.983 -178.331 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -75.32 141.66 43.35 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.527 -0.545 . . . . 73.52 109.527 177.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.81 126.49 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 124.64 1.176 . . . . 72.42 108.619 178.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 44.7 m -82.49 109.82 17.05 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.396 0.678 . . . . 75.21 109.612 175.29 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.5 130.24 47.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.507 0 C-N-CA 123.999 0.92 . . . . 65.43 109.248 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -69.81 118.7 12.99 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.043 0.537 . . . . 75.22 109.96 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.565 HD12 HD21 ' A' ' 125' ' ' LEU . 17.2 pt -108.02 131.53 21.68 Favored Pre-proline 0 CA--C 1.564 1.508 0 C-N-CA 124.509 1.124 . . . . 73.41 108.866 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.402 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 18.0 Cg_endo -62.06 140.05 82.11 Favored 'Trans proline' 0 C--N 1.38 2.231 0 C-N-CA 122.67 2.247 . . . . 71.14 113.763 -174.609 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 34.2 Cg_exo -64.61 127.55 19.12 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 123.329 2.686 . . . . 75.03 112.696 175.568 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 76.76 30.09 56.58 Favored Glycine 0 CA--C 1.528 0.847 0 O-C-N 123.49 0.494 . . . . 43.35 112.406 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.8 p -73.74 137.36 23.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.78 0 C-N-CA 122.89 0.476 . . . . 75.44 110.367 -177.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -103.67 173.31 6.36 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.135 0.969 . . . . 75.13 111.886 -171.176 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.8 tp10 -63.83 122.2 15.86 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-N 113.09 -1.868 . . . . 74.1 109.346 167.204 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 102.06 -8.39 55.67 Favored Glycine 0 N--CA 1.474 1.215 0 CA-C-O 119.758 -0.468 . . . . 74.41 113.127 178.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.0 m -78.37 121.99 25.19 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.094 0.447 . . . . 73.32 109.937 177.055 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.8 p -99.15 141.68 16.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 109.019 -0.734 . . . . 73.22 109.019 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.518 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 65.4 mt -108.43 104.21 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 124.344 1.058 . . . . 64.52 108.724 -176.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -88.68 121.12 30.72 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 123.261 0.625 . . . . 61.52 109.782 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 t -124.23 106.56 30.64 Favored Pre-proline 0 CA--C 1.557 1.23 0 N-CA-C 107.65 -1.241 . . . . 74.32 107.65 173.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.91 139.35 36.04 Favored 'Trans proline' 0 C--N 1.373 1.836 0 C-N-CA 122.935 2.423 . . . . 71.52 113.31 -174.647 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 77.4 0.15 71.12 Favored Glycine 0 C--N 1.352 1.426 0 CA-C-N 115.471 -0.786 . . . . 72.41 114.264 173.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 93.6 mmm -103.6 15.2 29.49 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.685 0.794 . . . . 75.32 111.712 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -94.35 -108.24 2.07 Favored Glycine 0 C--N 1.343 0.927 0 N-CA-C 111.534 -0.626 . . . . 51.41 111.534 174.029 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.424 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -66.1 106.28 1.54 Allowed Glycine 0 C--N 1.344 1.011 0 C-N-CA 123.693 0.663 . . . . 71.42 112.575 175.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -83.8 165.18 19.03 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 123.75 0.82 . . . . 65.12 109.878 175.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 111.79 -141.6 16.71 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 111.184 -0.766 . . . . 54.15 111.184 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -76.61 -52.37 2.18 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 118.247 -0.882 . . . . 72.43 111.159 172.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -82.51 118.91 2.93 Favored 'Trans proline' 0 C--N 1.391 2.776 0 C-N-CA 121.627 1.551 . . . . 55.33 111.657 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_endo -84.9 126.71 3.41 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.718 2.279 . . . . 55.41 113.593 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.424 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -110.2 161.89 12.79 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 115.928 -0.578 . . . . 75.31 112.021 174.736 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -99.89 162.48 12.96 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 124.676 1.19 . . . . 72.45 110.009 -179.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.61 HD21 HD11 ' A' ' 98' ' ' LEU . 54.3 tp -116.32 128.38 55.5 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.733 0.813 . . . . 63.54 109.796 178.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 90.7 mt -128.54 120.51 26.86 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 124.314 1.046 . . . . 61.43 109.729 177.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.518 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 93.7 mt -118.99 104.17 10.24 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 123.369 0.668 . . . . 73.04 110.745 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.4 t -86.22 98.5 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.982 0 CA-C-N 115.397 -0.82 . . . . 61.13 109.404 -172.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 96.3 t -61.29 117.0 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 123.987 0.915 . . . . 63.44 112.426 -173.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -112.88 101.08 9.16 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 126.103 1.761 . . . . 74.32 108.63 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.418 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 43.5 mt -71.49 114.25 9.37 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.148 -0.478 . . . . 70.34 110.779 -177.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 87.3 mt -61.53 146.73 89.4 Favored Pre-proline 0 CA--C 1.549 0.907 0 CA-C-N 114.752 -1.113 . . . . 61.41 110.636 178.348 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -64.39 -168.15 0.1 OUTLIER 'Trans proline' 0 C--N 1.378 2.131 0 C-N-CA 123.154 2.569 . . . . 74.22 113.81 -173.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 12.2 m-70 . . . . . 0 C--O 1.253 1.238 0 CA-C-O 118.014 -0.993 . . . . 64.0 108.664 -179.85 . . . . . . . . 0 0 . 1 stop_ save_